Curriculum Vitae

Gregg W. Stone MD, FACC, FSCAI

Personal Information:

Present positions:

8/04 - present	Professor of Medicine Columbia University Director of Cardiovascular Research and Education Center for Interventional Vascular Therapy Columbia University Medical Center Herbert Irving Pavilion, 5th Floor 161 Fort Washington Avenue New York, NY 10032 212 305-7060 (tel) 212 342-3550 (fax) gs2184@columbia.edu (e-mail)
7/98 – present	The Cardiovascular Research Foundation Co-Director of Medical Research and Education Chairman (2006-2008) 111 E. 59th St. 11th Floor New York City, NY 10022 646-434-4134 (tel) 646-434-4715 (fax) gstone@crf.org (e-mail)

Past positions:

10/99 – 7/04	Interventional Cardiology Lenox Hill Hospital 130 E. 77th St. 9th Floor, Black Hall New York City, NY 10021
7/98 – 10/99	Interventional Cardiology Director of the Cardiovascular Training and Education Center Washington Hospital Center Washington DC
7/89 - 7/98	Director of Interventional Cardiology The Cardiovascular Institute Mountain View, CA

Interventional Cardiology
El Camino Hospital
Mountain View, CA

Interventional Cardiology
Stanford University Medical Center
Palo Alto, CA

Home address: 21 Wyckham Hill Lane
Greenwich, CT 06831

Home phone: 203-422-0334
Home fax: 203-422-0329

Date of birth: February 22nd, 1957

Place of birth: Cleveland, Ohio

Family: Married, Dr. Amy E. Stone MD,
Pulmonary and Sleep Disorders Medicine
Daughter Samantha Gabrielle Stone

Education:

College (9/75-6/78):
The University of Michigan
Ann Arbor, MI 48104
Graduated in 3 years
Degree: B.S., Magna Cum Laude (High Distinction)
Major/Minor: Zoology/Theoretical Mathematics

Medical School (9/78-6/82):
The Johns Hopkins School of Medicine
Baltimore, MD 21205
Degree: M.D.
Graduated 1st decile

Internship and Residency (7/82-6/85):
Internal Medicine
Dr. R. Gordon Douglass, Chairman
The New York Hospital-Cornell Medical Center
New York City, NY 10021

Fellowship (7/85-6/88):
Cardiology
Dr. Jeremy H. Swan, Director

Cedars-Sinai Medical Center
Los Angeles, CA 90048

Fellowship (7/88-7/89):
Advanced Coronary Angioplasty
Dr. Geoffrey O. Hartzler, Preceptor
Mid America Heart Institute
St. Luke's Hospital
44th and Wornall Rds.
Kansas City, MO 64111

Licensure:
New York – 156307
Connecticut - 042683
Washington DC - MD31096
California - C41818
Missouri - R4H67
Nuclear Cardiology, California #4944-43

Board Certification:
American Board of Internal Medicine, 9/85, 95th percentile
American Board of Cardiovascular Diseases, 3/88, 98th percentile
American Board of Interventional Cardiology, 11/99, top decile
National Board of Physicians and Surgeons, Interventional Cardiology

Honors and Awards:
Phi Beta Kappa
Honor's College, University of Michigan
James B. Angell Scholar, University of Michigan
NIH Medical Student Research Training Award (national grant)
President, Academy of Transcatheter Cardiovascular Therapeutics, 2003, 2004
Consultant, American Medical Foundation for Peer Review and Education, 2003, 2004
European Society of Cardiology Guidelines for Percutaneous Intervention, 2002-2005
Founding Physician Award, Cardiovascular Research Foundation, 2004
NHLBI Strategic Plan, 2006
CIT Contribution Award, 2007
American Heart Association Top Research Project of 2008, HORIZONS-AMI trial
NHLBI Vulnerable Plaque Working Group, 2009
US News and World Report's "Top Doctors"
Lifetime Achievement Award, Indo-European Interventional Cardiology Council, 2009
The New Cardiovascular Horizons Lifetime Achievement Award, 2010
Chairman, Cardiovascular Research Initiative, Columbia University, 2011-12
World's Top 400 Most Influential Biomedical Researchers, 1996-2011, SciTech Strategies
Cedars-Sinai Howard I. Wilner, MD Alumnus of the Year Award, 2012
Simon Dack Award for Outstanding Scholarship, 2013

America's Best Doctors (Castle Connolly Medical), 2004-2017
Best Doctors in America, 2010-2017
Thomson Reuters Highly Cited Researcher (top 1% 2002-2012)
The World's Most Influential Scientific Minds 2014, 2015
Chien Foundation Award for Lifetime Achievement in PCI, 2015
Honorary Professorship, Nanjing Medical University (awarded 2015)
Named foundation: Stone Cardiac Institute of Nanjing First Hospital, Nanjing, China (2015)
Honorary Professorship (first Western physician), Shenyang Military Hospital, Shenyang, China (2016)
China Jinling Friendship Award, China Municipal Government, China (2016)
Friendship Medal Award recipient, State Administration of Foreign Experts Affairs of the P.R.C., Beijing (2017)

Course Director (ongoing yearly symposia - partial list)
Director, Transcatheter Cardiovascular Therapeutics (TCT), 1998 – present
Director, Transcatheter Valve Therapies (TVT), 2008 - present
Director, China Course on Interventional Therapies (CIT) in partnership with TCT, 2003 – present
Director, TCT Russia, 2012 – present
Director, TCT Mediterranean, 2011 – 2014
Director, P-C-I Live in partnership with TCT, 2010 - 2014
Director, National Interventional Cardiology Fellow's Course, 1994 – present
Director, Vulnerable Plaque Meeting, 2011 – present
Director, Joint Interventional Meeting (JIM), 2012 - present
International Course Director, SOLACI in Partnership with TCT, 2002 – present
International Course Director, TOPIC (Tokyo, Japan), 2004 – present
Director, Enter the Drug-eluting Stent Revolution – A Critical Appraisal, 2002-2014
Director, Complex and High-risk Indicated PCI, 2015
Director, Left Main and Chronic Total Occlusion Summit, 2011 - 2013
Director, Chronic Total Occlusion Summit, 2004 – 2010, 2014 - present
Director, Left Atrial Appendage Occlusion: A technique oriented course. 2014.Director, Bioreserobable Scaffolds, A Breakthrough PCI Technology. 2014 – present.
Director, Montreal Live in partnership with TCT, 2013 and 2014
Director, Advanced Endovascular Therapies, 2000 – 2002
Director, Harmonizing Interventional and Pharmacologic Strategies in ACS and AMI, 2000
Director, Standards in ACS: From Diagnosis to Discharge, 2003
Director, TCT Course at EuroPCR, 2002 - 2010
Director, Cardiovascular Management Strategies, 2006 – 2009
Co-Director, Innovations in Valve and Structural Heart Disease, 2015 - present
Co-Director, Joint Interventional Meeting 2003 – 2011
Co-Director, Complex Catheterization Course in Japan, 2004 – 2010
Co-Director, TCT Asia Pacific, 2005 - present

Co-Director, Pediatric & Adult Interventional Therapies for Congenital & Valvular Heart Disease (PICS/ENTICHS), 2006 – 2007
Program Executive Committee, American College of Cardiology I2 Summit Annual Scientific Sessions, 2009 – 2015
Late Breaking Trial Selection and Live Case Program Committees, American College of Cardiology Annual Scientific Sessions, 2009 - present

Editorial Positions:

Founder, TCTMD.com
Senior Consulting Editor, Structural Heart: The Journal of the Heart Team
Associate Editor, JACC Cardiovascular Imaging
Associate Editor, Reviews in Cardiovascular Medicine
Associate Editor, Revista Argentina de Cardioangiología Intervencionista
Section Editor (Coronary and Structural Interventions), Journal of the American College of Cardiology
Editorial Board, JACC Interventions
Editorial Board, European Heart Journal
Editorial Board, Circulation: Cardiovascular Interventions
Editorial Board, American Journal of Cardiology
Editorial Board, Catheterization and Cardiovascular Interventions
Editorial Board, The Journal of Invasive Cardiology
Editorial Board, The Journal of Interventional Cardiology
Editorial Board, Journal of Structural Heart Disease
Editorial Board, Current Interventional Cardiology Reports
Editorial Board, Critical Pathways in Cardiology
Editorial Board, International Journal of Cardiovascular Interventions
Editorial Board, Interventional Cardiology Review
Editorial Board, Journal of Journal of Clinically Innovative Cardiology
Editorial Board, Journal of Cardiovascular Pharmacology and Therapeutics
Editorial Board, Future Cardiology
Editorial Board, Expert Review of Cardiovascular Therapy
Editorial Board, Acute Cardiac Care
Editorial Board, Argentine Journal of Interventional Cardiology and Angiology
Editorial Board, Cardiology Today Intervention
Editorial Board, Argentine Journal of Interventional Cardiology
Editorial Advisory Panel, Treatment Strategies – Interventional Cardiology
Advisory Board, Annals of Internal Medicine
Reviewer, New England Journal of Medicine
Reviewer, Lancet
Reviewer, Journal of the American Medical Association
Reviewer, Circulation
Reviewer, Circulation Research
Reviewer, American Heart Journal
Past Physician Editor, Cardio Intervention
Abstract grader, AHA, ACC and TCT Annual Scientific Sessions

Board of Directors or Trustees

Board of Directors, Cardiovascular Research Foundation, NYC, NY (1999-2008)
Board of Trustees, Society for Cardiac Interventions and Angiography (2003-2006)
Board of Directors, Devax Medical Corp. (2002-2008)
Board of Directors, Endosonics Corp., Sacramento, CA (past)

Advisory Boards (past and present):

Coronary Artery Disease and Atherosclerosis NHLBI Level 1 Working Group.
Member, Medical Advisory Board, Guidant Vascular Intervention
Member, Medical Advisory Board, Boston Scientific Corp.
Member, Physician Advisory Board, Devices for Vascular Intervention
Member, Stent Physician Advisory Board, Johnson & Johnson/Cordis
Member, Physician Advisory Board, Medtronic AVE
Member, U.S. Cardiology Opinion Leader Board, Cordis Corp.
Chairman, Scientific Advisory Board, Endosonics Corp.
Member, Physician Advisory Board, Cardiovascular Dynamics, Inc.
Member, Investigational Advisory Board, Eclipse Corp.
Member, Scientific Advisory Board, Danforth Biomedical Inc.
Member, Cardiology Advisory Council, Mallinckrodt Inc.
Member, New Product Advisory Board, Guidant Vascular Intervention
Member, Stent Research and Development Advisory Board, Guidant VI
Member, Scientific Advisory Panel, Intella Interventional Systems, Inc.
Member, Scientific Advisory Boards, Biocompatibles Limited
Chairman, National Acute Myocardial Infarction Strategies Council
Member, Coronary Radiation Applications Advisory Board, Guidant
Member, Scientific Advisory Board, Radiance Corp.
Member, Scientific Advisory Board, Intraluminal Therapeutics
Member, Scientific Advisory Board, X-Site, Inc.
Member, Scientific Advisory Board, Emboli Protection Inc.
Member, Scientific Advisory Board, Endicor Medical, Inc.
Member, Clinical Advisory Board, Centocor/Lilly Cardiovascular
Member, Scientific Advisory Board, Quanam Medical
Co-Chairman, Bracco Diagnostics Advisory Board
Member, Medical and Scientific Advisory Board, Abbott Laboratories
Member, Medical Advisory Board, PercuSurge Inc.
Member, Medical Advisory Board, Magna Labs
Member, Scientific Advisory Board, Savacor, Inc.
Member, Scientific Advisory Board, Devax Medical
Member, Scientific Advisory Board, Radiant Medical, Inc.
Member, Scientific Advisory Board, Volcano Therapeutics
Chairman, Vulnerable Plaque Advisory Board, Guidant Corp.
Member, Scientific Advisory Board, Cardiac Dimensions
Member, Scientific Advisory Board, Confluent Medical
Chairman, Scientific Advisory Board, Thermocore Inc.
Member, Medical Advisory Board, A-Med Systems
Member, Scientific Advisory Board, FlowCardia Inc.

Member, Medical Advisory Board, InfraReDx
Member, Endovascular Heart Valve Therapy Council, Edwards Life Sciences
Chairman, Scientific Advisory Board, Guided Delivery Systems
Member, Scientific Advisory Board, CoreValve
Member, Scientific Advisory Board, MediGuide
Member, Scientific Advisory Board, AorTx
Member, Scientific Advisory Board, Setagon
Member, Scientific Advisory Board, ParinGenix
Member, Scientific Advisory Board, Cardium
Member, Scientific Advisory Board, Prescient Medical
Member, Scientific Advisory Board, Reva
Member, Scientific Advisory Board, Bioabsorbable Therapeutics Inc.
Member, Scientific Advisory Board, Edwards Life Sciences
Member, Scientific Advisory Board, St. Jude Medical
Member, Scientific Advisory Board, Osprey Medical
Member, Global Thrombosis Board, Merck, Sharpe and Dohme
Member, Variability in Response Board, Bristol-Meyers Squibb
Member, Anticoagulation and Antiplatelet Therapies Advisory Board, Lilly/Daiichi Sankyo
Member, Antiplatelet Therapies Advisory Board, AstraZeneca
Member, Atherosclerosis Compound Development Advisory Board, AstraZeneca
Chair, Bioabsorbable Vascular Scaffold Global Advisory Board, Abbott
Member, Bioabsorbable Vascular Scaffold Advisory Committee, Abbott Vascular
Member, Advisory Board, Janssen Therapeutics
Member, Mitral Valve Therapies Advisory Board, Abbott Vascular
Member, Scientific Advisory Board, Miracor
Member, Scientific Advisory Board, VNT
Member, Scientific Advisory Board, Vascular Dynamics
Member, Scientific Advisory Board, Ablative Solutions, Inc.
Member, Scientific Advisory Board, Pulnovo Medical
Member, Scientific Advisory Board, Aria
Member, Scientific Advisory Board, Backbeat

Selected Research:

National/International Trial Principal Investigator/Chairman

RELIEVE-HF I: V-wave in HFrEF and HFpRF pilot trial
RELIEVE-HF II: V-wave in HFrEF and HFpRF pivotal trial
COSIRA II: Reducer in Refractory Angina pivotal trial
CALM II: Mobius for resistant hypertension pivotal trial
DEFER-ANGIO: CT_{FFR} guided angiography in patients with suspected coronary artery disease
GUIDE-ANGIO: CT_{FFR} guided PCI in patients with suspected coronary artery disease
The ISCHEMIA Trial: Evaluation of an invasive strategy in stable ischemic heart disease
The RESOLVE collaborative investigation (FFR vs. iFR)
The HORIZONS-AMI Trial: Bivalirudin and paclitaxel-eluting stents in STEMI

HORIZONS-ABSORB AMI: ABSORB and Cangrelor Antithrombotic Strategies in STEMI
HYBRID revascularization in CAD (NIH)
BIONICS: BioNIR stent vs Resolute more-comer's randomized trial
NIREUS: BioNIR stent vs Resolute QCA randomized trial
BLADE: BIOrest in Diabetes
COAST: Micro-Crown Orbital Atherctomy
The COAPT Trial: MitraClip in heart failure patients with functional MR
The RIVER-PCI Trial (Ranolazine for incomplete revascularization)
The EXCEL Trial (Xience Prime vs. CABG in Left Main Disease)
ABSORB Global Trial Program: Study Chair
ABSORB III trial: Bioabsorbable vascular scaffolds in coronary artery disease
ABSORB IV trial: Boabsorbable vascular scaffolds in coronary artery disease
ABSORB IV RESOLVE Ischemia Study
The INFUSE-AMI Trial: Intracoronary abciximab infusion and thrombectomy in STEMI
WAVECREST: Left atrial appendage closure to prevent stroke
PRomPT trial: Peri-infarct pacing post large MI
VELOCITY: Peritoneal hypothermia in STEMI
The ADAPT-DES Study: Predictors of stent thrombosis and antiplatelet variability in response
The PROSPECT Study: Invasive detection of vulnerable plaque with VH-IVUS
The PROSPECT II Study: Invasive detection of vulnerable plaque with NIRS
PROSPECT ABSORB: Randomized trial of the Absorb scaffold in vulnerable plaque
Ilumien II: OCT vs. IVUS guided stent implantation
Ilumien III: OPTIMIZE PCI: Angio vs. IVUS vs. OCT guided stent implantation
REVELUTION: Drug-Filled Stent (DFS) First-in-Man multimodality serial imaging study
The TAXUS IV Paclitaxel-eluting Stent Trial
The TAXUS V Paclitaxel-eluting Stent Trial
The TAXUS V Paclitaxel-eluting Stent ISR trial
The PROGRESS in CTO trial
The SPIRIT III Everolimus-eluting Stent Trial
The SPIRIT IV Everolimus-eluting Stent Trial
The PLATINUM Everolimus-eluting Stent Trial
The PLATINUM Everolimus-eluting Stent Small Vessel and Long Lesion Study
The ACUITY Trial: Bivalirudin in acute coronary syndromes
TRIGGER-PCI Trial: Prasugrel in clopidogrel hyporesponders
CANARY Trial: Distal protection in high risk (NIRS positive) native coronaries
MASTER trial: MGUARD in STEMI randomized trial
MASTER II trial: MGUARD Prime in STEMI randomized trial
MASTER OCT: MGUARD Prime in STEMI flow area randomized trial
VERDICT Study: VH-IVUS and FFR assessment of intermediate coronary lesions
STANDPOINT Trial: Bivalirudin and thienopyridines in STEMI
The AMIHOT-II Trial: Supersaturated oxygen in AMI
Optimizied AMIHOT Trial: Supersaturated oxygen in AMI
The CADILLAC Trial: Bare metal stents and abciximab in STEMI
The ADEST Trial: Bivalirudin in an unselected large PCI registry

The TEMPO Trial: Temperature Outcomes in ACS
The X-TRACTION Trial
The X-TRACT Trial: X-Sizer in ACS and SVG
The X-TRACT-AMI Trial: X-Sizer in STEMI
The EMERALD Trial (distal protection in STEMI
The SVG BRITE Trial: RDX Brachytherapy for SVG Lesions
The SPARK Trial: FilterWire in SVG Intervention
The FIRE Trial: FilterWire vs. GuardWire in SVG Intervention
The BARRICADE Trial: JOMED Stent-Graft to Prevent Restenosis in SVG
The JOMED Stent-Graft Coronary Aneurysm and AV Fistula Study
The CONTRAST Trial: Fenoldopam for contrast nephropathy
The PAMI Stent Pilot: Bare metal stents in STEMI
The PAMI Heparin-Coated Stent Trial: Bare metal stents in STEMI
The PAMI Heparin-Coated Stent IVUS Substudy: Bare metal stents in STEMI
Percutaneous Myocardial Revascularization (PTMR) in Chronic Occlusions
PTMR as an Adjunct to PTCA
The CLOUT Trial: Clinical Outcomes with Ultrasound Trial in PTCA
The OSTI I Trial: Optimal Bare Metal Stent Implantation Study Phase I
The OSTI Phase IIA Trial
The OSTI Phase IIB Trial
The LAVA Trial: Laser Angioplasty in CAD
The HART-USA Trial: Holmium Angioplasty in Unstable Angina
The ATHENS Trial (Abciximab/Tirofiban Comparative Pharmacodynamic Study
The SYNERGY Angiographic Study: Enoxaparin vs. Heparin in ACS
The A-MED Systems temporary left ventricular assist device
The COOL RCN Pilot Study: Hypothermia for contrast nephropathy prevention
The COOL RCN Randomized Trial

<u>National/International Trial Steering/Executive Committee</u>
Senior PAMI
The ZOMAXX-II Trial
The VIP-1 and VIP-2 Trials
The EVOLUTION I Trial
The EVOLUTION II Trial
The EXCITE Trial (Xemilofiban)
The DANAMI-2 Trial - International Advisory Board/DSMB
The Benchmark IntraAortic Balloon Counterpulsation Registry
The AMISTAD-2 Study
The Hedgehog Rotablator Burr
The TARGET Trial (Abciximab/Tirofiban Comparative PCI Trial)
Matrix VSG vascular closure system trial - Steering Committee
Devax Bifurcation Stent
ORAR II (oral rapamycin)
The FREEDOM Trial (DES vs. CABG in diabetics with multivessel disease)
The PREMAIR Trial
The COMBAT Trial

CHAMPION PLATFORM Trial: Cangrelor during PCI
CHAMPION PCI Trial: Cangrelor during PCI
CHAMPION PHOENIX trial: Cangrelor during PCI
CTSN Network: FFR to guide CABG (pending)
FABLE: FFR guided bifurcation treatment (pending)

Local Principal Investigator for the following studies (partial list):
The ASCENT Trial (ACS OTW Multi-Link Stent randomized trial)
The ACS HP RX MultiLink Stent
The Primary Angioplasty in Myocardial Infarction Trials - I, II, III, Stent
The Cardiovascular Dynamics Drug infusion angioplasty system
The B. Braun "E" Cath Randomized Angioplasty Trial
The PAS Paragon stent randomized trial and registry
The Cordis/JJIS Crown Stent with PowerGrip Delivery System
6F Angio-Seal Wound Closure Device
The ACCESS randomized trial (Atorvastatin)
CONVINCE randomized trial (Coer-Verapamil)
Orbofiban (oral GP IIb-IIIa receptor antagonist) in Acute Ischemic Syndromes
The EXCITE Randomized study (xemilofiban)
The TECBEST II randomized trial
The Symphony Trial (Sibrafiban)
The AVE GFX 2.5 mm stent study
The AMIGO study (Multi-Link stenting ± atherectomy Randomized trial)
The Guidant Soni-Cross system for total occlusions
The PRESTO Trial (Tranilast) after coronary intervention
The Radiance RDX Intravascular Brachytherapy system (BRITE-II and SVG BRITE)
The Guidant Galileo Intravascular Brachytherapy system (SUPPRESS)
Astra Pharmaceuticals SC-931-5129 P2T inhibitor in PCI, Phase I and II
The Guidant Duet Stent Registries
The Guidant TriStar Stent
The Guidant ULTRA-REVIVE registry
The Intraluminal Therapeutics CTO OCT System (CATS)
The Intraluminal Therapeutics OCT Guided Radiofrequency Ablation System (GREAT)
The Boston Scientific VICTORY Stent
The Guidant VISION Stent
The Guidant DELIVER Trial (Randomized Taxol Coated PharmaLink Stent)
The X-Site RACE Trial
The Innercool ICE-IT study
The FACTOR trial (FlowCardia Ultrasonic recanalization of chronic total occlusions)
The Cardiac Dimensions Carillon mitral valve sinoplasty system
The Boston Scientific ATLAS long lesion and small vessel study
The Bridgepoint FAST-CTO trial

Books and Book Chapters

1. **Stone GW**, Grines CL, Topol EJ. "Update on Percutaneous Transluminal Coronary Angioplasty for Acute Myocardial Infarction". In: Current Review of Interventional Cardiology, 2nd edition, Edited by Eric Topol and Patrick Serruys. Current Medicine, Philadelphia, PA, 1-56:1995.

2. **Stone GW**, Grines CL. "Interventional strategies for the management of acute myocardial infarction". In: International Update on Interventional Cardiology, ed. by Patrick Serruys and Amar Kapoor. 1995.

3. St. Goar F and **Stone GW.** "Percutaneous management of acute myocardial infarction". In: Cardiology Clinics, 1994;12:559-571.

4. Grines CL, **Stone GW,** and O'Neill WW. PTCA in Unstable Ischemic Syndromes. In: Manual of Interventional Cardiology, 1st ed., edited by Freed M, Grines CL and Safian RD, *Physicians' Press,* Birmingham, MI, 1996, pp 105-153.

5. **Stone GW.** Primary Angioplasty in Acute Myocardial Infarction. In: Acute Ischemic Syndromes, edited by Eric J. Topol. Marcel Dekker, Inc., New York City, NY. 1997, pp 233-268.

6. Brodie BR and **Stone GW.** Primary PTCA - The Preferred Therapy for Acute Myocardial Infarction: A Handbook for Cardiologists, Interventionalists, and Hospital Administrators. Health Management Publications, Inc., Wayne, PA, 1998.

7. **Stone GW,** Ed. Applications in Imaging: Cardiac Interventions. Anderson Publishing, Ltd. Ocean, NJ, 1997.

8. Grines CL, **Stone GW,** and O'Neill WW. PTCA in Unstable Ischemic Syndromes. In: The New Manual of Interventional Cardiology, 2nd ed., edited by Freed M, Grines C and Safian RD, *Physicians' Press,* Birmingham, MI, 1998, pp 107-154.

9. DeGeare VS, **Stone GW** and Grines CL. Primary Catheter-Based Reperfusion in Acute Myocardial Infarction – A Protagonist's View. In Press "Heart Disease: Clinical Update", Eugene Braunwald, Ed., Saunders, 1999.

10. Linnemeier TJ, and **Stone GW,** Eds. Applications in Imaging: Cardiac Interventions. Anderson Publishing, Ltd. Ocean, NJ, 1998.

11. **Stone GW.** Percutaneous Transluminal Myocardial Revascularization (PTMR) – The Eclipse System and Studies. In: Handbook of Myocardial Revascularization and Angiogenesis, Kornowski R, Epstein SE and Leon MB, Eds, Martin Dunitz, London, 1999.

12. Lansky AJ, **Stone GW**. Percutaneous Intervention for Acute Coronary Syndromes. In: The Manual of Interventional Cardiology, 3rd ed., edited by Safian RD and Freed MS, *Physicians' Press,* Birmingham, MI, 2001, pp 85 - 140.

13. Dangas G, DeGeare VS Grines CL **Stone GW**. Interventional Procedures in Acute Myocardial Infarction. Cardiovascular Therapeutics, A Companion to Braunwald' s Heart Disease, 2nd edition, edited by Elliott Antman, W. B. Saunders, Phila, PA, 2002, pp 919-936.

14. Dangas G, **Stone GW.** Stenting in Acute Myocardial Infarction. In press in: Coronary Stenting, ed. by Igor Palacios and Sheldon Goldberg.

15. **Stone GW.** The Primary Angioplasty in Myocardial Infarction Studies: An Overview. In press in: Thrombolytic Therapy, ed. by Gerald C. Timmis, Futura Publishing Co., Armonk, NY, 2000.

16. **Stone GW,** Grines CL. Primary Angioplasty in Acute Myocardial Infarction: Comparative Analysis with Thrombolytic Therapy. Interventional Cardiovascular Medicine: Principles and Practice, 2nd ed. Edited by Richard S. Stack, Gary S. Roubin, and William W. O'Neill. Churchill Livingston, Philadelphia, PA, 2001, pp 227-300.

17. **Stone GW,** Grines CL. Beyond Primary PTCA: New Devices in Acute Myocardial Infarction. Interventional Cardiovascular Medicine: Principles and Practice, 2nd ed. Edited by Richard S. Stack, Gary S. Roubin, and William W. O'Neill. Churchill Livingston, Philadelphia, PA, 2001, pp 301-379.

18. **Stone GW,** Kandzari DE, Grines CL. Integrating Coronary Stents and Glycoprotein IIb/III Inhibitors into a Mechanical Reperfusion Strategy: The CADILLAC and ADMIRAL Trials. In: Primary Angioplasty in Acute Myocardial Infarction. Edited by Tcheng JE. Humana Press, Inc., Totawa, NJ, 2002, pp 139-168.

19. Dangas G and **Stone GW.** Stenting in Acute Myocardial Infarction. In press in: New Device Angioplasty. Edited by Palacios I and Goldberg S. 2002

20. Colombo A and **Stone GW**. The Boston Scientific TAXUS Trials. In press in: Handbook of Drug Eluting Stents. Edited by Patrick Serruys and Anthony Gershlick. Martin Dunitz, London, 2002.

21. **Stone GW,** Associate Editor. The Encyclopedia of Clinical Trials, John Wiley and Sons, In Press.

22. Colombo A and **Stone GW**. The Boston Scientific TAXUS Trials. In press in: Handbook of Drug Eluting Stents. Edited by Patrick Serruys and Anthony Gershlick. Martin Dunitz, London, 2005.

23. **Stone GW.** Coated Stents-Overview – Paclitaxel. In press in: Strategic Approaches in Coronary Intervention. Edited by Stephen G. Ellis and David R. Holmes. Lippincott Williams & Wilkins, Philadelphia, PA, 2005.

24. **Stone GW.** Coronary Stenting. In Cardiac Catheterization, Angiography and Intervention.7th Edition. Edited by Donald S. Baim, Lippincott Williams & Wilkins, Philadelphia, PA, 2006;pp 492-542.

25. Crouch ED, Ohman ME, **Stone GW.** Intravenous direct thrombin inhibition: acute coronary syndromes and heparin-induced thrombocytopenia. In press in: Therapeutic Strategies in Thrombosis, Ed. By S De Caterina, RD Kristensen, and DJ Moliterno, 2006. Atlas Medical Publishing, Oxford, UK, pp 77-106.

26. Kodali S and **Stone GW.** Tips and Tricks in Acute Myocardial Infarction. In: Problem-oriented Approach in Interventional Cardiology. Ed. By Antonio Colombo, 2006.

27. **Stone GW,** and Kirtane A. Bare metal and drug-eluting coronary stents. In: Textbook of Interventional Cardiology, 6th Edition. Ed by Eric J. Topol and Paul S. Teirstein, Elsevier Saunders, Phila., PA, 2012:pp 171-196.

28. Gujja K, Narula A, **Stone GW** and Kirtane AJ. Efficacy and Safety of Bare Metal and Drug-Eluting Stents. In Coronary Stenting, a companion to the Textbook of Interventional Cardiology, 6th Edition. Ed by Eric J. Topol and Paul S. Teirstein, Elsevier Saunders, Phila., PA, 2012:pp 81-92.

29. Farooq V, Serruys PW, **Stone GW,** Virmani R, Chieffo A, Fajadet J. Left main coronary artery disease. In Percutaneous Interventional Cardiovascular Medicine. Editors: E.Eeckhout, P.W.Serruys, W.Wijns, A.Vahanian, M.van Sambeek, R.de Palma. PCR Publishing/Europa Edition, Toulouse, France, 2012.

30. Kirtane AJ and **Stone GW.** Coronary stenting. In Grossman and Baim's Cardiac Catheterization, Angiography and Intervention. Ed. M Moscucci. Wolters Kluwer, Lippincott Williams & Wilkins, Phila., PA, 2013;pp 710-759.

31. Genereux P and **Stone GW.** Percutaneous Coronary Intervention for Unprotected Left Main Disease. Ed. Bhatt DL: Interventional Cardiology—A Companion to Braunwald's Heart Disease. 2015: In press.

32. Palmerini T, Kirtane A, and **Stone GW.** Bare Metal and Drug-Eluting Coronary Stents. Topol EJ. Textbook of Interventional Cardiology, 7e. 2015: In press.

33. Sergie Z, Yu J, Mehran R, **Stone GW.** Bleeding - Significance, Prevention and Management for the Interventional Cardiologist. Kapadia S, Cura F, Chew D,

L'Allier P, Roffi M, and Tuzcu M. Global Textbook of Interventional Cardiology. 2015: In press.

34. Brener S and **Stone GW.** Stent Thrombosis. In press is: Interventional Cardiology, 2nd edition. Ed by King SB, Yenung AC, Samady H and Fearon W. McGraw Hill Education, 2017.

Publications

1. Lands WEM, Sauter J, **Stone GW**. Oxygen requirement for prostaglandin biosynthesis. Prostaglandin Medicine 1(2):117-120, 1978.

2. Platia EW, Berdoff R, **Stone GW**, Reid PR. Comparison of acebutolol and propranolol therapy for ventricular arrhythmias. J Clin Pharm 25:130-137, 1985.

3. Ryman KS, Kubo SH, Lystash J, **Stone GW**, Cody RJ. Effect of nicardipine on rest and exercise hemodynamics in chronic congestive heart failure. Am J Cardiol 58:583-588, 1986.

4. **Stone GW**, Kubo SH, Cody RJ. Adverse influence of baroreceptor dysfunction on upright exercise in congestive heart failure. Am J Med 80:799-802, 1986.

5. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. A randomized trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty. Cath and Cardiovasc Diagn 18:227-31, 1989.

6. **Stone GW**, Hartzler GO. Spontaneous reversible spasm in an internal mammary artery graft causing acute myocardial infarction. Am J Cardiol 64:822-23, 1989.

7. **Stone GW**, Spaude S, Ligon RW, Hartzler GO. Usefulness of percutaneous transluminal coronary angioplasty in alleviating silent ischemia in patients with absent or minimal painful myocardial ischemia. Am J Cardiol 64:560-564, 1989.

8. **Stone GW**, Ligon RW, Rutherford BD, McConahay DR, Hartzler GO. Acute outcome and long term follow-up following coronary angioplasty in the young patient: an 8 year experience. Am Heart J 118:873-877, 1989.

9. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. Direct coronary angioplasty in patients with acute myocardial infarction: Outcome in patients with single vessel disease. J Am Coll Cardiol 15:534-543, 1990.

10. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. Procedural outcome of angioplasty for total coronary artery occlusion: an analysis of 971 lesions. J Am Coll Cardiol 15:849-856, 1990.

11. **Stone GW**, O'Kell R, Good TH, Hartzler GO. Lipomatous hypertrophy of the interatrial septum: diagnosis by percutaneous transvenous biopsy. Am Heart J 119:406-8, 1990.

12. **Stone GW**, Griffin B, Shah PK, Berman DS, Siegal RJ, Cook SL, Maurer G. Prevalence of unsuspected mitral regurgitation and left ventricular diastolic

dysfunction in coronary artery disease and acute pulmonary edema associated with normal or depressed left ventricular systolic function. Am J Cardiol 67:37-41, 1991.

13. Grines CL, Browne KF, Marco J, Rothbaum D, **Stone GW**, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vliestra R, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. New England Journal of Medicine 1993;328:673-9.

14. Wilson WSW and **Stone GW.** Late Results of Percutaneous Transluminal Coronary Angioplasty of Two or More Major Native Coronary Arteries. American Journal of Cardiology: 1994;73:1041-6.

15. **Stone GW.** Primary angioplasty in myocardial infarction. Cardio Intervention 1993;3:11-20.

16. **Stone GW**, Grines CL. Is there a role for percutaneous transluminal coronary angioplasty without antecedent thrombolysis in the treatment of acute myocardial infarction? Cardiol Rev 1994;2:2, 98-111.

17. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Predictors of in-hospital and 6 month outcome after acute myocardial infarction in the reperfusion era: The Primary Angioplasty in Myocardial Infarction (PAMI) Trial. J Am Coll Cardiol 1995;25:370-7.

18. **Stone GW.** The PTCA-CABG Trials - what have we learned? Cardio Intervention 1994;4-1:2-5.

19. **Stone GW.** What should have been taught in your angioplasty fellowship (Part 1). Cardio Intervention 1994;4-3:2-3.

20. **Stone GW.** What should have been taught in your angioplasty fellowship (Part 2). Cardio Intervention 1994;4-4:3-4.

21. **Stone GW.** Intracoronary Ultrasound Imaging. Therapeutic Research 1994;15:53-71.

22. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Implications of Recurrent Ischemia After Reperfusion Therapy in Acute Myocardial Infarction: A Comparison Of Thrombolytic Therapy and Primary Coronary Angioplasty. J Am Coll Cardiol 1995;26:66-72.

23. **Stone GW.** Intravascular Ultrasound Imaging During Coronary Intervention: Indispensable Adjunct or Unnecessary Expense? Cardio Intervention 1994;4-2:2-3.

24. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Comparison of In-Hospital Outcome in Men Versus Women Treated by Either Thrombolytic Therapy or Primary Coronary Angioplasty for Acute Myocardial Infarction. Am J Cardiol 1995;75:987-992.

25. **Stone GW**. Spontaneous Coronary Dissection Resulting in Acute Myocardial Infarction: Successful Treatment by Primary Angioplasty. Cathet & Cardiov Diagn 1996;38:62-66.

26. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Influence of Acute Myocardial Infarction Location on In-Hospital and Late Outcome After Primary Percutaneous Transluminal Coronary Angioplasty versus Tissue Plasminogen Activator. Am J Cardiol 1996;78:19-25.

27. **Stone GW,** St. Goar F, Linnemeier TJ. Initial Clinical Experience with a Novel Low-Profile Integrated Ultrasound-Angioplasty Catheter. Cath & Cardiov Diag 1996;38:303-307.

28. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Outcome of Different Reperfusion Strategies in Patients with Former Contraindications to Thrombolytic Therapy: A Comparison of Primary Angioplasty and Tissue Plasminogen Activator. Cath & Cardiov Diag 1996;39:333-339.

29. **Stone GW.** Primary Coronary Angioplasty in High Risk Patients with Acute Myocardial Infarction. J Inv Cardiol 1995;7:12F-21F.

30. **Stone GW.** Rotational Atherectomy for Stent Restenosis - Role of Intracoronary Ultrasound Guidance. Cath & Cardiov Diag 1996;3:73-77.

31. O'Keefe J, **Stone GW**, McCallister BD., Maddex C, Ligon R, Kacich RL, Kahn J, Cavero PG, Hartzler GO, McCallister BD. Combination Lovastatin and Probucol for the Prevention of Restenosis After Coronary Angioplasty. Am J Cardiology 1996;77:649-653.

32. **Stone GW**, Hodgson JMcB, St. Goar FG, Frey A, Mudra H, Sheehan H, and Linnemeier TJ. Improved Procedural Results of Coronary Angioplasty with Intravascular Ultrasound Guided Balloon Sizing: The CLOUT Pilot Trial. Circulation 1997;95:2044-2052.

33. **Stone GW,** Brodie BR, Morice MC, Griffin JJ, St. Goar FG, O'Neill WW and Grines CL. Primary Stenting in Acute Myocardial Infarction: Design and Interim Results of the PAMI Stent Pilot Trial. J Inv Cardiol 1997;9(suppl B):21B-30B.

34. Grines CL, **Stone GW,** O'Neill WW. Establishing a Program and Performance of Primary PTCA - The PAMI Way. J Inv Cardiol 1997;;9(suppl B):44B-52B.

35. **Stone GW**, Grines CL, Rothbaum D, Browne KF, O'Keefe J, Overlie P, Donohue B, Chelliah N, Vlietstra R, Catlin T, and O'Neill WW. Analysis of the relative costs and effectiveness of primary angioplasty compared to tissue plasminogen activator: The Primary Angioplasty in Myocardial Infarction Trial. J Am Coll Cardiol 1997;29:901-907.

36. **Stone GW,** Marsalese D, Brodie BR, Griffin JJ, Donohue B, Costantini C, Balestrini C, Wharton T, Esente P, Spain M, Moses J, Nobuyoshi M, Ayres M, Jones D, Mason D, Sachs D, Grines L, O'Neill WW, Grines CL. A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. J Am Coll Cardiol 1997;29:1459-1467.

37. **Stone GW,** St. Goar FG, Hodgson JMcB, Fitzgerald PJ, Alderman A, Yock PY, Coverdale J and Linnemeier TJ. Analysis of the relation between stent implantation pressure and expansion. Am J Cardiol 1999;83:1397-1400.

38. **Stone GW**, Grines CL, O'Neill WW. Primary coronary angioplasty versus thrombolysis. N Engl J Med 1997;337:1168-1170.

39. **Stone GW**. Primary Angioplasty in Acute Myocardial Infarction. Interventional Cardiology Newsletter 1997;5(1):1-10. Elsevier Science Inc., 1997.

40. **Stone GW**, de Marchena E, Dageforde D, Foschi A, Muhlestein JB, McIvor M, Rizik D, Vanderlaan R, McDonnell J. A prospective, randomized, multicenter comparison of laser facilitated balloon angioplasty versus stand alone balloon angioplasty in patients with obstructive coronary artery disease. J Am Coll Cardiol 1997;30:1714-1721.

41. Moses J, Moussa I, **Stone GW.** Clinical trials of coronary stenting in acute myocardial infarction. J Intervent Cardiol 1997;10:225-229.

42. Topaz O, McIvor M, **Stone GW,** Krucoff MW, Perin EC, Foschi AE, Sutton J, Nair R, DeMarchena E. Acute results, complications and effect of lesion characteristics on outcome with the solid-state, mid-infrared laser angioplasty system: final multi-center registry report. Lasers in Surgery and Medicine 1998;22:228-239.

43. Grines CL, Marsalese D, Brodie B, Griffin J, Donohue B, Costantini C, Balestrini C, **Stone GW,** Wharton T, Esente P, Spain M, Moses J, Nobuyoshi M, Ayres M, Jones D, Mason D, Sachs D, Grines LL, O'Neill W. Safety and cost effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. J Am Coll Cardiol 1998;31:967-972.

44. **Stone GW**, Brodie BR, Griffin JJ, Morice MC, Costantini C, St. Goar FG, Overlie PA, Popma JJ, McDonnell J, Jones D, O'Neill WW, Grines CL. A prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30 day results of the PAMI Stent Pilot Trial. J Am Coll Cardiol 1998;31:23-30.

45. **Stone GW.** Stenting in Acute Myocardial Infarction: Observational Studies and Randomized Trials - 1998. J Inv Cardiol 1998;10:16A-26A.

46. **Stone GW.** Stenting and Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction: An Introduction to the CADILLAC Trial. J Inv Cardiol 1998;10:36B-47B.

47. Grines CL, **Stone GW**, O'Neill WW. The PAMI (Primary Angioplasty in Myocardial Infarction) Studies: An overview. J Intervent Cardiol 1998;11:87-99.

48. Grines CL, Marsalese DL, Brodie B, Griffin J, Donohue B, Costantini CR, Balestrini C, **Stone G,** Wharton T, Esente P, Spain M, Moses J, Nobuyoshi M, Ayres M, Jones D, Mason D, Sachs D, Grines LL, O'Neill W. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol. 1998;31(5):967-72.

49. **Stone GW**, Brodie BR, Griffin JJ, Morice MC, Costantini C, St. Goar FG, Overlie PA, Popma JJ, McDonnell J, Jones D, O'Neill WW, Grines CL. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: The Primary Angioplasty in Myocardial Infarction (PAMI) Stent Pilot Trial. Circulation 1999;99:1548-1554.

50. **Stone GW.** Primary stenting in acute myocardial infarction. The promise and the proof. Circulation 1998;97:2482-2485.

51. Serruys PW, Grines CL, **Stone GW,** et al. Stent implantation in acute myocardial infarction using a heparin-coated stent: A pilot study as a preamble to a randomized trial comparing balloon angioplasty and stenting. J Intervent Cardiovasc Interventions 1998;1:19-27.

52. **Stone GW.** Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes. Am J Cardiol 1999;83:16E-20E.

53. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Kornowski R, Hong MK, Pichard AD, Satler LF, Kent KM, **Stone GW,** Leon MB. Angiographic patterns of in-stent restenosis. Classification and implications for long-term outcome. Circulation 1999;100(18):1872-8.

54. Fuchs S, Kornowski R, Mehran R, Satler LF, Pichard AD, Kent KM, **Stone GW,** Leon MB. Prognostic value of cardiac troponin I levels following catheter-based coronary interventions. J Am Coll Cardiol 1999;34(6):1704-10.

55. Grines CL, Cox D, **Stone GW,** Garcia E, Mattos LA, Giambartolomei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ, O'Neill WW, Morice MC. A randomized trial of primary angioplasty compared to heparin-coated stent implantation for acute myocardial infarction. N Engl J Med. 1999;341(26):1949-56.

56. Dangas G and **Stone GW.** Primary Angioplasty in Acute Myocardial Infarction – The United States Experience. Seminars in Interventional Cardiology 1999;4:21-34.

57. Gruberg L, Lansky AJ, Dangas G, **Stone GW**. IIb/IIIa Receptor Inhibitors During Primary Angioplasty for Acute Myocardial Infarction. Current Interventional Cardiology Reports 1999 Dec;1(4):359-367.

58. Nunn C, O'Neill WW, Rothbaum D, **Stone GW,** O'Keefe J, Overlie P, Donohue B, Grines L, Browne K, Vlietstra R, Catlin T, Grines CL. Long-term outcome following primary angioplasty: Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. J Am Coll Cardiol 1999;33:640-646.

59. **Stone GW**, Grines CL, Brodie BR, Griffin JJ, Morice MC, Costantini C, Overlie PA, Linnemeier TJ, Moses J, and O'Neill WW. Improved short-term outcomes of primary coronary stenting compared to primary balloon angioplasty at experienced centers: The PAMI study group experience. J Intervent Cardiol 1999;12:101-107.

60. Gruberg L, Mehran R, Dangas G, Hong MK, Mintz GS, Kornowski R, Lansky AJ, Kent KM, Pichard AD, Satler LF, **Stone GW,** Leon MB. Effect of plaque debulking and stenting on short- and long-term outcomes after revascularization of chronic total occlusions. J Am Coll Cardiol 2000;35(1):151-6.

61. Gruberg L, Hong MK, Mehran R, Mintz GS, Kent KM, Pichard AD, Satler LF, Wu H, Greenberg A, **Stone GW,** Leon MB. Optimally deployed stents in the treatment of restenotic versus de novo lesions. Am J Cardiol 2000 Feb 1;85(3):333-7.

62. **Stone GW,** Brodie BR, Griffin JJ, et al. The role of cardiac surgery in the hospital phase management of patients treated with primary angioplasty for acute myocardial infarction. Am J Cardiol 2000;85(11):1292-1296.

63. Kornowski R, Bhargava B, Fuchs S, Lansky AJ, Satler LF, Pichard AD, Kent KM, Mehran R, **Stone GW,** Leon MB. Procedural results and late clinical outcomes following percutaneous interventions using long (≥25mm) versus short (<20mm) stents. J Am Coll Cardiol. 2000;35(3):612-8.

64. DeGeare VS, **Stone GW,** Grines L, Brodie BR, Cox DA, Garcia E, Wharton TP, Boura JA, O'Neill WW, Grines CL. Angiographic and clinical predictors of increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing primary angioplasty: A pooled analysis of the PAMI Trials. Am J Cardiol 2000;86:30-34.

65. Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Satler LF, Kent KM, **Stone GW,** Leon MB. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions. An intravascular ultrasound study of 2,256 patients. Circulation 2000 Feb 15;101(6):604-10.

66. Dangas G, Mintz GS, Mehran R, Lansky AJ, Kornowski R, Pichard AD, Satler LF, Kent KM, **Stone GS,** and Leon MB. Preintervention Arterial Remodeling as an Independent Predictor of Target-Lesion Revascularization After Nonstent Coronary Intervention : An Analysis of 777 Lesions With Intravascular Ultrasound Imaging. Circulation 1999;99:3149-3154.

67. Kornowski R, Bhargava B, Fuchs S, Lansky AJ, Satler LF, Pichard AD, Hong MK, Kent KM, Mehran R, **Stone GW,** Leon MB. Procedural results and late clinical outcomes after percutaneous interventions using long (> or = 25mm) versus short (< 20mm) stents. J Am Coll Cardiol. 2000;35(3):612-8.

68. **Stone GW,** Brodie BR, Griffin JJ, Grines L, Boura J, O'Neill WW, Grines CL. Clinical and angiographic outcomes in patients with previous coronary artery bypass graft surgery treated with primary balloon angioplasty for acute myocardial infarction. Second Primary Angioplasty in Myocardial Infarction Trial (PAMI-2) Investigators. J Am Coll Cardiol. 2000;35(3):605-11.

69. Gruberg L, Hong MK, Mehran R, Mintz GS, Kornowski R, Lansky AJ, Kent KM, Pichard AD, Satler LF, Dangas G, Wu H, **Stone GW,** Leon MB. In-hospital and long-term results of stent deployment compared with balloon angioplasty for treatment of narrowing at the saphenous vein graft distal anastomosis site. Am J Cardiol. 1999;84(12):1381-4.

70. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Kent KM, Satler LF, **Stone GW,** Leon MB. Creatine kinase-MB enzyme elevation following

successful saphenous vein graft intervention is associated with late mortality. Circulation. 1999;100(24):2400-5.

71. Gruberg L, Dangas G, Mehran R, Hong MK, Waksman R, Mintz GS, Kent KM, Pichard AD, Satler LF, Lansky AJ, **Stone GW,** Leon MB. Percutaneous revascularization of the internal mammary artery graft: Short- and Long-Term Outcomes. J Am Coll Cardiol 2000;35:944-8.

72. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Kent KM, Satler LF, **Stone GW,** Leon MB. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation. 1999 Dec 14;100(24):2400-5.

73. Saucedo JF, Mehran R, Dangas G, Hong MK, Lansky A, Kent KM, Satler LF, Pichard AD, **Stone GW,** Leon MB. Long-term clinical events following creatine kinase--myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol. 2000;35:1134-41.

74. Mehran R, Dangas G, Mintz GS, Waksman R, Abizaid A, Satler LF, Pichard AD, Kent KM, Lansky AJ**, Stone GW,** Leon MB. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: Comparative mechanisms and results. Circulation. 2000;101(21):2484-2489.

75. Ahmed JM, Hong MK, Mehran R, Mintz GS, Lansky AJ, Pichard AD, Satler LF, Kent KM, Wu H, **Stone GW,** Leon MB. Comparison of debulking followed by stenting versus stenting alone for saphenous vein graft aortoostial lesions: immediate and one-year clinical outcomes. J Am Coll Cardiol. 2000;35(6):1560-8.

76. Ahmed JA, Dangas G, Lansky AJ, Mehran R, Hong MK, Mintz GS, Waksman R, Pichard AD, Satler LF, Kent KM, **Stone GW,** Leon MB. Influence of gender on early and late clinical outcomes after saphenous vein graft stenting. Am J Cardiol 2001;87:401-405.

77. DeGeare VS, **Stone GW,** Grines CL. Interventional procedures in acute myocardial infarction. Am Heart J 2001;141:15-25.

78. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky A, Kent KM, Pichard AD, Satler LF, **Stone GW,** Leon MB. Comparison of time course of target lesion revascularization following successful saphenous vein graft angioplasty versus successful native coronary angioplasty. Am J Cardiol 2000 Jan 15;85(2):256-8.

79. Dangas G, Mintz GS, Mehran R, Ahmed JM, Lansky AJ, Pichard AD, Satler LF, Kent KM, **Stone GW,** Leon MB. Stent implantation neutralizes the impact of preintervention arterial remodeling on subsequent target lesion revascularization. Am J Cardiol. 2000 Aug 15;86(4):452-5.

80. Mehran R, Dangas G, Abizaid A, Lansky AJ, Mintz GS, Pichard AD, Satler LF, Kent KM, Waksman R, **Stone GW,** Leon MB. Treatment of focal in-stent restenosis with balloon angioplasty alone vs. stenting: acute and long-term results. Am Heart J 2001;141:610-614.

81. Gruberg L, Dangas G, Leon MB, **Stone GW.** Platelet glycoprotein IIb/IIIa receptor antagonists during primary angioplasty and stenting for acute myocardial infarction. Cardiol Int 2000;1:30-36.

82. Ahmed JM, Hong MK, Mehran R, Dangas G, Mintz GS, Pichard AD, Satler LF, Kent KM, Wu H**, Stone GW,** Leon MB. Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting. J Am Coll Cardiol. 2000;36(4):1186-93.

83. Kornowski R, Fuchs S, Hong MK, Mehran R, Satler LF, Pichard AD, Kent KM, **Stone GW,** Leon MB. Prognostic value of recurrent episodes of creatine kinase-MB elevation following repeated catheter-based coronary interventions. Catheter Cardiovasc Interv.2000 Oct;51(2):131-7.

84. Fuchs S, Kornowski R, Mehran R, Gruberg L, Satler LF, Pichard AD, Kent KM, **Stone GW,** Leon MB. Clinical outcomes following rescue administration of abciximab in patients undergoing percutaneous coronary angioplasty. J Inv Cardiol. 2000 Oct;12(10):497-501.

85. Dangas G, Mehran R, Lansky AJ, Waksman R, Satler LF, Pichard AD, Kent KM, Mintz GS, **Stone GW,** Leon MB. Acute and long-term results of treatment of diffuse in-stent restenosis in aortocoronary saphenous vein grafts. Am J Cardiol. 2000 Oct 1;86(7):777-9.

86. Mattos LA, Grines CL, Cox D, Sousa JE, Costantini C, **Stone GW,** Morice MC, O'Neill W, Garcia E, Boura J. A comparative analysis of primary stenting and optimal balloon coronary angioplasty in acute myocardial infarction. Six month results from the STENT PAMI trial. Arq Bras Cardiol 2000;75:508-514.

87. Dangas G, Mehran R, Abizaid AS, Curry BH, Lansky AJ, Kent KM, Pichard AD, Satler LF, Paliou M, **Stone GW,** Leon MB. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. Am J Cardiol. 2001;87:470-472.

88. Kobayashi Y, Teirstein PS, Linnemeier TJ, **Stone GW,** Leon MB, Moses JW. Rotational atherectomy (stentablation) in a lesion with stent underexpansion due to heavily calcified plaque. Catheter Cardiovasc Interv 2001;52:208-211.

89. Anderson KM, Califf RM, **Stone GW,** et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2001;37(8):2059-65.

90. **Stone GW,** Tumlin JE, Mathur VS, Madyoon H, Lepor NS, McCollough P, Gupta S, O'Neill WW. Design and Rationale of CONTRAST - A Prospective, Randomized Placebo-Controlled Trial of Fenoldopam Mesylate for the Prevention of Radiocontrast Nephropathy. Reviews in Cardiovascular Medicine 2001;2 (Suppl 1):S31-S36.

91. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky AJ, Kent KM, Pichard AD, Satler LF, **Stone GW,** Leon MB. Are we making progress with percutaneous saphenous vein graft treatment? Comparison of 1990-94 and 1995-98 results. J Am Coll Cardiol 2001 Jul;38(1):150-4.

92. **Stone GW.** Glycoprotein IIb/IIIa inhibitors: More different than alike? Cathet Cardiovasc Interv 2001 Jul;53(3):304-7.

93. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, **Stone GW,** DiBattiste PM, Demopoulos L. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001 Jun 21;344(25):1888-94.

94. Gruberg L, Mehran R, Waksman R, Dangas G, Fuchs S, Wu H, Kent KM, Pichard AD, Satler LF, **Stone GW,** Leon MB. Creatine kinase-MB fraction elevation after percutaneous coronary intervention in patients with chronic renal failure. Am J Cardiol. 2001 Jun 15;87(12):1356-60.

95. Dangas G, Mehran R, Abizaid AS, Curry BH, Lansky AJ, Kent KM, Pichard AD, Satler LF, Paliou M, **Stone GW,** Leon MB. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. Am J Cardiol. 2001 Feb 15;87(4):470-2.

96. **Stone GW,** St. Goar FSG, Taussig A, Power JA, Kosinski E, Shawl F. Safety and efficacy of hybrid percutaneous transmyocardial laser revascularization and angioplasty in patients with lesions at high risk for restenosis – results of a phase I feasibility study. In Am Heart J 2001;142(4):679-83.

97. **Stone GW,** Cox D, Garcia E, Brodie BR, Morice MC, Griffin MD, Matos MD, Lansky AJ, O'Neill WW, Grines CL. TIMI-3 flow prior to mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: Analysis from the PAMI Trials. Circulation 2001;104(6):636-41.

98. **Stone GW,** Mehran R, Dangas G, Lansky AJ, Konowski R, Leon MB. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001;104(6):642-7.

99. Ferguson JL, Cohen M, Freedman RJ, **Stone GW,** Miller MF, Joseph DL, Ohman M. A The current practice of intra-aortic balloon counterpulsation: Results from the Benchmark Registry: J Am Coll Cardiol 2001;38:1456-62.

100. Lansky AJ, Dangas G, Mehran R, Desai KJ, Mintz GS, Wu H, Fahy M, **Stone GW,** Waksman R, Leon MB. Quantitative angiographic methods for appropriate endpoint analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. J Am Coll Cardiol 2002;39(2):274-80.

101. Cohen M, Ferguson JJ, Freedman RJ, Miller MF, Reddy RC, Graeber GM, Ohman EM, **Stone GW,** Joseph DL. Comparison of Outcomes After 8 versus 9.5 French Size Intra-Aortic Balloon Counterpulsation Catheters Based on 9332 Patients in the Prospective Benchmark^{tm} Registry. Cath Cardiovasc Interv 2002;56:200-6.

102. Cohen DJ, Taira DA, Berezin R, Eigelshoven M, Cox DA, Brodie BR, **Stone GW,** Grines CL. Cost-effectiveness of coronary stenting in acute myocardial infarction: Results from the Stent PAMI trial. Circulation 2001;104(25):3039-45.

103. Angeja BG, Gibson CM, Chin R, Frederick PD, Every NR, Ross AM, **Stone GW,** Barron HV. Predictors of door-to-balloon delay in primary angioplasty. Am J Cardiol 2002;89:1156-61.

104. Rinfret S, Grines CL, Cosgrove RS, Ho KK, Cox DA, Brodie BR, Morice MC, **Stone GW,** Cohen DJ. Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One year results from the STENT-PAMI trial. J Am Coll Cardiol 2001;38:1614-21.

105. Mattos LA, Grines CL, Sousa JE, Sousa AG, **Stone GW,** Cox D, Garcia E, Morice MC, O'Neill W, Grines L, Boura J. One-year follow-up after primary coronary intervention for acute myocardial infarction in diabetic patients. A substudy of the STENT PAMI trial. Arq Bras Cardiol. 2001 Dec;77(6):556-61.

106. **Stone GW,** Cox DA, Low R, et al. Safety and efficacy of a novel device for treatment of thrombotic and atherosclerotic lesions in native coronary arteries and saphenous vein grafts. Results of the phase-I multicenter X-TRACT feasibility study. Catheter Cardiovasc Interv. 2003;58:419-27.

107. **Stone GW,** Peterson M, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in AMI. J Am Coll Cardiol 2002;39:591-7.

108. Grube E, Schofer J, Webb J, Schuler G, Colombo A, Sievert H, Gerckens U, and **Stone GW.** Evaluation of a balloon occlusion and aspiration system for

protection from distal embolization during stenting in saphenous vein grafts. Am J Cardiol 2002;89:941-5.

109. Dangas G, Mehran R, Kokolis S, Feldman D, Satler LF, Pichard AD, Kent KM, Lansky AJ, **Stone GW,** Leon MB. Vascular complications after percutaneous interventions following hemostasis with manual compression versus arteriotomy closure devices. J Am Coll Cardiol 2001;38:638-41.

110. El-Omar MM, Dangas G, and **Stone GW.** A comparison of tirofiban and abciximab in patients undergoing coronary stent implantation: rationale, design and results of the TARGET trial. Curr Interv Cardiol Rep 2001;3:336-348.

111. Ashby DT, Dangas G, Mehran R, Lansky AJ, Fahy MP, Iakovou I, Satler LF, Pichard AD, Kent KM**, Stone GW,** Leon MB. Comparison of 1-year outcomes after percutaneous coronary intervention among current smokers, ex-smokers and non-smokers. Am J Cardiol 2002 Jan 15;89(2):221-4.

112. **Stone GW,** Teirstein PS, Rubenstein P, et al. A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecanalizable chronic total occlusions. J Am Coll Cardiol 2002;39:1686-91.

113. Dangas G, Mehran R, Fahy M, Leon MB, **Stone GW.** Complications of vascular closure devices—not yet evidence based. Reply**.** J AM Coll Cardiol 2002;39:1706-1708.

114. Brodie BR, **Stone GW,** Morice MC, Cox DA, Garcia E, Mattos LA, Boura J, O'Neill WW, Stuckey TD, Milks S, Lansky AJ, Grines CL. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). Am J Cardiol 2001;88:1085-90.

115. Kobayashi Y, Moussa I, Dangas G, Mehran R, Desai K, Adamian M, Collins M, Kreps E, **Stone GW,** Leon MB, Moses JW. Acute angiographic and clinical results of the NIR w/SOX stent. J Invasive Cardiol. 2002 Jan;14(1):14-8.

116. Cohen DJ, Taira DA, Berezin R, Cox DA, Morice MC, **Stone GW,** Grines CL. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation. 2001 Dec 18;104(25):3039-45.

117. **Stone GW.** The Bent Stent [commentary]. J Inv Cardiol 2001;14: 54-56.

118. **Stone GW,** Ohman ME, Miller MF, Joseph DJ, Christenson JT, Cohen M, Urban PM, Reddy RC, Freedman RJ, Staman KL, Ferguson JJ. Contemporary Utilization and Outcomes of Intra-aortic Balloon Counterpulsation in Acute

Myocardial Infarction: The Benchmark Registry. J Am Coll Cardiol 2003;41:1940-5.

119. Gruberg L, Dangas G, Mehran R, Mintz GS, Kent KM, Pichard AD, Satler LF, Lansky AJ, **Stone GW,** Leon MB. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. Catheter Cardiovasc Interv 2002 Jan;55(1):66-72.

120. Ashby DT, Dangas G, Mehran R, Lansky AJ, Fahy MP, Iakovou I, Satler LF, Pichard AD, Kent KM, **Stone GW,** Leon MB. Comparison of one-year outcomes after percutaneous coronary intervention among current smokers, ex-smokers, and nonsmokers. Am J Cardiol. 2002 Jan 15;89(2):221-4.

121. Lansky AJ, Dangas G, Mehran R, Desai KJ, Mintz GS, Wu H, Fahy M, **Stone GW,** Waksman R, Leon MB. Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. J Am Coll Cardiol. 2002;39:274-80.

122. **Stone GW,** Grines CL, Cox DA Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ, for the Controlled Abciximab in Device Investigation to Lower Late Angioplasty Complications (CADILLAC) investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.

123. Dangas G, Mehran R, Feldman D, Stoyioglou A, Pichard AD, Kent KM, Satler LF, Fahy M, Lansky AJ**, Stone GW,** Leon MB. Postprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention. Am J Cardiol 2002;89(5):586-9.

124. **Stone GW,** Moliterno DJ, Bertrand M, et al. Impact of clinical syndrome acuity on the differential response to two glycoprotein IIb/IIIa Inhibitors in patients undergoing coronary stenting: The TARGET trial. Circulation 2002;105:2347-54.

125. Iakovou I, Dangas G, Mehran R, Lansky AJ, Kobayashi Y, Adamian M, Polena S, Collins MB, Roubin GS, **Stone GW,** Leon MB, Moses JW. Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors. Am J Cardiol. 2002;89:976-9.

126. Ashby DT, Dangas G, Mehran R, Lansky AJ, Narasimaiah R, Iakovou I, Polena S, Satler LF, Pichard AD, Kent KM, **Stone GW,** Leon MB. Comparison of clinical outcomes using stents versus no stents after percutaneous coronary intervention for proximal left anterior descending versus proximal right and left circumflex coronary arteries. Am J Cardiol. 2002;89:1162-6.

127. Kipshidze NN, Kim HS, Iversen P, Yazdi HA, Bhargava B, New G, Mehran R, Tio F, Haudenschild C, Dangas G, **Stone GW,** Iyer S, Roubin GS, Leon MB, Moses JW. Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J Am Coll Cardiol 2002;39:1686-91.

128. Grube E, Colombo A, Hauptmann A, Londero H, Reifart N, Gerckens U, and **Stone GW**. Multicenter experience with a novel distal protection filter during carotid artery stent implantation. Catheter Cardiovasc Interv 2003;58:139-46.

129. Lansky AJ, Mehran R, Dangas G, Desai K, Costantini-Ortiz C, Cristea E, New G, Negoita M, **Stone GW**, Leon MB. New-device angioplasty in women: clinical outcome and predictors in a 7,372-patient registry. Epidemiology 2002;13:S46-S51.

130. **Stone GW.** Anticipating the Era of Drug-Eluting Stents. Cath Lab Digest 2002;10:1-12.

131. **Stone GW,** Rogers C, Ramee S, White C, Kuntz RE, Popma JJ, George J, Almany S, Bailey S. Distal filter protection during saphenous vein graft stenting: technical and clinical correlates of efficacy. J Am Coll Cardiol 2002;40:1882-8.

132. Ashby DT, **Stone GW,** Moses JW. Acute myocardial infarction and cardiogenic shock. Cath Cardiovasc Interv 2003;59:34-43.

133. **Stone GW,** Grines CL and Tcheng JE. Comparison of angioplasty with stenting in acute myocardial infarction (letter). N Engl J Med 2002;347:367-368.

134. **Stone GW.** Primary Angioplasty vs. “Earlier” Thrombolytic Therapy – Time for a Wake Up Call. The Lancet 2002;360:814-6.

135. Moliterno DJ, Yakubov SJ, DiBattiste PM, HerrmannHC, **Stone GW,** et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 2002;360:355–60.

136. Christenson JT, Cohen M, Ferguson JJ 3rd, Freedman RJ, Miller MF, Ohman EM, Reddy RC**, Stone GW,** Urban PM. Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery. Ann Thorac Surg. 2002 Oct;74(4):1086-90.

137. E. Magnus Ohman, Michael F. Miller, Debra L. Joseph, Marc Cohen, Robert J. Freedman, **Gregg W. Stone,** Philip M. Urban, Ramachandra C. Reddy, Jan T. Christenson, James J. Ferguson. Validation of a Multicenter Registry Database of Intra-Aortic Balloon Pumping in a Variety of Clinical Settings. HeartDrug 2003;3:8-13.

138. Harjai KJ, Boura J, Grines L, Goldstein J, **Stone GW,** Brodie B, Cox D, O'Neill WW, Grines C. Comparison of effectiveness of primary angioplasty for proximal versus distal right coronary artery culprit lesion during acute myocardial infarction. Am J Cardiol 2002 Dec 1;90(11):1193-7.

139. **Stone GW** and Teirstein PS. Percutaneous Laser Revascularization in Patients With Chronic Total Occlusions. J Am Coll Cardiol 2002 Dec 4;40(11):2062-3.

140. Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, Mintz GS, Kent KM, Pichard AD, Satler LF, **Stone GW,** Leon MB. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003 Jan;15(1):18-22

141. **Stone GW,** Mehran R, Midei M, et al. Beta Radiation for De Novo and In-Stent Restenotic Lesions in Saphenous Vein Grafts. Am J Cardiol 2003;92:312-314.

142. **Stone GW.** Primary angioplasty or thrombolysis for acute myocardial infarction? Lancet. 2003;361:78-9.

143. El-Omar MM, Dangas G, Mehran R, Lansky AJ, Kipshidze NN, Polena S, Fahy M, Moussa I, Glasser L, Moses JW, **Stone GW,** Leon MB. Usefulness of atrial fibrillation as a marker of outcome after percutaneous coronary intervention. Am J Cardiol. 2003;91:232-4.

144. Ashby DT, Dangas G, Aymong E, Farkouh MF, Mehran R, Moses JW, Leon MB, and **Stone GW.** Relationship between the degree of procedural anticoagulation and complications after coronary stent implantation. Am J Cardiol 2003;92:319-322.

145. Pellizon GG, Dixon SR, **Stone GW,** et al. Relation of admission white-blood cell count to long-term outcomes after primary coronary angioplasty for acute myocardial infarction (the Stent-PAMI trial). Am J Cardiol 2003;91:729-31.

146. Harjai KJ, **Stone GW,** Boura J, et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003;91:655-90.

147. Ashby DT, Dangas G, Aymong EA, Iakovou I, Kuepper F, Mehran R, **Stone GW,** Leon MB, and Moses JW. Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection. J Am Coll Cardiol 2003;41:749-52.

148. Ashby DT, Mehran R, Aymong EA, Lansky AJ, Iakovou I, Weisz G, New G, Moussa I, Dangas G, Moses JW, **Stone GW,** Leon MB. Comparison of outcomes

in men versus women having percutaneous coronary interventions in small coronary arteries. Am J Cardiol 2003;91:979-81.

149. Harjai KJ, **Stone GW,** Boura J, et al. Comparison of outcomes of diabetic and nondiabetic patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol 2003;91:1041-5.

150. Nguyen TT, O'Neill WW, Grines CL, **Stone GW,** Brodie BR, Cox DA, Grines LL, Boura JA, Dixon SR. One-year survival in patients with acute myocardial infarction and a saphenous vein graft culprit treated with primary angioplasty. Am J Cardiol 2003;91:1250-4.

151. Dixon SR, O'Neill WW, Sadeghi HM, **Stone GW,** et al. Usefulness of creatinine clearance in predicting early and late death after primary angioplasty for acute myocardial infarction. Am J Cardiol. 2003;91:1454-7.

152. Fujii K, Kobayashi Y, Mintz GS, Hirose M, Moussa I, Mehran R, Dangas G, Lansky AJ, Kreps E, Collins M, Colombo A, **Stone GW,** Leon MB, Moses JW. Dominant contribution of negative remodeling to development of significant coronary bifurcation narrowing. Am J Cardiol. 2003 Jul 1;92(1):59-61.

153. Schoenhagen P, **Stone GW,** Nissen SE, et al. Coronary Plaque Morphology and Frequency of Ulceration Distant From Culprit Lesions In Patients With Unstable and Stable Presentation. Arterioscler Thromb Vasc Biol. 2003;23:1895-900.

154. Casserly IP, Topol EJ, Jia G, Lange RA, Hamm C, Meier B, DiBattiste PM, Lakkis N, Chew DP, **Stone GW,** Cohen DJ, Moliterno DJ. Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes-observations from the TARGET trial. Am J Cardiol. 2003 Jul 15;92(2):125-9.

155. Hirose M, Kobayashi Y, Mintz GS, Moussa I, Mehran R, Lansky AJ, Dangas G, Kreps EM, Collins MB, **Stone GW,** Colombo A, Leon MB, Moses JW. Correlation of coronary arterial remodeling determined by intravascular ultrasound with angiographic diameter reduction of 20% to 60%. Am J Cardiol. 2003 Jul 15;92(2):141-5.

156. **Stone GW,** Rogers C, Hermiller J, et al. Randomized Comparison of Distal Protection With a Filter-Based Catheter and a Balloon Occlusion and Aspiration System During Percutaneous Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts. Circulation. 2003;108:548-553.

157. Limpijankit T, Mehran R, Mintz GS, Dangas G, Lansky AJ, Kao J, Ashby DT, Moussa I, **Stone GW,** Moses JW, Leon MB, Teirstein PS. Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III). Am J Cardiol 2003;92:315-8.

158. Costantini CO, Lansky AJ, Mintz GS, Shirai K, Teirstein PS, **Stone G,** Vandertie L, Proctor B, Fahy M, Yeung A, Raizner AE, Waksman R, Leon MB; INHIBIT trial. Implications of the presence and length of "geographic miss" on restenosis and the edge phenomenon in the INHIBIT trial. Am J Cardiol 2003;91:1261-5.

159. Harjai KJ, Grines C, **Stone GW,** et al. Frequency, determinants, and clinical implications of residual intracoronary thrombus following primary angioplasty for acute myocardial infarction. Am J Cardiol 2003;92:377-82.

160. Kobayashi Y, Mehran R, Mintz GS, Dangas G, Moussa I, Lansky AJ, **Stone GW,** Moses JW, Leon MB. Comparison of in-hospital and one-year outcomes after multiple coronary arterial stenting in patients > or =80 years old versus those <80 years old. Am J Cardiol 2003 Aug 15;92:443-6.

161. Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, **Stone GW.** Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003;108:1316-23.

162. Cox DA, **Stone GW,** Grines CL, et al. Outcomes of optimal or “stent-like” balloon angioplasty in acute myocardial infarction: The CADILLAC trial. J Am Coll Cardiol 2003;42:971-7.

163. Kandzari DE, Tcheng JE, Cohen DJ, Bakhai A, Grines CL, Cox DA, Effron M, Stuckey T, Griffin JJ, Turco M, Carroll JD, Fahy M, Mehran R, **Stone GW**. Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). Am J Cardiol. 2003;92:779-84.

164. Bartholomew BA, Harjai KJ, Grines CL, Boura JA, Grines LL, **Stone GW,** Cox DA, Brodie BR, O'Neill WW. Variation in hospital length of stay in patients with acute myocardial infarction undergoing primary angioplasty and the need to change the diagnostic-related group system. Am J Cardiol. 2003;92:830-3.

165. Kernis SJ, Harjai KJ, **Stone GW,** et al. The incidence, predictors, and outcomes of early reinfarction after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2003;42:1173-7.

166. Chan AW, Moliterno DJ, Berger PB, **Stone GW,** et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival. Results from the do Tirofiban and ReoPro give similar efficacy outcome trial (TARGET). J Am Coll Cardiol. 2003;42:1188-95.

167. Cohen M, Urban P, Christenson JT, Joseph DL, Freedman RJ Jr, Miller MF, Ohman EM, Reddy RC, **Stone GW,** Ferguson JJ. Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark((R)) Registry. Eur Heart J. 2003;24:1763-70.

168. Ashby DT, Aymong EA, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Carroll JD, Turco M, Lansky AJ, **Stone GW.** Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial). Am J Cardiol. 2003;92(9):1095-8.

169. Ashby DT, Aymong EA, Tcheng JE, Grines CL, Cox DA, Mehran R, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Lansky AJ, **Stone GW.** Outcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). Am J Cardiol. 2003;92(9):1091-4.

170. Iakovou I, Dangas G, Mehran R, Mintz GS, Lansky AJ, Aymong ED, Nikolsky E, Vagaonescu T, Glasser LA, **Stone GW,** Leon MB, Moses JW. Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients >/=75 years of age versus those <75 years of age. Am J Cardiol. 2003 Nov 1;92(9):1083-6.

171. **Stone GW,** McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA. 2003;290(17):2284-91.

172. Costantini CO, Lansky AJ, Mintz GS, Shirai K, Dangas G, Mehran R, **Stone GW,** Leon MB. Usefulness of the angiographic pattern of in-stent restenosis in predicting the success of gamma vascular brachytherapy. Am J Cardiol. 2003;92:1214-7.

173. Costantini CO, Lansky AJ, Mintz GS, Shirai K, Dangas G, Mehran R, Fahy M, Slack S, Coral M, Teirstein PS, Waksman R, **Stone GW,** Moses J, Leon MB. Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions. J Am Coll Cardiol. 2003 May 21;41(10):1725-31.

174. Iakovou I, Mintz GS, Dangas G, Abizaid A, Mehran R, Lansky AJ, Kobayashi Y, Hirose M, Ashby DT, **Stone GW,** Moses JW, Leon MB. Optimal final lumen area and predictors of target lesion revascularization after stent implantation in small coronary arteries. Am J Cardiol. 2003;92:1171-6.

175. Fujii K, Kobayashi Y, Mintz GS, Takebayashi H, Dangas G, Moussa I, Mehran R, Lansky AJ, Kreps E, Collins M, Colombo A, **Stone GW,** Leon MB, Moses JW. Intravascular ultrasound assessment of ulcerated ruptured plaques. A comparison of culprit and nonculprit lesions of patients with acute coronary

syndromes and lesions in patients without acute coronary syndromes. Circulation. 2003:108:2473-8.

176. Takebayashi H, Kobayashi Y, Dangas G, Fujii K, Mintz GS, **Stone GW,** Moses JW, Leon MB. Restenosis due to underexpansion of sirolimus-eluting stent in a bifurcation lesion. Catheter Cardiovasc Interv. 2003;60:496-9.

177. Halkin A, Keren G, **Stone GW,** Holmes DR, Rosenschein U. Coronary intervention in thrombus-rich lesions: beyond stents and glycoprotein IIb/IIIa inhibitors. Isr Med Assoc J. 2003;5:795-800.

178. Mehta RH, Harjai KJ, Cox D, **Stone GW,** Brodie B, Boura J, O'Neill W, Grines CL. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1739-46.

179. Sadeghi HM, **Stone GW,** Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108:2769-75.

180. Kobayashi Y, Mehran R, Mintz GS, Dangas G, Moussa I, Collins M, Brara P, Moussavian M, Lansky AJ, **Stone GW,** Leon MB, Moses JW, Teirstein PS. Acute and long-term outcomes of cutting balloon angioplasty followed by gamma brachytherapy for in-stent restenosis. Am J Cardiol. 2003;92:1329-31.

181. Costantini CO, Lansky AJ, Mintz GS, Shirai K, Teirstein PS, **Stone GW,** Vandertie L, Proctor B, Fahy M, Yeung A, Raizner AE, Waksman R, Leon MB. Implications of the presence and length of "geographic miss" on restenosis and the edge phenomenon in the INHIBIT trial. Am J Cardiol. 2003;91(10):1261-5.

182. **Stone GW,** Cox DA, Babb J, et al. Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus containing coronary arteries. J Am Coll Cardiol 2003;42:2007-2013.

183. Bakhai A, **Stone GW,** Grines CL, et al. Cost-Effectiveness of Coronary Stenting and Abciximab for Patients With Acute Myocardial Infarction: Results From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. Circulation 2003;108:2857-2863.

184. Iakovou I, Mintz GS, Dangas G, Abizaid A, Mehran R, Kobayashi Y, Lansky AJ, Aymong ED, Nikolsky E, **Stone GW,** Moses JW, Leon MB. Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 2003;42:1900-5.

185. Shirai K, Lansky AJ, Mintz GS, Costantini CO, Fahy M, Mehran R, Dangas G, Moses JW, **Stone GW,** Waksman R, Leon MB. Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. Am J Cardiol 2003;92:1409-13.

186. Mehta RH, Harjai KJ, Boura J, Cox D, **Stone GW,** O'Neill W, Grines CL. Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol 2003;92:1445-7.

187. **Stone GW,** Ellis SG, Cox DA, et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.

188. Nikolsky E, Mehran R, Mintz GS, Dangas GD, Lansky AJ, Aymong ED, Negoita M, Fahy M, Moussa I, Roubin GS, Moses JW, **Stone GW,** Leon MB. Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions. J Endovasc Ther 2004;11:60-70.

189. Iakovou I, Dangas G, Mintz GS, Mehran R, Lansky AJ, Aymong ED, Nikolsky E, Vagaonescu T, Glasser LA, **Stone GW,** Leon MB, Moses JW. Comparison of frequency of hemorrhagic stroke in patients <75 years versus > or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. Am J Cardiol 2004;93:346-9.

190. Halkin A, Aymong E, Cox DA, Mehran R, Lansky AJ, Fahy M, Weisz G, Garcia E, Tcheng JE, Grines CL, **Stone GW.** Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial). Am J Cardiol 2004;93:349-53.

191. Sanborn TA, Ogilby JD, Ritter JM, **Stone GW,** Klugherz BD, Fields RH, White CC, Wilensky RL. Reduced vascular complications after percutaneous coronary interventions with a nonmechanical suture device: Results from the randomized RACE study. Catheter Cardiovasc Interv 2004;61:327-32.

192. Mehran R, Iakovou I, Dangas G, Lansky AJ, **Stone GW,** Mintz GS, Kent KM, Pichard AD, Satler LF, Fahy M, Leon MB, Waksman R. Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes. Catheter Cardiovasc Interv 2004;61:354-9.

193. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Reyes A, Kreps E, Collins M, Colombo A, **Stone GW,** Teirstein PS, Leon MB, Moses JW. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation 2004;109:1085-8.

194. Addala S, Grines CL, Dixon SR, **Stone GW,** Boura JA, Ochoa AB, Pellizzon G, O'Neill WW, Kahn JK. Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score). Am J Cardiol 2004;93:629-32.

195. Kandzari DE, Hasselblad V, Tcheng JE, **Stone GW,** Califf RM, Kastrati A, Neumann FJ, Brener SJ, Montalescot G, Kong DF, Harrington RA. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J 2004;147:457-62.

196. Kipshidze NN, Iversen P, Kim HS, Yiazdi H, Dangas G, Seaborn R, New G, Tio F, Waksman R, Mehran R, Tsapenko M, **Stone GW,** Roubin GS, Iyer S, Leon MB, Moses JW. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter Cardiovasc Interv 2004;61:518-27.

197. Prasad A, **Stone GW,** Aymong E, et al. Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: An analysis from the CADILLAC trial. Am Heart J 2004;147:669-75.

198. Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, O'Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A, Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E, **Stone GW,** Leon MB, Knopf WD, O'Neill WW. Non–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions. Angiographic Follow-Up of the DELIVER Clinical Trial. Circulation 2004;109:1948-1954.

199. **Stone GW,** Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004;109:1942-1947.

200. Shirai K, Lansky AJ, Mehran R, Dangas GD, Costantini CO, Fahy M, Slack S, Mintz GS, **Stone GW,** Leon MB. Minimally invasive coronary artery bypass grafting versus stenting for patients with proximal left anterior descending coronary artery disease. Am J Cardiol. 2004 ;93:959-62.

201. Iakovou I, Dangas G, Mintz GS, Mehran R, Kobayashi Y, D Aymong E, Hirose M, Ashby DT, Lansky AJ, **Stone GW,** Leon MB, Moses JW. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. Am J Cardiol. 2004;93:963-8.

202. Mehran R, Dangas GD, Kobayashi Y, Lansky AJ, Mintz GS, Aymong ED, Fahy M, Moses JW, **Stone GW,** Leon MB. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol 2004;43:1348-54.

203. Pellizzon GG, Grines CL, Cox DA, Stuckey T, Tcheng JE, Garcia E, Guagliumi G, Turco M, Lansky AJ, Griffin JJ, Cohen DJ, Aymong E, Mehran R, O'Neill WW, **Stone GW.** Importance of mitral regurgitation in patients undergoing percutaneous coronary intervention for acute myocardial infarction; The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol. 2004;43:1368-74.

204. Hodgson JM, Bottner RK, Klein LW, Walpole HT Jr, Cohen DJ, Cutlip DE, Fenninger RB, Firth BG, Greenberg D, Kalisky I, Meskan T, Powell W, **Stone GW,** Zito JP, Clark MA. Drug-eluting stent task force: Final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues. Catheter Cardiovasc Interv. 2004;62:1-17.

205. Mehta RH, Harjai KJ, Grines L, **Stone GW,** Boura J, Cox D, O'Neill W, Grines CL. Sustained ventricular tachycardia or fibrillation in the cardiac catheterization laboratory among patients receiving primary percutaneous coronary intervention; Incidence, predictors, and outcomes. J Am Coll Cardiol. 2004;43(10):1765-72.

206. Kernis SJ, Harjai KJ, **Stone GW,** Grines LL, Boura JA, O'Neill WW, Grines CL. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol. 2004;43(10):1773-9.

207. Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Brodie B, Turco M, Rutherford BD, Aymong E, Lansky AJ, **Stone GW.** Impact of intravenous Beta-Blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol. 2004;43:1780-7.

208. Cox DA, **Stone GW**. Composite confusion: Reply. J Am Coll Cardiol. 2004;43(10):1927.

209. Nikolsky E, Mehran R, Dangas GD, Lasic Z, Mintz GS, Negoita M, Lansky AJ, **Stone GW,** Moussa I, Iyer S, Na Y, Moses JW, Leon MB. Prognostic significance of cerebrovascular and peripheral arterial disease in patients having percutaneous coronary interventions. Am J Cardiol. 2004;93:1536-9.

210. Iakovou I, Mehran R, Dangas G, Lansky AJ, **Stone GW,** Mintz GS, Aymong E, Ashby DT, Pichard AD, Satler LF, Kent K, Leon MB, Waksman R. Favorable effect of gamma-radiation for in-stent restenosis: Effect of diabetes on angiographic and clinical outcomes. Catheter Cardiovasc Interv. 2004;62:303-7.

211. Urban PM, Freedman RJ, Ohman EM, **Stone GW,** Christenson JT, Cohen M, Miller MF, Joseph DL, Bynum DZ, Ferguson JJ. In-hospital mortality associated with the use of intra-aortic balloon counterpulsation. Am J Cardiol. 2004;94:181-5.

212. Costantini CO, **Stone GW,** Mehran R, et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. J Am Coll Cardiol. 2004;44:305-12.

213. Hirose M, Kobayashi Y, Kreps EM, **Stone GW,** Moussa I, Leon MB, Moses JW. Luminal narrowing due to intramural hematoma shift from left anterior descending coronary artery to left circumflex artery. Catheter Cardiovasc Interv. 2004;62:461-5.

214. Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, Lansky AJ, Tsounias E, Moses JW, **Stone GW,** Leon MB, Dangas GD. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol. 2004;94:300-5.

215. Petersen JL, Mahaffey KW, Becker RC, Goodman SG, Kleiman NS, Marian AJ, **Stone GW,** Lansky AJ, Lincoff AM, Hazen SL, Nessel CC, Toro-Figueroa L, Tate L, Reist CJ, Cohen M, Califf RM, Ferguson JJ; SYNERGY Library. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. Am Heart J 2004;148:269-76.

216. Sadeghi HM, Grines CL, Chandra HR, Mehran R, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Lansky AJ, O'Neill WW, **Stone GW.** Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the CADILLAC trial). Am J Cardiol. 2004;94:637-40.

217. Guagliumi G, **Stone GW,** Cox DA, et al. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2004;110:1598-604.

218. Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Negoita M, Lansky AJ, **Stone GW.** Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol. 2004;44:547-53.

219. Nikolsky E, Mehran R, Halkin A, Aymong ED, Mintz GS, Lasic Z, Negoita M, Fahy M, Krieger S, Moussa I, Moses JW, **Stone GW,** Leon MB, Pocock SJ, Dangas G. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol. 2004;44(6):1200-9.

220. McLaughlin MG, **Stone GW,** Aymong E, et al. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. J Am Coll Cardiol. 2004;44:1215-23.

221. Halkin A, **Stone GW.** Polymer-based Paclitaxel-eluting stents in percutaneous coronary intervention. J Interv Cardiol. 2004;17(5):271-82.

222. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Jacoboff D, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Reyes A, Kreps E, Collins M, **Stone GW,** Leon MB, Moses JW. Vascular remodeling and plaque composition between focal and diffuse coronary lesions assessed by intravascular ultrasound. Am J Cardiol. 2004;94(8):1067-70.

223. Kandzari DE, Tcheng JE, Grines CL, Cox DA, Stuckey T, Griffin JJ, Turco M, Garcia E, Carroll JD, Fahy M, Lansky AJ, Mehran R, **Stone GW.** Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol. 2004;94(8):1029-33.

224. Nikolsky E, Mehran R, Aymong ED, Mintz GS, Lansky AJ, Lasic Z, Negoita M, Fahy M, Pocock SJ, Na Y, Krieger S, Moses JW, **Stone GW,** Leon MB, Dangas G. Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. Am J Cardiol. 2004;94(8):1023-7.

225. Dangas G, Aymong ED, Mehran R, Tcheng JE, Grines CL, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Lansky AJ, **Stone GW.** Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). Am J Cardiol. 2004;94(8):983-8.

226. Lansky AJ, Mehran R, Dangas G, Cristea E, Shirai K, Costa R, Costantini C, Tsuchiya Y, Carlier S, Mintz G, Cottin Y, **Stone G,** Moses J, Leon MB. Comparison of differences in outcome after percutaneous coronary intervention in men versus women <40 years of age. Am J Cardiol. 2004;93(7):916-9.

227. Lasic Z, Mehran R, Dangas G, Mintz G, Nikolsky E, Tsounias E, Udani PC, Adamian M, Adamian J, Moussa I, Collins M, **Stone G,** Moses J. Comparison of safety and efficacy between first and second generation of angio-seal closure devices in interventional patients. J Invasive Cardiol. 2004;16(7):356-8.

228. Heggunje PS, Harjai KJ, **Stone GW,** et al. Procedural success versus clinical risk status in determining discharge of patients after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44(7):1400-7.

229. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, **Stone GW,** Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-9.

230. Heggunje PS, Harjai KJ, **Stone GW,** et al. Procedural success versus clinical risk status in determining discharge of patients after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1400-7.

231. Dangas G, Aymong ED, Mehran R, Tcheng JE, Grines CL, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Lansky AJ, **Stone GW.** Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). Am J Cardiol. 2004;94:983-8.

232. Stone GW. Advantages of direct thrombin inhibition in high- and low-risk patients J Invasive Cardiol 2004;16(suppl G):12-17.

233. Nikolsky E, Mehran R, Aymong ED, Mintz GS, Lansky AJ, Lasic Z, Negoita M, Fahy M, Pocock SJ, Na Y, Krieger S, Moses JW, **Stone GW,** Leon MB, Dangas G. Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. Am J Cardiol. 2004;94:1023-7.

234. Kandzari DE, Tcheng JE, Grines CL, Cox DA, Stuckey T, Griffin JJ, Turco M, Garcia E, Carroll JD, Fahy M, Lansky AJ, Mehran R, **Stone GW.** Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol. 2004;94:1029-33.

235. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Jacoboff D, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Reyes A, Kreps E, Collins M, **Stone GW,** Leon MB, Moses JW. Vascular remodeling and plaque composition between focal and diffuse coronary lesions assessed by intravascular ultrasound. Am J Cardiol. 2004;94:1067-70.

236. Halkin A, **Stone GW.** Polymer-based Paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. J Interv Cardiol. 2004;17:271-82.

237. **Stone GW,** Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J. 2004;148:764-75.

238. Takebayashi H, Mintz GS, Carlier SG, Kobayashi Y, Fujii K, Yasuda T, Costa RA, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps E, Collins M, Colombo A, **Stone GW,** Leon MB, Moses JW. Nonunifrom strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. Circulation 2004;110:3430-4

239. Yang YM, Mehran R, Dangas G, Reyes A, Oin J, **Stone GW,** Leon MB, Moses JW. Successful use of the Frontrunner catheter in the treatment of in-stent coronary chronic total occlusions. Catheter Cardiovassc Interv 2004;63:462-468.

240. Stuckey TD, **Stone GW,** Cox DA, et al. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol. 2005;95:1-7.

241. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, **Stone GW,** Moses JW, Leon MB, Mehran R.Contrast-Induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13-9.

242. Costa RA, Lansky AJ, Mintz GS, Mehran R, Tsuchiya Y, Negoita M, Gilutz Y, Nikolsky E, Fahy M, Pop R, Cristea E, Carlier S, Dangas G, **Stone GW,** Leon MB, Muller R, Techen G, Grube E. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol. 2005;95:113-6.

243. Abbas AE, Brodie B, **Stone GW,** et al. Frequency of returning to work one and six months following percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2004;94:1403-5.

244. Lasic Z, Mehran R, Dangas G, Mintz G, Nikolsky E, Tsounias E, Udani PC, Adamian M, Adamian J, Moussa I, Collins M, **Stone GW,** Moses J. Comparison of safety and efficacy between first and second generation of angio-seal closure devices in interventional patients. J Invasive Cardiol. 2004 Jul;16(7):356-8.

245. Lansky AJ, Mehran R, Dangas G, Cristea E, Shirai K, Costa R, Costantini C, Tsuchiya Y, Carlier S, Mintz G, Cottin Y, **Stone GW,** Moses J, Leon MB. Comparison of differences in outcome after percutaneous coronary intervention in men versus women <40 years of age. Am J Cardiol. 2004;93:916-9.

246. Fujii K, Carlier SG, Mintz GS, Kobayashi Y, Jacoboff D, Nierenberg H, Takebayashi H, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW,** Leon MB, Moses JW. Creatine kinase-MB enzyme

elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque. Am J Cardiol. 2005;95:355-9.

247. Nikolsky E, Mehran R, Lasic Z, Mintz GS, Lansky AJ, Na Y, Pocock S, Negoita M, Moussa I, **Stone GW,** Moses JW, Leon MB, Dangas G. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int. 2005;67:706-13.

248. Lansky AJ, Hochman JS, Ward PA, Mintz GS, Fabunmi R, Berger PB, New G, Grines CL, Pietras CG, Kern MJ, Ferrell M, Leon MB, Mehran R, White C, Mieres JH, Moses JW, **Stone GW,** Jacobs AK. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. Circulation. 2005 Feb 22;111(7):940-53.

249. Takebayashi H, Kobayashi Y, Mintz GS, Carlier SG, Fujii K, Yasuda T, Moussa I, Mehran R, Dangas GD, Collins MB, Kreps E, Lansky AJ, **Stone GW,** Leon MB, Moses JW. Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. Am J Cardiol. 2005 Feb 15;95(4):498-502.

250. Prasad A, **Stone GW,** Stuckey TD, et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol. 2005 Feb 15;45(4):508-14.

251. Swaminathan A, **Stone GW,** Rogers C, et al. Influence of vessel diameter on the efficacy of distal protection devices during saphenous vein graft intervention. Am J Cardiol. 2005 Mar 1;95(5):651-4.

252. Gersh BJ, **Stone GW,** White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA. 2005 Feb 23;293(8):979-86.

253. Sorajja P, Gersh BJ, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, Garcia E, Tcheng JE, Mehran R, Lansky AJ, Kandzari DE, Grines CL, **Stone GW.** Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J. 2005;26(7):667-74.

254. **Stone GW,** Webb J, Cox DA, Brodie BR, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA. 2005 Mar 2;293(9):1063-72.

255. Nikolsky E, Kosinski E, Mishkel GJ, Kimmelstiel C, McGarry TF Jr, Mehran R, Leon MB, Russell ME, Ellis SG, **Stone GW.** Impact of obesity on

revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial). Am J Cardiol. 2005 Mar 15;95(6):709-15.

256. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, **Stone GW,** Wijns W. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European society of cardiology. Eur Heart J. 2005 Apr;26(8):804-47.

257. Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW,** Moses JW, Leon MB. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol. 2005 Apr 5;45(7):995-8.

258. Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, **Stone GW.** Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2005 Apr 5;111(13):1611-8.

259. De Luca G, Suryapranata H, **Stone GW,** et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005 Apr 13;293(14):1759-65.

260. Moses JW, Mehran R, Nikolsky E, Lasala JM, Corey W, Albin G, Hirsch C, Leon MB, Russell ME, Ellis SG, **Stone GW.** Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005 Apr 19;45(8):1165-71.

261. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, **Stone GW.** Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol. 2005 Apr 19;45(8):1172-9.

262. Lansky AJ, Costa RA, Mooney M, Midei MG, Lui HK, Strickland W, Mehran R, Leon MB, Russell ME, Ellis SG, **Stone GW.** Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol. 2005 Apr 19;45(8):1180-5.

263. Dangas G, Ellis SG, Shlofmitz R, Katz S, Fish D, Martin S, Mehran R, Russell ME, **Stone GW**. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. J Am Coll Cardiol. 2005 Apr 19;45(8):1186-92.

264. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA, Hermiller J, O'shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, **Stone GW.** Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005 Apr 19;45(8):1193-200.

265. Weissman NJ, Koglin J, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Kutcher M, Wong SC, Strickland W, Mooney M, Russell ME, Ellis SG, **Stone GW.** Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005 Apr 19;45(8):1201-5.

266. Wong SC, Hong MK, Ellis SG, Buchbinder M, Reisman M, Delago A, Kellett M, Popma JJ, Russell ME, Mehran R, Moses JW, **Stone GW.** Influence of Stent Length to Lesion Length Ratio on Angiographic and Clinical Outcomes After Implantation of Bare Metal and Drug-Eluting Stents (the TAXUS-IV Study). Am J Cardiol. 2005 May 1;95(9):1043-8.

267. Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E, Cox DA, Turco M, Stuckey TD, Na Y, Lansky AJ, Gersh BJ, O'Neill WW, Mehran R, **Stone GW.** Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol. 2005 May 3;45(9):1397-405.

268. **Stone GW.** Protecting the Patient from Saphenous Vein Graft Intervention. J Interv Cardiol. 2005 Apr;18(2):77-79.

269. **Stone GW**, Ellis SE, Russell ME. Paclitaxel-eluting stents. N Engl J Med 2004;350:2100.

270. Yang YM, **Stone GW,** Moses JW, Leon MB, Mintz GS. Novel method for extraction of a massive refractory coronary thrombus after stent implantation. Catheter Cardiovasc Interv. 2005;65:276-279.

271. Ross AM, Gibbons RJ, **Stone GW,** Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005;45:1775-80.

272. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, **Stone GW,** Wijns W. Guidelines for Percutaneous Coronary Interventions. Rev Esp Cardiol. 2005 Jun;58(6):679-728

273. de Ribamar Costa J Jr, Mintz GS, Carlier SG, Costa RA, Fujii K, Sano K, Kimura M, Lui J, Weisz G, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW,** Moses JW, Leon MB. Intravascular Ultrasonic Assessment of Stent Diameters Derived from Manufacturer's Compliance Charts. Am J Cardiol. 2005 Jul 1;96(1):74-8.

274. Halkin A, **Stone GW,** Dixon SR, et al. Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. Am J Cardiol. 2005 Aug 1;96(3):325-31.

275. Fujii K, Carlier SG, Mintz GS, Takebayashi H, Yasuda T, Costa RA, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW,** Moses JW, Leon MB. Intravascular ultrasound study of patterns of calcium in ruptured coronary plaques. Am J Cardiol. 2005 Aug 1;96(3):352-7.

276. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, **Stone GW,** Wijns W; Task Force per le Procedure Coronariche Percutanee della Societa Europea di Cardiologia. Guidelines for percutaneous coronary interventions. Ital Heart J Suppl. 2005 Jul;6(7):427-74.

277. Weisz G, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Rutherford BD, Mehran R, Aymong E, Lansky A, Grines CL, **Stone GW.** Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. Am Heart J. 2005 Aug;150(2):358-64.

278. Nikolsky E, Sadeghi HM, Effron MB, Mehran R, Lansky AJ, Na Y, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD, Grines CL, **Stone GW.** Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol. 2005 Aug 15;96(4):474-81.

279. Guerrero M, Harjai K, **Stone GW,** et al. Comparison of the prognostic effect of left versus right versus no bundle branch block on presenting electrocardiogram in acute myocardial infarction patients treated with primary angioplasty in the primary angioplasty in myocardial infarction trials. Am J Cardiol. 2005 Aug 15;96(4):482-8.

280. Teirstein PS, Kao J, Watkins M, Tannenbaum MA, Laufer N, Chang M, Mehran R, Dangas G, Russell ME, Ellis SG, **Stone GW.** Impact of Platelet Glycoprotein IIb/IIIa Inhibition on the Paclitaxel-Eluting Stent in Patients With Stable or Unstable Angina Pectoris or Provocable Myocardial Ischemia (A TAXUS IV Substudy). Am J Cardiol. 2005 Aug 15;96(4):500-5.

281. Costa RA, Mintz GS, Carlier SG, Lansky AJ, Moussa I, Fujii K, Takebayashi H, Yasuda T, Costa JR Jr, Tsuchiya Y, Jensen LO, Cristea E, Mehran R, Dangas GD, Iyer S, Collins M, Kreps EM, Colombo A, **Stone GW,** Leon MB, Moses JW. Bifurcation coronary lesions treated with the "crush" technique: an intravascular ultrasound analysis. J Am Coll Cardiol. 2005 Aug 16;46(4):599-605.

282. Brodie BR, Grines CL, **Stone GW.** Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United states (letter). Circulation. 2005 Aug 16;112(7):e99; author reply e99-100.

283. Guerrero M, Harjai K, **Stone GW,** et al. Usefulness of the Presence of Peripheral Vascular Disease in Predicting Mortality in Acute Myocardial Infarction Patients Treated With Primary Angioplasty (from the Primary Angioplasty in Myocardial Infarction Database). Am J Cardiol. 2005;96(5):649-54.

284. Mattichak SJ, Harjai KJ, Dutcher JR, Boura JA, **Stone G,** Cox D, Brodie BR, O'Neill WW, Grines CL. Left ventricular remodeling and systolic deterioration in acute myocardial infarction: findings from the Stent-PAMI Study. J Interv Cardiol. 2005;18(4):255-60.

285. Carlier S, Kakadiaris IA, Dib N, Vavuranakis M, O'Malley SM, Gul K, Hartley CJ, Metcalfe R, Mehran R, Stefanadis C, Falk E, **Stone G,** Leon M, Naghavi M. Vasa vasorum imaging: a new window to the clinical detection of vulnerable atherosclerotic plaques. Curr Atheroscler Rep. 2005;7(2):164-9.

286. Dangas G, Lasic Z, Mehran R, Cox D, Ghali MG, Henry TD, Teirstein PS, Stella JF, Browne KF Jr, Lewis SA, Knopf W, Leon MB, Moses JW, **Stone GW.** Effectiveness of the Concomitant Use of Bivalirudin and Drug-Eluting Stents (from the Prospective, Multicenter BivAlirudin and Drug-Eluting STents [ADEST] Study). Am J Cardiol. 2005;96(5):659-63.

287. Mukherjee D, Topol EJ, Bertrand ME, Kristensen SD, Herrmann HC, Neumann FJ, Yakubov SJ, Bassand JP, McClure RR, **Stone GW,** Ardissino D, Moliterno DJ. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. Eur Heart J. 2005; 26(23):2524-8.

288. **Stone GW,** Colombo A, Teirstein PS, et al. Percutaneous recanalization of chronically occluded coronary arteries: Procedural techniques, devices, and results. Catheter Cardiovasc Interv. 2005 Sep 9;66(2):217-236.

289. **Stone GW,** Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME; TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294(10):1215-23.

290. Kipshidze NN, Tsapenko MV, Leon MB, **Stone GW,** Moses JW. Update on drug-eluting coronary stents. Expert Rev Cardiovasc Ther. 2005;3(5):953-68.

291. Mehta RH, Harjai KJ, Cox DA, **Stone GW,** Brodie BR, Boura J, Grines L, O'Neill W, Grines CL; Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Comparison of coronary stenting versus conventional balloon angioplasty on five-year mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2005 Oct 1;96(7):901-6.

292. **Stone GW,** Kandzari DE, Mehran R, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation. 2005 Oct 11;112(15):2364-72.

293. **Stone GW,** Reifart NJ, Moussa I, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation. 2005 Oct 18;112(16):2530-7.

294. Moussa I, Ellis SG, Jones M, Kereiakes DJ, McMartin D, Rutherford B, Mehran R, Collins M, Leon MB, Popma JJ, Russell ME, **Stone GW.** Impact of Coronary Culprit Lesion Calcium in Patients Undergoing Paclitaxel-Eluting Stent Implantation (a TAXUS-IV Sub Study). Am J Cardiol. 2005 Nov 1;96(9):1242-7.

295. Voeltz MD, Feit F, **Stone GW,** Manoukian SV. Anemia and Outcomes in ACS. Acute Coronary Syndromes 2005;7:47-55.

296. Fujii K, Carlier SG, Mintz GS, Wijns W, Colombo A, Bose D, Erbel R, de Ribamar Costa J Jr, Kimura M, Sano K, Costa RA, Lui J, **Stone GW,** Moses JW, Leon MB. Association of plaque characterization by intravascular ultrasound virtual histology and arterial remodeling. Am J Cardiol. 2005 Dec 1;96(11):1476-83.

297. Halkin A, Mehran R, Casey CW, Gordon P, Matthews R, Wilson BH, Leon MB, Russell ME, Ellis SG, **Stone GW.** Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. Am Heart J. 2005;150:1163-70.

298. Halkin A, **Stone GW,** Grines CL, Cox DA, Stuckey TD, Garcia E, Guagliumi G, Mehran R, Rutherford BD, Griffin JJ, Na Y, Tcheng JE, Turco M. Outcomes of Patients Consented But Not Randomized in a Trial of Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (The CADILLAC Registry). Am J Cardiol. 2005;96:1649-55.

299. Nikolsky E, **Stone GW,** Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Negoita M, Lansky AJ, Mehran R. Impact of

body mass index on outcomes after primary angioplasty in acute myocardial infarction. Am Heart J. 2006;151:168-75.

300. Ellis SG, Popma JJ, **Stone GW,** Russell ME. Restenosis, statistics, and reasonable inferences. J Am Coll Cardiol. 2006;47:470-1.

301. Weissman NJ, **Stone GW.** Intravascular Ultrasound Analysis of Polymer-Based Paclitaxel-Eluting Stents: Reply. J Am Coll Cardiol. 2006;47:470.

302. Jonas M, **Stone GW,** Mehran R, et al. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur Heart J. 2006;27:920-928.

303. De Luca G, Suryapranata H, **Stone GW,** et al. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. J Am Coll Cardiol. 2006;47:685-6.

304. **Stone GW,** Gersh BJ. Facilitated angioplasty: paradise lost. Lancet. 2006;367:543-6.

305. **Stone GW,** Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents versus vascular brachytherapy for in-stent restenosis within bare metal stents. The TAXUS V ISR randomized trial. JAMA 2006;295:1253-1263.

306. Mehta RH, O'Neill WW, Harjai KJ, Cox DA, Brodie BR, Boura J, Grines L, **Stone GW,** Grines CL. Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions. Am J Cardiol. 2006;97:817-22.

307. Halkin A, **Stone GW,** Grines CL, Cox DA, Rutherford BD, Esente P, Meils CM, Albertsson P, Farah A, Tcheng JE, Lansky AJ, Mehran R. Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol. 2006;47:951-61.

308. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, **Stone GW,** Wijns W; European Society of Cardiology. Percutaneous coronary interventions. Guidelines of the European Society of Cardiology-ESC. Kardiol Pol. 2005;63:265-320.

309. Dawkins KD, **Stone GW,** Colombo A et al. Integrated analysis of medically treated diabetic patients in the TAXUS program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatments. EuroIntervention 2006;2:34-42.

310. Halkin A, Masud AZ, Rogers C, Hermiller J, Feldman R, Hall P, Haber RH, Cambier PA, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA, Mehran R, **Stone GW.** Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. Am Heart J. 2006;151:915.e1-7.

311. Popp RL, Lorell BH, **Stone GW,** Laskey W, Smith JJ, Kaplan AV. An Outline for Public Registration of Clinical Trials Evaluating Medical Devices J Am Coll Cardiol 2006;47:1518-1521.

312. Moussa I, Costa RA, Leon MB, Lansky AJ, Lasic Z, Cristea E, Trubelja N, Carlier SG, Mehran R, Dangas GD, Weisz G, Kreps EM, Collins M, **Stone GW,** Moses JW. A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the "crush technique". Am J Cardiol. 2006;97:1317-21.

313. **Stone GW** and Aronow HD. Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy. Mayo Clin Proc 2006;81(5):641-652.

314. Fujii K, Ochiai M, Mintz GS, Kan Y, Awano K, Masutani M, Ashida K, Ohyanagi M, Ichikawa S, Ura S, Araki H, **Stone GW,** Moses JW, Leon MB, Carlier SG. Procedural implications of intravascular ultrasound morphologic features of chronic total coronary occlusions. Am J Cardiol. 2006 May 15;97(10):1455-62.

315. Sano K, Mintz GS, Carlier SG, Fujii K, Yasuda T, Kimura M, Costa JR Jr, Costa RA, Lui J, Weisz G, Moussa I, Dangas GD, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW,** Moses JW, Leon MB. Intravascular ultrasonic differences between aorto-ostial and shaft narrowing in saphenous veins used as aortocoronary bypass grafts. Am J Cardiol. 2006 May 15;97(10):1463-6.

316. **Stone GW,** Popma JJ, Ellis SE. Paclitaxel-eluting stents, brachytherapy, and in-stent restenosis—Reply. JAMA 2006;296:1838-9.

317. Rodriguez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF, Delgado J, Fernandez-Pereira C, Pocovi A, Rodriguez-Granillo AM, Schulz D, Raizner AE, Palacios I, O'Neill W, Kaluza GL, **Stone G;** ORAR II Investigators. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol. 2006;47(8):1522-9.

318. Shishehbor MH, Topol EJ, Mukherjee D, Hu T, Cohen DJ, **Stone GW,** McClure R, Roffi M, Moliterno DJ. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era. Am J Cardiol. 2006 Jun 1;97(11):1585-90.

319. Moses JW, **Stone GW,** Nikolsky E, et al. Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials. J Am Coll Cardiol. 2006 Jun 6;47(11):2164-71.

320. Brodie BR, **Stone GW,** Cox DA, et al. Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. Am Heart J. 2006 Jun;151(6):1231-8.

321. Kandzari DE, Tcheng JE, Gersh BJ, Cox DA, Stuckey T, Turco M, Mehran R, Garcia E, Zimetbaum P, McGlaughlin MG, Lansky AJ, Costantini CO, Grines CL, **Stone GW.** Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction. Am Heart J. 2006 Jun;151(6):1288-95.

322. Dawkins KD, **Stone GW,** Colombo A, et al. Integrated analysis of medically treated diabetic patients in the Taxus program: benefits across stent oplatforms, paclitaxel release formulations, and diabetic treatments. EuroIntervention 2006;2:69-76.

323. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, **Stone GW.** Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006;27:2400-5.

324. Pinto DS, **Stone GW,** Ellis SG, et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol. 2006;48:32-6.

325. Bakhai A, **Stone GW,** Mahoney E, et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol. 2006 Jul 18;48(2):253-61.

326. Cox DA, **Stone GW,** Grines CL, et al. Comparative Early and Late Outcomes After Primary Percutaneous Coronary Intervention in ST-Segment Elevation and Non-ST-Segment Elevation Acute Myocardial Infarction (from the CADILLAC Trial). Am J Cardiol. 2006 Aug 1;98(3):331-7.

327. Lansky AJ, Yang YM, Khan Y, Costa RA, Pietras C, Tsuchiya Y, Cristea E, Collins M, Mehran R, Dangas GD, Moses JW, Leon MB, **Stone GW.** Treatment of coronary artery perforations complicating percutaneous coronary intervention with a polytetrafluoroethylene-covered stent graft. Am J Cardiol. 2006 Aug 1;98(3):370-4.

328. Jensen LO, Mintz GS, Carlier SG, Fujii K, Moussa I, Dangas G, Mehran R, **Stone GW,** Leon MB, Moses JW. Intravascular ultrasound assessment of fibrous

cap remnants after coronary plaque rupture. Am Heart J. 2006 Aug;152(2):327-32.

329. Harjai KJ, Mehta RH, **Stone GW,** et al. Does Proximal Location of Culprit Lesion Confer Worse Prognosis in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction? J Interv Cardiol. 2006 Aug;19(4):285-94.

330. Fujii K, Mintz GS, Carlier SG, di Ribamar Costa J Jr, Kimura M, Sano K, Tanaka K, Costa RA, Lui J, **Stone GW,** Moses JW, Leon MB. Intravascular ultrasound profile analysis of ruptured coronary plaques. Am J Cardiol. 2006 Aug 15;98(4):429-35.

331. Kimura M, Mintz GS, Carlier S, Takebayashi H, Fujii K, Sano K, Yasuda T, Costa RA, Costa JR Jr, Quen J, Tanaka K, Lui J, Weisz G, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW,** Moses JW, Leon MB. Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound. Am J Cardiol. 2006 Aug 15;98(4):436-42.

332. Forman MB, **Stone GW**, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev. 2006;24(2):116-47.

333. Grube E, Laborde JC, Gerckens U, Felderhoff T, Sauren B, Buellesfeld L, Mueller R, Menichelli M, Schmidt T, Zickmann B, Iversen S, **Stone GW.** Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation. 2006;114:1616-24.

334. Lasala JM, **Stone GW,** Dawkins KD, Serruys PW, Colombo A, Grube E, Koglin J, Ellis S. An Overview of the TAXUS Express, Paclitaxel-Eluting Stent Clinical Trial Program. J Interv Cardiol. 2006;19:422-31.

335. **Stone GW,** McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-16.

336. Sano K, Mintz GS, Carlier SG, Fujii K, Takebayashi H, Kimura M, Costa JR Jr, Tanaka K, Costa RA, Lui J, Weisz G, Moussa I, Dangas GD, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW,** Moses JW, Leon MB. Volumetric intravascular ultrasound assessment of neointimal hyperplasia and nonuniform stent strut distribution in sirolimus-eluting stent restenosis. Am J Cardiol. 2006;98:1559-62.

337. Brodie BR, Grines CL, **Stone GW.** Effect of door-to-balloon time on patient mortality. J Am Coll Cardiol. 2006 Dec 19;48(12):2600.

338. Carlier SG, Mintz GS, **Stone GW.** Imaging of atherosclerotic plaque using radiofrequency ultrasound signal processing. J Nucl Cardiol. 2006 Nov;13(6):831-40.

339. Kirtane AJ, **Stone GW,** Jacobs AK, Yeung AC. Best of the TCT Scientific Sessions 2006. Rev Cardiovasc Med. 2006 Fall;7(4):228-37.

340. Hodgson JM, **Stone GW,** Michael Lincoff A, Klein L, Walpole H, Bottner R, Weiner BH, Leon MB, Feldman T, Babb J, Dehmer GJ. Late stent thrombosis: Considerations and practical advice for the use of drug-eluting stents: A report from the society for cardiovascular angiography and interventions drug-eluting stent task force. Catheter Cardiovasc Interv. 2007 Feb 15;69(3):327-33.

341. **Stone GW.** Expert discussion of the latest trial results: summary remarks. Rev Cardiovasc Med. 2006;7 Suppl 3:S53-9.

342. Harjai KJ, **Stone GW,** Grines CL, et al.Usefulness of Routine Unfractionated Heparin Infusion Following Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction in Patients Not Receiving Glycoprotein IIb/IIIa Inhibitors. Am J Cardiol. 2007 Jan 15;99(2):202-7.

343. de Ribamar Costa J Jr, Mintz GS, Carlier SG, Fujii K, Sano K, Kimura M, Tanaka K, Costa RA, Lui J, Na Y, Castellanos C, Biro S, Moussa I, **Stone GW,** Moses JW, Leon MB. Intravascular ultrasound assessment of drug-eluting stent expansion. Am Heart J. 2007 Feb;153(2):297-303.

344. **Stone GW,** Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD. Routine Upstream Initiation vs. Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: The ACUITY Timing Trial. JAMA. 2007;297:591-602.

345. **Stone GW,** Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents. N Engl J Med. 2007;356:998-1008.

346. Young JJ, Cox DA, Stuckey T, Babb J, Turco M, Lansky AJ, Mehran R, **Stone GW.** Prospective, multicenter study of thrombectomy in patients with acute myocardial infarction: the X-Tract AMI registry. J Interv Cardiol. 2007;20:44-50.

347. De Luca G, Suryapranata H, **Stone GW,** Antoniucci D, Neumann FJ, Chiariello M. Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials. Am Heart J. 2007;153:343-53.

348. Ellis SG, Colombo A, Grube E, Popma J, Koglin J, Dawkins KD, **Stone GW.** Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol. 2007 Mar 13;49(10):1043-51.

349. **Stone GW.** Non-ST-elevation acute coronary syndromes. Lancet. 2007 Mar 10;369(9564):801-3.

350. **Stone GW,** White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW; Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007 Mar 17;369(9565):907-19.

351. Tanaka K, Carlier SG, Mintz GS, Sano K, Liu X, Fujii K, de Ribamar Costa J Jr, Lui J, Moses JW, **Stone GW,** Leon MB. The accuracy of length measurements using different intravascular ultrasound motorized transducer pullback systems. Int J Cardiovasc Imaging. 2007 Dec;23(6):733-8.

352. Nikolsky E, **Stone GW**. Utility of Drug-eluting Stents in Complex Lesions and High-risk Patients. Curr Treat Options Cardiovasc Med. 2007 Feb;9(1):11-28.

353. Mehta L, Devlin W, McCullough PA, O'neill WW, Skelding KA, **Stone GW,** Boura JA, Grines CL. Impact of body mass index on outcomes after percutaneous coronary intervention in patients with acute myocardial infarction. Am J Cardiol. 2007 Apr 1;99(7):906-10.

354. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB 3rd, Ohman EM, **Stone GW**. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol. 2007 Mar 27;49(12):1362-8.

355. Nikolsky E, Grines CL, Cox DA, Garcia E, Tcheng JE, Sadeghi M, Mehran R, Lansky AJ, Na Y, **Stone GW.** Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC Trial). Am J Cardiol. 2007 Apr 15;99(8):1055-61.

356. Prasad A, **Stone GW,** Stuckey TD, Costantini CO, Mehran R, Garcia E, Tcheng JE, Cox DA, Grines CL, Lansky AJ, Gersh BJ. Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty. Am J Cardiol. 2007 Apr 15;99(8):1067-71.

357. Nikolsky E, Pucelikova T, Mehran R, Balter S, Kaufman L, Fahy M, Lansky AJ, Leon MB, Moses JW, **Stone GW,** Dangas G. An evaluation of fluoroscopy time and correlation with outcomes after percutaneous coronary intervention. J Invasive Cardiol. 2007;19:208-13.

358. Kirtane AJ, **Stone GW**. The Anchor-Tornus technique: A novel approach to "uncrossable" chronic total occlusions. Catheter Cardiovasc Interv. 2007 Oct 1;70(4):554-7.

359. **Stone GW,** Ellis SG, Colombo A, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007;115:2842-2847.

360. Weissman NJ, Ellis SG, Grube E, Dawkins KD, Greenberg JD, Mann T, Cannon LA, Cambier PA, Fernandez S, Mintz GS, Mandinov L, Koglin J, **Stone GW.** Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials. Eur Heart J. 2007 Jul;28(13):1574-82.

361. De Luca G, Suryapranata H, **Stone GW,** Antoniucci D, Biondi-Zoccai G, Kastrati A, Chiariello M, Marino P. Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials. Int J Cardiol. 2007;119:306-9.

362. Escolar E, Mintz GS, Popma J, Michalek A, Kim SW, Mandinov L, Koglin J, **Stone G,** Ellis SG, Grube E, Dawkins KD, Weissman NJ. Meta-analysis of angiographic versus intravascular ultrasound parameters of drug-eluting stent efficacy (from TAXUS IV, V, and VI). Am J Cardiol. 2007;100(4):621-6.

363. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tcheng JE, Mehran R, Lansky AJ, Grines CL, **Stone GW.** Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J. 200l;28(14):1709-16.

364. Brodie BR, Webb J, Cox DA, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford B, Antoniucci D, Stuckey T, Krucoff M, Gibbons R, Lansky A, Na Y, Mehran R, **Stone GW.** Impact of time to treatment on myocardial reperfusion and infarct size with primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). Am J Cardiol. 2007;99(12):1680-6.

365. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, Lincoff AM, **Stone GW.** Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J. 2007 Aug;28(16):1936-45.

366. Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, Lansky AJ, **Stone GW.** Comparison of Myocardial Reperfusion in Patients Undergoing Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction With Versus Without Diabetes Mellitus (from the EMERALD Trial). Am J Cardiol. 2007;100(2):206-210.

367. Sorajja P, Gersh BJ, Mehran R, Lansky AJ, Krucoff MW, Webb J, Cox DA, Brodie BR, **Stone GW.** Impact of collateral flow on myocardial reperfusion and infarct size in patients undergoing primary angioplasty for acute myocardial infarction. Am Heart J. 2007 Aug;154(2):379-84.

368. **Stone GW,** Moses JW, Leon MB. Left main drug-eluting stents: natural progression or a bridge too far? J Am Coll Cardiol. 2007;50:498-500.

369. de Ribamar Costa J Jr, Mintz GS, Carlier SG, Mehran R, Teirstein P, Sano K, Liu X, Lui J, Na Y, Castellanos C, Biro S, Dani L, Rinker J, Moussa I, Dangas G, Lansky AJ, Kreps EM, Collins M, **Stone GW,** Moses JW, Leon MB. Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. Am J Cardiol. 2007 Sep 1;100(5):812-7.

370. Cheruvu PK, Finn AV, Gardner C, Caplan J, Goldstein J, **Stone GW,** Virmani R, Muller JE. Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: a pathologic study. J Am Coll Cardiol. 2007;50:940-9.

371. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, **Stone GW,** Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007 Sep 15;370(9591):937-48.

372. **Stone GW.** Timing of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2007;298:37-8.

373. Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes DR Jr, Krucoff MW, O'Neill WW, Waksman R, Williams DO, Popma JJ, Buchbinder M, Mehran R, Meredith IT, Moses JW, **Stone GW.** The truth and consequences of the COURAGE trial. J Am Coll Cardiol. 2007;50:1598-603.

374. **Stone GW,** Dixon SR, Grines CL, Cox DA, Webb JG, Brodie BR, Griffin JJ, Martin JL, Fahy M, Mehran R, Miller TD, Gibbons RJ, O'Neill WW. Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials. Am J Cardiol. 2007;100:1370-5.

375. Sano K, Mintz GS, Carlier SG, de Ribamar Costa J Jr, Qian J, Missel E, Shan S, Franklin-Bond T, Boland P, Weisz G, Moussa I, Dangas GD, Mehran R, Lansky AJ, Kreps EM, Collins MB, **Stone GW,** Leon MB, Moses JW. Assessing intermediate left main coronary lesions using intravascular ultrasound. Am Heart J. 2007 Nov;154(5):983-8.

376. Sano K, Mintz GS, Carlier SG, Solinas E, Costa Jde R Jr, Qian J, Missel E, Shan S, Franklin-Bond T, Boland P, Weisz G, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps E, Collins M, **Stone GW,** Moses JW, Leon MB. Treatment of restenotic drug-eluting stents: an intravascular ultrasound analysis. J Invasive Cardiol. 2007 Nov;19(11):464-8.

377. **Stone GW,** Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ; ACUITY Investigators. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA. 2007;298:2497-506.

378. Aoki J, Kirtane AJ, Dangas GD, Lansky AJ, Morales A, Kimura M, Kim YH, Moussa I, Weisz G, Kreps EM, Collins M, Frankin-Bond T, **Stone GW,** Moses JW, Leon MB, Mehran R. Clinical outcomes after heterogeneous overlap stenting with drug-eluting stents and bare-metal stents for de novo coronary artery narrowings. Am J Cardiol. 2008 Jan 1;101(1):58-62.

379. Pucelikova T, Mehran R, Kirtane AJ, Kim YH, Fahy M, Weisz G, Lansky AJ, Moussa I, Gray WA, Collins MB, Kodali SK, **Stone GW,** Moses JW, Leon MB, Dangas G. Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era. Am J Cardiol. 2008 Jan 1;101(1):63-8.

380. Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, Dangas G, Moses JW, Pucelikova T, Kandzari DE, Ellis SG, Leon MB, **Stone GW.** Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol. 2008 Jan 1;51(1):23-32.

381. Kirtane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, Fahy M, Leon MB, Moses JW, Mehran R, **Stone GW.** Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol. 2008 Feb 19;51(7):708-15.

382. Young JJ, Phillips HR, Marso SP, Granada JF, McPherson JA, Waksman R, Steinhubl SR, Schwartz RS, **Stone GW.** Vulnerable plaque intervention: State of the art. Catheter Cardiovasc Interv. 2008 Feb 15;71(3):367-74.

383. Missel E, Mintz GS, Carlier SG, Sano K, Qian J, Kaple RK, Castellanos C, Dangas G, Mehran R, Moses JW, **Stone GW,** Leon MB. Necrotic core and its ratio to dense calcium are predictors of high-risk non-ST-elevation acute coronary syndrome. Am J Cardiol. 2008 Mar 1;101(5):573-8.

384. Kim YH, Dangas GD, Solinas E, Aoki J, Parise H, Kimura M, Franklin-Bond T, Dasgupta NK, Kirtane AJ, Moussa I, Lansky AJ, Collins M, **Stone GW,** Leon MB, Moses JW, Mehran R. Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis.Am J Cardiol. 2008 Mar 15;101(6):801-6.

385. De Luca G, **Stone GW,** Suryapranata H, Laarman GJ, Menichelli M, Kaiser C, Valgimigli M, Di Lorenzo E, Dirksen MT, Spaulding C, Pittl U, Violini R, Percoco G, Marino P. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. Int J Cardiol. 2008;133:213-22.

386. Weisz G, **Stone GW.** Safety and efficacy of drug-eluting stents: on-label and off-label perspectives. Rev Cardiovasc Med. 2008;9:46-61.

387. Otsuka M, Bruining N, Van Pelt NC, Mollet NR, Ligthart JM, Vourvouri E, Hamers R, De Jaegere P, Wijns W, Van Domburg RT, **Stone GW,** Veldhof S, Verheye S, Dudek D, Serruys PW, Krestin GP, De Feyter PJ. Quantification of Coronary Plaque by 64-slice Computed Tomography: A Comparison with Quantitative Intracoronary Ultrasound. Invest Radiol. 2008;43:314-321.

388. **Stone GW,** Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008 Apr 23;299(16):1903-13.

389. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, **Stone GW.** The Harmonizing Outcomes with RevascularizatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J. 2008 Jul;156(1):44-56.

390. Kimura M, Mintz GS, Weissman NJ, Dawkins KD, Grube E, Ellis SG, Cannon LA, Masud Z, Mandinov L, Baim D, **Stone GW.** Meta-analysis of the Effects of Paclitaxel-Eluting Stents Versus Bare Metal Stents on Volumetric Intravascular Ultrasound in Patients With Versus Without Diabetes Mellitus. Am J Cardiol. 2008 May 1;101(9):1263-8.

391. Feit F, Manoukian SV, Ebrahimi R, Pollack CV, Ohman EM, Attubato MJ, Mehran R, **Stone GW.** Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2008 Apr 29;51(17):1645-52.

392. White HD, Chew DP, Hoekstra JW, Miller CD, Pollack CV Jr, Feit F, Lincoff AM, Bertrand M, Pocock S, Ware J, Ohman EM, Mehran R, **Stone GW.** Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2008 May 6;51(18):1734-41.

393. Pocock SJ, Fahy MP, Mehran R, **Stone GW.** Surrogate endpoints in stent trials. Reply. J Am Coll Cardiol. 2008;51:1992.

394. **Stone GW,** Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-30.

395. Ellis SG, O'Shaughnessy CD, Martin SL, Kent K, McGarry T, Turco MA, Kereiakes DJ, Popma JJ, Friedman M, Koglin J, **Stone GW.** Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis—the TAXUS V ISR trial. Eur Heart J 2008;29:1625–1634.

396. Dangas G, **Stone GW,** Weinberg MD, Webb J, Cox DA, Brodie BR, Krucoff MW, Gibbons RJ, Lansky AJ, Mehran R. Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial). Am Heart J. 2008 Jun;155(6):1090-6.

397. Missel E, Mintz GS, Carlier SG, Qian J, Shan S, Castellanos C, Kaple R, Biro S, Fahy M, Moses JW, **Stone GW,** Leon MB. In vivo virtual histology intravascular ultrasound correlates of risk factors for sudden coronary death in men: results from the prospective, multi-centre virtual histology intravascular ultrasound registry. Eur Heart J. 2008;29:2141-7.

398. Solinas E, Dangas G, Kirtane AJ, Lansky AJ, Franklin-Bond T, Boland P, Syros G, Kim YH, Gupta A, Mintz G, Fahy M, Collins M, Kodali S, **Stone GW,** Moses JW, Leon MB, Mehran R. Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. Am J Cardiol. 2008 Aug 1;102(3):311-5.

399. **Stone GW.** Angioplasty strategies in ST-segment-elevation myocardial infarction: part I: primary percutaneous coronary intervention. Circulation. 2008 Jul 29;118(5):538-51.

400. **Stone GW.** Angioplasty strategies in ST-segment-elevation myocardial infarction: part II: intervention after fibrinolytic therapy, integrated treatment recommendations, and future directions. Circulation. 2008 Jul 29;118(5):552-66.

401. Grad Y, Sievert H, Nishri B, **Stone GW,** Katzen BT, Yodfat O, Higashida R, Harris D, Wakhloo AK, Assaf Y, Norbash A, Bushi D, Lieber BB. A Novel Endovascular Device for Emboli Rerouting. Part I: Evaluation in a Swine Model. Stroke. 2008 Oct;39(10):2860-6.

402. White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, **Stone GW.** Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2008 Sep 2;52(10):807-14.

403. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, **Stone GW,** Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Jüni P. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ. 2008 Aug 29;337:a1331 (on-line).

404. Aoki J, Mintz GS, Weissman NJ, Mandinov L, Grube E, Dawkins KD, Ellis SG, Greenberg J, Yu A, Mann JT, Cannon L, Cambier PA, **Stone GW.** Impact of mild or moderate renal insufficiency on the intravascular ultrasonic analysis of chronic vascular response to paclitaxel-eluting and bare-metal stents (from the TAXUS IV, V, and VI trials). Am J Cardiol. 2008;102:1009-16.

405. **Stone GW,** Ellis SG, Colombo A, Grube E, Dawkins KD, Friedman M, Baim DS. Effect of prolonged thienopyridine use after drug-eluting stent implantation (from the TAXUS landmark trials data). Am J Cardiol. 2008;102:1017-22.

406. Lansky AJ, Tsuchiya Y, Brener M, Mehran R, Cristea E, Pietras C, Grines CL, Cox DA, Garcia E, Tcheng JE, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Leon MB, Moses J, **Stone GW.** Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial. Catheter Cardiovasc Interv. 2008;72:917-92.

407. Pinto DS, **Stone GW,** Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin RH, Mehran R, McLaurin BT, Cox DA, Ohman EM, Lincoff AM, Cohen DJ; ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators. Economic Evaluation of Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibition Versus Heparin With Routine Glycoprotein IIb/IIIa Inhibition for Early Invasive Management of Acute Coronary Syndromes. J Am Coll Cardiol. 2008;52:1758-1768.

408. Doi H, Maehara A, Mintz GS, Weissman NJ, Yu A, Wang H, Mandinov L, Popma JJ, Ellis SG, Grube E, Dawkins KD, and **Stone GW.** Impact of In-Stent Minimal Lumen Area at 9 Months Poststent Implantation on 3-Year Target Lesion Revascularization–Free Survival: A Serial Intravascular Ultrasound Analysis From the TAXUS IV, V, and VI Trials. Circ Cardiovasc Intervent 2008;1:111-118.

409. Goyal N, Stant J, Esposito F, Piri G, Collins M, Sayan O, Neuberg G, Miller L, Moses JW, **Stone GW,** Giglio J, Rabbani LE. Updating the chest pain algorithm: incorporating new evidence. Crit Pathw Cardiol. 2008 Dec;7(4):211-22.

410. Friedewald VE, Ambrose JA, **Stone GW,** Roberts WC, Willerson JT. The editor's roundtable: the vulnerable plaque. Am J Cardiol. 2008 Dec 15;102(12):1644-53.

411. Tsujita K, Maehara A, Mintz GS, Doi H, Kubo T, Castellanos C, Liu J, Yang J, Oviedo C, Franklin-Bond T, Dasgupta N, Biro S, Dani L, Dangas GD, Mehran R, Kirtane AJ, Lansky AJ, Kreps EM, Collins MB, **Stone GW,** Moses JW, Leon MB. Comparison of angiographic and intravascular ultrasonic detection of myocardial bridging of the left anterior descending coronary artery. Am J Cardiol. 2008 Dec 15;102(12):1608-13.

412. Kahn J, **Stone GW,** Leon MB, Cox CE, Dalton K, Feil K, Mintz GS. TCT 2008: New Data Lead to New Directions in Treating Cardiovascular Disease. Rev Cardiovasc Med. 2008 Fall;9(4):269-74.

413. Aoki J, Mintz GS, Weissman NJ, Mann JT, Cannon L, Greenberg J, Grube E, Masud AR, Koglin J, Mandinov L, **Stone GW.** Chronic Arterial Responses to Overlapping Paclitaxel-Eluting Stents Insights From Serial Intravascular Ultrasound Analyses in the TAXUS-V and -VI Trials. JACC Cardiovasc Interv. 2008 Apr;1(2):161-167.

414. Lincoff AM, Steinhubl SR, Manoukian SV, Chew D, Pollack CV Jr, Feit F, Ware JH, Bertrand ME, Ohman EM, Desmet W, Cox DA, Mehran R, **Stone GW;** ACUITY of Trial Investigators. Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention An Analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial. JACC Cardiovasc Interv. 2008 Dec;1(6):639-48.

415. Martin JL, Ellis SG, Colombo A, Grube E, Maloney T, Friedman MI, Baim DS, Dawkins K, Caputo R, **Stone GW.** Frequency of coronary artery bypass grafting following implantation of a paclitaxel-eluting or a bare-metal stent into a single coronary artery. Am J Cardiol. 2009 Jan 1;103(1):11-6.

416. Kaple RK, Maehara A, Sano K, Missel E, Castellanos C, Tsujita K, Fahy M, Moses JW, **Stone GW,** Leon MB, Mintz GS. The axial distribution of lesion-site atherosclerotic plaque components: an in vivo volumetric intravascular ultrasound radio-frequency analysis of lumen stenosis, necrotic core and vessel remodeling. Ultrasound Med Biol. 2009;35:550-7.

417. Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, Ohman EM, White HD, Parise H, Leon MB, **Stone GW.** Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation. 2009;119:687-98.

418. **Stone GW,** Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation. 2009;119:680-6.

419. De Luca G, Valgimigli M, Spaulding C, Menichelli M, Rocca HP, van der Hoeven BL, Di Lorenzo E, de la Llera LS, Pasceri V, Pittl U, Percoco G, Violini R, **Stone GW.** Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. J Thromb Thrombolysis. 2009;28:200-10.

420. Liu J, Maehara A, Mintz GS, Weissman NJ, Yu A, Wang H, Mandinov L, Popma JJ, Ellis SG, Grube E, Dawkins KD, **Stone GW.** An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents. Am J Cardiol. 2009;103:501-6.

421. Tsujita K, Maehara A, Mintz GS, Franklin-Bond T, Mehran R, **Stone GW,** Leon MB, Moses JW. In vivo intravascular ultrasonic assessment of anomalous right

coronary artery arising from left coronary sinus. Am J Cardiol. 2009 Mar 1;103(5):747-51.

422. **Stone GW.** Ischaemia versus bleeding: the art of clinical decision-making. Lancet. 2009;373:695-6.

423. Doi H, Maehara A, Mintz GS, Tsujita K, Kubo T, Castellanos C, Liu J, Yang J, Oviedo C, Aoki J, Franklin-Bond T, Dasgupta N, Lansky AJ, Dangas GD, **Stone GW,** Moses JW, Mehran R, Leon MB.Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture. Am J Cardiol. 2009;103:818-23.

424. Lopes RD, Alexander KP, Manoukian SV, Bertrand ME, Feit F, White HD, Pollack CV Jr, Hoekstra J, Gersh BJ, **Stone GW,** Ohman EM. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009;53:1021-30.

425. Mehran R, Pocock SJ, **Stone GW,** Clayton TC, Dangas GD, Feit F, Manoukian SV, Nikolsky E, Lansky AJ, Kirtane A, White HD, Colombo A, Ware JH, Moses JW, Ohman EM. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009; 30:1457-66.

426. Ng VG and **Stone GW.** Diabetics and Drug-eluting Stents in ST Segment Elevation Myocardial Infarction: Confidence in Numbers. Rev Esp Cardiol. 2009;62(4):343-6.

427. Brar SS, Leon MB, **Stone GW,** Mehran R, Moses JW, Brar SK, Dangas G. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol. 2009 May 5;53(18):1677-89.

428. Qian J, Maehara A, Mintz GS, Margolis MP, Lerman A, Rogers J, Banai S, Kazziha S, Castellanos C, Dani L, Fahy M, **Stone GW,** Leon MB. Impact of gender and age on in vivo virtual histology-intravascular ultrasound imaging plaque characterization (from the global Virtual Histology Intravascular Ultrasound [VH-IVUS] registry).Am J Cardiol. 2009;103:1210-4.

429. Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, **Stone GW.** Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). Am J Cardiol. 2009;103:1196-203.

430. **Stone GW,** Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009;360:1946-1459.

431. Tsujita K, Maehara A, Mintz GS, Doi H, Kubo T, Castellanos C, Liu J, Yang J, Oviedo C, Franklin-Bond T, Sugirtharaj DD, Dangas GD, Lansky AJ, **Stone GW,** Moses JW, Leon MB, Mehran R. Impact of myocardial bridge on clinical outcome after coronary stent placement. Am J Cardiol. 2009 May 15;103(10):1344-8.

432. Ebrahimi R, Dyke C, Mehran R, Manoukian SV, Feit F, Cox DA, Gersh BJ, Ohman EM, White HD, Moses JW, Ware JH, Lincoff AM, **Stone GW.** Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2009 May 26;53(21):1965-72.

433. Liu X, Doi H, Maehara A, Mintz GS, de Ribamar Costa J Jr, Sano K, Weisz G, Dangas GD, Lansky AJ, Kreps EM, Collins M, Fahy M, **Stone GW,** Moses JW, Leon MB, Mehran R. A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis. JACC Cardiovasc Interv. 2009 May;2(5):428-34.

434. Rabbani LE, Iyengar S, Dangas GD, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Stant J, Fahy M, Lansky AJ, Mehran R, **Stone GW.** Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. J Interv Cardiol. 2009;22:378-84.

435. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, **Stone GW**. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198-206.

436. Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, Newman W, Sanz M, Sood P, Doostzadeh J, Su X, White R, Cao S, Sudhir K, **Stone GW.** Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the spirit III randomized trial. Catheter Cardiovasc Interv. 2009;74:719-27.

437. Brar SS, **Stone GW.** Advances in percutaneous coronary intervention. Curr Cardiol Rep. 2009;11:245-51.

438. Hamon M, Rasmussen LH, Manoukian SV, Cequier A, Lincoff MA, Rupprecht HJ, Gersh BJ, Mann T, Bertrand ME, Mehran R, **Stone GW.** Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial. EuroIntervention. 2009;5:115-20.

439. Waxman S, Dixon SR, L'Allier P, Moses JW, Petersen JL, Cutlip D, Tardif JC, Nesto RW, Muller JE, Hendricks MJ, Sum ST, Gardner CM, Goldstein JA, **Stone GW,** Krucoff MW. In vivo validation of a catheter-based near-infrared spectroscopy system for detection of lipid core coronary plaques: initial results of the SPECTACL study. JACC Cardiovasc Imaging. 2009;2:858-68.

440. Prasad A, Gersh BJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Pocock SJ, McLaurin BT, Cox DA, Lansky AJ, Mehran R, **Stone GW**. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009 Jul 28;54(5):477-86.

441. Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, **Stone GW**. Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. JACC Cardiovasc Interv. 2009 Jul;2(7):624-32.

442. Qian J, Maehara A, Mintz GS, Margolis MP, Biro S, **Stone GW,** Leon MB. Relation between individual plaque components and overall plaque burden in the prospective, multicenter virtual histology intravascular ultrasound registry. Am J Cardiol. 2009 Aug 15;104(4):501-6.

443. Miller CD, Blomkalns AL, Gersh BJ, Pollack CV, Brogan GX, Diercks DB, Peacock WF, **Stone GW,** Hollander JE, Manoukian SV, Hoekstra JW; ACUITY Investigators. Safety and efficacy of bivalirudin in high-risk patients admitted through the emergency department. Acad Emerg Med. 2009;16:717-25.

444. Mehran R, Nikolsky E, Lansky AJ, Kirtane AJ, Kim YH, Feit F, Manoukian S, Moses JW, Ebrahimi R, Ohman EM, White HD, Pocock SJ, Dangas GD, **Stone GW.** Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. JACC Cardiovasc Interv. 2009 Aug;2(8):748-57.

445. Moses JW, Leon MB, **Stone GW.** Left Main Percutaneous Coronary Intervention Crossing the Threshold: Time for a Guidelines Revision! J Am Coll Cardiol. 2009;54:1512-4.

446. Doll JA, Nikolsky E, **Stone GW,** Mehran R, Lincoff AM, Caixeta A, McLaurin B, Cristea E, Fahy M, Kesanakurthy V, Lansky AJ. Outcomes of Patients with

Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE-2, ACUITY, and HORIZONS-AMI Trials. J Interv Cardiol. 2009;22:453-9.

447. Nikolsky E, Mehran R, **Stone GW.** Gastrointestinal bleeding in percutaneous coronary intervention and acute coronary syndromes. Am J Cardiol. 2009;104(5 Suppl):22C-9C.

448. Forman DE, Cox DA, Ellis SG, Lasala JM, Ormiston JA, **Stone GW,** Turco MA, Wei JY, Joshi AA, Dawkins KD, and Baim DS. Long-Term Paclitaxel-Eluting Stent Outcomes in Elderly Patients. Circ Cardiovasc Intervent 2009;2:178-187.

449. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, **Stone GW**; for the HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149-59.

450. Friedewald VE, Gibbons RJ, O'Neill WW, Popma JJ, **Stone GW,** and Roberts WC. The Editor's Roundtable: Intracoronary Hyperoxemic Therapy in Acute Myocardial Infarction. Am J Cardiol 2009;104:791–797.

451. Nikolsky E, **Stone GW,** Lee E, Lansky AJ, Webb J, Cox DA, Brodie BR, Turco MA, Rutherford BD, Kalynych AM, Antoniucci D, Krucoff MW, Gibbons RJ, Fahy M, Mehran R. Correlations between epicardial flow, microvascular reperfusion, infarct size and clinical outcomes in patients with anterior versus non-anterior myocardial infarction treated with primary or rescue angioplasty: analysis from the EMERALD trial. EuroIntervention. 2009;5:417-24.

452. Nikolsky E, **Stone GW,** Kirtane AJ, Dangas GD, Lansky AJ, McLaurin B, Lincoff AM, Feit F, Moses JW, Fahy M, Manoukian SV, White HD, Ohman EM, Bertrand ME, Cox DA, Mehran R. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009 Sep 29;54(14):1293-302.

453. Miu R, Serruys PW, **Stone GW.** Performance of Everolimus-Eluting Stents: Pooled Analysis from the SPIRIT Trials. J Intervent Cardiol 2009;22:S41-S47.

454. Tsujita K, Maehara A, Mintz GS, Kubo T, Doi H, Lansky AJ, Stone GW, Moses JW, Leon MB, Ochiai M.Intravascular ultrasound comparison of the retrograde versus antegrade approach to percutaneous intervention for chronic total coronary occlusions. JACC Cardiovasc Interv. 2009 Sep;2(9):846-54.

455. Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA, **Stone GW.** SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J. 2009 Oct;158(4):520-526.

456. Dangas G, Mehran R, Guagliumi G, Caixeta A, Witzenbichler B, Aoki J, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Rabbani LE, Parise H, **Stone GW;** HORIZONS-AMI Trial Investigators. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents In Acute Myocardial Infarction) Trial. J Am Coll Cardiol. 2009 Oct 6;54(15):1438-46.

457. Kandzari DE, Colombo A, Park SJ, Tommaso CL, Ellis SG, Guzman LA, Teirstein PS, Tamburino C, Ormiston J, **Stone GW**, Dangas GD, Popma JJ, Bass TA; American College of Cardiology Interventional Scientific Council. Revascularization for unprotected left main disease: evolution of the evidence basis to redefine treatment standards. J Am Coll Cardiol. 2009;54:1576-88.

458. Liu X, Tsujita K, Maehara A, Mintz GS, Weisz G, Dangas GD, Lansky AJ, Kreps EM, Rabbani LE, Collins M, **Stone GW,** Moses JW, Mehran R, Leon MB. Intravascular ultrasound assessment of the incidence and predictors of edge dissections after drug-eluting stent implantation. JACC Cardiovasc Interv. 2009;2:997-1004.

459. Maehara A, Mintz GS, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA Jr, Parise H, Mehran R, **Stone GW.** Volumetric intravascular ultrasound analysis of Paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy. Circulation. 2009;120:1875-82.

460. Gordon PC, Applegate RJ, Hermiller JB, Weinsier SB, Doostzadeh J, Cao S, Sudhir K, Lansky AJ, **Stone GW.** Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry. Catheter Cardiovasc Interv. 2009;75:179-86

461. Harrington RA, **Stone GW,** McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL. Platelet Inhibition with Cangrelor in Patients Undergoing PCI. N Engl J Med. 2009;361:2318-2329.

462. Bhatt DL, Lincoff AM, Gibson CM, **Stone GW,** McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J,

Skerjanec S, Harrington RA; the CHAMPION PLATFORM Investigators. Intravenous Platelet Blockade with Cangrelor during PCI. N Engl J Med. 2009;361:2330-2341.

463. Prasad A, **Stone GW,** Holmes DR, Gersh B. Reperfusion injury, microvascular dysfunction, and cardioprotection: the "dark side" of reperfusion. Circulation. 2009;120:2105-12.

464. Hermiller JB, Fergus T, Pierson W, Su X, Sood P, Sudhir K, **Stone GW**. Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: A post hoc analysis of the SPIRIT III randomized trial. Am Heart J. 2009;158:1005-10.

465. Nakatani D, Ako J, Yamasaki M, Shimohama T, Hasegawa T, Otake H, Waseda K, Tsujino I, Sakurai R, Koo BK, Chang H, Yock PG, Sudhir K, Pierson W, **Stone GW,** Saito S, Honda Y, Fitzgerald PJ. Preprocedural Inflammation Does Not Affect Neointimal Hyperplasia following Everolimus-Eluting Stent Implantation. J Invasive Cardiol. 2009;21:613-7.

466. **Stone GW**, Mintz GS. Unprotected left main intervention: the light at the end of the tunnel? Circ Cardiovasc Interv. 2009;2:156-8.

467. Forman DE, Cox DA, Ellis SG, Lasala JM, Ormiston JA, **Stone GW,** Turco MA, Wei JY, Joshi AA, Dawkins KD, Baim DS. Long-term paclitaxel-eluting stent outcomes in elderly patients. Circ Cardiovasc Interv. 2009;2:178-87.

468. **Stone GW,** Martin JL, de Boer MJ, Margheri M, Bramucci E, Blankenship JC, Metzger DC, Gibbons RJ, Lindsay BS, Weiner BH, Lansky AJ, Krucoff MW, Fahy M, Boscardin WJ; AMIHOT-II Trial Investigators. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv. 2009;2:366-75.

469. Ellis SG, **Stone GW,** Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DS; TAXUS IV Investigators. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv. 2009 Dec;2(12):1248-59.

470. Doi H, Maehara A, Mintz GS, Yu A, Wang H, Mandinov L, Popma JJ, Ellis SG, Grube E, Dawkins KD, Weissman NJ, Turco MA, Ormiston JA, **Stone GW.** Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. JACC Cardiovasc Interv. 2009 Dec;2(12):1269-75.

471. Garcia-Garcia HM, Mintz GS, Lerman A, Vince DG, Margolis MP, van Es GA, Morel MAM, Nair A, Virmani R, Burke AP, **Stone GW,** Serruys PW. Tissue characterization using radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting. EuroIntervention 2009;5:177-189.

472. Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, **Stone GW,** Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. J Invasive Cardiol. 2010;22:2-6.

473. Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, **Stone GW**. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation. 2010;121:43-51.

474. **Stone GW.** Ticagrelor in ACS: redefining a new standard of care? Lancet. 2010;375:263-5.

475. Jeremias A, Vasu S, Gruberg L, Kastrati A, **Stone GW,** Brown DL. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. Catheter Cardiovasc Interv. 2010;75:895-902.

476. Wu X, Maehara A, Mintz GS, Kubo T, Xu K, Choi SY, He Y, Guo N, Moses JW, Leon MB, De Bruyne B, Serruys PW, **Stone GW.** Virtual histology intravascular ultrasound analysis of non-culprit attenuated plaques detected by grayscale intravascular ultrasound in patients with acute coronary syndromes. Am J Cardiol. 2010;105:48-53.

477. **Stone GW,** Pocock SJ. Randomized trials, statistics, and clinical inference. J Am Coll Cardiol. 2010 Feb 2;55(5):428-31.

478. Sanborn TA, Ebrahimi R, Manoukian SV, McLaurin BT, Cox DA, Feit F, Hamon M, Mehran R, **Stone GW.** Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Circ Cardiovasc Interv. 2010 Feb 1;3(1):57-62.

479. Onuma Y, Serruys PW, Kukreja N, Veldhof S, Doostzadeh J, Cao S, **Stone GW;** on behalf of the SPIRIT II and III Investigators. Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials. Eur Heart J. 2010;31:1071-8.

480. Seth A, Serruys PW, Lansky A, Hermiller J, Onuma Y, Miquel-Hebert K, Yu S, Veldhof S, Sood P, Sudhir K, **Stone GW.** A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. EuroIntervention. 2010 Feb;5(7):788-94.

481. Goto K, Lansky AJ, Fahy M, Cristea E, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, **Stone GW.** Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Substudy. Circulation. 2010 Feb 23;121(7):853-62.

482. Kubo T, Maehara A, Mintz GS, Garcia-Garcia HM, Serruys PW, Suzuki T, Klauss V, Sumitsuji S, Lerman A, Marso SP, Margolis MP, Margolis JR, Foster MC, De Bruyne B, Leon MB, **Stone GW.** Analysis of the long-term effects of drug-eluting stents on coronary arterial wall morphology as assessed by virtual histology intravascular ultrasound. Am Heart J. 2010 Feb;159(2):271-7.

483. Oviedo C, Maehara A, Mintz GS, Araki H, Choi SY, Tsujita K, Kubo T, Doi H, Templin B, Lansky AJ, Dangas G, Leon MB, Mehran R, Tahk SJ, **Stone GW,** Ochiai M, Moses JW. Intravascular Ultrasound Classification of Plaque Distribution in Left Main Coronary Artery Bifurcations: Where Is the Plaque Really Located? Circ Cardiovasc Interv. 2010;3:105-12.

484. Tsujita K, Maehara A, Mintz GS, Lansky AJ, Kubo T, Doi H, Yang J, Bharaj H, Witzenbichler B, Guagliumi G, Brodie BR, Kellett MA Jr, Parise H, Mehran R, **Stone GW.** Serial Intravascular Ultrasound Analysis of the Impact of Myocardial Bridge on Neointimal Proliferation After Coronary Stenting in Patients with Acute Myocardial Infarction. J Interv Cardiol. 2010;23:114-22.

485. Oviedo C, Maehara A, Mintz GS, Tsujita K, Kubo T, Doi H, Castellanos C, Lansky AJ, Mehran R, Dangas G, Leon MB, **Stone GW,** Templin B, Araki H, Ochiai M, Moses JW. Is accurate intravascular ultrasound evaluation of the left circumflex ostium from a left anterior descending to left main pullback possible? Am J Cardiol. 2010;105:948-54.

486. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tcheng JE, Mehran R, Lansky AJ, Grines CL, **Stone GW.** Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2010;(55):1416-24.

487. Kubo T, Maehara A, Mintz GS, Doi H, Tsujita K, Choi SY, Katoh O, Nasu K, Koenig A, Pieper M, Rogers JH, Wijns W, Böse D, Margolis MP, Moses JW, **Stone GW,** Leon MB. The dynamic nature of coronary artery lesion morphology

assessed by serial virtual histology intravascular ultrasound tissue characterization. J Am Coll Cardiol. 2010;55:1590-7.

488. Uchida T, Popma J, **Stone GW,** Ellis SG, Turco MA, Ormiston JA, Muramatsu T, Nakamura M, Nanto S, Yokoi H, Baim DS. The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions. JACC CV Int 2010;3:403-11.

489. He Y, Maehara A, Mintz GS, Bharaj H, Castellanos C, Kesanakurthy S, Wu X, Guo N, Choi SY, Leon MB, **Stone GW,** Mehran R, Rabbani LE, Moses JW. Intravascular ultrasound assessment of cobalt chromium versus stainless steel drug-eluting stent expansion. Am J Cardiol. 2010;105:1272-5.

490. **Stone GW,** Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-74.

491. García-García HM, Mintz GS, Lerman A, Vince DG, Margolis MP, van Es GA, Morel MA, Nair A, Virmani R, Burke AP, **Stone GW,** Serruys PW. Tissue characterisation using intravascular radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting. EuroIntervention. 2009;5:177-89.

492. Tsujita K, Nikolsky E, Lansky AJ, Dangas G, Fahy M, Brodie BR, Dudek D, Möckel M, Ochala A, Mehran R, **Stone GW.** Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). Am J Cardiol. 2010;105:1385-94.

493. Brar SS, **Stone GW.** Decision-making: stenting in acute myocardial infarction. Future Cardiol. 2010;6:301-14.

494. Steinberg DH, Mintz GS, Mandinov L, Yu A, Ellis SG, Grube E, Dawkins KD, Ormiston J, Turco MA, **Stone GW,** Weissman NJ. Long-term impact of routinely detected early and late incomplete stent apposition: an integrated intravascular ultrasound analysis of the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies. JACC Cardiovasc Interv. 2010 May;3(5):486-94.

495. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, **Stone GW.** A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010 Jun 8;55(23):2556-66.

496. Bartorelli AL, Serruys PW, Miquel-Hébert K, Yu S, Pierson W, **Stone GW;** SPIRIT II SPIRIT III Investigators. An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials. Catheter Cardiovasc Interv. 2010 Jul 1;76(1):60-6.

497. Kirtane AJ, Parise H, Mehran R, Moses JW, Fahy M, Bertrand ME, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Ware JH, Pocock SJ, Lansky AJ, **Stone GW.** Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy). Am J Cardiol. 2010;106:180-186.

498. Koizumi T, Fitzgerald PJ, Honda Y, Ellis SG, Kent K, Martin SL, Brown CL, Masud AR, Patterson JB, Greenberg J, Friedman M, Uchida T, **Stone GW.** Vascular responses to the multiple overlapped paclitaxel-eluting stents for the treatment of bare-metal in-stent restenotic lesions: angiographic and intravascular ultrasound analysis from the TAXUS-V ISR Trial. Cardiovasc Revasc Med. 2010;11(3):140-148.

499. Sanidas EA, Mintz GS, Maehara A, Choi SY, Dangas G, Leon MB, Moses JW, **Stone GW.** Intracoronary Ultrasound for Optimizing Stent Implantation. Curr Cardiovasc Imaging Rep 2010;3:230–236.

500. Shimohama T, Ako J, Yamasaki M, Otake H, Tsujino I, Hasegawa T, Nakatani D, Sakurai R, Chang H, Kusano H, Waseda K, Honda Y, **Stone GW,** Saito S, Fitzgerald PJ, Sudhir K. SPIRIT III JAPAN versus SPIRIT III USA: a comparative intravascular ultrasound analysis of the everolimus-eluting stent. Am J Cardiol. 2010 Jul 1;106(1):13-7.

501. Chen SL, Chen JP, Mintz G, Xu B, Kan J, Ye F, Zhang J, Sun X, Xu Y, Jiang Q, Zhang A, **Stone GW.** Comparison between the NERS (New Risk Stratification) score and the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score in outcome prediction for unprotected left main stenting. JACC Cardiovasc Interv. 2010;3:632-41.

502. Lansky AJ, Goto K, Cristea E, Fahy M, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, Moses J, Leon M, **Stone GW.** Clinical and Angiographic Predictors of Short- and Long-Term Ischemic Events in Acute Coronary Syndromes: Results From the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) Trial. Circ Cardiovasc Interv. 2010;3:308-16.

503. Brodie BR, Gersh BJ, Stuckey T, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Grines CL, Cox D, Parise H, Prasad A, Lansky AJ, Mehran R, **Stone GW.** When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial

Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials. J Am Coll Cardiol. 2010;56:407-13.

504. Otake H, Ako J, Yamasaki M, Tsujino I, Shimohama T, Hasegawa T, Sakurai R, Waseda K, Honda Y, Sood P, Sudhir K, **Stone GW,** Fitzgerald PJ. Comparison of Everolimus- Versus Paclitaxel-Eluting Stents Implanted in Patients With Diabetes Mellitus as Evaluated by Three-Dimensional Intravascular Ultrasound Analysis. Am J Cardiol. 2010;106:492-497.

505. Brar SS, Mintz GS, Maehara A, **Stone GW.** Applications of grayscale and radiofrequency intravascular ultrasound to image atherosclerotic plaque. J Nucl Cardiol. 2010;17:913-27.

506. Lee MS, Bokhoor P, Park SJ, Kim YH, **Stone GW,** Sheiban I, Biondi-Zoccai G, Sillano D, Tobis J, Kandzari DE. Unprotected Left Main Coronary Disease and ST-Segment Elevation Myocardial Infarction A Contemporary Review and Argument for Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2010 Aug;3(8):791-795.

507. Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, Lansky AJ, Mehran R, **Stone GW.** Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevascularizatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovasc Interv. 2010;3:796-802.

508. Guo N, Maehara A, Mintz GS, He Y, Xu K, Wu X, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA Jr, Dressler O, Parise H, Mehran R, **Stone GW**. Incidence, Mechanisms, Predictors, and Clinical Impact of Acute and Late Stent Malapposition After Primary Intervention in Patients With Acute Myocardial Infarction. An Intravascular Ultrasound Substudy of the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. Circulation. 2010;122:1077-84.

509. **Stone GW.** Acute coronary syndromes: Finding meaning in OASIS 7. Lancet. 2010;376:1203-5.

510. Brar SS, Mintz GS, Maehara A and **Stone GW.** Applications of grayscale and radiofrequency intravascular ultrasound to image atherosclerotic plaque. J Nucl Cardiol 2010;17:913-927.

511. Kedhi E, **Stone GW.** Everolimus-eluting stents: insights from the SPIRIT IV and COMPARE trials. Expert Rev Cardiovasc Ther. 2010 Sep;8(9):1207-10.

512. **Stone GW,** Mintz GS. Letter by Stone and Mintz regarding article, "Unreliable assessment of necrotic core by virtual histology intravascular ultrasound in porcine coronary artery disease". Circ Cardiovasc Imaging. 2010 Sep 1;3(5):e4.

513. Garg S, **Stone GW,** Kappetein AP, Sabik JF 3rd, Simonton C, Serruys PW. Clinical and angiographic risk assessment in patients with left main stem lesions. JACC Cardiovasc Interv. 2010 Sep;3(9):891-901.

514. Doi H, Maehara A, Mintz GS, Tsujita K, Kubo T, Castellanos C, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA Jr, Parise H, Mehran R, Leon MB, Moses JW, **Stone GW.** Intravascular ultrasound findings of stent fractures in patients with Sirolimus- and Paclitaxel-eluting stents. Am J Cardiol. 2010 Oct 1;106(7):952-7.

515. Claessen BE, **Stone GW,** Smits PC, Kedhi E, Kikkert WJ, Piek JJ, Henriques JP. Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?: A meta-analysis of a first-generation vs. a second-generation drug-eluting stent system. Neth Heart J. 2010 Sep;18(9):451-3.

516. Campbell CL, Steinhubl SR, Hooper WC, Jozic J, Smyth SS, Bernstein D, De Staercke C, Syros G, Negus BH, Stuckey T, **Stone GW,** Mehran R, Dangas G. Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy. J Thromb Thrombolysis. 2011 Feb;31(2):139-45.

517. Applegate RJ, Hermiller JJ, Sanz M, Doostzadeh J, Pierson W, Su X, Lansky AJ, Sudhir K, **Stone GW.** Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. EuroIntervention. 2010;6(4):437-46.

518. **Stone GW,** Parise H, Witzenbichler B, Kirtane A, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Lansky AJ, Mehran R. Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. J Am Coll Cardiol. 2010;56:1597-604.

519. Diercks DB, Pollack CV Jr, Hollander JE, Blomkalns AL, Emerman CL, Rokos IC, Larson DM, Hoekstra JW, Mehran R, **Stone GW.** The Time Dependence of Antithrombin Initiation in Patients With Non-ST-segment Elevation Acute Coronary Syndromes: Subgroup Analysis From the ACUITY Trial. Ann Emerg Med. 2011;57:204-212.e1-6.

520. Ben-Gal Y, Moses JW, Mehran R, Lansky AJ, Weisz G, Nikolsky E, Argenziano M, Williams MR, Colombo A, Aylward PE, **Stone GW.** Surgical versus percutaneous revascularization for multivessel disease in patients with acute

coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. JACC Cardiovasc Interv. 2010;3:1059-67.

521. Wöhrle J, Desaga M, Metzger C, Huber K, Suryapranata H, Guetta V, Guagliumi G, Witzenbichler B, Parise H, Mehran R, **Stone GW.** Impact of Transfer for primary percutaneous coronary intervention on survival and clinical outcomes (from the HORIZONS-AMI trial). Am J Cardiol. 2010;106:1218-24.

522. Sciahbasi A, Biondi-Zoccai G, Romagnoli E, Valgimigli M, Rasoul S, Van't Hof A, Lioy E, **Stone GW.** Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: A meta-analysis of randomized trials. Int J Cardiol. 2010;155:243-248.

523. Capranzano P, Mehran R, Tamburino C, **Stone GW,** Dangas G. Clinical Impact of Enhanced Inhibition of P2Y 12-Mediated Platelet Aggregation in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Hosp Pract (Minneap). 2010;38:38-43.

524. Blankenship JC, Skelding KA, Scott TD, Berger PB, Parise H, Brodie BR, Witzenbichler B, Gaugliumi G, Peruga JZ, Lansky AJ, Mehran R, **Stone GW.** Predictors of Reperfusion Delay in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention from the HORIZONS-AMI Trial. Am J Cardiol. 2010;106:1527-33.

525. Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, Su X, Su G, Farhat N, Rizvi A, Simonton CA, Sudhir K, **Stone GW.** Outcomes in Diabetic and Nondiabetic Patients Treated With Everolimus- or Paclitaxel-Eluting Stents Results From the SPIRIT IV Clinical Trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol. 2010;56:2084-9.

526. Rokos IC, French WJ, Mattu A, Nichol G, Farkouh ME, Reiffel J, **Stone GW.** Appropriate Cardiac Cath Lab activation: Optimizing electrocardiogram interpretation and clinical decision-making for acute ST-elevation myocardial infarction. Am Heart J. 2010 Dec;160(6):995-1003.

527. Kumar D, Dangas G, Mehran R, Kirtane A, Bertrand M, Ebrahimi R, Guagliumi G, Brar S, Fahy M, Heller E, Moses J, **Stone G.** Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators). Am J Cardiol. 2010;106(7):941-5.

528. Applegate R, Hermiller J, Williams J, Gordon P, Doostzadeh J, Cao S, Su X, Sudhir K, Lansky A, Simonton C, **Stone G.** Evaluation of the effects of

everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv. 2010;76(5):644-51.

529. Lansky AJ, **Stone GW.** Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv. 2010 Dec 1;3(6):602-10.

530. Gersh BJ and **Stone GW.** Pharmacological Facilitation of Coronary Intervention in ST-Segment Elevation Myocardial Infarction: Time Is of the Essence. J Am Coll Cardiol Intv 2010;3:1292–94.

531. Mikhail GW, Gerber RT, Cox DA, Ellis SG, Lasala JM, Ormiston JA, **Stone GW,** Turco MA, Joshi AA, Baim DS, and Colombo A. Influence of Sex on Long-Term Outcomes After Percutaneous Coronary Intervention With the Paclitaxel-Eluting Coronary Stent: Results of the "TAXUS Woman" Analysis. J Am Coll Cardiol Intv 2010;3:1250–59.

532. Kereiakes DJ, Sudhir K, Hermiller JB, Gordon PC, Ferguson J, Yaqub M, Sood P, Su X, Yakubov S, Lansky AJ, and **Stone GW**. Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention: The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. J Am Coll Cardiol Intv 2010;3:1229–39.

533. Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, **Stone GW.** Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents. J Am Coll Cardiol Intv 2010;3:1220–8.

534. Guagliumi G, Costa MA, Sirbu V, Musumeci G, Bezerra HG, Suzuki N, Matiashvili A, Lortkipanidze N, Mihalcsik L, Trivisonno A, Valsecchi O, Mintz GS, Dressler O, Parise H, Maehara A, Cristea E, Lansky AJ, Mehran R, **Stone GW.** Strut Coverage and Late Malapposition With Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Acute Myocardial Infarction: Optical Coherence Tomography Substudy of the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. Circulation. 2011;123:274-81.

535. Claessen BE, Mehran R, Leon MB, Heller EA, Weisz G, Syros G, Mintz GS, Franklin-Bond T, Apostolidou I, Henriques JP, **Stone GW,** Moses JW, Dangas GD. Two-Year Safety and Effectiveness of Sirolimus-Eluting Stents (from a Prospective Registry). Am J Cardiol. 2011;107(4):528-34.

536. Caixeta A, **Stone GW,** Mehran R, et al. Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial. J Thromb Thrombolysis. 2011;31:154-64.

537. **Stone GW,** Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-35.

538. Applegate RJ, Yaqub M, Hermiller JB, Sood P, Yu S, Doostzadeh J, Williams JE, Farhat N, Caputo R, Lansky AJ, Cutlip DE, Sudhir K, **Stone GW.** Long-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial). Am J Cardiol. 2011;107:833-40.

539. Ahmadi N, Hajsadeghi F, Blumenthal RS, Budoff MJ, **Stone GW,** Ebrahimi R.Mortality in Individuals Without Known Coronary Artery Disease but With Discordance Between the Framingham Risk Score and Coronary Artery Calcium. Am J Cardiol. 2011;107:799-804.

540. Harnek J, Webb JG, Kuck KH, Tschope C, Vahanian A, Buller CE, James SK, Tiefenbacher CP, **Stone GW.** Transcatheter Implantation of the MONARC Coronary Sinus Device for Mitral Regurgitation 1-Year Results From the EVOLUTION Phase I Study (Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for The Treatment of Mitral Regurgitation). JACC Cardiovasc Interv. 2011;4:115-22.

541. Ng VG, Lansky AJ, Hermiller JB, Farhat N, Applegate RJ, Yaqub M, Sood P, Su X, Simonton CA, Sudhir K, **Stone GW.** Three-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial). Am J Cardiol. 2011;107:841-8.

542. Parise H, Maehara A, **Stone GW,** Leon MB, Mintz GS. Meta-analysis of randomized studies comparing intravascular ultrasound versus angiographic guidance of percutaneous coronary intervention in pre-drug-eluting stent era. Am J Cardiol. 2011;107:374-82.

543. Hachamovitch R, Rozanski A, Shaw LJ, **Stone GW,** Thomson LE, Friedman JD, Hayes SW, Cohen I, Germano G, Berman DS. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32:1012-2].

544. Claessen B, Mehran R, **Stone GW.** Evaluating the need for a practical risk score to predict major bleeding in acute coronary syndromes. Interventional Cardiology, 2010;2:757-759.

545. Caixeta A, Dangas GD, Mehran R, Feit F, Nikolsky E, Lansky AJ, Aoki J, Moses JW, Steinhubl SR, White HD, Ohman EM, Manoukian SV, Fahy M, **Stone GW.** Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Am Heart J. 2011;161:298-306.e1.

546. Hakim DA, Dangas GD, Caixeta A, Nikolsky E, Lansky AJ, Moses JW, Claessen B, Sanidas E, White HD, Ohman EM, Manoukian SV, Fahy M, Mehran R, **Stone GW.** Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Am Heart J. 2011;161:391-6.

547. Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, **Stone GW.** Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv. 2011;4:191-7.

548. Witzenbichler B, Wöhrle J, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Hood KL, Parise H, Lansky AJ, Nikolsky E, Mehran R, **Stone GW.** Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction: The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. Circ Cardiovasc Interv. 2011;4:130-138.

549. Kahn J, **Stone GW,** Mintz GS, Cox CE, Dalton K, McKeown LA, Leon MB. TCT 2010: Clinical Trials Focus on Device-Based Therapies for Cardiovascular Disease. Rev Cardiovasc Med. 2010;11:240-7.

550. Gibson CM, Maehara A, Lansky AJ, Wohrle J, Stuckey T, Dave R, Cox D, Grines C, Dudek D, Steg G, Parise H, Wolff SD, Cristea E, **Stone GW.** Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. Am Heart J. 2011;161:478-486.

551. Sanidas EA, Maehara A, Mintz GS, Kashiyama T, Guo J, Pu J, Shang Y, Claessen B, Dangas GD, Leon MB, Moses JW, **Stone GW,** Ueda Y. Angioscopic and Virtual Histology Intravascular Ultrasound Characteristics of Culprit Lesion

Morphology Underlying Coronary Artery Thrombosis. Am J Cardiol. 2011; 107:1285-90.

552. Ambrosio G, Steinhubl S, Gresele P, Tritto I, Zuchi C, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Mehran R and **Stone GW.** Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. Eur J CV Prev & Rehab. 2011;18:121–128.

553. **Stone GW,** Goldberg S, O'Shaughnessy C, Midei M, Siegel RM, Cristea E, Dangas G, Lansky AJ, Mehran R. 5-Year Follow-Up of Polytetrafluoroethylene-Covered Stents Compared With Bare-Metal Stents in Aortocoronary Saphenous Vein Grafts The Randomized BARRICADE (Barrier Approach to Restenosis: Restrict Intima to Curtail Adverse Events) Trial. JACC Cardiovasc Interv. 2011 Mar;4(3):300-9.

554. Ormiston JA, Turco MA, Hall JJ, Cannon LA, Yakubov SJ, Lucca MJ, **Stone GW,** O'Shaughnessy CD, Kozina JA, Gilchrist IC, Bertolet BD, Worthley SG, Underwood PL, Dawkins KD. Long-Term Benefit of the TAXUS Liberté Stent in Small Vessels and Long Lesions. Circ J. 2011;75:1120-9.

555. **Stone GW,** Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD; PLATINUM Trial Investigators. A Prospective, Randomized Evaluation of a Novel Everolimus-Eluting Coronary Stent The PLATINUM (A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of up to Two De Novo Coronary Artery Lesions) Trial. J Am Coll Cardiol. 2011;57:1700-8.

556. Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möeckel M, **Stone GW;** for the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators. Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation. 2011;123:1745-1756.

557. **Stone GW,** Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, Kereiakes DJ; SPIRIT IV Investigators. Randomized Comparison of Everolimus- and Paclitaxel-Eluting Stents 2-Year Follow-Up From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV Trial. J Am Coll Cardiol. 2011;58:19-25.

558. Ben-Gal Y, **Stone GW,** Smith CR, Williams MR, Weisz G, Stewart AS, Takayama H, Genereux P, Argenziano M. On-pump versus off-pump surgical revascularization in patients with acute coronary syndromes: Analysis from the

Acute Catheterization and Urgent Intervention Triage Strategy trial. J Thorac Cardiovasc Surg. 2011;142:e33-9.

559. Kereiakes DJ, Smits PC, Kedhi E, Parise H, Fahy M, Serruys PW, **Stone GW.** Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. EuroIntervention. 2011;7:74-83.

560. Meredith IT, Whitbourn R, Scott D, El-Jack S, Zambahari R, **Stone GW,** Teirstein PS, Starzyk RM, Allocco DJ, Dawkins KD. PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses. EuroIntervention. 2011;7:84-90.

561. Galper BZ, Stant J, Reilly M, Walter S, Collins M, Sayan O, Neuberg G, Miller L, Moses JW, **Stone GW,** Giglio J, Rabbani LE. Updating the chest pain algorithm: incorporating new evidence on emerging antiplatelet agents. Crit Pathw Cardiol. 2011;10:9-16.

562. Choi SY, Witzenbichler B, Maehara A, Lansky AJ, Guagliumi G, Brodie B, Kellett MA Jr, Dressler O, Parise H, Mehran R, Dangas GD, Mintz GS, **Stone GW.** Intravascular Ultrasound Findings of Early Stent Thrombosis After Primary Percutaneous Intervention in Acute Myocardial Infarction: A Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Substudy. Circ Cardiovasc Interv. 2011;4:239-47.

563. Wu X, Mintz GS, Xu K, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA Jr, Dressler O, Parise H, Mehran R, **Stone GW,** Maehara A. The Relationship Between Attenuated Plaque Identified by Intravascular Ultrasound and No-Reflow After Stenting in Acute Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovasc Interv. 2011;4:495-502.

564. **Stone GW**, Ellis SG, Colombo A, Grube E, Popma JJ, Uchida T, Bleuit JS, Dawkins KD, Russell ME. Long-Term Safety and Efficacy of Paclitaxel-Eluting Stents Final 5-Year Analysis From the TAXUS Clinical Trial Program. JACC Cardiovasc Interv. 2011;4:530-42.

565. Harnek J, Webb JG, Kuck KH, Tschope C, Vahanian A, Buller CE, James SK, Tiefenbacher CP, **Stone GW.** EVOLUTION I Letter Reply. JACC Cardiovasc Interv. 2011;4:593-4.

566. Palmerini T, Mehran R, Dangas G, Nikolsky E, Witzenbichler B, Guagliumi G, Dudek D, Genereux P, Caixeta A, Rabbani L, Weisz G, Parise H, Fahy M, Xu K,

Brodie B, Lansky A, **Stone GW.** Impact of Leukocyte Count on Mortality and Bleeding in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Interventions: Analysis from the Harmonizing Outcome With Revascularization and Stent in Acute Myocardial Infarction Trial. Circulation. 2011;123:2829-37.

567. Dangas GD, Mehran R, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möckel M, Caixeta A, Parise H, White H, **Stone GW.** Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis. J Am Coll Cardiol. 2011;57:2309-16.

568. Lansky A, Goto K, Fahy M, Cristea E, Mehran R, **Stone GW,** Feit F, Ohman EM, Alexander KP, White HD, Bertrand ME, Desmet W, Hamon M. Response to letters regarding article, “Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy”. Circulation. 2011;123:e410-1.

569. Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R, Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, **Stone GW.** Prognostic Value of the SYNTAX Score in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) Trial. J Am Coll Cardiol. 2011;57:2389-97.

570. **Stone GW,** Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R; on behalf of the HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377:2193-204.

571. **Stone GW,** Vora K, Schindler J, Diaz C, Mann T, Dangas G, Best P, Cutlip DE; COOL-RCN Investigators. Systemic hypothermia to prevent radiocontrast nephropathy (from the COOL-RCN randomized trial). Am J Cardiol. 2011;108:741-6.

572. Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE, Caixeta A, Feit F, Manoukian SV, White H, Bertrand M, Ohman EM, Parise H, Lansky AJ, Lincoff AM, **Stone GW.** Impact of Bleeding on Mortality After Percutaneous Coronary Intervention Results From a Patient-Level Pooled Analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization

and Stents in Acute Myocardial Infarction) Trials. JACC Cardiovasc Interv. 2011;4:654-64.

573. Tricoci P, Newby LK, Hasselblad V, Kong DF, Giugliano RP, White HD, Théroux P, **Stone GW,** Moliterno DJ, Van de Werf F, Armstrong PW, Prabhakaran D, Rasoul S, Bolognese L, Durand E, Braunwald E, Califf RM, Harrington RA. Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized Clinical Trials. Circ Cardiovasc Qual Outcomes. 2011 Jul 1;4(4):448-58.

574. Hermiller JB, Nikolsky E, Lansky AJ, Applegate RJ, Sanz M, Yaqub M, Sood P, Cao S, Sudhir K, **Stone GW.** Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention. 2011;7:307-313.

575. Rokos IC, French WJ, Mattu A, Farkouh M, Reiffel J, **Stone GW.** Appropriate cardiac catheterization laboratory activation: Author reply. Am Heart J. 2011 Jul;162(1):e5.

576. Cristea E, **Stone GW,** Mehran R, Kirtane AJ, Brener SJ. Changes in reference vessel diameter in ST-segment elevation myocardial infarction after primary percutaneous coronary intervention: Implications for appropriate stent sizing. Am Heart J. 2011 Jul;162(1):173-7.

577. Brener SJ, Mehran R, Brodie BR, Guagliumi G, Witzenbichler B, Cristea E, Xu K, Lansky AJ, **Stone GW.** Predictors and Implications of Coronary Infarct Artery Patency at Initial Angiography in Patients With Acute Myocardial Infarction (from the CADILLAC and HORIZONS-AMI Trials). Am J Cardiol. 2011;108:918-23

578. Witzenbichler B, Mehran R, Guagliumi G, Dudek D, Huber K, Kornowski R, Stuckey TD, Fahy M, Parise H, **Stone GW.** Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with RevascularizatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovasc Interv. 2011;4:760-8.

579. Goto K, Lansky AJ, Nikolsky E, Fahy M, Feit F, Ohman EM, White HD, Mehran R, Bertrand ME, Desmet W, Hamon M, **Stone GW.** Prognostic Significance of Coronary Thrombus in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes A Subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial. JACC Cardiovasc Interv. 2011;4:769-77.

580. Lee MS, Stone GW, Park SJ, Teirstein P, Moses J, Colombo A, Kandzari DE. Percutaneous coronary intervention of unprotected left main coronary artery disease: Procedural strategies and technical considerations. Catheter Cardiovasc Interv. 2011;4:831-43

581. Planer D, Mehran R, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Reyes SL, **Stone GW.** Prognostic Utility of Left Ventricular End-Diastolic Pressure in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Am J Cardiol. 2011;108:1068-74.

582. Kornowski R, Mehran R, Dangas G, Nikolsky E, Assali A, Claessen BE, Gersh BJ, Wong SC, Witzenbichler B, Guagliumi G, Dudek D, Fahy M, Lansky AJ, **Stone GW;** HORIZONS-AMI Trial Investigators. Prognostic Impact of Staged Versus "One-Time" Multivessel Percutaneous Intervention in Acute Myocardial Infarction Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. J Am Coll Cardiol. 2011;58:704-11.

583. Claessen BE, Dangas GD, Godino C, Lee SW, Obunai K, Carlino M, Suh JW, Leon MB, Di Mario C, Park SJ, **Stone GW,** Moses JW, Colombo A, Mehran R; Multinational Cto Registry. Long-Term Clinical Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusions in Patients With Versus Without Diabetes Mellitus. Am J Cardiol. 2011;108:924-31.

584. **Stone GW,** Kedhi E, Kereiakes DJ, Parise H, Fahy M, Serruys PW, Smits PC. Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus. Circulation. 2011;124:893-900.

585. **Stone GW,** Maehara A, Mintz GS. The Reality of Vulnerable Plaque Detection. J Am Coll Cardiol Img. 2011;4;902-904.

586. Lee MS, Park SJ, Kandzari DE, Kirtane AJ, Fearon WF, Brilakis ES, Vermeersch P, Kim YH, Waksman R, Mehilli J, Mauri L, **Stone GW.** Saphenous Vein Graft Intervention. J Am Coll Cardiol Intv 2011;4:831-843.

587. **Stone GW,** Ohman EM. Antithrombin alternatives in STEMI. Lancet. 2011;378:643-5.

588. Goto K, Nikolsky E, Lansky AJ, Dangas G, Witzenbichler B, Parise H, Guagliumi G, Kornowski R, Claessen BE, Fahy M, Mehran R, **Stone GW.** Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). Am J Cardiol. 2011;108:1387-94.

589. Lee JB, Mintz GS, Lisauskas JB, Biro SG, Pu J, Sum ST, Madden SP, Burke AP, Goldstein J, **Stone GW,** Virmani R, Muller JE, Maehara A. Histopathologic Validation of the Intravascular Ultrasound Diagnosis of Calcified Coronary Artery Nodules. Am J Cardiol. 2011;108:1547-51.

590. **Stone GW,** Moses JW. Interventional cardiology: How should the appropriateness of PCI be judged? Nat Rev Cardiol. 2011;8:544-6.

591. Möckel M, Vollert J, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Kornowski R, Dudek D, Farkouh ME, Parise H, Mehran R, **Stone GW;** Horizons-AMI Trial Investigators. Comparison of Direct Stenting With Conventional Stent Implantation in Acute Myocardial Infarction. Am J Cardiol. 2011;108:1697-703.

592. Kirtane AJ, **Stone GW.** How to minimize stent thrombosis. Circulation. 2011;124:1283-7.

593. Ito H, Hermiller JB, Yaqub M, Newman W, Sood P, Wang JC, Cannon L, Maddux JE, Sudhir K, **Stone GW.** Performance of Everolimus-Eluting versus Paclitaxel-Eluting Coronary Stents in Small Vessels: Results from the SPIRIT III and SPIRIT IV Clinical Trials. J Interv Cardiol. 2011;24:505-513.

594. Kim JS, Wallace-Bradley D, Alviar CL, Conditt G, Milewski K, Afari ME, Cheng Y, Gallego C, Tellez A, **Stone GW,** Kaluza GL, Granada JF. Correlation of Angiographic Late Loss With Neointimal Proliferation in Stents Evaluated by OCT and Histology in Porcine Coronary Arteries. JACC Cardiovasc Imaging. 2011;4:1002-10.

595. Capodanno D, **Stone GW,** Morice MC, Bass TA, Tamburino C. Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery in Left Main Coronary Artery Disease A Meta-Analysis of Randomized Clinical Data. J Am Coll Cardiol. 2011;58:1426-1432.

596. Mehran R, Claessen BE, Godino C, Dangas GD, Obunai K, Kanwal S, Carlino M, Henriques JP, Di Mario C, Kim YH, Park SJ, **Stone GW,** Leon MB, Moses JW, Colombo A; Multinational Chronic Total Occlusion Registry. Long-Term Outcome of Percutaneous Coronary Intervention for Chronic Total Occlusions. JACC Cardiovasc Interv. 2011;4:952-961.

597. Claessen BE, Mehran R, Mintz GS, Weisz G, Leon MB, Dogan O, de Ribamar Costa J Jr, **Stone GW,** Apostolidou I, Morales A, Chantziara V, Syros G, Sanidas E, Xu K, Tijssen JG, Henriques JP, Piek JJ, Moses JW, Maehara A, Dangas GD. Impact of Intravascular Ultrasound Imaging on Early and Late Clinical Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC Cardiovasc Interv. 2011;4:974-981.

598. Saltzman AJ, **Stone GW,** Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovasc Interv. 2011;4:1011-1019.

599. Rokos IC, Farkouh ME, Reiffel J, Dressler O, Mehran R, **Stone GW.** Correlation between index electrocardiographic patterns and Pre-intervention angiographic findings: Insights from the HORIZONS-AMI trial. Catheter Cardiovasc Interv. 2011;79:1092-8.

600. Lansky AJ, Yaqub M, Hermiller JB, Smith RS, Farhat N, Caputo R, Williams JE, Sanz M, Koo K, Sood P, Sudhir K, **Stone GW.** Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention. 2010;6 Suppl J:J44-52.

601. Goldstein JA, Maini B, Dixon SR, Brilakis ES, Grines CL, Rizik DG, Powers ER, Steinberg DH, Shunk KA, Weisz G, Moreno PR, Kini A, Sharma SK, Hendricks MJ, Sum ST, Madden SP, Muller JE, **Stone GW,** Kern MJ. Detection of Lipid-Core Plaques by Intracoronary Near-Infrared Spectroscopy Identifies High Risk of Periprocedural Myocardial Infarction. Circ Cardiovasc Interv. 2011;4:429-37.

602. Kelly DJ, Gershlick T, Witzenbichler B, Guagliumi G, Fahy M, Dangas G, Mehran R, **Stone GW.** Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: The HORIZONS-AMI trial. Am Heart J. 2011;162:663-70.

603. Suh JW, Mehran R, Claessen BE, Xu K, Baber U, Dangas G, Parise H, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, **Stone GW.** Impact of In-Hospital Major Bleeding on Late Clinical Outcomes After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. J Am Coll Cardiol. 2011;58:1750-6.

604. Sievert H, Franke J, Grad Y, Nishri B, Assaf Y, Yodfat O, Römer A, Robertson GC, **Stone GW.** A Novel Carotid Device for Embolic Diversion: Lessons Learned from a "First in Man" Trial in Patients with Atrial Fibrillation. Cardiovasc Intervent Radiol. 201135:406-12.

605. Planer D, Smits PC, Kereiakes DJ, Kedhi E, Fahy M, Xu K, Serruys PW, **Stone GW.** Comparison of Everolimus- and Paclitaxel-Eluting Stents in Patients With Acute and Stable Coronary Syndromes Pooled Results From the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System)

and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials. JACC Cardiovasc Interv. 2011;4:1104-15.

606. Pu J, Mintz GS, Brilakis ES, Banerjee S, Abdel-Karim AR, Maini B, Biro S, Lee JB, **Stone GW,** Weisz G, Maehara A. In vivo characterization of coronary plaques: novel findings from comparing greyscale and virtual histology intravascular ultrasound and near-infrared spectroscopy. Eur Heart J. 2012 Feb;33(3):372-83.

607. Palmerini T, Dangas G, Mehran R, Caixeta A, Genereux P, Fahy M, Xu K, Cristea E, Lansky A, **Stone GW.** Predictors and Implications of Stent Thrombosis in Non-ST-Segment Elevation Acute Coronary Syndromes: The ACUITY Trial. Circ Cardiovasc Interv. 2011 Dec 1;4(6):577-84.

608. Généreux P, Palmerini T, Caixeta A, Cristea E, Mehran R, Sanchez R, Lazar D, Jankovic I, Corral MD, Dressler O, Fahy MP, Parise H, Lansky AJ, **Stone GW.** SYNTAX Score Reproducibility and Variability Between Interventional Cardiologists, Core Laboratory Technicians, and Quantitative Coronary Measurements. Circ Cardiovasc Interv. 2011 Dec 1;4(6):553-61.

609. Friedewald VE, Boden WE, **Stone GW,** Yancy CW, Roberts WC. The Editor's Roundtable: Role of Percutaneous Coronary Intervention and Drug-Eluting Stents in Patients With Stable Coronary Heart Disease. Am J Cardiol. 2011;108:1417-25.

610. Granada JF, Milewski K, Uribe MP, Moncada M, Fernandez A, Blanco G, Kaluza GL, Wykrzykowska JJ, Serruys PW, **Stone GW,** Delgado JA. First clinical evaluation of a luminal self-expanding shield in patients with intermediate coronary lesions. EuroIntervention. 2011;7:780-8.

611. Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, **Stone GW.** Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. JACC Cardiovasc Interv. 2011;4:1209-15.

612. Lee MS, Park SJ, Kandzari DE, Kirtane AJ, Fearon WF, Brilakis ES, Vermeersch P, Kim YH, Waksman R, Mehilli J, Mauri L, **Stone GW.** Saphenous vein graft intervention: Reply. JACC Cardiovasc Interv. 2011;4:1250-1.

613. Choi SY, Maehara A, Cristea E, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA Jr, Dressler O, Lansky AJ, Parise H, Mehran R, Mintz GS, **Stone GW.**

Usefulness of Minimum Stent Cross Sectional Area as a Predictor of Angiographic Restenosis After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the HORIZONS-AMI Trial IVUS Substudy). Am J Cardiol. 2012;109:455-60.

614. Prasad A, Dangas G, Srinivasan M, Yu J, Gersh BJ, Mehran R, **Stone GW.** Incidence and angiographic characteristics of patients with apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONS-AMI trial: An Analysis from a Multicenter, International Study of ST-elevation Myocardial Infarction. Catheter Cardiovasc Interv. 2014;83:343-8.

615. Brener SJ, Cristea E, Mehran R, Dressler O, Lansky AJ, **Stone GW.** Relationship between angiographic dynamic and densitometric assessment of myocardial reperfusion and survival in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: The Harmonizing Outcomes with Revascularization and Stents in AMI (HORIZONS-AMI) trial. Am Heart J. 2011;162:1044-51.

616. Maron DJ, **Stone GW,** Berman DS, Mancini GB, Scott TA, Byrne DW, Harrell FE Jr, Shaw LJ, Hachamovitch R, Boden WE, Weintraub WS, Spertus JA. Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists. Am Heart J. 2011;162:1034-1043.

617. Généreux P, Mehran R, Palmerini T, Caixeta A, Kirtane AJ, Lansky AJ, Brodie BR, Witzenbichler B, Mockel M, Guagliumi G, Peruga JZ, Dudek D, Fahy MP, Dangas G, **Stone GW.** Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. EuroIntervention. 2011;7:905-16.

618. Wöhrle J, Merkle N, Kunze M, Cristea E, Mehran R, Rottbauer W, **Stone GW.** Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: The HORIZONS-AMI CMRI substudy. Catheter Cardiovasc Interv. 2011;79:1083-9.

619. Nikolsky E, Mehran R, Dangas GD, Yu J, Parise H, Xu K, Pocock SJ, **Stone GW.** Outcomes of Patients Treated With Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial). Am J Cardiol. 2011;109:831-8.

620. Mehta RH, Yu J, Piccini JP, Tcheng JE, Farkouh ME, Reiffel J, Fahy M, Mehran R, **Stone GW.** Prognostic Significance of Postprocedural Sustained Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous

Coronary Intervention (from the HORIZONS-AMI Trial). Am J Cardiol. 2011;109:805-12

621. Applegate RJ, Hermiller JB, Gordon PC, Yaqub M, Sood P, Su X, Cao S, Sudhir K, **Stone GW.** Predictors of early and late outcomes after everolimus and paclitaxel-eluting coronary stents. EuroIntervention. 2011;7:1030-42.

622. Guagliumi G, Sirbu V, Musumeci G, Gerber R, Biondi-Zoccai G, Ikejima H, Ladich E, Lortkipanidze N, Matiashvili A, Valsecchi O, Virmani R, **Stone GW**. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv. 2012;5:12-20.

623. Claessen BE, Dangas GD, Weisz G, Witzenbichler B, Guagliumi G, Möckel M, Brener SJ, Xu K, Henriques JP, Mehran R, **Stone GW.** Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. Eur Heart J. 2012;33:768-75.

624. Brener SJ, Mehran R, Dressler O, Cristea E, **Stone GW.** Diabetes Mellitus, Myocardial Reperfusion, and Outcome in Patients With Acute ST-Elevation Myocardial Infarction Treated With Primary Angioplasty (from HORIZONS-AMI). Am J Cardiol. 2012;109:1111-6.

625. Kornowski R, **Stone GW.** Multivessel revascularization in ST-segment elevation myocardial infarction (letter). J Am Coll Cardiol. 2012;59:431-2.

626. **Stone GW.** Bivalirudin in acute myocardial infarction: NICE guidance. Heart. 2012;98:435-7.

627. White HD, Chew DP, Dauerman HL, Mahaffey KW, Gibson CM, **Stone GW,** Gruberg L, Harrington RA, Bhatt DL. Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012;163:182-190.

628. Acharji S, Baber U, Mehran R, Fahy M, Kirtane AJ, Lansky AJ, **Stone GW.** Prognostic Significance of Elevated Baseline Troponin in Patients With Acute Coronary Syndromes and Chronic Kidney Disease Treated With Different Antithrombotic Regimens: A Substudy From the ACUITY Trial. Circ Cardiovasc Interv. 2012;5:157-65.

629. D'Ascenzo F, Bollati M, Clementi F, Castagno D, Lagerqvist B, de la Torre Hernandez JM, Ten Berg JM, Brodie BR, Urban P, Jensen LO, Sardi G, Waksman R, Lasala JM, Schulz S, **Stone GW,** Airoldi F, Colombo A, Lemesle G, Applegate RJ, Buonamici P, Kirtane AJ, Undas A, Sheiban I, Gaita F, Sangiorgi G, Modena MG, Frati G, Biondi-Zoccai G. Incidence and predictors of coronary

stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2013;167(2):575-84.

630. Palmerini T, Caixeta A, Genereux P, Cristea E, Lansky A, Mehran R, Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, **Stone GW.** Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial. Am Heart J. 2012;163(3):383-391.

631. **Stone GW,** Clayton TC, Mehran R, Dangas G, Parise H, Fahy M, Pocock SJ. Impact of major bleeding and blood transfusions after cardiac surgery: Analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. Am Heart J. 2012;163(3):522-9.

632. Maehara A, Cristea E, Mintz GS, Lansky AJ, Dressler O, Biro S, Templin B, Virmani R, de Bruyne B, Serruys PW, **Stone GW.** Definitions and methodology for the grayscale and radiofrequency intravascular ultrasound and coronary angiographic analyses. JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S1-9.

633. Wykrzykowska JJ, Mintz GS, Garcia-Garcia HM, Maehara A, Fahy M, Xu K, Inguez A, Fajadet J, Lansky A, Templin B, Zhang Z, de Bruyne B, Weisz G, Serruys PW, **Stone GW.** Longitudinal distribution of plaque burden and necrotic core-rich plaques in nonculprit lesions of patients presenting with acute coronary syndromes. JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S10-8.

634. Claessen BE, Maehara A, Fahy M, Xu K, **Stone GW,** Mintz GS. Plaque composition by intravascular ultrasound and distal embolization after percutaneous coronary intervention. JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S111-8.

635. Brugaletta S, Garcia-Garcia HM, Serruys PW, Maehara A, Farooq V, Mintz GS, de Bruyne B, Marso SP, Verheye S, Dudek D, Hamm CW, Farhat N, Schiele F, McPherson J, Lerman A, Moreno PR, Wennerblom B, Fahy M, Templin B, Morel MA, van Es GA, **Stone GW.** Relationship between palpography and virtual histology in patients with acute coronary syndromes.JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S19-27.

636. Papadopoulou SL, Neefjes LA, Garcia-Garcia HM, Flu WJ, Rossi A, Dharampal AS, Kitslaar PH, Mollet NR, Veldhof S, Nieman K, **Stone GW,** Serruys PW, Krestin GP, de Feyter PJ. Natural history of coronary atherosclerosis by multislice computed tomography. JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S28-37.

637. Marso SP, Mercado N, Maehara A, Weisz G, Mintz GS, McPherson J, Schiele F, Dudek D, Fahy M, Xu K, Lansky A, Templin B, Zhang Z, de Bruyne B, Serruys

PW, **Stone GW.** Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S42-52.

638. Lansky AJ, Ng VG, Maehara A, Weisz G, Lerman A, Mintz GS, De Bruyne B, Farhat N, Niess G, Jankovic I, Lazar D, Xu K, Fahy M, Serruys PW, **Stone GW.** Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes. JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S62-72.

639. Sanidas EA, Mintz GS, Maehara A, Cristea E, Wennerblom B, Iñiguez A, Fajadet J, Fahy M, Dressler O, Weisz G, Templin B, Zhang Z, Lansky AJ, de Bruyne B, Serruys P, **Stone GW.** Adverse cardiovascular events arising from atherosclerotic lesions with and without angiographic disease progression. JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S95-S105.

640. Brener SJ, Mintz GS, Cristea E, Weisz G, Maehara A, McPherson JA, Marso SP, Farhat N, Botker HE, Dressler O, Xu K, Templin B, Zhang Z, Lansky AJ, de Bruyne B, Serruys PW, **Stone GW.** Characteristics and clinical significance of angiographically mild lesions in acute coronary syndromes. JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S86-94.

641. McPherson JA, Maehara A, Weisz G, Mintz GS, Cristea E, Mehran R, Foster M, Verheye S, Rabbani L, Xu K, Fahy M, Templin B, Zhang Z, Lansky AJ, de Bruyne B, Serruys PW, **Stone GW.** Residual plaque burden in patients with acute coronary syndromes after successful percutaneous coronary intervention. JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S76-85.

642. Baber U, **Stone GW,** Weisz G, Moreno P, Dangas G, Maehara A, Mintz GS, Cristea E, Fahy M, Xu K, Lansky AJ, Wennerblom B, Mathey DG, Templin B, Zhang Z, Serruys PW, Mehran R. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S53-61.

643. Guo J, Maehara A, Mintz GS, Ashida K, Pu J, Shang Y, Leon MB, **Stone GW,** Moses JW, Ochiai M. A virtual histology intravascular ultrasound analysis of coronary chronic total occlusions. Catheter Cardiovasc Interv. 2013;81(3):464-70.

644. Xu K, Mintz GS, Kubo T, Wu X, Guo N, Yang J, Witzenbichler B, Guagliumi G, Brodie B, Dressler O, Cristea E, Parise H, Mehran R, **Stone GW,** Maehara A. Long-Term Follow-Up of Attenuated Plaques in Patients With Acute Myocardial Infarction: An Intravascular Ultrasound Substudy of the HORIZONS-AMI Trial. Circ Cardiovasc Interv. 2012;5:185-92.

645. Pervaiz MH, Sood P, Sudhir K, Hermiller JB, Hou L, Hattori K, Su X, Cao S, Wang J, Applegate RJ, Kereiakes DJ, Yaqub M, **Stone GW,** Cutlip DE. Periprocedural Myocardial Infarction in a Randomized Trial of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents: Frequency and Impact on Mortality According to Historic Versus Universal Definitions. Circ Cardiovasc Interv. 2012;5:150-6.

646. Palmerini T, Biondi-Zoccai G, Riva DD, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, **Stone GW.** Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393-402.

647. Kereiakes DJ, Popma JJ, Cannon LA, Kandzari DE, Kimmelstiel CD, Meredith IT, Teirstein PS, Verheye S, Allocco DJ, Dawkins KD, **Stone GW.** Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials. EuroIntervention. 2012;8:187-95.

648. **Stone GW,** Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM; for the INFUSE-AMI Investigators. Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction: The INFUSE-AMI Randomized Trial. JAMA. 2012;307:1817-26.

649. Lansky AJ, Brar SS, Yaqub M, Sood P, Applegate RJ, Lazar D, Jankovic I, Hermiller JB, Koo K, Sudhir K, **Stone GW.** Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years. Am J Cardiol. 2012;110:21-9.

650. De Luca G, Brener SJ, Mehran R, Lansky AJ, McLaurin BT, Cox DA, Cristea E, Fahy M, **Stone GW.** Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: Insights from the ACUITY trial. Int J Cardiol. 2013;167:727-32.

651. Claessen BE, **Stone GW,** Mehran R, Witzenbichler B, Brodie BR, Wöhrle J, Witkowski A, Guagliumi G, Zmudka K, Henriques JP, Tijssen JG, Sanidas EA, Chantziara V, Hakim D, Leon S, Xu K, Dangas GD. Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. J Thromb Thrombolysis. 2012;34:165-79.

652. Généreux P, Palmerini T, Caixeta A, Rosner G, Green P, Dressler O, Xu K, Parise H, Mehran R, Serruys PW, **Stone GW**. Quantification and Impact of Untreated Coronary Artery Disease After Percutaneous Coronary Intervention:

The Residual SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) Score. J Am Coll Cardiol. 2012;59:2165-74

653. Wakabayashi K, Mintz GS, Weissman NJ, **Stone GW,** Ellis SG, Grube E, Ormiston JA, Turco MA, Pakala R, Xue Z, Desale S, Laynez-Carnicero A, Romaguera R, Sardi G, Pichard AD, Waksman R. Impact of drug-eluting stents on distal vessels. Circ Cardiovasc Interv. 2012;5:211-9.

654. Rozenman Y, Mehran R, Witzenbichler B, Dangas G, Desaga M, Kochman J, Nilsen DW, Finkelstein A, Mosseri M, **Stone GW.** Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction. Catheter Cardiovasc Interv. 2012:81:E9-E14.

655. Trenk D, **Stone GW,** Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJ. A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J Am Coll Cardiol. 2012;59:2159-64.

656. Golinvaux N, Maehara A, Mintz GS, Lansky AJ, McPherson J, Farhat N, Marso S, de Bruyne B, Serruys PW, Templin B, Cheong WF, Aaskar R, Fahy M, Mehran R, Leon M, **Stone GW.** An intravascular ultrasound appraisal of atherosclerotic plaque distribution in diseased coronary arteries. Am Heart J. 2012;163:624-31.

657. De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Díaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Cortese G, Suryapranata H, **Stone GW;** for the Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation. Drug-Eluting vs Bare-Metal Stents in Primary Angioplasty: A Pooled Patient-Level Meta-analysis of Randomized Trials. Arch Intern Med. 2012;172:611-621.

658. Rosner GF, Kirtane AJ, Genereux P, Lansky AJ, Cristea E, Gersh BJ, Weisz G, Parise H, Fahy M, Mehran R, **Stone GW.** Impact of the Presence and Extent of Incomplete Angiographic Revascularization After Percutaneous Coronary Intervention in Acute Coronary Syndromes: The ACUITY Trial. Circulation. 2012;125:2613-20.

659. Sergie Z, Mehran R, **Stone GW.** What is the optimal antithrombotic strategy in primary percutaneous coronary intervention? Curr Opin Cardiol. 2012;27:361-7.

660. McEntegart MB, Kirtane AJ, Cristea E, Brener S, Mehran R, Fahy M, Moses JW, **Stone GW.** Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention in Patients With Non-ST-Segment Elevation Acute Coronary

Syndromes Are Associated With Adverse Outcomes: Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. J Am Coll Cardiol. 2012 May 15;59(20):1745-51.

661. Dangas GD, Claessen BE, Mehran R, Brener S, Brodie BR, Dudek D, Witzenbichler B, Peruga JZ, Guagliumi G, Moses JW, Lansky AJ, Xu K, **Stone GW.** Clinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital: Results From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) Trial. J Am Coll Cardiol. 2012 May 15;59(20):1752-9.

662. Yun KH, Mintz GS, Farhat N, Marso SP, Taglieri N, Verheye S, Foster MC, Margolis MP, Templin B, Xu K, Dressler O, Mehran R, **Stone GW,** Maehara A. Relation Between Angiographic Lesion Severity, Vulnerable Plaque Morphology and Future Adverse Cardiac Events (from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree Study). Am J Cardiol. 2012;110:471-7.

663. Hermiller JB, Sudhir K, Applegate RJ, Rizvi A, Wang J, Gordon PC, Yaqub M, Cao S, Ferguson JM, Smith RS Jr, Sood P, **Stone GW.** Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. EuroIntervention. 2012 May 15;8(1):87-93.

664. Leonardi S, Mahaffey KW, White HD, Gibson CM, **Stone GW,** Steg GW, Hamm CW, Price MJ, Todd M, Dietrich M, Gallup D, Liu T, Skerjanec S, Harrington RA, Bhatt DL. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012 May;163(5):768-776.

665. Amin AP, Reynolds MR, Lei Y, Magnuson EA, Vilain K, Durtschi AJ, Simonton CA, **Stone GW,** Cohen DJ. Cost-Effectiveness of Everolimus- Versus Paclitaxel-Eluting Stents for Patients Undergoing Percutaneous Coronary Revascularization (from the SPIRIT-IV Trial). Am J Cardiol. 2012;110:765-70.

666. Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes D, Sangiorgi D, Reggiani LB, Kaiser C, Kim HS, De Waha A, Ribichini F, **Stone GW.** Stent Thrombosis With Everolimus-Eluting Stents: Meta-Analysis of Comparative Randomized Controlled Trials. Circ Cardiovasc Interv. 2012;5:357-64.

667. Xu Y, Mintz GS, Tam A, McPherson JA, Iniguez A, Fajadet J, Fahy M, Weisz G, De Bruyne B, Serruys PW, **Stone GW,** Maehara A. Prevalence, Distribution, Predictors, and Outcomes of Patients with Calcified Nodules in Native Coronary Arteries: A Three-Vessel Intravascular Ultrasound Analysis from PROSPECT. Circulation. 2012;126:537-45.

668. Singh HS, Dangas GD, Guagliumi G, Yu J, Witzenbichler B, Kornowski R, Grines C, Gersh B, Dudek D, Mehran R, **Stone GW.** Comparison of Abciximab Versus Eptifibatide During Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). Am J Cardiol. 2012;110:940-7.

669. Lee MS, Park KW, Kang SH, Sheiban I, Mahmud E, Thani KB, Cheng R, Cho JH, Jin DK, Gwon HC, Chae IH, Aragon J, Gillis K**, Stone GW,** Kim HS. Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with everolimus-eluting stents. J Invasive Cardiol. 2012 Jul;24(7):316-9.

670. Planer D, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Xu K, Fahy M, Mehran R, **Stone GW.** Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The HORIZONS-AMI trial. Int J Cardiol. 2012;167:2572-9.

671. **Stone GW.** In search of vulnerable plaque. Circ Cardiovasc Imaging. 2012;5:428-30.

672. Vranckx P, Farooq V, Garg S, Van Es GA, Silber S, Windecker S, **Stone GW,** Serruys PW. Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting. Heart. 2012;98:1424-30.

673. Rosner GF, **Stone GW,** Stant J, Burr J, Tirado A, Collins M, Moses J, Leon MB, Giglio J, Rabbani LE. Updating an institutional chest pain algorithm: incorporating new evidence on emerging pharmacotherapy. Crit Pathw Cardiol. 2012 Sep;11(3):107-13.

674. Brener SJ, Cristea E, Lansky AJ, Fahy M, Mehran R, **Stone GW.** Operator Versus Core Laboratory Assessment of Angiographic Reperfusion Markers in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction. Circ Cardiovasc Interv. 2012;5:563-9.

675. Tobbia P, Brodie BR, Stuckey T, McLaurin BT, Cox DA, Fahy M, Xu K, Mehran R, **Stone GW.** Are adverse events following an invasive strategy in patients with non-ST-segment elevation acute coronary syndromes more frequent at US Sites versus non-US sites? analysis from the ACUITY trial. Catheter Cardiovasc Interv. 2013;82:E365-74.

676. Claessen BE, Dangas GD, Godino C, Henriques JP, Leon MB, Park SJ, **Stone GW,** Moses JW, Colombo A, Mehran R; On behalf of the Multinational CTO Registry. Impact of target vessel on long-term survival after percutaneous coronary intervention for chronic total occlusions. Catheter Cardiovasc Interv. 2013;82:76-82.

677. Palmerini T, Biondi-Zoccai G, Reggiani LB, Sangiorgi D, Alessi L, De Servi S, Branzi A, **Stone GW.** Risk of stroke with coronary artery bypass graft surgery compared with percutaneous coronary intervention. J Am Coll Cardiol. 2012;60:798-805.

678. Wu X, Maehara A, He Y, Xu K, Oviedo C, Witzenbichler B, Lansky AJ, Dressler O, Parise H, **Stone GW,** Mintz GS. Plaque shift and distal embolism in patients with acute myocardial infarction: A volumetric intravascular ultrasound analysis from the HORIZONS-AMI trial. Catheter Cardiovasc Interv. 2013;82:203-9.

679. Saito S, Nakamura S, Fujii K, Nakamura M, Isshiki T, Hirayama H, Kikuchi T, Fujita H, Nonogi H, Mitsudo K, Kimura T, Igarashi K, Saito K, Lansky AJ, **Stone GW,** Honda Y, Waseda K, Fitzgerald PJ, Sudhir K. Mid-Term Results of Everolimus-Eluting Stent in a Japanese Population Compared With a US Randomized Cohort: SPIRIT III Japan Registry With Harmonization by Doing. J Invasive Cardiol. 2012;24:444-50.

680. Fleg JL, **Stone GW,** Fayad ZA, Granada JF, Hatsukami TS, Kolodgie FD, Ohayon J, Pettigrew R, Sabatine MS, Tearney GJ, Waxman S, Domanski MJ, Srinivas PR, Narula J. Detection of High-Risk Atherosclerotic Plaque: Report of the NHLBI Working Group on Current Status and Future Directions. JACC Cardiovasc Imaging. 2012;5:941-55.

681. Batchelor WB, Ellis SG, Ormiston JA, **Stone GW,** Joshi AA, Wang H, Underwood PL. Racial Differences in Long-Term Outcomes after Percutaneous Coronary Intervention with Paclitaxel-Eluting Coronary Stents. J Interv Cardiol. 2013;26:49-57.

682. Van De Hoef TP, Nolte F, Delewi R, Henriques JP, Spaan JA, Tijssen JG, Siebes M, Wykrzykowska JJ, **Stone GW,** Piek JJ. Intracoronary Hemodynamic Effects of Pressure-Controlled Intermittent Coronary Sinus Occlusion (PICSO): Results from the First-In-Man Prepare PICSO Study. J Interv Cardiol. 2012;25:549-56.

683. Kedhi E, **Stone GW,** Kereiakes DJ, Serruys PW, Parise H, Fahy M, Simonton CA, Sudhir K, Sood P, Smits PC. Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. EuroIntervention. 2012;8:599-606.

684. Nikolsky E, McLaurin BT, Cox DA, Manoukian SV, Xu K, Mehran R, **Stone GW.** Outcomes of Patients With Prior Coronary Artery Bypass Grafting and Acute Coronary Syndromes: Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. JACC Cardiovasc Interv. 2012;5:919-26.

685. Costa JR Jr, Abizaid A, Dudek D, Silber S, Leon MB, Stone GW. Rationale and design of the MGUARD for Acute ST Elevation Reperfusion (MASTER) Trial.Catheter Cardiovasc Interv. 2013;82:184-90.

686. Daneault B, Généreux P, Kirtane AJ, Witzenbichler B, Guagliumi G, Paradis JM, Fahy MP, Mehran R, **Stone GW.** Comparison of Three-Year Outcomes After Primary Percutaneous Coronary Intervention in Patients With Left Ventricular Ejection Fraction <40% Versus ≥40% (from the HORIZONS-AMI Trial). Am J Cardiol. 2013;111:12-20.

687. Claessen BE, Chieffo A, Dangas GD, Godino C, Lee SW, Obunai K, Carlino M, Chantziara V, Apostolidou I, Henriques JP, Leon MB, Di Mario C, Park SJ, **Stone GW,** Moses JW, Colombo A, Mehran R; the Multinational CTO Registry. Gender Differences in Long-Term Clinical Outcomes After Percutaneous Coronary Intervention of Chronic Total Occlusions. J Invasive Cardiol. 2012;24:484-488.

688. Ndrepepa G, Neumann FJ, Deliargyris EN, Mehran R, Mehilli J, Ferenc M, Schulz S, Schömig A, Kastrati A, **Stone GW.** Bivalirudin Versus Heparin Plus a Glycoprotein IIb/IIIa Inhibitor in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: Pooled Analysis from the ACUITY and ISAR-REACT 4 Trials. Circ Cardiovasc Interv. 2012;5:705-12.

689. Brener SJ, Weisz G, Maehara A, Mehran R, McPherson J, Farhat N, Marso SP, Fahy M, Xu K, Cristea E, Mintz GS, De Bruyne B, Serruys P, **Stone GW.** Does clinical presentation affect outcome among patients with acute coronary syndromes undergoing percutaneous coronary intervention? Insights from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study. Am Heart J. 2012 Oct;164(4):561-7.

690. Nilsen DW, Mehran R, Wu RS, Yu J, Nordrehaug JE, Brodie BR, Witzenbichler B, Nikolsky E, Fahy M, **Stone GW.** Coronary reperfusion and clinical outcomes after thrombus aspiration during primary percutaneous coronary intervention: Findings from the HORIZONS-AMI trial. Catheter Cardiovasc Interv. 2013;82:594-601.

691. Palmerini T, Sangiorgi D, Reggiani LB, Kirtane AJ, **Stone GW,** Serruys PW, Smits PC, Kedhi E, Kereiakes D, Kaiser C, Kim HS, De Waha A, Ribichini F. Response to letter regarding article, "stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials". Circ Cardiovasc Interv. 2012;5:e73.

692. Yamasaki M, Tsujino I, Lima-Filho MO, Ako J, Shimohama T, Hasegawa T, Sakurai R, Sudhir K, **Stone GW,** Waseda K, Honda Y, Fitzgerald PJ. Comparison of vascular response to the everolimus-eluting stent versus the paclitaxel-eluting stent: intravascular ultrasound results from the SPIRIT III trial. EuroIntervention. 2012;8:724-31.

693. **Stone GW.** Simple aspiration in acute myocardial infarction: too simple to be true? Eur Heart J. 2012;33:3005-7.

694. **Stone GW,** Abizaid A, Silber S, Dizon JM, Merkely B, Costa RA, Kornowski R, Abizaid A, Wojdyła R, Maehara A, Dressler O, Brener SJ, Bar E, Dudek D. Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial. J Am Coll Cardiol. 2012;60:1975-84.

695. Fiocca L, Guagliumi G, Rossini R, Parise H, Musumeci G, Sirbu V, Lortkipanidze N, Yu J, Mihalcsik L, Vassileva A, Valsecchi O, Gavazzi A, Mehran R, **Stone GW.** Characteristics and Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Excluded from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. Am J Cardiol. 2013;111:196-201.

696. Sachdeva A, Bavisetty S, Beckham G, Shen AY, Aharonian V, Mansukhani P, **Stone GW,** Leon M, Moses J, Moore N, Hyett R, Contreras R, Brar SS. Discontinuation of Long-Term Clopidogrel Therapy Is Associated With Death and Myocardial Infarction After Saphenous Vein Graft Percutaneous Coronary Intervention. J Am Coll Cardiol. 2012;60:2357-63.

697. Kahn J, Mintz GS, Dalton K, Maxwell YL, McKeown LA, Leon MB, **Stone GW.** TCT 2011: New Findings Shine a Spotlight on Novel Device-Based Therapies for Cardiovascular Disease. Rev Cardiovasc Med. 2012;13(2-3):e124-36.

698. Dangas GD, Claessen BE, Mehran R, Xu K, Fahy M, Parise H, Henriques JP, Ohman EM, White HD, **Stone GW.** Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. JACC Cardiovasc Interv. 2012 Nov;5(11):1097-105.

699. Palmerini T, Genereux P, Caixeta A, Cristea A, Lansky A, Mehran R, Della Riva D, Fahy M, Xu K, **Stone GW.** A New Score for Risk Stratification of Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The ACUITY-PCI (Acute Catheterization and Urgent Intervention Triage Strategy–Percutaneous Coronary Intervention) Risk Score. J Am Coll Cardiol Intv. 2012;5:1108-1116.

700. Jarai R, Dangas G, Huber K, Xu K, Brodie BR, Witzenbichler B, Metzger DC, Radke PW, Yu J, Claessen BE, Genereux P, Mehran R, **Stone GW.** B-type Natriuretic Peptide and Risk of Contrast-Induced Acute Kidney Injury in Acute ST-Segment Elevation Myocardial Infarction: A Substudy from the HORIZONS-AMI Trial. Circ Cardiovasc Interv. 2012;5:813-20.

701. Kikkert WJ, Claessen BE, **Stone GW,** Mehran R, Witzenbichler B, Brodie BR, Wöhrle J, Witkowski A, Guagliumi G, Zmudka K, Henriques JP, Tijssen JG, Sanidas EA, Chantziara V, Xu K, Dangas GD. Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy. J Thromb Thrombolysis. 2013;35:200-8.

702. Ruiz-García J, Lerman A, Weisz G, Maehara A, Mintz GS, Fahy M, Xu K, Lansky AJ, Cristea E, Farah TG, Teles R, Botker HE, Templin B, Zhang Z, de Bruyne B, Serruys PW, **Stone GW.** Age- and gender-related changes in plaque composition in patients with acute coronary syndrome: the PROSPECT study. EuroIntervention. 2012 Dec 20;8(8):929-38.

703. Yu J, Mehran R, Dangas GD, Claessen BE, Baber U, Xu K, Parise H, Fahy M, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, **Stone GW.** Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovasc Interv. 2012 Dec;5(12):1231-8.

704. Larsen AI, Nilsen DW, Yu J, Mehran R, Nikolsky E, Lansky AJ, Caixeta A, Parise H, Fahy M, Cristea E, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, **Stone GW.** Long-term Prognosis of Patients Presenting With ST-Segment Elevation Myocardial Infarction With No Significant Coronary Artery Disease (from The HORIZONS-AMI Trial). Am J Cardiol. 2013;111:643-8.

705. Brener SJ, Cristea E, Kirtane AJ, McEntegart MB, Xu K, Mehran R, **Stone GW.** Intra-procedural Stent Thrombosis: A New Risk Factor for Adverse Outcomes in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. JACC Cardiovasc Interv. 2013;6:36-43.

706. Hakim DA, Mintz GS, Sanidas E, Rusinova R, Weisz G, Leon MB, Moses JW, **Stone GW,** Maehara A. Serial Gray Scale Intravascular Ultrasound Findings in Late Drug-Eluting Stent Restenosis. Am J Cardiol. 2013;111:695-9.

707. De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, **Stone GW;** For the DESERT cooperation. Impact of Diabetes on Long-Term Outcome After Primary Angioplasty: Insights from the DESERT cooperation. Diabetes Care. 2013;36:1020-5.

708. Zhao Z, Witzenbichler B, Mintz GS, Jaster M, Choi SY, Wu X, He Y, Margolis MP, Dressler O, Cristea E, Parise H, Mehran R, **Stone GW,** Maehara A. Dynamic Nature of Nonculprit Coronary Artery Lesion Morphology in STEMI: A Serial

IVUS Analysis From the HORIZONS-AMI Trial. JACC Cardiovasc Imaging. 2013;6:86-95.

709. Dangas GD, Claessen BE, Mehran R, Xu K, **Stone GW.** Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. EuroIntervention. 2013;8:1033-9.

710. Yakushiji T, Maehara A, Mintz GS, Saito S, Araki H, Oviedo C, Choi SY, Tahk SJ, Leon MB, **Stone GW,** Moses JW, Ochiai M. An intravascular ultrasound comparison of left anterior descending artery/first diagonal branch versus distal left main coronary artery bifurcation lesions. EuroIntervention. 2013;8:1040-6.

711. Cubeddu RJ, Palacios IF, Blankenship JC, Horvath SA, Xu K, Kovacic JC, Dangas GD, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, **Stone GW,** Mehran R. Outcome of Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention During On-Versus Off-hours (A Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial Substudy). Am J Cardiol. 2013;111:946-54.

712. Rusinova RP, Mintz GS, Choi SY, Araki H, Hakim D, Sanidas E, Yakushiji T, Weisz G, Mehran R, Franklin-Bond T, Fahy M, Leon MB, **Stone GW,** Moses JW, Tahk SJ, Ochiai M, Maehara A. Intravascular Ultrasound Comparison of Left Main Coronary Artery Disease Between White and Asian Patients. Am J Cardiol. 2013;111:979-84.

713. Tamburino C, Capranzano P, Capodanno D, Dangas G, Zimarino M, Bass TA, Mehran R, Antoniucci D, Colombo A, La Manna A, Di Salvo ME, **Stone GW.** Percutaneous recanalization of chronic total occlusions: Wherein lies the body of proof? Am Heart J. 2013;165:133-42.

714. Dudek D, Mehran R, Dziewierz A, Witzenbichler B, Brodie BR, Kornowski R, Fahy M, Lansky AJ, Rakowski T, Legutko J, Bryniarski L, **Stone GW.** Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: The HORIZONS-AMI trial. Catheter Cardiovasc Interv. 2013;82(6):869-77.

715. Lee PV; Compiled by Morton Kern from the comments of, Rao SV, Bell M, Ragosta M, Welt F, Ohman EM, Uretsky B, De Bruyne B, Garratt KN, Rosenfield K, Turi Z, Bass TA, Tommaso C, Mintz GS, Vetrovec G, Krucoff MW, Yeung AC, Kereiakes DJ, Klein LW, Weiner B, **Stone GW,** Samady H, Applegate R, Bailey S, Bach R, Jeremias A, Pichard A, Morrison D. Conversation in cardiology: Should FFR and IVUS be counted as PCI? Catheter Cardiovasc Interv. 2013;82:110-5.

716. Biondi-Zoccai G, Frati G, D'Ascenzo F, **Stone GW,** Lotrionte M, Palmerini T. Network meta-analyses and mixed treatment comparisons: Are they true scientific endeavors? Int J Cardiol. 2013;168:1575-1576.

717. Palmerini T, Généreux P, Mehran R, Dangas G, Caixeta A, Della Riva D, Mariani A, Xu K, **Stone GW.** Association Among Leukocyte Count, Mortality, and Bleeding in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] Trial). Am J Cardiol. 2013;111:1237-45.

718. Navarese EP, Gurbel PA, Andreotti F, Tantry U, Jeong YH, Kozinski M, Engstrøm T, Di Pasquale G, Kochman W, Ardissino D, Kedhi E, **Stone GW,** Kubica J. Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review and Meta-analysis. Ann Intern Med. 2013;158:261-70.

719. Kereiakes DJ, **Stone GW.** In mildly symptomatic patients, should an invasive strategy with catheterization and revascularization be routinely undertaken?: In mildly symptomatic patients, an invasive strategy with catheterization and revascularization should be routinely undertaken. Circ Cardiovasc Interv. 2013;6:107-13.

720. Tobbia P, Brodie BR, Witzenbichler B, Metzger C, Guagliumi G, Yu J, Kellett MA, Stuckey T, Fahy M, Mehran R, **Stone GW.** Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. EuroIntervention. 2013;8:1134-42.

721. Leonardi S, Truffa AA, Neely ML, Tricoci P, White HD, Gibson CM, Wilson M, **Stone GW,** Harrington RA, Bhatt DL, Mahaffey KW. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart. 2013;99:1282-7.

722. Hoebers LP, Claessen BE, Dangas GD, Park SJ, Colombo A, Moses JW, Henriques JP, **Stone GW,** Leon MB, Mehran R; on behalf of the Multinational CTO Registry. Long-term clinical outcomes after percutaneous coronary intervention for chronic total occlusions in elderly patients (≥75 years): Five-year outcomes from a 1,791 patient multi-national registry. Catheter Cardiovasc Interv. 2013;82:85-92.

723. Leonardi S, Stebbins A, Lopes RD, Lokhnygina Y, Todd M, Bhatt DL, **Stone GW,** Lincoff AM, Dauerman HL, Gibson CM, White HD, Parikh KH, Gruberg L, Herrmann HC, McLaurin BT, Goodman SG, Mahaffey KW. Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the

CHAMPION percutaneous coronary intervention trial. Coron Artery Dis. 2013;24:321-7.

724. Nikolsky E, Mehran R, Yu J, Witzenbichler B, Brodie BR, Kornowski R, Brenner S, Xu K, Dangas GD, **Stone GW.** Comparison of Outcomes of Patients With ST-Segment Elevation Myocardial Infarction With Versus Without Previous Coronary Artery Bypass Grafting (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial). Am J Cardiol. 2013;111:1377-86.

725. Bhatt DL, **Stone GW,** Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; the CHAMPION PHOENIX Investigators. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. N Engl J Med. 2013;368:1303-13.

726. De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, **Stone GW;** DESERT Cooperation. Meta-Analysis Comparing Efficacy and Safety of First Generation Drug-Eluting Stents to Bare-Metal Stents in Patients With Diabetes Mellitus Undergoing Primary Percutaneous Coronary Intervention. Am J Cardiol. 2013;111:1295-304.

727. Yakushiji T, Inaba S, Maehara A, Brener SJ, Witzenbichler B, Guagliumi G, Brodie BR, Kellett MA Jr, Xu K, Mehran R, Mintz GS, **Stone GW.** Frequency, Mechanisms, and Implications of Late Peri-Stent Contrast Staining: Analysis (from the HORIZONS-AMI Trial). Am J Cardiol. 2013;111:1587-92.

728. Forrest JK, Lansky AJ, Meller SM, Hou L, Sood P, Applegate RJ, Wang JC, Skelding KA, Shah A, Kereiakes DJ, Sudhir K, Cristea E, Yaqub M, **Stone GW.** Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years. Am J Cardiol. 2013;111:1580-6.

729. Kereiakes DJ, **Stone GW.** Appropriate Use Criteria to Reduce Underuse and Overuse of Revascularization. J Am Coll Cardiol. 2013;61:2024.

730. Caixeta A, Lansky AJ, Mehran R, Brener SJ, Claessen B, Généreux P, Palmerini T, Witzenbichler B, Guagliumi G, Brodie BR, Dudek D, Fahy M, Dangas GD, **Stone GW.** Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. EuroIntervention. 2013;9:220-7.

731. Rakowski T, Dudek D, Dziewierz A, Yu J, Witzenbichler B, Guagliumi G, Kornowski R, Hartmann F, Lansky AJ, Brener SJ, Mehran R, Stone GW. Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. EuroIntervention. 2013;8:1307-14.

732. Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW, Bhatt DL, Goto S, Cohen M, Mohanavelu S, Burton P, **Stone G,** Braunwald E. Reduction of Stent Thrombosis in Patients with Acute Coronary Syndrome Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51. J Am Coll Cardiol. 2013;62:286-90.

733. Guo J, Maehara A, Guo N, Ashida K, Chirumamilla A, Shang Y, Pu J, Sanidas E, Moses JW, Leon MB, Weisz G, **Stone GW,** Mintz GS, Ochiai M. Virtual histology intravascular ultrasound comparison of coronary chronic total occlusions versus non-occlusive lesions. Int J Cardiovasc Imaging. 2013;29:1249-54.

734. **Stone GW.** The next 10 years in interventional cardiology. Expert Rev Cardiovasc Ther. 2013;11:537-40.

735. Farkouh ME, Reiffel J, Dressler O, Nikolsky E, Parise H, Cristea E, Baran DA, Dizon J, Merab JP, Lansky AJ, Mehran R, **Stone GW.** Relationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention: The HORIZONS-AMI ECG Substudy Report. Circ Cardiovasc Interv. 2013;6:216-23.

736. De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, **Stone GW;** DESERT cooperation. Impact of Age on Long-Term Outcome After Primary Angioplasty With Bare-Metal or Drug-Eluting Stent (From the DESERT Cooperation). Am J Cardiol. 2013;112:181-6.

737. Palmerini T, Biondi-Zoccai G, Riva DD, Mariani A, Savini C, Eusanio MD, Genereux P, Frati G, Marullo AG, Landoni G, Greco T, Branzi A, Servi SD, Credico GD, Taglieri N, Williams MR, **Stone GW**. Risk of stroke with percutaneous coronary intervention compared with on-pump and off-pump coronary artery bypass graft surgery: Evidence from a comprehensive network meta-analysis. Am Heart J. 2013;165:910-917.

738. Mehta RH, Harjai KJ, Boura JA, Tcheng JE, Dixon SR, **Stone GW,** Grines CL. Short-term outcomes of balloon angioplasty versus stent placement for patients undergoing primary percutaneous coronary intervention: Implications for patients requiring early coronary artery bypass surgery. Am Heart J. 2013;165:1000-7.

739. Wöhrle J, Brodie B, Witzenbichler B, Dudek D, Kornowski R, Metzger C, Grines C, McAndrew TC, Parise H, Sergie Z, Mehran R, **Stone GW.** Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery. Am J Cardiol. 2013;112:753-60.

740. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, **Stone GW.** Clinical Outcomes with Drug-Eluting and Bare Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction: Evidence from a Comprehensive Network Meta-analysis. J Am Coll Cardiol. 2013;62:496-504.

741. Brener SJ, Dambrink JH, Maehara A, Chowdhary S, Gershlick AH, Genereux P, Koolen J, Mehran R, Fahy M, Gibson CM, **Stone GW.** Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI. EuroIntervention. 2014;9:1195-201.

742. Mindrescu C, Brener SJ, Guerchicoff A, Fahy M, Parise H, Mehran R, **Stone GW.** Impact of Scheduled Angiographic Follow-Up in Patients Treated With Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. J Interv Cardiol. 2013;26:319-24.

743. Brener SJ, Witzenbichler B, Maehara A, Dizon J, Fahy M, El-Omar M, Dambrink JH, Genereux P, Mehran R, Oldroyd K, Parise H, Gibson CM, **Stone GW.** Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: The Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial. Am Heart J. 2013;166:64-70.

744. Meller SM, Lansky AJ, Costa RA, Soffler M, Costantini CO, Brodie BR, Cox DA, Stuckey TD, Fahy M, Grines CL, **Stone GW.** Implications of Myocardial Reperfusion on Survival in Women Versus Men With Acute Myocardial Infarction Undergoing Primary Coronary Intervention. Am J Cardiol. 2013;112:1087-1092.

745. Dohi T, Mintz GS, McPherson JA, de Bruyne B, Farhat NZ, Lansky AJ, Mehran R, Weisz G, Xu K, **Stone GW,** Maehara A. Non-Fibroatheroma Lesion Phenotype and Long-Term Clinical Outcomes: A Substudy Analysis From the PROSPECT Study. JACC Cardiovasc Imaging. 2013;6:908-16.

746. Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, **Stone GW.** Pulmonary artery denervation to treat pulmonary arterial hypertension: a single-center, prospective, first-in-man PADN-1 study. J Am Coll Cardiol. 2013;62:1092-100.

747. De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera

LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, **Stone GW;** for the DESERT cooperation. Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation. Thromb Haemost. 2013;110:826-33.

748. Brener SJ, Maehara A, Dizon JM, Fahy M, Witzenbichler B, Parise H, El-Omar M, Dambrink JH, Mehran R, Oldroyd K, Gibson CM, **Stone GW** Relationship Between Myocardial Reperfusion, Infarct Size, and Mortality: The INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) Trial. JACC Cardiovasc Interv. 2013;6:718-24.

749. Farooq V, Vergouwe Y, Généreux P, Bourantas CV, Palmerini T, Caixeta A, Garcìa-Garcìa HM, Diletti R, Morel MA, McAndrew TC, Kappetein AP, Valgimigli M, Windecker S, Dawkins KD, Steyerberg EW, Serruys PW, **Stone GW.** Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Validation of the Logistic Clinical SYNTAX (Synergy Between Percutaneous Coronary Interventions With Taxus and Cardiac Surgery) Score. JACC Cardiovasc Interv. 2013;6:737-45.

750. Madder RD, Goldstein JA, Madden SP, Puri R, Wolski K, Hendricks M, Sum ST, Kini A, Sharma S, Rizik D, Brilakis ES, Shunk KA, Petersen J, Weisz G, Virmani R, Nicholls SJ, Maehara A, Mintz GS, **Stone GW,** Muller JE.Detection by Near-Infrared Spectroscopy of Large Lipid Core Plaques at Culprit Sites in Patients With Acute ST-Segment Elevation Myocardial Infarction. JACC Cardiovasc Interv. 2013;6:838-46.

751. Khattab AA, Stieger S, Kamat PJ, Vandenberghe S, Bongoni A, **Stone GW,** Seiler C, Meier B, Hess OM, Rieben R. Effect of pressure-controlled intermittent coronary sinus occlusion (PICSO) on myocardial ischaemia and reperfusion in a closed-chest porcine model. EuroIntervention. 2013;9:398-406.

752. **Stone GW,** Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD; for the ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382:614-23.

753. Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, **Stone GW.** Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization an expert consensus document from the society for cardiovascular angiography and interventions (SCAI). Catheter Cardiovasc Interv. 2014;83(1):27-36.

754. Kikkert WJ, Claessen BE, **Stone GW,** Mehran R, Witzenbichler B, Brodie BR, Wöhrle J, Witkowski A, Guagliumi G, Zmudka K, Henriques JP, Tijssen JG,

Sanidas EA, Chantziara V, Xu K, Dangas GD. D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy. J Thromb Thrombolysis. 2014;37:155-64.

755. Yadav M, Palmerini T, Caixeta A, Madhavan MV, Sanidas E, Kirtane AJ, **Stone GW,** Généreux P. Prediction of Coronary Risk by SYNTAX and Derived Scores. J Am Coll Cardiol. 2013;62(14):1219-30.

756. Windecker S, Bax JJ, Myat A, **Stone GW,** Marber MS. Future treatment strategies in ST-segment elevation myocardial infarction. Lancet. 2013;382:644-57.

757. De Luca G, Verdoia M, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, Hoeven Bv, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, **Stone GW;** DESERT Cooperation. Gender-related differences in outcome after BMS or DES implantation in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: Insights from the DESERT cooperation. Atherosclerosis. 2013;230:12-6.

758. Phillips LM, Hachamovitch R, Berman DS, Iskandrian AE, Min JK, Picard MH, Kwong RY, Friedrich MG, Scherrer-Crosbie M, Hayes SW, Sharir T, Gosselin G, Mazzanti M, Senior R, Beanlands R, Smanio P, Goyal A, Al-Mallah M, Reynolds H, **Stone GW,** Maron DJ, Shaw LJ. Lessons learned from MPI and physiologic testing in randomized trials of stable ischemic heart disease: COURAGE, BARI 2D, FAME, and ISCHEMIA. J Nucl Cardiol. 2013;20:969-75.

759. Stefanini GG, Baber U, Windecker S, Morice MC, Sartori S, Leon MB, **Stone GW,** Serruys PW, Wijns W, Weisz G, Camenzind E, Steg PG, Smits PC, Kandzari D, Von Birgelen C, Galatius S, Jeger RV, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet. 2013;382(9908):1879-88.

760. Steg PG, Bhatt DL, Hamm CW, **Stone GW,** Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA; for the CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382:1981-92.

761. Ertelt K, Généreux P, Mintz GS, Reiss GR, Kirtane AJ, Madhavan MV, Fahy M, Williams MR, Brener SJ, Mehran R, **Stone GW.** Impact of the Severity of Coronary Artery Calcification on Clinical Events in Patients Undergoing Coronary Artery Bypass Grafting (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). Am J Cardiol. 2013;112(11):1730-7.

762. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, **Stone GW.** Response to letter by Messeri et al. Am Heart J. 2013;166(3):e19.

763. Sanidas EA, Brener SJ, Maehara A, Généreux P, Witzenbichler B, El-Omar M, Fahy M, Mehran R, Gibson CM, **Stone GW.** Outcomes in diabetic patients undergoing primary percutaneous coronary intervention for acute anterior myocardial infarction: Results from the INFUSE-AMI study. Catheter Cardiovasc Interv. 2014;83:704-10.

764. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Genereux P, Branzi A, **Stone GW.** Stent Thrombosis with Drug-Eluting Stents: Is the Paradigm Shifting? J Am Coll Cardiol. 2013;62(21):1915-21.

765. Geisler T, Müller K, Karathanos A, Bocksch W, Gawaz M, Deliargyris E, Bernstein D, Lincoff AM, Mehran R, Dangas G, **Stone GW.** Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. EuroIntervention. 2014;10:97-104.

766. Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, **Stone GW.** Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease: Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2013;6:914-22.

767. Palmerini T, Brener SJ, Genereux P, Maehara A, Della Riva D, Mariani A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Fahy M, Xu K, Gibson CM, **Stone GW.** Relation Between White Blood Cell Count and Final Infarct Size in Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the INFUSE AMI Trial). Am J Cardiol. 2013;112(12):1860-6.

768. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, **Stone GW,** Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to ADP Associated with Ischemia and Bleeding. J Am Coll Cardiol. 2013;62(24):2261-73.

769. Palmerini T, Brener SJ, Mehran R, Dangas G, Genereux P, Riva DD, Mariani A, Xu K, **Stone GW.** Leukocyte Count Is a Modulating Factor for the Mortality Benefit of Bivalirudin in ST-Segment-Elevation Acute Myocardial Infarction: The HORIZONS-AMI Trial. Circ Cardiovasc Interv. 2013;6(5):518-26.

770. **Stone GW,** Witzenbichler B, Godlewski J, Dambrink JH, Ochala A, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Dizon JM, Wolff SD, Brener SJ, Mehran R, Maehara A, Gibson CM. Intralesional Abciximab and Thrombus Aspiration in Patients With Large Anterior Myocardial Infarction: One-Year Results From the INFUSE-AMI Trial. Circ Cardiovasc Interv. 2013;6(5):527-34.

771. Brener SJ, Dizon JM, Mehran R, Guerchicoff A, Lansky AJ, Farkouh M, Brodie B, Guagliumi G, Witzenbichler B, Fahy M, Parise H, **Stone GW.** Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: Analysis from the HORIZONS-AMI trial. Am Heart J. 2013;166:676-683.

772. Maehara A, Mintz GS, **Stone GW.** OCT Versus IVUS: Accuracy Versus Clinical Utility. JACC Cardiovasc Imaging. 2013 Oct;6(10):1105-7.

773. **Stone GW,** Narula J. The myth of the mild vulnerable plaques. JACC Cardiovasc Imaging. 2013;6:1124-6.

774. Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, **Stone GW.** Consideration of a New Definition of Clinically Relevant Myocardial Infarction After Coronary Revascularization: An Expert Consensus Document From the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013;62:1563-70.

775. **Stone GW,** Clayton T, Deliargyris EN, Prats J, Mehran R, Pocock SJ. Reduction in Cardiac Mortality with Bivalirudin in Patients With and Without Major Bleeding: The HORIZONS-AMI Trial. J Am Coll Cardiol. 2014;63:15-20.

776. Rao SV, Turi ZG, Wong SC, Brener SJ, **Stone GW.** Radial versus femoral access. J Am Coll Cardiol. 2013 Oct 22;62(17 Suppl):S11-20.

777. Angiolillo DJ, Ferreiro JL, Price MJ, Kirtane AJ, **Stone GW.** Platelet function and genetic testing. J Am Coll Cardiol. 2013 Oct 22;62(17 Suppl):S21-31.

778. Kirtane AJ, Sandhu P, Mehran R, McEntegart M, Cristea E, Brener SJ, Xu K, Fahy M, Généreux P, Wessler JD, **Stone GW.** Association Between Intraprocedural Thrombotic Events and Adverse Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (a Harmonizing Outcomes With RevascularizatiON and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Substudy). Am J Cardiol. 2014;113(1):36-43.

779. Caixeta A, Généreux P, Palmerini T, Lansky AJ, Mehran R, Dangas GD, Xu K, Brener SJ, **Stone GW.** Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary

Intervention (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] Trial). Am J Cardiol. 2014;113(2):203-10.

780. Rene AG, Généreux P, Ezekowitz M, Kirtane AJ, Xu K, Mehran R, Brener SJ, **Stone GW.** Impact of Atrial Fibrillation in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] Trial). Am J Cardiol. 2014;113(2):236-42.

781. Généreux P, **Stone GW,** Harrington RA, Gibson CM, Steg PG, Brener SJ, Angiolillo DJ, Price MJ, Prats J, Lasalle L, Liu T, Todd M, Skerjanec S, Hamm CW, Mahaffey KW, White HD, Bhatt DL. Impact of Intra-procedural Stent Thrombosis during Percutaneous Coronary Intervention: Insights from the CHAMPION PHOENIX Trial. J Am Coll Cardiol. 2014;63(7):619-29.

782. Jeremias A, Maehara A, Généreux P, Asrress KN, Berry C, De Bruyne B, Davies JE, Escaned J, Fearon WF, Gould KL, Johnson NP, Kirtane AJ, Koo BK, Marques KM, Nijjer S, Oldroyd KG, Petraco R, Piek JJ, Pijls NH, Redwood S, Siebes M, Spaan JA, Van't Veer M, Mintz GS, **Stone GW.** Multicenter Core Laboratory Comparison of the Instantaneous Wave-Free Ratio and Resting Pd/Pa with Fractional Flow Reserve: The RESOLVE Study. J Am Coll Cardiol. 2014;63:1253-61.

783. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Smits PC, Kaiser C, D'Ascenzo F, Frati G, Mancone M, Genereux P, **Stone GW.** Clinical Outcomes with Bioabsorbable Polymer-based versus Durable Polymer-based Drug-Eluting Stents and Bare Metal Stents: Evidence from a Comprehensive Network Meta-analysis. J Am Coll Cardiol. 2014;63(4):299-307.

784. Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, **Stone GW.** Five-Year Results of a Randomized Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting Stents: Final Results From the SPIRIT III Trial. JACC Cardiovasc Interv. 2013;6(12):1263-6.

785. Lee MS, Wolfe M, **Stone GW.** Transradial versus transfemoral percutaneous coronary intervention in acute coronary syndromes: re-evaluation of the current body of evidence. JACC Cardiovasc Interv. 2013;6:1149-52.

786. Weisz G, Farzaneh-Far R, Ben-Yehuda O, Debruyne B, Montalescot G, Lerman A, Mahmud E, Alexander KP, Ohman EM, White HD, Olmsted A, Walker GA, **Stone GW.** Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial. Am Heart J. 2013;166:953-959.e3.

787. Brener SJ, Kereiakes DJ, Simonton CA, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Smith RS Jr, Ying SW, Cutlip DE, **Stone GW.** Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: Final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Am Heart J. 2013;166:1035-42.

788. Bourantas CV, Garcia-Garcia HM, Farooq V, Maehara A, Xu K, Généreux P, Diletti R, Muramatsu T, Fahy M, Weisz G, **Stone GW,** Serruys PW. Clinical and Angiographic Characteristics of Patients Likely to Have Vulnerable Plaques: Analysis From the PROSPECT Study. JACC Cardiovasc Imaging. 2013;6(12):1263-72.

789. Dudek D, Mehran R, Dziewierz A, Brener SJ, Rakowski T, Brzezinski M, Brodie BR, Xu K, Fahy M, Lansky AJ, Zmudka K, **Stone GW.** Impact of bifurcation target lesion on angiographic, electrocardiographic, and clinical outcomes of patients undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). EuroIntervention. 2013;9:817-23.

790. Witzenbichler B, Maehara A, Weisz G, Neumann FJ, Rinaldi MJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Brodie BR, Stuckey TD, Mazzaferri EL Jr, Xu K, Parise H, Mehran R, Mintz GS, **Stone GW.** Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents: The ADAPT-DES Study. Circulation. 2014;129(4):463-70.

791. Nascimento FO, Yang S, Larrauri-Reyes M, Pineda AM, Cornielle V, Santana O, Heimowitz TB, **Stone GW,** Beohar N. Usefulness of the Troponin-Ejection Fraction Product to Differentiate Stress Cardiomyopathy from ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2014;113(3):429-33.

792. Meier P, Lansky AJ, Fahy M, Xu K, White HD, Bertrand ME, Mehran R, **Stone GW.** The impact of the coronary collateral circulation on outcomes in patients with acute coronary syndromes: results from the ACUITY trial. Heart. 2014;100:647-51

793. Nazif TM, Mehran R, Lee EA, Fahy M, Parise H, Stone GW, Kirtane AJ. Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. Am Heart J. 2014;167(1):43-50.

794. Inaba S, Mintz GS, Shimizu T, Weisz G, Mehran R, Marso SP, Xu K, de Bruyne B, Serruys PW, **Stone GW,** Maehara A. Compensatory enlargement of the left main coronary artery: insights from the PROSPECT study. Coron Artery Dis. 2014;25(2):98-103.

795. Palmerini T, Tomasi L, Barozzi C, Della Riva D, Mariani A, Taglieri N, Leone O, Ceccarelli C, Servi SD, Branzi A, Genereux P, **Stone GW,** Ahamed J. Detection of Tissue Factor Antigen and Coagulation Activity in Coronary Artery. Thrombi Isolated from Patients with ST-Segment Elevation Acute Myocardial Infarction. PLoS ONE 2013:8(12):e81501. doi:10.1371/journal.pone.0081501.

796. **Stone GW.** Acute coronary syndromes in 2013: Optimizing revascularization strategies in patients with ACS. Nat Rev Cardiol. 2014;11(2):67-8.

797. Kern MJ, Applegate RJ, Bell M, Brilakis ES, Butman SM, Bach RG, Kaul P, Klein LW, Krucoff MW, Moore JA, Price MJ, Rao SV, **Stone GW,** Uretsky BF. Conversations in Cardiology: Bridging antiplatelet therapy before surgery. Catheter Cardiovasc Interv. 2014;83:748-52.

798. Yadav M, Généreux P, Palmerini T, Caixeta A, Madhavan MV, Xu K, Brener SJ, Mehran R, **Stone GW.** SYNTAX Score and the risk of stent thrombosis after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: An ACUITY trial substudy. Catheter Cardiovasc Interv. 2015;85:1-10.

799. Inaba S, Mintz GS, Farhat NZ, Fajadet J, Dudek D, Marzocchi A, Templin B, Weisz G, Xu K, de Bruyne B, Serruys PW, **Stone GW,** Maehara A. Impact of Positive and Negative Lesion Site Remodeling on Clinical Outcomes: Insights From PROSPECT. JACC Cardiovasc Imaging. 2014 Jan;7(1):70-8.

800. Généreux P, Madhavan MV, Mintz GS, Maehara A, Kirtane AJ, Palmerini T, Tarigopula M, McAndrew T, Lansky AJ, Mehran R, Brener SJ, **Stone GW.** Relation Between Coronary Calcium and Major Bleeding After Percutaneous Coronary Intervention in Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy and Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trials). Am J Cardiol. 2014;113(6):930-5.

801. Saito S, Hagiwara N, Seki A, Igarashi K, Muramatsu T, Yajima J, Yokoi H, Nakamura M, Fujii K, Isshiki T, **Stone GW,** Teirstein PS, Meredith IT, Allocco DJ, Dawkins KD. Japanese and non-Japanese patient outcomes in the PLATINUM randomized trial comparing the PROMUS Element and XIENCE V everolimus-eluting stents. J Cardiol. 2014;64:105-12.

802. Wang TY, McCoy L, Henry TD, Effron MB, Messenger JC, Cohen DJ, Mark DB, **Stone GW,** Zettler M, Singh M, Fonarow GC, Peterson ED; TRANSLATE-ACS Study Investigators. Early Post-Discharge Bleeding and Antiplatelet Therapy Discontinuation Among Acute Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention. J Am Coll Cardiol. 2014;63:1700-2

803. Dangas GD, Kini AS, Sharma SK, Henriques JP, Claessen BE, Dixon SR, Massaro JM, Palacios I, Popma JJ, Ohman M, **Stone GW,** O'Neill WW. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). Am J Cardiol. 2014;113:222-8.

804. Meredith IT, Teirstein PS, Bouchard A, Carrié D, Möllmann H, Oldroyd KG, Hall J, Allocco DJ, Dawkins KD, **Stone GW.** Three-Year Results Comparing Platinum-Chromium PROMUS Element and Cobalt-Chromium XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Narrowing (from the PLATINUM Trial). Am J Cardiol. 2014;113:1117-23.

805. Madhavan MV, Tarigopula M, Mintz GS, Maehara A, **Stone GW,** Généreux P. Coronary Artery Calcification: Pathogenesis and Prognostic Implications. J Am Coll Cardiol. 2014;63:1703-14.

806. Généreux P, Madhavan MV, Mintz GS, Maehara A, Palmerini T, Lasalle L, Xu K, McAndrew T, Kirtane A, Lansky AJ, Brener SJ, Mehran R, **Stone GW.** Ischemic Outcomes after Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes: Pooled analysis from the HORIZONS-AMI and ACUITY trials. J Am Coll Cardiol. 2014;63:1845-54.

807. Brener SJ, Dambrink JH, Maehara A, Chowdhary S, Gershlick AH, Genereux P, Koolen J, Mehran R, Fahy M, Gibson CM, **Stone GW.** Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI. EuroIntervention. 2014 Feb 22;9(10):1195-201.

808. Ng VG, Lansky AJ, Meller S, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie B, Shah R, Mehran R, **Stone GW.** The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. Eur Heart J Acute Cardiovasc Care. 2014 Mar 1;3(1):67-77.

809. Dizon JM, Brener SJ, Maehara A, Witzenbichler B, Biviano A, Godlewski J, Parise H, Dambrink JH, Mehran R, Gibson CM, **Stone GW.** Relationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: analysis from the INFUSE-AMI trial. Eur Heart J Acute Cardiovasc Care. 2014 Mar 1;3(1):78-83.

810. Tarantini G, Brener SJ, Barioli A, Gratta A, Parodi G, Rossini R, Navarese EP, Niccoli G, Frigo AC, Musumeci G, Iliceto S, **Stone GW**. Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: A meta-regression analysis of randomized trials. Am Heart J. 2014 Mar;167(3):401-412.

811. Larsen AI, Tomey MI, Mehran R, Nilsen DW, Kirtane AJ, Witzenbichler B, Guagliumi G, Brener SJ, Généreux P, Kornowski R, Dudek D, Gersh BJ, **Stone GW.** Comparison of Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Discharged on Versus Not on Statin Therapy (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). Am J Cardiol. 2014;113:1273-9.

812. Narula A, Mehran R, Weisz G, Dangas GD, Yu J, Généreux P, Nikolsky E, Brener SJ, Witzenbichler B, Guagliumi G, Clark AE, Fahy M, Xu K, Brodie BR, **Stone GW.** Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. Eur Heart J. 2014;35:1533-40.

813. Brener SJ, Oldroyd KG, Maehara A, El-Omar M, Witzenbichler B, Xu K, Mehran R, Gibson CM, **Stone GW.** Outcomes in Patients With ST-Segment Elevation Acute Myocardial Infarction Treated With Clopidogrel Versus Prasugrel (from the INFUSE-AMI Trial). Am J Cardiol. 2014;113:1457-60.

814. Robertson JO, Ebrahimi R, Lansky AJ, Mehran R, **Stone GW,** Lincoff AM. Impact of Cigarette Smoking on Extent of Coronary Artery Disease and Prognosis of Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: An Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. JACC Cardiovasc Interv. 2014;7:372-9.

815. Xie Y, Mintz GS, Yang J, Doi H, Iñiguez A, Dangas GD, Serruys PW, McPherson JA, Wennerblom B, Xu K, Weisz G, **Stone GW,** Maehara A. Clinical Outcome of Nonculprit Plaque Ruptures in Patients With Acute Coronary Syndrome in the PROSPECT Study. JACC Cardiovasc Imaging. 2014;7(4):397-405.

816. Kedhi E, Généreux P, Palmerini T, McAndrew TC, Parise H, Mehran R, Dangas GD, **Stone GW.** Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus: Analysis from 18 Pooled Randomized Trials. J Am Coll Cardiol. 2014;63(20):2111-8.

817. Lansky AJ, Ng VG, Meller S, Xu K, Fahy M, Feit F, Ohman EM, White HD, Mehran R, Bertrand ME, Desmet W, Hamon M, **Stone GW.** Impact of Nonculprit Vessel Myocardial Perfusion on Outcomes of Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Analysis From the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy). JACC Cardiovasc Interv. 2014;7(3):266-75.

818. **Stone GW.** Bioresorbable vascular scaffolds: is imaging everything? EuroIntervention. 2014;9(11):1255-7.

819. Inaba S, Mintz GS, Yun KH, Yakushiji T, Shimizu T, Kang SJ, Généreux P, Weisz G, Rabbani LE, Moses JW, **Stone GW,** Maehara A. Mechanical

complications of everolimus-eluting stents associated with adverse events: an intravascular ultrasound study. EuroIntervention. 2014;9(11):1301-8.

820. **Stone GW.** Balancing ischaemia and bleeding with dual antiplatelet therapy: a resolute endeavour. Eur Heart J. 2014;35:1914-6.

821. Lee MS, Applegate B, Rao SV, Kirtane A, Seto A, **Stone GW.** Minimizing femoral artery access complications during percutaneous coronary intervention: A comprehensive review. Catheter Cardiovasc Interv. 2014 ;84:62-9.

822. Pu J, Mintz GS, Biro S, Lee JB, Sum ST, Madden SP, Burke AP, Zhang P, He B, Goldstein JA, **Stone GW,** Muller JE, Virmani R, Maehara A. Insights into Echo-attenuated Plaques, Echolucent Plaques, and Plaques with Spotty Calcification: Novel Findings from Comparisons among Intravascular Ultrasound, Near-Infrared Spectroscopy, and Pathological Histology in 2294 Human Coronary Artery Segments. J Am Coll Cardiol. 2014;63:2220-33.

823. De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, **Stone GW.** Drug-eluting stents in patients with anterior STEMI undergoing primary angioplasty: a substudy of the DESERT cooperation. Clin Res Cardiol. 2014;103:685-99.

824. Keeley EC, Mehran R, Brener SJ, Witzenbichler B, Guagliumi G, Dudek D, Kornowski R, Dressler O, Fahy M, Xu K, Grines CL, **Stone GW.** Impact of Multiple Complex Plaques on Short- and Long-Term Clinical Outcomes in Patients Presenting With ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial). Am J Cardiol. 2014;113:1621-7.

825. Muramatsu T, Onuma Y, van Geuns RJ, Chevalier B, Patel TM, Seth A, Diletti R, García-García HM, Dorange CC, Veldhof S, Cheong WF, Ozaki Y, Whitbourn R, Bartorelli A, **Stone GW,** Abizaid A, Serruys PW; ABSORB Cohort B, the ABSORB EXTEND, and the SPIRIT First, II, III, and IV Investigators. One-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds: A Pooled Analysis of the ABSORB and the SPIRIT Trials. JACC Cardiovasc Interv. 2014;7:482-93.

826. **Stone GW.** Revascularization Decisions in Coronary Artery Disease: Hitting a Moving Target. JACC Cardiovasc Interv. 2014;7:507-9.

827. Ng VG, **Stone GW.** Diabetics and Drug-eluting Stents in ST Segment Elevation Myocardial Infarction: Confidence in Numbers. Rev Esp Cardiol (Engl Ed). 2009;62:343-6.

828. Herrmann J, Gersh BJ, Goldfinger JZ, Witzenbichler B, Guagliumi G, Dudek D, Kornowski R, Brener SJ, Parise H, Fahy M, McAndrew TC, **Stone GW**, Mehran R. Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). Am J Cardiol. 2014;114:9-16.

829. Planer D, Mehran R, Ohman EM, White HD, Newman JD, Xu K, **Stone GW.** Prognosis of Patients With Non-ST-Segment-Elevation Myocardial Infarction and Nonobstructive Coronary Artery Disease: Propensity-Matched Analysis From the Acute Catheterization and Urgent Intervention Triage Strategy Trial. Circ Cardiovasc Interv. 2014;7:285-93.

830. De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Diaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, **Stone GW**; for the DESERT cooperation. Impact of hypertension on clinical outcome in STEMI patients undergoing primary angioplasty with BMS or DES: Insights from the DESERT cooperation. Int J Cardiol. 2014;175:50-4.

831. **Stone GW.** Improving outcomes with bivalirudin in primary percutaneous coronary intervention. Eur Heart J. 2014;35:2269-72.

832. Bagai A, Dangas GD, **Stone GW,** Granger CB. Reperfusion strategies in acute coronary syndromes. Circ Res. 2014;114:1918-28.

833. Kobayashi N, Maehara A, Allocco D, Witzenbichler B, Ellis SG, Turco MA, Ormiston JA, Guagliumi G, Jiang S, McAndrew TC, Dawkins KD, **Stone GW,** Mintz GS, Weissman NJ. Stenting for ST-segment elevation myocardial infarction is associated with less neointimal hyperplasia in the pooled IVUS analysis from HORIZONS-AMI and the TAXUS IV and V and ATLAS workhorse, long lesion, and direct stent studies. Coron Artery Dis. 2014;25:575-81.

834. Shaw LJ, Berman DS, Picard MH, Friedrich MG, Kwong RY, **Stone GW,** Senior R, Min JK, Hachamovitch R, Scherrer-Crosbie M, Mieres JH, Marwick TH, Phillips LM, Chaudhry FA, Pellikka PA, Slomka P, Arai AE, Iskandrian AE, Bateman TM, Heller GV, Miller TD, Nagel E, Goyal A, Borges-Neto S, Boden WE, Reynolds HR, Hochman JS, Maron DJ, Douglas PS; National Institutes of Health/National Heart, Lung, and Blood Institute–Sponsored ISCHEMIA Trial Investigators. Comparative Definitions for Moderate-Severe Ischemia in Stress Nuclear, Echocardiography, and Magnetic Resonance Imaging. JACC Cardiovasc Imaging. 2014;7:593-604.

835. Kelly CR, Weisz G, Maehara A, Mintz GS, Mehran R, Lansky AJ, Parise H, de Bruyne B, Serruys PW, **Stone GW.** Relation of C-Reactive Protein Levels to Instability of Untreated Vulnerable Coronary Plaques (from the PROSPECT Study). Am J Cardiol. 2014;114:376-83.

836. Stone SG, Serrao GW, Mehran R, Tomey MI, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Brener SJ, Dangas G, **Stone GW.** Incidence, Predictors, and Implications of Reinfarction After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial. Circ Cardiovasc Interv. 2014;7:543-51.

837. Sattur S, Brener SJ, **Stone GW.** Pharmacologic Therapy for Reducing Myocardial Infarct Size in Clinical Trials: Failed and Promising Approaches. J Cardiovasc Pharmacol Ther. 2015;20:21-35.

838. Karmpaliotis D and **Stone GW.** Percutaneous Recanalisation of Coronary Artery Chronic Total Occlusions: A 2014 Update. EMJ Int Cardiol 2014;1:28-37.

839. Guerchicoff A, Brener SJ, Maehara A, Witzenbichler B, Fahy M, Xu K, Gersh BJ, Mehran R, Gibson CM, **Stone GW.** Impact of Delay to Reperfusion on Reperfusion Success, Infarct Size, and Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction: The INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction). JACC Cardiovasc Interv. 2014;7:733-40.

840. Majidi M, Kosinski AS, Al-Khatib SM, Smolders L, Cristea E, Lansky AJ, **Stone GW,** Mehran R, Gibbons RJ, Crijns HJ, Wellens HJ, Gorgels AP, Krucoff MW. Implications of ventricular arrhythmia "bursts" with normal epicardial flow, myocardial blush, and ST-segment recovery in anterior ST-elevation myocardial infarction reperfusion: A biosignature of direct myocellular injury "downstream of downstream". Eur Heart J Acute Cardiovasc Care. 2015;4:51-9.

841. Saito S, Hagiwara N, Seki A, Igarashi K, Muramatsu T, Yajima J, Yokoi H, Nakamura M, Fujii K, Isshiki T, **Stone GW,** Teirstein PS, Meredith IT, Allocco DJ, Dawkins KD. Japanese and non-Japanese patient outcomes in the PLATINUM randomized trial comparing the PROMUS Element and XIENCE V everolimus-eluting stents. J Cardiol 2014;64:105-112.

842. Zhang YJ, Iqbal J, Campos CM, Klaveren DV, Bourantas CV, Dawkins KD, Banning AP, Escaned J, de Vries T, Morel MA, Farooq V, Onuma Y, Garcia-Garcia HM, **Stone GW,** Steyerberg EW, Mohr FW, Serruys PW. Prognostic Value of Site SYNTAX Score and Rationale for Combining Anatomic and Clinical Factors in Decision Making: Insights From the SYNTAX Trial. J Am Coll Cardiol. 2014;64:423-32.

843. Palmerini T, Biondi-Zoccai G, **Stone GW.** Stent selection to minimize the risk of stent thrombosis. Curr Opin Cardiol.2014 ;29:578-85.

844. Brener SJ, Brodie BR, Guerchicoff A, Witzenbichler B, Guagliumi G, Xu K, Mehran R, **Stone GW.** Impact of Pre-Procedural Cardiopulmonary Instability in

Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). Am J Cardiol. 2014;114:962-7.

845. Gili S, D'Ascenzo F, Moretti C, Omedè P, Vilardi I, Bertaina M, Biondi Zoccai G, Sheiban I, **Stone GW,** Gaita F. Impact on Prognosis of Periprocedural Myocardial Infarction after Percutaneous Coronary Intervention. J Interv Cardiol. 2014;27:482-90.

846. Madhavan MV, Généreux P, Kirtane AJ, Xu K, Witzenbichler B, Mehran R, **Stone GW.** Postprocedural Anticoagulation for Specific Therapeutic Indications After Revascularization for ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). Am J Cardiol. 2014;114:1322-8.

847. Palmerini T, Calabrò P, Piscione F, De Servi S, Cattaneo M, Maffeo D, Toso A, Bartorelli A, Palmieri C, De Carlo M, Capodanno D, Barozzi C, Tomasi L, Della Riva D, Mariani A, Taglieri N, Reggiani LB, Bianchi R, De Rosa R, Mariani M, Podda G, Généreux P, **Stone GW,** Angiolillo DJ. Impact of GEne Polymorphisms, Platelet REactivity and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The GEPRESS Study. JACC Cardiovasc Interv. 2014;7:1117-27.

848. Xu B, Généreux P, Yang Y, Leon MB, Xu L, Qiao S, Wu Y, Yan H, Chen J, Zhao Y, Zhao Y, Palmerini T, **Stone GW,** Gao R. Validation and Comparison of the Long-Term Prognostic Capability of the SYNTAX Score II Among 1,528 Consecutive Patients Who Underwent Left Main Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2014;7:1128-37.

849. Pracon R, Opolski MP, Mintz GS, Pregowski J, Kruk M, Popma JJ, Mandinov L, Wang H, Ellis SG, Grube E, Dawkins KD, **Stone GW,** Weissman NJ. Serial Intravascular Ultrasound Analysis of Stent Strut Distribution and Fracture: An Integrated Analysis of the Taxus IV, V, and VI Trials. J Invasive Cardiol. 2014;26:501-11.

850. Dudek D, Brener SJ, Rakowski T, Dziewierz A, Abizaid A, Silber S, Yaacoby E, Dizon JM, Costa RA, Maehara A, Dressler O, **Stone GW.** Efficacy of an Embolic Protection Stent as a Function of Delay to Reperfusion in ST-Segment Elevation Myocardial Infarction (from the MASTER Trial). Am J Cardiol. 2014;114:1485-9.

851. Ertelt K, Généreux P, Mintz GS, Brener SJ, Kirtane AJ, McAndrew TC, Francese DP, Ben-Yehuda O, Mehran R, **Stone GW.** Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation

myocardial infarction: analysis from the HORIZONS-AMI Trial. Cardiovasc Revasc Med. 2014;15:375-80.

852. Palmerini T, Biondi-Zoccai G, **Stone GW.** Stent selection to minimize the risk of stent thrombosis. Curr Opin Cardiol 2014;29:578–585.

853. Généreux P, Campos CM, Yadav M, Palmerini T, Caixeta A, Xu K, Francese DP, Dangas GD, Mehran R, Leon MB, Serruys PW, **Stone GW.** Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index. EuroIntervention. 2015 Oct;11(6):634-42.

854. Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, **Stone GW.** Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). Am J Cardiol. 2014;114:1638-45.

855. Auer J, **Stone GW.** Routine angiographic surveillance for risk stratification in PCI-treated patients: fact or fiction? Eur Heart J. 2015;36:71-4.

856. Kunadian V, Mehran R, Lincoff AM, Feit F, Manoukian SV, Hamon M, Cox DA, Dangas GD, **Stone GW.** Effect of Anemia on Frequency of Short- and Long-Term Clinical Events in Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). Am J Cardiol. 2014;114:1823-1829.

857. Pocock SJ, **Stone GW**, Mehran R, Clayton TC. Individualizing treatment choices using quantitative methods. Am Heart J. 2014;168:607-10.

858. Garcia-Garcia HM, Serruys PW, Campos CM, Muramatsu T, Nakatani S, Zhang YJ, Onuma Y, **Stone GW.** Assessing Bioresorbable Coronary Devices: Methods and Parameters. JACC Cardiovasc Imaging. 2014;7:1130-1148.

859. Costa RA, Abizaid A, Lotan C, Dudek D, Silber S, Dizon JM, Maehara A, Dressler O, Brener SJ, **Stone GW.** Impact of thrombus burden on outcomes after standard versus mesh-covered stents in acute myocardial infarction (from the MGuard for Acute ST Elevation Reperfusion Trial). Am J Cardiol. 2015;115:161-6.

860. Tomey MI, Mehran R, Brener SJ, Maehara A, Witzenbichler B, Dizon JM, El-Omar M, Xu K, Gibson CM, **Stone GW.** Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: An analysis of Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI). Am Heart J. 2015;169:86-93.

861. Kang SJ, Mintz GS, Witzenbichler B, Metzger DC, Rinaldi MJ, Duffy PL, Weisz G, Stuckey TD, Brodie BR, Shimizu T, Xu K, Kirtane AJ, **Stone GW,** Maehara A. Effect of obesity on coronary atherosclerosis and outcomes of percutaneous coronary intervention: grayscale and virtual histology intravascular ultrasound substudy of assessment of dual antiplatelet therapy with drug-eluting stents. Circ Cardiovasc Interv. 2015;8:e001392. DOI: 10.1161/CIRCINTERVENTIONS.114.001392.

862. **Stone GW,** Mehran R, Goldstein P, Witzenbichler B, Van't Hof A, Guagliumi G, Hamm CW, Généreux P, Clemmensen P, Pocock SJ, Gersh BJ, Bernstein D, Deliargyris EN, Steg PG. Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: Pooled Patient-Level Analysis From the HORIZONS-AMI and EUROMAX Trials. J Am Coll Cardiol. 2015 Jan 6;65(1):27-38.

863. Dudek D, Dziewierz A, Brener SJ, Abizaid A, Merkely B, Costa RA, Bar E, Rakowski T, Kornowski R, Dressler O, Abizaid A, Silber S, **Stone GW.** Mesh-Covered Embolic Protection Stent Implantation in ST-Segment-Elevation Myocardial Infarction: Final 1-Year Clinical and Angiographic Results From the MGUARD for Acute ST Elevation Reperfusion Trial. Circ Cardiovasc Interv. 2015 Feb;8(2):e001484. doi: 10.1161/CIRCINTERVENTIONS.114.001484.

864. **Stone GW,** Mehran R, Steg PG. Follow the Data: Bivalirudin (and Not Heparin Alone) During Percutaneous Coronary Intervention Provides the Best Clinical Outcomes. JACC Cardiovasc Interv. 2015;8(1PB):225-227.

865. Brener SJ, Ertelt K, Mehran R, Genereux P, Xu K, Witzenbichler B, Brodie BR, Guagliumi G, **Stone GW.** Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: Lessons from HORIZONS-AMI. Am Heart J. 2015;169(2):242-8.

866. Dong L, Mintz GS, Witzenbichler B, Metzger DC, Rinaldi MJ, Duffy PL, Weisz G, Stuckey TD, Brodie BR, Yun KH, Xu K, Kirtane AJ, **Stone GW,** Maehara A. Comparison of Plaque Characteristics in Narrowings With ST-Elevation Myocardial Infarction (STEMI), Non-STEMI/Unstable Angina Pectoris and Stable Coronary Artery Disease (from the ADAPT-DES IVUS Substudy). Am J Cardiol. 2015;115:860-6.

867. Nichol G, Strickland W, Shavelle D, Maehara A, Ben-Yehuda O, Genereux P, Dressler O, Parvataneni R, Nichols M, McPherson J, Barbeau G, Laddu A, Elrod JA, Tully GW, Ivanhoe R, **Stone GW.** Prospective, Multicenter, Randomized, Controlled Pilot Trial of Peritoneal Hypothermia in Patients With ST-Segment-Elevation Myocardial Infarction. Circ Cardiovasc Interv. 2015 Mar;8(3):e001965. doi: 10.1161/CIRCINTERVENTIONS.114.001965.

868. Jeremias A, **Stone GW.** Fractional flow reserve for the evaluation of coronary stenoses: limitations and alternatives. Catheter Cardiovasc Interv. 2015;85(4):602-3.

869. White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, **Stone GW,** Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA. Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC Cardiovasc Interv. 2015;8:424-33.

870. Möbius-Winkler S, Majunke N, Sandri M, Mangner N, Linke A, **Stone GW,** Dähnert I, Schuler G, Sick PB. Percutaneous left atrial appendage closure: Technical aspects and prevention of periprocedural complications with the watchman device. World J Cardiol. 2015 Feb 26;7(2):65-75.

871. Kang SJ, Mintz GS, Weisz G, Mehran R, Rabbani LE, Verheye S, Serruys PW, Xu K, **Stone GW,** Maehara A. Age-Related Effects of Smoking on Coronary Artery Disease Assessed by Gray Scale and Virtual Histology Intravascular Ultrasound. Am J Cardiol. 2015;26:476-83.

872. Plent S, Fan W, Kirtane A, Brener SJ, Genereux P, Mehran R, Pinto DS, McEntegart M, Cohen DJ, **Stone GW.** Cost implications of intraprocedural thrombotic events during PCI. Catheter Cardiovasc Interv. 2015;86:30-9.

873. Campos CM, van Klaveren D, Farooq V, Simonton CA, Kappetein AP, Sabik JF 3rd, Steyerberg EW, **Stone GW,** Serruys PW. Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II. Eur Heart J. 2015;36:1231-41.

874. Dohi T, Maehara A, Brener SJ, Généreux P, Gershlick AH, Mehran R, Gibson CM, Mintz GS, **Stone GW.** Utility of Peak Creatine Kinase-MB Measurements in Predicting Myocardial Infarct Size, Left Ventricular Dysfunction, and Outcome After First Anterior Wall Acute Myocardial Infarction (from the INFUSE-AMI Trial). Am J Cardiol. 2015;115:563-70.

875. Campos CM, Fedewa RJ, Garcia-Garcia HM, Vince DG, Margolis MP, Lemos PA, **Stone GW,** Serruys PW, Nair A. Ex vivo validation of 45 MHz intravascular ultrasound backscatter tissue characterization. Eur Heart J Cardiovasc Imaging. 2015;16:1112-9.

876. **Stone GW.** Left main revascularization: reality versus the real world. Circ Cardiovasc Interv. 2015 Mar;8(3):e002380. doi: 10.1161/CIRCINTERVENTIONS.115.002380.

877. Gada H, Kirtane AJ, Kereiakes DJ, Bangalore S, Moses JW, Généreux P, Mehran R, Dangas GD, Leon MB, **Stone GW.** Meta-Analysis of Trials on Mortality After Percutaneous Coronary Intervention Compared With Medical Therapy in Patients With Stable Coronary Heart Disease and Objective Evidence of Myocardial Ischemia. Am J Cardiol. Am J Cardiol. 2015;115:1194-9.

878. Kobayashi N, Maehara A, Mintz GS, Wolff SD, Généreux P, Xu K, Mehran R, Gibson CM, Brener SJ, **Stone GW.** Usefulness of the Left Anterior Descending Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (an INFUSE-AMI Substudy). Am J Cardiol. 2015 Dec 1;116(11):1658-65.

879. Hanson ID, David SW, Dixon SR, Metzger DC, Généreux P, Maehara A, Xu K, **Stone GW.** "Optimized" delivery of intracoronary supersaturated oxygen in acute anterior myocardial infarction: A feasibility and safety study. Catheter Cardiovasc Interv. 2015;86 Suppl 1:S51-7.

880. Warren J, Mehran R, Yu J, Xu K, Bertrand ME, Cox DA, Lincoff AM, Manoukian SV, Ohman EM, Pocock SJ, White HD, **Stone GW.** Incidence and Impact of Totally Occluded Culprit Coronary Arteries in Patients Presenting With Non-ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2015;115:428-33.

881. Kang SJ, Mintz GS, Pu J, Sum ST, Madden SP, Burke AP, Xu K, Goldstein JA, **Stone GW,** Muller JE, Virmani R, Maehara A. Combined IVUS and NIRS Detection of Fibroatheromas: Histopathological Validation in Human Coronary Arteries. JACC Cardiovasc Imaging. 2015;8:184-94.

882. Yu J, Mehran R, Grinfeld L, Xu K, Nikolsky E, Brodie BR, Witzenbichler B, Kornowski R, Dangas GD, Lansky AJ, **Stone GW.** Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONS-AMI trial. Catheter Cardiovasc Interv. 2015;85:359-68.

883. Guerchicoff A, **Stone GW,** Mehran R, Xu K, Nichols D, Claessen BE, Guagliumi G, Witzenbichler B, Henriques JP, Dangas GD. Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute st-segment elevation myocardial infarction: Results of the HORIZONS-AMI trial. Catheter Cardiovasc Interv. 2015;85:335-42.

884. Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li J, Li Y, Xu B, **Stone GW;** BRIGHT Investigators. Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The BRIGHT Randomized Clinical Trial. JAMA. 2015;313:1336-46.

885. Palmerini T, Benedetto U, Bacchi-Reggiani L, Riva DD, Biondi-Zoccai G, Feres F, Abizaid A, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Genereux P, Bhatt DL, Orlandi C, De Servi S, Petrou M, Rapezzi C, **Stone GW.** Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385:2371-82.

886. Palmerini T, Sangiorgi D, Valgimigli M, Biondi-Zoccai G, Feres F, Abizaid A, Costa RA, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Mariani A, Della Riva D, Genereux P, Leon MB, Bhatt DL, Bendetto U, Rapezzi C, **Stone GW.** Short-versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol. 2015;65:1092-102.

887. Chung ES, Fischer TM, Kueffer F, Anand IS, Bax JJ, Gold MR, Gorman R, Theres H, Udelson J, Stancak B, Svendsen JH, **Stone GW,** Leon A. The Post-Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. J Card Fail. 2015;21:601-7.

888. Asgar AW, Mack MJ, **Stone GW.** Secondary Mitral Regurgitation in Heart Failure: Pathophysiology, Prognosis, and Therapeutic Considerations. J Am Coll Cardiol. 2015;65:1231-1248.

889. Redfors B, Vedad R, Angerås O, Råmunddal T, Petursson P, Haraldsson I, Ali A, Dworeck C, Odenstedt a J, Ioaness D, Libungan B, Shao Y, Albertsson P, **Stone GW,** Omerovic E. Mortality in takotsubo syndrome is similar to mortality in myocardial infarction — A report from the SWEDEHEART registry. International Journal of Cardiology 2015;185:282–289.

890. Chen SL, Ye F, Zhang JJ, Xu T, Tian NL, Liu ZZ, Lin S, Shan SJ, Ge Z, You W, Liu YQ, Qian XS, Li F, Yang S, Kwan TW, Xu B, **Stone GW.** Randomized Comparison of FFR-Guided and Angiography-Guided Provisional Stenting of True Coronary Bifurcation Lesions: The DKCRUSH-VI (Double Kissing Crush Versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions VI) Trial. JACC Cardiovasc Interv. 2015;8:536-46.

891. Hassanin A, Brener SJ, Lansky AJ, Xu K, **Stone GW.** Prognostic impact of multivessel versus culprit vessel only percutaneous intervention for patients with multivessel coronary artery disease presenting with acute coronary syndrome. EuroIntervention. 2015;11:293-300.

892. Sanborn TA, Tomey MI, Mehran R, Généreux P, Witzenbichler B, Brener SJ, Kirtane AJ, McAndrew TC, Kornowski R, Dudek D, Nikolsky E, **Stone GW.** Femoral vascular closure device use, bivalirudin anticoagulation and bleeding

after primary angioplasty for STEMI: Results from the HORIZONS-AMI trial. Catheter Cardiovasc Interv. 2015;85:371-9.

893. Madhavan MV, Généreux P, Palmerini T, Caixeta A, Xu K, McAndrew TC, Francese DP, Kirtane AJ, Mehran R, **Stone GW.** The Association Between the Extent of Coronary Artery Disease and Major Bleeding Events After Percutaneous Coronary Intervention: From the ACUITY Trial. J Invasive Cardiol. 2015;27:203-211.

894. Nikolsky E, Mehran R, Dangas GD, Xu K, Parvataneni R, Witzenbichler B, Guagliumi G, Kornowski R, Généreux P, Brener SJ, **Stone GW.** Cerebrovascular Events After a Primary Percutaneous Coronary Intervention Strategy for Acute ST-Segment- Elevation Myocardial Infarction: Analysis From the HORIZONS-AMI Trial. Circ Cardiovasc Interv. 2015 Apr;8(4). pii: e002283. doi: 10.1161/CIRCINTERVENTIONS.114.002283.

895. van de Hoef TP, Nijveldt R, van der Ent M, Neunteufl T, Meuwissen M, Khattab A, Berger R, Kuijt WJ, Wykrzykowska J, Tijssen JG, van Rossum AC, **Stone GW,** Piek JJ. Pressure-controlled intermittent coronary sinus occlusion (PICSO) in acute ST-segment elevation myocardial infarction: results of the Prepare RAMSES safety and feasibility study. EuroIntervention. 2015;11:37-44.

896. Maisano F, Alfieri O, Banai S, Buchbinder M, Colombo A, Falk V, Feldman T, Franzen O, Herrmann H, Kar S, Kuck KH, Lutter G, Mack M, Nickenig G, Piazza N, Reisman M, Ruiz CE, Schofer J, Søndergaard L, **Stone GW,** Taramasso M, Thomas M, Vahanian A, Webb J, Windecker S, Leon MB. The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement? Eur Heart J. 2015;36:1651-9.

897. De Luca G, Dirksen MT, Kelbæk H, Thuesen L, Vink MA, Kaiser C, Chechi T, Spaziani G, Di Lorenzo E, Suryapranata H, **Stone GW.** Paclitaxel-eluting versus bare metal stents in primary PCI: a pooled patient-level meta-analysis of randomized trials. J Thromb Thrombolysis. 2015;39:101-12.

898. Généreux P, Bernard S, Palmerini T, Caixeta A, Rosner G, Reiss GR, Xu K, Mehran R, **Stone GW.** Incidence, predictors, and impact of neurological events in non-ST-segment elevation acute coronary syndromes: the ACUITY trial. EuroIntervention. 2015;11:399-406.

899. Kirtane AJ, **Stone GW.** STEMI care in China: a world opportunity. Lancet. 2015 Jan 31;385(9966):400-1.

900. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, Ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, **Stone GW,** Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors:

collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015;36:1762-71.

901. Souza CF, Doi H, Mintz GS, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie BR, Kellett MA Jr, Xu K, Mehran R, **Stone GW,** Maehara A. Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up: an analysis from the HORIZONS-AMI Trial. Coron Artery Dis. 2015;26:469-75.

902. **Stone GW,** Narula J. Emergence of plaque erosion as an important clinical entity. JACC Cardiovasc Imaging. 2015;8:623-5.

903. Généreux P, Rutledge DR, Palmerini T, Caixeta A, Kedhi E, Hermiller JB, Wang J, Krucoff MW, Jones-McMeans J, Sudhir K, Simonton CA, Serruys PW, **Stone GW.** Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: insights from the Xience V coronary stent system trials. Circ Cardiovasc Interv. 2015 May;8(5). pii: e001362. doi: 10.1161/CIRCINTERVENTIONS.114.001362.

904. Gada H, Kirtane AJ, Kereiakes DJ, Bangalore S, Moses JW, Généreux P, Mehran R, Dangas GD, Leon MB, **Stone GW.** Meta-analysis of trials on mortality after percutaneous coronary intervention compared with medical therapy in patients with stable coronary heart disease and objective evidence of myocardial ischemia. Am J Cardiol. 2015;115:1194-9.

905. **Stone GW,** Maehara A, Muller JE, Rizik DG, Shunk KA, Ben-Yehuda O, Genereux P, Dressler O, Parvataneni R, Madden S, Shah P, Brilakis ES, Kini A; CANARY Investigators. Plaque Characterization to Inform the Prediction and Prevention of Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention: The CANARY Trial (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow). JACC Cardiovasc Interv. 2015;8:927-936.

906. Campos CM, Christiansen EH, **Stone GW,** Serruys PW. The EXCEL and NOBLE trials: similarities, contrasts and future perspectives for left main revascularisation. EuroIntervention. 2015;11 Suppl V:V115-9.

907. Sabik JF, **Stone GW.** Left main revascularization: surgical and interventional perspectives. J Am Coll Cardiol. 2015 May 26;65(20):2207-10.

908. Hanson ID, Goldstein JA, Dixon SR, **Stone GW.** Comparison of coronary artery lesion length by NIRS-IVUS versus angiography alone. Coron Artery Dis. 2015;26(6):484-9.

909. Kang SJ, Mintz GS, Witzenbichler B, Metzger DC, Rinaldi MJ, Duffy PL, Weisz G, Stuckey TD, Brodie BR, Shimizu T, Litherland C, Kirtane AJ, **Stone GW,**

Maehara A. Age-related effects of smoking on culprit lesion plaque vulnerability as assessed by grayscale and virtual histology-intravascular ultrasound. Coron Artery Dis. 2015;26:476-83.

910. Ben-Gal Y, Mohr R, Feit F, Ohman EM, Kirtane A, Xu K, Mehran R, **Stone GW.** Surgical Versus Percutaneous Coronary Revascularization for Multivessel Disease in Diabetic Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome: Analysis From the Acute Catheterization and Early Intervention Triage Strategy Trial. Circ Cardiovasc Interv. 2015;8(6). pii: e002032. doi: 10.1161/CIRCINTERVENTIONS.114.002032.

911. Angiolillo DJ, Bhatt DL, Steg PG, **Stone GW,** White HD, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Mahaffey KW, Harrington RA. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. J Thromb Thrombolysis. 2015;40:317-22.

912. Baber U, Mehran R, Kirtane AJ, Gurbel PA, Christodoulidis G, Maehara A, Witzenbichler B, Weisz G, Rinaldi MJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Xu K, Parise H, Brodie BR, Stuckey TD, **Stone GW.** Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease: Results From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Registry. Circ Cardiovasc Interv. 2015;8(6):e001683. doi: 10.1161/CIRCINTERVENTIONS.115.001683.

913. Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, Vlachojannis GJ, Jensen LO, Christiansen EH, Berencsi K, Valgimigli M, Orlandi C, Petrou M, Rapezzi C, **Stone GW.** Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. J Am Coll Cardiol. 2015;65:2496-507.

914. Rizik DG, Klassen KJ, Burke RF, Hodgson JM, **Stone GW.** Interventional Management of Unprotected Left Main Coronary Artery Disease: Patient Selection and Technique Optimization. J Interv Cardiol. 2015;28:326-38.

915. Ahmadi A, Leipsic J, Blankstein R, Taylor C, Hecht H, **Stone GW,** Narula J. Do Plaques Rapidly Progress Prior to Myocardial Infarction? The Interplay Between Plaque Vulnerability and Progression. Circ Res. 2015;117:99-104.

916. Alexopoulos D, Bhatt DL, Hamm CW, Steg PG, **Stone GW.** Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap. Am Heart J. 2015;170:3-12.

917. Werner GS, Hecht H, **Stone GW.** Utility of CT Angiography to Guide Coronary Intervention of Chronic Total Occlusions. JACC Cardiovasc Imaging. 2015;8:814-6.

918. Mennuni MG, Dangas GD, Mehran R, Ben-Gal Y, Xu K, Généreux P, Brener SJ, Feit F, Lincoff AM, Ohman EM, Hamon M, **Stone GW**. Coronary Artery Bypass Surgery Compared With Percutaneous Coronary Intervention for Proximal Left Anterior Descending Artery Treatment in Patients With Acute Coronary Syndrome: Analysis From the ACUITY Trial. J Invasive Cardiol. 2015;27:468-73.

919. Madhavan MV, Généreux P, Kirtane AJ, Xu K, Witzenbichler B, Mehran R, **Stone GW.** Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial. Eur Heart J Acute Cardiovasc Care. 2015: [Epub ahead of print].

920. Fordyce CB, Gersh BJ, **Stone GW,** Granger CB. Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury. Trends Pharmacol Sci. 2015;36:605-16.

921. **Stone GW,** Vahanian AS, Adams DH, et al. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the Mitral Valve Academic Research Consortium. Eur Heart J. 2015:36:1851-1877.

922. **Stone GW,** Adams DH, Abraham WT, et al. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium. Eur Heart J. 2015:36:1878-1891.

923. Giustino G, Baber U, Stefanini GG, Aquino M, **Stone GW,** Sartori S, Steg PG, Wijns W, Smits PC, Jeger RV, Leon MB, Windecker S, Serruys PW, Morice MC, Camenzind E, Weisz G, Kandzari D, Dangas GD, Mastoris I, Von Birgelen C, Galatius S, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015;116:845-52.

924. Teirstein PS, Meredith IT, Feldman RL, Rabinowitz AC, Cannon LA, Lee TC, Dens J, Dubois CL, Mooney MR, Pompili VJ, Saito S, Allocco DJ, Dawkins KD, **Stone GW.** Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions. Catheter Cardiovasc Interv. 2015;85:207-15.

925. **Stone GW,** Vahanian AS, Adams DH, Abraham WT, Borer JS, Bax JJ, Schofer J, Cutlip DE, Krucoff MW, Blackstone EH, Généreux P, Mack MJ, Siegel RJ, Grayburn PA, Enriquez-Sarano M, Lancellotti P, Filippatos G, Kappetein AP;

Mitral Valve Academic Research Consortium (MVARC). Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium. J Am Coll Cardiol. 2015;66:278-307.

926. **Stone GW,** Adams DH, Abraham WT, Kappetein AP, Généreux P, Vranckx P, Mehran R, Kuck KH, Leon MB, Piazza N, Head SJ, Filippatos G, Vahanian AS; Mitral Valve Academic Research Consortium (MVARC). Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research Consortium. J Am Coll Cardiol. 2015;66:308-21.

927. Giacoppo D, Madhavan MV, Baber U, Warren J, Bansilal S, Witzenbichler B, Dangas GD, Kirtane AJ, Xu K, Kornowski R, Brener SJ, Généreux P, **Stone GW,** Mehran R. Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials. Circ Cardiovasc Interv. 2015;8(8):e002475. doi: 10.1161/CIRCINTERVENTIONS.114.002475.

928. Brener SJ, Maehara A, Mintz GS, Weisz G, de Bruyne B, Serruys PW, **Stone GW**. Effect of Prior Aspirin Treatment on Patients with Acute Coronary Syndromes: Insights From the PROSPECT Study. J Invasive Cardiol. 2015 Dec;27(12):536-41.

929. Möckel M, Muller R, Searle J, Slagman A, De Bruyne B, Serruys P, Weisz G, Xu K, Holert F, Müller C, Maehara A, **Stone GW.** Usefulness of Beta2-Microglobulin as a Predictor of All-Cause and Nonculprit Lesion-Related Cardiovascular Events in Acute Coronary Syndromes (from the PROSPECT Study). Am J Cardiol. 2015;116:1034-40.

930. Han Y, Li Y, **Stone GW.** Varying Responses to Antithrombotic Treatment by Race/Ethnicity--Reply. JAMA. 2015;314:625.

931. Nührenberg TG, Stratz C, Leggewie S, Hochholzer W, Valina CM, Gick M, Kirtane AJ, **Stone GW,** Neumann FJ, Trenk D. Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. An ADAPT-DES substudy. Thromb Haemost. 2015 Nov;114(5):1020-7.

932. Généreux P, Giustino G, Witzenbichler B, Weisz G, Stuckey TD, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Yadav M, Francese DP, Palmerini T, Kirtane AJ, Litherland C, Mehran R, **Stone GW.** Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015;66:1036-45.

933. Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, Saito S, Yajima J, Hagiwara N, Mitsudo K, Popma JJ, Serruys PW, Onuma Y, Ying S, Cao S, Staehr P, Cheong WF, Kusano H, **Stone GW;** ABSORB Japan Investigators. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015 Dec 14;36(47):3332-42.

934. Kereiakes DJ, Ellis SG, Popma JJ, Fitzgerald PJ, Samady H, Jones-McMeans J, Zhang Z, Cheong WF, Su X, Ben-Yehuda O, **Stone GW.** Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: Design of and rationale for the ABSORB III randomized trial. Am Heart J. 2015;170:641-651.

935. Brodie BR, Garg A, Stuckey TD, Kirtane AJ, Witzenbichler B, Maehara A, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Mehran R, Parvataneni R, **Stone GW.** Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry: Insights From ADAPT-DES. Circ Cardiovasc Interv. 2015;8(10). pii: e002568. doi: 10.1161/CIRCINTERVENTIONS.114.002568.

936. Kobayashi N, Maehara A, Brener SJ, Généreux P, Witzenbichler B, Guagliumi G, Peruga JZ, Mehran R, Mintz GS, **Stone GW.** Usefulness of the Left Anterior Descending Coronary Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). Am J Cardiol. 2015;116(11):1658-65.

937. Shan P, Mintz GS, McPherson JA, De Bruyne B, Farhat NZ, Marso SP, Serruys PW, **Stone GW,** Maehara A. Usefulness of Coronary Atheroma Burden to Predict Cardiovascular Events in Patients Presenting With Acute Coronary Syndromes (from the PROSPECT Study). Am J Cardiol. 2015;116(11):1672-7.

938. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, **Stone GW;** ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015;373(20):1905-15.

939. Weisz G, Smilowitz NR, Kirtane AJ, Rinaldi MJ, Parvataneni R, Xu K, Stuckey TD, Maehara A, Witzenbichler B, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Brodie BR, Mazzaferri EL Jr, Mehran R, **Stone GW.** Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study. Circ Cardiovasc Interv. 2015;8(10). pii: e001952. doi: 10.1161/CIRCINTERVENTIONS.114.001952.

940. Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, Su X, Li L, Kuo HC, Ying SW, Cheong WF, Zhang Y, Su X, Xu B, Popma JJ, **Stone GW;** ABSORB China Investigators. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients with Coronary Artery Disease: ABSORB China trial. J Am Coll Cardiol. 2015;66(21):2298-309. d

941. Rizik DG, Cannon L, **Stone GW,** Kennedy M, Piard-Ruster K, Staehr P, Ellis SG, Kereiakes DJ. Systemic Pharmacokinetics of Everolimus Eluted From the Absorb Bioresorbable Vascular Scaffold: An ABSORB III Substudy. J Am Coll Cardiol. 2015;66(21):2467-9.

942. Zheng B, Mintz GS, McPherson JA, De Bruyne B, Farhat NZ, Marso SP, Serruys PW, **Stone GW,** Maehara A. Predictors of Plaque Rupture Within Nonculprit Fibroatheromas in Patients With Acute Coronary Syndromes: The PROSPECT Study. JACC Cardiovasc Imaging. 2015;8:1180-7.

943. **Stone GW,** Granada JF. Very Late Thrombosis After Bioresorbable Scaffolds: Cause for Concern? J Am Coll Cardiol. 2015;66:1915-7.

944. Asgar AW, Mack MJ, **Stone GW.** Reply: Secondary Mitral Regurgitation. J Am Coll Cardiol. 2015;66:1947.

945. Pineda AM, Chandra R, Gowani SA, Santana O, Mihos CG, Kirtane AJ, **Stone GW,** Kurlansky P, Smith CR, Beohar N. Completeness of revascularization and its impact on the outcomes of a staged approach of percutaneous coronary intervention followed by minimally invasive valve surgery for patients with concomitant coronary artery and valvular heart disease. Catheter Cardiovasc Interv. 2015 Nov 3:[Epub ahead of print].

946. Palmerini T, Zoccai GB, Benedetto U, **Stone GW.** Mortality risk with dual antiplatelet therapy? - Authors' reply. Lancet. 2015;386:1535.

947. Chen SL, Zhang H, Xie DJ, Zhang J, Zhou L, Rothman AM, **Stone GW.**Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Study. Circ Cardiovasc Interv. 2015 Nov;8(11). pii: e002837. doi: 10.1161/CIRCINTERVENTIONS.115.002837.

948. Maehara A, Ben-Yehuda O, Ali Z, Wijns W, Bezerra HG, Shite J, Généreux P, Nichols M, Jenkins P, Witzenbichler B, Mintz GS, **Stone GW.**Comparison of Stent Expansion Guided by Optical Coherence Tomography Versus Intravascular Ultrasound: The ILUMIEN II Study (Observational Study of Optical Coherence Tomography [OCT] in Patients Undergoing Fractional Flow Reserve [FFR] and Percutaneous Coronary Intervention). JACC Cardiovasc Interv. 2015;8:1704-14.

949. Dohi T, Maehara A, Witzenbichler B, Rinaldi MJ, Mazzaferri EL Jr, Duffy PL,

Weisz G, Neumann FJ, Henry TD, Cox DA, Stuckey TD, Brodie BR, Litherland C, Brener SJ, Kirtane AJ, Mintz GS, **Stone GW**. Etiology, Frequency, and Clinical Outcomes of Myocardial Infarction After Successful Drug-Eluting Stent Implantation: Two-Year Follow-Up From the ADAPT-DES Study. Circ Cardiovasc Interv. 2015;8(12):e002447. doi: 10.1161/CIRCINTERVENTIONS.114.002447.

950. Mihos CG, Santana O, Pineda AM, **Stone GW,** Hasty F, Beohar N. Percutaneous Coronary Intervention Followed by Minimally Invasive Mitral Valve Surgery in Ischemic Mitral Regurgitation. Innovations (Phila). 2015;10(6):394-7.

951. Prati F, Romagnoli E, Limbruno U, Pawlowski T, Fedele S, Gatto L, Di Vito L, Pappalardo A, Ramazzotti V, Picchi A, Trivisonno A, Materia L, Pfiatkosky P, Paoletti G, Marco V, Tavazzi L, Versaci F, **Stone GW.** Randomized evaluation of intralesion versus intracoronary abciximab and aspiration thrombectomy in patients with ST-elevation myocardial infarction: The COCTAIL II trial. Am Heart J. 2015 Dec;170(6):1116-23.

952. Bettinger N, Palmerini T, Caixeta A, Dressler O, Litherland C, Francese DP, Giustino G, Mehran R, Leon MB, **Stone GW,** Généreux P. Risk stratification of patients undergoing medical therapy after coronary angiography. Eur Heart J. 2015 Dec 18. [Epub ahead of print].

953. Warren J, Mehran R, Baber U, Xu K, Giacoppo D, Gersh BJ, Guagliumi G, Witzenbichler B, Magnus Ohman E, Pocock SJ, **Stone GW**. Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. Am Heart J. 2016;171:40-7.

954. Pocock SJ, Clayton TC, **Stone GW**. Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials. J Am Coll Cardiol. 2015;66:2757-66.

955. Tarigopula M, Généreux P, Madhavan MV, Parvataneni R, Weisz G, Mehran R, **Stone GW**. Revascularization Strategies for Calcified Lesions in Patients Presenting With Acute Coronary Syndromes (From the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] Trial). J Invasive Cardiol. 2016;28:10-6.

956. Jackson LR 2nd, Ju C, Zettler M, Messenger JC, Cohen DJ, **Stone GW**, Baker BA, Effron M, Peterson ED, Wang TY. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. JACC Cardiovasc Interv. 2015;8:1880-9.

957. Pocock SJ, Clayton TC, **Stone GW**. Challenging Issues in Clinical Trial Design:

Part 4 of a 4-Part Series on Statistics for Clinical Trials. J Am Coll Cardiol. 2015;66:2886-98.

958. Brener SJ, Mehran R, Lansky AJ, Ayele GM, **Stone GW**. Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. Eur Heart J Acute Cardiovasc Care. 2015 Dec 31. [Epub ahead of print].

959. Prasad A, Gersh BJ, Mehran R, Brodie BR, Brener SJ, Dizon JM, Lansky AJ, Witzenbichler B, Kornowski R, Guagliumi G, Dudek D, **Stone GW**. Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction: An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). JACC Cardiovasc Interv. 2015 Dec 28;8(15):1966-74.

960. Kirtane AJ, Parikh PB, Stuckey TD, Xu K, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Brodie BR, Mazzaferri EL Jr, Parvataneni R, Maehara A, Généreux P, Mehran R, **Stone GW**. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). JACC Cardiovasc Interv. 2015;8:1978-87.

961. Ng VG, Lansky AJ, Toro S, Parise H, Cristea E, Mehran R, **Stone GW.** Prognostic utility of myocardial blush grade after PCI in patients with NSTE-ACS: Analysis from the ACUITY trial. Catheter Cardiovasc Interv. 2016 Aug;88(2):215-24.

962. Giustino G, Baber U, Salianski O, Sartori S, **Stone GW**, Leon MB, Aquino M, Stefanini GG, Steg PG, Windecker S, O' Donoghue M, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Dangas GD, Cha JY, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Genereux P, Chieffo A, Mehran R. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. Circ Cardiovasc Interv. 2016;9(7):674-84.

963. Chen SL, Zhang H, Xie DJ, Zhang J, Zhou L, Rothman AM, **Stone GW**. Response to Letter Regarding Article, "Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Study". Circ Cardiovasc Interv. 2016;9(1):e003463. doi: 10.1161/CIRCINTERVENTIONS.115.003463.

964. Liang Z, Li Y, Wang J, Wang D, Wang S, Ma L, Liu H, Yang L, **Stone GW**, Han Y. The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial. Catheter Cardiovasc Interv. 2016. [Epub ahead of print].

965. **Stone GW**, Hochman JS, Williams DO, Boden WE, Ferguson TB Jr, Harrington RA, Maron DJ. Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise. J Am Coll Cardiol. 2016;67:81-99.

966. Yu J, Mehran R, Clayton T, Gibson CM, Brodie BR, Witzenbichler B, Lincoff AM, Deliargyris EN, Gersh BJ, Pocock SJ, **Stone GW**, Dangas GD. Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials. Catheter Cardiovasc Interv. 2016;87(3):391-400.

967. Schoos MM, Dangas GD, Mehran R, Kirtane AJ, Yu J, Litherland C, Clemmensen P, Stuckey TD, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Brodie BR, Mazzaferri EL Jr, Maehara A, **Stone GW**. Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). Am J Cardiol. 2016;117(2):192-200.

968. Ng VG, Baumbach A, Grinfeld L, Lincoff AM, Mehran R, **Stone GW**, Lansky AJ. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). Am J Cardiol. 2016;117(2):186-91.

969. Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, Davidson-Ray L, Witkowski A, Mulkay AJ, Osmukhina A, Farzaneh-Far R, Ben-Yehuda O, **Stone GW,** Ohman EM.Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.Circulation. 2016;133(1):39-47.

970. O'Donoghue ML, Bhatt DL, **Stone GW**, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Deliargyris EN, Mahaffey KW, White HD, Harrington RA. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. Circulation. 2016;133:248-55.

971. Baber U, Giustino G, Sartori S, Aquino M, Stefanini GG, Steg PG, Windecker S, Leon MB, Wijns W, Serruys PW, Valgimigli M, **Stone GW**, Dangas GD, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Mastoris I, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016;9:28-38.

972. Liang Z, Li Y, Wang J, Wang D, Wang S, Ma L, Liu H, Yang L, **Stone GW**, Han Y. The safety and effectiveness of bivalirudin in female patients with acute

myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial. Catheter Cardiovasc Interv. 2016 Jan 13. [Epub ahead of print].

973. Schoos MM, Dangas GD, Mehran R, Kirtane AJ, Yu J, Litherland C, Clemmensen P, Stuckey TD, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Brodie BR, Mazzaferri EL Jr, Maehara A, **Stone GW**. Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). Am J Cardiol. 2016 Jan 15;117(2):192-200.

974. Ng VG, Baumbach A, Grinfeld L, Lincoff AM, Mehran R, **Stone GW**, Lansky AJ. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). Am J Cardiol. 2016 Jan 15;117(2):186-91.

975. Wessler JD, Généreux P, Mehran R, Ayele GM, Brener SJ, McEntegart M, Ben-Yehuda O, **Stone GW**, Kirtane AJ. Which Intraprocedural Thrombotic Events Impact Clinical Outcomes After Percutaneous Coronary Intervention in Acute Coronary Syndromes?: A Pooled Analysis of the HORIZONS-AMI and ACUITY Trials. JACC Cardiovasc Interv. 2016;9(4):331-7.

976. O'Donoghue ML, Bhatt DL, **Stone GW**, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Deliargyris EN, Mahaffey KW, White HD, Harrington RA. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. Circulation. 2016 Jan 19;133(3):248-55.

977. Palmerini T, **Stone GW**. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence. Eur Heart J. 2016 Jan 21;37:353-64.

978. **Stone GW**, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, Cheong WF, Jones-McMeans J, Su X, Zhang Z, Serruys PW. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387:1277-89.

979. Gutierrez JA, Harrington RA, Blankenship JC, **Stone GW,** Steg PG, Gibson CM, Hamm CW, Price MJ, Généreux P, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL; CHAMPION PHOENIX Investigators. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Eur Heart J. 2016;37(14):1122-30.

980. Weisz G, Généreux P, Iñiguez A, Zurakowski A, Shechter M, Alexander KP, Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, **Stone GW;** RIVER-PCI investigators. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a

multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10014):136-45.

981. Généreux P, Redfors B, Witzenbichler B, Maehara A, Yadav M, Weisz G, Francese DP, Parvataneni R, Brener SJ, Mehran R, Kirtane AJ, **Stone GW**. Angiographic predictors of 2-year stent thrombosis in patients receiving drug-eluting stents: Insights from the ADAPT-DES study. Catheter Cardiovasc Interv. 2016 Jan 27. [Epub ahead of print].

982. Caixeta A, Généreux P, de Siqueira ME, Baruzzi A, Abizaid A, **Stone GW**. MSCT Identification of Vulnerable Plaque. JACC Cardiovasc Imaging. 2016;9:207-9.

983. **Stone GW,** Chung ES, Stancak B, Svendsen JH, Fischer TM, Kueffer F, Ryan T, Bax J, Leon A; PRomPT Trial Investigators. Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction. Eur Heart J. 2016;37:484-93.

984. Yadav M, Généreux P, Giustino G, Madhavan MV, Brener SJ, Mintz G, Caixeta A, Xu K, Mehran R, **Stone GW**. Effect of Baseline Thrombocytopenia on Ischemic Outcomes in Patients With Acute Coronary Syndromes Who Undergo Percutaneous Coronary Intervention. Can J Cardiol. 2016;32:226-33.

985. Jatene T, Harrington RA, **Stone GW,** Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL; CHAMPION PHOENIX Investigators.Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. J Am Coll Cardiol. 2016;67:596-8.

986. Yun KH, Mintz GS, Witzenbichler B, Inaba S, Shimizu T, Metzger DC, Rinaldi MJ, Mazzaferri EL Jr, Duffy PL, Weisz G, Stuckey TD, Brodie BR, Kirtane AJ, **Stone GW**, Maehara A. Relationship Between Platelet Reactivity and Culprit Lesion Morphology: An Assessment from the ADAPT-DES Intravascular Ultrasound Substudy. JACC Cardiovasc Imaging. 2016;9(7):849-54.

987. Wessler JD, Généreux P, Mehran R, Ayele GM, Brener SJ, McEntegart M, Ben-Yehuda O, **Stone GW**, Kirtane AJ. Which Intraprocedural Thrombotic Events Impact Clinical Outcomes After Percutaneous Coronary Intervention in Acute Coronary Syndromes?: A Pooled Analysis of the HORIZONS-AMI and ACUITY Trials. JACC Cardiovasc Interv. 2016;9:331-7.

988. Gao R, **Stone GW**. Reply: Incidence of Stent Thrombosis With Bioresorbable Vascular Scaffolds in Comparison With Drug-Eluting Stents. J Am Coll Cardiol. 2016;67:892-4.

989. Ng VG, Mori K, Costa RA, Kish M, Mehran R, Urata H, Saku K, **Stone GW**, Lansky AJ. Impact of gender on infarct size, ST-segment resolution, myocardial blush and clinical outcomes after primary stenting for acute myocardial infarction: Substudy from the EMERALD trial. Int J Cardiol. 2016;207:269-76.

990. Geisler T, Droppa M, Gawaz M, Steinhubl SR, Bertrand ME, Lincoff AM, Cequier AR, Desmet W, Rasmussen LH, Hoekstra JW, Bernstein D, Deliargyris EN, Mehran R, **Stone GW.** Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial. Catheter Cardiovasc Interv. 2016;88(2):174-81.

991. Kanwar SS, **Stone GW**, Singh M, Virmani R, Olin J, Akasaka T, Narula J. Acute coronary syndromes without coronary plaque rupture. Nat Rev Cardiol. 2016;13(5):257-65.

992. Hambraeus K, Jensevik K, Lagerqvist B, Lindahl B, Carlsson R, Farzaneh-Far R, Kellerth T, Omerovic E, **Stone G**, Varenhorst C, James S. Long-Term Outcome of Incomplete Revascularization After Percutaneous Coronary Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry). JACC Cardiovasc Interv. 2016;9:207-15.

993. Weisz G, Smilowitz NR, Kirtane AJ, Rinaldi MJ, Parvataneni R, Xu K, Stuckey TD, Maehara A, Witzenbichler B, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Brodie BR, Mazzaferri EL Jr, Mehran R, **Stone GW**. Response to Letter Regarding Article, "Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study". Circ Cardiovasc Interv. 2016 Mar;9(3):e003530.

994. Ali ZA, Karimi Galougahi K, Nazif T, Maehara A, Hardy MA, Cohen DJ, Ratner LE, Collins MB, Moses JW, Kirtane AJ, **Stone GW**, Karmpaliotis D, Leon MB. Imaging- and physiology-guided percutaneous coronary intervention without contrast administration in advanced renal failure: a feasibility, safety, and outcome study. Eur Heart J. 2016 Mar 7. [Epub ahead of print].

995. Gogas BD, Yang B, Piccinelli M, Giddens DP, King SB 3rd, Kereiakes DJ, Ellis SG, **Stone GW**, Veneziani A, Samady H. Novel 3-Dimensional Vessel and Scaffold Reconstruction Methodology for the Assessment of Strut-Level Wall Shear Stress After Deployment of Bioresorbable Vascular Scaffolds From the ABSORB III Imaging Substudy. JACC Cardiovasc Interv. 2016;9:501-3.

996. Sakellarios A, Bourantas CV, Papadopoulou SL, Tsirka Z, de Vries T, Kitslaar PH, Girasis C, Naka KK, Fotiadis DI, Veldhof S, **Stone GW**, Reiber JH, Michalis LK, Serruys PW, de Feyter PJ, Garcia-Garcia HM. Prediction of atherosclerotic disease progression using LDL transport modelling: a serial computed tomographic coronary angiographic study. Eur Heart J Cardiovasc Imaging. 2016 Mar 16. [Epub ahead of print].

997. **Stone GW.** Bioresorbable Vascular Scaffolds: More Different Than Alike? JACC Cardiovasc Interv. 2016;9:575-7.

998. Généreux P, **Stone GW**, O'Gara PT, Marquis-Gravel G, Redfors B, Giustino G,

Pibarot P, Bax JJ, Bonow RO, Leon MB. Natural History, Diagnostic Approaches, and Therapeutic Strategies for Patients With Asymptomatic Severe Aortic Stenosis. J Am Coll Cardiol. 2016;67(19):2263-88.

999. Albuquerque FN, Bortnick A, Iqbal J, Ishibashi Y, **Stone GW,** Serruys PW. Dual antiplatelet therapy, drug-eluting stents and bioresorbable vascular scaffolds: Evolutionary perspectives. Catheter Cardiovasc Interv. 2016;87(5):909-19.

1000. Giustino G, Baber U, Aquino M, Sartori S, **Stone GW**, Leon MB, Genereux P, Dangas GD, Chandrasekhar J, Kimura T, Salianski O, Stefanini GG, Steg PG, Windecker S, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, Von Birgelen C, Saporito R, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. JACC Cardiovasc Interv. 2016;9:674-84.

1001. **Stone GW**, Selker HP, Thiele H, Patel MR, Udelson JE, Ohman EM, Maehara A, Eitel I, Granger CB, Jenkins PL, Nichols M, Ben-Yehuda O. Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. J Am Coll Cardiol. 2016 Apr 12;67(14):1674-83.

1002. Giustino G, Kirtane AJ, Généreux P, Baber U, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger C, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Brodie BR, Stuckey TD, Dangas GD, Francese DP, Litherland C, Mehran R, **Stone GW**. Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016;117(11):1703-13.

1003. Pinto DS, Kohli P, Fan W, Kirtane AJ, Kociol RD, Meduri C, Deliargyris EN, Prats J, Reynolds MR, **Stone GW,** Michael Gibson C. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database. Catheter Cardiovasc Interv. 2016;87(3):363-73.

1004. Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ, **Stone GW**, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol. 2016;67(19):2224-34.

1005. Thompson K, Razi R, Lee MS, Shen A, **Stone GW,** Hiremath S, Mehran R, Brar SS. Statin use prior to angiography for the prevention of contrast-induced acute

kidney injury: a meta-analysis of 19 randomised trials. EuroIntervention. 2015;12(3):366-74.

1006. Généreux P, Bettinger N, Redfors B, Lee AC, Kim CY, Lee MS, Shlofmitz RA, Moses JW, **Stone GW**, Chambers JW. Two-year outcomes after treatment of severely calcified coronary lesions with the orbital atherectomy system and the impact of stent types: Insight from the ORBIT II trial. Catheter Cardiovasc Interv. 2016 Apr 16. [Epub ahead of print].

1007. Iannaccone M, D'Ascenzo F, Templin C, Omedè P, Montefusco A, Guagliumi G, Serruys PW, Di Mario C, Kochman J, Quadri G, Biondi-Zoccai G, Lüscher TF, Moretti C, D'amico M, Gaita F, **Stone GW.** Optical coherence tomography evaluation of intermediate-term healing of different stent types: systemic review and meta-analysis. Eur Heart J Cardiovasc Imaging. 2016 Apr 20. [Epub ahead of print].

1008. Fujimoto S, Kondo T, Takamura K, Baber U, Shinozaki T, Nishizaki Y, Kawaguchi Y, Matsumori R, Hiki M, Miyauchi K, Daida H, Hecht H, **Stone GW,** Narula J. Incremental prognostic value of coronary computed tomographic angiography high-risk plaque characteristics in newly symptomatic patients. J Cardiol. 2016;67(6):538-44.

1009. Bourantas CV, Papadopoulou SL, Serruys PW, Sakellarios A, Kitslaar PH, Bizopoulos P, Girasis C, Zhang YJ, de Vries T, Boersma E, Papafaklis MI, Naka KK, Fotiadis DI, **Stone GW,** Reiber JH, Michalis LK, de Feyter PJ, Garcia-Garcia HM. Noninvasive Prediction of Atherosclerotic Progression: The PROSPECT-MSCT Study. JACC Cardiovasc Imaging. 2016;9(8):1009-11.

1010. Goto K, Mintz GS, Litherland C, Lansky AJ, Weisz G, McPherson JA, De Bruyne B, Serruys PW, **Stone GW**, Maehara A. Lumen Measurements From Quantitative Coronary Angiography and IVUS: A PROSPECT Substudy. JACC Cardiovasc Imaging. 2016;9(8):1011-3.

1011. Iñiguez A, Brener SJ, Jiménez VA, Maehara A, Mintz GS, Xu K, Weisz G, Lansky AJ, De Bruyne B, Serruys PW, **Stone GW**. Significance of prior percutaneous revascularisation in patients with acute coronary syndromes: insights from the prospective PROSPECT registry. EuroIntervention. 2016;11:1468-74.

1012. Pineda AM, Carvalho N, Mihos CG, Gowani SA, Santana O, Desouza KA, **Stone GW**, Beohar N. Managing Multi-Vessel Coronary Artery Disease in Patients with ST Elevation Myocardial Infarction: A Comprehensive Review. Cardiol Rev. 2016. [Epub ahead of print].

1013. Giustino G, Kirtane AJ, Baber U, Généreux P, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger C, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Brodie BR, Stuckey TD, Gurbel PA, Dangas GD, Francese DP, Ozan O, Mehran R, **Stone GW**. Impact of Anemia on Platelet Reactivity and

Ischemic and Bleeding Risk from the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016;117(12):1877-83.

1014. D'Ascenzo F, Moretti C, Bianco M, Bernardi A, Taha Md S, Cerrato E, Omedè P, Montefusco A, Frangieh AH, Lee CW, Campo G, Chieffo A, Quadri G, Pavani M, Zoccai GB, Gaita F, Park SJ, Colombo A, Templin C, Lüscher TF, **Stone GW**. Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated With Second-Generation Drug-Eluting Stents. Am J Cardiol. 2016;117(11):1714-23.

1015. Capodanno D, Gargiulo G, Capranzano P, Mehran R, Tamburino C, **Stone GW.** Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. Eur Heart J Acute Cardiovasc Care. 2016;5:253-62.

1016. Dangas GD, Schoos MM, Steg PG, Mehran R, Clemmensen P, van 't Hof A, Prats J, Bernstein D, Deliargyris EN, **Stone GW**. Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials. Circ Cardiovasc Interv. 2016;9(5):e003272. doi: 10.1161/CIRCINTERVENTIONS.115.003272.

1017. Xu B, Gao R, Yang Y, Cao X, Qin L, Li Y, Li Z, Li X, Lin H, Guo Y, Ma Y, Wang J, Nie S, Xu L, Cao E, Guan C, **Stone GW**; PANDA III Investigators. Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics: The PANDA III Trial. J Am Coll Cardiol. 2016;67:2249-58.

1018. Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, Généreux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, Lansky AJ, Francese DP, Dangas GD, **Stone GW**. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. Am J Cardiol. 2016;118(1):6-16.

1019. **Stone GW**. DAPT Duration After Coronary Stenting: Assessing Risk-Benefit Tradeoffs in Individual Patients. J Am Coll Cardiol. 2016;67:2503-5.

1020. Ducrocq G, Steg PG, Van't Hof A, Zeymer U, Mehran R, Hamm CW, Bernstein D, Prats J, Deliargyris EN, **Stone GW**. Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials. Eur Heart J Acute Cardiovasc Care. 2016 Jun 10. [Epub ahead of print].

1021. Vaduganathan M, Harrington RA, **Stone GW**, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition

(CHAMPION) PHOENIX Trial. Circ Cardiovasc Interv. 2016;9(6). pii: e003612. doi: 10.1161/CIRCINTERVENTIONS.116.003612.

1022. Kedhi E, Kennedy MW, Maehara A, Lansky AJ, McAndrew TC, Marso SP, De Bruyne B, Serruys PW, **Stone GW**. Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus: Insights From the PROSPECT Study. JACC Cardiovasc Imaging. 2016 Jun 23. [Epub ahead of print].

1023. Brener SJ, Kirtane AJ, Stuckey TD, Witzenbichler B, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Mehran R, Parvataneni R, Brodie BR, **Stone GW**. The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study. JACC Cardiovasc Interv. 2016;9(14):1450-7.

1024. Ahmadi A, **Stone GW**, Leipsic J, Shaw LJ, Villines TC, Kern MJ, Hecht H, Erlinge D, Ben-Yehuda O, Maehara A, Arbustini E, Serruys P, Garcia-Garcia HM, Narula J. Prognostic Determinants of Coronary Atherosclerosis in Stable Ischemic Heart Disease: Anatomy, Physiology, or Morphology? Circ Res. 2016 Jul 8;119(2):317-29.

1025. Wang L, Mintz GS, Witzenbichler B, Metzger DC, Rinaldi MJ, Duffy PL, Weisz G, Stuckey TD, Brodie BR, Inaba S, Xu K, Kirtane AJ, **Stone GW,** Maehara A. Differences in Underlying Culprit Lesion Morphology Between Men and Women: An IVUS Analysis From the ADAPT-DES Study. JACC Cardiovasc Imaging. 2016;9(4):498-9.

1026. Kereiakes DJ, Onuma Y, Serruys PW, **Stone GW.** Bioresorbable Vascular Scaffolds for Coronary Revascularization. Circulation. 2016;134(2):168-82.

1027. Kobayashi N, Mintz GS, Witzenbichler B, Metzger DC, Rinaldi MJ, Duffy PL, Weisz G, Stuckey TD, Brodie BR, Parvataneni R, Kirtane AJ, **Stone GW,** Maehara A. Prevalence, Features, and Prognostic Importance of Edge Dissection After Drug-Eluting Stent Implantation: An ADAPT-DES Intravascular Ultrasound Substudy. Circ Cardiovasc Interv. 2016;9(7):e003553. doi: 10.1161/CIRCINTERVENTIONS.115.003553.

1028. **Stone GW,** Gao R, Kimura T, Simonton C, Serruys PW. Optimum technique to reduce risk of stent thrombosis - Authors' reply. Lancet. 2016;388(10040):127-8.

1029. Sawaya FJ, Morice MC, Spaziano M, Mehran R, Didier R, Roy A, Valgimigli M, Kim HS, Woo Park K, Hong MK, Kim BK, Jang Y, Feres F, Abizaid A, Costa RA, Colombo A, Chieffo A, Giustino G, **Stone GW,** Bhatt DL, Palmerini T, Gilard M. Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials. Catheter Cardiovasc Interv. 2016 Jul 18. [Epub ahead of print].

1030. Ahmadi A, **Stone GW**, Leipsic J, Serruys PW, Shaw L, Hecht H, Wong G,

Nørgaard BL, O'Gara PT, Chandrashekhar Y, Narula J. Association of Coronary Stenosis and Plaque Morphology With Fractional Flow Reserve and Outcomes. JAMA Cardiol. 2016;1:350-7.

1031. Doshi D, Ben-Yehuda O, Bonafede M, Josephy N, Karmpaliotis D, Parikh MA, Moses JW, **Stone GW**, Leon MB, Schwartz A, Kirtane AJ. Underutilization of Coronary Artery Disease Testing Among Patients Hospitalized With New-Onset Heart Failure. J Am Coll Cardiol. 2016;68(5):450-8.

1032. Qiu F, Mintz GS, Witzenbichler B, Metzger DC, Rinaldi MJ, Duffy PL, Weisz G, Stuckey TD, Brodie BR, Parvataneni R, Kirtane AJ, **Stone GW**, Maehara A. Prevalence and Clinical Impact of Tissue Protrusion After Stent Implantation: An ADAPT-DES Intravascular Ultrasound Substudy. JACC Cardiovasc Interv. 2016;9:1499-507.

1033. Kirtane AJ, Doshi D, Leon MB, Lasala JM, Ohman EM, O'Neill WW, Shroff A, Cohen MG, Palacios IF, Beohar N, Uriel N, Kapur NK, Karmpaliotis D, Lombardi W, Dangas GD, Parikh MA, **Stone GW**, Moses JW. Treatment of Higher-Risk Patients With an Indication for Revascularization: Evolution Within the Field of Contemporary Percutaneous Coronary Intervention. Circulation. 2016;134(5):422-31.

1034. Cavender MA, Bhatt DL, **Stone GW**, White HD, Steg PG, Gibson CM, Hamm CW, Price MJ, Leonardi S, Prats J, Deliargyris EN, Mahaffey KW, Harrington RA; CHAMPION PHOENIX Investigators. Consistent Reduction in Peri-Procedural Myocardial Infarction with Cangrelor as Assessed by Multiple Definitions: Findings from CHAMPION PHOENIX. Circulation. 2016 Aug 1. [Epub ahead of print].

1035. Leonardi S, Lopes RD, Steg PG, Abnousi F, Menozzi A, Prats J, Mangum S, Wilson M, Todd M, **Stone GW**, Gibson CM, Hamm CW, Price MJ, White HD, Harrington RA, Bhatt DL, Mahaffey KW. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. Eur Heart J Acute Cardiovasc Care. 2016 Aug 2. [Epub ahead of print].

1036. Bhatti NK, Karimi Galougahi K, Paz Y, Nazif T, Moses JW, Leon MB, **Stone GW**, Kirtane AJ, Karmpaliotis D, Bokhari S, Hardy MA, Dube G, Mohan S, Ratner LE, Cohen DJ, Ali ZA. Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease. J Am Heart Assoc. 2016;5(8). pii: e003648. doi: 10.1161/JAHA.116.003648.

1037. Academic Research Organization Consortium for Continuing Evaluation of Scientific Studies--Cardiovascular (ACCESS CV). Sharing Data from Cardiovascular Clinical Trials--A Proposal. N Engl J Med. 2016;375:407-9.

1038. Gennaro G, Brener SJ, Redfors B, Kirtane AJ, Généreux P, Maehara A, Neunteufl T, Metzger DC, Mehran R, Gibson CM, **Stone GW**. Effect of Smoking

on Infarct Size and Major Adverse Cardiac Events in Patients With Large Anterior ST-Elevation Myocardial Infarction (from the INFUSE-AMI Trial). Am J Cardiol. 2016 Jul 28. [Epub ahead of print].

1039. Rao SV, **Stone GW**. Arterial access and arteriotomy site closure devices. Nat Rev Cardiol. 2016 Aug 25. [Epub ahead of print].

1040. Pocock SJ, **Stone GW**. The Primary Outcome Fails - What Next? N Engl J Med. 2016;375:861-870.

1041. Selvaraj S, Bhatt DL, **Stone GW**, et al. "Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: Findings from CHAMPION PHOENIX. Am Coll Cardiol. 2016 Aug 25. [Epub ahead of print].

1042. Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A, Costa RA, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Gilard M, Morice MC, Sawaya F, Sardella G, Genereux P, Redfors B, Leon MB, Bhatt DL, **Stone GW**, Colombo A. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. J Am Coll Cardiol. 2016 Aug 25. [Epub ahead of print].

1043. Onuma Y, Sotomi Y, Shiomi H, Ozaki Y, Namiki A, Yasuda S, Ueno T, Ando K, Furuya J, Igarashi K, Kozuma K, Tanabe K, Kusano H, Rapoza R, Popma JJ, **Stone GW**, Simonton C, Serruys PW, Kimura T. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention. 2016;12(7). [Epub ahead of print].

1044. Pocock SJ, **Stone GW**. The Primary Outcome Is Positive - Is That Good Enough? N Engl J Med. 2016;375:971-9.

1045. Tarantini G, D'Amico G, Brener SJ, Tellaroli P, Basile M, Schiavo A, Mojoli M, Fraccaro C, Marchese A, Musumeci G, **Stone GW**. Survival After Varying Revascularization Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease: A Pairwise and Network Meta-Analysis. JACC Cardiovasc Interv. 2016;9:1765-76.

1046. Rohla M, Tentzeris I, Freynhofer MK, Farhan S, Jarai R, Egger F, Weiss TW, Wojta J, Geppert A, Kastrati A, **Stone GW**, Huber K. Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experience. Wien Klin Wochenschr. 2016 Sep 13. [Epub ahead of print].

1047. Lee SY, Hong MK, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Kim HS, Valgimigli M, Palmerini T, **Stone GW.** Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. Clin Res Cardiol. 2016 Sep 8. [Epub ahead of print].

1048. Kappetein AP, Serruys PW, Sabik JF, Leon MB, Taggart DP, Morice MC, Gersh BJ, Pocock SJ, Cohen DJ, Wallentin L, Ben-Yehuda O, van Es GA, Simonton CA, **Stone GW**. Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial. EuroIntervention. 2016;12:861-72.

1049. Giustino G, Mastoris I, Baber U, Sartori S, **Stone GW**, Leon MB, Serruys PW, Kastrati A, Windecker S, Valgimigli M, Dangas GD, Von Birgelen C, Smits PC, Kandzari D, Galatius S, Wijns W, Steg PG, Stefanini GG, Aquino M, Morice MC, Camenzind E, Weisz G, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Chieffo A, Mehran R. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Cardiovasc Interv. 2016 Sep 26;9(18):1890-901.

1050. Abtan J, Steg PG, **Stone GW**, Mahaffey KW, Gibson CM, Hamm CW, Price MJ, Abnousi F, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL; CHAMPION PHOENIX Investigators. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. JACC Cardiovasc Interv. 2016 Sep 26;9(18):1905-13.

1051. Vora AN, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Faries DE, Zettler ME, Fonarow GC, Baker BA, **Stone GW**, Wang TY. Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. J Am Heart Assoc. 2016 Sep 23;5(9). pii: e003946.

1052. Chen SL, Zhang H, Xie DJ, Zhang FF, Zhou L, Zhang J, Chen MX, Stone GW. Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension: Results From a Controlled Before and After Study. Int J Cardiol Res. 2016;3(2):68-77.

1053. Roleder T, Karimi Galougahi K, Chin CY, Bhatti NK, Brilakis E, Nazif TM, Kirtane AJ, Karmpaliotis D, Wojakowski W, Leon MB, Mintz GS, Maehara A, **Stone GW**, Ali ZA. Utility of near-infrared spectroscopy for detection of thin-cap neoatherosclerosis. Eur Heart J Cardiovasc Imaging. 2016 Sep 27. pii: jew198. [Epub ahead of print].

1054. Singh M, Bhatt DL, Stone GW, Rihal CS, Gersh BJ, Lennon RJ, Narula J, Fuster V. Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. Mayo Clin Proc. 2016;91(10):1413-1447.

1055. Sotomi Y, Onuma Y, Suwannasom P, Tateishi H, Tenekecioglu E, Zeng Y, Cavalcante R, Jonker H, Dijkstra J, Foin N, Koon JN, Collet C, de Winter RJ, Wykrzykowska JJ, **Stone GW**, Popma JJ, Kozuma K, Tanabe K, Serruys PW, Kimura T. Is quantitative coronary angiography reliable in assessing the lumen gain after treatment with the everolimus-eluting bioresorbable polylactide scaffold? EuroIntervention. 2016;12:e998-e1008.

1056. Onuma Y, Sotomi Y, Shiomi H, Ozaki Y, Namiki A, Yasuda S, Ueno T, Ando K, Furuya J, Igarashi K, Kozuma K, Tanabe K, Kusano H, Rapoza R, Popma JJ, Stone GW, Simonton C, Serruys PW, Kimura T. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention. 2016;12:1090-1101.

1057. Schoos MM, De Luca G, Dangas GD, Clemmensen P, Ayele GM, Mehran R, Stone GW. Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial. EuroIntervention. 2016;12:1144-1153.

1058. Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A, Costa RA, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Gilard M, Morice MC, Sawaya F, Sardella G, Genereux P, Redfors B, Leon MB, Bhatt DL, **Stone GW,** Colombo A. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. J Am Coll Cardiol. 2016 Oct 25;68(17):1851-1864.

1059. Bettinger N, Palmerini T, Caixeta A, Dressler O, Litherland C, Francese DP, Giustino G, Mehran R, Leon MB, **Stone GW,** Généreux P. Risk stratification of patients undergoing medical therapy after coronary angiography. Eur Heart J. 2016 Oct 21;37(40):3103-3110.

1060. Ali ZA, Karimi Galougahi K, Nazif T, Maehara A, Hardy MA, Cohen DJ, Ratner LE, Collins MB, Moses JW, Kirtane AJ, **Stone GW,** Karmpaliotis D, Leon MB. Imaging- and physiology-guided percutaneous coronary intervention without contrast administration in advanced renal failure: a feasibility, safety, and outcome study. Eur Heart J. 2016 Oct 21;37(40):3090-3095.

1061. **Stone GW,** Sabik JF, Serruys PW, Simonton CA, Généreux P, Puskas J, Kandzari DE, Morice MC, Lembo N, Brown WM 3rd, Taggart DP, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogáts G, Mansour S, Noiseux N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman P, Bochenek A, Schampaert E, Pagé P, Dressler O, Kosmidou I, Mehran R, Pocock SJ, Kappetein AP; EXCEL Trial Investigators. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med. 2016;375:2223-35.

1062. Lee SY, Hong MK, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Kim HS, Valgimigli M, Colombo A, Gilard M, Palmerini T, **Stone GW**. Association

Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents. Circ Cardiovasc Interv. 2016 Nov;9(11). [Epub ahead of print].

1063. Ali ZA, Maehara A, Généreux P, Shlofmitz RA, Fabbiocchi F, Nazif TM, Guagliumi G, Meraj PM, Alfonso F, Samady H, Akasaka T, Carlson EB, Leesar MA, Matsumura M, Ozan MO, Mintz GS, Ben-Yehuda O, **Stone GW**; ILUMIEN III: OPTIMIZE PCI Investigators. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. Lancet. 2016;388:2618-28.

1064. Gargiulo G, Windecker S, da Costa BR, Feres F, Hong MK, Gilard M, Kim HS, Colombo A, Bhatt DL, Kim BK, Morice MC, Park KW, Chieffo A, Palmerini T, **Stone GW**, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ. 2016 Nov 3;355:i5483.

1065. Chin CY, Mintz GS, Saito S, Witzenbichler B, Metzger DC, Rinaldi MJ, Mazzaferri EL Jr, Duffy PL, Weisz G, Stuckey TD, Brodie BR, Litherland C, Kirtane AJ, **Stone GW**, Maehara A. Relation Between Renal Function and Coronary Plaque Morphology (from the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Virtual Histology-Intravascular Ultrasound Substudy). Am J Cardiol. 2016 Oct 7. [Epub ahead of print].

1066. Ohya M, Kadota K, Sotomi Y, Kozuma K, Tanabe K, Uematsu M, Kawasaki T, Morino Y, Tobaru T, Nakao K, Tachibana K, Kishi K, Shibata Y, Ying S, Kusano H, **Stone GW**, Popma JJ, Onuma Y, Serruys PW, Kimura T. Impact of lesion calcification on angiographic outcomes after Absorb everolimus-eluting bioresorbable vascular scaffold implantation: an observation from the ABSORB Japan trial. EuroIntervention. 2016 Nov 8. [Epub ahead of print].

1067. **Stone GW**. Periprocedural Myocardial Infarction: The "SCAI" Is the Limit. JACC Cardiovasc Interv. 2016 Nov 14;9(21):2229-2231.

1068. Schoos MM, Mehran R, Dangas GD, Yu J, Baber U, Clemmensen P, Feit F, Gersh BJ, Guagliumi G, Ohman EM, Pocock SJ, Witzenbichler B, **Stone GW**. Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. Am J Cardiol. 2016 Oct 11. [Epub ahead of print].

1069. Karim Galougahi K, Ben-Yehuda O, Maehara A, Mintz GS, **Stone GW,** Ali ZA. "*The scaffolding must be removed once the house is built*" - spontaneous coronary artery dissection and the potential of bioresorbable scaffolds. J Thorac Dis. 2016 Oct;8(10):E1398-E1403.

1070. Inaba S, Mintz GS, Burke AP, **Stone GW**, Virmani R, Matsumura M, Parvataneni

R, Puri R, Nicholls SJ, Maehara A. Intravascular Ultrasound and Near-Infrared Spectroscopic Characterization of Thin-Cap Fibroatheroma. Am J Cardiol. 2016 Oct 31. [Epub ahead of print].

1071. Karimi Galougahi K, Shlofmitz RA, Ben-Yehuda O, Généreux P, Maehara A, Mintz GS, **Stone GW**, Moses JW, Ali ZA. Guiding Light: Insights Into Atherectomy by Optical Coherence Tomography. JACC Cardiovasc Interv. 2016;9:2362-2363.

1072. Vaduganathan M, Harrington RA, **Stone GW**, Deliargyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA Cardiol. 2016 Nov 30. [Epub ahead of print].

1073. Bavishi C, Chatterjee S, **Stone GW**. Does Current Evidence Favor Drug-Eluting Stents Over Bare-Metal Stents for Saphenous Venous Graft Interventions?: Insights From an Updated Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016;9:2456-2458.

1074. Redfors B, He CH, Palmerini T, Caixeta A, Giustino G, Ayele GM, Kirtane AJ, Mehran R, **Stone GW**, Généreux P. The SYNTAX Score Does Not Predict Risk of Adverse Events in Patients With Non-ST Elevation Acute Coronary Syndrome Who Undergo Coronary Artery Bypass Graft Surgery. J Invasive Cardiol. 2016 Dec 15. [Epub ahead of print].

1075. Redfors B, Kirtane AJ, Pocock SJ, Ayele GM, Deliargyris EN, Mehran R, **Stone GW**, Généreux P. Bleeding Events Before Coronary Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. J Am Coll Cardiol. 2016 Dec 20;68(24):2608-2618.

1076. Wang B, Mintz GS, Witzenbichler B, Souza CF, Metzger DC, Rinaldi MJ, Duffy PL, Weisz G, Stuckey TD, Brodie BR, Matsumura M, Yamamoto MH, Parvataneni R, Kirtane AJ, **Stone GW**, Maehara A. Predictors and Long-Term Clinical Impact of Acute Stent Malapposition: An Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) Intravascular Ultrasound Substudy. J Am Heart Assoc. 2016 Dec 22;5(12). pii: e004438. doi: 10.1161/JAHA.116.004438.

1077. Chen SL, Zhang H, Xie DJ, Zhang J, Zhou L, Chen M, **Stone GW.** Pericardial effusion is correlated with clinical outcome after pulmonary artery denervation for pulmonary arterial hypertension. Oncotarget 2016. [Epub ahead of print].

1078. Kereiakes DJ, Ellis SG, Kimura T, Abizaid A, Zhao W, Veldhof S, Vu MT, Zhang Z, Onuma Y, Chevalier B, Serruys PW, **Stone GW**. Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy. JACC

Cardiovasc Interv. 2016 Dec 1. [Epub ahead of print].

1079. Matsumura M, Mintz GS, Kang SJ, Sum ST, Madden SP, Burke AP, Goldstein J, Parvataneni R, **Stone GW**, Muller JE, Virmani R, Maehara A. Intravascular ultrasound and near-infrared spectroscopic features of coronary lesions with intraplaque haemorrhage. Eur Heart J Cardiovasc Imaging. 2016 Dec 25. [Epub ahead of print].

1080. Vora AN, Rao SV, **Stone GW.** Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. N Engl J Med. 2016 Dec 29;375:2602.

1081. Sawlani NN, Harrington RA, **Stone GW,** Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2017 Jan;10(1). [Epub ahead of print].

1082. Généreux P, Redfors B, Witzenbichler B, Arsenault MP, Weisz G, Stuckey TD, Rinaldi MJ, Neumann FJ, Christopher Metzger D, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Francese DP, Marquis-Gravel G, Mintz GS, Kirtane AJ, Maehara A, Mehran R, **Stone GW.** Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. Int J Cardiol. 2016 Dec 26. [Epub ahead of print].

1083. Guimarães LF, Généreux P, Silveira D, Pesaro AE, Falcão F, Barbosa BR, de Souza CF, Fonseca FA, Alves CM, Carvalho AC, **Stone GW,** Caixeta A. $P2Y_{12}$ receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: Analysis from the SAMPA randomized trial. Int J Cardiol. 2016 Dec 27. [Epub ahead of print].

1084. Vaduganathan M, Harrington RA, **Stone GW,** Deliargyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL; CHAMPION Investigators. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2017;69:176-185.

1085. De Silva K, Myat A, Cotton J, James S, Gershlick A, **Stone GW**. Bleeding associated with the management of acute coronary syndromes. Heart. 2017 Jan 13. [Epub ahead of print].

1086. Santana O, Singla S, Mihos CG, Pineda AM, Stone GW, Kurlansky PA, George I, Kirtane AJ, Smith CR, Beohar N. Outcomes of a Combined Approach of Percutaneous Coronary Revascularization and Cardiac Valve Surgery. Innovations (Phila). 2017 Jan 13. [Epub ahead of print].

1087. Elze MC, Gregson J, Baber U, Williamson E, Sartori S, Mehran R, Nichols M, Stone GW, Pocock SJ. Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. J Am Coll Cardiol.

2017 Jan 24;69(3):345-357.

1088. Doshi D, Ben-Yehuda O, Bonafede M, Josephy N, Karmpaliotis D, Parikh MA, Moses JW, Stone GW, Leon MB, Schwartz A, Kirtane AJ. Routine Ischemic Work-Up for Patients With New-Onset Heart Failure. J Am Coll Cardiol. 2017 Jan 24;69(3):364-365.

1089. Worthley SG, Abizaid A, Kirtane AJ, Simon DI, Windecker S, Brar S, Meredith IT, Shetty S, Sinhal A, Almonacid AP, Chamié D, Maehara A, Stone GW; RevElution Investigators. First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent: Angiographic, IVUS, OCT, and Clinical Outcomes From the RevElution Study. JACC Cardiovasc Interv. 2017 Jan 23;10(2):147-156.

1090. Tarantini G, D'Amico G, Brener SJ, Tellaroli P, Stone GW. Treatment Strategies for Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: Is Staged PCI Truly the Best Option? JACC Cardiovasc Interv. 2017 Jan 23;10(2):207-210.

1091. Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Sangiorgi D, Biondi-Zoccai G, Généreux P, Angelini GD, Pufulete M, White J, Bhatt DL, Stone GW. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J. 2017 Jan 21. [Epub ahead of print].

1092. Yin D, Matsumura M, Rundback J, Yoho JA, Witzenbichler B, **Stone GW,** Mintz GS, Maehara A. Comparison of plaque morphology between peripheral and coronary artery disease (from the CLARITY and ADAPT-DES IVUS substudies). Coron Artery Dis. 2017 Jan 21. [Epub ahead of print].

1093. Patel A, Nazif T, **Stone GW,** Ali ZA. Intraluminal bioresorbable vascular scaffold dismantling with aneurysm formation leading to very late thrombosis. Catheter Cardiovasc Interv. 2017 Feb 1. [Epub ahead of print].

1094. Yu J, Mehran R, Baber U, Ooi SY, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Brodie BR, Stuckey TD, Maehara A, Xu K, Ben-Yehuda O, Kirtane AJ, **Stone GW.** Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).

1095. Kelly CR, Kirtane AJ, Stant J, **Stone GW,** Minutello RM, Wong SC, Manuzon H, Gerow-Smith R, Kelley N, Rabbani LE. An Updated Protocol for Evaluating Chest Pain and Managing Acute Coronary Syndromes. Crit Pathw Cardiol. 2017 Mar;16(1):7-14.

1096. Guimarães LF, **Stone GW,** Caixeta A. Delayed onset of novel P2Y12 receptor antagonists action post fibrinolysis. Int J Cardiol. 2017 Feb 11. pii: S0167-5273(17)30775-1. doi: 10.1016/j.ijcard.2017.02.034. [Epub ahead of print].

1097. Kadohira T, Mintz GS, Souza CF, Witzenbichler B, Metzger DC, Rinaldi MJ, Mazzaferri EL Jr, Duffy PL, Weisz G, Stuckey TD, Brodie BR, Crowley A, Kirtane AJ, **Stone GW,** Maehara A. Impact of chronic statin therapy on clinical presentation and underlying lesion morphology in patients undergoing percutaneous intervention: an ADAPT-DES IVUS substudy. Coron Artery Dis. 2017 Feb 24. doi: 10.1097/MCA.0000000000000480. [Epub ahead of print].

1098. Gersh BJ, **Stone GW,** Bhatt DL. Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease: Do We Have the Evidence? Circulation. 2017 Feb 28;135(9):819-821.

1099. Tamez H, Pinto DS, Kirtane AJ, Litherland C, Yeh RW, Dangas GD, Mehran R, Deliargyris EN, Ortiz G, Gibson CM, **Stone GW.** Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial. JAMA Cardiol. 2017 Mar 1. doi: 10.1001/jamacardio.2016.5669. [Epub ahead of print].

1100. Sotomi Y, Onuma Y, Miyazaki Y, Asano T, Katagiri Y, Tenekecioglu E, Jonker H, Dijkstra J, de Winter RJ, Wykrzykowska JJ, **Stone GW,** Popma JJ, Kozuma K, Tanabe K, Serruys PW, Kimura T. Is quantitative coronary angiography reliable in assessing the late lumen loss of the everolimus eluting bioresorbable polylactide scaffold in comparison with the cobalt chromium metallic stent? EuroIntervention. 2017 Mar 7. pii: EIJ-D-17-00070. doi: 10.4244/EIJ-D-17-00070. [Epub ahead of print].

1101. Bavishi C, Sardar P, Chatterjee S, Khan AR, Shah A, Ather S, Lemos PA, Moreno P, **Stone GW.** Intravascular ultrasound-guided vs angiography-guided drug-eluting stent implantation in complex coronary lesions: Meta-analysis of randomized trials. Am Heart J. 2017;185:26-34.

1102. Kosmidou I, Redfors B, Dordi R, Dizon JM, McAndrew T, Mehran R, Ben-Yehuda O, Mintz GS, **Stone GW.** Incidence, Predictors, and Outcomes of High-Grade Atrioventricular Block in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the HORIZONS-AMI Trial). Am J Cardiol. 2017 Feb 16. pii: S0002-9149(17)30118-2. doi: 10.1016/j.amjcard.2017.01.019. [Epub ahead of print].

1103. Chin CY, Matsumura M, Maehara A, Zhang W, Lee CT, Yamamoto MH, Song L, Parviz Y, Jhalani NB, Mohan S, Ratner LE, Cohen DJ, Ben-Yehuda O, **Stone GW,** Shlofmitz RA, Kakuta T, Mintz GS, Ali ZA. Coronary Plaque Characteristics in Hemodialysis-Dependent Patients as Assessed by Optical Coherence Tomography. Am J Cardiol. 2017 Feb 9. pii: S0002-9149(17)30121-2. doi:

10.1016/j.amjcard.2017.01.022. [Epub ahead of print].

1104. Gupta R, Kirtane AJ, Ozan MO, Witzenbichler B, Rinaldi MJ, Metzger DC, Weisz G, Stuckey TD, Brodie BR, Mehran R, Ben-Yehuda O, **Stone GW.** Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Circ Cardiovasc Interv. 2017 Mar;10(3). pii: e004904. doi: 10.1161/CIRCINTERVENTIONS.116.004904. [Epub ahead of print].

1105. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, **Stone GW,** Windecker S, Steyerberg EW, Valgimigli M; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017 Mar 11;389(10073):1025-1034.

1106. Redfors B, Palmerini T, Caixeta A, Ayele GM, Francese DP, Mehran R, Brilakis ES, Kirtane AJ, Karmpaliotis D, **Stone GW,** Généreux P. Impact of Chronic Total Occlusions on Revascularization Scores and Outcome Prediction. J Invasive Cardiol. 2017 Mar 15. pii: JIC2017315-2. [Epub ahead of print].

1107. Doshi D, Ben-Yehuda O, Bonafede M, Josephy N, Karmpaliotis D, Parikh MA, Moses JW, **Stone GW,** Leon MB, Schwartz A, Kirtane AJ. Characteristic Left Ventricular Regional Wall Motion Abnormality Can Help Prevent Unnecessary Ischemic Workup. J Am Coll Cardiol. 2017 Mar 21;69(11):1517-1518.

1108. Weymann A, Ali-Hasan-Al-Saegh S, Sabashnikov A, Popov AF, Mirhosseini SJ, Nombela-Franco L, Testa L, Lotfaliani M, Zeriouh M, Liu T, Dehghan H, Yavuz S, de Oliveira Sá MP, Baker WL, Jang JS, Gong M, Benedetto U, Dohmen PM, D'Ascenzo F, Deshmukh AJ, Biondi-Zoccai G, Calkins H, **Stone GW.** Surgery And Cardiology-Group Imcsc-Group IM. Platelets Cellular and Functional Characteristics in Patients with Atrial Fibrillation: A Comprehensive Meta-Analysis and Systematic Review. Med Sci Monit Basic Res. 2017 Mar 17;23:58-86.

1109. Bax JJ, **Stone GW.** Bioprosthetic surgical and transcatheter heart valve thrombosis. Lancet. 2017 Mar 17. pii: S0140-6736(17)30764-X. doi: 10.1016/S0140-6736(17)30764-X. [Epub ahead of print].

Abstracts

1. Bulkley BH, Platia EV, **Stone GW**, Hochman JS. Ventricular aneurysms and endocardial pathology: relationship to malignant arrhythmias. Circulation 64(Suppl-IV):IV-306, 1981.

2. Platia EV, Berdoff R, **Stone G**, Ord S, Reid PR. Comparison of acebutolol and propranolol therapy for ventricular arrhythmias. Clinical Research 29:276A, 1981.

3. **Stone GW**, Griffin B, Brown D, Siegal R, Maurer G, Cook S, Shah PK, Berman DS. Systolic and diastolic dysfunction in acute pulmonary edema: A prospective consecutive series. J Nucl Med 28(Suppl):1987.

4. **Stone GW**, Griffin B, Brown D, Siegal R, Maurer G, Cook S, Berman DS, Shah PK. Is diastolic dysfunction the cause of acute pulmonary edema with normal global systolic dysfunction? Circulation 76(Suppl IV):IV-514, 1987.

5. Yang L, Barry CN, Rozanski A, **Stone G**, Nichols K, Friedman J, Areeda J, Suyenaga K, Syun M, Berman D. Validation of the ambulatory ventricular function monitor (VEST) for measuring left ventricular ejection fraction (LVEF). J Nucl Med 29:741, 1988.

6. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. Acute outcome and long term follow-up of patients with acute myocardial infarction and single vessel disease treated with angioplasty without thrombolytic therapy. J Am Coll Cardiol 13:94A, 1989.

7. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. Factors relating to improvement in regional wall motion and ejection fraction in patients with acute myocardial infarction and single vessel disease treated with coronary angioplasty without prior thrombolytic therapy. Cath and Cardiovasc Diagn 17:65-66, 1989.

8. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. Elective angioplasty of totally occluded coronary arteries: an analysis of 971 cases. Circulation 80:II-480, 1989.

9. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. Outcome following multilesion angioplasty targeted to the "culprit coronary artery" in pts with unstable angina. J Am Coll Cardiol 15:169A, 1990.

10. Grines CL, Browne K, Rothbaum D, Overlie P, Marco J, O'Keefe J, **Stone GW**, Chelliah N, Strzelecki M, O'Neill WW. The Primary Angioplasty in Myocardial Infarction (PAMI) Trial: Preliminary Report. Circulation;84(Suppl II):II-538, 1991.

11. Grines CL, Browne KF, Vandormael M, **Stone GW**, O'Keefe J, Overlie P, Puchrowicz-Ochocki S, Strzelecki M, O'Neill WW. Primary Angioplasty in Myocardial Infarction (PAMI) Trial. Circulation;86(Suppl I):I-641, 1992.

12. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Primary Angioplasty Reduces In-Hospital Mortality and Morbidity in Acute Anterior Myocardial Infarction - Results of the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. J Am Coll Cardiol 21:331A, 1993.

13. **Stone GW,** St. Goar F, Klette MA, Linnemeier TJ. Initial Clinical Experience with a Novel Low-Profile Integrated Coronary Ultrasound-Angioplasty Catheter: Implications for Routine Use. J Am Coll Cardiol 21:134A, 1993.

14. **Gregg W. Stone**, Cindy L. Grines, Ronald Vlietstra, Michel Vandormael, Donald Rothbaum, James O'Keefe, Paul Overlie, Brian Donohue, Noah Chelliah, Mellisa May, Sylvia Puchrowicz-Ochocki, William W. O'Neill. Primary Angioplasty is the Preferred Therapy for Women and the Elderly with Acute Myocardial Infarction - Results of the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. J Am Coll Cardiol 21:330A, 1993.

15. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, Timmis GC, O'Neill WW. Acute Outcome After Primary Angioplasty in Myocardial Infarction - The Primary Angioplasty In Myocardial Infarction (PAMI) Trial. J Am Coll Cardiol 21:331A, 1993.

16. Wilson WS and **Stone GW**. Is Prolonged Angina Free Survival Possible in Pts with Multivessel Disease Treated by PTCA?- Effect of Multiple, Repeated Procedures. Circulation, 88;I-217,1993.

17. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, Timmis GC. Primary Angioplasty Reduces Recurrent Ischemic Events Compared to tPA in Myocardial Infarction: Implications for Early Discharge. Circulation, 88;I-105,1993.

18. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Adverse Catheterization Laboratory Events after Primary PTCA vs. PTCA Following Thrombolytic Therapy - A Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. J Am Coll Cardiol 1A-484A;244A, 1994.

19. Bernard ST, Grines CL, Browne K, Marco J, Rothbaum D, **Stone GW**, O'Keefe J, Overlie P, Donohue B, Chelliah N, Puchrowicz-Ochocki S, Timmis GC, O'Neill WW. Does antecedent angina predict whether reperfusion by thrombolysis or primary angioplasty will be most beneficial? J Am Coll Cardiol 1A-484A;244A, 1994.

20. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Hartzler GO, Overlie P, Donohue B, Chelliah N, Corbell N, Puchrowicz S, O'Neill WW. Predictors of In-Hospital and 6-Month Outcome after Myocardial Infarction in the Reperfusion Era - A Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. J Am Coll Cardiol 1A-484A;226A, 1994.

21. Topaz O, McIvor M, **Stone G,** Foschi A, Sutton J, de Marchena E, and the Holmium Laser Multicenter Investigators. Solid State Laser Coronary Angioplasty: Multicenter Registry Report. Circulation 1994;90:I-332.

22. Grines CL, Griffin JJ, Brodie BR, **Stone GW**, Donohue BC, Balestrini C, Wharton TP, Spain MG, Shimshak T, Jones D, Mason D, O'Neill WW. The Second Primary Angioplasty for Myocardial Infarction Study (PAMI-II): Preliminary Report. Circulation 1994;90:I-433.

23. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, Timmis G. Outcome of Different Reperfusion Strategies in Thrombolytic "Eligible" Versus "Ineligible" Patients with Acute Myocardial Infarction. J Am Coll Cardiol 1995;25:401A.

24. **Gregg W. Stone,** Cindy L. Grines, Kevin F. Browne, Jean Marco, Donald Rothbaum, James O'Keefe, Paul Overlie, Brian Donohue, Noah Chelliah, Sylvia Puchrowicz-Ochocki, William W. O'Neill. Is Primary Angioplasty Less Effective in Patients Presenting in the Early Morning Hours? - A Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. J Am Coll Cardiol 1995;25:295A.

25. **Gregg W. Stone**, Cindy L. Grines, Kevin F. Browne, Jean Marco, Donald Rothbaum, James O'Keefe, Geoffrey O. Hartzler, Paul Overlie, Brian Donohue, Noah Chelliah, Sylvia Puchrowicz, William W. O'Neill. Does Primary Angioplasty Improve the Prognosis of Patients with Diabetes and Acute Myocardial Infarction? J Am Coll Cardiol 1995;25:401A.

26. Patricia Cavero, James O'Keefe, **Gregg W. Stone,** Ben McCallister, Cheryl Dreiling, Robert Ligon, Ray Kacich. Lovastatin and Probucol for the Prevention of Restenosis After Coronary Angioplasty. J Am Coll Cardiol 1995;25:226A.

27. Raffi Krikorian, Sylvia Puchrowicz, James O'Keefe, Cindy Grines, Kevin F. Browne, Donald Rothbaum, Ronald Vlietstra, **Gregg W. Stone**, William W. O'Neill. Differential Effects of Long-term Beta-blocker Therapy Following Thrombolysis Versus Primary Angioplasty. J Am Coll Cardiol 1995;25:402A.

28. Bruce Brodie, Cindy L. Grines, Michael Spain, John Griffin, Carlos Balestrini, **Gregg W. Stone,** Costantino Costantini, Paolo Esente, Michael Ayres, Masakiyo Nobuyoshi, Bryan Donohue, Noah Chelliah, Donald Rothbaum, Thomas Wharton,

Denise Jones, Denise Mason, Debra Sachs, William W. O'Neill. A Prospective, Randomized Trial Evaluating Early Discharge (Day 3) Without Non-Invasive Risk Stratification in Low Risk Patients with Acute Myocardial Infarction: PAMI-2. J Am Coll Cardiol 1995;25::5A.

29. **Stone GW.** Who is suitable for early discharge after acute myocardial infarction? ACCEL 27:1, January 1995.

30. John Griffin, Cindy L. Grines, Dominic Marsalese, Michael Spain, Bruce Brodie, Bryan Donohue, Thomas Wharton, **Gregg W. Stone,** Carlos Balestrini, Costantino Costantini, Thomas Shimshak, Juan Luis Delcan, Denise Jones, Denise Mason, Debra Sachs, William W. O'Neill. A Prospective, Randomized Trial Evaluating the Prophylactic Use of Balloon Pumping in High Risk Myocardial Infarction Patients: PAMI-2. J Am Coll Cardiol 1995;25:86A.

31. John Hodgson, **Gregg W. Stone,** Fred St. Goar, Thomas Linnemeier, Helen Sheehan for the CLOUT Investigators. Can Intracoronary Ultrasound Improve PTCA Results?: Preliminary Core Lab Ultrasound Analysis from the CLOUT Pilot Study. J Am Coll Cardiol 1995;25:143A.

32. **Gregg W. Stone,** Fred G. St. Goar, Tom Linnemeier, Helen Sheehan and John Hodgson for the CLOUT Investigators. Can the Results of Standard Balloon Angioplasty be Improved with Intracoronary Ultrasound Guidance? - The CLOUT Pilot Study. J Inv Cardiol 1995;7:23A.

33. **Gregg W. Stone,** Michael McIvor, On Topaz, Joseph Sutton, Eduardo J. DeMarchena. Holmium Laser Multicenter Registry Results: Effect of lesion morphology on procedural success and complications. J Inv Cardiol 1995;7:5A.

34. JMcB Hodgson, **GW Stone**, HM Sheehan, FG. St. Goar, T Linnemeier for the CLOUT Investigators. Intravascular ultrasound guided "oversized" balloon angioplasty: initial results from the CLOUT pilot trial. Cath and CV Diag 1995;35:81.

35. **Gregg W. Stone**, Dominic Marsalese, Bruce Brodie, John Griffin, Bryan Donohue, Costantino Costantini, Carlos Balestrini, Thomas Wharton, Denise Jones, Debra Sachs, Cindy L. Grines. The Routine Use of Intra Aortic Balloon Pumping After Primary PTCA Improves Clinical Outcomes in Very High Risk Patients with Acute Myocardial Infarction - Results of the PAMI-2 Trial. Circulation 1995;92 (suppl I):I-139.

36. **Gregg W. Stone**, Dominic Marsalese, Bruce Brodie, John Griffin, Bryan Donohue, Costantino Costantini, Carlos Balestrini, Thomas Wharton, Denise Jones, Debra Sachs, Gerald Timmis. Is Prophylactic IABP Use Beneficial or Harmful in a High Risk Elderly Population with Acute Myocardial Infarction? - PAMI-2. Circulation 1995;92 (suppl I):I-139.

37. Cindy Grines, Dominic Marsalese, Bruce Brodie, John Griffin, Bryan Donohue, A. Sampolesi, Costantino Costantini, **Gregg Stone,** Michael Spain, Denise Jones, Debra Sachs, Denise Mason, William O'Neill. Acute Cath Provides the Best Method of Risk Stratifying MI Patients. Circulation 1995;92 (suppl I):I-531.

38. Victoria Hollingsworth, Dominic Marsalese, Bruce Brodie, John Griffin, Bryan Donohue, Costantino Costantini, A. Sampolesi, **Gregg Stone**, M Nobuyoshi, Michael Ayres, Thomas Shimshak, Denise Jones, Denise Mason, Debra Sachs, Cindy Grines. Should Primary PTCA be Performed Around the Clock? Circulation 1995;92 (suppl I):I-663.

39. Thomas P. Wharton, Dominic Marsalese, Bruce Brodie, John Griffin, Bryan Donohue, Costantino Costantini, Carlos Balestrini, **Gregg W. Stone**, Paolo Esente, Jeffrey Moses, Nancy McNamara, Denise Jones, Debra Sachs, Cindy L. Grines. How Often do Infarct-Related Arteries Show Early Perfusion Without Prior Thrombolytic Therapy, and Should These Vessels be Dilated Acutely? Circulation 1995;92 (suppl I):I-530.

40. Cindy Grines, Bruce Brodie, John Griffin, Bryan Donohue, A. Sampolesi, Costantino Costantini, Debra Sachs, Thomas Wharton, Paolo Esente, Michael Spain, **Gregg Stone**. Which Primary PTCA Patients may Benefit from New Technologies? Circulation 1995;92 (suppl I):I-146.

41. Tom Linnemeier, **Gregg W. Stone,** John McB. Hodgson, Coverdale J, Sheehan H, Landin R, Hodes Z, Ball M, Rothbaum D, Lips D, Elsner G, Riddell R, Dodin E, Yamada G, Lewis S. OSTI: Optimal Stent Implantation Protocol. The Journal of Endovascular Surgery 1996;3:I-25.

42. **Gregg W. Stone,** Tom Linnemeier, Fred G. St. Goar, Harald Mudra, Helen Sheehan and John McB. Hodgson. Improved Outcome of Balloon Angioplasty with Intracoronary Ultrasound Guidance - Core Lab Angiographic and Ultrasound Results from the CLOUT Study. J Am Coll Cardiol 1996;27(Suppl A):155A.

43. **Gregg W. Stone,** Fred G. St. Goar, Tom Linnemeier, Helen Sheehan and John McB. Hodgson for the CLOUT Investigators. Variability in Balloon Sizing During Routine PTCA - Quantitative Coronary and Ultrasound Analysis. J Am Coll Cardiol 1996;27(Suppl A):361A.

44. **Gregg W. Stone,** Tom Linnemeier, Fred St. Goar, Ron Landin, Michael Ball, Don Rothbaum, Zachary Hodes, Janice Coverdale, Helen Sheehan, John McB. Hodgson. What is the Optimal Pressure for Stent Implantation (How High is High)? J Am Coll Cardiol 1996;27(Suppl A):154A.

45. O'Neill W, Griffin J, **Stone GW,** Brodie B, Jones D, Sachs D, Esente P, Spain M, Ayres M, Grines CL. Operator and institutional volume do not affect the

procedural outcome of primary angioplasty therapy. J Am Coll Cardiol 1996;27(Suppl A):13A.

46. Grines CL, Brodie B, Griffin J, Donohue B, Costantini C, Balestrini C, **Stone GW,** Wharton T, Mitina L, Graham M, Jones D, Sachs D, O'Neill WW. Prophylactic intraaortic balloon pumping for acute myocardial infarction does not improve left ventricular function. J Am Coll Cardiol 1996;27(Suppl A):167A.

47. Theodore Schreiber, Dominic Marsalese, Bryan Donohue, A. Sampolesi, Costantino Costantini, **Gregg Stone**, Denise Jones, Debra Sachs, Denise Mason, Thomas Wharton, Donald Rothbaum, Bruce Brodie, William W. O'Neill, Cindy Grines. Identification of Ultra Low-Risk Patients Following Primary Angioplasty for Acute Myocardial Infarction. J Am Coll Cardiol 1996;27(Suppl A):83A.

48. John Griffin, William W. O'Neill, Bruce Brodie, Sherry Theodosiou, Denise Jones, Debra Sachs, C. Costantini, C. Balestrini, **Gregg Stone**, Cindy Grines. Primary PTCA results in similar in-hospital outcomes in females and males presenting with acute MI. J Am Coll Cardiol 1996;27(Suppl A):154A.

49. Peter P. Scalise III, William W. O'Neill, Bryan Donohue, Denise Jones, Bruce Brodie, John Griffin, C. Costantini, C. Balestrini, **Gregg Stone**, Cindy Grines. Significance of antecedent angina (AA) in Primary PTCA: the PAMI-II Experience. J Inv Cardiol 1996;8:88.

50. Bryan Donohue, William W. O'Neill, Erik Jackson, Bruce Brodie, John Griffin, C. Balestrini, **Gregg Stone**, Thomas Wharton, Denise Jones, Cindy Grines. Cost analysis of different management strategies for myocardial infarction. J Am Coll Cardiol 1996;27(Suppl A):221A.

51. Timothy J. Byrne, William W. O'Neill, Bryan Donohue, Bruce Brodie, **Gregg Stone**, Adrien Van Strien, Floyd Casaday, Peter Scalise III. John Cava, Susan Petruolo, Denise Jones, Cindy Grines. Primary Angioplasty in Acute Myocardial Infarction: Does Urgent Transport Incur Added Risk? J Inv Cardiol 1996;8:67.

52. Bruce Brodie, Terry Bowers, William W. O'Neill, John Griffin, Bryan Donohue, C. Costantini, C. Balestrini, **Gregg Stone**, Denise Jones, Cindy Grines. Why do smokers have a better prognosis with acute myocardial infarction? Insights from the PAMI-2 trial. J Am Coll Cardiol 1996;27(Suppl A):193A.

53. **Gregg W. Stone,** Marie C. Morice, Bruce Brodie, John Griffin, Costantino Costantini, Fred St. Goar, Paul Overlie, Denise Jones, William W. O'Neill, Cindy L. Grines. Primary Stenting in Acute Myocardial Infarction: Interim Report from the PAMI Stent Pilot Trial. Eur Heart J 1996;17(Suppl):297

54. **Gregg W. Stone,** Tom Linnemeier, Fred St. Goar, Janice Coverdale, Helen Sheehan and John McB. Hodgson. Defining the Relationship Between Implantation Pressure and Stent Expansion: Core Lab Results from the Optimal Stent Implantation (OSTI) Trial. Eur Heart J 1996;17(Suppl):518

55. **Gregg W. Stone,** Bruce Brodie, John Griffin, Bryan Donohue, Costantino Costantini, Denise Jones, Marianne Graham, Cindy L. Grines. Should the Risk of Delaying Reperfusion Prohibit Inter-Hospital Transfer to Perform Primary PTCA in Acute Myocardial Infarction? Circulation 1996;94:I-331.

56. **Gregg W. Stone,** Bruce Brodie, John Griffin, Marie-Claude Morice, Fred St. Goar, Costantino Costantini, Paul Overlie, Denise Jones, William W O'Neill, Cindy L. Grines. A Prospective, Multicenter Trial of Primary Stenting in Acute Myocardial Infarction - The PAMI Stent Pilot Study. Circulation 1996;94:I-570.

57. **Gregg W. Stone,** Cindy L. Grines, Donald Rothbaum, Tom Catlin, William W. O'Neill. Primary Angioplasty Reduces Hospital Costs While Improving Outcomes in AMI - Comprehensive Cost Efficacy Analysis from the PAMI Study. Circulation 1996;94:I-330.

58. **Gregg W. Stone,** Eduardo de Marchena, David Dageforde, Alberto Foschi, Brent Muhlestein, Michael McIvor, David Rizik, Ronald Vanderlaan. A Prospective, Randomized, Multicenter Comparison of Laser Angioplasty Versus Balloon Angioplasty - The LAVA Trial. Circulation 1996;94:I-435.

59. **Gregg W. Stone,** Tom J. Linnemeier, Fred G. St. Goar, Helen Sheehan and John Hodgson. Correlation of Angiographic and Ultrasound Measures in Patients Undergoing Coronary Stenting Vs. Balloon Angioplasty. Circulation 1996;94:I-261.

60. **Gregg W. Stone,** Tom Linnemeier, Axel Frey, Harald Mudra, Fred St. Goar, Helen Sheehan and John McB. Incidence and Implications of Coronary Dissection after PTCA Using Oversized Balloons with Intravascular Ultrasound Guidance - The CLOUT Trial. Circulation 1996;94:I-261.

61. **Gregg W. Stone,** Bruce Brodie, John Griffin, Costantino Costantini, Carlos Balestrini, Denise Jones, Marianne Graham, Cindy L. Grines. Primary Angioplasty in Patients with Prior Bypass Surgery. Circulation 1996;94:I-243.

62. **Gregg W. Stone,** William W. O'Neill, Denise Jones, Cindy L. Grines. The Central Unifying Concept of TIMI-3 Flow after Primary PTCA and Thrombolytic Therapy in Acute Myocardial Infarction. Circulation 1996;94:I-515.

63. **Gregg W. Stone,** Tom J. Linnemeier, Fred G. St. Goar, John Hodgson, Janice Coverdale, Paul Yock and Peter Fitzgerald. Defining the Relationship Between

Stent Implantation Pressure and Optimal Expansion - Core Lab Analysis from the OSTI Trial. Circulation 1996;94:I-259.

64. Nobuyoki Komiyama, **Gregg W. Stone**, Edwin L. Alderman, Frederick St. Goar, Tom. J. Linnemeier, Paul G. Yock, Peter J. Fitzgerald. Relative stent expansion is dependent upon target segment calcification: An intravascular ultrasound assessment. Circulation 1996;94:I-262.

65. Linnemeier T, **Stone G**, Hodgson J, et al. OSTI: Optimal Stent Implantation Trial I. The Journal of Endovascular Surgery 1997;4:I-21.

66. **Stone GW**. The PAMI Trials. The Journal of Endovascular Surgery 1997;4:I-37.

67. **Gregg W. Stone**, Bruce Brodie, John Griffin, Fred St. Goar, Marie-Claude Morice, Costantino Costantini, Paul A. Overlie, Denise Jones, William W O'Neill, Cindy L. Grines. Safety and Feasibility of Primary Stenting in Acute Myocardial Infarction - In-hospital and 30 Day Results of the PAMI Stent Pilot Trial. J Am Coll Cardiol 1997;29:389A.

68. **Gregg W. Stone**, Fred St. Goar, Peter Fitzgerald, Ed Alderman, Paul Yock, John McB. Hodgson, Tom Linnemeier. The Optimal Stent Implantation Trial - Final Core Lab Angiographic and Ultrasound Analysis. J Am Coll Cardiol 1997;29:369A.

69. **Gregg W. Stone**, Fred St. Goar, Tom Linnemeier, John McB. Hodgson, Paul Yock, Ed Alderman, Peter Fitzgerald. Clinical, Angiographic and Ultrasound Predictors of Stent Expansion After High Pressure Implantation. J Am Coll Cardiol 1997;29:275A.

70. Grines, CL, Morice MC, Mattos L, **Stone GW**, O'Neill WW, Firth B, Fernandez EG, Kiemeney F, Jones D, Serruys P. A prospective, multicenter trial using the JJIS heparin-coated stent for reperfusion of acute myocardial infarction. J Am Coll Cardiol 1997;29:389A.

71. Frey AW, Muller C, Mudra H, Klauss V, Roskamm H, Linnemeier T, Hodgson JM, **Stone GW**. Verbesserung der Ergebnisse nach angiographisch erfolgreicher PTCA durch mit intrakoronarem Ultraschall (ICUS) bestimenten Dilatations-ballons: Die multizentrische CLOUT Pilot Studie. Presented at the 63rd Annual Scientific Sessions of the German Heart Association, Mannheim, Germany, April 4th, 1997.

72. Abizaid AS, **Stone GW,** Rothbaum DA, Brodie BR, Griffin JJ, Shimshak T, Costantini C, St. Goar FG, Overlie PA, McDonnell J, Jones D. Quantitative angiographic outcomes for stenting in acute myocardial infarction: core lab analysis from the PAMI Stent Pilot Trial. Circulation 1997;96:I-237.

73. Oshima A, Handen CE, Alderman E, Linnemeier TJ, **Stone GW,** Yock PY, Fitzgerald PJ. Inflow and outflow disease in stent reference segment: IVUS analysis of the second Optimal Stent Implantation (OSTI-2) trial. Am J Cardiol 1997;78:57S.

74. **Stone GW,** Brodie BR, Griffin JJ, Morice MC, Costantini C, St. Goar FG, Overlie PA, McDonnell J, Jones D, and Grines CL. Improved short-term outcomes of primary stenting compared to primary angioplasty in acute myocardial infarction - the PAMI stent pilot trial. Circulation 1997;96:I-594.

75. **Stone GW,** Brodie BR, Griffin JJ, Morice MC, Costantini C, St. Goar FG, Overlie PA, McDonnell J, Jones D, and Grines CL. Is stenting the treatment of choice for thrombus containing lesions? core lab analysis from the PAMI Stent Pilot Trial. Circulation 1997;96:I-397.

76. Tilli FV, O'Neill WW, Marsalese DL, Brodie BR, Griffin JJ, Donohue B, **Stone GW,** Jones DE, Graham M, Grines LL, Grines CL. Pre-hospital delay accounts for increased time to treatment in women undergoing direct angioplasty for acute myocardial infarction. Circulation 1997;96:I-398.

77. **Stone GW**, Kiesz RS, Oshima A, Alderman E, Bailey S, Sanborn T, Roberts DK, Yock P, St. Goar FG, and Linnemeier TJ. Improved Procedural Results of Coronary Stenting with Focal Balloon “Overexpansion” - The OSTI-2A Trial. Circulation 1997;96:I-402.

78. Grines C, Cox E, Fernandez EG, Katz S, Giambartolomei, **Stone GW,** Mattos L, Madonna O, Eijgelshoven M, Jones D, O'Neill WW, Morice MC. Stent PAMI: A multicenter randomized trial of heparin coated stenting for AMI vs. primary PTCA for AMI. Late Breaking Trials II, The 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 31, 1998.

79. **Stone GW,** Brodie B, Griffin J, et al. In-hospital and late outcomes following primary stenting in acute myocardial infarction - comparison with primary PTCA. J Am Coll Cardiol 1998;31:270A.

80. **Stone GW,** Brodie B, Griffin J, et al. Adverse outcomes prior to hospital discharge after primary stenting for acute myocardial infarction are often predictable, and related to correctable technical factors. J Am Coll Cardiol 1998;31:271A.

81. **Stone GW,** Linnemeier T, St. Goar F, et al. Incremental value of IVUS after coronary stenting when a "perfect" angiographic result is obtained. J Am Coll Cardiol 1998;31:103A.

82. Griffin J, Brodie B, Morice MC, Costantini C, Popma JJ, Overlie PA, St. Goar F, Kenerson JG, Merritt A., Theodosiou S, McDonnell JA, O'Neill WW, Grines CL,

Stone GW. Incidence and predictors of 6 month angiographic restenosis and reocclusion after primary infarct stenting - core lab analysis from the PAMI Stent Pilot Study. J Am Coll Cardiol 1998;31:210A.

83. **Stone GW,** Kiesz S, Bailey S, et al. Improved procedural results of coronary stenting with focal balloon "overexpansion" - final core lab analysis from the prospective, multicenter OSTI-2A trial. J Am Coll Cardiol 1998;31:16A.

84. **Stone GW,** O'Keefe J, Brodie B, O'Neill WW, Grines CL. Lack of relationship between the time to reperfusion and short-term mortality after primary infarct angioplasty. J Am Coll Cardiol 1998;31:271A.

85. Tilli F, Grines C, **Stone GW,** et al. Is operator interpretation or core lab analysis more accurate in predicting in-hospital adverse events after primary PTCA? J Am Coll Cardiol 1998;31:417A.

86. **Stone GW**, Morice MC, Costantini C, et al. Clinical and angiographic restenosis after primary stenting in acute myocardial infarction: Final results of the PAMI Stent Pilot Trial. Eur Heart J 1998;19:59.

87. Morice MC, Grines C, Cox D, Garcia Fernandez E, Katz S, Giambartolomei A, **Stone GW,** Mattos L, Griffin J, Brodie B, Kiemeneij F, Madonna O, Eijgelshoven M, Jones D, O'Neill WW. One month preliminary results of the PAMI trial. Eur Heart J 1998;19:239.

88. **Stone GW.** Beyond primary PTCA: stenting and abciximab in acute myocardial infarction. J Endovasc Surg 1998;5:I-32.

89. **Stone GW.** Improved short-term outcomes of primary stenting compared to primary angioplasty in acute myocardial infarction: the PAMI Stent Pilot Trial. ACCEL 30:2, February 1998.

90. **Stone GW,** Bailey S, Roberts DK, et al. Long-term results following "maximal stenting" using ultrasound guided balloon overexpansion - the Second Optimal Stent Implantation Study. Circulation: 1998;98:I-160.

91. **Stone GW,** Brodie BR, Griffin J, et al. Angiographic luminal "gain" occurs within the first 6 months after stenting thrombotic lesions in patients with acute myocardial infarction - a unique phenomenon. Circulation: 1998;98:I-295.

92. **Stone GW,** Shawl FA, Taussig A, Power JA, Kosinski E, St. Goar FG. Percutaneous myocardial laser revascularization in patients with class III-IV angina and lesions at high risk for restenosis - results of a phase I study as a preamble to a large, randomized trial. Circulation: 1998;98:I-557.

93. **Stone GW,** Garcia E, Griffin J, et al. Does stent implantation in acute myocardial infarction degrade TIMI flow and result in higher early mortality than PTCA? - The PAMI Stent Randomized Trial. Circulation: 1998;98:I-150.

94. **Stone GW,** Brodie BR, Griffin J, et al. Stenting of thrombotic lesions in acute myocardial infarction results in less late loss and greater freedom from restenosis than non-thrombotic lesions - core lab analysis from the PAMI Stent Pilot Trial. Circulation: 1998;98:I-152.

95. **Stone GW,** Garcia E, Giambartolomei A, et al. The powerful interaction between age and gender in determining short-term mortality after mechanical reperfusion therapy in acute myocardial infarction. Insights from the PAMI Stent Randomized Trial. Circulation: 1998;98:I-152.

96. **Stone GW,** Garcia E, Brodie BR, et al. By sealing dissection planes, primary stenting reduces ischemia driven target vessel revascularization at 30 days compared to primary PTCA - Analysis from the PAMI Stent Randomized Trial. Circulation: 1998;98:I-287.

97. Grines C, Cox D, Fernandez EG, **Stone G,** Mattos L, Katz S, Giambartolomei A, Brodie B, Donohue B, Griffin J, Madonna O, Eijgelshoven M, Graham M, O'Neill W, Morice MC. Stent PAMI: Final results of a multicenter randomized trial of heparin coated stenting vs. primary PTCA for AMI. Circulation: 1998;98:I-22.

98. Johnston JD, Wharton T, Turco M, Slota P, O'Neill WW, **Stone GW,** Brodie B, Grines LL, Graham M, Barsamian M, Grines CL. Primary PTCA is performed effectively and with less delay at community hospitals without surgical backup, compared to tertiary care centers. Circulation: 1998;98:I-770.

99. **Stone GW.** Is abciximab necessary with coronary stenting? ACCEL 30:4, April 1998.

100. Mattos L, Grines CL, Sousa JE, **Stone GW,** et al. Final procedural diameter stenosis and its influence on the 6 month outcome after primary PTCA: results from the Stent PAMI Trial. J Am Coll Cardiol 1999;33:92A.

101. Mattos L, Sousa JE, **Stone GW,** et al. Primary stenting versus PTCA in diabetic patients with acute myocardial infarction: six month results of the Stent PAMI Trial. J Am Coll Cardiol 1999;33:33A.

102. Grines CL, **Stone GW,** Cox DA, et al. Stent PAMI 6 month angiographic follow-up: incidence and predictors of reocclusion following primary PTCA and stenting. J Am Coll Cardiol 1999;33:397A.

103. Ahmed JM, Hong MK, Mehran R, Kent KM, Pichard AD, Satler LF, Greenberg A, Deforty D, Slack S, Wu H, **Stone GW,** Leon MB. Rescue ReoPro (Abciximab)

does not improve peri-procedural outcomes in patients undergoing high risk angioplasty of degenerated saphenous vein grafts. J Am Coll Cardiol 1999;33:11A.

104. Gruberg L, Mehran R, Hong MK, Dangas G, Kornowski R, Laird JR, Peterson M, Satler LF, Pichard AD, Kent KM, **Stone GW,** Leon MB. Percutaneous revascularization of the internal mammary artery graft: in-hospital and long-term outcome. J Am Coll Cardiol 1999;33:51A.

105. Gruberg L, Mehran R, Hong MK, Lansky AJ, Pichard AD, Peterson M, Walters CT, Murphy M, Laird JR, Satler LF, Kent KM, **Stone GW,** Leon MB. Stents do not improve acute and long-term clinical outcomes in patients with chronic renal failure and coronary disease. J Am Coll Cardiol 1999;33:28A.

106. Hong MK, Mintz GS, Satler LF, Pappas CK, Pichard AD, Kent KM, Peterson M, Murphy M, **Stone GW,** Leon MB. Full lesion stent coverage reduces subsequent target lesion revascularization: an intravascular ultrasound study. J Am Coll Cardiol 1999;33:61A.

107. Lansky AJ, Mehran R, Popma JJ, Hanzel G, Kent KM, **Stone GW,** et al. Insulin treatment of diabetic women predicts a worse outcome after intracoronary stenting. Clinical results of 564 consecutive patients. J Am Coll Cardiol 1999;33:97A.

108. Lansky AJ, **Stone GW,** Mehran R, et al. Impact of baseline TIMI flow on outcomes after primary stenting versus primary PTCA in acute myocardial infarction. Results from PAMI Stent. J Am Coll Cardiol 1999;33:368A.

109. Mehran R, Dangas G, Mintz GS, Hong MK, Lansky AJ, Peterson M, Abizaid AS, Ahmed JM, Kornowski R, Pichard AD, Satler LF, Kent KM, **Stone GW,** Leon MB. Excimer laser vs. rotational atherectomy for the treatment of diffuse in-stent restenosis: acute and long-term results. J Am Coll Cardiol 1999;33:62A.

110. Mehran R, Kornowski R, Dangas G, Lansky AJ, Hong MK, Pichard AD, Laird JR, Satler LF, Kent KM, **Stone GW,** Leon MB. Multivessel stenting reduces in-hospital complication compared with repeat aortocoronary bypass surgery. J Am Coll Cardiol 1999;33:51A.

111. Mehran R, Pfister A, Corso P, Dullum M, Dangas G, Lansky AJ, Hong MK, Greenberg A, Deible R, Pichard AD, Satler LF, Kent KM, **Stone GW,** Leon MB. Minimally invasive direct coronary artery bypass (MIDCAB): have we reached the plateau of the learning curve? J Am Coll Cardiol 1999;33:551A.

112. Mehran R, Mintz GS, Dangas G, Hong MK, Peterson M, Kornowski R, Lansky AJ, Kent KM, Pichard AD, Satler LF, **Stone GW,** Leon MB. One year follow-up after

intravascular ultrasound guided coronary stenting of 2075 lesions. J Am Coll Cardiol 1999;33:74A.

113. Mehran R, Lansky AJ, Hong MK, Dangas G, Kornowski R, Peterson M, Waksman R, Pichard AD, Satler LF, Kent KM, **Stone GW,** Leon MB. Percutaneous revascularization of patients with prior coronary bypass surgery: saphenous vein graft or native coronary stenting? J Am Coll Cardiol 1999;33:51A.

114. Mehran R, Lansky AJ, Dangas G, Hanzel G, Ahmed JM, Byrne M, Peterson M, **Stone GW,** Kent KM, Pichard AD, Satler LF, Leon MB. The impact of diabetes on the outcomes after treatment if in stent restenosis. J Am Coll Cardiol 1999;33:98A.

115. Mehran R, Dangas G, Mintz GS, Hong MK, Lansky AJ, Peterson M, Hanzel G, Laroche A, Slack S, Laird JR, Pichard AD, Kent KM, Satler LF, **Stone GW,** Leon MB. PTCA alone versus stent alone therapy for focal in-stent restenosis: acute and long-term results. J Am Coll Cardiol 1999;33:26A.

116. Mehran R, Dangas G, Mintz GS, Waksman R, Hong MK, Abizaid A, Abizaid AS, Kornowski R, Lansky AJ, Laird JR, Kent KM, Pichard AD, Satler LF, **Stone GW,** Leon MB. In-stent restenosis: “the great equalizer” – disappointing clinical outcomes with ALL interventional strategies. J Am Coll Cardiol 1999;33:63A.

117. Peterson M, Carter A, Mehran R, Kornowski R, Golden B, Negotia MA, Pichard AD, Satler LF, Kent KM, Mintz GS, Lansky AJ, **Stone GW,** Leon MB. Can debulking prior to stenting be justified as standard treatment for right coronary artery ostial lesions? J Am Coll Cardiol 1999;33:27A.

118. Brodie BR, **Stone GW,** Morice MC, et al. Importance of time to reperfusion on outcomes after primary PTCA for acute myocardial infarction: results from Stent PAMI. J Am Coll Cardiol 1999;33:353A.

119. Cox DA, **Stone GW,** Grines CL, et al. Do proximal LAD lesions in acute myocardial infarction benefit from stenting? The PAMI Stent Randomized Trial. J Am Coll Cardiol 1999;33:353A.

120. Cox DA, **Stone GW,** Grines CL, et al. Predictors of minimal lumen diameter after stenting in acute myocardial infarction: Insights from the PAMI Stent Trial. J Am Coll Cardiol 1999;33:368A.

121. Cox DA, **Stone GW,** Niess GS, et al. Does “stent-like” primary PTCA in acute myocardial infarction confer long-term freedom from restenosis similar to primary stenting? Analysis from the PAMI Stent Randomized Trial. J Am Coll Cardiol 1999;33:382A.

122. Flachskampf FA, Ziada KM, Pieper M, Crowe T, Nissen SE, Tuczu M, Brodie BR, Griffin J, Feit F, Costantini C, Mintz GS, Grines CL, **Stone GW.** Do interventionalists undersize devices during acute infarct intervention? Comparison of angiographic and intravascular measures from the PAMI Stent Randomized Trial. J Am Coll Cardiol 1999;33:54A.

123. **Stone GW,** Morice MC, Lansky AJ, et al. Routine stent implantation reduces restenosis after primary angioplasty in acute myocardial infarction – results from the PAMI Stent Randomized Trial. J Am Coll Cardiol 1999;33:361A.

124. **Stone GW,** Morice MC, Cox D, et al. Predictors of six month event-free survival after mechanical reperfusion in acute myocardial infarction - the PAMI Stent Randomized Trial. J Am Coll Cardiol 1999;33:379A.

125. **Stone GW,** Marcovitz P, Lansky AJ, et al. Differential effects of stenting and angioplasty in women versus men undergoing a primary mechanical reperfusion strategy in acute myocardial infarction - the PAMI Stent Randomized Trial. J Am Coll Cardiol 1999;33:357A.

126. **Stone GW,** Mehran R, Lansky AJ, et al. Long-term influence of CPK-MB elevation on mortality after percutaneous intervention – analysis of 7359 patients. J Am Coll Cardiol 1999;33:80A.

127. **Stone GW,** Mehran R, Lansky AJ, et al. What is the clinical significance of an elevated CPK-MB band fraction after percutaneous intervention if the total CPK is normal? J Am Coll Cardiol 1999;33:80A.

128. **Stone GW,** Morice MC, Cox D, et al. Outcomes of bail-out stenting after failed primary angioplasty in acute myocardial infarction – analysis from the PAMI Stent Randomized Trial. J Am Coll Cardiol 1999;33:361A.

129. **Stone GW,** Frey A, Linnemeier T, et al. 2.5 year follow-up of the CLOUT study – long-term implications for an aggressive IVUS guided balloon angioplasty strategy. J Am Coll Cardiol 1999;33:81A.

130. O'Neill WW, **Stone GW,** Morice MC, et al. Ventricular function after mechanical reperfusion therapy: observations from the Stent-PAMI Trial. J Am Coll Cardiol 1999;33:398A.

131. Bailey SR, Kiesz RS, Linnemeier TJ, Cooper-Reade GM, St. Goar FG, **Stone GW.** Stent implantation in small vessels using ultrasound guided implantation: comparison of late outcome of LAD and non-LAD lesions. J Am Coll Cardiol 1999;33:68A.

132. Hasnie AMA, Grines CL, Boura JA, Grines LL, O'Neill WW, Garcia E, Brodie B, **Stone GW.** Mechanisms of failed primary PTCA for acute MI. Submitted to the

22nd annual scientific sessions of the Society for Cardiac Angiography and Interventions, May 1999.

133. DeGeare VS, O'Neill WW, Grines L, **Stone GW,** Brodie BR, Cox DA, Garcia E, Wharton T, Boura JA, Grines CL. Angiographic and clinical predictors of increased in-hospital mortality in elderly patients with acute myocardial infarction. Submitted to the 22nd annual scientific sessions of the Society for Cardiac Angiography and Interventions, May 1999.

134. Morice MC, Grines CL, Eijgelshoven M, van Es GA, **Stone GW,** Mattos L, Garcia E, Madonna O, Cox D, Kiemeney F, Van der Giessen W. Twelve-month follow-up of the Stent PAMI trial. Submitted to the 1999 Annual Scientific Sessions of the European Society of Cardiology.

135. Morice MC, Rutsch W, Mattos L, **Stone GW,** Eijgelshoven M, Cox D, Garcia E, Kiemeney F, Pieper M, Grines CL. Characteristics and in-hospital outcome of patients included in the registry of the Stent PAMI trial. Submitted to the 1999 Annual Scientific Sessions of the European Society of Cardiology.

136. Robert J. Freedman Jr, Michael F. Miller, E. Magnus Ohman, Debra L. Joseph, Robert R. Cuffey Jr., Marc Cohen, Geoffrey M. Graeber, James J. Ferguson, **Gregg W. Stone.** Proactive vs. Reactive Use of IABP Support in High Risk Cases. Am J Cardiol 1999; 84(supp1 6A): 125P.

137. C. Costantini, S. Tarbine, E. Sousa, A. Sampaolesi, S. Silva, C. Gosttchall, A. Rodriguez, R. De Barros, M. Martinez Rios, G. Bonzon, E. Ribeiro, **G. Stone,** on behalf of SOLACI Investigators. Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) Pilot Study--Preliminary Results. Am J Cardiol 1999; 84(supp1 6A): 101P.

138. Luis Gruberg, George D. Dangas, Roxana Mehran, Lucy B. Van Voorhees, Chester Clark, **Gregg W. Stone,** Mun K. Hong, Gary S. Mintz, Ran Kornowski, Alexandra J. Lansky, Kenneth M. Kent, Ron Waksman, Augusto D. Pichard, Lowell F. Satler, Martin B. Leon. Outcome of Critically Ill Patients With Acute Renal Failure Requiring Hemodialysis After Percutaneous Coronary Interventions Am J Cardiol 1999; 84(supp1 6A): 71P.

139. Luis Gruberg, George Dangas, Roxana Mehran, **Gregg W. Stone,** Mun K. Hong, Gary S. Mintz, Ron Waksman, Ran Kornowski, Alexandra J. Lansky, Javed Ahmed, Kenneth M. Kent, Augusto D. Pichard, Lowell F. Satler, Martin B. Leon. Stenting of the Internal Mammary Artery Graft: Angiographic Characteristics, In-hospital and Long-term Outcomes. Am J Cardiol 1999; 84(supp1 6A): 48P.

140. Shmuel Fuchs, Ran Kornowski, Roxana Mehran, Lowell F. Satler, Augusto D. Pichard, Kenneth M. Kent, Mun K. Hong, Steve T. Slack, **Gregg W. Stone,** Martin B. Leon Cardiac Troponin I Levels and Clinical Outcomes in Patients With

Acute Coronary Syndromes: The Potential Role of Early Percutaneous Coronary Interventions. Am J Cardiol 1999; 84(supp1 6A): 100P.

141. AMA Hasnie, CL Grines, JA Boura, LL Grines, WW O'Neill, E. Garcia, B. Brodie, **G. Stone.** Mechanisms of Failed Primary PTCA for Acute MI. Am J Cardiol 1999; 84(supp1 6A): 33P.

142. Shmuel Fuchs, Ran Kornowski, Roxana Mehran, Alexandra J. Lansky, Lowell F. Satler, Augusto D. Pichard, **Gregg W. Stone,** Martin B. Leon. Prognostic Value of Cardiac Troponin I Levels Following Percutaneous Coronary Interventions. Am J Cardiol 1999; 84(supp1 6A): 33P.

143. J. Gary Gustafson, Cindy L. Grines, David A. Cox, Elogio Garcia, **Gregg W. Stone,** Mariann Graham, Judith A. Boura, Lorelei L. Grines, William W. O'Neill, Marie Claude-Morice. Spontaneous Patency in the Early Hours of AMI: Incidence, Predictors and Prognostic Implications. Am J Cardiol 1999; 84(supp1 6A): 103P.

144. Luis Gruberg, George Dangas, Roxana Mehran, **Gregg W. Stone,** Mun K. Hong, Gary S. Mintz, Ron Waksman, Ran Kornowski, Alexandra J. Lansky, Kenneth M. Kent, Augusto D. Pichard, Lowell F. Satler, Martin B. Leon. Should Balloon Angioplasty be the Standard of Care for Internal Mammary Artery Percutaneous Revascularization? Am J Cardiol 1999; 84(supp1 6A): 47P.

145. Shmuel Fuchs, Ran Kornowski, Javed M. Ahmed, Alexandra Lansky, Roxana Mehran, Lowell F. Satler, Augusto D. Pichard, Kenneth M. Kent, Chester E. Clark, **Gregg W. Stone,** Martin B. Leon Percutaneous Coronary Interventions in Atherosclerotic Coronary Artery Aneurysms: Short and Long-term Clinical Outcomes. Am J Cardiol 1999; 84(supp1 6A): 80P.

146. Waksman R, White LR, Chan RC, Mehran R, Bhargava B, Lansky AJ, Pichard AD, **Stone GW,** Leon MB. Intracoronary beta radiation therapy for patients with in-stent restenosis: Beat WRIST 6 month clinical and angiographic results. Circulation 1999;100(18):I-75.

147. Waksman R, Mehran R, Bhargava B, Chan RC, Lansky AJ, Gierlach LM, **Stone GW,** Leon MB. Recurrent restenosis after “failed” intra-coronary radiation therapy: angiographic patterns and predictors. Circulation 1999;100(18):I-222.

148. Dangas G, Mehran R, Peterson M, Duncan C, Paliou MN, Purush A, Hong MK, **Stone GW.** Combination antiplatelet therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after native coronary stent implantation. Circulation 1999;100(18):I-379.

149. Waksman R, Bhargava B, Chan RC, Mehran R, Gierlach LM, Gruberg L, **Stone GW,** Leon MB. Late total occlusions following intracoronary radiation therapy for patients with in-stent restenosis. Circulation 1999;100(18):I-222.

150. **Stone GW,** Castner CM, Cuffey RR, et al. Contemporary patterns of utilization and outcomes of intraaortic balloon counterpulsation in acute myocardial infarction: the Benchmark Registry. Circulation 1999;100(18):I-809.

151. **Stone GW,** Dangas G, Peterson M, et al. Prognostic value of peri-procedural CK-MB elevation after percutaneous intervention in patients with and without Q-wave infarction. Circulation 1999;100(18):I-85.

152. Cohen DR, **Stone GW,** Cox D, et al. Cost-effectiveness analysis of primary stenting in the PAMI Stent randomized trial. Circulation 1999;100(18):I-87.

153. Waksman R, Mehran R, Chan RC, Murphy M, **Stone GW,** Duncan C, et al. One year follow-up after intracoronary gamma radiation therapy for in-stent restenosis: results from a randomized clinical trial. Circulation 1999;100(18):I-154.

154. **Stone GW.** The CADILLAC Trial. Late Breaking Trials. The 72nd Annual Scientific Sessions of the American Heart Association, November 8th, 1999.

155. Mattos LA, Grines CL, Sousa JE, Morice MC, Garcia E, **Stone GW,** Boura JA, Cox DA, O'Neill WW, Eigelshoven M, Brodie BR, Graham M. The safety of routine ticlopidine administration after primary coronary interventions in acute myocardial infarction: a serial hematologic analysis from the STENT PAMI trial. Circulation 1999;100(18):I-86.

156. Mattos LA, Grines CL, Sousa JE, **Stone GW,** Morice MC, Garcia E, Cox DA, O'Neill WW, Firth B, Boura JA, Graham M, Eigelshoven M. Influence of maximal inflation pressure in acute myocardial infarction: 30 day and 6 month outcomes from the STENT PAMI trial. Circulation 1999;100(18):I-856.

157. Fuchs S, Kornowski R, Satler LF, Pichard AD, Kent KM, **Stone GW,** Leon MB. Cardiac troponin I levels and clinical outcomes in patients with acute coronary syndromes: The role of early percutaneous revascularization. Int J Cardiovasc Intervent 1999;2(2):48.

158. Fuchs S, Kornowski R, Mehran R, Lansky AJ, Satler LF, Pichard AD, **Stone GW,** Leon MB. Prognostic value of cardiac troponin I levels following catheter based coronary interventions. Int J Cardiovasc Intervent 1999;2(2):7.

159. Ahmed JA, Mehran R, Dangas G, Hong MK, Negoita M, Lansky AJ, Faraj H, Hashmi N, Okubagzi P, Modi N, Astatkie M, Kent KM, Weissman NJ, Curry B, Kupper F, Satler LF, Pichard AD, **Stone GW,** Leon MB. Predictors of late clinical outcomes in patients with unstable angina undergoing percutaneous coronary intervention. J Am Coll Cardiol 2000;35(2):18A.

160. Lansky AJ, **Stone GW,** Grube E**,** et al. A multicenter registry of the JoSTENT PTFE Stent Graft for the treatment of arterial perforations complicating percutaneous coronary interventions. J Am Coll Cardiol 2000;35(2):26A.

161. **Stone GW,** Cox D, Lowe RI, Matthews R, Leon MB. First United States experience with a novel atherectomy and thrombectomy device in thrombotic lesions in native coronary arteries and saphenous vein grafts. J Am Coll Cardiol 2000;35(2):40A.

162. **Stone GW,** Bailey S, Roberts DK, Linnemeier TJ, St. Goar FG, Sanborn T, Fitzgerald PJ, Alderman EL, Kiesz S. A Prospective, Multicenter Trial of the Safety, Feasibility, and Efficacy of Ultrasound Guided "Maximal" Stenting to the Media-Adventitial Border - Final Late Clinical and Angiographic Results from the OSTI-2 Study. J Am Coll Cardiol 2000;35(2):46A.

163. Gruberg L, Mehran R, Dangas G, **Stone GW,** Hong MK, Mintz GS, Waksman R, Kornowski R, Lansky AJ, Kent KM, Satler LF, Pichard AD, Leon MB. Acute renal failure requiring hemodialysis after percutaneous coronary intervention: In-hospital and one-year outcomes. J Am Coll Cardiol 2000;35(2):53A.

164. Gruberg L, Mehran R, Dangas G, Hong MK, Mintz GS, Waksman R, Kornowski R, Lansky AJ, Kent KM, Satler LF, Pichard AD, **Stone GW,** Leon MB. Revascularization of the internal mammary artery graft: in-hospital and one year outcomes. J Am Coll Cardiol 2000;35(2):54A.

165. Grines LL, Cox DA, Garcia E, Johnston JJ, Turco MA, Wharton TP, Griffin JJ, McGarvey J, Shaddinger D, Graham M, Boura JA, O'Neill WW, **Stone GW,** Grines CL. Divergent effects of "directional" versus "mandated" stenting on acute myocardial infarction survival in women. J Am Coll Cardiol 2000;35(2):56A.

166. Mattos L, Grines CL, Sousa E, **Stone GW,** et al. One year follow-up after primary coronary intervention for acute myocardial infarction in diabetic patients: Stent PAMI Trial results. J Am Coll Cardiol 2000;35(2):72A.

167. Mehran R, Dangas G, Gruberg L, Lansky AJ, Okubagzi P, Astatkie M, Purush A, Desai K, Kupper F, Faraj H, Kent KM, **Stone GW,** Leon MB. The detrimental effect of chronic renal insufficiency and diabetes mellitus on late prognosis after percutaneous coronary interventions. J Am Coll Cardiol 2000;35(2):73A.

168. Fuchs S, Kornowski R, Mehran R, Satler LF, Hong MK, Slack S, **Stone GW,** Leon MB. The deleterious prognostic impact of cardiac troponin I re-elevation following percutaneous coronary interventions in patients with acute coronary syndromes. J Am Coll Cardiol 2000;35(2):75A.

169. Kornowski R, Fuchs S, Mehran R, Satler LF, Pichard AD, Kent KM, Slack S, Hong MK, **Stone GW,** Leon MB. Prognostic value of recurrent episodes of CK-

MB elevation following repeated catheter-based coronary interventions. J Am Coll Cardiol 2000;35(2):75A.

170. Mehran R, Pfister A, Dangas G, Dullum MKC, Peterson MA, Hashmi N, Stamou SC, Deible R, Purush A, **Stone GW,** Leon MB, Corso PJ. Acute and long-term outcomes of minimally invasive direct coronary artery bypass (MIDCAB) surgery. A comparison to single vessel stenting of the left anterior descending artery. J Am Coll Cardiol 2000;35(2):354A.

171. Cox DA, **Stone GW,** Brodie BR, et al. Stent PAMI: Are excellent outcomes achieved only be experienced sites? J Am Coll Cardiol 2000;35(2):363A.

172. **Stone GW,** Cox DA, Garcia E, et al. Relative prognostic importance of preserved antegrade coronary blood flow before compared to after angioplasty in patients undergoing primary PTCA. J Am Coll Cardiol 2000;35(2):363A.

173. Grines CL, Cox DA, **Stone GW,** et al. Stent PAMI: 12 month results and predictors of mortality. J Am Coll Cardiol 2000;35(2):402A.

174. **Stone GW,** Lansky AJ, Mehran R, et al. Beyond TIMI-3 flow: The importance of restored myocardial perfusion for survival in high risk patients undergoing primary or rescue PTCA. J Am Coll Cardiol 2000;35(2):403A.

175. Cox DA, **Stone GW,** Brodie BR, et al. Do proximal RCA lesions in acute MI benefit from stenting?: The Stent PAMI randomized trial. J Am Coll Cardiol 2000;35(2):403A.

176. Mehran R, Dangas G, Gruberg L, Lansky AJ, Okubagzi P, Astatkie M, Purush A, Desai K, Kupper F, Faraj H, Kent K, **Stone GW**, et al. Chronic renal insufficiency and diabetes mellitus have an additive adverse effect on late clinical outcome after percutaneous coronary revascularization. J Inv Cardiol 2000;12(5):253.

177. J Ahmed, GD Dangas, R Mehran, MK Hong, GS Mintz, AD Pichard, LF Satler, KM Kent, **GW Stone,** M.B. Leon. Clinical, procedural, angiographic and intravascular ultrasound predictors of late cardiac events in patients with unstable angina undegoing percutaneous interventions. Eur Heart J 2000;21:168.

178. J Ahmed, GD Dangas, R Mehran, MK Hong, GS Mintz, AD Pichard, LF Satler, KM Kent, **GW Stone,** M.B. Leon. Predictive factors of target lesion revascularisation and late cardiac events after stent implantation in saphenous vein grafts. Eur Heart J 2000;21:637.

179. Mehran R, Dangas G, Gruberg L, A. Lansky AJ, Okubagzi P, Astakie M, Purush A, Desai K, Kupper F, Faraj H, Kent KM, **Stone GW,** Leon MB. Chronic renal insufficiency and diabetes mellitus have an additive adverse effect of late clinical

outcomes after percutaneous coronary revascularization. J Inv Cardiol 2000;12:253.

180. Gruberg L, Dangas G, Mehran R, Waksman R, Mintz GS, Satler L, Laird J, Astakie M, Santiago M, Brahimi AK, **Stone GW,** Leon MB. The impact of further renal impact function deterioration after percutaneous coronary intervention in patients with chronic renal insufficiency. J Inv Cardiol 2000;12:253.

181. Gruberg L, Dangas G, Mehran R, Lansky AJ, Satler L, Astakie M, Santiago M, Bui A, Brahimi AK, **Stone GW,** Leon MB. Short and long term outcomes after stenting of coronary arteries in patients with chronic renal failure. J Inv Cardiol 2000;12:253.

182. Gruberg L, Dangas G, Mehran R, Lansky AJ, Astakie M, Santiago M, Bui A, Brahimi AK, Satler L, **Stone GW,** Leon MB. Short and long term clinical outcomes after percutaneous revascularization of the internal mammary artery graft. J Inv Cardiol 2000;12:256.

183. Mehran R, Dangas G, Pfister A, **Stone GW,** Leon MB, Corso PJ. Minimally invasive direct coronary artery bypass (MIDCAB) surgery versus single-vessel stenting of the left anterior descending artery. J Inv Cardiol 2000;12:265.

184. Dangas G, Mehran R, Lansky AJ, Faraj H, Negoita M, Astakie M, Santiago M, Pichard AD, **Stone GW,** Leon MB. Arteriotomy closure devices versus manual compression after percutaneous coronary intervention: Is there a difference in vascular complications? J Inv Cardiol 2000;12:267.

185. Mattos LA, Grines CL, Cox D, Sousa JE, Costantini C, Stone G, Morice MC, O'Neill W, Garcia E, Boura J. A comparative analysis of primary stenting and optimal balloon coronary angioplasty in acute myocardial infarction. Six month results from the STENT PAMI trial. Arq Bras Cardiol 2000;75:499-514.

186. Dangas G, Laird JR, Mehran R, Pappas CK, Astakie M, Bui A, Santiago M, Lansky AJ, **Stone GW,** Leon MB. Impact of baseline real insufficiency in the one-year clinical outcome following renal artery stenting in patients with uncontrolled hypertension. J Inv Cardiol 2000;12:268.

187. Ahmed JM, Dangas G, Lansky AJ, Mehran R, Hong MK, Pichard AD, Satler LF, Kent KM, **Stone GW,** Leon MB. Impact of gender on immediate and late clinical outcomes after stent implantation in saphenous vein grafts. J Inv Cardiol 2000;12:270.

188. Ahmed JM, Dangas G, Mehran R, Hong MK, Astakie M, Mintz GS, Pichard AD, Satler LF, Kent KM, **Stone GW,** Leon MB. “Rescue” abciximab therapy does not improve periprocedural complications in patients undergoing percutaneous intervention of degenerated saphenous vein grafts. J Inv Cardiol 2000;12:270.

189. Ahmed JM, Hong MK, Mehran R, Dangas G, Pappas C, Kent KM, Pichard AD, Satler LF, Mintz GS, Greenberg A, Slack S, **Stone GW,** Leon MB. Effect of diabetes after stent implantation in saphenous vein grafts: immediate and late clinical outcomes. J Inv Cardiol 2000;12:270.

190. Ahmed JM, Dangas G, Mehran R, Hong MK, Mintz GS, Pappas C, Pichard AD, Satler LF, Kent KM, **Stone GW,** Leon MB. Clinical, angiographic and intravascular ultrasound predictors of target lesion revascularization and late cardiac events following stent implantation in saphenous vein grafts. J Inv Cardiol 2000;12:271.

191. Serruys P, Grines C, **Stone G,** Garcia E, Kiemeney F, Morice M, Sousa J, Hamm C, Costantini C, Probst P, Rutsch W, Penn I, Fernandez-Aviles F, Vandormael M, Bartorelli A, Bilodeau L, Eijgelshoven M. Stent implantation in acute myocardial infarction using a heparin-coated stent: a pilot study as a preamble to a randomized trial comparing balloon angioplasty and stenting. Int J Cardiovasc Intervent 1998;1:19-27.

192. Ahmed JM, Hong MK, Mehran R, Larrain G, Kent K, Pichard AD, Satler LF, Mintz GS, **Stone GW,** Leon MB. Debulking plus stenting versus stenting alone for aorto-ostial saphenous vein graft lesions: procedural results and late clinical outcomes. J Inv Cardiol 2000;12:271.

193. Ahmed JM, Dangas G, Mehran R, Hong MK, Mintz GS, Pichard AD, Satler LF, Kent KM, **Stone GW,** Leon MB. Predictors of target lesion revascualrization and late cardiac events in patients with unstable angina undergoing percutaneous coronary intervention. J Inv Cardiol 2000;12:271.

194. M. Adamian, Y. Kobayashi, G. Dangas, A. Lansky, G. New, I. Moussa, **G. Stone,** M. Leon, J. Moses. Elective Versus "Rescue" Abciximab Administration in Percutaneous Coronary Interventions. Am J Cardiol 2000; 86(supp1 8A): 78i.

195. M. Adamian, A. Lansky, R. Mehran, A.S. Abizaid, A. Abizaid, G. Dangas, **G. Stone,** J. Moses, M. Leon. "Rescue" Administration of Platelet GP IIb/IIIa Inhibitors During Percutaneous Coronary Interventions: Are There Any Gender Differences in Outcome? Am J Cardiol 2000; 86(supp1 8A): 90i.

196. M. Adamian, G. Dangas, R. Mehran, A. Abizaid, A.S. Abizaid, L. Gruberg, A. Lansky, **G. Stone,** J. Moses, M. Leon. One-Year Clinical Outcome in Diabetic Patients with Single-Vessel Versus Multivessel Native Coronary Stenting. Am J Cardiol 2000; 86(supp1 8A): 90i.

197. M. Adamian, R. Mehran, Y. Kobayashi, G. Dangas, M. Collins, **G. Stone,** M. Leon, A. Colombo, J. Moses. Recurrence After Treatment of In-Stent Restenosis

In Large Vessels: Impact of Diabetes Mellitus. Am J Cardiol 2000; 86(supp1 8A): 125i.

198. M. Adamian, A. Abizaid, A.S. Abizaid, R. Mehran, G. Dangas, A. Lansky, **G. Stone,** J. Moses, M. Leon. Acute and Long-Term Outcome of Stenting Multiple Saphenous Vein Graft Lesions in Diabetics Versus Non-Diabetics. Am J Cardiol 2000; 86(supp1 8A): 90i.

199. Y. Kobayashi, I. Moussa, R. Mehran, A. Abizaid, M. Adamian, G. Mintz, G. Dangas, **G. Stone,** M. Leon, J. Moses. Are All "Small" Vessels Really Small? Implications for Stent Implantation. Am J Cardiol 2000; 86(supp1 8A): 23.

200. J. Ahmed, A. Pichard, M. Hong, A. Abizaid, A. S. Abizaid, G. Dangas, **G. Stone,** A. Lansky, R. Mehran, M. Leon. Direct Stenting in Saphenous Vein Grafts: Immediate and Late Clinical Outcome. Am J Cardiol 2000; 86(supp1 8A): 3i.

201. G. Dangas, D. J. D'Agate, R. Mehran, D. Feldman, A. J. Lansky, K. M. Kent, A. D. Pichard, L. F. Satler, H. Wu, **G.W. Stone,** M. B. Leon. Racial Differences in Clinical Outcome After Percutaneous Coronary Interventional Procedures. Am J Cardiol 2000; 86(supp1 8A): 49i.

202. Y. Kobayashi, R. Mehran, G. Dangas, I. Moussa, A. Abizaid, M. Adamian, **G. Stone,** M. Leon, J. Moses. Stent Implantation Compared to Balloon Angioplasty in Small Vessels. Am J Cardiol 2000; 86(supp1 8A): 91.

203. **Stone GW,** Rubinstein P, Schmidt D, et al. A Prospective, Randomized, Multicenter Trial of Percutaneous Transmyocardial Laser Revascularization in Patients with Non-Recanalizable Chronic Total Occlusions. Circulation 2000;18(suppl2):II-689.

204. Kobayashi Y, Dangas GD, Adamian MG, Faraj H, Glasser LA, **Stone GW.** Effect of Plaque Morphology Behind the Stent on Lumen Enlargement after Angioplasty for Treatment of In-Stent Restenosis: An Intravascular Ultrasound Study. Circulation 2000;18(suppl2):II-691.

205. **Stone GW,** Grines CL, Cox DA, et al. A Prospective, Randomized Trial Comparing Primary Balloon Angioplasty with or without Abciximab to Primary Stenting with or without Abciximab in Acute Myocardial Infarction - Primary Endpoint Analysis from the Cadillac Trial. Circulation 2000;18(suppl2):II-664.

206. Cohen M, Ferguson JJ, Freedman RJ, Miller MF, **Stone GW.** Comparison of Outcomes after 8 vs. 9.5 French Size Intra-Aortic Balloon Counterpulsation Catheters Based on 7212 Patients in the Prospective Benchmark Registry**.** Circulation 2000;18(suppl2):II-854.

207. Dangas G, Feldman D, D'Agate DJ, Santiago M, Faraj H, Ahmed JM, Wu H, Slack ST, **Stone GW.** Impact of Race on Clinical Outcome after Percutaneous Coronary Interventions: Results in 6945 Patients. Circulation 2000;18(suppl2):II-479.

208. A Abizaid, G Dangas, AS Abizaid, R Mehran, M Negoita, C Ciora, R Narasimaiah, AD Pichard, AJ Lansky, **GW Stone,** GS Mintz, MB Leon. Intravascular Ultrasound Versus Angiography-Guided Stent Implantation: Acute and Long-Term Outcome in 2,883 Patients. J Am Coll Cardiol 2001;37:648A.

209. Y Kobayashi, G Dangas, R Mehran, I Moussa, G New, O Balan, GS Roubin, S Iyer, N Al-Mubarak, N Cohen, **GW Stone,** MB Leon. Stenting Elderly Patients in the New Millennium: Results in the Year 2000. J Am Coll Cardiol 2001;37:648A.

210. G Dangas, R Mehran, AJ Lansky, D Feldman, DJ D'Agate, LF Satler, KM Kent, AD Pichard, L Gruberg, JM Ahmed, **GW Stone,** MB Leon. Gender and Racial Differences in Clinical Outcomes After Percutaneous Coronary Interventions. J Am Coll Cardiol 2001;37:648A.

211. AS Abizaid, R Mehran, G Dangas, S Fuchs, A Abizaid, AJ Lansky, R Kornowski, R Waksman, AD Pichard, LF Satler, **GW Stone,** MB Leon. Positive Troponin-I Predicts Early and Late Mortality After Percutaneous Coronary Intervention. J Am Coll Cardiol 2001;37:648A.

212. A Abizaid, G Dangas, AS Abizaid, R Mehran, M Negoita, C Ciora, R Narasimaiah, AD Pichard, AJ Lansky, **GW Stone,** GS Mintz, MB Leon. Intravascular Ultrasound Versus Angiography-Guided Stent Implantation: Acute and Long-Term Outcome in 2,883 Patients. J Am Coll Cardiol 2001;37:648A.

213. AS Abizaid, R Mehran, G Dangas, S Fuchs, A Abizaid, AJ Lansky, R Kornowski, R Waksman, AD Pichard, LF Satler, **GW Stone,** MB Leon. Positive Troponin-I Predicts Early and Late Mortality After Percutaneous Coronary Intervention. J Am Coll Cardiol 2001;37:648A.

214. A Abizaid, AD Pichard, R Mehran, GS Mintz, L Gruberg, J Ahmed, **GW Stone,** AS Abizaid, LF Satler, KM Kent, G Dangas, MB Leon. Intravascular Ultrasound-Guided Provisional Stenting in Small Coronary Stenosis. J Am Coll Cardiol 2001;37:648A.

215. AJ Lansky, R Mehran, K Desai, C Constantini-Ortiz, B Proctor, T Conway, M Fahy G Dangas, **GW Stone,** R Waksman, JW Moses, MB Leon. Impact of Gamma and Beta Radiation vs. Placebo on the Changing Pattern of In-Stent Restenosis: A Matched Angiographic Analysis. J Am Coll Cardiol 2001;37:648A.

216. Y Kobayashi, R Mehran, G Dangas, I Moussa, AS Abizaid, A Abizaid, M Adamian, G New, AJ Lansky, GS Roubin, S Iyer, **GW Stone,** JW Moses, MB

Leon. Effect of Coronary Plaque Calcification on the Final Lumen Dimensions After Stenting Without Rotational Atherectomy: An Intravascular Ultrasound Study J Am Coll Cardiol 2001;37:648A.

217. Y Kobayashi, I Moussa, R Mehran, G Dangas, AJ Lansky, G New, M Adamian, AS Abizaid, A Abizaid, S Iyer, G Roubin, **GW Stone,** MB Leon, JW Moses. Stenting Without Rotational Atherectomy in Lesions With at Least Moderate Calcification by IVUS but Insignificant Calcification Angiographically J Am Coll Cardiol 2001;37:648A.

218. A Abizaid, G Dangas, R Mehran, Y Kobayashi, AS Abizaid GS Mintz, MG Adamian, R Narasimaiah, C Ciora, AD Pichard, **GW Stone,** MB Leon. One-Year Results After Multivessel Stenting in Diabetic vs. Non-Diabetic Patients J Am Coll Cardiol 2001;37:648A.

219. A Abizaid, GS Mintz, AS Abizaid, R Mehran, G Dangas, AD Pichard, LF Satler, I Hijazi, R Narasimaiah, KM Kent, AJ Lansky, **GW Stone,** MB Leon. Intravascular Ultrasound Predictors of Late Recurrence After Stent Implantation in Small Coronary Arteries. J Am Coll Cardiol 2001;37:648A.

220. JE Tcheng, ME Effron, CL Grines, E Garcia, D Cox, T Stuckey, J Carroll, G Guagliumi, B Rutherford, P Essente, AJ Lansky, J Griffin, **GW Stone.** Abciximab Use During Percutaneous Intervention in Patients With Acute Myocardial Infarction Improves Early and Late Clinical Outcomes: Final Results of the CADILLAC Trial. J Am Coll Cardiol 2001;37:648A.

221. T Stuckey, CL Grines, D Cox, JE Tcheng, E Garcia,J Carroll, G Guagliumi, B Rutherford, P Essente, AJ Lansky, J Griffin, **GW Stone.** Does Stenting and Glycoprotein IIb/IIIa Receptor Blockade Improve the Prognosis of Diabetics Undergoing Primary Angioplasty in Acute Myocardial Infarction? The CADILLAC Trial. J Am Coll Cardiol 2001;37:648A.

222. CL Grines, E Garcia, JE Tcheng, T Stuckey, J Carroll, G Guagliumi, B Rutherford, P Essente, AJ Lansky, J Griffin, **GW Stone.** Effect of Stent Implantation and Glycoprotein IIb/IIIa Receptor Blockade on TIMI Flow and Mortality After Primary PTCA in Acute Myocardial Infarction: Final Results of the CADILLAC Trial. J Am Coll Cardiol 2001;37:648A.

223. **Stone GW,** Grines CL, Cox D, et al. A Prospective, Multicenter, International Randomized Trial Comparing Four Reperfusion Strategies in Acute Myocardial Infarction: Principal Report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol 2001;37:648A.

224. MG Adamian, R Mehran, Y Kobayashi, G Dangas, I Moussa, M Collins, AJ Lansky, G New, **GW Stone**, MB Leon, A Colombo, JW Moses. Recurrence After

Treatment of In-Stent Restenosis: Does Diabetes Impact Outcomes in Large Vessels? J Am Coll Cardiol 2001;37:648A.

225. C Costantini, S Tarbine, E Sousa, A Sampaolesi, S Silva, C Gosttchall, A Rodriguez, M Martinez Rios, G Bonzon, E Ribeiro, F Tortoledo, **GW Stone.** Impact of Operators Skill on Direct PTCA Outcomes in Acute Myocardial Infarction. A View of the SOLACI Registry. J Am Coll Cardiol 2001;37:648A.

226. Finta , Frumin H, Boura J, **Stone GW,** Brodie BR, Cox DA, Garcia E, Grines LL, Skelding KA, Grines CL. Are Risk Factors for Sudden Death in Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention Different? Analysis of the PAMI Database. J Am Coll Cardiol 2001;37:648A.

227. Ahmed JA, Dangas GD, Mehran R, Pichard AD, Satler LF, Kent KM, Hong MK, **Stone GW,** Martin B. Leon MB. Clinical, Angiographic, and Intravascular Ultrasound Predictors of Target Lesion Revascularization and Late Cardiac Events After Stent Implantation in Saphenous Vein Grafts. J Am Coll Cardiol 2001;37:648A.

228. Dixon SR, Grines CL, Cox DA, **Stone GW,** Garcia E, Mattos LA, Brodie BR, Alessandro Giambartolomei A, Grines LL,. Boura JA, O'Neill WW, Morice MC. Creatinine Clearance but Not Serum Creatinine on Admission Predicts Early and Late Death After Primary Angioplasty. J Am Coll Cardiol 2001;37:648A.

229. AS Abizaid, R Mehran, G Dangas, S Fuchs, A Abizaid, AJ Lansky, R Kornowski, R Waksman, AD Pichard, LF Satler, **GW Stone,** MB Leon. Positive Troponin-I Predicts Early and Late Mortality After Percutaneous Coronary Intervention. J Am Coll Cardiol 2001;37:648A.

230. A Abizaid, G Dangas, AS Abizaid, R Mehran, M Negoita, C Ciora, R Narasimaiah, AD Pichard, AJ Lansky, **GW Stone,** GS Mintz, MB Leon. Intravascular Ultrasound Versus Angiography-Guided Stent Implantation: Acute and Long-Term Outcome in 2,883 Patients. J Am Coll Cardiol 2001;37:648A.

231. AS Abizaid, R Mehran, G Dangas, S Fuchs, A Abizaid, AJ Lansky, R Kornowski, R Waksman, AD Pichard, LF Satler, **GW Stone,** MB Leon. Positive Troponin-I Predicts Early and Late Mortality After Percutaneous Coronary Intervention. J Am Coll Cardiol 2001;37:648A.

232. AS Abizaid, R Mehran, A Abizaid, G Dangas, , L Gruberg, AD Pichard, Waksman R, LF Satler, KM Kent, AJ Lansky, **GW Stone,** MB Leon. Intravascular Ultrasound-Guided Provisional Stenting in Small Coronary Stenosis. J Am Coll Cardiol 2001;37:648A.Staged Versus Non Staged Approach for Multivessel Percutaneous Coronary Interventions. J Am Coll Cardiol 2001;37:648A.

233. DJ Moliterno, HC Herrmann, ER Powers, CL Grines, SJ Yakubov, DJ Cohen, HG Parker, MJ Frey**, GW Stone,** Topol EJ, for the TARGET Investigators. The Effects of Tirofiban Versus Abciximab Among Diabetic Patients Undergoing Stent Placement: The TARGET Trial. J Am Coll Cardiol 2001;37:648A.

234. DA Cox, TStuckey, R Low, L Cannon, R Iwaoka, A Lansky, **GW Stone**. Adjunctive Thrombectomy Combined With Stenting for AMI: The Endicor X-SIZER AMI Registry. J Am Coll Cardiol 2001;37:648A.

235. DJ Cohen, C Grines, D Cox, T Stuckey, J Carroll, J Griffin, RS Cosgrove, L Githiora, RH Berezin, J Tcheng**, GW Stone.** Cost-Effectiveness of Abciximab and Stenting in Acute Myocardial Infarction: Results from the CADILLAC Trial. J Am Coll Cardiol 2001;37:648A.

236. Adamian MG, Lansky AJ, Feldman DN, Grayver E, Dangas G, Mehran R, Abizaid AS, New G, Abizaid A, Kobayashi Y, Moussa I, Collins M, **Stone GW,** Moses JW, Leon MB. Gender differences in outcome after platelet GP IIb/IIIa inhibitor administration during percutaneous coronary intervention. J Inv Cardiol 2001;13:475.

237. Adamian MG, Mehran R, Dangas G, Feldman DN, Grayver E, Kobayashi Y, New G, Moussa I, Satler L, Pichard AG, Kent KM, Lansky AJ, **Stone GW,** Leon MB. Elective versus “rescue” abciximab administration in percutaneous coronary interventions. J Inv Cardiol 2001;13:475.

238. Feldman DN, Dangas G, Mehran R, Aymong E, Grayver E, Kobayashi Y, Gruberg L, Kent KM, Pichard AG, Satler L, Lansky AJ, **Stone GW,** Leon MB. Impact of chronic renal failure on one-year clinical outcome in non-diabetic patients after PCI. J Inv Cardiol 2001;13:477.

239. Adamian MG, Dangas G, Mehran R, Feldman DN, Grayver E, Abizaid AS, Abizaid A, Pichard AG, Satler L, Kent KM, Lansky AJ, **Stone GW,** Leon MB. One-year clinical outcome in diabetic patients with single vs. multivessel native coronary stenting. J Inv Cardiol 2001;13:477.

240. Kobayashi Y, Mehran R, Dangas G, Feldman DN, Grayver E, Moussa I, Adamian MG, New G, Roubin GS, Iyer S, Al-Mubarik N, **Stone GW,** Leon MB, Moses JW. Stent implantation compared to balloon angioplasty in small vessels. J Inv Cardiol 2001;13:477.

241. Kobayashi Y, Dangas G, Feldman DN, Grayver E, Mehran R, Abizaid A, New G,Coehn N, Collins M, Adamian MG, Moussa I, **Stone GW,** Leon MB, Moses JW. Are all “small” vessels really small? Implications for optimal stent implanation. J Inv Cardiol 2001;13:481.

242. Feldman DN, Dangas G, Mehran R, Aymong E, Grayver E, Kobayashi Y, Gruberg L, Kent KM, Pichard AG, Satler L, Lansky AJ, **Stone GW,** Leon MB. Vascular complications in non-diabetic patients with chronic renal failure and dialysis after PCI. J Inv Cardiol 2001;13:483.

243. M. Adamian, M. Farkouh, R. Mehran, G. Dangas, I. Moussa, D. Feldman, D. Ashby, A. Reyes, I. Iakovou, Y. Adamyan, M. Mohamed, A.J. Lansky, **G.W. Stone,** J.W. Moses, M.B. Leon. Effect of Diabetes Mellitus on Immediate and 1-Year Outcome After Stenting in Acute Myocardial Infarction. Am J Cardiol 2001; 88(supp1 5A):214.

244. D.N. Feldman,, G. Dangas, R. Mehran, E. Aymong, E. Grayver1, Y. Kobayashi1, L. Gruberg, K.M. Kent, A.D. Pichard, L.F. Satler,A.J. Lansky, **G.W. Stone,** M.B. Leon. Impact of Dialysis and Chronic Renal Failure in Nondiabetic Patients on 1-Year Clinical Outcome after Percutaneous Coronary Intervention. Am J Cardiol 2001; 88(supp1 5A):122.

245. C.O. Costantini, K. Shirai, K. Desai, A. Lansky, N. Dave, R. Mehran, G. Dangas, M. Negoitia, Y. Iakovu, D. Ashby, M. El-Omar, M. Hirose, **G. Stone,** R. Waksman, M. Leon. Debulking Verus No Debulking Before Vascular Brachytherapy. Am J Cardiol 2001; 88(supp1 5A):176.

246. D. A. Cox, C. L. Grines, E. Garcia, T. Stuckey, J. E. Tcheng, G. Guagliumi, A. Johnson, J. Griffin, A. J. Lansky, **G. W. Stone.** Does "Optimal" Percutaneous Transluminal Coronary Angioplasty (PTCA) Provide Equivalent Outcomes in Acute Myocardial Infarction (AMI) Compared with Stenting? Insights from the CADILLAC Trial. Am J Cardiol 2001; 88(supp1 5A):80.

247. E. Garcia, D.A. Cox, C.L. Grines, T. Stuckey, J.E. Tcheng, B.D. Rutherford, J. McLean, J. Carroll, A.J. Lansky, **G.W. Stone.** Does Primary Stenting Benefit Proximal LAD Infarction? The CADILLAC Trial. Am J Cardiol 2001; 88(supp1 5A):196.

248. D.T. Ashby, M. El-Omar, Y. Iakovou, E. Aymong, M. Negoita, I. Hjazi, R. Mehran, G. Dangas, J. Moses, **G.W. Stone,** M.B. Leon. Effect of Body Mass Index on In-Hospital Outcomes After Percutaneous Coronary Interventions. Am J Cardiol 2001; 88(supp1 5A):126.

249. R.A. Corpus, J.A. Boura, **G.W. Stone,** B.R. Brodie, D.A. Cox, E. Garcia, L.L. Grines, W.W. O'Neill, C.L. Grines. Outcome After Acute Myocardial Infarction in Young Patients: Analysis of the Percutaneous Intervention for Acute Myocardial Infarction (PAMI) Database. Am J Cardiol 2001; 88(supp1 5A):221.

250. G. Guagliumi, D.A. Cox, C.L. Grines, E. Garcia, T. Stuckey, J.E. Tcheng, J. Pasquini, J. Carroll, A.J. Lansky, **G.W. Stone.** Outcomes in Elderly Patients

Undergoing Primary Coronary Intervention for AMI: Insights from the CADILLAC Trial. Am J Cardiol 2001; 88(supp1 5A):197.

251. D. Cox, T. Stuckey, J. Babb, R. Low, L. Cannon, R. Iwaoka, B. Brodie, A. Lansky, **G. Stone.** The EndiCOR X-SIZER Acute Myocardial Infarction (AMI) Registry: Adjunctive Thrombectomy Combined with Stenting for AMI. Am J Cardiol 2001; 88(supp1 5A):76.

252. Srinivas Addala, Cindy L Grines, Judith A Boura, Gregory Pellizzon, Simon R Dixon, **Gregg W. Stone,** Joel K Kahn. The PAMI Clinical Risk Score : Predicting Mortality in 3452 patients with ST Elevation MI without Cardiogenic Shock treated with Primary Angioplasty. Circulation 2001;104:II-630.

253. Eve Aymong, Roxana Mehran, Alexandra J Lansky, **Gregg W. Stone,** Martin Bert Leon, Paul Teirstein. Effect of Radiation in Prevention of Target Vessel Revascularization: Results from the SCRIPPS II Trial. Circulation 2001;104:II-578.

254. Costantino Costantini-Ortiz, Alexandra J Lansky, Paul Teirstein, Kartik Desai, Roxana Mehran, Kazuyuki Shirai, George Dangas, **Gregg W. Stone,** Martin Fahy, Eve Aymong, Magdy Badereldin, Martin Leon. Patterns of Restenosis after P-32 Vascular Brachytherapy in the INHIBIT trial. Circulation 2001;104:II-576.

255. David Cox, Thomas Stuckey, Joseph Babb, Reggie Low, Yemi Johnson, Louis Cannon, Mark Turco, Alexandra Lansky, **Gregg W. Stone.** The EndiCOR X-SIZER AMI Registry: Improvement in Myocardial Blush Scores with Adjunctive Thrombectomy Combined with Stenting for AMI. Circulation 2001;104:II-504.

256. James J Ferguson III, Marc Cohen, Robert Freedman, Magnus Ohman, **Gregg W. Stone,** Jan Christenson, Ramachandra Reddy, Philip Urban, Michael Miller. Evolving Indications, Complications and Outcomes of IABC: Results of the Benchmark® Registry. Circulation 2001;104:II-439.

257. Alexandra J Lansky, David Cox, Thomas Stuckey, Manuela Negoita, Kartik Desai, Costantino Costantini, Nishe Dave, Brian Proctor, Octavia Balan, Ecatarina Cristea, **Gregg W. Stone.** Improved Myocardial Blush Score after Acute Myocardial Infarction Intervention with the X-SIZER Device. Results from the X-TRACT AMI Trial. Circulation 2001;104:II-466.

258. Alexandra J Lansky, Roxana Mehran, Kartik Desai, Magdi El-Omar, Costantino Costantini, Kazuyuki Shirai, Moses Tasawali, Nishe Dave, Faranza Arif, Chinenye Obicheta, Martin Fahy, **Gregg W. Stone.** Time Course of Restenosis Following Iridium-192 IntraVascular Brachytherapy for In-Stent Restenosis. Circulation 2001;104:II-546.

259. Kazuyuki Shirai, Alexandra J Lansky, Kartik Desai, Tereza Conway, Brian Proctor, Ecatarina Cristea, Martin Fahy, Maria Corral, Nishe Dave, Cristina Brestowski, **Gregg W. Stone,** Paul Teirstein. Feasibility and Efficacy of Tandem Positioning on Angiographic Outcomes in the INHIBIT Trial. Circulation 2001;104:II-546.

260. Kazuyuki Shirai, Roxana Mehran, Alexandra J Lansky, George Dangas, Martin Fahy, **Gregg W Stone,** Manuela Negoita, Kartik Desai, Ecatarina Cristea, Valavanur Subramanian. Minimally Invasive Coronary Artery Bypass Grafting Versus Stenting for Patients with Proximal LAD Disease: Long Results in a Matched Population of 775 Patients. Circulation 2001;104:II-423.

261. **Gregg W. Stone,** Steve Ramee, Steve Bailey, Steve Almany, John George, Jeffrey Moses, Christopher White, Marian Hawkey, Richard Kuntz, Campbell Rogers. Safety and Efficacy of Distal Protection During Saphenous Vein Graft Intervention with the EPI FilterWire EX™ - First Report from the U.S. Phase I Feasibility Study. Circulation 2001;104:II-623.

262. Farzana Arif, Yoshio Kobayashi, Makoto Hirose, Octavia Balan, Arlene Reyes, Ioannis Iakovou, Milena Adamian, Roxana Mehran, George Dangas, Alexandra J. Lansky, Issam Moussa, **Gregg W. Stone,** Martin B. Leon, Jeffrey W. Moses, Gary S. Mintz. Different Mechanism of Lumen Enlargement in Lesions With Stent Underexpansion After Balloon Angioplasty for In-Stent Restenosis Compared to Those With Optimal Stent Expansion: an Intravascular Ultrasound Study. J Am Coll Cardiol 2002;39:36A.

263. Makoto Hirose, Yoshio Kobayashi,Farzana Arif, Octavia Balan, Arlene Reyes, Ioannis Iakovou, C. Constantini, Issam Moussa, George Dangas, Roxana Mehran, Alexandra J. Lansky, **Gregg W. Stone,** Martin B. Leon, Jeffrey W. Moses. Different Mechanism of Lumen Enlargement during Balloon Angioplasty Between Focal and Diffuse In-Stent Restenosis. J Am Coll Cardiol 2002;39:37A.

264. Andrea S. Abizaid, Roxana Mehran, Gary S. Mintz, Alexandra J. Lansky, **Gregg W. Stone,** Alexandre Abizaid, George Dangas, Thos Limpijankit, Yanis Iakovou, Jeffrey W. Moses, Martin B. Leon. Direct Stenting Improves Target Lesion Revascularization in Saphenous Vein Graft Lesions: An Intravascular Ultrasound-Guided Study. J Am Coll Cardiol 2002;39:35A.

265. Dale T. Ashby, George Dangas, Roxana Mehran, Alexandra J. Lansky, Milena Adamian, Michael Collins, Edward Kreps, Gishel New, Issam Moussa, **Gregg W. Stone,** Gary S. Roubin, Sriram Iyer, Jeffrey W. Moses, Martin B. Leon, Paul S. Teirstein. Do Multiple Prior Interventions for In-Stent Restenosis Impact the Success of Gamma Brachytherapy? J Am Coll Cardiol 2002;39:58A.

266. Milena Adamian, Roxana Mehran, George Dangas, Gishel S. New, A.S. Abizaid, Alexandra J. Lansky, Giora Weisz, M.A. Grise, Michael Collins, Edward M. Kreps,

Issam Moussa, **Gregg W. Stone,** Jeffrey W. Moses, Martin B. Leon, Paul S. Teirstein. Does Vessel Size Have an Impact on Recurrence Rates Following Gamma Vascular Brachytherapy: Acute and 9 Month Results From SCRIPPS III Registry. J Am Coll Cardiol 2002;39:64A.

267. Costantino O. Costantini, Alexandra J. Lansky, Roxana Mehran, Martin Fahy, Kazuyuki Shirai, Nishi Dave, **Gregg W. Stone,** George Dangas, Martin B. Leon. Efficacy of Gamma Vascular Brachytherapy for Ostial vs. Non-Ostial In Stent Restenotic Lesions. J Am Coll Cardiol 2002;39:66A.

268. Milena Adamian, Issam Moussa, Roxana Mehran, George Dangas, Alexandra J. Lansky, Gary S. Mintz, M. Moussavian, Alexandre Abizaid, Mohamed Mohamed, R.Kuntz, **Gregg W. Stone,** Jeffrey W. Moses, Martin B Leon, Paul S. Teirstein. Gamma Vascular Brachytherapy Neutralizes the Negative Impact of Diabetes Mellitus on Clinical Outcomes After PCI for In-Stent Restenosis: Pooled Data From GAMMA I, II and SCRIPPS III Trials. J Am Coll Cardiol 2002;39:64A.

269. Dale T. Ashby, Roxana Mehran, Alexandra J. Lansky, Ioannis Iakovou, Giora Weisz, Costantino Costantini, Kazuyuki Shirai, Izat Hjazi, Michael Farkouh, George Dangas, **Gregg W. Stone,** Gishel New, Jeffrey W. Moses, Martin B. Leon. Gender Differences in Clinical Outcomes After PCI in Small Coronary Arteries. J Am Coll Cardiol 2002;39:2A.

270. Costantino Costantini-Ortiz, Alexandra J. Lansky, Kartik Desai, Roxana Mehran, Kazuyuki Shirai, Ecaterina Cristea, Hora Marginean, George Dangas, **Gregg W. Stone,** Martin B. Leon. Geographic Miss is Not Associated with Restenosis or the Edge Phenomenon in the INHIBIT Trial. J Am Coll Cardiol 2002;39:13A.

271. Milena Adamian**, Gregg W. Stone,** Roxana Mehran, George Dangas, A.S. Abizaid, Alexandre Abizaid, Mohamed Mohamed, Yuliya Adamian, Arlene Reyes, Izat Hjazi, Iannis Iakovou, Makoto Hirose, Alexandra J. Lansky, Jeffrey W. Moses, Martin B. Leon. Have the Outcomes of Rescue Angioplasty After Failed Thrombolytic Therapy in Acute Myocardial Infarction Improved in the Stent Era? J Am Coll Cardiol 2002;39:309A.

272. Iakovou, R. Merhan, G. Mintz, G. Dangas, Y. Koboyashi, A. Abizaid, D. Ashby, T. Limpijankit, R. Narasimaiah, I. Hjazi, N. Kipshidze, A. L. Lansky**, G. W. Stone,** J. W. Moses, M. B. Leon. Increased CKMB Release is a Trade-off for Optimal Stent Implantation. An Intravascular Ultrasound Study. J Am Coll Cardiol 2002;39:28A.

273. **G.W. Stone,** D.J. Moliterno, M. Bertrand, F.J. Neumann, H.C. Herrmann, E.R. Powers, C.L. Grines, D.J. Cohen, E.A. Cohen, M. Cohen, P.M. DiBattiste for the TARGET Investigators. Impact of Clinical Syndrome Acuity on the Differential Response to Two Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial. J Am Coll Cardiol 2002;39:22A.

274. Iakovou, G. Dangas, A. J. Lansky, M. Negoita, I. Hjazi, D. Ashby, C. Costantini, M. Guiry, R. Brandwein, M. Losquadro, J. Forman, J. W. Moses, **G. W. Stone,** M. B. Leon, R. Mehran. Impact of Gender on the Incidence and Outcome of Contrast Induced Nephropathy After Percutaneous Coronary Intervention. J Am Coll Cardiol 2002;39:2A.

275. Kazuyuki Shirai, Alexandra J. Lansky, Roxana Mehran, Kartik Desai, Costantino Costantini-Ortiz, Brian Proctor, Teraza Conway, Martin Fahy, Maria Corral, Christina Brestowski, George Dangas, **Gregg W. Stone,** Paul Teirstein, Jeffrey Moses, Martin B. Leon. Impact of Lesion Length on Vascular Brachytherapy Failure: A Comparison of Beta (b) Versus Gamma (g) Irradiation in 990 Patients. J Am Coll Cardiol 2002;39:13A.

276. Dale T. Ashby, George Dangas, Michael Farkouh, Ioannis Iakovou, Giora Weisz, Izat Hjazi, Milena Adamian, Eve Aymong, Mohamed Mohamed, Roxana Mehran**, Gregg W. Stone,** Alexandra J. Lansky, Michael Collins, Jeffrey W. Moses, Martin B. Leon. Impact of Smoking Habit on Clinical Outcomes After Percutaneous Coronary Intervention. J Am Coll Cardiol 2002;39:63A.

277. Costantino Costantini-Ortiz, Alexandra J. Lansky, Roxana Mehran, Kartik Desai, George Dangas, **Gregg W. Stone,** Ron Waksman, Jeffrey Moses, Martin B. Leon. Impact of Vessel Size After Coronary Vascular Brachytherapy: A Report of 990 Patients. J Am Coll Cardiol 2002;39:14A.

278. I. Iakovou, G. Dangas, A. Abizaid, G. Mintz, R. Mehran, Y. Kobayashi, D. Ashby, M. Hirose, S. Iyer, **G. W. Stone,** M. Collins, G. Roubin, M. Astatkie, J. W. Moses, M. B. Leon. In SVGs Bigger is not Significantly Better. An Intravascular Ultrasound Study. J Am Coll Cardiol 2002;39:74A.

279. Andrea S. Abizaid, Roxana Mehran, Alexandra J. Lansky, George Dangas, Alexandre Abizaid, Mohamed Mohamed, Izat Hjazi**, Gregg W. Stone,** Martin B. Leon. IVUS Guidance Decreases Target Lesion Revascularization in Long-Diffuse Coronary Lesions. J Am Coll Cardiol 2002;39:55A.

280. Thosaphol Limpijankit, George Dangas, Roxana Mehran, Alexandra J. Lansky, **Gregg W. Stone,** Nicholas Kipshidze, Michael Astatkie, Marian Hawkey, Dale Ashby, Mohamed Mohamed, Issam Moussa, Michael B. Collins, Jeffrey W. Moses, Martin B. Leon. Predictors and Prognostic Values of CK-MB Cardiac Enzymes Elevation After Coronary Intervention With Radiation Treatment in In-Stent Restenosis. J Am Coll Cardiol 2002;39:23A.

281. Iakovou, G. Dangas, A. J. Lansky, M. Negoita, I. Hjazi, D. Ashby, J. Forman, M. Guiry, R. Brandwein, M. Losquadro, T. Limpijankit, **G. W. Stone,** J. W. Moses, M. B. Leon, R. Mehran. Predictors of Contrast Induced Nephropathy After Percutaneous Coronary Intervention in Patients With and Without Chronic Renal

Failure. J Am Coll Cardiol 2002;39:56A.

282. Thosaphol Limpijankit, Alexandre Abizaid, Roxana Mehran, George Dangas, Alexandra J. Lansky, Nicholas Kipshidze, **Gregg W. Stone,** Michael B. Collins, Jeffrey W. Moses, Martin B. Leon. Predictors of Radiation Failure After Treatment of In-Stent Restenosis With Gamma Vascular Brachytherapy: Pooled Analysis From GAMMA I, II and SCRIPPS III Studies. J Am Coll Cardiol 2002;39:46A.

283. Alexandra J. Lansky, Cindy Grines, Kartik Desai, Ecatarina Cristea, Maria Corral, David Cox, Susan Gedney, John J. Griffin, Thomas Stuckey, Eulogia Garcia, Barry D. Rutherford, **Gregg W. Stone.** Primary Stenting Optimizes the Outcome of Women With Acute Myocardial Infarction: Results From the CADILLAC Trial. J Am Coll Cardiol 2002;39:39A.

284. Dale T. Ashby, George Dangas, Roxana Mehran, Thos Limpijankit, Giora Weisz, **Gregg W. Stone,** Costantino Costantini, Alexandra J. Lansky, Martin B. Leon, Gishel New, Sriram Iyer, Edward Kreps, Gary S. Roubin, Michael Collins, Jeffrey W. Moses. Relationship of the Degree of Procedural Anticoagulation to Outcomes After Stent Implantation. J Am Coll Cardiol 2002;39:27A.

285. Makoto Hirose, Yoshio Kobayashi, Roxana Mehran, Issam Moussa, George Dangas, Ramona Pop, Milena Adamian, Michael Collins, Mark A. Grise, Alexandra J. Lansky, Gary S. Mintz, **Gregg W. Stone,** Jeffrey W. Moses, Martin B. Leon, Paul S. Teirstein. Re-treatment Immediately After Gamma Radiation for In-Stent Restenosis Results in Need for Target Vessel Revascularization Beyond Target Lesion. J Am Coll Cardiol 2002;39:65A.

286. Yoshio Kobayashi, Issam Moussa, Makoto Hirose, Farzana Arif, Octavia Balan, Arlene Reyes, Mohamed Mohamed, Milena Adamian, Roxana Mehran, George Dangas, Alexandra J. Lansky, **Gregg W. Stone,** Martin B. Leon, Jeffrey W. Moses, Gary S. Mintz. Small Proximal Vessels Are Not Always Small: An Intravascular Ultrasound Study. J Am Coll Cardiol 2002;39:5A.

287. Milena Adamian, Roxana Mehran, George Dangas, Michael Farkou, Alexandre Abizaid, Arlene Reyes, Izat Hjazi, Manuela Negoita, Yuliya Adamyan, Cristian Cioara, Ramona Pop, Alexandra J. Lansky**, Gregg W. Stone,** Jefffrey W. Moses, Martin B. Leon. Stenting in Acute MI in Patients With Chronic Renal Failure: Predictors of In-Hospital and Long-Term Outcome. J Am Coll Cardiol 2002;39:309A.

288. Costantino O. Costantini, Alexandra J. Lansky, Roxana Mehran, Gary S. Mintz, Kartik Desai, Kazuyuki Shirai, Horia Marginean, **Gregg W. Stone,** George Dangas, Martin B. Leon. Vascular Brachytherapy for Ostial In-Stent Restenotic Lesions. J Am Coll Cardiol 2002;39:46A.

289. Iakovou, G. Dangas, A. J. Lansky, G. Mintz, D. Ashby, M. Losquadro, M. Guiry, N. Kipshidze, R. Brandwein, T. Limpijankit, J. Forman, I. Hjazi, **G. W. Stone,** M. B. Leon, R. Mehran. Incidence, predictors and economic impact of contrast induced nephropathy. Results in 8,628 patients treated with percutaneous coronary interventions. J Am Coll Cardiol 2002;39:2A.

290. Iakovou, G. Dangas, A. J. Lansky, M. Negoita, I. Hjazi, D. Ashby, C. Costantini, M. Guiry, R. Brandwein, M. Losquadro, J. Forman, J. W. Moses, **G. W. Stone,** M. B. Leon, R. Mehran. Impact of Gender on the Incidence and Outcome of Contrast Induced Nephropathy After Percutaneous Coronary Intervention. J Am Coll Cardiol 2002;39:2A.

291. Milena Adamian, Issam Moussa, Roxana Mehran, George Dangas, Michael Farkouh, Yuliya Adamyan, M Mohammed, Manuela Negoita, Arlene Reyes, M Losquardro, M. Collins, EM Kreps, Jefffrey W. Moses, **Gregg W. Stone,** Martin B. Leon. The role of mucomyst administration prior to percutaneous interventions on renal function in patients with chronic renal failure. J Am Coll Cardiol 2002;39:1A.

292. Kazuyuki Shirai, Alexandra Lansky, Roxana Mehran, Kartik Desai, Costantino Costantini-Ortiz, B. proctor, T. Conway, Martin Fahy, N. Dave, I. Hijazi, George Dangas, **Gregg W. Stone,** PS Teirstein, JW Moses, Martin Leon. Should Small Proximal Arteries be Stented? J Am Coll Cardiol 2002;39:21A.

293. Harjai KJ, Grines CL, **Stone GE,** et al. Frequency, determinants and clinical implications of angiographically-visible thrombus following primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2002;39:49A.

294. Baumgart D, Limpijanki T, Serruys P, Colombo A, Silber S, eeckhout E, Urban P, Bonan R, Zeihar A, Gershlick AH, Dangas G, Lansky AJ, Mehran R, **Stone GW,** Leon MB. Efficacy of long radiation treatment in native in-stent restenosis: a subanalysis from the RENO registry. J Am Coll Cardiol 2002;39:57A.

295. Garcia E, Cox D, Grines CL, Morena R, Tcheng J, Stuckey T, Rutherford B, McClean J, Lansky A, **Stone GW.** Does stenting benefit patients with left anterior descending infarction? Results from the CADILLAC trial. J Am Coll Cardiol 2002;39:74A.

296. Moliterno DJ, Lange RA, Hamm C, Meier B, Dibattiste PM, Lakkis N, Gang J, Chew DP, Cohen DM, **Stone GW,** Demopoulos L, Topol EJ. Prolongation of activated clotting time (ACT) with tirofiban vs. abciximab and its association to clinical outcome: results from TARGET. J Am Coll Cardiol 2002;39:74A.

297. Mehran R, Lotan C, Kranjec I, Holmer E, Haase K, Camenzind E, Zelizko M, maillard L, Gomes SR, Vandormael MG, Lansky AJ, Dangas G, **Stone GW,** Ashby DT, Leon MB. The HEP@NET study: an internet-based registry examining

the efficacy of heparin-coating in patients undergoing coronary stent implantation. J Am Coll Cardiol 2002;39:75A.

298. Harjai KJ, Grines CL, Pham T, **Stone GE,** et al. Disparate clinical outcomes of diabetic and nondiabetic patients undergoing primary angioplasty for acute myocardial infarction: is diabetes mellitus an independent predictor of poor outcome? J Am Coll Cardiol 2002;39:289A.

299. Guagliumi G, Cox DA, Grines CL, Garcia E, Stuckey T, Tcheng J, Pasquini J, Carroll J, Lansky A, **Stone GW.** Does abciximab and stenting improve outcomes in elderly patients undergoing primary PCI for acute myocardial infarction: data from the CADILLAC trial. J Am Coll Cardiol 2002;39:289A.

300. Skelding KA, Harjai K, Mehta L, **Stone GW,** et al. Gender is an independent predictor of both in-hospital and one-year outcomes ollowing primary intervention for acute myocardial infarction. J Am Coll Cardiol 2002;39:290A.

301. Cox DA, Stuckey T, Babb J, Low R, Cannon L, Iwoaka R, Turco M, Brodie B, Lansky A, **Stone GW.** Early and late results of thrombectomy prior to stenting in acute myocardial infarction: principal report of the Endicor X-SIZER AMI registry. J Am Coll Cardiol 2002;39:308A.

302. Ledford CM, Grines CL, **Stone GW,** et al. Long-term outcomes in patients with acute myocardial infarction undergoing primary percutaneous intervention: a pooled analysis of the primary angioplasty in myocardial infarction trials. J Am Coll Cardiol 2002;39:309A.

303. Nguyen TT, O'Neill WW, Dixon SR, Boura JA, Grines L, Cox DA, **Stone GW,** Brodie BR, Grines CL. Poor one year prognosis in acute myocardial infarction patients with saphenous vein grafts as the infarct related vessel treated by primary balloon angioplasty. J Am Coll Cardiol 2002;39:309A.

304. Corpus RA, Boura JA, **Stone GW,** et al. Outcome after acute myocardial infarction in young patients: analysis of the PAMI database. J Am Coll Cardiol 2002;39:314A.

305. Stuckey T, Grines CL, Brodie BR, Cox DA, Griffin JJ, Carrol J, Guagliumi G, Garcia E, Rutherford B, Turco M, Tcheng J, **Stone GW.** Effect of stent implantation and glycoprotein IIb/IIIa receptor blockade on target vessel revascularization in diabetics after primary PCI in acute myocardial infarction: the CADILLAC trial. J Am Coll Cardiol 2002;39:337A.

306. Cox DA, Grines CL, Garcia E, Stuckey T, Tcheng J, Guagliumi G, Johnson A, Lansky A, Griffin JJ, **Stone GW.** Does optimal or stent-like PTCA provide equivalent outcomes compared to primary stenting in acute myocardial infarction: early and late results from the CADILLAC trial. J Am Coll Cardiol 2002;39:337A.

307. Harjai KJ, **Stone GW,** Boura J, et al. The salutary effect of prior beta blocker therapy on clinical outcomes following primary angioplasty for acute myocardial infarction: a pooled analysis from the Primary Angioplasty in Myocardial Infarction (PAMI) 1, 2 and Stent PAMI trials. J Am Coll Cardiol 2002;39:337A.

308. Ross A, Gibbons R, Kloner RA, Marder VJ, **Stone GW,** Alexander RW. Acute Myocardial Infarction Study of Adenosine (AMISTAD II). J Am Coll Cardiol 2002;39:338A.

309. G Weisz, G Dangas, A Colombo, I Moussa, M Collins, M Adamian, Y Adamyan, D Ashby, V LaRoche, A Lansky, R Mehran, P Teirstein, **GW Stone,** JW Moses, MB. Leon. T-Stenting Technique with Sirolimus-Eluting Stents for Bifurcation Lesions. Am J Cardiol 2002 90(suppl 6A): 5H.

310. D Cox, T Stuckey, J Babb, MTurco, R Iwaoka, LCannon, R Low, A Lansky**, G Stone.** The X-SIZER Acute Myocardial Infarction (AMI) Registry: Improvement in Myocardial Blush Scores and ST-Segment Resolution with the Use of Thrombectomy Before Stenting in AMI. Am J Cardiol 2002;90(suppl 6A):18H.

311. C Rogers, **G Stone.** The FilterWire EX Distal Protection Device for Use During Saphenous Vein Graft Interventions: Preliminary FIRE Trial Results. Am J Cardiol 2002;90(suppl 6A):26H.

312. H Arjomand, B Roukoz, S Surabhi, A Espinoza, M Cohen, Z Turi, **G Stone,** D Baim, S Goldberg. In-hospital Outcome of Saphenous Vein Graft Intervention with Membrane-Covered Stents with and without Distal Protection. Am J Cardiol 2002;90(suppl 6A):27H.

313. KJ Harjai, CL Grines**, GW Stone,** D Cox, B Brodie, JA Boura, L Grines, WW O'Neill. Technical Success of Primary Angioplasty Overrides Clinical Risk Status in Determining Outcome of Acute Myocardial Infarction: Guidelines for Discharge Planning. Am J Cardiol 2002;90(suppl 6A):48H.

314. G Weisz, DA Cox, E Garcia, JE Tcheng, JJ Griffin, G Guagliumi, TD Stuckey, JD Carroll, R Mehran, CL Grines, **GW Stone.** The Smoker's Paradox Revisited: Insights from the CADILLAC Trial. Am J Cardiol 2002;90(suppl 6A):52H.

315. MA Turco, DA Cox, T Stuckey, J Babb, B Brodie, DE Shaddinger, **GW Stone.** Impact of Glycoprotein IIb/IIIa Inhibitors in Conjunction with the X-SIZER Thrombectomy Catheter System During Acute Myocardial Infarction (AMI) Intervention: Results from the X-SIZER AMI Registry. Am J Cardiol 2002;90(suppl 6A):52H.

316. DA Cox, M Turco, T Stuckey, J Babb, B Brodie, J McLean, A Lansky5, **GW Stone.** Stent Placement Combined with Thrombectomy Improves Outcomes in

Thrombotic Lesions: Results from the X-SIZER Acute Myocardial Infarction Registry. Am J Cardiol 2002;90(suppl 6A):53H.

317. B Roukoz, H Arjomand, S Surabhi, D McCormick, Z Turi, **G Stone,** D Baim, S Goldberg. Initial US Experience with Covered Stents in the Treatment of Saphenous Vein Graft Lesions: 30-Day Follow-Up. Am J Cardiol 2002;90(suppl 6A):79H.

318. I Iakovou, G Dangas, R Mehran, G Mintz, A Abizaid, F Kuepper Y Kobayashi, D Ashby, M Hirose, **GW Stone,** MB Leon. Neutral Impact of Preintervention Remodeling of Saphenous Vein Grafts on Subsequent Target Lesion Revascularization. Am J Cardiol 2002;90(suppl 6A):132H.

319. M Adamian, R Mehran, I Moussa, G Dangas, GS Mintz, AJ Lansky, Y Adamyan, S Ibrahim, M Fahy, C Cioara, M Losquadro, A Reyes, **GW Stone,** JW Moses, MB Leon. Mucomyst Administration in Percutaneous Coronary Interventions in Patients with Impaired Renal Function: A Matched Comparison. Am J Cardiol 2002;90(suppl 6A):144H.

320. G Weisz, R Mehran, S Polena, D Ashby, I Moussa, **G Stone,** GS Roubin, JW Moses, MB Leon, G Dangas. In Patients Receiving Oral Antiplatelet Agents, Platelet Glycoprotein IIIa Heterozygous Polymorphism Does Not Increase Risk of Percutaneous Coronary Intervention. Am J Cardiol 2002;90(suppl 6A):161H.

321. M Adamian, M Farkouh, R Mehran, I Moussa, G Weisz, I Hjazi, R Pop, T Limpanjikit, Y Adamyan, M Collins, M Losquadro, G Dangas, **GW Stone,** JW Moses, MB Leon. A Matched Comparison of Safety and Feasibility of Bivalirudin in Patients with Diabetes Mellitus During Percutaneous Coronary Interventions. Am J Cardiol 2002;90(suppl 6A):161H.

322. M Adamian, R Mehran, GS Mintz, G Dangas, I Moussa, DT Ashby, S Ibrahim, Y Adamyan, M Negoita, A Reyes, R Narasimaiah, EM Kreps, **GW Stone,** JW Moses, MB Leon. Safety and Feasibility of Direct Thrombin Inhibitor Bivalirudin During Percutaneous Coronary Interventions in Patients with Chronic Renal Failure. Results of the Pilot Study. Am J Cardiol 2002;90(suppl 6A):162H.

323. TA Sanborn, JD Ogilby, J Ritter**, GW Stone,** B Klugherz, R Fields, C White, J McGarvey, DL Morris, R Wilensky. Reduced Vascular Complications After Percutaneous Coronary Interventions with a Nonmechanical Suture Device: Results from the Randomized Rapid Ambulation After Closure (RACE) Study. Am J Cardiol 2002;90(suppl 6A):172H.

324. F Kuepper, AJ Lansky, G Dangas, I Iakovou, DT Ashby, CO Costantini, M Farkouh**, GW Stone,** MB Leon, R Mehran. Patients with Diabetes After Percutaneous Interventions in Saphenous Vein Grafts: Sex-Based Differences in Clinical Outcomes at 1-Year Follow-up. Am J Cardiol 2002;90(suppl 6A):178H.

325. S Addala, CL Grines, SR Dixon, **GW Stone,** JA Boura, AB Ochoa, G Pellizzon, JK Kahn. PAMI Risk Score: Predicting Mortality in ST Elevation Myocardial Infarction Treated with Primary Angioplasty. Am J Cardiol 2002;90(suppl 6A):182H.

326. D Cox, C Grines, T Stuckey, E Garcia, J Griffin, J Tcheng, J Pasquini, G Guagliumi, B Brodie, M Turco, A Lansky, **G Stone.** Do Acute Myocardial Intervention Patients Without ST-Segment Elevation Have Better Outcomes After Primary Percutaneous Coronary Intervention? An Analysis from the CADILLAC Trial. Am J Cardiol 2002;90(suppl 6A):184H.

327. BA Bartholomew, KJ Harjai, JA Boura, LL Grines, **GW Stone,** D Cox, B Brodie, W O'Neill, CL Grines. Declining Length of Stay in Primary Angioplasty in Myocardial Infarction (PAMI) Studies Despite Increased Disease Severity. Am J Cardiol 2002;90(suppl 6A):185H.

328. D Cox, C Grines, A Lansky, T Stuckey, E Garcia, J Williams, J Tcheng, G Guagliumi, J Griffin, **G Stone.** Impact of Small Vessel Size on Long-Term Outcomes After Primary Angioplasty and Stenting in Acute Myocardial Infarction: Results from the CADILLAC Trial. Am J Cardiol 2002;90(suppl 6A):185H.

329. BA Bartholomew, KJ Harjai, JA Boura, LL Grines, **GW Stone,** D Cox, B Brodie, M Yerkey, W O'Neill, CL Grines. Factors Affecting Length of Stay in Acute Myocardial Infarction Patients Undergoing Primary Angioplasty. Am J Cardiol 2002;90(suppl 6A):185H.

330. B.A Bartholomew, KJ Harjai, JA Boura, M Yerkey, LL Grines, **GW Stone,** D Cox, B Brodie, WW O'Neill, CL Grines. Variation in Hospital Length of Stay in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty: Do We Need Multiple Diagnostic Related Groups**?** Am J Cardiol 2002;90(suppl 6A):186H.

331. MW Yerkey, KJ Harjai, **GW Stone,** DA Cox, TD Stuckey, JA Boura, BA Bartholomew, SJ Kernis, CL Grines. Late Hemodynamic Compromise After Successful Primary Angioplasty for Acute Myocardial Infarction. Am J Cardiol 2002;90(suppl 6A):189H.

332. **GW Stone,** R Mehran, M Midei, R Waksman, G Schaer, AJ Lansky, M Buchbinder. Beta Radiation for De Novo and In-stent Restenotic Lesions in Saphenous Vein Grafts: The SVG BRITE Trial. Circulation 2002;106(19):II-335.

333. AJ Lansky C Costantini, K Desai, M Adamian, D Cox, JE Tcheng, J Griffin, T Stuckey, E Garcia, J Carroll, **GW Stone.** Exposing the Gender Gap in Outcomes After Primary Intervention for Acute Myocardial Infarction: Results From the CADILLAC Trial. Circulation 2002;106(19):II-491.

334. G Weisz, GD Dangas, A Colombo, I Moussa, M Collins, M Adamian, Y Adamian, D Ashby, V Laroche, P Teirstein, **GW Stone,** JW Moses. Sirolimus-Eluting stents for Bifurcation Lesions: Comparison to Standard "Bare" Stents Using the T-Stenting Technique. Circulation 2002;106(19):II-519.

335. SG Ellis, JB Hermiller, DA Cox, MA Turco, JD Greenberg, JT Mann, ME Russell, **GW Stone.** The U.S. pivotal randomized trial of a polymer-based slow-rate release paclitaxel eluting stent: 30-day results of TAXUS-IV SR. Circulation 2002;106(19):II-393.

336. A Bakhai, **GW Stone,** SA Murphy, L Githiora, RH Berezin, CL Grines, DA Cox, JE Tcheng, DJ Cohen. Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial. Circulation 2002;106(19):II-518.

337. Kandzari DE, Tcheng JE, Grines CL, Cohen DJ, Bakhai A, Cox DA, Stuckey TD, Effron M, Griffin JJ, Turco M, Carroll JD, Fahy M, Mehran R, **Stone GW.** Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trial. J Am Coll Cardiol. 2003;41(6 Suppl B):538-9.

338. Aymong ED, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Turco M, Carroll JD, Rutherford BD, Lansky AJ, Mehran R, **Stone GW.** Predictors and sequelae of subacute thrombosis after percutaneous intervention in acute myocardial infarction: The CADILLAC trial. J Am Coll Cardiol. 2003;41(6 Suppl B):393.

339. McLaughlin MG, Gardner G, Aymong ED, Mehran R, Lansky AJ, Grines CL, Tcheng JE, Cox DA, Stuckey TD, Garcia E, Guagliumi G, Turco M, Zimetbaum P, **Stone GW.** ST-segment elevation resolution as a predictor of mortality in patients with thrombolysis in myocardial infarction III flow in the infarct artery after primary angioplasty: The CADILLAC trial. J Am Coll Cardiol. 2003;41(6 Suppl B):392.

340. Costantini CO, Lansky AJ, Shirai K, Cristea E, Brestowski C, Slack S, Fahy M, Grines CL, Carroll JD, Thomas S, Guagliumi G, Rutherford B, Turco M, Mathias D, Leon MB, **Stone GW.** Clinical implications of myocardial perfusion status assessed by myocardial blush after primary angioplasty in acute myocardial infarction: Analysis from the CADILLAC trial. J Am Coll Cardiol. 2003;41(6 Suppl B):391-2.

341. Mehrdad Sadeghi H, Grines CL, Mehran R, Dixon SR, Lansky AJ, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Turco M, Carroll JD, Rutherford BD, **Stone GW.** Marked mortality risk of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2003;41(6 Suppl B):384.

342. Mehrdad Sadeghi H, Grines CL, **Stone GW,** et al. Circadian fluctuations in thrombogenicity in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2003;41(6 Suppl B):384.

343. Turco MA, Fahy M, Mehran RA, Lansky A, Grines CL, Tcheng JE, Garcia E, Guagliumi G, Cox DA, Stuckey TD, Shaddinger DE, **Stone GW.** Predictors of treatment delay in patients with acute myocardial infarction undergoing primary angioplasty: An analysis from the CADILLAC trial. J Am Coll Cardiol. 2003;41(6 Suppl B):376.

344. Pellizzon GG, Harjai K, Addala S, Ochoa A, **Stone GW,** Cox DA, Grines L, Boura JA, Brodie BR, O'Neill WW, Grines CL. Multiple lesion coronary intervention is associated with higher mortality in primary angioplasty for acute myocardial infarction: The stent PAMI trial. J Am Coll Cardiol. 2003;41(6 Suppl B):369.

345. Turco MA, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Carroll JD, Grines CL, Rutherford BD, Slack S, Fahy M, Mehran R, Lansky AJ, **Stone GW.** Baseline features and clinical results in patients excluded from randomization from a large international trial of reperfusion strategies in acute myocardial infarction: The CADILLAC Registry. J Am Coll Cardiol. 2003;41(6 Suppl B):368.

346. Brodie BR, Cox DA, Stuckey TD, Turco M, Garcia E, Griffin JJ, Fahy M, Tcheng JE, Grines CL, Mehran R, **Stone GW.** How important is time to treatment with primary percutaneous coronary intervention for acute myocardial infarction? Results from the CADILLAC trial. J Am Coll Cardiol. 2003;41(6 Suppl B):368.

347. Kandzari DE, E Tcheng J, Grines CL, Effron M, Fox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey TD, Turco M, Lansky AJ, Mehran R, **Stone GW.** Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: The CADILLAC trial. J Am Coll Cardiol. 2003;41(6 Suppl B):357.

348. Brodie BR, Gersh B, Stuckey TD, Zimetbaum P, McLaughlin MG, Aymong ED, Mehran R, O'Neill B, Tcheng JE, Turco M, Cox DA, Grines CL, **Stone GW.** Relationship between time to treatment, electrocardiographic ST-segment resolution, and outcomes with primary percutaneous coronary intervention for acute myocardial infarction: Results from the CADILLAC trial. J Am Coll Cardiol. 2003;41(6 Suppl B):342-3.

349. Vagaonescu TD, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BR, Fahy M, Mehran R, **Stone GW.** Impact of an elevated white blood cell count and treatment with abciximab on survival in patients with acute myocardial infarction undergoing percutaneous coronary intervention: The CADILLAC trial. Cathet Cardiovasc Interv 2003;59:127.

350. P.S. Chowdhury, K.J. Harjai, J.A. Boura, **G. Stone,** D. Cox, B. Brodie, J.A. Goldstein, W.W. O'Neill, C.L. Grines. Incidence, Predictors, and Prognostic Implications of Coronary Artery Dissection in the Setting of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. Am J Cardiol 2003;92:4L

351. S. Kesanakurthy, G.D. Dangas, Z. Lasic, T. Vagaonescu, A. Halkin, Z. Qin, **G. Stone,** J.W. Moses, M.B. Leon, R. Mehran. Clinical Outcomes With the Use of Bivalirudin Versus Unfractionated Heparin in Octagenarians Undergoing Percutaneous Coronary Interventions. Am J Cardiol 2003;92:11L.

352. E. Nikolsky, A. Halkin, S. Krieger, R. Mehran, E. Aymong, G.S. Mintz, M. Negoita, Y. Gilutz, I. Hjazi , R. Narasimaiah**, G.W. Stone,** J.W. Moses, M.B. Leon, G.D. Dangas. Arteriotomy Closure Devices in Patients Undergoing Percutaneous Coronary Procedures: A Meta-Analysis. Am J Cardiol 2003;92:17L.

353. R. Mehran, S. Marx, S. Kesanakurthy, Y. Adamian, Z. Qin , I. Moussa, M. Collins, G. New, S. Polena, J. Cosico , M. Negoita, A.J. Lansky, J.W. Moses, **G.W. Stone,** M.B. Leon, A.R. Marks , G. Dangas. Oral Rapamycin for Prevention of In-Stent Restenosis: Long-Term Clinical, Angiographic, and Intracoronary Ultrasound Results. Am J Cardiol 2003;92:26L.

354. D. Cox, J. Popma, C. Rogers, J. Hermiller, R. Feldman, P. Hall, R. Haber, A. Masud, P. Cambier, M. Turco, G. Tully, **G. Stone.** Baseline Clinical and Procedural Predictors of Adverse Events During Stenting in Saphenous Vein Grafts Using Distal Protection With the FilterWire EX or With the GuardWire: The FIRE Trial. Am J Cardiol 2003;92:32L.

355. A.Z. Masud, J. Hermiller, R. Feldman, P. Hall, R. Haber, P.A. Cambier, R. Caputo, M.A. Turco, R. Kovach, B. Brodie, H. Herrmann, R.E. Kuntz1, J. Popma1, S.R. Ramee, D. Cox, J.G. Conley, C. Rogers, **G.W. Stone.** The FIRE Trial: 30-Day and 6-Month Results of a Multicenter Randomized Trial Comparing Distal Protection with the FilterWire EX and GuardWire During Saphenous Vein Graft Intervention. Am J Cardiol 2003;92:33L.

356. D. Cox, A. Masud, F. Myers, R. Kovach, P. Cambier, B.R. Brodie, G. Mishkel, J. Hermiller, G. Tully, **G. Stone.** Stenting in Saphenous Vein Grafts with Distal Protection Using the Second Generation FilterWire EZ: The BLAZE Registry. Am J Cardiol 2003;92:33L.

357. A.Z. Masud, C. Rogers, J. Hermiller, R. Feldma , P. Hal , R. Haber, R. Kovach, P. Cambier, R. Caputo, D.A. Cox, R. Pop, M. Fahy, R. Mehran, **G.W. Stone.** Results of Intervention in Ostial and Nonostial Saphenous Vein Graft Lesions Using Different Distal Protection Devices. The FIRE Trial. Am J Cardiol 2003;92:33L.

358. J.B. Hermiller, A. Masud, D. Cox, R. Feldman, P. Hall, R. Haber, P. Cambier, R. Caputo, M. Turco, R. Kovach, B.R. Brodie, H.C. Herrmann, J. Popma, R. Mehran, E. Aymong, C. Rogers, **G.W. Stone.** Impact of Transient Flow Reduction on the Efficacy of Embolic Protection Filters: Results From the FIRE Trial. Am J Cardiol 2003;92:34L.

359. H.M. Sadeghi, C.L. Grines, R. Mehran, A.J. Lansky, M. Fahy, D.A. Cox, J.E. Tcheng, S.R. Dixon, J.J. Griffin, T.D. Stuckey, B.R. Brodie, M. Turco, J.D. Carroll, **G.W. Stone.** Incidence and Implications of In-Hospital Acquired Thrombocytopenia in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction. Am J Cardiol 2003;92:40L.

360. C.O. Costantini, H. Marginea, E. Cristea, Y. Tsushiya, R.A. Costa, T. Stuckey, M. Turco, G. Guagliumi, D.A. Cox, J.E. Tcheng, C.L. Grines, J.J. Griffin, A.J. Lansky, **G.W. Stone.** Are There Any Angiographic Predictors of Abciximab Benefit After Primary Angioplasty for Acute Myocardial Infarction? Analysis From the CADILLAC Trial. Am J Cardiol 2003;92:41L.

361. T.D. Stuckey, C.L. Grines, D.A. Cox, B.R. Brodie, M. Turco, P. Zimetbaum, J.E. Tcheng, E. Garcia, J.J. Griffin, G. Guagliumi, R.A. Mehran, E. Aymong, **G.W. Stone.** Does Stenting and Glycoprotein IIb/IIIa Receptor Blockade Improve ST Segment Recovery and Outcome in Patients Undergoing Primary Angioplasty in Acute Myocardial Infarction? The CADILLAC Trial. Am J Cardiol 2003;92:41L.

362. K.J. Harjai, C.L. Grines, G**.W. Stone**, A.J. Lansky, E. Aymong, M. Fahy, D.A. Cox, E. Garcia, J.E. Tcheng, J.J. Griffin, G. Guagliumi, T. Stuckey, M. Turco, B.D. Rutherford, J.D. Carroll, B.R. Brodie. Does the Use of Heparin After Primary Angioplasty for Acute Myocardial Infarction in Patients Not Receiving Glycoprotein IIb/IIIa Antagonists Alleviate Recurrent Cardiac Ischemia? Insights From the CADILLAC Study. Am J Cardiol 2003;92:42L.

363. C.O. Costantini, A.J. Lansky, R.A. Costa, R. Mehran, E. Aymong, D.A. Cox, J.E. Tcheng, T. Stuckey, J.D. Carroll, E. Garcia, G. Guagliumi, M. Fahy, J.J. Griffen, C.L. Grines, **G.W. Stone.** Impact of Myocardial Blush Analysis Methodologies in Predicting Short and Long-Term Mortality After Primary Angioplasty. The CADILLAC Trial. Am J Cardiol 2003;92:43L.

364. M.A. Turco, P. Zimetbaum, M. McLaughlin, E. Aymong, R. Mehran, D. Cox, C. Grines, J. Tcheng, E. Garcia, J. Griffin, G. Guagliumi, T. Stuckey, **G.W. Stone.** Is ST Segment Resolution Predictive of Mortality after Primary PCI in Both Anterior and Non-Anterior Infarction? Analysis from the CADILLAC Trial. Am J Cardiol 2003;92:43L.

365. C.O. Costantini, K. Shirai, R.A. Costa, M. Turco, D.A. Cox, T. Stuckey, J.J. Griffin, J.D. Carroll, M. Tarawalli, Y. Tsushiya, A.J. Lansky, **G.W. Stone.** Prognostic

Implications of Site Location After Primary Angioplasty: Analysis of U.S. Versus Non-U.S. Sites in the CADILLAC Trial. Am J Cardiol 2003;92:69L.

366. R.A. Costa1, Y. Tsuchiya1, D.A. Cox, J. Babb, D. Nukta, L. Bilodeau, L. Cannon, T.D. Stuckey, J. Hermiller, E. Aymong, S. Slack, R. Mehran, A.J. Lansky, **G.W. Stone.** Late Outcomes of Patients Treated With Thrombectomy Prior to Stenting in Saphenous Vein Grafts and Thrombus Containing Native Coronary Arteries: Results From the X-TRACT Trial. Am J Cardiol 2003;92:73L.

367. T.D. Stuckey, D.A. Cox, M.A. Turco, B.R. Brodie, J. Babb, A. Lansky, R. Kuntz, M. Krucoff, **G.W. Stone.** Impact of Prestent Thrombectomy on Periprocedural Myonecrosis in Thrombus Containing Lesions in Saphenous Vein Grafts and Native Coronary Arteries: Results of the X-Tract Trial. Am J Cardiol 2003;92:73L.

368. Y. Tsuchiya, R.A. Costa, M. Fahy, S. Slack, E. Aymong, R. Mehran, A.J. Lansky, **G.W. Stone,** D.A. Cox, J. Babb, D. Nukta, L. Bilodeau, L. Cannon, T. Stuckey. Impact of Gender on Outcomes of Thrombectomy in Patients Undergoing Stenting of Diseased Saphenous Vein Grafts or Thrombotic Native Coronary Arteries--Results From the X-TRACT Trial. Am J Cardiol 2003;92:74L.

369. Y. Tsuchiya1, R.A. Costa1, M. Fahy, S. Slack1, E. Aymong, R. Mehran, A.J. Lansky, **G.W. Stone,** D.A. Cox, J. Babb, D. Nukta, L. Bilodeau, L. Cannon, T. Stuckey. Utility of Thrombectomy in Women Undergoing Stenting of Diseased Saphenous Vein Grafts and Thrombus Containing Native Coronary Arteries--Results From the X-TRACT Trial. Am J Cardiol 2003;92:74L.

370. E. Nikolsky, R. Mehran, E. Aymong, G.S. Mintz, G. Dangas, A.J. Lansky, M. Negoita, M. Fahy, R. Pop, G.S. Roubin, J.W. Moses , **G.W. Stone ,** M.B. Leon. The Impact of Symptomatic Peripheral Arterial Disease on 1-Year Mortality in Patients Undergoing Percutaneous Coronary Interventions. Am J Cardiol 2003;92:77L.

371. Aymong E, Limpijankit T, Fahy M, Mehran R, Leon M, Moses J, **Stone GW,** et al. Interaction of diabetes and acute coronary syndromes in predicting death, myocardial infarction and non-target lesion revascularization at 1-year follow-up after percutaneous coronary intervention. Am J Cardiol 2003;92:80L.

372. Moussa, M. Jaff, S. Iyer, R. Mehran, H. Klein, G. Dangas, **G.W. Stone,** A. Lansky, M.B. Leon, J.W. Moses. Detection of Peripheral Arterial Disease in Patients Presenting for Coronary Angiography or Intervention for Coronary Artery Disease: The Peripheral Arterial Disease in Interventional Patients. Am J Cardiol 2003;92:83L.

373. Moussa, M.B. Leon, R. Mehran, G. Dangas, G. Weiss, A. Lansky**, G.W. Stone,** J.W. Moses. The Impact of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors on

Outcome of Diabetic Patients Undergoing Sirolimus-Eluting Versus Bare Metal Stent Implantation: Results From the SIRIUS Trial. Am J Cardiol 2003;92:91L.

374. Halkin, E. Aymong, E. Nikolsky, A. Lansky, R. Mehran, D.A. Cox, C.L. Grines, J.J. Griffin, **G.W. Stone.** Prediction of Survival by Index Left Ventricular Ejection Fraction Measured During Primary Percutaneous Intervention in Patients with Acute Myocardial Infarction. Am J Cardiol 2003;92:112L.

375. Halkin, E. Aymong, A. Lansky, R. Mehran, D.A. Cox, C.L. Grines, E. Garcia, G. Guagliumi, **G.W. Stone.** Determinants of Convalescent Left Ventricular Function After Acute Myocardial Infarction Treated by Primary Percutaneous Intervention. Am J Cardiol 2003;92:113L.

376. R.A. Costa1, Y. Tsuchiya1, M. Tarawali1, H. Marginean1, R. Sanchez1, E. Cristea1, R. Mehran, T. Stuckey, G. Guagliumi, D.A. Cox, J.E. Tcheng, J.D. Carroll, J.J. Griffen, C.L.Grines, A.J.Lansky, **G.W. Stone.** Impact of Age on the Outcomes of Women With Acute Myocardial Infarction Undergoing Primary Coronary Stenting. Am J Cardiol 2003;92:115L.

377. S.J. Kernis, K.J. Harjai, **G.W. Stone,** L.L. Grine1, J.A. Boura, W.W. O'Neill. Does Beta-Blocker Therapy Improve Clinical Outcomes of Acute Myocardial Infarction After Successful Primary Angioplasty? Am J Cardiol 2003;92:117L.

378. R. Mehran, E. Aymong, J. Moses, A. Lansky, **G. Stone,** M. Leon, I. Moussa, G. Dangas. Early Clinical Benefit with Bivalirudin Compared to Unfractionated Heparin During Percutaneous Coronary Intervention. Am J Cardiol 2003;92:134L.

379. R. Mehran, E. Aymong, **G. Stone,** J. Moses, M. Leon, G. Dangas. Very High Activated Clotting Time Values With Bivalirudin Therapy During Percutaneous Coronary Intervention Do Not Confer High Bleeding Risk. Am J Cardiol 2003;92:134L.

380. Iakovou, G. Dangas, G.S. Mintz, R. Merhan, A.J. Lansky, E.D. Aymong, E. Nikolsky, T. Vagaonescu, D.T. Ashby, **G.W. Stone,** M.B. Leon, J.W. Moses. Glycoprotein IIb/IIIa inhibitors use during percutaneous coronary interventions in very elderly patients increases the risk of hemorrhagic stroke. Am J Cardiol 2003;92:134L.

381. E. Nikolsky, R. Mehran, E. Aymong, G.S. Mintz, G. Dangas, A.J. Lansky, M. Negoita, R. Pop, J.W. Moses, **G.W. Stone,** M.B. Leon. The Impact of Anemia on Outcome After Percutaneous Coronary Intervention. Am J Cardiol 2003;92:138L.

382. E. Aymong, M. Fahy, A. Lansky, R. Mehran, C.L. Grines, D.A. Cox, C.E. Garcia, J.E. Tcheng, J.J. Griffin, G. Guagliumi, T. Stuckey, M. Turco, **G.W. Stone.** Can Stents and Glycoprotein IIb/IIIa Inhibitors Improve the Prognosis of Young Patients with Acute Myocardial Infarction? A Report from the Controlled

Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Study. Am J Cardiol 2003;92:142L.

383. E. Nikolsky, E. Aymong, A.J. Lansky, **G.W. Stone,** M. Turco, D.A. Cox, J.E. Tcheng, T. Stuckey, J.D. Carroll, J.J. Griffin, C.L. Grines. Anemia Worsens Prognosis After Primary Angioplasty in Acute Myocardial Infarction: Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (Cadillac Study). Am J Cardiol 2003;92:143L.

384. S. Kesanakurthy, R. Mehran, A. Tchelebi, **G. Stone,** Z. Lasic, Z. Qin, T. Vagaonescu, N. Coplan, S. Balter, J.W. Moses, G.D. Dangas. Superior Clinical Outcomes with Bivalirudin During Intracoronary Brachytherapy. Am J Cardiol 2003;92:172L.

385. Halkin, E. Nikolsky, E. Aymong, R. Mehran, J.E. Tcheng2, D.A. Cox, T. Stuckey, A.J. Lansky, **G.W. Stone.** The Survival Benefit of Periprocedural beta-Blockers in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty Is Determined by Use of These Drugs Before Admission. Am J Cardiol 2003;92:228L.

386. T.D. Vagaonescu, C.L. Grines, D.A. Cox, E. Garcia, J.E. Tcheng, J.J. Griffin, G. Guagliumi, T. Stuckey, M. Turco, J.D. Carroll, B.D. Rutherford, M. Fahy, C. Costantini, R. Mehran, **G.W. Stone.** Does Treatment with Abciximab Influence Survival in Patients with Acute Myocardial Infarction and Elevated Baseline White Blood Cell Count Undergoing Primary Angioplasty? The CADILLAC Trial. Am J Cardiol 2003;92:228L.

387. Masud A, Hermiller J, Brodie B, Cambier P, Haber R, Hall P, Hermann H, Popma J, **Stone G,** Ramee S, Caputo R, Cox D, Kuntz R, Feldman R. Thirty day and six month results of a multicenter randomized trial comparing distal protection with a filter-based catheter to balloon occlusion and aspiration during percutaneous intervention of saphenous vein grafts: The FIRE Trial. Circulation 2003;108:IV-640.

388. Prasad A, **Stone G,** Aymong A, et al. Impact of ST-segment resolution following primary angioplasty on outcomes after myocardial infarction in the elderly: An analysis from the CADILLAC trial. Circulation 2003;108:IV-537.

389. **Stone GW,** Ellis S, Cox DA, et al. The Pivotal U.S. Study of the Slow-Rate Release Polymer-Based Paclitaxel-Eluting TAXUS Stent in Patients with De Novo Coronary Lesions: 1-Year Clinical Results of the TAXUS-IV Trial. Circulation 2003;108:IV-533.

390. Stuckey TD, Cox DA, Brodie BR, Griffin JJ and **Stone GW.** Does stenting and glycoprotein IIb/IIIa receptor blockade improve ST segment recovery and

outcomes in patients undergoing primary angioplasty in acute myocardial infarction: The CADILLAC trial. Circulation 2003;108:IV-577.

391. Ellis S, **Stone GW,** Popma JJ, et al. The TAXUS-IV trial: Final angiographic results. Circulation 2003;108:IV-533.

392. Halkin A, Aymong E, Nikolsky E, Tcheng JE, Rutherford BD, Costantini C, Grines CL and **Stone GW.** Marked survival benefit of peri-procedural beta-blockers in patients with acute myocardial infarction undergoing primary angioplasty not previously treated with beta-blockers. Circulation 2003;108:IV-467.

393. Aymong E, Nikolsky E, Cox DA, Griffin JJ, Stuckey TD, Costantini C, Lansky AJ, and **Stone GW.** Additive prognostic value of myocardial perfusion score and ST segment resolution after primary angioplasty in AMI. Core laboratory analysis from the CADILLAC trial. Circulation 2003;108:IV-457.

394. Costantini C, Lansky AJ, Grines CL, Shirai K, Costa RA, Fahy M, Marginean H, Griffin JJ, and **Stone GW.** Impact of myocardial blush methodologies in predicting short- and long-term mortality after primary angioplasty - the CADILLAC trial. Circulation 2003;108:IV-415.

395. **Stone GW,** David A. Cox DA, Bruce R. Brodie BR, et al. Primary Angioplasty in Acute Myocardial Infarction with Distal Protection of the Microcirculation: Results from the Roll-in Phase of the EMERALD Trial. Circulation 2003;108:IV-414.

396. Hermiller JB, Ellis SG, Cannon L, Mooney M, Lui H, Midei M, Koglin J, Russell ME, Popma JJ, **Stone GW**. TAXUS IV Diabetic subset Analysis: Improvements in Nine-Month Outcomes in Diabetics on Oral Medication as Well as Insulin. JACC 2004 43:V:11A

397. **Stone GW**, Ellis, SG, O'Shaughnessy, CO, et al. Reduction in Late Loss and Restenosis in Patients with Small Vessels Treated With the Slow Rate-Release, Polymer-Based Paclitaxel-Eluting Stent: Results From TAXUS-IV. JACC 2004;43:V-87A

398. Mintz GS, Nikolsky E, Wijns W, Kobayashi Y, Erbel R, Mehran, R, Pop R, Colombo A, Serruys P, Carlier SG, Abizaid A, Vince DG, Moses JW, **Stone GW**, Leon, MB. Virtual Histology of Intravascular Ultrasound Images: feasibility and Clinical Correlations in Humans. JACC 2004;43:V-33A

399. Dae MW, Gao DW, Stillson CA, **Stone GW**, Ursell P. Hypothermia, but not N-Acetylcysteine or Fenoldopam, Prevents Experimental Contrast –Induced Nephropathy. JACC 2004;43:V-48A

400. Weisz G, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud Z, Cambier P, Caputo R, Turco M, Kovach R, Brodie B, Herrmann HC, Cod DA, Mehran R,

Stone GW. Predilation Before Distal Protection Device Placement Is Associated with Increased Procedure-Related Myocardial Infarction: Analysis from the FIRE Trial. JACC 2004;43:V 52A

401. Fujii K, Kobayashi Y, Mintz GS, Jacoboff D, Takebayashi, Yasuda T, Moussa I, Mehran R, Dangas G, Lansky AJ, Kreps E, Collins M, **Stone GW**, Leon MB, Moses JW. Creatinine-Kinase-MB Elevation After Coronary Artery Stenting In Lesions With Ruptured Plaque. JACC 2004;43:V-54A

402. Nikolsky E, Halkin A, Mehran R, Krieger SR, Ayomg EA, Lasic Z, Negoita M, Sulaiman R, Costa RA, Moses JW, **Stone GW**, Leon MB, Dangas GD. Vascular Complications Associated With Arteriotomy Closure Devices in Patients Undergoing Percutaneous Coronary Procedures: A Meta-Analysis. JACC 2004;43:V-62A

403. Takebayashi H, Kobayashi Y, Mintz GS, Fujii K, Yasuda T, Mehran R, Jacoboff D, Dangas GD, Lansky AJ, Moussa I, Collins MB, Kreps E, **Stone GW**, Leon MB, Moses JW. Intravascular Ultrasound and Drug-Eluting Stents. JACC 2004:43:V-65A

404. Weissman, NJ, Ellis S, Turco M, Greenberg J, Mann JT, Kutcher M, Wong, SC, O'Shaughnessy C, Russell M, **Stone GW**. TAXUS IV: Results From the Intravascular Ultrasound Substudy. JACC 2004:43:V-66A.

405. Fujii K, Kobayyashi Y, Mintz GS, Takebayashi H, Yasuda T, Jacoboff D, Moussa I, Mehran R, Dangas G, Lansky AJ, Kreps E, Collins M, Stone GW, Leon MB, Moses JW. Contribution of Stent Underexpansion to Target Lesion Revascularization After Sirolimus-Eluting Stenting for In-Stent Restenosis. JACC 2004:43:V-66A

406. Jonas M, **Stone GW**, Hermiller J et al. Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment During Saphenous Vein Graft Stenting: Differential Effects After Randomization to Occlusion or Filter-Based Embolic Protection. JACC 2004:43:V-71A

407. Swaminathan A, Herrmann, HC, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A, Cambier P, Caputo RP, Cox DA, Pop R, Fahy M, Mehran R, **Stone GW**. Impact of Vessel Size on Outcomes of Different Distal Protection Devices During Saphenous Vein Graft Intervention: A FIRE Trial Substudy. JACC 2004:42:V-72A.

408. Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Negoita M, Cristea E, Marginean H, Corral M, Tarawali M, Babb J, Cox DA, **Stone GW**. The Impact of Myocardial Blush Grade on Clinical Outcomes of patients Treated With Saphenous Vein Grafts and Thrombotic Native Coronary Arteries: Analysis from the X-TRACT Trial. JACC 2004:42:V-72A

409. Weisz G, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud Z, Cambier P, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Cox DA, Mehran R, **Stone GW**. Relationship Between Embolic Material Retrieval and Adverse Events With Different Distal Protection Devices During Saphenous Vein Graft Stenting. JACC 2004:42:V-72A

410. **Stone GW**, Ellis SG, O'Shaughnessy C et al. Reduction in Late Loss and Restenosis in Patients With Small Vessels Treated With the Slow Rate-Release, Polymer-Based Paclitaxel-Eluting Stent: Results From TAXUS-IV. JACC 2004:42:V-87A.

411. Lasic Z, Mehran R, Nikolsky E, Negoita M, Costa R, Cox DA, Babb J, Nukta D, Bilodeau L, Cannon L, Stuckey TD, Hermiller J, Lansky AJ, Leon MB, **Stone GW**. Implications and Prevention of Large Periprocedural Myocardial Infarction After Percutaneous Intervention of Diseased Saphenous Vein Grafts and Thrombotic Native Coronary Lesions. JACC 2004:42:V-88A

412. Nikolsky E, Mehran R, Lansky AJ, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Rutherford B, **Stone GW**. Impact of Body Mass Index on Outcomes After Primary Angioplasty in Acute Myocardial Infarction: The Obesity Paradox. JACC 2004:42:V-244A.

413. Costa RA, Lansky AJ, Costantini CO, Tsuchiya Y, Caluser C, Sahid B, Fahy M, Nikolsky E, Aymong E, Negoita M, Mehran R, Cox DA, Grines CL, **Stone GW**. Predictors of Survival after Primary Percutaneous Coronary Intervention: The Impact of Myocardial Perfusion Grade in Female Patients. JACC 2004:42:V-266A.

414. Pellizzon GG, Marso SP, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Lansky AJ, Mehran R, Rutherford BD, **Stone GW**. Predictors of Reinfarction after ST Elevation Myocardial Infarction and Glycoprotein Receptor Blockade: Analysis From the CADILLAC Trial. JACC 2004:42:V-266A.

415. Nikolsky E, Halkin A, Aymong EA, Mehran R, Lansky A, Grines CL, Turco M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Cohen DA, Rutherford BD, **Stone GW**. Anemia Worsens Prognosis After Primary Angioplasty in Acute Myocardial Infarction: Analysis from the CADILLAC Trial. JACC 2004:42:V-267A.

416. **Stone GW**, Webb J, Cox DA et al.. Primary Angioplasty in Acute Myocardial Infarction With Distal Protection of the Microcirculation: Principal Results From the Prospective, Randomized EMERALD Trial. JACC 2004:42:V-285A.

417. Brodie BR, Costantini C, Aymong E, Stuckey TD, Cox DA, Zimetbaum P, McLaughlin M, Garcia E, Turco MA, Mehran R, Grines CL Lansky AJ, **Stone GW**. Relationship Between Time to Reperfusion, ST-Segment Resolution, Myocardial Blush Scores and Mortality With Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Results from the CADILLAC Trial. JACC 2004:42:V-303A.

418. Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Brodie B, Turco M, Rutherford BD, Aymong EA, Lansky AJ, **Stone GW**. Impact of Intravenous Beta-Blockade During Primary Percutaneous Intervention on Convalescent Left Ventricular Function. JACC 2004:42:V-303A.

419. Turco MA, **Stone GW**, Hall PX et al. The First Use of Medical Simulation for the Training of a New Device Roll-Out. JACC 2004:42:V-423A

420. Ellis S, Popma JJ, Weissman N, Turco M, Caputo R, Bergin P, Greenberg J, Raizner A, Koglin J, Russell ME, **Stone GW**. Impact of Late Loss on Clinical, Angiographic and Intravascular Ultrasound Outcomes in the TAXUS IV Trial. JACC 2004:42:V-12A.

421. Nikolsky E, Mehran R, Lasic Z, Weisz G, Negoita M, Na Y, Krieger CI, Dunne-Tramis A.M., Sikand R, Gilutz Y, Kesanakurthy S, Mogg M, Raj N, **Stone GW,** Moses JW, Leon MB, Dangas, GD. Anemia is a Novel Risk Factor for Contrast-Induced Nephropathy after Percutaneous Coronary Intervention. Am J Cardiol. 2004;94(suppl 6A): 23E

422. Mehran R, Kesanakurthy S, Dangas GD, Lasic Z, Iyer S, Yadegar D, Moussa I, Nikolsky E, Kreps E, Collins M, Weisz G, Sulaiman R, Scott T, Moses JW, **Stone GW,** Leon MB. The Risk of Stent Thrombosis after Drug-Eluting Stenting in an Unselected Population. Am J Cardiol. 2004;94(suppl 6A):26E

423. Turco MD, Virmani R, **Stone GW,** Webb J, Cox DA, Brodie BR, Rutherford B, Krucoff M, Gibbons R, Jones D, Weber DK, Mehran R. Is Debris Retrieval from the Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty of Prognostic Importance? Results from the Roll-In Phase of the EMERALD Trial. Am J Cardiol. 2004;94(suppl 6A):35E

424. Clark MA, Bakhai A, Lavelle T, Berezin R, Shi C, Justason B, **Stone GW,** Ellis S, Cohen D. Cost-Effectiveness of the TAXUS™ Paclitaxel-Eluting Coronary Stent System vs. Bare Stent Implantation in the Diabetic Population: The TAXUS IV Trial. Am J Cardiol. 2004;(suppl 6A):72E.

425. Nikolsky E, Kosinski E, Mishkel GJ, Kimmelstiel C, McGarry, Jr. TF, Mehran, R, Leon MB, Russell ME, Ellis SG, Negoita M, Pop R, Fahy M, **Stone GW**. Impact of Obesity on Revascularization and Restenosis Rates after Bare-Metal and

Drug-Eluting Stent Implantation: Analysis from the TAXUS IV Trial. Am J Cardiol. 2004;94(suppl 6A):73E

426. Weisz G, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud Z, Cox DA, Cambier P, Caputo R, Turco M, Mehran R, Popma J, **Stone GW**. Thrombus Score in Saphenous Vein Grafts Predicts Adverse Events After Stenting with Distal Embolic Protection.. Am J Cardiol. 2004;94(suppl. 6A): 104E

427. Moussa I, Leon MB, Lansky A, Lasic Z, Trubelja N, Yang YM, Katherine V, Ibraheem M, Mehran R, Cristea E, Coral M, Weisz G, Nikolsky E, Coplan N, Iyer S, Kreps E, Collins M, **Stone GW,** Dangas G, Moses JW. Treatment of Coronary Bifurcation Lesions with Sirolimus-Eluting Stents using the "Crush Technique." Am J Cardiol. 2004;94(suppl 6A):109E.

428. Fujii K, Carlier SG, Mintz GS, Wijns W, Colombo A, Costa, Jr. JDR, Takebayashi H, Yasuda T, Costa RA, **Stone GW,** Moses JW, Leon MB. A Comparison of Morphologic Features Between Patients With and Without Diabetes: A Virtual Histology Study. Am J Cardiol. 2004;94(suppl 6A):115E.

429. Yasuda T, Carlier S, Mintz GS, Fujii K, Takebayashi H, Costa, Jr. JDR, Costa R, Sano K, Kimura M, **Stone GW,** Leon MB, Moses JW. Intravascular Ultrasound Assessment of Ulcerated Ruptured Plaques in Saphenous Vein Grafts. Am J Cardiol. 2004;94(suppl 6A):116E.

430. Weisz G, Moussa I, Kesanakurthy S, Halkin A, Yadegar D, Mehran R, Dangas G, Collins M, Kreps E, **Stone GW,** Moses JW. Early Experience with Sirolomus-Eluting Stents for Unprotected Left Main Coronary Artery. Am J Cardiol. 2004;94(suppl 6A):132E.

431. Halkin A, Mehran R, Casey CW, Gordon P, Matthews R, Wilson BH, Leon MB, Russell ME, Ellis SG, **Stone GW**. Impact of Renal Insufficiency on Restenosis & Adverse Clincal Events after Paclitaxel Eluting and Bare metal Stent Implantation: Results from the TAXUS IV Trial. Am J Cardiol. 2004;94(suppl 6A).

432. Costa RA, Lansky AJ, Tsuchiya Y, Mehran R, Cristea E, Pop R, Sahid B, Chen Y, Brodie BR, Cox DA, Dulas D, Kalynych A, Qureshi M, Rutherford B, Schultheiss HP, Turco M, Webb J, Krucoff M, Gibbons R, **Stone GW.** Impact of Staged Nontarget Vessel Revascularization on Clinical Outcomes After Primary Stenting for Acute Myocardial Infarction: Results from the EMERALD Trial. Am J Cardiol. 2004;(suppl 6A):172E.

433. Costa RA, Mintz GS, Carlier S, Moussa I, Fujii K, Takebayashi H, Takenori Y, Costa Jr, JDR, Tsuchiya Y, Lasic Z, Halkin A, Lansky AJ, Dangas G, Mehran R, Collins M, Kreps E, **Stone GW,** Colombo A, Leon MB, Moses JW. Coronary Bifurcation Lesions Treated with the Crush Technique: An Intravascular Analysis. Am J Cardiol. 2004;(suppl 6A):182E.

434. Nikolsky E, Grines CL, Cox, DA, Garcia E, Mehran R, Tcheng JE,. Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Negoita M, Halkin A, Weisz G, Na Y, Slack S, Lansky AJ, **Stone GW.** Implications of Stroke after Primary Angioplasty in Acute Myocardial Infarction. Am J Cardiol. 2004;94(suppl 6A):200E.

435. Costa RA, Lansky AJ, Tsuchiya Y, Cristea E, Tarawalli M. Sanchez R, Chen Y, Mooney M, Midei MG, Lui H, Strickland W, **Stone GW.** Impact of Female Sex on Outcomes After Paclitaxel-Eluting Stent Implantation in Patients with de Novo Coronary Lesions: Results of the TAXUS IV Trial. Am J Cardiol. 2004;94(suppl 6A):204E

436. Lasic Z, Mehran R, Moussa I, Nikolsky E, Addo T, Kipshidze N, Collins M, Kreps E, Qin J, Plent S, Tsounias E, Sikand R, Trubelja N, Mohammad A, Katsishevsky L, Moses JW, Leon MB, **Stone GW**, Dangas G. Sirolimus-Eluting Stents Plus Bivalirudin and Outcome of Percutaneous Coronary Intervention in Saphenous Vein Grafts: Results of the ADEST Study. Am J Cardiol. 2004;94)suppl 6A):209E.

437. Lasic Z, Mehran R, Nikolsky E, Gilutz Y, Addo T, Mogg M, Negoita M, Dunne-Tramis AM, Sikand R, Plent S, Collins M, Kreps E, Moussa I, Trubelja N. Tsounias E, Kipshidze N, Moses JW, Leon MB, **Stone GW,** Dangas G. Bivalirudin- and Sirolimus-Eluting Stents in Multilesion Percutaneous Coronary Intervention: Results of the ADEST Study. Am J Cardiol. 2004;94(suppl 6A):210E.

438. Mehran R, Kesanakurthy S, Dangas G, Iyer S, Spatareanu C, Elliott N, Bajraktari F, Lander J, Nikitina A, Mousssa I, Kreps E, Collins M, Moses JW, **Stone GW,** Leon MB. Drug-Eluting Stents and Patterns of In-Stent Restenosis. Am J Cardiol 2004;94(suppl 6A):211E.

439. Caputo R, CoxDA, Popma JJ, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Ellis SG, **Stone GW**. Paclitaxel-Eluting Stents Reduce Need for Subsequent Coronary Artery Bypass Graft Surgery by Changing the Incidence and Pattern of Restenosis. Am J Cardiol. 2004;94(suppl 6A)211E

440. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, **Stone GW.** What is the Threshold for "Acceptable" Late Loss in the Drug-Eluting Stent Era? Insights from the TAXUS IV Angiographic Substudy. Am J Cardiol. 2004;94(suppl 6A):212E.

441. Kutcher MA, Applegate RJ, Hermiller J, Cox DA, O'Shaughnessy C, Feldman R, Moak AS, Smalling R, Mehran R, Russell ME, Ellis SG, **Stone GW.** Optimal

Stent Implantation Pressure in the Drug-Eluting Stent Era: Observations from the TAXUS IV Study. Am J Cardiol. 2004:94(suppl 6A):213E.

442. Lasic Z, Mehran R, Negoita M, Gilutz Y, Mogg M, Roopan S, Plent S, Nikolsky E, Addo T, Krieger C, Pop R, Na Y, Arif M, Kotsishevsky L, Tsounias E, Moussa I, Kreps E, Moses JW, Leon MB, **Stone GW,** Dangas G. Outcome of Percutaneous Coronary Intervention in Diabetic Patients Treated with Bivalirudin- and Sirolimus-Eluting Stents: Results of the ADEST Study. Am J Cardiol. 2004;94(suppl 6A):218E.

443. Sheldon WS, O'Shaughnessy CD, Popma JJ, Ellis SE, **Stone GW,** Williams DO, Davidson CJ, Brown CL, Russell, ME. Clinical and Angiographic Reduction in Restenosis in Longer Drug-Eluting Stents Compared with Bare-Metal Stents from the TAXUS IV Trial. Am J Cardiol. 2004;94(suppl 6A):220E.

444. Kandzari DE, Cox DA, Stuckey T, Turco M, Mehran R, Gersh BJ, Garcia E, Zimmetbaum P, McLaughlin M, Lansky AJ, Costantini CO, Grines CL, Tcheng JE, **Stone GW.** Reperfusion Success and Prognosis in patients with Anterior Compared with Nonanterior Infarction: Insights from the CADILLAC Trial. Am J Cardiol. 2004;94(suppl 6A): 230E.

445. Sorajja P, Gersh BJ, Cox DA, Turco MA, Tcheng JE, Carroll JD, Brodie B, Garcia E, Guagliumi G, Grines CL, **Stone GW.** Adverse Impact of Multivessel Disease on ST-Segment Recovery and Clinical Outcome in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. Am J Cardiol. 2004;94(suppl 6A):233E.

446. Halkin A, Turco M, Cox, DA, Stuckey TD, Garcia E, Guagliumi G, Mehran R, Rutherford BD, Griffin JJ, Tcheng JE, Grines CL, **Stone GW**. Outcomes of Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Excluded from Randomization: The CADILLAC Trial. Am J Cardiol. 2004;(suppl 6A):234E.

447. Costa RA, Lansky AJ, Tsuchiya Y, Mehran R, Cristea E, Tarawalli M, Corral M, Pop R, Cox DA, Kalynych A, Turco M, Schultheiss HP, Krucoff M, Gibbons R, Brodie BR, Webb J, Qureshi M, Dulas D, Rutherford B, **Stone GW.** Correlation Between Myocardial Blush Grades with ST-Segment Resolution, Infarct Size, and Clinical Outcomes After primary Coronary Intervention: Results from the EMERALD Trial. Am J Cardiol. 2004;94(suppl 6A):235E

448. Sorajja P, Lansky AJ, Grines CL, Costantini C, McLaughlin MG, Tcheng JE, Gersh BJ, **Stone GW.** Prediction of Survival After Primary Percutaneous Coronary Intervention by Integration of ST-Segment Recovery and Myocardial Blush. Am J Cardiol. 2004;94(suppl 6A):237E

449. Costa RA, Lansky AJ, Tsuchiya Y, Mehran R, Cristea E, Pop R, Sanchez R, Caluser C, Brodie BR, Cox DA, Dulas D, Kalynych A, Qureshi M, Rutherford B, Schultheiss HP, Turco M, Webb J, Krucoff M, Gibbons R, **Stone GW.** Impact of Female Sex on Reperfusion Success and Clinical Outcomes in Patients with Acute Myocardial Infarction Undergoing Primary Coronary Stenting: Results from the EMERALD Trial. Am J Cardiol 2004;94(suppl6A):237E.

450. Takebayashi H, Mintz GS, Carlier SG, Kobayashi Y, Fujii K, Yasuda T, Costa RA, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps E, Colilns M, Colombo A, **Stone GW,** Leon MB, Moses JW. Nonuniform Strut Distribution Correlates with More Neointimal Hyperplasia after Sirolimus-Eluting Stent Implantation. Circulation, Nov. 2004; 110: 3430-3434.

451. **Stone GW**, Goldberg S, Mehran R, O'Shaughnessy C, Midei M, Siegel R, George B, Satler L, Raizner A, Negoita M, Fahy M, Arjomand-Fard H, Lansky AJ. A prospective, Randomized U.S. Trial of the PTFE Covered JOSTENT for the treatment of Diseased Saphenous Vein Grafts: The BARRICADE Trial. JACC, February 2005;45:27A

452. Dangas G, Mehran R, Lasic Z, Cox D, Ghali MGH, Henry TD, Teirstein PS, Stella JF, Browne, Jr. KF, Lewis SA, Knopf W, Kreps E, Leon MB, Collins M, Moses JS, **Stone GW.** Clinical Evaluatin of the Concomitant Use of Bivalirudin and Drug-eluting Stents: Results of the Prospective, Multicenter ADEST Study. JACC, February 2005;45:32A

453. **Stone GW**, Lincoff AM, Weisz G, Ebrahimi R, Keren G, Carr J, Feit F, Mehran R, Moses JW, Leon MB, Schwartz A. Predictors and Clinical Impact of the Procedural ACT Level in Patients Receiving Bivalirudin during PCI; A REPLACE II Sub Study. JACC, February 2005;45:32A

454. Fujii K, Carlier SG, Mintz GS, Yang Y, Moussa I, Costa RA, Costa, Jr. JR, Kimura M, Sano K, Dangas G, Mehran R, Lansky AJ, **Stone GW**, Moses JW, Leon MB. Intravascular Ultrasound Assessment of Stent Thrombosis After Successful Implantation of Sirolimus-eluting Stents. JACC, February 2005;45:34A.

455. Addo T, Lincoff AM, Mehran R, Dangas G, Kleiman NS, Jackman DS, Feit F, **Stone GW**. Impact of Vascular Closure Devices on Hemorrhagic Complications After Angioplasty with Bivalirudin Compared to Heparin Plus IIb/IIIa Inhibitors: Analysis from REPLACE-2. JACC, February 2005;45:36A.

456. Prasad A, **Stone GW**, Stuckey T, Constantini C, Zimelbaum P, McLaughlin M, Mehran R, Garcia E, Tcheng J, Cox D, Grines C, Lansky A, Gersh B. Impact of Diabetes Mellitus on Myocardial Perfusion Following Primary Angioplasty in Patients with Acute Myocardial Infarction. JACC, February 2005;45:39A

457. Ellis S, **Stone GW**, Cox DA, Hermiller J, O'Shaughnessy CD, Mann JT, Turco M, Caputo R, Bergin PJ, Greenberg J, Raizner A, Popma JJ, Russell ME. Durability of the Polymer-Based, Paclitaxel-eluting TAXUS Stent in Key Patient Subsets: Two-Year Results from the TAXUS-IV Trial. JACC, February 2005;45:49A

458. Nikolsky E, Grines CL, Cox DA, Stuckey T, Garcia E, Guagliumi G, Tcheng JE, Mehran R, Negoita M, Sikand R, Lansky AJ, **Stone GW**. Stroke After Primary Angioplasty in Acute Myocardial Infarction: Analysis From the CADILLAC Trial. JACC, February 2005;45:52A.

459. Costa RA, Mintz GS, Carlier SG, Fujii K, Takebayashi H, Yasuda T, Costa, Jr. J, Kimura M, Sani K, Tsuchiya Y, Lansky AJ, Mehran R, Dangas GD, Collins M, Kreps EM, Moussa I, Colombo A, **Stone GW**, Moses JW, Leon MB. Coronary Bifurcation Lesions Treated with the Crush Technique – An Intravascular Ultrasound (IVUS) Analysis. JACC, February 2005;45:56A.

460. Fujii K, Carlier SG, Mintz GS, Wijns W, Colombo A, Costa RA, Costa, Jr. JR, Takebayashi H, Yasuda T, Kimura M, Sano K, Moussa I, Dangas G, Mehran R, **Stone GW**, Moses JW, Leon MB. Association of Arterial Remodeling and Plaque Characterization by Intravascular Ultrasound Virtual Histology™ Analysis. JACC, February 2005;45:59A.

461. Carlier S, Costa, Jr. JR, Mintz G, Fujii K, Sano K, Kimura M, Costa R, Kreps E, Moses JW, **Stone GW**, Martin MB. Tissue Characterization of Human Coronary Plaques by Spectral Analysis of Backscattered Intravascular Ultrasound Signal: Initial Experience in 400 Arteries. JACC, February 2005;45:60A

462. Nikolsky E, Lincoff MA, Mehran R, Sarembock IJ, Cohen DJ, Spriggs D, **Stone GW.** Contemporary Outcomes of Coronary Artery Perforation During Percutaneous Coronary Intervention: Insights from the REPLACE-2 Trial. JACC, February 2005;45:61A

463. Sheldon WS, O'Shaughnessy CD, Cox DA, Hermiller J, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Weissman N, Russell ME, Ellis SG, **Stone GW**. Angiographic and Clinical Reduction in Restenosis with Polymer-based Paclitaxel-eluting Stents as a Function of Lesion Length: Analysis from the TAXUS IV Study. JACC, February 2005;45:64A

464. Nikolsky E, Kosinski E, Mishkel J, McGarry TF, Kimmelstiel C, Na Y, Negoita M, Mehran R, **Stone GW**. Impact of Body Mass Index on Restenosis after Bare-Metal and Drug-eluting Stent Implantation: Analysis from the TAXUS-IV Study. JACC, February 2005;45:65A.

465. Moussa I, Ellis SG, Moses JW, Jones M, Kereiakes DJ, McMartin D, Rutherford B, Mehran R, Collins M, Leon MB, Popma JJ, Russell ME, **Stone GW**. The

Impact of Culprit Lesion Calcification in Patients Undergoing Paclitaxel-Eluting Stent Implantation: A TAXUS-IV Sub Study. JACC, February 2005;45:65A

466. Costa RA, Mintz GS, Carlier SG, Fujii K, Takebayashi H, Yasuda T, Costa, Jr. J, Kimura M, Sano K, Tsuchiya Y, Lansky AJ, Mehran R, Dangas GD, Collins M, Kreps EM, Moussa I, Colombo A, Stone GW, Moses JW, Leon MB. Impact of Final Stent Dimensions on Restenosis After Crush Drug-Eluting Stent Implantation for Bifurcation Lesions. JACC, February 2005;45:66A

467. Rodriguez AE, Rodriguez-Alemparte M, Fernandez-Pereira C, Pocovi A, Tronge J, Kaluza G, Raizner A, **Stone GW**. Efficacy and Tolerability of Oral Rapamycin to Prevent Restenosis After Coronary Stent Implantation: The Prospective, Randomized ORAR II Study. JACC, February 2005;45:70A.

468. Escolar E, Mintz GS, Koglin J, Lam P, Popma JJ, Russell M, Ellis S, **Stone GW**, Grube E, Dawkins K, Weissman NJ. Neointima Thickness: A Direct Intravascular Ultrasound Measure of Late Lumen Loss from the TAXUS IV and VI IVUS Substudy. JACC, February 2005;45:71A.

469. Costa, Jr. JR, Carlier S, Mintz GS, Costa R, Fujii K, Sano K, Takebayashi H, Yasuda T, Kimura M, Moses JW, **Stone GW**, Leon MB. A Critical Appraisal of Stent Diameters Derived from Manufacturer's Compliance Charts: An Intravascular Ultrasound Study. JACC, February 2005;45:72A.

470. Mehran R, Dangas GD, Kesanakurthy S, Siegal RM, Abizaid A, Abizaid A, Moussa I, Mintz GS, Lansky AJ, Collins MB, Kreps E, Nikolsky E, Schwartz A, **Stone GW**, Moses JW, Leon MB. The Changing Incidence and Patterns of In-Stent Restenosis: Impact of Drug-eluting Stents. JACC, February 2005;45:75A.

471. Dangas GD, Mehran R, Webb J, Cox DA, Brodie BR, Qureshi M, Dulas D, Kalynych A, Turco M, Schultheiss HP, Rutherford B, Krucoff M, Gibbons R, Lansky AJ, Spatareanu C, Popp R, Jones D, Schwartz A, Stone GW. JACC, February 2005;45:80A.

472. Weisz G, Lincoff M, Moussa I, Ebrahimi R, Keren G, Carr J, Feit F, Mehran R, Moses JW, Leon MB, **Stone GW**. Relationship Between Activated Clotting Times and Procedural Outcomes in Patients Undergoing Coronary Intervention with Unfractionated Heparin and Glycoprotein IIb/IIIa Inhibitors. JACC, February 2005;45:82A

473. **Stone GW**, Brodie BR, Caputo R, Feldman R, Rogers C, Cox DA, Roberts DK, Masud AZ, Hermiller J, Cambier P, Kovach R, Negoita M, Schwartz A, Pop R, Fahy M, Sikand R, Mehran R. Thirty Day and Six Month Outcomes after Saphenous Vein Graft Stenting with distal protection in patients Excluded from Randomized Trials; The FilterWire EX High Risk Registry. JACC, February 2005;45:83A.

474. **Stone GW**, Ellis SG, O'Shaughnessy CD, Satler L, Martin S, McGarry T, Turco M, Kereiakes DJ, Jacobs WC, Russell ME. A Prospective, Multicenter Randomized Trial of the Paclitaxel-Eluting Stent Versus Vascular Brachytherapy in Patients with Coronary In-Stent Restenosis: the TAXUS-V ISR Trial. JACC, February 2005;45:83A.

475. Tuschiya Y, Lansky AJ, Costa RA, Pietras C, Mehran R, Cristea E, Sanchez R, Sahid B, Negoita M, Gilutz Y, Fay M, Dangas G, Carlier S, Moussa I, **Stone GW**, Moses JW, Leon MB, Muller R, Rink M, Storger H, Hauptmann KE, Grube E. The Effect of Everolimus-eluting Stents in Different Vessel Sizes – Results from the FUTURE 1 & 2 Trials. JACC, February 2005;45:85A.

476. Weisz, G, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud Z, Cox D, Cambier P, Cauto R, Turco M, Mehran R, Popma J, Stone GW. Severity of Thrombus Score Predicts Adverse Events after Stenting in Saphenous Vein Grafts with Distal Embolic Protection: the FIRE Trial. JACC, February 2005;45:85A

477. Mintz GS, Koglin J, Lam P, Popma JJ, Russell ME, Grube E, Dawkins K, Ellis S. **Stone GW**, Weissman N. Paclitaxel Increases the Length of Stent that is Free of Intimal Hyperplasia: An Intravascular Ultrasound Analysis from TAXUS-IV and TAXUS VI. JACC, February 2005;45:88A.

478. **Stone GW**, Webb J, Cox DA, Brodie BR, Qureshi M, Dulas D, Kalynych A, Turco M, Schultheiss H, Rutherford B, Kruckoff MW, Gibbons R, Lansky AJ, Schwartz A, Pop R, Jones D, Mehran R. Effectiveness of Distal Embolic Protection During Primary Angioplasty: Final 6-Month Results from the Prospective, Randomized, EMERALD Trial. JACC, February 2005;45:200A.

479. **Stone GW**, O'Neill WW, Dixon S, Cox DA, Webb JG, Brodie B, Griffith JJ, Martin J, Gibbons R, Fahy M, Mehran R, Grines C. Predictors of Infarct Size by Technetium-99m Sestamibi Imaging after Angioplasty in Acute Myocardial Infarction: Meta-Analysis from Four contemporary Randomized Trials. JACC, February 2005;45:208A.

480. Krucoff M, Johanson P, Baeza R, Brodie BR, Webb J, Cox DA, Qureshi M, Dulas D, Kalynych A. Turco M, Schultheiss HP, Rutherford B, Lansky AJ, Negoita M, Na Y, Mehran R, **Stone GW**. Continuous 12-Lead ST-Segment Recovery Predicts Ejection Fraction, Clinical Outcome and Death after PCI for Acute ST-Elevation MI: Results from the EMERALD study. JACC, February 2005;45208A.

481. Mehta RJ, O'Neill W, Harjai KJ, Boura J, Fox D, Brodie B, **Stone GW**, Grines CL. Primary Percutaneous Coronary Interventions: Predictors of One-Year Mortality Among Patients Surviving 30 Days. JACC, February 2005;45:211A.

482. O'Neill W, Grines CL, Dixon SR, Griffin JJ, Martin JL, Cox DA, Webb JG, Brodie BR, Mehran R, Gibbons RJ, Held J, **Stone GW**. Does a 90-Minute Door-to Balloon time Matter? Observations from Four Current Reperfusion Trials. JACC, February 2005;45:225A.

483. O'Neill W, Dixon SR, **Stone GW**, Griffin JJ, Cox DA, Webb JG, Mehran R, Brodie BR, Martin JL, Gibbons RJ, Held J, Grines CL. Excellent Clinical Outcomes in High Risk Non-shock Acute Myocardial Infarction Patients Treated in the Contemporary Mechanical Reperfusion Era: A Pooled Analysis of 4 Clinical Trials. JACC, February 2005;45:232A.

484. Bartholomew BA, Grines CL, **Stone GW**, Nikolsky E, Boura JA, Cox DA, Brodie BR, O'Neill WW. Blood Loss after Primary Percutaneous Intervention is Associated with Death and Major Adverse Cardiac Events in Acute Myocardial Infarction. JACC, February 2005;45:233A.

485. De Luca G, Suryapranata, **Stone GW**, Antoniucci D, Tcheng JE, Neumann F-J, Van der Werf F, Antman EM, Topol EJ. Adjunctive Abciximab to Reperfusion Therapy in Patients with Acute St-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Trials. JACC, February 2005;45:251A

486. Nikolsky E, Singh M, Grines CL, Tcheng JE, Garcia E, Cox DA, Turco M, Stuckey TD, Na Y, Lansky AJ, Gersh BJ, O'Neill WW, Mehran R, **Stone GW**. Prediction of Mortality Following Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: The CADILLAC Risk Score. JACC, February 2005;45:347A.

487. Cox D, Lui H, Caputo R, Bonnier H, Kovach R, Masud AZ, Brodie B, Stuckey T, Herrmann H, Hermiller J, Lansky AJ, Tully G, **Stone GW**. Lower MACE Can be Achieved in SVG PCI: Stenting in Saphenous Vein Grafts with Distal Protection Using a Second Generation Filter-Based Catheter--The Combined BLAZE I and BLAZE II Registries. AM J CARDIOL 2005;96:9.

488. Moussa I, Mehran R, Lansky AJ, Krucoff M, Gibbons R, Qureshi M, Kalynych A, Turco M, Schultheiss HP, **Stone GW.** Does Vessel Size Have an Impact on The Efficacy of Distal Protection in Patients Undergoing Primary Angioplasty? An EMERALD Trial Analysis. AM J CARDIOL 2005;96:56.

489. Lansky AJ, Costa RA, Mehran R, Mori K, Cristea E, Na Y, Sanchez R, Cassidy L, Brodie B, Cox DA, Dulas D, Kalynych A, Qureshi M, Rutherford B, Schultheiss HP, Turco M, Webb J, Gibbons R, Krucoff M, **Stone GW**. Association of Myocardial Blush Grade (MBG) and ST-Segment Resolution (STR) Predicts Late Major Ischemic Events after Mechanical Reperfusion in Acute Myocardial Infarction (AMI) - Results from the EMERALD Trial. AM J CARDIOL 2005;96:58.

490. Nikolsky E, Mehran R, Grines CL, Turco M, Cox DA, Tcheng JE, Brodie BR, Guagliumi G, Griffin JJ, Lansky AJ, Negoita M, Mercado DJ, Addo T, **Stone GW.** Impact of Baseline Platelet Count on Outcomes of Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Analysis from the CADILLAC trial. AM J CARDIOL 2005;96:61.

491. Lee E, Dangas G, Mehran R, Nikolsky E, Lansky AK, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antoniucci D, Krucoff M, Gibbons R, Jones D, **Stone GW**. Microvascular Function and Myocardial Perfusion after Acute MI Angioplasty in Anterior Versus Non-Anterior Infarcts: Results from the EMERALD Trial. AM J CARDIOL 2005;96:111.

492. Nikolsky E, Mehran R, Grines CL, Turco M, Cox DA, Stuckey T, Guagliumi G, Griffin JJ, Lansky AJ, Na Y, Turcanu G, Sulaiman R, Kodali S, Spatareanu C**, Stone GW.** Blood Transfusion in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Analysis from the CADILLAC trial. AM J CARDIOL 2005;96:123.

493. Dangas G, Mehran R, Moses JW, Collins MB, Nikolsky E, Lansky AJ, Weisz G, Puruhit A, Leon MB, Brodie BB, Krucoff M, Grines C, Dixon SR, **Stone GW.** Epicardial Vessel Patency, Myocardial Perfusion and Infarct Size after Percutaneous Revascularization in Acute Anterior Versus Non-Anterior Infarcts: Pooled Analysis from 4 Randomized Trials. AM J CARDIOL 2005;96:128.

494. Brodie BR, Webb J, Cox DA, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford B, Antoniucci D, Stuckey T, Krucoff M, Gibbons R, Lansky AJ, Na Y, Mehran R, **Stone GW.** Impact of Time to Treatment with Primary PCI on Infarct Size and Myocardial Reperfusion: Results from the EMERALD Trial. AM J CARDIOL 2005;96:141.

495. Addo TA, Kodali S, Weinberger J, Mehran R, Fahy M, Pop R, Dixon S, O'Neill W, Grines C, Gibbons R, Leon MB, **Stone GW.** Multi-Vessel Disease Does not affect Infarct Size but affects Clinical Outcomes following Primary Angioplasty for Acute Myocardial Infarction. AM J CARDIOL 2005;96:142.

496. Sorajja P, **Stone GW,** Miller TD, Dangas G, Dixon S, Gersh BJ, O'Neill W, Mehran R, Gibbons R. Rescue Percutaneous Coronary Angioplasty is an Independent Predictor of Infarct Size in Patients with Acute Myocardial Infarction. AM J CARDIOL 2005;96:144.

497. Costa RA, Carlier SG, Mintz GS, Fujii K, Costa J, Kimura M, Sano K, Tanaka K, Cristea E, Na Y, Lansky AJ, Dangas GD, Mehran R, Collins M, Kreps EM, **Stone GW,** Moses JW, Leon MB. Incidence and Implications of Incomplete "Crush" Stent Apposition after Sirolimus-Eluting Treatment of Coronary Bifurcation Lesions - An Intravascular Ultrasound (IVUS) Analysis. AM J CARDIOL 96:179

498. Mori K, Lansky AJ, Costa RA, Mintz GS, Nikolsky E, Mehran R, Dangas G, Fahy M, Bittl, JA, Harrington R, Kleiman NS, Feit F, Lincoff AM, **Stone GW**. Do Women Undergoing Elective Percutaneous Intervention (PCI) Have Similar Late Outcomes Compared to Men at All Age Groups? A REPLACE-2 Sub-study. AM J CARDIOL 2005;96:277.

499. Nikolsky E, **Stone GW,** Mehran R, Mori K, Weinberger J, Dangas G, Bittl JA, Harrington RA, Kleiman NS, Feit F, Na Y, Addo T, Negoita M, Cohen Y, Lincoff AM. Impact of Age and Choice of Procedural Anti-thrombotic Regimen on Ischemic and Hemorrhagic Outcomes following Percutaneous Coronary Intervention: Analysis from the REPLACE-2 Trial. AM J CARDIOL 2005;96:312.

500. Weissman N, Ellis SG, Mintz GS, Cannon LA, McGarry T, Greenberg J, Mann T, Kutcher MA, Koglin J, Russell ME, **Stone GW.** Intravascular Ultrasound Results from the TAXUS V Study: The TAXUS Stent Reduces Neointimal Proliferation in Long Lesions and Overlapping Stents. AM J CARDIOL 2005;96:317.

501. Carlier S, Weissman NJ, Mintz G, Koglin J, Turco M, Greenberg J, Mann JT, Kutcher M, Caputo R, Mehran R, Russell ME, Ellis SG, **Stone GW**. Paclitaxel-Eluting Stents Reduce Neointimal Hyperplasia in Both Diabetic and Non-Diabetic Coronary Arteries: A Volumetric Intravascular Ultrasound TAXUS-IV Study. AM J CARDIOL 2005;96:345.

502. Nikolsky E, Lincoff MA, Mehran R, Bittl, JA, Harrington RA, Gurm H, Micsa L, Kesanakurthy V, Na Y, Addo T, Kodali S, Mercado DJ, Turcanu G, **Stone GW.** Lower Body Mass Index is a Risk Factor for Hemorrhagic Complications Following Percutaneous Coronary Interventions: Analysis from the REPLACE-2 Trial. AM J CARDIOL 2005;96:387.

503. Weisz, G, Gray W, Hathaway L, Knipper P, Bertling C, Gong M, Na Y, **Stone GW,** Leon MB. Interventional Vascular Simulation is Mostly Beneficial for Training of Fellows and Teaching the Use of New Devices and Procedures. AM J CARDIOL 2005;96:399.

504. Fujii K, Ochiai M, Mintz GS, Carlier SG, Kan Y, Awano K, Masutani M, Ashida K, Kawasaki D, Ichikawa S, Ura S, Araki H, Lui J, Sano K, Kimura M, De Ribamar Costa J, **Stone GW,** Leon MB. Incidence and Location of Coronary Calcification in Chronic Total Occlusions: An Intravascular Ultrasound Study. AM J CARDIOL 2005;96:415.

505. Kimura M, Carlier SG, Mintz SG, Lui J, De Ribamar Costa J, Sano K, Takebayashi H, Yasuda T, Fujii K, Mehran R, Dangas G, Moses JW, Leon MB. Serial Intravascular Ultrasound Analysis of Vascular Remodeling at Sites of Incomplete Stent Apposition after Sirolimus-Eluting Stent Implantation. AM J CARDIOL 2005;96:436.

506. Costa R, Carlier SG, Mintz GS, Fujii K, Kimura M, Sano K, Qian J, Tanaka K, Lui J, Weinberger J, Dangas G, Collins M, Kreps EM, 2005;Moses JW, Martin MB. “Black Holes” in Sirolimus-Eluting Stent Failures: A Marker of an Aggressive Variant of Restenosis. AM J CARDIOL 2005;96:441.

507. Moses JM, Nikolsky E, Mintz GS, Dangas G, Grube E, Lansky AJ, Weisz G, Addo T, Na Y, **Stone GW,** Leon MB, Mehran R. Drug-Eluting Stents May Challenge the Treatment Paradigm of Patients with Intermediate Coronary Lesions. AM J CARDIOL 2005;96:470.

508. Esteban E, Mintz GS, Koglin J, Lam P, Popma J, Russell M, Ellis SG, **Stone GW,** Grube E, Dawkins K, Weissman NJ. Predictors of Target Lesion Revascularization after Drug-Eluting Stent Implantation: Angiographic and Intravascular Ultrasound of the TAXUS IV and VI Studies. AM J CARDIOL 2005;96:479.

509. Esteban E, Mintz GS, Koglin J, Lam P, Popma JJ, Russell ME, Ellis SG, **Stone GW,** Grube E, Dawkins K Weissman NJ . Intimal Hyperplasia Thickness is Independent of Stent Size in Paclitaxel Polymer Coated (TAXUS) Stents. AM J CARDIOL 2005;96:480.

510. De Ribamar Costa J, Mintz GS, Carlier SG, Fujii K, Kimura M, Sano K, Costa R, Qian J, Tanaka K, Lui J, Na Y, Dangas G, Collins M, Krepps EM, Moussa I, Weisz G, **Stone GW,** Moses JW, Leon MB. Limitations of the Stent-Package Compliance Chart in Predicting Final Drug-Eluting Stent Dimensions: An Intravascular Ultrasound Study. AM J CARDIOL 2005;96:495.

511. De Ribamar Costa J, Leon MB, Mintz GS, Mehran R, Teirstein P, Waksman R, Mauri L, Turco M, Lee D, Fujii K, Costa R, Sano K, Kimura M, Qian J, Tanaka K, Lui J, Na Y, Dangas G, Weinberger J, Moussa I, Krepps EM, **Stone GW,** Moses JW, Carlier SG

512. Results from the Intravascular Ultrasound Sub-Study from the Angio-Sculpt® Scoring Balloon Catheter Multi-center Clinical Trial. AM J CARDIOL 2005;96:501.

513. Tanaka K, Carlier SG, Mintz GS, Fujii K, Kimura M, Sano K, De Ribamar Costa J, Lui J, **Stone GW,** Leon MB. The Accuracy of Stent Length Measurements Using Different Intravascular Ultrasound Motorized Transducer Pullback Systems. AM J CARDIOL 2005;96:509.

514. Fujii K, Carlier SG, Mintz SG, De Ribamar Costa J, Kimura M, Sano K, Tanaka K, Quin J, Lui J, Moussa I, Dangas G, Mehran R, Collins M, Kreps EM, **Stone GW,** Moses JW, Leon MB. A Pre-Rupture Intravascular Ultrasound Profile of Vulnerable Plaques. AM J CARDIOL 2005;96:513.

515. Jensen LO, Mintz GS, Carlier SG, Fujii K, Moussa I, Dangas G, Mehran R, **Stone GW,** Leon MB, Moses JM. Intravascular Ultrasound Analysis of the Residual Fibrous Cap after Vulnerable Plaque Rupture. AM J CARDIOL 2005;96:515.

516. Shishenhbor M, Lincoff, AM, Lansky AJ, Mahaffey KW, **Stone GW,** Yang H, Marian AJ, Ferguson JJ, Califf RM, Goodman SG, Kleiman, NS, Topol E, Hazen SL. Lipid Peroxidation Productions Independently Predict Mortality in Patients Presenting with Non-ST-segment Elevation Acute Coronary Syndrome: A SYNERGY Library Analysis. Circulation 2005;112:1902.

517. Addo TA, Kodali S, Weinberger J, Mehran R, Grines C, Gibbons R, Dixon S, O'Neill B, **Stone GW**. Impact of Multi-Vessel Disease on Infarct Size and Clinical Outcomes following Primary Angioplasty for Acute Myocardial Infarction. Circulation 2005;112:2698..

518. Shishenhbor M, Lincoff AM, Yang H, Mahaffey KW, Becker RC Goodman SG, Lansky AJ, Marian AJ, **Stone GW,** Kleiman NS, Ferguson JJ, Califf RM, Topol E, Hazen SL. Plasminogen Activator Inhibitor-1 Activity Predicts Clinical Outcome in Patients Presenting with Non-ST Segment Elevation Acute Coronary Syndromes: A SYNERGY Library Analysis. Circulation 2005;112:759.

519. Miller TD, Gibbons RJ, Web J, Cox DA, Brodie BR, Kruckoff MW, Mehran R, Lansky AJ, **Stone GW.** Diabetic Patients with Acute Myocardial Infarction Treated with Primary Angioplasty have Decreased Coronary Perfusion, Larger Infarcts and Higher Mortality then Patients without Diabetes. Circulation 2005;112:1830.

520. Mann T, Ellis SG, Kellett M, Russell Raymond ME, Coy K, Stine R, Masud AR Zaki, Douglas J, Koglin J, **Stone GW**. Beneficial Effect of the 2.25mm Paclitaxel-Eluting TAXUS Stent in Patients with Small Coronary Arteries: Results from the TAXUS-V Trial. Circulation 2005;112:2617.

521. Cannon LA, Ellis SG, Chang M, Jacobs C, Brown C, Kieval J, Turco M, Iyer SS, Koglin J, **Stone GW.** Risks and Benefits of the Paclitaxel-Eluting TAXUS Stent in large Vessels: Results from the 4.0mm Stent Subgroup of the TAXUS-V Trial. Circulation 2005;112:2619.

522. De Ribamar Costa J, Mintz GS, Carlier SG, Fujii K, Sano K, Kimura M, Qian J, Tanaka K, Na Y, Lui J, Sangas G, Moussa I, **Stone GW,** Weinberger J, Moses JW, Leon MB. Limitations of Manufacturers' Compliance in Predicting Final Drug-Eluting Stent Dimensions: An Intravascular Ultrasound Study. Circulation 2005;112:2892.

523. Fujii K, Carlier SG, Mintz GS, De Ribamar Costa J, Kimura M, Sano K, Lui J, Qian J, Tanaka K, Moussa I, Dangas G, Mehran R, Kreps EM, Collins M, **Stone**

GW, Moses JW, Leon MB. A Pre-Rupture Intravascular Ultrasound Profile of Vulnerable Plaque. Circulation 2005;112:2910.

524. Ellis SG, O'Shaughnessy CD, Powers E, Goli V, Vellinga T, Midwall J, Low R, Russell ME, **Stone GW.** Twelve Month Clinical Outcomes of Paclitaxel-Eluting Stents in Complex Lesions (TAXUS V). Focus on Late Clinical Benefits and Stent Thrombosis Risk. Circulation 2005;112:3062.

525. **Stone GW,** Ellis SG, Cox DA, O'Shaughnessy CD, Mann T, Turco M, Caputo R, Greenberg JD, Raizner AE, Popma JJ, Koglin J, Russell ME. Three-Year Safety and Efficacy of the Polymer-Based Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial. Circulation 2005;112:2063.

526. Moses JM, Nikolsky E, Mintz GS, Dangas G, Grube E, Na Y, Lansky AJ, **Stone GW,** Leon MB, Mehran R. Drug-Eluting Stents in the Treatment of Intermediate Lesions: Pooled Analysis from Four Randomized Trials. Circulation 2005;112:3068..

527. Nikolsky G, Mehran R, Grines CL, Turco M, Cox DA, Tcheng JE, Brodie BR, Guagliumi G, Griffin JJ, Addo T, Kodali S, Lansky AJ, Na Y, Negoita M, **Stone GW.** Higher Baseline Platelet Count predicts Reinfarction and Death in patients Undergoing Primary Percutaneous Coronary intervention for Acute Myocardial Infarction: Analysis from the CADILLAC Trial. Circulation 2005;112:3255.

528. Lansky AJ, Costa RA, Mehran R, Mori K, Cristea E, Silva EC, Addo T, Na Y, Dox DA, Brodie BR, Dulas D, Kalynych A, Qureshi M, Rutherford B, Schiltheiss HP, Turco M, Gibbons R, Kruckoff M, **Stone GW**. Implications of Myocardial Blush Grade (MBG) on Late Clinical Outcomes After Mechanical Reperfusion in Acute Myocardial Infarction (AMI) and its Interaction with Different Biomarkers of Reperfusion – Results from the EMERALD Trial. Circulation 2005;112:3566.

529. Kimura M, Carlier SG, Mintz GS, De Ribamar Costa J, Sano K, Yasuda T, Fujii K, Takebayashi H, Mehran R, Dangas G, **Stone GW,** Moses JM, Leon MB. The Vascular Remodeling at the Site of Post-Procedural Incomplete Stent Apposition after Sirolimus-Eluting Stent Implantation. Circulation 2005;112:3576..

530. Weissman NJ, Ellis SG, Mintz GS, Cannon LA, McGarry T, Greenberg J, Mann JT, Kutcher M, Koglin J, Russell ME, **Stone GW.** Insights on the Effect of Polymer-Based Paclitaxel-Eluting Stents in Long Lesions and Overlapping Stents: Final Results from the TAXUS-V IVUS Substudy. Circulation 2005;112:3581.

531. Kimura M, Carlier SG, Mintz GS, Fujii K, DeRibamar Costa J, Sano K, Takebayashi H, Yasuda T, Dangas G, Mehran R, **Stone GW,** Moses JW, Leon MB. Stent Edge Vascular Responses after Sirolimus Eluting Stent Implantation: SA Serial Intravascular Ultrasound Analysis. Circulation 2005;112:3582.

532. Kloner RA, Gibbons RJ, Ross AM, Alexander RW, Forman MB, **Stone GW**. Impact of Time to Presentation and Reperfusion Modality on the Efficacy of Adenosine During Reperfusion Therapy for Acute Myocardial Infarction: The AMISTAD-2 Trial. JACC 2006:47(Suppl A):175A

533. Kodali S, Mehran R, Agahtehrani A, Addo T, Na Y, Dangas G, Goyal N, Nikolsky E, Weisz G, Sherman W, Lansky AJ, Rabbani L, **Stone GW**, Moses JW, Leon MB. Predictors of Target Lesion Revascularization and Target Vessel Revascularization After Implantation of Sirolimus-Eluting Stent: Pooled Analysis from 6 Randomized Trials and Registries. JACC 2006:47(Suppl A):187A

534. **Stone GW**, Ellis SG, Popma JJ, Cox DA, Hermiller J, Cannon L, Mann JT, Mehran R, Koglin J, Russell ME. Do the Traditional Risk Factors of Vessel Size, Lesion Length and Diabetes Mellitus Predict Restenosis With TAXUS Stents? Insights From a TAXUS Meta-Analysis. JACC 2006:47 (suppl A):188A

535. Pocock S, **Stone GW**, Fahy M, Mehran R, Lansky AJ, Nikolsky E, Moses JW, Leon MB, Popma JJ. Relationship Between Late Loss, Diameter Stenosis and Target Lesion Revascularization After Stent Implantation: An Examination of Surrogate Endpoints From a Pooled Analysis of Eight Large Randomized DES Trials. JACC 2006:47 (suppl A):188A

536. Mehran RM, Collins M, Krebs E, Lansky AJ, Dangas G, Moussa I, Weisz G, Nikolsky E, Negoita M, Kodali S, Liuzzo J, Sulaiman R, Moses JM, **Stone GW**, Leon MB. Overlapping Sirolimus-Eluting Stents: Analysis from the Matrix Registry. JACC 2006:47 (suppl A):203A

537. Nikolsky E, Mehran R, Grines CL, Turco M, Cox DA, Stuckey T, Guagliumi G, Griffin JJ, Lansky AJ, Negoita M, Mercado DJ, Moussa I, Na Y, **Stone GW**. Blood Transfusion in patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Analysis from the CADILLAC Trial. JACC 2006:47 (suppl A):215A

538. Lee EA, Dangas G, Mehran R, Nikolsky E, Lansky AJ, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antoinucci D, Kruckoff MW, Gibbons RJ, Jones D, **Stone GW**. Microvascular Flow and Myocardial Perfusion After Acute MI Angioplasty in Anterior Versus Non-Anterior Infarcts: Results from the EMERALD Trial. JACC 2006:47 (suppl A):220A

539. Ellis SG, Colombo A, Grube E, Popma J, Koglin J, Russell ME, **Stone GW**. Early and Late Stent Thrombosis After Paclitaxel-Eluting Stents: Analysis From the Integrated TAXUS Randomized Trail Program. JACC 2006:47 (suppl A):221A

540. Nikolsky E, Mehran R, Dangas G, Leon MB, Moses JW, Lansky AJ, Na Y, Lincoff AM, **Stone GW**. Risk Score for Prediction of Major Bleeding After Percutaneous Coronary Intervention. JACC 2006:47 (suppl A):231A

541. Cohen MG, Danna P, Fearon W, Price MJ, Weisz G, Moses JW, Yeung A, Cohen P, Mehran R, Madyoon H, Mathur V, Leon MB, Collins M, **Stone GW**, Rogers C. Safety and Performance of Targeted Renal Therapy for Prevention of Contrast-Induced Nephropathy:Data From the Be-Rite Registry. JACC 2006:47 (suppl B):29B

542. Weisz, G, Gray W, Hathaway L, Knipper P, Bertling C, Gong M, **Stone GW**, Leon MB. Interventional Vascular Simulation is Mostly Beneficial for Training of Fellows and Teaching the Use of New Devices and Procedures. JACC 2006:47 (suppl B):10B

543. Mintz G, Weissman NJ, Popma J, Dawkins K, Grube E, Ellis S, Katz-Sawyer D, Lam P, Koglin J, **Stone GW**. What is the Best Quantitative Surrogate of Target Lesion Revascularization? An Angiographic and Volumetric Intravascular Ultrasound Meta-analysis from the TAXUS IV, V and VI Trials. JACC 2006:47 (suppl B):11B

544. Costa RA, Lansky AJ, Cristea E, Fahy M, Leon MB, Moses JW, **Stone GW**. Methodology and Validation of Myocardial Blush Grade (MBG) Assessment in patients with Acute Myocardial Infarction (AMI) Undergoing Mechanical Reperfusion. JACC 2006:47 (suppl B):19B

545. Mintz, G, Weissman, N, Dawkins K, Grube E, Ellis S, Fernandez S, Greenberg J, Kutcher M, Zhou F, Koglin J, **Stone GW**. Frequency, Predictors and Clinical Outcomes of Late-Acquired Incomplete Stent Apposition in Patients Treated with TAXUS Stents: A Volumetric Intravascular Ultrasound Meta-Analysis From the TAXUS IV, V and VI Trials. JACC 2006:47 (suppl B):26B

546. Mintz G, Weissman N, Dawkins K, Grube E, Ellis S, Fong H, Cannon L, Masud ARZ, Mandinov L, Koglin J, **Stone GW**. TAXUS Neutralizes the Impact of Diabetes Mellitus on In-Stent Restenosis: A Volumetric Intravascular Ultrasound Meta-Analysis From the TAXUS IV, V and VI Trials. JACC 2006:47 (suppl B):30B

547. Costa RA, Lansky AJ, Mori K, Mehran R, Sahid B, Cristea E, Silva EC, Brodie BR, Dulas D, Cox DA, Kalynych A, Qureshi M, Rutherford B, Schultheiss HP, Turco M, Webb J, Kruckoff M, Gibbons R, **Stone GW**. Impact of Staged Non-Target Vessel Revascularization of Clinical Outcomes Following Primary Stenting for Acute Myocardial Infarction (AMI): Results from the EMERALD Trial. JACC 2006:47 suppl B):52B

548. Mori K, Lansky AJ, Costa RA, Mehran R, Cristea E, Sahid B, Filipovic Z, Brodie BR, Cox DA, Dulas D, Kalynych A, Qureshi M, Ruitherford B, Schultheiss HP, Turco M, Webb J, Kruckoff M, Gibbons R, **Stone GW**. Gender Differences in Outcomes Adter Primary Stenting for Acute Myocardial Infarction: A Substudy From the EMERALD Trial. JACC 2006:47 (suppl B):52B

549. Fujii K, Ochiai M, Mintz GS, Kan Y, Awano K, Mastuani M, Ashida K, Ohyanagi M, Ichikawa S, Ura S, Araki H, **Stone GW**, Moses JW, Leon MB, Carlier SG. Procedural Implications for the Intravascular Ultrasound Morphologic Features of Chronic Total Coronary Occlusions. JACC 2006:47 (suppl B):54B

550. Sano K, Carlier S, Mintz GS, Fujii K, Costa J, Kimura M, Tanaka K, Dangas G, Mehran R, Moussa I, Kreps E, Collins MB, **Stone GW**, Moses JE, Leon MB. The Magnitude of Neointimal Hyperplasia as a Mechanism of In-Stent Restenosis in Diabetes Mellitus After Sirolimus Eluting Stent Implantation: A Volumetric Intravascular Ultrasound Study. JACC 2006:47 (suppl B):10B

551. DeRibamar Costa J, Mintz GS, Carlier SG, Fujii K, Kimura <. Sano K, Tanaka K, Na Y, Lui J, Biro S, Castellanos C, Dangas G, Kreps E, Collins M, Moussa I, **Stone GW,** Moses JW, Leon MB. Assessing Drug-Eluting Stent Expansion: Lessons Learned from Intravascular Ultrasound. JACC 2006:47 (suppl B):11B

552. Manoukian SV, Voeltz MD, Feit F, Mehran R, Dangas GD, Nikolsky E, Lincoff AM, King III, SB, Ohman EM, **Stone GW**. Transfusion is Associated with Increased 30-Day Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial. AM J CARDIOL 2006:98(suppl 8A):1M.

553. Feit F, Manoukian SV, Ebrahimi R, Pollack CV, Ohman EM, Attubato MJ, Mehran R, **Stone GW**. Is Bivalirudin Monotherapy Sufficient For Diabetic Patients With Acute Coronary Syndrome (ACS) Undergoing PCI? AM J CARDIOL 2006:98(suppl 8A):14M.

554. Alexander KP, Ohman EM, Bertrand ME, Feit F, Pollack CV, Hoekstra J, Gersh BJ, White HD, **Stone GW**. Outcomes in Elderly Patients Undergoing PCI Treated with Bivalirudin Monotherapy versus Glycoprotein IIb/IIIa Inhibitors with Heparin or LMWH: Results from the Randomized ACUITY trial. AM J CARDIOL 2006:98(suppl 8A):18M.

555. Hermiller JB, Ellis SG, Cox DA, O'Shaugnessy CD, Mann T, Turco M, Caputo R, Bergin PJ, Greenberg JD, Raizner AE, Popma JJ, Koglin J, **Stone GW**. Four-Year Clinical Outcomes of the Polymer-based Paclitaxel-eluting TAXUS Stent: The TAXUS IV Trial. AM J CARDIOL 2006:98(suppl 8A):27M.

556. Mehran R, Moses JW, Nikolsky E, Dangas G, Manoukian S, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Gersh B, Pocock SJ, Ware

JH, Feit F, Colombo A, **Stone GW**. Drug Eluting Stents in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions: The ACUITY Trial. AM J CARDIOL 2006:98(suppl 8A):27M.

557. Solinas E, Nikolsky E, Pucelikova T, Franklin-boind T, Fahy M, Syros G, Boland P, Bur A, Cho C, Moussa I, Dangas G, **Stone GW**, Moses J, Leon MB, Mehran R. Treatment of Drug-Eluting Stent Failure: Analysis of Consecutive Patients. AM J CARDIOL 2006:98(suppl 8A):30M.

558. Nikolsky E, Lincoff M, Harrington RA, Bittle JA, Feit F, Solinas E, Pucelikova T, Agahtehrani A, Costa J, Kesanakurthy V, Kimura M, Mehran R, Dangas G, **Stone GW**. Decrease in Hemoglobin in the Absence of Overt Bleeding after Percutaneous Coronary Intervention is a Predictor of One-year Mortality. AM J CARDIOL 2006:98(suppl 8A):31M.

559. Ebrahimi R, Manoukian SV, Feit F, Lincoff AM, Mehran R, Pollack CV, Cox DA, Dyke C, Gersh BJ, Steinhubl SR, Moses JW, Ohman EM, White HD, **Stone GW**. Implications of Preoperative Thienopyridine Use Prior to Coronary Artery Bypass Graft Surgery_ Time for a Paradigm Shift? AM J CARDIOL 2006:98(suppl 8A):31M.

560. Cheruvu PK, Finn A, Virmani R, Goldstein J, **Stone GW**, Gardner C, Caplan J, Muller JE. Focality and Composition of Thin Cap Fibroatheroma, Suspected Precursors of Coronary Plaque Rupture. AM J CARDIOL 2006:98(suppl 8A):36M.

561. Jozic J, Steinhubl SR, Dangas GD, Hooper WC, **Stone GW**. Markers of Inflammation and Their Changes Over Time in Relationship to Clinical Outcomes and Therapeutic Interventions in the Acute Coronary Syndrome Patient: Results From the ACUITY Inflammation Sub-Study. AM J CARDIOL 2006:98(suppl 8A):36M.

562. Manoukian SV, Voeltz MD, Feit F, Mehran R, Nikolsky E, Dangas GD, Ebrahimi R, Lincoff AM, King III SB, **Stone GW**. Major Bleeding is Associated with Increased 30-Day Mortality and Ischemic Complications in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The ACUITY Trial. AM J CARDIOL 2006:98(suppl 8A):45M.

563. Webb JG, Kuck K-H, Stone G, Vahanian A, Sarano M, Weismann N, Buller C, James S, Harnek J. Percutaneous Mitral Annuloplasty With The MONARC System: Preliminary Results From The EVOLUTION Trial. AM J CARDIOL 2006:98(suppl 8A):49M.

564. Tanaka K, Carlier SG, Mintz GS, Castellanos C, McPherson J, Farhat N, Marso S, de Bruyne B, Serruys P, **Stone GW**. High Risk Fibroatheroma Lesions Are Remote from the Minimal Lumen Area Site: A Virtual Histology IVUS Analysis from the PROSPECT Study. AM J CARDIOL 2006:98(suppl 8A):94M.

565. Sano K, Mintz GS, Carlier SG, Costa JdR, Liu X, Kimura M, Tanaka K, Dangas GD, Mehran R, **Stone GW**, Leon MB, Moses JW. Assessing Intermediate Left Main Coronary Lesions: Lessons Learned from Intravascular Ultrasound. AM J CARDIOL 2006:98(suppl 8A):99M.

566. Leon M, Klauss V, **Stone G**, Suzuki T, Ferreira RC, Konig A, Wijns W. The Right Coronary Artery Has a Different Plaque Component Profile When Compared to the Other Two Epicardial Arteries:VH-IVUS Report from the Global VH-IVUS Registry. AM J CARDIOL 2006:98(suppl 8A):103M.

567. Ellis SG, Cannon LA, Mann T, Greenberg JD, DeMaio S, Goli V, Knapp W, McGarry T, Kutcher MA, Koglin J, **Stone GW**. Safety and Efficacy of the Polymer-based, Paclitaxel-Eluting TAXUS Stent in Complex Lesions: Two-Year Clinical Results from the TAXUS V de novo Trial. AM J CARDIOL 2006:98(suppl 8A):142M-143M.

568. Ellis SG, Kent K, Raizner AE, Zaki-Masud AR, Kereiakes DJ, O'Shaugnessy CD, Turco MA, Martin SL, Brown CL, Greenberg J, McGarry T, Koglin J, **Stone GW**. 1-Year Results from the TAXUS-V ISR Trial: A Randomized Trial of Paclitaxel-Eluting Coronary Stents versus Vascular Brachytherapy for Treatment of Restenosis in Bare Metal Stents. AM J CARDIOL 2006:98(suppl 8A):143M.

569. Mori K, Lansky AJ, Costa RA, Bertrand M, Feit F, Pietras C, Cristea E, Pocock S, Ohman M, **Stone GW**. Angiographic Findings in the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. AM J CARDIOL 2006:98(suppl 8A):144M-145M.

570. Solina E, Nikolsky E, Pucelikova T, Franklin-Bond T, Fahy M, Syros G, Goyal N, Sano K, Costa J, Collins M, Dangas G, **Stone GW**, Moses J, Leon MB, Mehran R. Patterns of In-Stent Restenosis in Patients Treated with Drug-Eluting Stents and Predictors of Repeat Failure. AM J CARDIOL 2006:98(suppl 8A):178M.

571. Kimura M, Mintz GS, Carlier SG, Na Y, Dani L, Castellanos C, Biro S, Lui J, Mori K, Tanaka K, Sano K, Fujii K, Liu X, Costa JdR, Nikolsky E, Mehran R, Lansky AJ, Dangas G, Kreps E, Collins M, **Stone GW**, Moses JW, Leon MB. Different Mechanisms of Neointimal Hyperplasia Formation at the Edges vs the Body of Sirolimus Eluting Stents. An Intravascular Ultrasound Analysis. AM J CARDIOL 2006:98(suppl 8A):181M.

572. Hamon M, Rasmussen LH, Manoukian S, Cequier A, Lincoff M, Rupprecht H-J, Bersh B, Bertrand M, **Stone GW**. Impact of the arterial access site on bleeding complications in patients with acute coronary syndromes undergoing early invasive management: The ACUITY Trial. AM J CARDIOL 2006:98(suppl 8A):187M.

573. Pinto DS, **Stone GW**, McLaurin BT, Cox DA, Shi C, Schneider EA, Machon DA, Berezin RH, Mehran R, Moses JW, Ohman EM, White HD, Bertrand ME, Lincoff AM, Cohen DJ. Cost-Effectiveness of Bivalirudin Monotherapy for Patients Undergoing an Early Invasive Management for Acute Coronary Syndromes without ST-Elevation: Results from the Randomized ACUITY Trial. AM J CARDIOL 2006:98(suppl 8A):195M.

574. Cox D, Pollack CV, Hoekstra J, White HD, Ebrahimi R, Rasmussen LH, Rupprecht HJ, **Stone GW**. Safety and Efficacy of Bivalirudin in ACS Patients Undergoing PCI: Impact of Duration of Upstream Infusion in the ACUITY Trial. AM J CARDIOL 2006:98(suppl 8A):195M-196M.

575. Costa RA, **Stone GW**, Mahaffey K, Califf R, White H, Ferguson J, Gulba D, Col J, Lansky AJ. Impact of Enoxaparin on Coronary Flow and Myocardial Blush Grade After Early Invasive Treatment During Acute Coronary Syndrome (ACS) - Results From the SYNERGY Library. AM J CARDIOL 2006:98(suppl 8A):196M-197M.

576. Solinas E, Nikolsky E, Pucelikova T, Na Y, Orta M, Cole H, Desgupta N, Irozuru M, Magennis E, Morales A, Dangas G, **Stone GW**, Moses GW, Leon MB, Mehran R. Gender Comparison in Patients Undergoing PCI using Sirolimus-Eluting Stents. AM J CARDIOL 2006:98(suppl 8A):249M-250M.

577. Mori K, Lansky AJ, Costa RA, Cequier A, Pollack CV, Hoekstra J, Bertrand M, Gersh B, **Stone GW**. Gender Differences in Outcomes Following Percutaneous Coronary Intervention of Patients with Non-ST elevation Acute Coronary Syndrome: A Substudy of the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. AM J CARDIOL 2006:98(suppl 8A):250M.

578. Cheruvu PK, Finn AV, Gardner C, Caplan J, Goldstein JA, **Stone GW**, Virmani R, Muller JE. Density and Distribution of Thin-Cap Fibroatheroma and Ruptured Plaque in Human Coronary Arteries -- A Pathologic Study. Circulation 2006:114(suppl II):II-22.

579. Prasad A, **Stone G**, Stuckey T, Constantini C, Mehran R, Garcia E, Tcheng J, Cox D, Grines C, Lansky A, Gersh, B. Relationship Between Leukocyte Count, Myonecrosis, Myocardial Perfusion and Outcomes Following Primary Angioplasty. Circulation 2006:114(suppl II):II-347.

580. Escolar E, Mintz GS, Popma JJ, Lam P, Michalek A, Kim S-W, Dawkins KD, Madinov L, Koglin J, Grube E, Ellis SG, **Stone GW**, Weissman NJ. Angiographic versus Intravascular Ultrasound Parameters of Drug-Eluting Stent Efficacy: A Meta-Analysis from TAXUS IV, V and VI. Circulation 2006:114(suppl II):II-395.

581. Koizumi T, Fitzgerald PJ, Honda Y, Ellis SG, Kent K, Martin SL, Brown CL, Masud ARZ, Patterson JB, Greenberg J, Koglin J, **Stone GW**. A Randomized Comparison of Paclitaxel-Eluting Stents vs. Intra-coronary Brachytherapy in the

Treatment of In-stent Restenosis: Intravascular Ultrasound Results from the TAXUS-V ISR Trial. Circulation 2006:114(suppl II):II-547.

582. **Stone GW**, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Mehran R, Moses JW. Comparison of Heparin Plus IIb/IIIa Inhibition Versus Bivalirudin With or Without IIb/IIIa Inhibition in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The ACUITY Trial. Circulation 2006:114(suppl II):II-551.

583. Feit F, Manoukian SV, Ebrahimi R, Pollack CV Jr, Ohman EM, Attubato MJ, Mehran R, **Stone GW**. Bivalirudin Monotherapy Improves 30 Day Clinical Outcomes In Diabetics With Acute Coronary Syndrome (ACS). Report From The ACUITY Trial. Circulation 2006:114(suppl II):II-551.

584. White HD, Hoekstra J, Pollack CV Jr, Ohman EM, **Stone GW**. Safety and Efficacy of Crossover from Enoxaparin or Unfractionated Heparin to Bivalirudin: Results from ACUITY. Circulation 2006:114(suppl II):II-551.

585. Manoukian SV, Voeltz MD, Feit F, Ebrahimi R, Mehran R, Nikolsky E, Moses JW, Lincoff AM, King SB III, **Stone GW**. Major Bleeding is Associated with Increased Short-Term Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial. Circulation 2006:114(suppl II):II-551-II-552.

586. Costa R, **Stone GW**, Clare R, Mahaffey KW, Califf RM, White HD, Ferguson JJ III, Gulba DC, Col JJ, Lansky A. Impact of Enoxaparin on Thrombus Formation, Coronary Blood Flow, and Myocardial Perfusion After Early Invasive Treatment During Acute Coronary Syndrome: Results from the SYNERGY Library. Circulation 2006:114(suppl II):II-600.

587. **Stone GW**, Colombo A, Grube E, Ellis SG, Dawkins KD, Jovanovich D, Koglin J. Long-Term Outcomes Following Treatment of In-Stent Restenosis with Drug-Eluting Stents: Insights from the TAXUS Meta-Analysis. Circulation 2006:114(suppl II):II-689.

588. Ohman EM, Bertrand ME, Feit F, White HD, **Stone GW**, Pollack CV Jr, Hoekstra J, Gersh BJ. Outcomes in Elderly Patients Treated with Bivalirudin Monotherapy Versus Glycoprotein IIb/IIIa Inhibitors with Heparin or LMWH: Results from the Randomized ACUITY Trial. Circulation 2006:114(suppl II):II-701.

589. Desmet W, Rasmussen LH, Lincoff AM, Cequier AR, Rupprecht H-J, Gersh BJ, Manoukian SV, Bertrand ME, **Stone GW**. Safety and Efficacy of Bivalirudin in Patients with non-ST Elevation Acute Coronary Syndromes Undergoing Medical Management: Results from the Randomized ACUITY Trial. Circulation 2006:114(suppl II):II-701.

590. Liu X, Mintz G, Carlier S, Sano K, Costa J Jr, Tanaka K, Moussa I, Dangas G, Mehran R, Lansky A, Collins M, **Stone G**, Moses J, Leon M. Intravascular Ultrasound Assessment of the Incidence and Predictors of Edge Dissections and Intramural Hematomas After Drug-Eluting Stent Implantation. Circulation 2006:114(suppl II):II-732.

591. Costa JR Jr, Leon MB, Mintz GS, Mehran R, Teirstein P, Sano K, Kimura M, Tanaka K, Liu X, Lui J, Na Y, Castellanos C, Biro S, Dani L, Rinker J, Dangas G, **Stone GW**, Moses JW, Carlier SG. Impact of Different Pre-dilatation Strategies on Stent Expansion: An Intravascular Ultrasound Study. Circulation 2006:114(suppl II):II-732.

592. **Stone GW**, Dixon SR, Foster M, Diaz C, Thambar S, Carrozza J, Griffin J, Nseir G, Rutherford BD, O'Neill W. Systemic Hypothermia to Prevent Contrast Nephropathy: the COOL RCN Pilot Trial. Circulation 2006:114(suppl II):II-811-II-812.

593. Pollack C, Hoekstra JW, White HD, Hollander JE, Diercks DB, Ebrahimi R, Rasmussen LH, Rupprecht H-J, **Stone GW**. Safety and Effectiveness of Bivalirudin in Non ST-Segment Elevation Acute Coronary Syndromes by Duration of Upstream Infusion in the ACUITY Trial: Implications for Emergency Department and Upstream Management. Circulation 2006:114(suppl II):II-814.

594. Haugen SJ, Brodie BR, Cox DA, **Stone GW,** Lansky AJ, Carroll JD, Kruckoff MW, Mehran R, Lindenfeld J, Webb J. Left ventricular end diastolic pressure is a predictor of suboptimal myocardial reperfusion in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction. JACC 2007;49:9A.

595. Jozic J, Mehran R, Hooper WC, Steinhubl SR, Dangas G, **Stone GW**. Major bleeding in acute coronary syndrome patients is associated with a marked pro-inflammatory response: Results from the ACUITY inflammatory biomarker sub-study. JACC 2007;49:9A.

596. Miller CD, Diercks DB, Brogan GX, **Stone GW**, Gersh B, Pollack CV, Hoekstra JW, Peacock FW, Manoukian SV, Hollander JE, Blomkalns AL. Safety and efficacy of Bivalirudin in high-risk patients with acute coronary syndrome admitted through the emergency department: Implications for upstream management. JACC 2007;49:9A.

597. Ebrahimi R, Feit F, Dyke C, Moses J, Manoukian S, Lincoff AM, Gersh B, Mehran R, **Stone GW**. Outcome in Acute Coronary SyndromePatients Managed Surgically Bases on Clopidogrel Exposure and Delay to Surgery. JACC 2007;49:9A.

598. Ostuka M, Weustink A, Mollet N, Dudek D, Serryus P, Lighthart J, Hamers R, Vouvouri E, DeFeyter P, Van Pelt N, **Stone GW**, Wijns W, Verheye S, Bruining N. Three-dimensional quantification of coronary plaque burden by 64-slice computed tomography: A PROSPECT-MSCT study. JACC 2007;49:9A.

599. Ebrahimi R, Lincoff AM, Feit F, Mehran R, Moses J, Syke C, Gersh B, **Stone GW**, Manoukian S. Upstream therapy with Bivalirudin is as safe and effective as heparin for patients with acute coronary syndrome undergoing coronary artery bypass surgery: A report from the ACUITY trial. JACC 2007;49:9A.

600. **Stone GW**, Wennerblom B, Mintz GS, Lansky AJ, Mehran R, Marso S, Carlier S, DeBruyne B, Farhat N, Serruys P, McPherson J. A Prospective, natural history study of multimodality invasive imaging to characterize vulnerable plaque. First report of the baseline findings from the PROSPECT Trial. JACC 2007;49:9B.

601. **Stone GW**, Pollack C, Mehran R, Hoekstra J, Ware JH, Ohman EM, McLaurin BT, Cequir A, Feit F, Rasmussen LH, Colombo A, Desmet W, Lincoff AM, Ebrahimi R, Bertrand ME, Moses JW, Cox DA, Aylwayd P, Darius H, Pocock SJ, White HD, Hamon M, Rupprecht HJ, Lansky A. A prospective, randomized trial of Bivalirudin in acute coronary syndromes:One year results from the ACUITY Trial. JACC 2007;49:9B.

602. **Stone GW**, Koglin J, Ellis SG, Grube E, Colombo A, Baim D, Dawkins KD. Are paclitaxel-eluting stents safe and effective compared to bare metal stents? Long term results from the TAXUS Meta-analysis. JACC 2007;49:9B.

603. Mehran R, Ohman M, Bertrand M, Manoukian S, Dangas G, Kirtane A, Gersh B, Cequir A, **Stone GW**, Hamon M, Stella J, Pollack C, Cohen D, Feit F, Desmet W, Stuckey T, Pocock S, Hoekstra J. Chronic kidney disease is associated with increased mortality, bleeding and ischemic events in moderate and high-risk patients with acute coronary syndromes: An ACUITY substudy. JACC 2007;49:9B.

604. Nikolsky E, Pucelikova T, Mehran R, **Stone GW**, Bittle JA, De Los Santos F, Kimura M, Feit F, Solinas E, Dangas G, Lincoff AM, Harrington RA. Implications of hemoglobin decrease in the absence of overt bleeding after percutaneous coronary intervention. JACC 2007;49:9B.

605. Solinas E, Rabbani L, Lansky AJ, Kreps E, **Stone GW**, Weisz G, Moussa I, Sano K, Obunai K, Atmakuri S, Moses JW, Pucelikova T, Boland P, Franklin-Bond T, Nikolsky E, Leon MB, Mehran R, Dangas G, Kirtane A, Syros G. Long-term (one year) follow-up after treatment of drug-eluting stent Restenosis (DES-ISR) with repeat DES: to SWITCH or not to SWITCH? JACC 2007;49:9B.

606. Manoukian SV, Mehran R, Ebrahimi R, Fazel R, Dangas G, Feit F, Voeltz MD, Hoekstra J, King SB, Ohman EM, Lincoff AM, Pollack CV, Hamon M, **Stone**

GW. Major bleeding is an independent Predictor of short-term mortality in moderate and high-risk acute coronary syndromes:An analysis from the ACUITY Trial. JACC 2007;49:9B.

607. Kirtane AJ, Pollack C, Feit F, Bertrand M, Desmet W, Cequir A, Ohman EM, **Stone GW**, Dangas G Manoukian S, Mehran R, Stuckey T, Pocock S, Gersh B, Hamon M, Cohen D, Hoekstra J, Stella J. Outcomes of Bivalirudin in moderate- and high-risk patients with acute coronary syndromes and renal insufficiency: An ACUITY substudy. JACC 2007;49:9B.

608. Kimura M, **Stone GW**, Popma, JJ, Mehran R, Baim DC, Ellis SG, Kirtane A, Koglin J. Predictors for Diffuse in-stent Restenosis after Taxus stent implantation: Analysis from the TAXUS IV and V Trials. Predictors for diffuse in-stent Restenosis after TAXUS stent implantation: Analysis from the TAXUS IV and V trials. JACC 2007;49:9B.

609. Pucelikova T, Mehran R, Kirtane AJ, Dangas G, Solinas E, Morales A, Williams M, Agahtehrani A, Gray W, Collins M, Weisz G, Kreps E, Lansky AJ, Leon MB, **Stone GW**, Kodali S, Boland P, Aoki P, Kimura M, Moussa I, Nikolsky E, Moses JW, Franklin-Bond T, Kim YH. Short and long term outcomes after stent assisted percutaneous treatment of Saphenous vein grafts with drug-eluting stents: Have we made any progress? JACC 2007;49:9B.

610. Weisz G, Parise H, Fahy M, Ramee S, Reisman M, Moussa I, Leon MB, **Stone GW**, Gray W. Evaluation of proficiency using a simulator:Results from the assessment of operator performance by the Simbionix carotid stenting study (ASSESS). Am J Cardiol 2007;(suppl 8a):13.

611. Missel E, Mintz GS, Qian J, Kaple RK, Shan S, Lui J, Castellanos C, Dangas G, Mehran R, Moses JW, **Stone GW**, Leon MB. Coronary Plaque Burden is Related to Serum HDL-C levels, But not to Other Lipid Parameters: Volumetric Intravascular Ultrasound Analysis. Am J Cardiol 2007;(suppl 8a):18.

612. Mehran R, Kirtane AJ, Dangas GD, Ohman EM, Pocock SJ, Gersh BJ, Bertrand ME, Hamon M, Manoukian SV, Hoekstra J, Pollack CV, Desmet W, Feit F, Stella J, Cequir AR, Stuckey T, Cohen DJ, Lansky AJ, **Stone GW**. Long-term Outcomes of Patients with Acute Coronary Syndromes and Chronic Renal Insufficiency Undergoing Percutaneous Coronary Intervention and bring treated with Bivalirduin vs Heparin plus a Glycoprotein IIb/IIIa Inhibitor: Results from the Randomized ACUITY Trial. Am J Cardiol 2007;(suppl 8a):54.

613. Steinhubl S, Feit F, Colombo A, Ebrahimi R, Cox DA, McLaurin BT, Mehran R, Dangas GD, Manoukian SV White HD Lincoff AM, Moses JW, Bertrand ME, Ohman EM, Desmet W, **Stone GW**. Clopidogrel Pretreatment Versus Clopidogrel Exposure Prior to PCI in the ACUITY Trial: Does it Really Matter? Am J Cardiol 2007;(suppl 8a):55.

614. Manoukian SV, Voeltz MD, Feit F, Dangas GD, Fazel R, Ebrahimi E, Hamon M, Lincoff AM, Moses JW, King S, White HD, Ohman EM, Mehran R, **Stone GW**. Impact of Anemia on on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Am J Cardiol 2007;(suppl 8a):56.

615. Ellis S, Cannon LA, Mann T, Greenberg JD, Cambier P, O'Shaughnessy CD, DeMaio S, Hall P, Powers E, Friedman M, **Stone GW**. Three-Year Clinical Results From the TAXUS V de novo Trial: Long-Term Safety and Efficacy of the Paclitaxel-Eluting TAXUS Stent in Complex Lesions. Am J Cardiol 2007;(suppl 8a):64.

616. **Stone GW**, Ellis SG, Cox DA, Hermiller JB, O'Shaughnessy CD, Mann T, Turco M, Caputo R, Bergin PJ, Greenberg JD, Raizner, AE, Popma JJ, Baim DS. Safety and Durable Efficacy of the Polymer-based Paclitaxel-eluting TAXUS Stent: Final 5 year outcomes from the TAXUS IV Trial. Am J Cardiol 2007;(suppl 8a):65.

617. White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin B, Cox DA, Pocock SJ, Ware JH, Feit F, Manoukian SV, Lansky AJ, Mehran R, Moses JW, **Stone GW**. Safety and Efficacy of Bivalirudin with an without Glycoprotein IIb/AAAa Inhibitors in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: One Year Results from the Randomized ACUITY Trial. Am J Cardiol 2007;(suppl 8a):102.

618. Manoukian SV, Voeltz MD, Feit F, Dangas GD, Fazel R, Ebrahimi E, Hamon M, Lincoff AM, Moses JW, King S, White HD, Ohman EM, Mehran R, **Stone GW**. Impact of Transfusion on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Am J Cardiol 2007;(suppl 8a):116.

619. Kuck KH, Webb J, Harnek J, Buller C, Pauschinger M, Tiefenbacher C, James S, Vahanian A, **Stone GW**. Percutaneous Treatment of Functional Mitral Regurgitation: Interim Evolution Study Results with the Monare System. Am J Cardiol 2007;(suppl 8a):124.

620. White H, Chew DP, Hoekstra JW, Pollack CV, Feit F, Ohman EM, Mehran R, Miller C, **Stone GW**. Safety and Efficacy of Switching from either Unfractionated Heparin or Enoxaparin Plus a Glycoprotein IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with non-ST Elevation Acute Coronary Syndromes Managed with an Invasive Strategy: Results from the Randomized ACUITY Trial. Am J Cardiol 2007;(suppl 8a):137.

621. Dawkins KD, **Stone GW**, Colombo A, Ellis SG, Grube E, Leadley K, Baim DS. Safety and Clinical Utility of the RAXUS Express Stent in Unstable and

Stable Angina. A Pooled Analysis of TAXUS Randomized Clinical Trials. Am J Cardiol 2007;(suppl 8a):139.

622. Ebrahimi E, Feit F, Manoukian SV, Lincoff AM, Dyke C, Gersh BJ, Mehran R, Moses JW, **Stone GW**. Preoperative Thienopyridine with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Atery Bypass Surgery Reduces Adverse Ischemic Events: One-Year Results from the ACUITY Trial. Am J Cardiol 2007;(suppl 8a):147.

623. Obuani K, Moses JW, Leon MB, **Stone GW**, Dangas GD, Moussa I, Collins MB, Kreps EM, Sherman W, Weisz G, Kodali SK, Kimura M, Gupta A, Amakuri S, Franklin-Bond T, Naraya R, Dasgupta N, Mehran R. Are Second Attempts Justified After a Failed Intervention in Coronary Chronic Total Occlusions? Am J Cardiol 2007;(suppl 8a):216.

624. Obuani K, Moses JW, **Stone GW**, Mehran R, Dangas GD, Collins MB, Kreps EM, Moussa I, Sherman W, Weisz G, Kirtane A, kimura M, Amakuri S, Gupta A, Franklin-Bond T, Syros G, Tyagi S, Leon MB. Clinical Outcomes After Successful Percutaneous Revascularization of Chronic Total Occlusions in the Drug-Eluting Stent Era. Am J Cardiol 2

625. Lansky AJ, Mehran R,Mori K, Costa R, Cequir AR, Pollack CV, Hoekstra J, Bertrand ME, Gersh BJ, **Stone GW**. Gender Differences in Long-Term Outcomes Following Percutaneous Intervention of Patients with Non-ST Elevation Acute Coronary Syndrome: Results from the ACUITY Trial. Am J Cardiol 2007;(suppl 8a):391.

626. Manoukian SV, Fazel R, Sanborn TA, Ebrahimi R, Feit F, Hamon M, Voeltz MD, Dangas GD, Moses JW, King SB, White HD, Ohman EM, Mehran R, **Stone GW**. Predictors of Major Vascular Access Site Complications in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Insights from the ACUITY Trial. Am J Cardiol 2007;(suppl 8a):393.

627. Manoukian SV, Feit F, Voeltz MD, Dangas GD, Ebrahimi R, Hamon M, Chew DP, Desmet W, Steinhubl SR, Lincoff AM, King SB, Ojhman OM, White HD, Mehran R, **Stone GW**. Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The ACUITY Trial. Am J Cardiol 2007;(suppl 8a):394.

628. Aoki J, Mehran R, Kirtane A, Kim YH, Boland P, Dasgupta N, Franklin-Bond T, Grigos A, Herscher M, Higginbotham L, Isiaka V, Singh R, Kreps E, Weisz G, Lansky AJ Collins M, Moussa I, **Stone GW**, Leon MB, Moses JW, Dangas GD. Impact of Diabetic Status and Insulin Treatment on Two-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation in the MATRIX Registry. Am J Cardiol 2007;(suppl 8a):425.

629. Kirtane A, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, Fahy M, Leon MB, Moses JW, Mehran R, **Stone GW**. Paclitaxel-Eluting Coronary Stents in Patients with Diabetes Mellitus: Pooled Analysis from Five Randomized Trials. Am J Cardiol 2007;(suppl 8a):428.

630. Martin JL, Ellis SG, Colombo A, Grube E, Friedman M, Koglin J, **Stone GW**. Incidence and Predictors of Coronary Artery Bypass Surgery Following Bare-Metal and TAXUS Drug-Eluting Coronary Stent Implantation. Am J Cardiol 2007;(suppl 8a):504.

631. Ellis SG, Colombo A, Grube E, Friedman M, Koglin J, Baim DS, **Stone GW**. Long-term and Clinical Efficacy Outcomes of the Paclitaxel-Eluting Stent from a Patient-level Meta-Analysis of the TAXUS Clinical Trials. Am J Cardiol 2007(suppl 8a):534.

632. Rabbani L, Stant J, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Mehran R, **Stone GW**. Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. Am J Cardiol 2007;(suppl 8a):552.

633. Missel E, Mintz GS, Carlier SG, Qian J, Shan S, Castellanos C, Kaple R, Biro S, Dangas G, Mehran R, Moses JW, Stone GW, Leon MB. High-Risk Lipid Profile Related to the Ratio of Necrotic Core to Calcification in Human Coronary Arteries:Results from the Prospective Multi-center, Global VH-IVUS Registry. Am J Cardiol 2007;(suppl 8a):602.

634. Missel E, Mintz GS, Carlier SG, Sano K, Qian J, Shan S, Kaple RK, Castellanos C, Lui J, Dangas G, Mehran R, Moses JW, Stone GW, Leon MB. Necrotic Core and its Ratio to Dense Calcium are Predictors of High-Risk Non ST-Elevation Acute Coronary Syndromes: Results from the prospective, multi-center, Global VH-IVUS Registry. Am J Cardiol 2007;(suppl 8a):605.

635. Missel E, Mintz GS, Carlier SG, Qian J, Shan S, Castellanos C, Kaple RK, Dangas G, Mehran R, Moses JW, **Stone GW**, Leon MB. Necrotic Core and its Ratio to Dense Calcium are Predictors of High-Risk Non-ST-Elevation Acute Coronary Syndromes: Results from the Prospective, Multi-Center, Global VH-IVUS Registry. Circulation 2007;116:171.

636. Yamasaki M, Ako J, Tsujino I, Sakurai R, Waseda K, Hasegawa T, Shimohama T, Honda Y, Lansky AJ, Sudhir K, **Stone GW**, Fitzgerald PJ. Post-Procedural Incomplete Stent Apposition after Implantation of Everolimus-Eluting or Paclitaxel-Eluting Stents: Insights from the Randomized SPIRIT III Trial. Circulation 2007;116:1717.

637. Missel E, Mintz GS, Carlier SG, Qian J, Shan S, Castellanos C, Kaple RK, Dangas G, Mehran R, Moses JM, **Stone GW**, Leon MB. In Vivo Virtual Histology

Intravascular Ultrasound Correlates of Risk Factors for Suden Coronary Death in Men: Results from the Prospective, Global, Multi-center VH-IVUS Registry. Circulation 2007;116:1982.

638. Vasi S, **Stone GW**, Brown DL. Short and Long Term Effects of Abciximab in Patients Undergoing Primary Stenting for Acute Myocardial Infarction: Meta-Analysis of Randomized Trials. Circulation 2007;116:1998.

639. Ormiston HA, Turco MA, Mandinov L, Popma JJ, Hall JJ, NMishkel GJ, Mann T, McGarry TF, Cannon LA, **Stone GW**, O'Shaughnessey CD, Gilchrist IC, Koglin J, Baim DS. TAXUS ATLAS SMALL VESSEL: First Report of 9-Month Clinical and Angiographic Outcomes – Evaluation of the TAXUS Liberte 2.25mm Stent, a Drug-Eluting Stent Specifically Designed for Small Vessels. Circulation 2007;116:2154.

640. Manoukian SV, Feit F, Voeltz MD, Ebrahimi R, Hamon M, Chew DP, Dangas GD, Desmet W, Lincoff AM, Moses JW, Pollack CV, Hoekstra JW, King SB, White HD, Ohman EM, Mehran R, **Stone GW**. Impact of the ACUITY and TIMI Major Bleeding Definitions on One-Year Mortality in Patients with Acute Coronary Syndromes. Circulation 2007;116:2217.

641. Mehran R, Kirtane AJ, Dangas GD, Ohman EM, Pocock S, Bersh BJ, Bertrand ME, Hamon M, Manoukian SV, Hoekstra J, Pollack CV, Desmet W, Feit F, Stella J, Cequier AR, Cohen DJ, Lansky AJ, **Stone GW**. Long-Term Outcomes of Acute Coronary Syndrome Patients with Chronic Renal Insufficiency treated with Bivalirudin vs Heparin plus a Glycoprotein IIb/IIIa Inhibitor: One Year Results from the Randomized ACUITY Trial. Circulation 2007;116:2222.v

642. **Stone GW**, Ellis SG, Colombo A, Kong DK, Koglin J, Friedman MI, Baim DS. Effect of Prolonged Thienopyridene Use on Long-term Clinical Outcomes After Drug-Eluting Stents: Landmark Analysis from the TAXUS Trials. Circulation 2007;116:2357.

643. Aoki J, **Stone GW**, Mehran R, Moses JW, Bertrand ME, Lincoff AM, Ohman OM, White HD, Parise H, Leon MB, Lansky AJ. Predictors of Early Stent Thrombosis in Patients with Acute Coronary Syndromes in the Drug-Eluting Stent Era: Analysis from the ACUITY Trial. Circulation 2007;116:2564.

644. Sakurai R, Courtney BK, Yamasaki M, Tsujuno I, Waseda K, Hasegawa T, Shimohama T, Ako J, Hongo Y, Morino Y, Miyazawa A, Hur SO, Koizumi T, Honda Y, Yock PG, Lansky AJ, Sudhir K**, Stone GW,** Fitzgerald PJ. Neointimal Hyperplasia Patterns Among 3 Drug-Eluting Stents: A Comparative Intravascular Ultrasound Analysis of Everolimus, Sirolimus and Paclitaxel Eluting Stents. Circulation 2007;116:2770.

645. Yamasaki M, Tsujino I, Sakurai R, Waseda K, Hasegawa T, Shimohama T, Ako J, Honda Y, Sood P, Lansky A, Sudhir K, **Stone GW**, Fitzgerald PJ. Comparison of Everolimus-Eluting Stents with Paclitaxel-Eluting Stents in DeNovo Native Coronary Artery Lesions: Intravascular Ultrasound Results from the SPIRIT III Trial. Circulation 2007;116:2771.

646. Kirtane AJ, Parise H, Mehran R, Moses JW, Fahy M, Bertrand ME, Ohman EM, White HD, Feit F, Colombo A, Mc Laurin BT, Cox DA, Ware JH, Pocock S, **Stone GW**. Comparison of Catheterization Lab Initiated Abciximab and Double-Bolus Eptifibatide during Percutaneous Coronary Intervention in Acute Coronary Syndromes: An ACUITY Substudy. Circulation 2007;116:2830.

647. Ebrahimi R, Feit F, Manoukian SV, Lincoff AM, Dyke C, Gersh B, Mehran R, Moses JW, **Stone GW**. Implications of preoperative Thienopyridine Use in Patients with non-ST Elevation Acute Coronary Syndrome Undergoing Coronary Artery Bypass Surgery: One year results from the ACUITY Trial. Circulation 2007;116:3204.v

648. Kirtane AJ, Parise H, Mehran R, Moses JW, Fahy M, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, **Stone GW**. Comparison of Upstream Tirofaban and Eptifibatide Use in Patients with Moderate and High Risk Acute Coronary Syndromes: An ACUITY Substudy. Circulation 2007;116:3219.

649. Feit F, Manoukian SV, Dangas GD, Lincoff Am, Ohman EM, Attubato MJ, Mehran R, **Stone GW**. Bivalirudin Monotherapy Provides Similar One-Year Survival Compared to Heparin GP IIb/IIIa Inhibitos in Diabetic Patients with Acute Coronary Syndromes. Results from the Randomized ACUITY Trial. Circulation 2007;116:3220.

650. Amakaturi SR, Mehran R, Obuani K, Gupta A, Syros G, Kreps EM, Collins MB, Gray WA, Moses JW, Leon MB, **Stone, GW**, Dangas GD. Circulation 2007;116:3347.

651. Dangas G, Guagliumi G, Witzenbichler B, Bhatt D, Feit F, Ohman EM, Wong SC, Parise H, Mehran R, **Stone GW**. Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:The HORIZONS AMI Trial. *J Am Coll Cardiol Intv* 2008;1:B1.

652. Oviedo CR, Maehara A, Mintz GS, Liu J, Yang J, Tsujita K, Kubo T, Doi H, Castellanos C, Lansky AJ, Mehran R, Dangas GD, Moses JW, Leon MB, **Stone GW**. A Critical Intravascular Ultrasound Appraisal of the Angiographic Classification of Bifurcation Lesions: Where Is the Plaque Really Located? *J Am Coll Cardiol Intv* 2008;1:B10.

653. Missel E, Mintz GS, Maehara A, Biro S, Castellanos C, Kaple R, Dangas G, Moses J, **Stone GW**, Leon MB. High-Risk Lipid Profile Is Related to the Ratio of Necrotic Core to Calcification in Human Coronary Arteries: Results From the Prospective, Multicenter VHIVUS Registry. *J Am Coll Cardiol Intv* 2008;1:B11.

654. Cox DA, Hermiller J, Cannon L, O'Shaugnessy C, Mann JT, Turco M, Greenberg J, Maloney T, Fahy M, Ellis S, **Stone G**. Are DES Beneficial in Large Vessels Compared to BMS?: Data from the TAXUS IV and V Randomized Clinical Trials. *J Am Coll Cardiol Intv* 2008;1:B15.

655. Ellis SG, Colombo A, Grube E, **Stone GW**, Friedman M, Baim DS. Characterization of Target Lesion Revascularization After TAXUS Express Paclitaxel-Eluting Stent Implantation. *J Am Coll Cardiol Intv* 2008;1:B16.

656. **Stone GW**, Ellis SG, Hermiller JB, Popma JJ, Weissman NJ, Mandinov L, Baim DS. Is Diabetes a Risk Factor for Restenosis and Adverse Clinical Outcomes After Paclitaxel-eluting Stent Implantation? Pooled Analysis of the TAXUS IV and TAXUS V Trials. *J Am Coll Cardiol Intv* 2008;1:B16.

657. Missel E, Mintz GS, Garcia-Garcia H, Kaple RK, Castellanos C, Biro S, Moses JW, **Stone GW**, Leon MB. Among Serum Lipid Profile Parameters High-Density Lipoprotein Cholesterol Is the Major Determinant of Coronary Plaque Burden: A Volumetric Intravascular Ultrasound Analysis. *J Am Coll Cardiol Intv* 2008;1:B26.

658. Shimohama T, Ako J, Yamasaki M, Tsuhino I, Hassan AHM, Hasegawa T, Sakurai R, Waseda K, Yock PG, Honda Y, Sudhir K, **Stone GW,** Fitzgeral PJ. Eight-Month Volumetric IVUS Analysis in DM and Non- DM Patients Treated With XIENCE V Everolimus-Eluting Coronary Stent. *J Am Coll Cardiol Intv* 2008;1:B43.

659. Lansky AJ, Midei M, Newman W, Sanz M, Sood P, Doostzadeh J, Su X, Cao S, White R, Sudhir K**, Stone GW**. Gender-Based Evaluation of XIENCE V Everolimus-Eluting Coronary Stent System: Clinical and Angiographic Results From the SPIRIT III Randomized Trial. *J Am Coll Cardiol Intv* 2008;1:B46.

660. Kubo T, Maehara A, Mintz GS, Doi H, Tsujita K, Yang J, Liu J, Oviedo C, Tam A, Bharaj H, Guillaume J, Abendroth R, Biro S, Aaskar R, Castellanos C, Dani L, Moses JW, Leon MB, Vince DG, Margolis MP, **Stone GW**, Margolis JR. Analysis of the Long-term Effects of Drug-eluting Stents on Coronary Arterial Healing by Virtual Histology Intravascular Ultrasound. *J Am Coll Cardiol Intv* 2008;1:B51.

661. Dudek D, Zmudka K, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Kornowski R, Hartmann F, Möckel M, Ochala A, Parise H, Mehran R, **Stone GW.** Impact of advanced age on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: The HORIZONS AMI trial. *J Am Coll Cardiol Intv* 2008;1:B67.

662. Witzenbichler B, Guagliumi G, Desaga M, Kochman J, Nilsen D, Finkelstein A, Mosseri M, Parise H, Mehran R, **Stone GW**. Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: The HORIZONS AMI trial. *J Am Coll Cardiol Intv* 2008;1:B67.

663. Obunai K, Dangas GD, Moses JW, Brar S, Collins MB, Kreps EM, Gupta A, Atmakuri SR, Tyagi S, Leon MB, **Stone GW,** Mehran R. Clinical and Angiographic Predictors for Successful and Unsuccessful Percutaneous Revascularization of Coronary Chronic Total Occlusions. *J Am Coll Cardiol Intv* 2008;1:B73-4.

664. Chirumalilla A, Brar S, Dangas G, Isiaka V, Papkostas E, Morales A, Franklin-Bond T, **Stone GW,** Leon MB, Moses JW, Lansky A, Mehran R. The Association of Race/Ethnicity with Contrast Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention. *J Am Coll Cardiol Intv* 2008;1:B84.

665. Chirumalilla A, Brar S, Dangas G, Lansky A, Weisz G, Kirtane A, Higginbotham L, Franklin-Bond T, Leon MB, Moses JW, **Stone GW**. Percent Change in Renal Function After Contrast Exposure is Associated with Long-term Adverse Events in Patients Undergoing Percutaneous Coronary Interventions. *J Am Coll Cardiol Intv* 2008;1:B84-5.

666. Guagliumi G, Witzenbichler B, Peruga J, Brodie B, Dudek D, Kornowski R, Kochman J, Almagor Y, Nilsen D, Kirtane A, Parise H, Mehran R, **Stone GW**. Safety and effectiveness of bivalirudin compared to either abciximab or eptifibatide in patients with acute myocardial infarction undergoing primary angioplasty: The HORIZONS AMI trial. *J Am Coll Cardiol Intv* 2008;1:B87.

667. Mehran R, Witzenbichler B, Guagliumi G, Guetta V, Suryapranata H, Huber K, Woehrle J, Metzger C, Dangas G, Parise H, **Stone GW**. Impact of baseline renal function on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: The HORIZONS AMI trial. *J Am Coll Cardiol Intv* 2008;1:B87-8.

668. Brodie BR, Stuckey T, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Kornowski R, Hartmann F, Dangas G, Wong SC, Parise H, Mehran R, **Stone GW**. Major Adverse Events in STEMI Patients Treated with Primary Angioplasty Occur More Frequently at U.S. Compared with Non U.S. Sites: Analysis from the HORIZONS AMI Trial. *J Am Coll Cardiol Intv* 2008;1:B88.

669. Brar S, Chirumamilla A, Mehran R, Syros G, Singh V, Singh B, Taviloglu G, Higginbotham L, **Stone GW**, Moses JW, Leon MB, Dangas G. Long Term Adherence to Dual Antiplatelet Therapy and Late Adverse Cardiovascular Events. *J Am Coll Cardiol Intv* 2008;1:B88.

670. Liu J, Maehara A, Mintz GS, Weissman NJ, Ellis SG, Grube E, Dawkins KD, Yu A, Wang H, Mandinov L, **Stone GW**. Optimal criteria for stent edge landing zones: An integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI Studies. *J Am Coll Cardiol Intv* 2008;1:B92.

671. Sorajja P, Gersh B, McLaurin B, Cox D, Bertrand M, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Mehran R, Ohman EM, **Stone GW**. Increased Mortality in Patients with Acute Coronary Syndromes and Delay to Angioplasty of Greater than 24 Hours after Hospital Admission: An ACUITY Substudy. *J Am Coll Cardiol* 2008;l51(10)(suppl):A215.

672. Manoukian SV, Feit F, Steinhubl SR, Voeltz MD , Dangas GD, Ebrahimi R, Mehran R, **Stone GW.** Major Bleeding Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With Acute Coronary Syndromes: Results From the ACUITY Trial. *J Am Coll Cardiol* 2008;51(10)(suppl):A219.

673. Manoukian SV, Voeltz MD, Feit F, Rao SV, Steinhubl SR, Dangas GD, Mehran R, **Stone GW**. Transfusion Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With Acute Coronary Syndromes: Results From the ACUITY Trial. *J Am Coll Cardiol* 2008; 51(10)(suppl):A220.

674. Manoukian SV, Dangas GD, Voeltz MD, Feit F, Mehran R, **Stone GW**. Anemia Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With Acute Coronary Syndromes: Results From the ACUITY Trial. *J Am Coll Cardiol* 2008;51(10)(suppl):A220.

675. Pinto DS, **Stone GW**, York M, Reynolds MR, McLaurin BT, Cox D, Schneider E, Shi C, Walczak J, Machon DA, Berezin R, Mehran R, Ohman EM, Lincoff AM, Cohen DJ. Economic Evaluation of Bivalirudin With or Without Glycoprotein IIB/IIIA Inhibition Versus Heparin With Routine Glycoprotein IIB/IIIA Inhibition for Early Invasive Management of Acute Coronary Syndromes. *J Am Coll Cardiol* 2008;51(10)(suppl):A219.

676. Obunai K, Brar S, Moses JW, Leon MB, **Stone GW**, Dangas GD, Franklin-Bond T, Godino C, Bassanelli G, Montorfano M, Carlino M, Lelasi A, Chieffo A, Colombo A, Mehran R. Clinical Impact of Successful Percutaneous Revascularization of Chronic Total Occlusions: 3-Year Follow-up Results from an International Multicenter CTO Registry. *Am J Cardiol* 2008;102 (suppl 8A):11i

677. Mehran R, Dangas GD, Weisz G, Manoukian SV, Colombo A, Moses J, Feit F, Pocock S, Ohman EM, Lincoff AM, White HD, Lansky AJ, **Stone GW**. Contrast-Induced Nephropathy Redefined: Impact of Any Kidney Injury on Clinical Outcomes in Patients with ACS undergoing Angiography: Results from the ACUITY Trial. *Am J Cardiol* 2008;102 (suppl 8A): 33i

678. Brar S, Leon MB, Mehran R, Moses JW, **Stone GW**, Dangas GD. Meta-analysis of Drug-eluting Stents in Acute Myocardial Infarction: Results in 23,711 Patients from Randomized Controlled Trials and Registries. *Am J Cardiol* 2008;102 (suppl 8A): 34i

679. Kirtane AJ, Mehran R, Parise H, Pocock S, Clayton T, Witzenbichler B, Guagliumi G, Peruga J, Kornowski R, Nikolsky E, Ohman EM, Kastrati A, Dangas GD, Lanksy AJ, **Stone GW.** Relative Prognostic Utility of Different Bleeding Scales Among Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction: The HORIZONS-AMI Trial. *Am J Cardiol* 2008;102 (suppl 8A): 46i

680. Parise H, Mehran R, Witzenbichler B, Guagliumi G, Peruga J, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh B, Pocock S**,** Dangas G, Wong SC, Kirtane AJ, Lanksy AJ, **Stone GW.** Relative Impact of MACE and Varying Definitions of Major Bleeding on Mortality: Results from the HORIZONS-AMI Trial. *Am J Cardiol* 2008;102 (suppl 8A): 47i

681. Caixeta A, Aoki J, Dangas GD, Mehran R, Moses JW, Steinhubl SR, Feit F, White HD, Ohman EM, Manoukian SV, Prats J, **Stone GW**. Incidence and Clinical Consequence of Acquired Thrombocytopenia Following Antithrombotic Therapies in Patients with Acute Coronary Syndromes: Insights from the ACUITY Trial. *Am J Cardiol* 2008;102 (suppl 8A): 49i

682. Caixeta A, Aoki J, Dangas GD, Mehran R, Witzenbicher B, Guagliumi G, Peruga JZ, Brodie B, Dudek D, Kornowski R, Hartmann F, Parise H, **Stone GW**. Impact of Baseline Thrombocytopenia on the Treatment of Primary Angioplasty in Acute Myocardial Infarction: The HORIZONS-AMI Trial. *Am J Cardiol* 2008;102 (suppl 8A):57i

683. Mehran R, Brar S, Dangas G, Fiscella D, Caixeta A, Weisz G, Rabbani L, Sfakianakis K, Stent J, Moses JW, **Stone GW**. Prognostic Utility of the Baseline White Blood Cell Count in Patients with Acute Coronary Syndromes: The ACUITY Trial. *Am J Cardiol* 2008;102 (suppl 8A): 60i

684. R Wu, N Verma, M Herscher, L Higginbotham, P Boland, N Dasgupta, D Fiscella, T Franklin-Bond, K Morgan, J Stant, F Esposito, G Piri, L Gaus, S Walter, L Rabbani, G Weisz, S Brar, **G Stone**, M Leon, J Moses**,** G Dangas. Thrombectomy Prior to Stent Implantation in Patients with Visible Thrombus: Is There a Benefit?. *Am J Cardiol* 2008;102 (suppl 8A): 121i

685. Kirtane AJ, Mehran R, Brar S, Fahy M, Dangas GD, Feit F, Moses JW, Manoukian S, White HD, Lanksy AJ, **Stone GW.** Outcomes Related to Drug-Eluting Stents vs. Bare Metal Stents in Saphenous Vein Graft Intervention: An ACUITY Substudy. *Am J Cardiol* 2008;102 (suppl 8A): 154-5i

686. Caixeta A, Weisz G, Mehran R, Collins MB, Singh V, Lanksy AJ, Kodali S, Franklin-Bond T, Matharoo N, Wu R, Franklin D, Morgan K, **Stone GW**, Moses J, Fahy M, Leon M, Dangas G. The Safety and Effectiveness of Cypher Stent for Bifurcation versus Non-Bifurcation Lesion. Two-Year Follow-Up Analysis From the MATRIX Registry. *Am J Cardiol* 2008;102 (suppl 8A): 155-6i

687. Feit F, Manoukian SV, Ohman EM, Attubato MJ, Mehran R, Chew D, White HD, **Stone GW.** Bivalirudin Monotherapy Provides Similar One-Year Survival Compared to Heparin plus GP IIb/IIIa Inhibitors Among Diabetic Patients Undergoing Percutaneous Coronary Intervention: Results from the ACUITY Trial. *Am J Cardiol 2008*;102 (suppl 8A):1i

688. Obunai K, Brar S, Moses JW, Leon MB, **Stone GW**, Dangas GD, Franklin-Bond T, Godino C, Bassanelli G, Montorfano M, Carlino M, Lelasi A, Chieffo A, Colombo A, Mehran R. Clinical Impact of Successful Percutaneous Revascularization of Chronic Total Occlusions: 3-Year Follow-up Results from an International Multicenter CTO Registry*. Am J Cardiol 2008*;102 (suppl 8A):11i

689. Dixon SR, L'Allier P, Moses JW, Petersen J,Cutlip D, Grines C, Weisz G, Hendricks MJ,
Sum ST, Muller JE, Krucoff MW, Tardif J-C, Waxman S, **Stone GW,** Goldstein JA. Near-Infrared Spectroscopic Measurement of Lipid-Core Coronary Plaque Length: Implications for Complete Lesion Coverage in Patients Undergoing Stenting. *Am J Cardiol 2008*;102 (suppl 8A):19i

690. Möckel M, Vollert J, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Kornowski R, Dudek D, Moore C, Parise H, Mehran R, **Stone GW.** Impact of Direct Stenting on The Outcomes of Primary Angioplasty in Acute Myocardial Infarction: The HORIZONS-AMI Trial. *Am J Cardiol 2008*;102 (suppl 8A):34-5i

691. R Wu, N Verma, M Herscher, L Higginbotham, P Boland, N Dasgupta, D Fiscella, T Franklin-Bond, K Morgan, J Stant, F Esposito, G Piri, L Gaus, S Walter, L Rabbani, G Weisz, S Brar, **G Stone**, M Leon, J W Moses, G Dangas. Thrombectomy Prior to Stent Implantation in Patients with Visible Thrombus: Is There a Benefit? *Am J Cardiol* 2008;102 (suppl 8A):121i

692. Kirtane AJ, Mehran R, Brar S, Fahy M, Dangas GD, Feit F, Moses JW, Manoukian S, White HD, Lanksy AJ, **Stone GW.** Outcomes Related to Drug-Eluting Stents vs. Bare Metal Stents in Saphenous Vein Graft Intervention: An ACUITY Substudy. *Am J Cardiol 2008*;102 (suppl 8A):154-5i

693. Wöhrle J, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh B, Parise H, Mehran R, **Stone GW**. Does Presentation at a Non PCI Facility Requiring Transfer Worsen Prognosis in

Patients With Acute MI Undergoing Primary Angioplasty? The HORIZONS-AMI Trial. *Am J Cardiol* 2008;102 (suppl 8A):56i

694. Ebrahimi R, Manoukian SV, Feit F, Lincoff AM, Dyke C, Gersh B, Mehran R, Moses JW, **Stone GW**. Upstream Bivalirudin Monotherapy Results in Similar One Year Survival as Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients With Non-ST-Elevation Acute Coronary Syndromes Undergoing Bypass Graft Surgery: A Report From the ACUITY Trial. *Am J Cardiol* 2008;102 (suppl 8A):59i

695. Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh B, Lansky AJ, Parise H, Mehran R, **Stone GW.** Do Vascular Closure Devices Reduce Bleeding Complications After Primary PCI in ST-Segment Elevation Myocardial Infarction? The HORIZONS-AMI Trial. *Am J Cardiol 2008*;102 (suppl 8A):75i

696. Tsujita K, Maehara A, Mintz GS, Kubo T, Doi H, Castellanos C, Liu J, Yang J, Oviedo C, **Stone GW**, Leon MB, Moses JW, Ochiai M. Intravascular Ultrasound Comparison of Retrograde vs Antegrade Approach to Percutaneous Intervention for Chronic Total Coronary Occlusion. *Am J Cardiol 2008*;102 (suppl 8A):109i

697. Weisz G, Mehran R, Rabbani L, Kornowski R, Hartmann F, Wong SC, Lanksy A, Parise H, **Stone GW.** Contrast-Induced Nephropathy is Frequent and is a Powerful Independent Predictor of Morbidity and Mortality In Patients With Acute Myocardial Infarction Treated With Primary PCI: The HORIZONS-AMI Trial. *Am J Cardiol* 2008;102 (suppl 8A):115-6i

698. Shimohama T, Otake H, Ako J, Yamasaki M, Tsujino I, Waseda K, Hasegawa T, Sakurai R, Nakatani D, Chang H, Yock PG, Honda Y, Kusano H, Sudhir K, Saito S, **Stone GW,** Fitzgerald PJ. IVUS Analysis in the SPIRIT III Japan Treated with XIENCET V Everolimus-Eluting Stent Compared to the SPIRIT III US Arm. *Am J Cardiol* 2008;102 (suppl 8A):138i

699. Gordon PC, Weinsier SB, Su X, White R, Doostzadeh J, Cao S, Sood P, Sudhir K, **Stone GW**. Angiographic and Clinical Outcomes from the XIENCE V 4.0mm Registry Arm of the SIII Trial. *Am J Cardiol* 2008;102 (suppl 8A):152i

700. Hermiller J, Fergus T, Pierson W, Su X, White R, Sood P, Sudhir K, **Stone G.** Clinical and Angiographic Results of Small Vessel Stenting from the SPIRIT III Randomized Trial: A Comparison of the 2.5mm Everolimus-Eluting XIENCE and Paclitaxil-Eluting TAXUS Stents. *Am J Cardiol* 2008;102 (suppl 8A):149i

701. Otake H, Ako J, Yamasaki M, Tsujino I, Shimohama T, Hasegawa T, Sakurai R, Waseda K, Yock P, Honda Y, Sudhir K, **Stone G**. Vascular Response to Overlapping Everolimus-eluting stents: Comparison with Paclitaxel-eluting Stents. *Am J Cardiol* 2008;102 (suppl 8A):170i

702. Oviedo C, Maehara A, Mintz GS, Fiscella D, Tsujita K, Doi H, Kubo T, Liu J, Yang J, Aaskar R, Dani L, Biro S, Moses JW, Leon MB, **Stone GW.** Spatial Distribution Of Fibroatheromas In The Left Main Bifurcation, A Virtual Histology Assessment. *Am J Cardiol* 2008; 102 (suppl 8A):195i

703. Kubo T, Maehara A, Mintz GS, Doi H, Tsujita K, Yang J, Liu J, Oviedo C, Tam A, Bharaj H, Abendroth R, Biro S, Aaskar R, Castellanos C, Dani L, Moses JW, Vince G, Margolis P, Margolis JR, **Stone GW**, Leon MB. Natural History of Coronary artery Lesion Morphology Assessed by Serial VH-IVUS Tissue Characterization. Circulation 2008:118:18

704. Nikolsky E, Mehran R, Mintz GS, Ellis SG, Lansky AJ, Fahy M, Donohoe D, **Stone GW**, Weisz G, Leon MB, Moses JW. Drug-Eluting Stents in the Treatment of Intermediate Lesions: Pooled Analysis from 14 Randomized Clinical Trials. Circulation 2008:118:18

705. Kirtane AJ, Gupta A, Iyengar S, Mehran R, Moses JW, Leon MB, Applegate R, Hannan E, Harjai K, Racz M, Jensen LO, Park SJ, Perry R, Saia F, Simonton C, Tu JV, Waksman R, **Stone GW**. Drug-Eluting Stent Versus Bare Metal Stent Use: Metanalysis of Randomized Trials and Observational Studies. Circulation 2008:118:18

706. Chirumamilla A, Mehran R, Weisz G, Brar SS, Rabbani R, Morales A, Reddy S, Sugirtharaj DD, Franklin D, Fiscella D, Sfakianakis K, Collins MB, Leon MB, **Stone GW**, Moses JW, Dangas G. Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention: One Year Outcome. Circulation 2008:118:18

707. Nikolsky E, Megran R, Dangas G, Ellis SG, Lansky AJ, Fahy M, Donohoe D, **Stone, GW**, Leon MB, Moses JW. Long-term Follow-up of Patients with Unstable Angina Treated with Drug-Eluting Stents: Pooled Analysis from 14 Clinical Trials. Circulation 2008:118:18

708. Brar S, Galper B, Dangas G, Fiscella D, Dasgupta N, Wu R, Hirscher M, **Stone GW**, Moses JW, Leon MB, Mehran R. What are the Reasons for Clopidogrel Discontinuation after PCI? Circulation 2008:118:18

709. Brar S, McLaurin B, Cox DA, Bertand ME, Lincoff AM, Moses JW, White HD, Ohman EM, Mehran R, Lansky A, Parise H, **Stone GW**. Anti-thrombotic Strategies in Patients with Elevated Biomarkers Undergoing PCI: Results from the ACUITY Trial. Circulation 2008:118:18

710. Parise H, Mehran R, Witzenbichler B, Guagliumi F, Peruga JZ, Brodie BR, Dudek D, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane A, Lansky AJ, **Stone GW**. Impact of Major Adverse Cardiac Events and Major Bleeding on

Overall Mortality in Patients with Acute Myocardial Infarction: Results from the HORIZONS-AMI Trial. Circulation 2008:118:18

711. Brar S, McLaurin BT, Cox DA, Feit F, Colombo A, Aylward P, Cequir AR, Darius H, Desmet W, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Kirtane A, Lansky A, Parise H, **Stone GW**. Bivalirudin in Patients with Acute Coronary Syndromes Undergoing Saphenous Vein Graft Percutaneous Coronary Intervention: A Subgroup Analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial. Circulation 2008:118:18

712. Mehta R, Harjai KJ, Boura JA, Tcheng JE, **Stone GW**, Grines CL. Is Balloon Angioplasty without Stent Placement Adequate for Patients in Whom Early Coronary Artery Bypass Surgery is Planned after Primary Percutaneous Intervention? Circulation 2008:118:18

713. Robertson JO, Ebrahimi R, Lansky AJ, Mehran R, **Stone GW**, Lincoff AM. Angiographic Evidence of Early Coronary Artery Disease and Increased Risk of Mortality in Smokers with Non ST Segment elevation acute coronary syndromes: An Analysis of the ACUITY Trial. Circulation 2008:118:18

714. Kubo T, Maehara A, Mintz GS, Doi H, Tsujita K, Yang J, Liu J, Oviedo C, Tam A, Bharaj H, Abendroth R, Biro S, Aaskar R, Castellanos C, Dani L, Moses JW, Vince G, Margolis P, Margolis JR, **Stone GW**, Leon MB. Healing of Thin-Capped Fibroatheroma Assessed by Serial VH-IVUS Tissue Characterization. Circulation 2008:118:18

715. Tsujita K, Maehara A, Mintz GS, Kubo T, Doi H, Castellanos C, Liu J, Yang J, Oviedo C, Kaple RK, Malpica EM, Biro S, Dani L, Aaskar R, Moses JW, Leon MB, **Stone GW**. Distribution of Thin-Cap Fibroatheroma and Necrotic Core after Stenting in Patients with Acute Coronary Stndrome: A Virtual Histology Intravascular Ultrasound Study. Circulation 2008:118:18

716. Blankenship JC, Scott TD, Skelding KA, Berger PB, Parise H, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Lansky AJ, Mehran R, **Stone GW**. Presentation To Non PCI Center IS Major Modifiable Factor Associated with Delayed Door to balloon Time in HORIZONS AMI. Circulation 2008:118:18

717. Shimo T, Otake H, Ako J, Yamasaki M, Tsujino I, Waseda K, Hasegawa T, Sakurai R, Nakatani D, Chang H, Yock PG, Honda Y, Kusano H, Sudhir K, Saito S, **Stone GW**, Fitzgerald PJ. SPIRIT III Japan: Eight-Month IVUS Analysis Everolimus –Eluting Stent Compared to the US Arm. Circulation 2008:118:18

718. Tsujita K, Maehara A, Mintz GS, Kubo T, Doi H, Castellanos C, Liu J, Yang J, Oviedo C, **Stone GW**, Leon MB, Moses JW, Ochiai M. Etiology of Chronic Total Coronary Occlusions Assessed by in Vivo Intravascular Ultrasound analysis. Circulation 2008:118:18

719. Kirtane AJ, Mehran R, Parise H, Witzencichler B, Guagliumi G, Peruga JZ, Brodie B, Dudek D, Pocock S, Clayton TC, Tourkova V, Dangas G, Lansky AJ, **Stone GW**. The Impact of Blood Trnasfusion and Other Bleeding Measures on Subsequent Mortality Among Patients Undergoing Primary PCI for Acute Myocardial Infarction: The HORIZONS AMU Trial. Circulation 2008:118:18

720. Otake H, Ako J, Yamasaki M, Tsujino I, Shimohama T, Hasegawa T, Sakurai R, Waseda K, Honda Y, Yock PG, Cheong WF, Sudhir K, **Stone GW**, Fitzgerald PJ. Arterial Responses at Proximal and Distal Edges of Everolimus-Eluting Stents: Insights from the SPIRIT III Randomized Controlled Trial. Circulation 2008:118:18

721. Mehran R, Dangas G, Parise H, Guagliumi G, Witzenbichler B, Grinfeld L, Peruga JZ, Kornowski R, Dudek D, Hoard R, Jastrati A, Herzzentrum D, Brar S, Wu R, Fiscella D, Brodie B, Lansky AJ, **Stone GW**. Prognostic Impact of the Baseline White Blood Cell Count in Patients with Acute myocardial Infarcation Undergoing Primary PCI: Results from the HORIZONS-AMI Trial. Circulation 2008:118:18

722. Goto K, Lansky AJ, Crostea E, Bertrand ME, Lincoff AM, Moses JW, Fahy M, Mehran R**, Stone GW**. Clinical and Angiographic Predictors of 30-day and One-Year Ischemic Cardiac Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An ACUITY Substudy. Circulation 2008:118:18

723. Hirumamilla A, Maehara A, Mintz GS, Mehran R, Caixeta A, Brar S, Iyengar S, Rabbani L, Oveido C, Fiscella D, Sfakianakis K, Kreps EM, Collins MB, Singh V, Melon MB, **Stone GW**, Moses JW, Dangas G. Clopidogrel Resistance and Coronary Artery Plaque Burden in Patients Undergoing Percutaneous Coronary Intervention. Circulation 2008:118:18

724. Obunai K, Godino C, Bassanelli G, Montorfano M, Carlino M, Colantonio R, Mehran R, Dangas G, **Stone GW**, Moses JW, Leon MB, Brar S, Sasgupta N, Chieffo A, Colombo A. Clinical and Angiographic Outcomes After Percutaneous Revascularization of Chronic Total Occlusions with Bare-Metal and Drug-Eluting Stents: 3-year follow-up Results from an International Multicenter CTO Registry. Circulation 2008:118:18

725. Lansky AJ, Goto K, Cristea E, Fahy M, Mehran R, **Stone GW**. Clinical and Angiographic Predictors of 30-Day and One-Year Cardiac Ischemic Events in Patients with Non-ST Elevation Acute Coronary Syndromes: Results from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) Trial. Circulation 2008:118:18

726. Yang J, Maehara A, Mintz GS, Kubo T, Doi H, Tsujita K, Liu J, Oviedo C, Castellanos C, Moses JW, Kuznicki JJ, Vince GD, Margolis P, Margolis JR, **Stone GW**, Leon MB. Are Lesions that Appear Echolucent on Greyscale IVUS Imaging "Vulnerable"? A Virtual Histology Intravascular Ultrasound Analysis. Circulation 2008:118:18

727. Otake H, Ako J, Yamasaki M, Tsujino I, Shimohama T, Hasegawa T, Sakurai R, Waseda K, Yock PG, Honda Y, Sood P, Sudhir K, **Stone GW**. Fitzgerald PJ. Efficacy of the Everolimus-eluting Stent in Diabetic Patients: Comparison with the Paclitaxel-eluting Stent. Circulation 2008:118:18

728. Goto K, Lansky Aj, Mutlu H, Cristea E, Mehran R, Cox D, Bertrand M, Feit F, Hamon S, Manoukian SV, Dangas G, Ohman EM, Gersh B, Moses JW, **Stone GW**. Myocardial Blush Predicts Outcomes in Patients with Acute Coronary Syndromes: Ananalysis of the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) Trial. Circulation 2008:118:18.

729. Opolski MP, Pracon R, Mintz GS, Weissman NJ, Mandinov L, Pregowski J, Kruk M, Witowski A, Wang H, Ellis SG, Grube E, Dawkins KD, **Stone GW.** Stent Strut Distribution at Implantation and 9-Month Follow-up in RAXIS and Bare Metal Stents and Its Effect on Neointimal Hyerplasia. An intravascular Ultrasound Integrated Analysis of the Randomized TAXUS IV, V and VI Trials. JACC 2009;53:A8.

730. Onuma Y, Serruys PW, Kukureja N, **Stone GW**. Randomized Comparison of Everolimus-eluting and Paclitaxel-eluting Stents: Pooled analysis of Two-Year Clinical Follow-up from the SPIRIT II and III Trials. JACC 2009;53:A9.

731. Nikolsky E, Mehran R, Parise H, Lansky AJ, Dangas, GD, Manoukian SV, Voeltz M, Alexander KP, Ohman EM, Dudek D, Lincoff AM, **Stone GW**. Impact of Different Antithrombotic Regimens on Ischemic and Hemorrhagic Outcomes Following Percutaneous Coronary Intervention in Elderly: Pooled analysis from the REPLACE-2 , ACUITY and HORIZONS-AMI Trials. JACC 2009;53:A27.

732. Weisz G, Mehran R, Dangas G, Nikolsky E,Rabbani L, Ben-Gai Y, Fahy M, Singh V, Lansky AJ, Moses JW, **Stone GW**. Impact of PCI vs. CABG on the Development of Acute Renal Failure in Patients with Acute Coronary Syndromes: Insights from the ACUITY Trial. JACC 2009;53:A29.

733. Goto K, Lansky AJ, Cristea E, Fahy M, Feit F, Ohman ME, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Manoukian SV, Ebrahimi R, Pollack CV, Attubato MJ, Mehran R, **Stone GW**. Clinical and Angiographic Predictors of Death or Myocardial Infarction in Diabetics with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An ACUITY Subanalysis. JACC 2009;53:A30.

734. Feit F, Gurum HS, Witzenbichler B, Parise H, Lincoff AM, Manoukian SV, White HD, Pocock SJ, Mehran R, **Stone GW**. Outcomes of patients with diabetes mellitus undergoing PCI treated with Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor. Pooled analysis from the REPLACE-2, ACUITY and Horizons-AMI Trials. JACC 2009;53:A31.

735. Mehran R, Dangas GD, Lansky AJ, Nikolsky E, Chew DP, Lincoff AM, Topol E, Pocock SJ, Witzenbichler B, Parise H, **Stone GW**. Bivalirudin therapy reduces 30-day bleeding complications in patients with chronic renal insufficiency: A pooled analysis of the REPLACE-2, ACUITY and HORIZONS Trials. JACC 2009;53:A36.

736. Weisz G, Mehran R, Rabbani L, Nikolsky E, Kornowski R, Hartmann F, Wong SC, Lansky AJ, Parise H, **Stone GW.** Contrast-induced nephropathy occurs frequently and is a powerful independent predictor of morbidity and mortality in patients with acute myocardial infarction undergoing primary PCI. JACC 2009;53:A36.

737. Dangas GD, Guagliumi G, Witzenbichler B, Bhatt D, Feit F, Ohman M, Wong SC, Nikolsky E, Caixeta A, Parise H, Lansky AJ, Mehran R, **Stone, GW**. Impact of Clopidogrel Loading Dose on the Effectiveness of Bivalirudin in Primary Angioplasty for Acute Myocardial Infarction: The HORIZONS –AMI Trial. JACC 2009;53:A57.

738. Lansky AJ, Parise H, Grinfeld L, Lincoff AM, Pocock SJ, Mehran R, **Stone GW**. Bivalirudin Therapy Reduces 30 day Bleeding Complications in Women Undergoing PCI for Acute Coronary Syndrome: Results of the REPLACE-2, ACUITY and HORIZONS pooled Analysis. JACC 2009;53:A63.

739. Lansky AJ,Goto K, Fahy M, Jung J, Nikolsky E, Ohman ME, White HD, Bertrand ME, Lincoff AM, Moses JW, Mehran R, **Stone GW**. Clinical and Angiographic Risk Score to Predict Ischemic Outcomes at 1 year in Acute Coronary Syndromes: The ACUITY Risk Score. JACC 2009;53:A63.

740. Dudek D, Mehran R, Zmudka K, Witzenbichler B, Guagliumi G, Perugz JZ, Brodie BR, Kornowski R, Hartmann F, Mockel M, Ochala A, Parise H, Nikolsky E, Lansky AJ, **Stone GW.** Late Outcomes of Elderly Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty: One Year Results from the HORIZONS-AMI Trial. JACC 2009;53:A66.

741. Goto K, Lansky AJ, Crostea E, Fahy M, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, **Stone GW.** Impact of Bivalirudin Monotherapy on 30-day outcomes in patients with Acute Coronary Syndromes and Complex Coronary Stenoses Undergoing Percutaneous Coronary Intervention. JACC 2009;53:A66.

742. Godino C, Mehran R, Dangas GD, Obunai K, Leon MB, **Stone GW**, Moses JW, Brar S, Colantonio R, Montofano M, Carlino M, Chieffo A, Colombo A. Clinical Impact of Percutaneous Coronary Intervention in Totally occluded left anterior descending artery. JACC 2009;53:A79.

743. Oviedo C, Maehara A, Mintz GS, Fiscella D, Tsujita K, Kubo T, Doi H, Castellanos C, Yang J, Mehran R, Dangas GD, Leon MB, **Stone GW**, Araki H, Ochiai M, Moses JW. Is an accurate evaluation of the left circumflex ostium from the left anterior descending-left main possible? AN Intravascular Ultrasound Study. JACC 2009;53:A90.

744. L'lallier, PL, Tardif JC, Dixon SR, Moses JW, Petersen JL, Weisz G, Cutlip DE, Kruckoff MW, Mueller JE, Hendricks MJ, Sum ST, **Stone GW**, Goldstein JA, Waxman S. Frequency of Lipid Core Plaque as Determined by Near-Infrared Spectroscopy at Target Lesion Sites in Patients Undergoing PCI. JACC 2009;53:A90.

745. Goldstein JA, Dixon SR, L'Allier PL, Moses JW, Petersen JL, Cutlip DE, Weisz G, Safian RD, Hendricks MJ, Sum ST, Mueller JE, Kruckoff MW, Tardif JC, Waxman S, **Stone GW**. Near-Infrared Spectroscopic Detection of Lipid-Core Coronary Plaques Remote From the Target Lesion in Patients Undergoing PCI. JACC 2009;53:A99.

746. Wu X, Maehara A, Mintz GS, Kubo T, Doi H, Tsujita K, Yang J, Oviedo C, Xu K, He Y, Choi SY, castellanos C, Moses JW, Leon MB, DeBruyne B, Serruys PW, **Stone GW.** Virtual Histology Intravascular Ultrasound Analysis of attenuated Plaques Detected by Greyscale Intravascular Ultrasound in Patients with Acute Coronary Syndromes: a PROSPECT Substudy. JACC 2009;53:A99.

747. Ellis SG, Anwaruddin S, O'Shaughnessy CD, Kent KM, Martin SL, McGarry TF, Kereiakis DJ, Baim DS, **Stone GW**. Paclitaxel-eluting Stents for the Treatment of Bare Metal Stent Restenosis: Three-Year Results of the TAXUS V ISR Trial. JACC 2009;53:A14.

748. Nikolsky E, Mehran R, Lansky AJ, Caixeta A, Dangas GD, Weisz G, Giuran IB, Fahy M, Lincoff AM, Witzenbichler B, **Stone GW**. Impact of Gastrointestinal Bleeding on Outcomes of Patients Treated with Contemporary Antithrombotic Strategies: Pooled Analysis From 3 Randomized Trials. JACC 2009;53:A28.

749. Witzenbichler B, Mehran R, Guagliumi G, Kornowski R, Desaga M, Kochman J, Nilsen DW, Finkelstein A, Mosseri M, Parise H, Nikolsky E, Lansky AJ, **Stone GW**. Late Outcomes of Patients with Diabetes Mellitus and Acute Myocardial Infarction Undergoing Primary Angioplasty: One Year Results from the HORIZONS AMI Trial JACC 2009;53:A33.

750. Nikolsky E, Lansky AJ, Mehran R, Caixeta A, Dangas GD, Benetato I, Desmet W, **Stone GW**. Outcomes of Patients with Acute Coronary Syndromes and Non-obstructive Coronary Artery Disease: Analysis from the Randomized ACUITY Trial. JACC 2009;53:A47.

751. Grinfeld L, Lansky Aj, Belardi J, Witzenbichler B, Guagliumi G, Zmudka K, Moeckel M, Ochala A, Ruzyllo W, Benetato I, Parise H, Mehran R, **Stone GW**. Impact of Gender on the Safety and Effectiveness of Bivalirudin in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty The HORIZONS-AMI Trial. JACC 2009;53:A59.

752. Sanborn T, Ebrahimi E, Manoukian SV, McLaurin B, Cox DA, Feit F, Hamon M, Mehran R, **Stone GW**. Impact of Vascular Closure Devices and Antithrombotic/Antiplatelet Therapy on Access Site Bleeding. Insights from the ACUITY Trial. JACC 2009;53:A70.

753. Mehran R, Nikolsky E, Lansky AJ, Witzenbichler B, Guagliumi G, Guetta V, Suryapranata H, Huber K, Woehrle J, Metzger C, Dangas GD, Giuran IB, Parise H, **Stone GW**. Impact of Kidney Disease on One- Year Outcomes of Patients with Acute Myocardial Infarction Undergoing primary Angioplasty: Results from the HORIZONS AMI Trial. JACC 2009;53:A74.

754. Caixeta A, Mehran R, Nikolsky E, Lansky AJ, Dangas GD, Moses JW, Kirtane A, Fahy M, **Stone GW**, Leon MB. Four Year Clinical Outcomes After Drug-Eluting and Bare-Metal Stents in Patients with Diabetes Mellitus: Pooled Analysis from 10 Randomized Clinical Trials. JACC 2009;53:A2.

755. Caixeta A, Mehran R, Nikolsky E, Lansky AJ, Dangas GD, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie B, Dudek D, Kornowski R, Hartmann F, Parise H, **Stone GW**. Prognostic Utility of TIMI Flow After Primary PCI in Acute Myocardial Infarction: Insights from the HORIZONS-AMI Trial. JACC 2009;53:A53.

756. Wohrle J, Brodie BR, Guagliumi F, Witzenbichler B, Peruga JZ, Dudek D, Kornowski, Hartmann F, Gersh BJ, Weisz G, Parise H, Mehran R, Vandertie L, Gambone L, **Stone GW**. Presentation at a non PCI facility requiring transfer does NOT worsen long-term prognosis in patients with STEMI undergoing Primary Angioplasty: The HORIZONS-AMI Trial. AM J CARDIOL 2009;104:2.

757. He Y, Nikolsky E, Wu X, Woehrle J, Huber K, Surypranata H, Guetta V, Lansky AJ, Mehran R, Dangas G, **Stone GW**. Impact of Thrombus on Clinical Outcomes of Patients with STEMI Undergoing PCI: Analysis from the HORIZONS AMI Trial. AM J CARDIOL 2009;104:5.

758. Nilsen DWT, Wu R, Nordrehaug JE, Bonarjee V, Tuseth V, Peruga JZ, Brodie BB, Dudek D, Mockel M, Ochala A, Lansky AJ, Mehran R, Nikolsky E, Fahy M, **Stone GW.** Impact of Thrombus Aspiration during Primary Percutaneous Coronary

Intervention in Acute Myocardial Infarction: Analysis from the HORIZONS-AMI Trial. AM J CARDIOL 2009;104:7.

759. Nikolsky E, Mehran R, Ohman ME, Bertrand ME, Lincoff AM, Moses JW, Cristea E, White HD, Goto K, Fahy M. Lansky AJ, **Stone GW**. Bivalirudin versus Heparin Plus Glycoprotein Inhibitors in Patients with acute coronary syndromes and prior coronary artery bypass grafting: Analysis from the ACUITY Trial. AM J CARDIOL 2009;104:10.

760. Mehran R, Pocock S, Clayton T, Lansky AJ, Kirtane A, Dangas G, Manoukian SV, Feit F, White HD, Ohman EM, **Stone GW**. Individual Patient Risks of Major Bleeding and Myocardial Infarction and Their Implications for Mortality and Treatment Choice in Acute Coronary Syndromes: Findings from the ACUITY Trial. AM J CARDIOL 2009;104:15.

761. Kornowski R, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Mehran R, Nikolsky E, Gower MJ, Ortiz S, Banu D, Fahy M, **Stone GW**. Prognostic Impact of Staged vs “One Time” Intervention for Multivessel Disease During Primary PCI in STEMI: Insights from the HORIZONS AMI Trial. AM J CARDIOL 2009;104:18.

762. Ben Gal Y, Mehran R, Moses JW, Weisz G, Ebrahimi R, Lansky AJ, Williams M, Nikolsky E, Gopinathan M, Kesanakurthy V, **Stone GW**. Percutaneous Coronary Interventions versus Surgical Revascularization in the management of Acute Coronary Syndrome. Sub Analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) Trial. AM J CARDIOL 2009;104:21.

763. **Stone GW**, Colombo A, Grube E, Uchida T, Dawkins KD, Baim DS, Ellis SG. Long Term Safety and Clinical Efficacy Outcomes of the Paclitaxel Eluting Stent from a Patient-Level Pooled Analysis of the TAXUS Clinical Trials. AM J CARDIOL 2009;104:37.

764. Sakata K, Ako J, Waseda K, Yamasaki M, Tsujino I, Shimohama T, Otake H, Hasegawa T, Sakurai R, Yock PG, Sudhir K, Kusano H, **Stone GW**, Fitzgerald PJ, Honda Y. Impact of Lumen Narrowing within Everolimus-Eluting Stents on Downstream Vessel Segments. AM J CARDIOL 2009;104:44.

765. Wohrle J, Merkle N, Nusser T, Kunze M, Parise H, Nikolsky E, Maehara A, Lansky AJ, Mehran R, **Stone GW**. Infarct Size after primary angioplasty with Bivalirudin Compared to Unfractionated Heparin Plus Abciximab in STEMI: The HORIZONS –AMI MRI Substudy. AM J CARDIOL;104:176.

766. Rokos I, Farkouh M, Reiffel J, Dressler O, Mattu A, Nikolsky E, Kirtane A, Lansky AJ, Mehran R**, Stone GW**. Association of ST-elevation in Lead AVR with Acute Left Main Coronary Occclusion: Analysis from the HORIZONS –AMI Trial. AM J CARDIOL 2009;104:260.

767. Guo N, Nikolsky E, Lansky AJ, Ben Gal Y, Maehara A, McLaurin BT, Cox DA, Moses JW, Feit F, Colombo A, Mehran R, Lasalle L, **Stone GW**. Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients with Acute Coronary Syndromes and Proximal LAD Disease: Analysis from the ACUITY Trial. AM J CARDIOL 2009;104:287.

768. Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, Lansky AJ, Mehran R, **Stone GW**. Impact of Bivalirudin Therapy in High Risk Patients with acute Myocardial Infarction: One-Year Results from the HORIZONS AMI Trial. AM J CARDIOL 2009;104:304.

769. Nikolsky E, Doll JA, Mehran R, Parise H, Gambone L, Vandertie L, Witzenbichler B, Caixeta A, Guagliumi G, Peruga JZ, Cristea E, Kesanakurthy V, Brodie BR, Dudek D, Lansky AJ, **Stone GW**. Outcomes of Patients Treated with Triple Antithrombotic Therapy after Stenting for ST-Segment Elevation Myocardial Infarction: Analysis from the HORIZONS AMI Trial. AM J CARDIOL 2009;104:305.

770. Wohrle J, Witzenbichler B, Guagliumi G, Brodie BR, Dudek D, Kornowski R, Hartmann F, Parise H, Lansky AJ, Mehran R, Ryan B, Kellock A, Moore C, **Stone GW**. One Year Outcomes of Primary Angioplasty in Acute Anterior Myocardial Infarction with Bivalirudin Compared to Unfractionated Heparin Plus GPIIb/IIIa Inhibitors: The HORIZONS-AMI Trial. AM J CARDIOL 2009;104:306.

771. Farkouh M, Reiffel J, Dressler O, Nikolsky E, Parise H, Cristea E, Lansky AJ, Mehran R, **Stone GW**. Impact of Antithrombotic Therapy and Stent Type on ST-Segment Resolution after Primary Angioplasty for Acute Myocardial Infarction: The HORIZONS-AMI Trial. AM J CARDIOL 2009;104;309.

772. Goto K, Nikolsky E, Lansky AJ, Fahy M, Witzenbichler B, Guagliumi G, Peruga JZ, Cristea E, Jankovic I, LaSalle L, Mehran R, **Stone GW**. Smoking Status Outcomes of Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: The HORIZONS–AMI Trial. AM J CARDIOL 2009;104:321.

773. Lansky AJ, Applegate R, Hermiller JB, Cristea E, Dressler O, Sudhir K, Doostzadeh J, Su X, Koo K **Stone GW**. Side-Branch Occlusion with Xience V Everolimus-eluting and TAXUS Express 2 Paclitaxel-eluting Stents: 2 year results from the SPIRIT III Randomized Trial. AM J CARDIOL 2009;104:364.

774. Ellis SG, Cannon LA, Mann T, Cambier P, O'Shaughnessy CD, DeMaio S, Hall P, Powers ER, Uchida R, Dawkins KD, Baim DS, **Stone GW**. Final 5-Year Outcomes from the TAXUS V denovo Trial: Long Term Safety and Effectiveness

of the Paclitaxel-Eluting TAXUS Stent in Complex Lesions. AM J CARDIOL 2009;104:365.

775. Hermiller J, Applegate RJ, Sanz M, Midei MG, Doostzadeh J, Pierson W, Cao S, Sudhir K, **Stone GW.** Evaluation of Everolimus-Eluting and Paclitaxel-Eluting Stents in Elderly Patients: 2-year Results from the SPIRIT III Randomized Trial. AM J CARDIOL 2009;104:384.

776. Doi H, Maehara A, Mintz G, Yu A, Wang H, Madinov L, Popma JJ, Ellis SG, Grube E, Dawkins KD, Weissman MJ, **Stone GW**. Impact of Post-Intervetnion Minimal Stent Area on Long-Term Patency of Paclitaxel-Eluting Stents: An Integrated Intravascular Ultrasound Analysis from the TAXUS IV, V, VI, and TAXUS ATLAS WH, LL and DS Trials. AM J CARDIOL 2009;104:371.

777. Doi H, Maehara A, Mintz G, Tsujita K, Kubo T, Castellanos C, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA, Parise H, Mehran R, **Stone GW**, Leon MB, Moses JW. Intravascular Ultrasound Patterns of Sirolimus and Paclitaxel Eluting Stent Fractures. AM J CARDIOL 2009;104:375.

778. Applegate RJ, Hermiller JB, Sanz M, Doostzadeh J, Pierson W, Su X, Lansky AJ, Sudhir K, **Stone GW**. Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients with Two Treated Vessels: 2-Year Results from the SPIRIT III Randomized Trial. AM J CARDIOL 2009;104:405.

779. Allplegate RJ, Hermiller JB, Williams JE, Pierson W, Cao S, Su X, Dushir K, Lansky AJ, **Stone GW**. Evaluation of the Effect of Everolimus-Eluting and Paclitaxel-Eluting Stents on Target Lesions with Jailed Side Branches: 2-Year Results from the SPIRIT III Randomized Trial. AM J CARDIOL 2009;104:406.

780. Afolabi-Brown O, Nikolsky E, Mehran R, Lansky AJ, Caixeta A, Fahy M, McLaurin B, Cox D, Feit F, Colombo A, Corral M, Gower MJ, Suryadevara R, **Stone GW**. Impact of Different Glycoprotein IIb/IIIa Inhibitors in Patients with Acute Coronary Syndromes and Baseline Kidney Disease: Analysis from the ACUITY Trial. AM J CARDIOL 2009;104:472.

781. Tsujita K, Maehara A, Mintz GS, Lansky AJ, Kubo T, Doi H, Yang J, Castellanos C, Choi SY, He T, Guo N, Wu X, Bharaj H, Witzenbichler B, Guagliumi G, Brodie BR, Kellett MA, Parise H, Mehran R, **Stone GW**. Impact of Myocardial Bridge on Neointimal Proliferation after Coronary Stenting in patients with Acute Myocardial Infarction: A Serial Intravascular Ultrasound Study. AM J CARDIOL 2009;104:479.

782. Tsujita K, Nikolsky E, Lansky A, Maehara A, Mintz GS, Gambone L, Vandertie L, Caixeta A, Dangas G, Brodie BR, Dudek D, Mockel M, Ochala A, Mehran R, **Stone GW**. Impact of Baseline Anemia and Choice of Antithrombotic Therapy in

Patients with ST-Segment Elevation Myocardial Infarcation Undergoing Primary ngioplasty: The HORIZONS-AMI Trial. AM J CARDIOL 2009;104:505.

783. Feit F, Gurm HS, Manoukian SC, Lincoff AM, Witzenbichler V, Parise H, White HD, Mehran R, **Stone GW**. One-Year Mortality in patients with Diabetes Mellitus Undergoing PCI: Pooled analysis from the REPLACE-2, ACUITY and HORIZONS AMI Trials. AM J CARDIOL 2009;104:507.

784. Lansky AJ, Parise H, Grinfeld L, Lincoff AM, Mehran R, **Stone GW**. Long-Term Mortality with Bivalirudin Therapy in Women Undergoing PCI for Acute Coronary Syndrome: Results of the REPLACE-2, ACUITY and HORIZONS Pooled Analysis. AM J CARDIOL 2009;104:511.

785. Mehran R, Nikolsky E, Dangas G, Chew DP, Lincoff AM, Caixeta A, Topol E, Witzenbichler B, Parise H, Lansky AJ, **Stone GW**. Long-term Mortality After PCI in Patients with Chronic Kidney Disease: A Pooled Analysis of the REPLACE-2, ACUITY and Horizons Trials. AM J CARDIOL 2009;104:512.

786. Schwenkglenks M, Szucs TD, Brazier JE, Blackman DJ, Cyr P, Olchanski N, **Stone GW.** Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. A HORIZONS trial analysis using UK valuations. Value in Health 2009;12:A334.

787. Takashi K, Bezera HG, Guagliumi G, Musumeci G, Valescchi O, Aprile A, Kyuno H, Tahara S, Maehara A, Mintz GS, Lasky A, Dressler O, Mehran R, Costa M, **Stone GW**. Unhealed plaque ruptures after stenting in acute myocardial infarction assessed by intracoronary optical coherence tomography: Incidence, Predictors and clinical implication. Circulation 2009;120(suppl 2):S921**.**

788. He Y, Maehara A, Mintz GS, Choi, SY, Oviedo C, Kubo T, Doi H, Tsujita K, Yang J, Wu X, Guo N, Xu K, Lansky AJ, Moses JW, Leon MB, **Stone GW**, Araki H, Ochiai M. Intravascular ultrasound evaluation of both the left anterior descending and left circumflex branches after left main bifurcation stenting. Circulation 2009;120(suppl 2):S927**.**

789. He Y, Maehara A, Mintz GS, Choi, SY, Oviedo C, Kubo T, Doi H, Tsujita K, Yang J, Wu X, Guo N, Xu K, Lansky AJ, Moses JW, Leon MB, **Stone GW**, Araki H. Variability of distal left main assessment comparing intravascular ultrasound imaging from left anterior descending vs. left circumflex artery Circulation 2009;120(suppl 2):S946.

790. Tahara S, Guagliumi G, Bezerra H, Musumeci G, Sirbu V, Kyono H, Maehara A, Valescchi O, Aprile A, Mintz GS, Dressler O,Lansky AJ, Mehran R, **Stone GW**, Costa M. Delayed strut coverage in a diabetic population treated with Paclitaxel

eluting and bare metal stents: Sub-analysis of the HORIZONS –OCT study. Circulation 2009;120(suppl 2):S946.

791. Kubo T, Maehara A, Mintz GS, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett, MA, Parise, H, Mehran R, **Stone GW**. Impact of baseline thrombus on acute tissue protrusion and late neointimal formation after stent implantation in acute myocardial infarction: An intravascular ultrasound substudy from the HORIZONS-AMI Trial. Circulation 2009;120(suppl 2):S948**.**

792. Guo N, Maehara A, Mintz GS, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett, MA, Parise, H, Mehran R, **Stone GW.** Determinants of the Magnitude of late stent malapposition after primary stenting in acute myocardial infarction: An intravascular ultrasound substudy of the HORIZONS-AMI Trial. Circulation 2009;120(suppl 2):S966**.**

793. Goto K, Nikolsky E, Fahy M, Cristea E, Lansky AJ, Mehran R, **Stone GW**. Prognostic significance of thrombus in patients with undergoing Percutaneous coronary intervention for acute coronary syndromes: ACUITY(Acute Catheterization and Urgent Intervention Triage strategy) Subanalysis. Circulation 2009;120(suppl 2):S978**.**

794. Ben Gai Y, Mehran R, Moses JW, Weisz G, Ebrahimi R, Lansky AJ, Williams MR, Nikolsky E, Argenziano M, Kodali S, **Stone GW**. Surgical versus Percutaneous revascularization for the treatment of patients with multivessel disease in the setting of acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial. Circulation 2009;120(suppl 2):S983**.**

795. Nilsen D, Wu R, Lansky AJ, Mehran R, Fahy M, Nikolsky E, Witzenbichler B, Guagliumi G, Perugz JA, Brodie BR, Dudek D, Mockel M, **Stone GW**. Impact of thrombus aspiration in patients with STEMI undergoing primary PCI: Analysis from the HORIZONS-AMI trial. Circulation 2009;120(suppl 2):S986**.**

796. Wu X, Maehara A, Mintz GS, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA, Parise H, Mehran R, **Stone, GW**. Attenuated plaque identified by intravascular ultrasound predicts no-reflow after stenting in acute myocardial infarction: The HORIZONS-AMI Trial. Circulation 2009;120(suppl 2):S1000**.**

797. Afolabi-Brown O, Nikolsky E, Lansky AJ, Mehran R, Fahy M, McLaurin BT, Cox DA, Feit F, Colombo A, Caixeta A, **Stone GW**. Bleeding and ischemic complications in patients with acute coronary syndromes and chronic kidney disease in relation to different glycoprotein IIb/IIIa inhibitors: Analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) Trial. Circulation 2009;120(suppl 2):S1028**.**

798. Baran D, Farkouh ME, Reiffel J, Dressler O, Nikolsky E, Mehran R, Lansky AJ, **Stone GW**. Resolution of pathological Q-waves is associated with improved outcomes after primary PCI for Acute Myocardial Infarction. Circulation 2009;120(suppl 2):S1070**.**

799. Farkouh ME, Nikolsky E, Reiffel J, Dressler O, Mehran R, Lansky AJ, **Stone GW**. Correlations between reciprocal ST-segment depression on the baseline echocardiogram, angiographic findings and clinical outcomes in patients with STEMI treated with Primary PCI. Circulation 2009;120(suppl 2):S1071**.**

800. Acharji S, Nikolsky E, Mehran R, Lansky AJ, Dangas GD, Feit F, Kirtane A, Caixeta A, Kesanakurthy, **Stone GW.** Outcomes of patients with acute coronary syndromes and chronic renal insuffieicny: Prognostic importance of troponin elevation and role of adjunctive antithrombotic therapy (analysis from the ACUITY Trial). Circulation 2009;120(suppl 2):S1126**.**

801. Hachamovitch R, Rozanski A, Shaw LJ, **Stone GW**, Thomson LE, Kang X, Sayes S, Miranda-Peats R, Germano G, Berman D. Impact of ischemia and scar on the noninvasive identification of a therapeutic benefit with revascularization versus medical therapy Circulation 2009;120(suppl 2):S389**.**

802. Caiexta A, Lansky AJ, Cristea E, De Bruyne D, McPherson J, Maehara A, Mintz GS, Mehran R, Nikolsky E, Templin B, Serruys PW, **Stone GW**. Spatial coronary arterial distribution of non-culprit lesion atherosclerotic events: Analysis from the PROSPECT Trial. J Am Coll Cardiol 2010;55:A189.

803. Choi SY, Maehara A, Mintz GS, Kubo T, Margolis P, **Stone GW**, Leon MB. Relationship among serial coronary arterial remodeling, stenosis progression and plaque composition: A VH-IVUS Tissue characterization analysis. J Am Coll Cardiol 2010;55:A203.

804. Sanidas E. Maehara A, Mintz GS, Kashiyama T, Choi SY, Lee JB, Dangas G, Leon MB, Moses JM, Stone GW Ueda Y. What is the underlying plaque morphology of coronary thrombosis? An angioscopic and virtual histology intravascular ultrasound correlative study. J Am Coll Cardiol 2010;55:A94.

805. Applegate RJ, Sudhir K, Hermiller JB, Doostzadeh J, Yu S, Hattori K, Lansky AJ, Cutlip DJ, Simonton CA, **Stone GW**. Long-term safety profile of XIENCE V Everolimus-eluting compared to TAXUS Express Paclitaxel-Eluting stents. J Am Coll Cardiol 2010;55:A126.

806. Acharji S, Nikolsky E, Weisz G, Dangas G, Feit F, Manoukian S, Lansky AJ, Mehran R, **Stone GW**. Impact of troponin elevation on outcomes of patients with acute coronary syndromes and chronic renal insufficiency. J Am Coll Cardiol 2010;55:A118.

807. McPherson J, Maehara A, Mintz GS, Lansky AJ, Cristea E, Templin B, Mehran R, Dangas G, Zhang Z, Wennerblom B, Iniguez A , Fajadet J, Foster M, DeBruyne B, Serruys P, **Stone GW.** Are Vulnerable plaques widely disseminated or focal? A baseline 3-vessel IVUS analysis from the PROSPECT Trial. J Am Coll Cardiol 2010;55:A178.

808. Choi SY, Nikolsky E, Lansky AJ, Mehran R, Maehara A, McLaurin BT, Cox DA, Feit F, **Stone GW**. Impact of Antithrombotic regimen and Troponin status on outcomes of Percutaneous coronary intervention in acute coronary syndromes: The ACUITY Trial. J Am Coll Cardiol 2010;55:A179.

809. Choi SY, Witzenbichler B, Maehara A, Mintz GS, Lansky AJ, Guagliumi G, Brodie B, Kellett MA, Parise H, Mehran R, Dangas GD, **Stone GW.** IVUS predictors of early stent thrombosis after primary Percutaneous intervention in acute myocardial infarction: A HORIZONS-AMI substudy. J Am Coll Cardiol 2010;55:A182.

810. Witzenbichler B, Woehrle J, Guagliumi G, Peruga J, Brodie B, Dudek D, Kornowski R, Hartmann F, Parise H, Lansky AJ, Nikolsky E, Mehran R, **Stone GW**. Impact of paclitaxel-eluting stents in diabetic patients with acute myocardial infarction undergoing primary angioplasty: Analysis from the HORIZONS AMI Trial. J Am Coll Cardiol 2010;55:A182.

811. Mehran R, Nikolsky E, Witzenbichler B, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Caixeta A, Haratani N, Dangas GD, Lansky AJ, **Stone GW**. Compliance with dual antiplatelet therapy and subsequent adverse events in patients with STEMI undergoing stent implantation: Analysis from the HORIZONS-AMI Trial. J Am Coll Cardiol 2010;55:A185.

812. Nikolsky E, Mehran R, Dangas GD, Lansky A, Rabbani L, Guagliumi G, Kornowski R, Hartmann F, Fahy M, Witzenbichler B, Peruga JZ, Gambone L, Parise H, **Stone GW**. Impact of intravenous heparin administered prior to primary Percutaneous coronary intervention: Analysis from the HORIZONS-AMI Trial. J Am Coll Cardiol 2010;55:A185.

813. Caixeta A, Genereux P, Nikolsky E, Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Rabbani L, Cristea E, Wong SC, Dangas GD, Fahy M, **Stone GW**. Transradial vs transfemoral approach for primary angioplasty in acute myocardial infarction: analysis from the HORIZONS-AMI Trial. J Am Coll Cardiol 2010;55:A186.

814. Lansky AJ, Maehara A, Mintz G, Ng V, Veldhof S, DeBruyne B, McPherson J, Cristea E, Templin B, Parise H, Fahy M, Serruys PW, **Stone GW**. Impact of gender on the extent of coronary atherosclerosis and plaque characterization in acute coronary syndromes: Insights from the PROSPECT Trial. J Am Coll Cardiol 2010;55**:**A186.

815. Nikolsky E, Mehran R, Ohman EM, Bertrand ME, Lincoff AM, Moses JW, Cristea E, White HD, Fahy M, Lansky AJ, **Stone GW**. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: Analysis from the ACUITY Trial. J Am Coll Cardiol 2010;55:A190.

816. Maehara A, Mintz GS, Lansky AJ, Cristea E, Mehran R, Dangas G, Templin B, McPherson J, DeBruyne B, Farhat N, Winnerblom B, Iniguez A, Marso S, Serruys PW, **Stone GW**. Incomplete three-vessel intravascular imaging in the PROSPECT Trial: Implications for pre-emptive vulnerable plaque detection. J Am Coll Cardiol 2010;55:A190.

817. Lima-Filho MO, Lansky AJ, Yamasaki M, Aki J, Wahle A, Yu P, Shimohama T, Waseda K, Koo BK, Nakatami D, Otake H, Honda Y, Sudhir K, **Stone GW**, Fitzgerald P. Angiographic features related to incomplete stent apposition in SPIRIT III Trial. A quantitative analysis of vessel curvature. J Am Coll Cardiol 2010;55:A190.

818. Hermiller JB, Applegate R, Doostzadeh J, Pierson W, Shah A, Peterson J, Sudhir K, **Stone GW**. Performance of XIENCE V Everolimus-eluting vs TAXUS Express Paclitaxel-eluting coronary stents in small vessels: Pooled results of the SPIRIT III and SPIRIT IV Clinical Trials. J Am Coll Cardiol 2010;55:A192.

819. Caixeta A, Nikolsky E, Leon S, Fahy M, Cristea E, **Stone GW**, Lansky AJ, Mehran R. Validation of a risk score to predict contrast–induced acute kidney injury after percutaneous coronary intervention in patients with ACS: Results from the ACUITY Trial. J Am Coll Cardiol 2010;55:A210.

820. He Y, Nikolsky E, Lansky AJ, Mehran R, Caixeta A, Dangas G, Rabbani L, **Stone GW**. Correlation of thrombus area with angiographic and clinical outcomes in patients with ST-Segment elevation myocardial infarction undergoing primary PCI: Analysis from the HORIZONS–AMI Trial. J Am Coll Cardiol 2010;55:A124.

821. Tsujita K, Nikolsky E, Lansky AJ, Gambone L, Vandertie L, Caixeta A, Dangas G, Brodie BR, dudek D, Mockel M, Ochala A, Mehran R, **Stone GW**. Impact of anemia in men and women with ST-segment elevation myocardial infarction: The HORIZONS-AMI Trial. J Am Coll Cardiol 2010;55:A138.

822. Wohrle J, Witzenbichler B, Guagliumi G, Brodie BR, Dudek D, Kornowski R, Hartmann F, Parise H, Lansky AJ, Moore C, Mehran R, **Stone GW**. Impact of Paclitaxel-eluting stents in patients with anterior myocardial infarction undergoing primary angioplasty compared with bare metal stents: Analysis from the HORIZONS AMI Trial. J Am Coll Cardiol 2010;55:A183.

823. Lansky AJ, Ng V, Goto K, Fahy M, Mehran R, Ebrahimi R, Hammond M, Ohman EM, Feit F, Manoukian S, Lincoff AM, **Stone GW**. Impact of left ventricular

function on mortality in patients with acute coronary syndromes: Analysis of the acute catheterization and urgent intervention triage strategy (ACUITY) Trial. J Am Coll Cardiol 2010;55:A186.

824. Geisler T, Gawaz M, Steinhubl SR, Bertrand M, Lincoff AM, Cequier A, Desmet W, Rasmussen L, Hoekstra J, Mehran R, **Stone GW**. Impact of anticoagulation regimen in patients with non ST-elevation acute coronary syndromes undergoing and early invasive strategy independent of revascularization: The ACUITY Trial. J Am Coll Cardiol 2010;55**:**A114.

825. Challa KK, Nikolsky E, Mehran R, Lansky AJ, Dangas GD, Caiexta A, McLaurin BT, Cox DA, Moses JW, Feit F, Embacher M, **Stone GW**. Drug-eluting versus bare-metal stents in treatment of diabetic patients with acute coronary syndromes: Analysis from the randomized ACUITY Trial. J Am Coll Cardiol 2010;55:A122.

826. Kereiakes, DJ, Sudhir K, Hermiller JB, Lansky AJ, Doostzadeh J, Pierson W, Su X, Gordon PC, **Stone GW**. Comparison of Everolimus-eluting and Paclitaxel-eluting coronary stents in patients undergoing multi-vessel stenting: Pooled analysis from the SPIRIT III and SPIRIT IV randomized trials. J Am Coll Cardiol 2010;55**:**A140.

827. Lansky AJ, NG V, Witzenbichler B, Guagliumi G, Peruga JZ, Goto K, Parise H, Mehran R, **Stone GW**. The impact of left ventricular function on mortality in patients with ST-segment elevation acute myocardial infarction: Analysis of the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) Study. J Am Coll Cardiol 2010;55:A186.

828. Goto K, Nikolsky E, Lansky AJ, Caixeta A, Fahy M, Dangas GD, Witzenbichler B, Guagliumi G, Mehran R, **Stone GW.** Impact of smoking and alternative Antithrombotic strategies on outcomes of patients with ST-segment elevation myocardial infarction: Analysis from the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) Trial. J Am Coll Cardiol 2010;55:A186.

829. Larsen AI, Nilsen Dennis, Nikolsky E, Lansky AJ, Caixeta A, Parise H, Fahy M, Cristea E, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Mehran R, **Stone GW**. Patients admitted with ST-segment elevation myocardial infarction and a normal or near normal coronary angiogram have a favorable prognosis: Analysis from HORIZONS-AMI Trial. J Am Coll Cardiol 2010;55:A187.

830. Maehara A, Mintz GS, Cristea E, Lansky AJ, Mehran R, Dangas G, Templin B, Cheong WF, McPherson J, DeBruyne B, Farhat M, Marso S, Fajadet J, Foster M, Serruys PW, **Stone GW**. Even after Percutaneous coronary intervention of angiographically significant lesions, IVUS-defined high-grade stenoses are

common. A baseline IVUS analysis from the PROSPECT Trial. J Am Coll Cardiol 2010;55:A204.

831. Brown OA, Nikolsky E, Mehran R, Rabbani L, Fahy M, Leon S, Caixeta A, Brodie BR, Dudek D, Mockel M, Ochala A, **Stone GW**. Impact of admission blood glucose level on bleeding and ischemic complications in patients with acute myocardial infarction: Analysis from the harmonizing outcomes with revascularization and stents in acute myocardial infarction trial. J Am Coll Cardiol 2010;55:A104.

832. Kujit W, Roe MT, Green CL, Verouden NJ, Haeck JD, Tzivoni D, Koch K, **Stone GW,** Lansky AJ, DeWinter R, Krucoff MW. Quantification of amplitude, speed and completeness of ST-segment recovery after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: What is the "Best ST" recovery to predict clinical outcome? J Am Coll Cardiol 2010;55:A134.

833. Ambrosio G, Steinhubl S, Gresele P, Tritto I, Bentivoglio M, Zuchi C, Cox DA, McLaurin BT, Moses JW, White HD, Feit F, Aylward PE, Colombo A, Darius D, Ebrahimi R, Hamon M, Mehran R, **Stone GW**. Impact of prior chronic antiplatelet therapy on short and long term adverse events in patients presenting with an acute coronary syndrome: Insights from the ACUITY Trial. J Am Coll Cardiol 2010;55**:**A113.

834. Dangas G, Mehran R, White H, Caixeta A, Lansky AJ, Brodie B, Guagliumi G, Witzenbichler B, Dudek D, **Stone G**. Effect of Switching to Bivalirudin versus adding a GPIIb/IIIa inhibitor in patients with acute myocardial infarction treated with prerandomization heparin in the HORIZONS-AMI Trial. European Heart Journal 2010;31:207**.**

835. Chiruamilla A, Mehran R, Kanwal S, Cha JY, Bond TF, Falkenstern JR, Wong V, Fahy M, **Stone GW**, Dangas G. Does Diabetes mellitus increase Clopidogrel resistance in patients undergoing percutaneous coronary intervention? European Heart Journal 2010;31:388-389**.**

836. Mehran R, Claessen BE, Godino C, Obuani K, Dangas G, Carlino M, Kim YH, DiMario C, Park SJ, **Stone GW**, Colombo A, Moses J, Leon MB. Long-Term Clinical Safety and Efficacy of Drug-Eluting Stents for the Treatment of Chronic Total Occlusions: Report from a Multi-National 763 Patient Registry. J Am Coll Cardiol 2010:56:13;B:28**.**

837. Claessen B, Mehran R, Godino C, Obuani K, Dangas G, Carlino M, Kim YH, DiMario C, Park SJ, **Stone GW**, Colombo A, Moses J, Leon MB. Long-Term Clinical Outcomes after Percutaneous Coronary Intervention with Drug-Eluting Stents versus Bare Metal Stents for Chronic Total Occlusions: Two-Year Outcomes from a 1,781 Patient Multi-National Registry. J Am Coll Cardiol 2010:56:29.

838. Claessen B, Mehran R, Obuani K, Godino C, Kim YH, DiMario C, Park SJ, **Stone GW**, Colombo A, Leon MB, Moses J. Impact of Target Vessel on Long-Term Survival after Percutaneous Coronary Intervention for Chronic Total Occlusions: Two-Year Outcomes from a 1,781 Patient Multi-National Registry. J Am Coll Cardiol 2010:56:32.

839. **Stone GW**, Yaqueb M, Sood P, Rizvi A, Newman W, Kourosh M, Wang JC, Caputo R, Hattori K, Su X, Simonton CA, Lansky AJ, Cutlip DE, Sudhir K, Kereiakes DJ. A Large-Scale Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Outcomes from the SPIRIT IV Trial. J Am Coll Cardiol 2010:56:35.

840. Claessen B, Mintz GS, Mehran R, Mehran R, Maehara A, Weisz G, Sanidas E, Syros G, Franklin-Bond T, Apostolidou I, Henriquez J, **Stone GW**, Moses J, Leon MB, Dangas GD. Intravascular Ultrasound-Guides Drug-Eluting Stent Placement is Associated with Reduced Incidence of Recurrent Clinical Events (Death or MI). J Am Coll Cardiol 2010:56:41.

841. Kirtane AJ, Sood P, Applegate RJ, Manejeh Y, Omuma Y, Wang JC, Su X, Miguel-Herbert K, Lansky AJ, Kereiakes D, Simonton CA, Sudhir K, Serruys PW, **Stone GW**. Predictors of Stent Thrombosis after Everolimus-Eluting and Paclitaxel-Eluting Stents: The Pooled SPIRIT II, III, and IV Randomized Trial Experience. J Am Coll Cardiol 2010:56:45**.**

842. Lansky AJ, Yaqueb M, Sood P, Applegate RJ, Wang JC, Rizvi A, Skelding K, Smith RS, Cao S, Hermiller JB, Sudhir K, **Stone GW**. Evaluation of Everlolimus-Eluting and Paclitaxel-eluting Stents in patients with Jailed Side Branches: The SPIRIT IV Trial. J Am Coll Cardiol 2010:56:47.

843. Singh HS, Mehran R, **Stone GW**, Dangas GD. Two-Year Clinical Follow-up Comparing Eptibifibatide and Abciximab in Patients Undergoing Primary Percutaneous Revascularization for ST-Elevation Myocardial Infarction Results from the HORIZONS –AMI Trial. J Am Coll Cardiol 2010:56:83.

844. Cubeddu RJ, Blankenship JC, Dangas G, Lansky AJ, Palacios IF, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, **Stone GW**, Mehran R. STEMI Presentation During Off-Hours Does Not Compromise Times or Mortality: A HORIZONS AMI Substudy. J Am Coll Cardiol 2010:56:87.

845. Genereux P, Palmerini T, Caixeta A, Cristea E, Mehran R, Sanchez R, Lazar D, Jankovic I, Corral MD, Dressler O, Fahy M, Lansky AJ, **Stone GW**. Syntax Score Reproducibility and Agreement between Interventional Cardiologists and Core Laboratory Technician Measurements. J Am Coll Cardiol 2010:56:157.

846. **Stone GW**, Sood P, Applegate RJ, Yaqueb M, Hermiller JB, Newman W, Sanz M, Cao S, Bezenek S, Williams J, Lansky AJ, Cutlip DJ, Sudhir K. Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Four-Year Clinical Outcomes from the SPIRIT III Trial. .J Am Coll Cardiol 2010:56:250.

847. Claessen BE, **Stone GW**, Smits PC, Kedhi E, Kikkert W, Piek J, Henriques JPS. Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents: A Meta-Analysis of 4 Trials. J Am Coll Cardiol 2010:56:276.

848. Ormiston JA, Turco MA, **Stone GW**, O'Shaughnessy DC, Gilchrist IC, Yakubov SJ, Raizner AE, Underwood PL, Dawkins KD. Long-Term Effectiveness of the TAXUS Liberte Stent in Small Vessels: The TAXUS ATLAS Small Vessel Trial. J Am Coll Cardiol 2010:56:293.

849. Turco MA, Popma JJ, Ormiston JA, **Stone GW**, Ellis SG, Underwood PL, Dawkins KD. Improved Periprocedural Side Branch Flow with TAXUS Liberte in Long Lesions: A Comparative Analysis with Multiple Stents in TAXUS V. J Am Coll Cardiol 2010:56:297.

850. **Stone GW**, Parise H, Witzenbichler B, Kirtane A, Guagliumi G, Perugz JZ, Brodie BR, Dudek D, Mockel M, Lansky AJ, Mehran R. Selection Criteria for Drug-Eluting Versus Bare Metal Stents: The HORIZONS-AMI Trial. J Am Coll Cardiol 2010:56:427.

851. Nikolsky E, Mehran R, Metzger DC, Wohrle J, Huber K, SuryapranataH, Guetta V, Witkowski A, Ruzyllo W, Reyes SL, **Stone GW.** Outcomes of Patients with ST-Segment Elevation Myocardial Infarction and Prior Coronary Artery Bypass Grafting: The HORIZONS-AMI Trial. J Am Coll Cardiol 2010:56:427**.**

852. Dudek D, Rakowski R, Dziewierz A, Witzenbichler B, Guagliumi G, Kornowski R, Hartmann F, Lansky AJ, Mehran R, **Stone GW**. Impact of Infarct-related Artery Patency Before Primary PCI on Outcome in Patients with Acute Myocardial Infarction. The HORIZONS-AMI Trial. J Am Coll Cardiol 2010:56:432.

853. Huber K, Mehran R, **Stone GW**, Lansky AJ, Guagliumi G, Brodie BR, Jarai R, Kornowski R, Dangas G. Impact of Baseline BNP Level on Early and Late Clinical Outcomes After Acute MI;2-year Results of the HORIZONS-AMI Study. J Am Coll Cardiol 2010:56:433.

854. Caixeta A, Mehran R, Dangas G, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie B, Dudek D, Kornowski R, Hartmann F, Claessen B, Leon S, Lansky AJ, **Stone GW**. Clinical Outcomes in Patients with Right Coronary Artery versus Left Circumflex Artery Myocardial Infarction Treated with Primary PCI: Results of the HORIZONS-AMI Trial. J Am Coll Cardiol 2010:56:435**.**

855. Kelly D, Gershlick T, Guagliumi G, Mehran R, **Stone GW**. Incidence, Severity and Predictors of Congestive Heart Failure Following Primary PCI: The HORIZONS-AMI Trial. J Am Coll Cardiol 2010:56:436.

856. Dudek D, Dziewierz A, Rakowski T, Brzesinski M, Witzenbichler B, Guagliumi G, Perugz JZ, Brodie BR, Mehran R, Lansky AJ, **Stone GW**. Impact of Bifurcation Target Lesion on Angiographic, Electrocardiographic and Clinical Outcomes of Patients Undergoing Primary PCI: A HORIZONS-AMI Substudy. J Am Coll Cardiol 2010:56:439.

857. Palmerini T, Mehran R, Dangas, G, Witzenbichler B, Guagliumi G, Dudek D, Genereux P, Caixeta A, Rabbani L, Weisz G, Parise H, Brodie BR, Lansky AJ, **Stone GW**. Impact of White Blood Cell Counts on Mortality and Major Bleeding in Patients with STEMI Undergoing Primary PCI:1-Year Results from HORIZONS-AMI. J Am Coll Cardiol 2010:56:451.

858. Huber K, Mehran R, **Stone GW**, Guagliumi G, Brodie BR, Dudek D, Witzenbichler B, Jarai R, Lansky AJ, Dangas G. Impact of Baseline hs-CRP level on Early and Late Stent Thrombosis After Acute MI:2-Year Results of the HORIZONS-AMI Study. J Am Coll Cardiol 2010:56:456.

859. El Din D, El Hakin A, Dangas G, Caixeta A, Nikolsky E, Lansky AJ, Moses JW, Palmerini T, Fahy M, White H, Ohman EM, Manoukian SV, Mehran R, **Stone GW**. Impact of Baseline Thrombocytopenia on the Early and Late Outcomes After ST-Elevation Myocardial Infarction Treated with Primary Angioplasty: Analysis from the HORIZONS AMI Trial. J Am Coll Cardiol 2010:56:461.

860. Kirtane A, Sood P, Applegate RJ, Yaqueb M, Onuma Y, Wang JC, Su X, Miquel-Herbert K, Lansky AJ, Kereiakis DJ, Simonton CA, Dudhir K, Serruys PW, **Stone GW.** Predictors of Stent Thrombosis after Everolimus-Eluting and Paclitaxel-Eluting Stents: The Pooled SPIRIT Randomized Trial Experience at Two Years Follow-Up. Circulation 2010;122:A17174.

861. Singh HS, Dangas G, Mehran R, Guagliumi G, Witzenbichler B, Kornowski R, Grines CL, Gersh BJ, Dudek D, **Stone GW.** Two-Year Clinical Results Comparing Abciximab vs Eptifibatide in Combination with 600mg vs 300mg Clopidogrel Loading Dose in Patients with ST-Elevation Myocardial Infarction: Results from the HORIZONS-AMI Trial. Circulation 2010;122:A17531.

862. Kedji E, **Stone GW,** Kereiakes DJ, Serruys PW, Parise H, Fahy M, Smits PC. Stent Thrombosis After Everolimus-eluting versus Paclitaxel-eluting Coronary Stents Insights from the SPIRIT II, SPIRIT III and SPIRIT IV and COMPARE Pooled Database. Circulation 2010;122:A14593.

863. Chin CT, Kelly RV, Cohen MG, Cohen M, Trout JR, **Stone GW,** Christenson JT, Freedman RJ, Reddy RC, Joseph D, Ohman EM. The Impact of Anticoagulation

During Intra-Aortic Balloon Counterpulsation Pump Placement on In-Hospital Outcomes in 18,875 Patients Undergoing Cardiac Revascularization. Circulation 2010;122:A10175.

864. Lee JB, Mintz GS, Lisauskas JB, Pu J, Sum ST, Madden SP, Burke AP, Goldstein J, **Stone GW,** Virmani R, Mueller JE, Maehara A. Histiolopathologic Validation of Intravascular Ultrasound Diagnosis of a Calcified Coronary Nodule, a Type of Plaque Suspected to be Vulnerable. Circulation 2010;122:A21455.

865. Claessen BE, Mehran R, Obunai K, Godino C, Chieffo A, Dangas GD, Carlino M, Kim YH, DiMario C, Park SJ, **Stone GW,** Colombo A, Moses JW, Leon MB. Gender Differences in Percutaneous Coronary Intervention for Chronic Total Occlusions: a Report from the 1,781 Patient Multinational CTO Registry. Circulation 2010;122:A20362.

866. **Stone GW,** Kedhi E, Serruys PW, Parise H, Fahy M, Smits PC, Kereiakes DJ. Are the Clinical Outcomes with Everolimus-eluting versus Paclitaxel-eluting Coronary Stents Different in Patients With and Without Diabetes? Insights from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE Randomized Trials. Circulation 2010;122:A17024.

867. Claessen BE, Mehran R, Godino C, Obunai K, Dangas G, Carlino M, Kim YH, DiMario C, Park SJ, **Stone GW,** Colombo A, Leon MB, Moses JW. Impact of Successful Percutaneous Coronary Intervention of a Chronic Total Occlusion: Five-Year Outcomes from a 1,781 Patient Multinational Registry. Circulation 2010;122:A19992.

868. Caixeta A, Lansky AJ, Mehran R, Witzenbichler B, Guagliumi G, Perugz JZ, Brodie B, Dudek D, Kornowski R, Hartmann F, Claessen B, Fahy M, Dangas G, **Stone GW.** Predictors of Suboptimal TIMI Flow after Primary Angioplasty for Acute Myocardial Infraction: Results from the HORIZONS-AMI Trial. Circulation 2010;122:A20882.

869. **Stone GW,** Rizvi A, Newman W, Allplegate RJ, Cannon L, Maddux J, Williams J, Sood P, Cao S, Simonton CA, Dushir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Is Premature Thienopyridine Discontinuation Safe with Everolimus-Eluting Stents? Analysis from the SPIRIT IV Trial. Circulation 2010;122:A17066.

870. Batcheldor WB, Ellis SG, Ormiston JA, **Stone GW,** Turco MA, Joshi AA, Wang H, Underwood PL. Long-Term Outcomes after percutaneous Coronary Intervention with Paclitaxel-Eluting Coronary Stents in Black Versus White Patients. Circulation 2010;122:A19665.

871. Mehta RH, Piccini JP, Tcheng JT, Fahy M, Mehran R, **Stone GW.** Prognostic Significance of Post-Procedural Sustained Ventricular Tachycardia or Fibrillation

in Patients Undergoing Primary Percutaneous Coronary Intervention: Insights from the HORIZONS AMI Trial. Circulation 2010;122:A12961.

872. Leonardi S, Stebbins A, Lopes RD, Lokhygina Y, Bhatt DL, **Stone GW,** Lincoff MA, Dauerman HL, Gibson CM, White HD, Parick K, Gruberg L, Herrmann HC, Mclaurin BT, Goodman S, Harrington RA, Mahaffey KW. Circulation 2010;122:A14813.

873. Claessen B, Mehran R, Godino C, Obunai K, Carlino M, Dangas G, Kim YH, DiMario C, Park SJ, **Stone GW,** Colombo A, Leon MB, Moses JW. Temporal Trends in Percutaneous Coronary Intervention for Chronic Total Occlusions: a report from the 1,781 Patient Multinational CTO Registry. Circulation 2010;122:A20246.

874. Planer D, Smits PC, Kereiakis DJ, Kedhi E, Fahy M, Serruys PW, **Stone GW.** Comparison of the Everolimus-Eluting and Paclitaxel-eluting stents in patients with acute and stable coronary syndromes. Results from the SPIRIT II, III, IV and COMPARE Trials. JACC 2011:57:904.

875. Zhao Z, Witzenbichler B, Mintz GS, Choi SY, Wu X, He Y, Dressler O, Cristea E, Parise H, Mehran R, **Stone GW,** Maehara A. Dynamic nature of non-culprit coronary artery lesion morphology in ST-Segment elevation myocardial infarction patients: A Serial Virtual Histology-Intravascular Ultrasound analysis from the HORIZONS-Acute Myocardial Infarction Trial. JACC 2011:57:916.

876. Saltzman AJ, Claessen BE, Narula A, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Lansky AJ, Nikolsky E, Dangas GD, **Stone GW,** Mehran R. Impact of chronic kidney disease on long-term outcomes in ST-elevation myocardial infarction patients treated with percutaneous coronary intervention and alternative antithrombotic treatment strategies: A HORIZONS AMI Substudy. JACC 2011:57:916.

877. Narula A, Weisz G, Dangas G, Claessen B, Saltzman A, Kornowski R, Brodie B, Dudek D, Nikolsky E, Witzenbichler B, Guagliumi G, Fahy M, Parise H, **Stone GW,** Mehran R. Incidence and Risk Classification First described in 1,967 for Risk Factors for Contrast-Induced Nephropathy in Primary Percutaneous Coronary Intervention: An Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial (HORIZONS-AMI). JACC 2011:57:331.

878. Planer D, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Mockel M, Leon-Reyes S, Mehran R, **Stone GW.** Correlation and Prognostic Utility between left ventricular end diastolic pressure and left ventricular ejection fraction in patients with STEMI Undergoing Primary PCI: The HORIZONS-AMI Trial. JACC 2011:57:14 Supplement A,1104:353.

879. Claessen BE, **Stone GW,** Mehran R, Witzenbichler B, Brodie BR, Ruzyllo W, Zinudka K, Guagliumi G, Wohrle J, Huber K, Kochman J, Sanidas E, Hakim D, Chantziara V, Leon S, Dangas G. Clinical Utility of Biomarkers to predict stent thrombosis after STEMI Treated with DES: A HORIZONS-AMI Substudy with 2 year followup. JACC 2011:57:314.

880. Won-Suh J, Mehran R, Dangas G, Claessen BE, Parise H, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wohrle J, Dudek D, Weisz G, **Stone GW.** Comparison of Long Term Clinical Prognosis after Primary Percutaneous Coronary Intervention According to the Presence of in-hospital Major Bleeding Events: 3 year follow-up Result of HORIZON-AMI. JACC 2011:57:316.

881. Witzenbichler B, **Stone GW,** Claessen BE, Brodie BR, Ruzyllo W, Guagliumi G, Wohrle J, Huber K, Kochman J, Zmudka K, Hartmann F, Apostolidou I, Syros G, Leon S, Mehran R, Dangas G. Relationship between Biomarkers and Subsequent Major Adverse Cardiovascular Events after ST-Elevation Myocardial Infarction: A HORIZONS-AMI Substudy. JACC 2011:57:317.

882. Sanidas E, Maehara A, Barkana E, Hidalgo A, Hakim D, Singh V, Rabbani L, Mehran R, Wong D, Mintz GS, **Stone GW,** Leon MB, Moses JW, Weisz G. Enhanced Stent Imaging Improves the Diagnosis of Stent Underexpansion and Optimizes Stent Deployment. JACC 2011:57:162.

883. Baber U, Mehran R, Weisz G, Dangas G, Moreno PR, Maehara A, Cristea E, Fahy M, Xu K, Lansky AJ, Marso SP, DeBruyne B, Serruys PW, **Stone GW.** Differences in Coronary Plaque Composition and morphology in Patients with and without Chronic Kidney Disease Presenting with Acute Coronary Syndromes:Insights from the PROSPECT Study. JACC 2011:57:110.

884. Genereaux P, Goldberg S, O'Shaughnessy C, Midei M, Siegel E, Mintz GS, Cristea E, Dangas G, Lansky AJ, Mehran R, **Stone GW.** Five Year Follow-up of Polytetrafluoroethylene-Covered Stents Compared with Bare Metal Stents in Aortocoronary Saphenous Vein Grafts: The Randomized BARRICAIDE Trial. JACC 2011:57:107.

885. Kereiakis DJ, Smits PC, Kedhi E, Parise H, Fahy M, Serruys PW, **Stone GW.** Multivariable Predictors of Clinical Restenosis Cardiac Death or Myocardial Infarction to 2 years following Everolimus or Paclitaxel Drug-Eluting Stent Deployment: The SPIRIT II, III, IV and COMPARE Trial Experience. JACC 2011:57:2901.

886. Claessen BE, Godino C, Obunai K, Kanwal S, Carlino M, Kim, YH, DiMario C, Park SJ, **Stone GW,** Colombo A, Dangas GD, Leon MB, Moses JW, Mehran R. Long-Term Clinical Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions in Patients with and without Diabetes Mellitus: Five-

Year Outcomes from a 1,791 Patient Multi-National Registry. JACC 2011:57:2902.

887. Kovacic JC, Mehran R, Dangas G, Claessen B, Parise H, Fahy M, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wohrle J, Dudek D, Weisz G, **Stone GW**. Impact of Aspirin Dose on Long Term Clinical Outcomes after Stenting for Acute Myocardial Infarction: 3-Year Follow-up Data from the HORIZONS-AMI Trial. JACC 2011:57:2903.

888. Kereiakes DJ, Smits PC, Kedhi E, Parise H, Fahy M, Serruys PW, **Stone GW.** Percutaneous Revascularization in Multivessel Coronary Disease is Improved with Everolimus-Eluting Stent DeploymentL Pooled Analysis from the SPIRIT II, III, IV and COMPARE Trials. JACC 2011:57:2905.

889. McPherson JA, Maehara A, Weisz G, Mintz GS, Cristea E, Mehran R, Fahy M, Lansky AJ, DeBruyne B, Serruys PW, **Stone GW.** Patients with IVUS-Defined High-Grade Stenoses Left behind after Percutaneous Coronary Intervention for Acute Coronary Syndrome Have more Fibroatheromas and Worse Clinical Outcomes despite a Lower Overall Plaque Burden: Analysis from the PROSPECT Trial. JACC 2011:57:2906.

890. Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Wohrle J, Hartmann F, Parise H, Lansky AJ, Nikolsky E, Mehran R, **Stone GW.** Impact of Paclitaxel-Eluting Stents in Diabetic and Non-Diabetic Patients with acute Myocardial Infarction Undergoing Primary Angioplasty: 3-Year Results from the HORIZONS-AMI Trial. JACC 2011:57:2906.

891. Kornowski R, Mehran R, Dangas G, Assali A, Nikolsky E, Gersh BJ, Song SC, Witzenbichler B, Guagliumi G, Dudek D, Fahy M, Lansky AJ, **Stone GW.** Prognostic Impact of Staged versus “One-Time” Multivessel PCI in Acute ST-Segment Elevation Myocardial Infarction: Long-Term Analysis from the HORIZONS-AMI Trial. JACC 2011:57:2906.

892. Caixeta A, Weisz G, Maehara A, Mintz GS, Cristea E, Mehran R, Xu K, Lansky AJ, McPherson J, DeBruyne B, Serruys PW, **Stone GW.** Impact of Hypercholesterolemia on Atherosclerotic Plaque Composition: A Virtual Histology Intravascular Ultrasound analysis from the PROSPECT Study. JACC 2011:57:2911.

893. Rusinova R, Maehara A, Mintz GS, Choi SY, Araki H, Hakim D, Sanidas E, Weisz G, Mehran R, Franklin-Bond T, Fahy M, Leon MB, **Stone GW,** Moses JW, Tahk SJ, Ochiai M. Intravascular Ultrasound Comparison between Caucasian and Asian Left Main Coronary Artery Disease. JACC 2011:57:2911.

894. Claessen BE, Smits PC, Kereiakes DJ, Kedhi E, Fahy M, Serruys PW, **Stone GW.** Two-Year Outcomes with Everolimus-Eluting Stents vs Paclitaxel-Eluting

Stents according to Lesion Length and Vessel Diameter: Pooled Analysis from the SPIRIT II, III, IV and COMPARE Randomized Trials. JACC 2011:57:591.

895. Amin AP, Reynolds MR, Lei Y, Mahoney EM, Roberts K, Durtschi AJ, Simonton CA, **Stone GW,** Cohen DJ. Cost Effectiveness of Everolimus vs Paclitaxel-Eluting Stents for Patients Undergoing Percutaneous Coronary Revascularization. 2- Year Results from the SPIRIT IV Trial. JACC 2011:57:598.

896. Lansky AJ, Ng, V, Cristea E, Mehran R, Fany M, **Stone GW.** Prognostic Utility of Myocardial Blush Grade After PCI in Patients with NSTEMI Analysis from the ACUITY Trial. JACC 2011:57:505.

897. Caixeta A, Palmerini T, Genereaux P, Cristea E, Lansky AJ, Mehran R, Dangas G, Corral MD, Jankovic I, Lazar D, Sanchez R, Fahy M, Xu K, **Stone GW.** Prognostic Utility of the SYNTAX Score in Patients with Single vs Multivessel Disease Undergoing Percutaneous Coronary Intervention: Insights from the ACUITY Trial. JACC 2011:57:506.

898. Claessen BE, **Stone GW**, Mehran R, Witzenbichler B, Brodie BR, Ruzyllo W, Zmudka K, Guagliumi G, Wohrle J, Huber K, Kochman J, Hartmann F, Sanidas E, Hakim D, Chantziara V, Leon S, Dangas GD. Relationship between Biomarkers and Subsequent Clinical and Angiographic Restenosis after Paclitaxel-eluting stents for Treatment of STEMI: A HORIZONS-AMI Substudy. JACC 2011:57:2506:532.

899. Mehran R, Claessen BE, Dangas G, Suh JW, Parise H, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wohrle J, Dudek D, Weisz G, Moses JW, **Stone GW.** Discharge Medication Use in patients Who Experience Bleeding Complications after Primary PCI: Analysis from HORIZONS-AMI. JACC 2011:57:534.

900. Witzenbichler B, Mehran R, Guagliumi G, Desaga M, Kochman J, Nilsen DW, Finkelstein A, Mosseri M, Parise H, Cristea E, **Stone GW.** Impact of Bivalirudin Procedural Anticoagulation in Patients with Diabetes Mellitus and Acute Myocardial Infarction Undergoing Primary Angioplasty:3-Year Results from the HORIZONS AMI Trial. JACC 2011:57:558.

901. Kedhi E, Smits PC, Serruys PW, Kereiakes DJ, Parise H, Fahy M, **Stone GW.** Everolimus-Eluting vs Paclitaxel-Eluting Stents. Two-Year Results from a Patient-Level Pooled Analysis from the SPIRIT II, III, IV and COMPARE Randomized Trials. JACC 2011:57:507.

902. Hakim D, Mintz GS, Rusinova R, Weisz G, Singh VP, Leon MB, **Stone GW,** Moses JW, Maehara A. Grayscale Intravascular Ultrasound Evidence of In-Stent Neoatherosclerosis 3 Years after Drug-Eluting Stent Implantation JACC 2011:57:573.

903. Caixeta A, Weisz G, Maehara A, Mintz GS, Cristea E, Mehran R, Fahy M, Xu K, Lansky AJ, Marso S, DeBruyne B, Serruys PW, **Stone GW.** Association between Vulnerable Plaque and Serum LDL-Cholesterol Level as Assessed with Virtual Histology Intravascular Ultrasound: Analysis from PROSPECT. JACC 2011:57:577.

904. Sanidas E, Mintz GS, Cristea E, Maehara Ak, DeBruyne B, Mehran R, Mcpherson J, Parise H, Lansky AJ, Templin B, Serruys PW, **Stone GW.** Are all Non-Culprit Lesions That Cause Events Similar? A PROSPECT Substudy Analysis. JACC 2011:57:2510:528.

905. Claessen BE, Obunai K, Godino O, Kanwal S, Carlino M, Kim HK, DiMario C, Park SJ, **Stone GW,** Colombo A, Dangas G, Moses JW, Leon MB, Mehran R. Procedural and Long-Term Clinical Outcomes after Percutaneous Coronary Intervention of Chronic Total Occlusions on Women: A Report in the Multinational CTO Registry. JACC 2011:57:593.

906. Jaral R, Huber K, Claessen B, Dangas G, Mehran R, **Stone GW.** Relationship between elevated BNP levels in STEMI and Clinical Outcomes the HORIZONS-AMI Trial. JACC 2011;58,(supplB):376.

907. Marso S P, Mercado N, Maehara A, Weisz G, Mintz G, McPherson J, Schiele F, Dudek D, Fahy M, Xu K, Lansky AJ, Debruyne B, Serruys P, **Stone GW.** Relationship between Plaque Composition Assessed with Radiofrequency IVUS and Clinical Outcomes in Patients with Acute Coronary Syndromes and Diabetes Mellitus or Metabolic Syndrome: The PROSPECT Trial. JACC 2011;58,(supplB):663.

908. Xu Y, Mintz GS, Tam A, McPherson J, Imiguez A, Fajadet J, Fahy M, Weisz G, DeBruyne B, Serruys PW, **Stone GW,** Maehara A Prevalence, Distribution, Predictors, and Outcomes of Patients with Calcified Nodules in Native Coronary Arteries: A Three-Vessel Intravascular Ultrasound Analysis from PROSPECT. JACC 2011;58,(supplB):107.

909. **Stone GW**, Sood P, Applegate RJ, Yaqub M, Hermiller JB, Newman W, Sanz M, Cao S, Bezenek S, Williams JE, Lansky AJ, Sutlip DE, Sudhir K. Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First report of the Five-Year Clinical Outcomes from the SPIRIT III Trial. JACC 2011;58,(supplB):29.

910. **Stone GW,** Yaqub M, Sood P, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Hattori K, Su X, Simonton CA, Lansky AJ, Cutlip DE, Sudhir K, Kereiakes DJ. A Large-Scale Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Three-Year Clinical Outcomes from the SPIRIT IV Trial. JACC 2011;58,(supplB):30.

911. Tobbia P, Brodie BR, Stuckey T, Witzenbichler B, Metzger C, Guagliumi G, Kellett MA, Fahy M, Mehran R, **Stone GW.** Are Adverse Events Following Promary PCI for STEMI More Frequent in US Sites than Sutes Outside of the US (OUS)? Three-Year Analysis from the HORIZONS-AMI Trial. JACC 2011;58,(supplB):37.

912. McEntegart MB, Kirtane AJ, Cristea E, Brener S, Mehran R, Fahy M, Moses JW, **Stone GW.** Intra-Procedural Thrombotic Events During Purcutaneous Coronary Intervention in patients with Non ST Elevation Acute Coronary Syndromes are Associated with Adverse Outcomes: Analysis from the ACUITY Trial. JACC 2011;58,(supplB):32.

913. Sachdeva A, Bavisetty S, Beckham G, Mansukhan P, Aharonian V, **Stone GW,** Moore N, Hyett E, Contreras R, Brar SS. Death and Acute Myocardial Infarction Associated with Stopping Clopidogrel After Saphenous Vein Graft Percutaneous Coronary Intervention. JACC 2011;58,(supplB):53.

914. Kirtane AJ, Cristea E, Brener S, McEntegart M, Mehran R, Fahy M, Moses JW, **Stone GW.** Association Between Intraprocedural Thrombotic Events and Adverse Outcomes Following Percutaneous Coronary Intervention for STEMIL The HORIZONS-AMI Trial. JACC 2011;58,(supplB):70.

915. Hermiller JB, Rutledge DR, Sudhir K, **Stone GW,** Serruys PW, Mao VW, Zhao W, Yaqub M, Sood P, Wang J, Cao S, Zheng Q, Jonnavilthua L, Simonton CA, Kruckoff MW. Stent Thrombosis after Implantation of Xience V Everolimus-Eluting Coronary Stent Systems in On-Label and Off-Label Populations: Pooled Two-Year Results from Seven Xience V Coronary Stent Trials. JACC 2011;58,(supplB):77.

916. **Stone GW,** Rutledge DR, Sudhir K, Hermiller JB, Serruys PW, Mao VW, Zhao W, Yaqueb M, Sood P, Cao S, Zheng Q, Jonnavithula LK, Simonton CA, Kruckoff MW. Stent Thrombosis and Dual Antiplatelet Interruption: Insights from the XIENCE V Everolimus-Eluting Coronary Stent System Trials. JACC 2011;58,(supplB):78.

917. Claessen BE, Dangas GD, Mehran R, Witzenbichler B, Guagliumi G, Peruga JZ, White HD, Xu K, **Stone GW.** Clinical Outcomes After Acute, Subacute, Late and Very Late Stent Thrombosis after Primary PCI for STEMI: An Analysis from HORIZONS-AMI. JACC 2011;58,(supplB):79.

918. Planer D, Witzenbichler B, Guagliumi G, Brodie BR, Zu K, Fahy M, Mehran R, **Stone GW.** Impact of Hyperglycemia in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: The HORIZONS-AMI Trial. JACC 2011;58,(supplB):89.

919. Sachdeva A, Bavisetty S, Beckham G, Aharonian V, Mansukhani P, **Stone GW,** Moore N, Contreras R, Brar S. The Association between Duration of Clopidogrel Therapy After Saphenous Vein Graft Intervention and Long-Term Death and Myocardial Infarction. JACC 2011;58,(supplB):173.

920. Teirstein PS, **Stone GW,** Meredith IT, Mann T, Pompili V, Cannon LA, Mooney MR, Saito S, Allocco SJ, Dawkins KD. Platinum Chromium Everolimus-Eluting Stent in Long Coronary Lesions. JACC 2011;58,(supplB):240.

921. Claessen BE, Dangas GD, Weisz G, Witzenbichler B, Guagliumi G, Mockel M, Xu K, Henriquez JP, Mehran R, **Stone GW.** Prognostic Impact of a Chronic Total Occlison in a Non-Infarct Related Artery in Patients with ST-Elevation Myocardial Infarction: Three-Year Results from the HORIZONS-AMI Trial. JACC 2011;58,(supplB):274.

922. Wang TY, Honeycut E, Henry TD, Effron MB, Messenger JC, Cohen DJ, Mark DB, **Stone GW,** Singh M, Rozek M, Fonarow GC, Peterson ED. Post-Discharge Bleeding and Thienopyridene Discontinuation among AMI Patients Treated with PCI: Insights from the TRANSLATE-ACS Study. JACC 2011;58,(supplB):344.

923. Nikolsky E, Gersh BJ, Dangas GD, Wong SC, Xu K, Fahy M, Mehran R, **Stone GW.** Cardiovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing a Primary PCI Management Strategy: Analysis from the HORIZONS-AMI Trial. JACC 2011;58,(supplB):363.

924. Planer D, Lincoff AM, Moses JW, White HD, Dangas G, Fahy M, Mehran R, **Stone GW.** Prognosis of Patients Presenting with Acute Coronary Syndromes with Elevated Serum Troponin and Non-Obstructive Coronary Artery Disease: The ACUITY Trial. JACC 2011;58,(supplB):387.

925. Tobbia P, Brodie BR, Stuckey T, McLaurin B, Cox D, Fahy M, Xu K, Mehran R, **Stone GW.** Are Adverse Events Following an Invasive Strategy in Patients with Non-ST Segment Elevation Acute Coronary Syndromes (NSTEACS) More Frequent at US Sites vs Non US Sites (OUS)? Analysis from the ACUITY Trial. JACC 2011;58,(supplB):389.

926. Yu J, Mehran J, Grinfeld L, Xu K, Fahy M, Nikolsky E, Pinnelas R, Clark AE, Brodie BR, Mockel M, Witzenbichler B, Kornowski R, Dudek D, Lansky AJ, Dangas G, **Stone GW.** Outcomes of Women After Acute Myocardial Infarction: Results from the HORIZONS-AMI Study. JACC 2011;58,(supplB):419.

927. Yu J, Mehran J, Xu K, Clark AE, Pinnelas R, Witzenbichler B, Kornowski R, Guagliumi G, Nikolsky E, Brodie BR, Lansky AJ, Dangas G, **Stone GW.** Predictors of Major Adverse Events in Female Patients with Acute Myocardial Infarction Undergoing Primary PCI: Three Year Results from the HORIZONS-AMI Study. JACC 2011;58,(supplB):420.

928. Claessen B, **Stone GW,** Mehran R, Witzenbichler B, Brodie BR, Guagliumi G, Wohrle J, Huber K, Syros G, Sanidas E, Chantziara V, Hakim D, Xu K, Dangas G. Biomarkers to Predict Contrast Induced Nephropathy after Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A HORIZONS-AMI Substudy. JACC 2011;58,(supplB):493.

929. Brener SJ, Cristea E, Mehran R, Dressler O, Lansky AJ, **Stone GW.** Relationship Between Angiographic Dynamic Densitometric Assessment of Myocardial Reperfusion and Survival in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: The HORIZONS-AMI Trial. JACC 2011;58,(supplB):616.

930. Maini B, Buyantseva L, Dhanju A, **Stone GW.** In Vivo Tissue Characterization of Coronary Lipid Plaques: Comparison of Optical Coherence Tomography and Near-Infrared Spectroscopy JACC 2011;58,(supplB):650.

931. Hakim D, Maehara A, Mintz GS, Banerjee S, Abdel-Karim A, Yakushiji T, Sum ST, Madden SP, **Stone GW,** Muller JE, Brilakis ES. Near Infrared Spectroscopic assessment of lipid core plaque changes after coronary artery stenting. JACC 2011;58,(supplB):666.

932. McPherson JA, Maehara A, Weisz G, Mintz GS, Cristea E, Mehran R, Foster M, Verheye S, Rabbani L, Xu K, Fahy M, Lansky AJ, Debruyne B, Serruys PW, **Stone GW.** Extent, Characterization, and Clinical Implications of Untreated Lesions with High Plaque Burden after Successful Percutaneous Coronary Intervention: A PROSPECT Substudy. JACC 2011;58,(supplB):680.

933. Suh JW, Mintz GS, Weisz G, Maehara A, Xu K, Lansky AJ, Cristea E, Mehran R, McPherson J, Farhat N, Marso SP, DeBruyne B, Serruys PW, **Stone GW.** The Utility of Three Primary Prevention Scoring Systems (Framingham, PROCAM, and SCORE) in Predicting Future Events in Patients with Acute Coronary Syndromes: The PROSPECT Trial. JACC 2011;58,(supplB):689.

934. Garcia JR, Lerman A, Weisz G, Maehara A, Mintz GS, Xu K, Lansky AJ, Cristea E, Farah TG, Teles R, Botker H, Debruyne B, Serruys PW, **Stone GW.** Age and Sex Related Plaque Composition of Non Culprit Lesions in Patients with Acute Coronary Syndromes: The PROSPECT Study. JACC 2011;58,(supplB):690.

935. Leonardi S, Koehler ML, Truffa A, Trioci P, White H, Gibson CM, **Stone GW,** Harrington E, Bhatt DL, Mahaffey KW. A Novel Approach to Define Type 4a Myocardial Infarction in Acute Coronary Syndrome Patients Undergoing Early Invasive Management: Insights From the CHAMPION PLATFORM Trial Circulation. 2011;124:A10045.

936. Claessen B, Dangas GD, Mehran R, Xu K, Fahy M, Parise H, Ohman EM, White HD, **Stone GW.** Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes Circulation. 2011;124:A16422.

937. Yu J, Dangas G, Xu K, Sartori S, Claessen B, Fahy M, Parise H, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wohrle J, Dudek D, **Stone GW,** Mehran R. Do Geographic Trends in Aspirin Discharge Dose Alter Outcomes After STEMI and Primary PCI: Results From the HORIZONS-AMI Trial Circulation. 2011;124:A13942.

938. Kuijit W, Kruckoff MW, Damman P, Lopes RD, Green CL, Pieper KS, Stevens SR, Christenson RH, Tijssn JG, **Stone GW,** De Winter R, Lincoff AM, Roe MT. Prediction of Myocardial Infarct Size Using Multiple Concomitant Angiographic, Biochemical and Electrocardiographic Biomarkers in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Circulation. 2011;124:A14862.

939. Dangas G, Mehran R, Baber U, Feit F, Cox D, Brodie BR, Witzenbichler B, Deliargyris E, Gersh BJ, **Stone GW.** Impact of Bivalirudin Therapy on Mortality in Patients With High Risk Features Undergoing PCI: A Patient-Level Pooled Analysis From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. Circulation. 2011;124:A 15919.

940. Baber U, Brener S, Sergie Z, Yu J, Dangas G, Xu K, Dangas G, Mehran R, **Stone GW**. Impact of Chronic Kidney Disease on Myocardial Blush an ST-Segment Resolution Following Primary Percutaneous Coronary Intervention: The HORIZONS-AMI Trial. JACC 2012:59:12 Supplement A, A7.

941. Razzouk L, Feit F, Maehara A, Mintz G, Xu K, Iniguez A, Schiele F, Niess G, Mehran R, Templin B, Weisz G, **Stone GW**. Is Minimal Liminal Area by Intravascular Ultrasound the Critical Determinant of Future MACE in Intermediate Lesions? Insights from PROSPECT? The HORIZONS-AMI Trial. JACC 2012:59:12 Supplement A, A12.

942. Genereux P, Palmerini T, Caixeta A, Rosner G, Green P, Dressler O, Dangas G, Mehran R, Dangas G, **Stone GW.** Quantification and Impact of Untreated Coronary Artery Disease After PCI: The Residual SYNTAX Score. JACC 2012:59:12 Supplement A, A12.

943. Yu J, Pinnelas R, Clachijannis G, Baber U, Dangas G, Xi K, Witzenbichler B, Guagliumi G, Woehrle J, Brodie B, Mehran R, **Stone GW.** Which Glomerular Filtration Rate Equation Best Predicts Poor Outcomes in Patients with Acute Myocardial Infarction Undergoing Primary PCI: Results from the HORIZONS-AMI Study. JACC 2012:59:12 Supplement A, A17.

944. Yakushiki T, Maehara A, Hiroshi A, Saito S, Leon M, **Stone GW,** Moses J, Mintz G, Ochiai M. Different Pattern of Chronic Total Occlusions in the Right and Left Coronary Arteries: An Intravascular Ultrasound Study. JACC 2012:59:12 Supplement A, A26.

945. Sakamoto K, Wasenda K, Yock P, Holmes D, **Stone GW,** Fitzgerald P, Honda Y. Effects of Inter-Stent Compressed Intimal Volume After Drug-Eluting Stent Treatments for Bare Metal In-Stent Restenosis: A Volumetric Intravascular Ultrasound Analysis. JACC 2012:59:12 Supplement A, A27.

946. HoYun K, Mintz G, Farhat N, Marso S, Taglieri N, Verheye S, Foster M, Xu K, Dressler O, Mehran R, **Stone GW,** Maehara A. The Relationship Between Lesion Severity and Vulnerable Plaque Morphology: Lessons from the PROSPECT Study. JACC 2012:59:12 Supplement A, A30.

947. Inaba S, Maehara A, Farhat N, Templin B, Weisz G, DeBruyne D, Serruys P, Mintz G, **Stone GW.** The Remodeling Paradox and Clinical Outcomes: Insights from PROSPECT. JACC 2012:59:12 Supplement A, A39.

948. Yakushiji T, Inaba S, Maehara A, Cristea E, Brener S, Witzenbichler B, Guagliumi G, Xu K, Mehran R, **Stone GW**, Mintz G. JACC 2012:59:12 Supplement A, A42.

949. Yu J, Mehran R, Vlachojannis G, baber U, Xu K, Lansky A, Grines C, Guagliumi G, Kornowski R, Witzenbichler B, Dangas G, **Stone GW.** Impact of High Dose Aspirin in Men vs Women after Acute Myocardial Infarction: Results from the HORIZONS AMI Trial. JACC 2012:59:12 Supplement A, A64.

950. Stuckey T, Kirtane AJ, Parise H, Witzenbichler B, Weisz G, Rinaldi M, Neumann FJ, Metzger D, Henry T, Cox D, Duffy P, Brodie B, Mazzaferri E, Cristea E, Mehran R, **Stone GW.** Impact of Point-of-Care Platelet Function Testing Among Diabetic and Non-Diabetic Patients Undergoing PCI with Drug-Eluting Stents: AN ADAPT-DES Substudy. JACC 2012:59:12 Supplement A, A65.

951. Woehrle J, Parise H, Mehran R, **Stone GW.** Impact of Bivalirudin and Paclitaxel-eluting Stents in Patients with STEMI Undergoing Primary PCI of the Left Anterior Descending Artery: The HORIZONS-AMI Trial. JACC 2012:59:12 Supplement A, A67.

952. Vlachojannis G, Mehran R, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie B, Fahy M, Kornowski R, Gersh B, Parise H, Dangas G, **Stone GW.** Dual Antiplatelet and Long-term Clinical Outcomes After Primary PCI: The HORIZONS-AMI Trial. JACC 2012:59:12 Supplement A, A69.

953. Yu J, Dangas G, Baber U, Vlachojannis G, Clayton T, Pocock S, Feit F, Cox D, Brodie B, Lincoff AM, Deliargyris E, Gersh B, Gibson CM, Mehran R, **Stone GW.**

Impact of Ejection Fraction on Mortality in Patients Undergoing PCI: A Patient-Level Pooled Analysis from the REPLACE-2, ACUITY and HORIZONS-AMI Trials. JACC 2012:59:12 Supplement A, A70.

954. Rinaldi M, Kirtane AJ, Parise H, Witzenbichler B, Weisz G, Neumann FJ, Metzger D, Henry T, Cox D, Duffy P, Brodie B, Stuckey T, Mazzaferri E, Cristea E, Mehran R, **Stone GW.** Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing PCI with Drug-Eluting Stents: An ADAPT-DES Substudy. JACC 2012:59:12 Supplement A, A70.

955. Kirtane AJ, Parise H, Witzenbichler B, Weisz G, Rinaldi M, Neumann FJ, Metzger D, Henry T, Cox D, Duffy P, Brodie B, Stuckey T, Mazzaferri E, Cristea E, Mehran R, **Stone GW.** Does Platelet Function Testing Add Significant Incremental Risk Stratification to Unselected Patients Undergoing DES Implantation? The ADAPT-DES Substudy. JACC 2012:59:12 Supplement A, A70.

956. Yakushiji T, Mintz G, Witzenbichler B, Guagliumi G, Cristea E, Dressler O, Mehran R, **Stone GW,** Maehara A. Impact of Early and Late Stent Malapposition On Long-term Clinical Outcomes: Three-Year follow-up From the HORIZONS AMI IVUS Substudy. JACC 2012:59:12 Supplement A, A74.

957. Kereiakes D, Cannon L, Kandzari D, Kimmelstiel C, Meredith I, Popma J, **Stone GW,** Teirstein P, Verheye S, Allocco D, Dawkins K. Longitudinal Stent Deformation: Quantitative Coronary Angiographic Analysis from the Perseus WH and Platinum WH Randomized Controlled Clinical Trials. JACC 2012:59:12 Supplement A, A77.

958. Kedhi E, **Stone GW,** Kereiakes D, Serruys P, Parise H, Fahy M, Simonton C, Sudhir K, Sood P, Smits P. Stent Thrombosis: Insights on Outcomes, Predictors and Impact of Dual Antiplatelet Therapy Interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE Trials. JACC 2012:59:12 Supplement A, A77.

959. Kelly C, Weisz G, Maehara A, Mintz G, McPherson J, Verheye S, Xu K, Fahy M, Templin B, DeBruyne B, Serruys P, **Stone GW.** CRP Levels 180 Days After PCI for ACS, but Not Earlier, Predict Late Adverse Cardiac Events Independent of Plaque Characteristics: The PROSPECT Study. JACC 2012:59:12 Supplement A, A81.

960. Brener S, Mintz G, Cristea E, Weisz G, Maehara A, McPherson J, Marso S, Farhat N, Botker HW, Dressler O, Xu K, Templin B, Zhang Z, Lansky A, Debruyne B, Serruys P, **Stone GW.** Characteristics and Clinical Significance of Angiographically Mild Lesions in Acute Coronary Syndromes: Insights from the PROSPECT Study. JACC 2012:59:12 Supplement A, A86.

961. Genereux P, Bernard S, Palmerini T, Caixeta A, Rosner G, Green P, Dangas G, Mehran R, **Stone GW.** Incidence, Predictors and Impact of Stroke in Acute Coronary Syndrome: Insights from the ACUITY Trial. JACC 2012:59:12 Supplement A, A92.

962. Jarai R, Dangas G, Huber K, Xu K, Mehran R, **Stone GW,** Claessen BE. B-Type Natriuretic Peptide and the Risk of Contrast Induced Nephropathy in STEMI: Analysis from the HORIZONS-AMI Trial. JACC 2012:59:12 Supplement A, A97.

963. Brener S, Mehran R, Dressler O, Cristea E, **Stone GW.** Diabetes Mellitus, Myocardial Reperfusion and Outcome in Patients with Acute ST-elevation Myocardial Infarction Treated with Primary Angioplasty: Insights from HORIZONS AMI. JACC 2012:59:12 Supplement A, A113.

964. Rosner G, Kirtane A, Genereux P, Lansky A, Cristea E, Gersh B, Weisz B, Parise H, Mehran R, **Stone GW.** Impact of Incomplete Coronary Revascularization on One-Year Outcomes after Percutaneous Coronary Intervention in Acute Coronary Syndromes: The ACUITY Trial. JACC 2012:59:12 Supplement A, A131.

965. Wakabayashi K, Mintz G, **Stone G,** Weissman N, Ellis S, Grube E, Ormiston J, Turco M, Pakala R, Carnicero A, Romaguera R, Sardi G, Pichard A, Waksman R. Impact of Drug-Eluting Stents on Distal Vessel. JACC 2012:59:12 Supplement A, A369.

966. Shimizu T, Maehara A, Farah T, Reles R, Lerman A, Hamm C, Templin B, Lansky A, Xu K, Weisz G, Serruys P, Mintz G, **Stone GW.** Relationship Between Coronary Artery Calcification, High-Risk “Vulnerable Plaque” Characteristic and Future Adverse Cardiac Events: The PROSPECT Study. JACC 2012:59:12 Supplement A, A515.

967. **Stone GW,** Teirstein P, Meredith I, Bouchard A, Carrie D, Millman H, Oldroyd K, Hall J, Allocco D, Dawkins K. Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus–Eluting Stents in De Novo Coronary Artery Lesions. JACC 2012:59:12 Supplement A, A78.

968. Maehara A, Mintz G, Witzenbichler B, Metzger C, Rinaldi M, Mazzaferri E, Duffy P, Weisz G, Stuckey T, Brodie B, Xu K, Parise H, Mehran R, **Stone G.** IVUS Predictors of Stent Thrombosis: Results From the Prospective, Multicenter ADAPT-DES Study . J Am Coll Cardiol 2012; 60 (Suppl B):B6.

969. Witzenbichler B, Maehara A, Weisz G, Neumann F, Rinaldi M, Metzger C, Henry T, Cox D, Duffy P, Brodie B, Stuckey T, Mazzaferri E, Xu K, Mehran R, Parise H, Mintz G, **Stone G.** Use of IVUS Reduces Stent Thrombosis: Results from the

Prospective, multicenter ADAPT-DES Study. J Am Coll Cardiol 2012; 60 (Suppl B):B6.

970. Madder R, Madden S, Puri R, Hendrick M, Vanoosterhout S, Sum S, Kini A, Sharma S, Rizik D, Brilakis E, Shunk K, Goldstein j , Weisz G, Virmani R, Nicholls S, Maehara Mintz G, **Stone G**, Muller J. Detection by Near-Infrared Spectroscopy of Large Lipid Core Plaques at Culprit Sites in Patients with Acute ST Segment Elevation Myocardial Infarction. J Am Coll Cardiol 2012; 60 (Suppl B):B7.

971. **Stone G,** Clayton T, Mehran R, Deliagyris M, Prats j, Pocock S. Bivalirudin reduces cardiac mortality in patients with and without major bleeding: The HORIZONS-AMI trial. J Am Coll Cardiol 2012; 60 (Suppl B):B16.

972. Brener S, Maehara A, Dizon J, Fahy M, Witzenbichler B, Parise H, El-Omar M, Dambrink J, Mehran R, Oldroyd K, Gibson M, **Stone G**. Angiographic Reperfusion Indices Predict Infarct Size and Mortality: The INFUSE-AMI Trial . J Am Coll Cardiol 2012; 60 (Suppl B):B18.

973. Dambrink j, Brener S, Maehara A, Chowdhary S, Gershlick A, Kooken J, Mehran R, Fahy M, Gibson C, **Stone G**. Effects of Mechanical Thrombectomy and Intracoronary Abciximab on Coronary Flow and Infarct Size During Primary PCI: Analysis from the INFUSE-AMI Trial. J Am Coll Cardiol 2012; 60 (Suppl B):B18.

974. Maehara A, Mintz G, Brener S, Dambrink J, El-Omar M, Gershlick A, Fahy M, Mehran R, Gibson C, **Stone G.** Effect of Intracoronary Abciximab and Aspiration Thrombectomy on Microvascular Obstruction in Large Anterior Myocardial Infarction: The INFUSE-AMI MRI Substudy. J Am Coll Cardiol 2012; 60 (Suppl B):B19.

975. Rene A, Généreux P, Ezekowitz M, Kirtane A, Mehran R, **Stone G.** Impact of Atrial Fibrillation in Patients with STEMI Before and After Primary PCI: Insights from the HORIZONS-AMI Trial. J Am Coll Cardiol 2012; 60 (Suppl B):B20.

976. Dangas G, Sharma S, Kini A, Theodoropoulos K, Henriques J, **Stone G**, O Neill W. Impact of Hemodynamic Support With Impella vs Intraaortic Balloon Counterpulsation on Prognostically Important Ischemic Endpoints: Results from the PROTECT II Trial. J Am Coll Cardiol 2012; 60 (Suppl B):B21.

977. Baber U, Mehran R, Kini A, theodoropoulos K, Gukathasan N, **Stone G.** Impact of Gender on Adverse Cardiovascular Events Following Percutaneous Coronary Interventions: Pooled Analysis from the SPIRIT II,III and IV trials. J Am Coll Cardiol 2012; 60 (Suppl B):B23.

978. Baber U, Mehran R, Brener S. Maehara A, Dudek D, Neunteuff T, Metzger C, Gibson C, **Stone G.** Impact of Chronic Kidney Disease on Myocardial Infarct Size

and Adverse Events in ST-Elevation Myocardial Infarction: Results from the INFUSE-AMI trial. J Am Coll Cardiol 2012; 60 (Suppl B):B43.

979. Jarai R. Dangas G, Huber K, Mehran R, **Stone G**, Xu K. Prognostic Value of Different Definitions of Contrast Induced Acute Kidney Injury in STEMI: Analysis from the HORIZONS-AMI Trial. J Am Coll Cardiol 2012; 60 (Suppl B):B43.

980. Gukathasan N, Mehran R, Brener S, Maehara A, Sergie Z, Metzger C, Oldroyd K, Parise H, Fahy M, Gibson C, **Stone G.** Impact of gender on adverse cardiac events in patients with large anterior myocardial infarctions: Results from the INFUSE-AMI Trial. J Am Coll Cardiol 2012;60 (Suppl B):B105.

981. Hoebers L, Claessen B, Dangas G, Colombo A, DiMario C, Henriques J, Leon M, **Stone G**, Moses J, Park S, Mehran R. Long-Term Clinical Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions in elderly Patients (≥75 years): five-Year Outcomes from a 1,791 Patient Multi National Registry. J Am Coll Cardiol 2012; 60 (Suppl B):B128.

982. Brener S, Witzenbichler B, Maehara A, Dizon J, Fahy M, El-Omar, Dambrink J, Mehran R, Oldroyd K, Parise H, Gibson C, **Stone G.** Clinical Outcomes after Anterior ST-Elevation Myocardial Infarction According to LAD Lesion Location: the INFUSE-AMI Trial. J Am Coll Cardiol 2012; 60 (Suppl B):B135.

983. Stone S, Mehran R, Witzenbichler B, Guagliumi G, Peruga J, Brodie B, Dudek D, Mockel M, **Stone G.** Frequency, Timing and Implications of Reinfarction after Primary Stenting in ST-Segment Elevation Myocardial Infarction: The HORIZONS-AMI Trial. J Am Coll Cardiol 2012; 60 (Suppl B):B135.

984. Planer D, Ohman E, White H, Moses J, Fahy M, Mehran R. **Stone G.** Prognosis of Patients Presenting with Non ST Segment Elevation Myocardial Infarction and Non obstructive Coronary Artery Disease: Propensity Score Matched Cohort from the ACUITY Trial. J Am Coll Cardiol 2012; 60 (Suppl B):B136.

985. Rosner G, Green P, Kirtane A, Généreux P, Lansky A, Gersh B, Weisz G, Parise H, Fahy M, Brener S. Mehran R, **Stone G.** Relationship between Reference Vessel Diameter and the Incidence and Impact of Incomplete Coronary Revascularization Following PCI in ACS: the ACUITY Trial. J Am Coll Cardiol 2012; 60 (Suppl B):B137.

986. Daneault B, Généreux P, Kirtane A, Witzenbichler B,Guagliumi G, Paradis J, Fahy M, Mehran R, **Stone G.** Impact of Left Ventricular Dysfunction and Multi-Vessel Disease after Primary Percutaneous Coronary Intervention: three Year Outcomes from HORIZONA-AMI Trial. J Am Coll Cardiol 2012; 60 (Suppl B):B138.

987. Newman J, Dangas G, Brener S, Xu K, Généreux P, Lansky A, Nikolsky E, Mehran R, **Stone G.** Outcomes in Patients with Non-obstructive Coronary Artery Disease With and Without Cardiac Biomarker Elevations: the ACUITY Trial. J Am Coll Cardiol 2012; 60 (Suppl B):B139.

988. Palmerini T, Brener S. Dambrink J, Fahy M, Gibson C, Godlewski J, Maehara A, Oehala A, Parise H, **Stone G,** Witzenbichler B. Relationship Between White Blood Cell Count and Final Infarct Size in Patients with ST –Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Analysis from the INFUSE-AMI Trial. J Am Coll Cardiol 2012; 60 (Suppl B):B140.

989. Claessen B, Dangas G, Mehran R, Xu K, **Stone G.** Stent Thrombosis after primary PCI for STEMI in relation to non-usage of dual antiplatelet therapy over time: Results of the HORIZONS-AMI trial. J Am Coll Cardiol 2012; 60 (Suppl B):B141.

990. Mockel M, De Bruyne B, Serruys P, Weisz G, Holert F, Muller C, Muller R, Slagman A, Xu K, Searle J, **Stone G.** Prediction of lesion type related MACE by sFLT-1 and GDF-15, Results from the PROSPECT Study. J Am Coll Cardiol 2012; 60 (Suppl B):B145.

991. El-Omar M, Brener S, Maehara A, Scott T, Mehran R, Aengevaeren W, Dudek D, Fahy M, Gibson C, **Stone G.** Low overall Rates of Angiographically Visible Distal Embolization in INFUSE-AMI: Possible Explanation for Lack of Efficacy of Manual Aspiration Thrombectomy. J Am Coll Cardiol 2012; 60 (Suppl B):B147.

992. Dizon J, Brener S, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink J, Mehran R, Gibson C, **Stone G.** Simple Measures of ST-Segment Resolution Predict Infarct Size: The INFUSE-AMI Trial. J Am Coll Cardiol 2012; 60 (Suppl B):B148.

993. Maehara A, Mintz G, Brener S, Witzenbichler B, Zeymer U, Gershlick A, Fahy M, Mehran R, Gibson C, **Stone G.** Microvascular Obstruction Detected by MRI is a Predictor of Recovery from Myocardial Stunning: the INFUSE –AMI Trial. J Am Coll Cardiol 2012; 60 (Suppl B):B149.

994. Inaba S, Mintz G, Yun K, Yakushiji T, Shimizu T, Weisz G, Leon M, Moses J, **Stone G**, Maehara A. Partial strut fracture in Everolimus-eluting stents: An intravascular ultrasound study. J Am Coll Cardiol 2012; 60 (Suppl B):B157.

995. Teirstein P, **Stone G,** Meredity I, Feldman R, Dens J, Rabinowitz A, Dubois C, Allocco D, Dawkins K. Two Year Outcomes Following Implantation of 32mm and 38mm Platinum Chromium Everolimus Eluting Element Stents in Long Coronary Lesions. J Am Coll Cardiol 2012;60 (Suppl B):B177.

996. Généreux P, Kirtane A, Brener S, Maehara A, Palmerini T, Fahy M, Mehran R, **Stone G.** Impact of Mederate and Severe Coronary Calcification on 1-year Outcomes after PCI with DES: A Pooled Analysis of 11,651 Patients from 14 Randomized Trials. J Am Coll Cardiol 2012;60 (Suppl B):B195.

997. **Stone G**, Kereiakes D, Hermiller J Krucoff M, Seth A, Grube E, Morice M, Cutlip D. Implication of peri-procedural biomarker elevation after stent implantation: analysis from the pooled XIENCE V trials. J Am Coll Cardiol 2012;60 (Suppl B):B196.

998. Sachdeva A,Bavisetty S, Becham G, Shen A, Aharonian V, Mansukhani P, **Stone G,** Leon M, Moses J, Moore N, Hyett R, Contreras R, Brar S. Discontinuation of Long Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention. J Am Coll Cardiol 2012;60(Suppl B):B212.

999. Baumbach A, Dauerman H, Cortese B, Hamon M, Prats J, Deliargyris E, Mehran R, **Stone G.** Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with; Modified Pharmacologic regimens? J Am Coll Cardiol 2012;60 (Suppl B):B219.

1000. Waseda K, Shimohama T, Yamasaki M, Tsujino I, Yock P, Shigeru S, Kamakura S, **Stone G,** Yaqub M, Cao, S, Sudhir K, Fitzgerald P, Honda Y. Intravascular Ultrasound and Angiographic Predictors of 5-Year Target Lesion Revascularization: Very Long-Term Clinical Follow-up of the SPIRIT III Trial. Circulation 2012;126:Issue 21 Supplement.

1001. Genereux P, Maehara A, Kirtane A, Brener S, Palmerini T, Lasalle L, McAndrew T, Lansky A, Mehran R, Mintz G, **Stone G.** Impact of Coronary Calcification on one-year outcomes after PCI in STEMI and NSTEMI: pooled analysis from Horizons and Acuity trials. JACC 2013;61:2106-217.

1002. Madhaven M, Witzenbichler B, Genereux P, Fahy M, Mehran R, **Stone G.** Risks and benefits of post-procedural anticoagulation in patients with STEMI undergoing primary PCI: analysis from the horizons-AMI trial. JACC 2013;61:2909-7.

1003. Popma J, Almonacid A, Kereiakes D, Meredith I, Teirstein P, Allocco D, Dawkins K, **Stone G.** Stent design impacts geometric vessel distortion following coronary artery stenting in severely angulated lesions; Angiographic analysis of the platinum trial. JACC 2013;61:2101-217.

1004. Inaba S, Mintz G, Witzenbichler B, Metzger C, Rinaldi M, Mazzaferri E, Duffy P, Weisz G, Stuckey T, Brodie B, Xu K, Mehran R, **Stone G,** Maehara A. Impact of positive and negative coronary remodeling on culprit lesion morphometry: the ADAPT-DES IVUS substudy. JACC 2013;61:2108-246.

1005. Genereux P, Maehara A, Kirtane A, Brener S, Palmerini T, Lasalle L, Sanidas E, Tarigopula M, Yadav M, McAndrew T, Fahy M, Lansky A, Mehran R, Mintz G, **Stone G.** Association between coronary calcification and bleeding after PCI in ACS: pooled analysis from horizons-AMI and acuity trials. JACC 2013;61:1215M-201.

1006. Stuckey T, Kirtane A, Xu K, Witzenbichler B, Weisz G, Rinaldi M, Neumann F, Metzger C, Henry T, Cox D, Duffy P, Brodie B, Mazzaferri E, Cristea E, Parise H, Mehran R, **Stone G.** Lack of association between on-treatment platelet reactivity and ischemic outcomes in diabetic patients: one year results of the adapt-des study. JACC 2013;61:2904-1.

1007. Brener S, Mehran R, Dizon J, McAndrew T, Parise H, **Stone G.** Complimentary Predictive Value of Myocardial Blush Grade and St-Segment Resolution After Primary PCI: an Analysis from Horizons-AMI. JACC 2013;61,10;2908-7.

1008. **Stone G,** Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink J, Ochala A, Carlton T, Cristea E, Wolf S, Brener S, Chowdhary S, El-Omar M, Neunteufi T, Metzger C, Dizon J, Mehran R, Gibson C. Intracoronary Abciximab and Aspiration Thrombectomy During Primary PCI for Anterior Stemi: One-Year Results from the Randomized Infuse-AMI Trial. JACC 2013;61:2908-5.

1009. Lansky A, Ng V, Fahy M, Dizon J, Mehran R, **Stone G.** The Impact of Electrocardiographic Left Ventricular Hypertrophy on Mortality in Patients with Stemi Undergoing Primary PCI: Analysis from the Horizons-Ami Trial. JACC 2013;61:2113-262.

1010. Rinaldi M, Kirtane A, Xu k, Witzenbichler B, Weisz G, Neumann F, Metzger C, Henry T, Cox D, Duffy P, Brodie B, Stuckey T, Mazzaferri E, Cristea E, Parise H, Mehran R, **Stone G.** Impact of Point-of-Care Platelet Function Testing Among Patients with and without Acute Coronary Syndromes Undergoing PCI with Drug-Eluting Stents: an Adapt-des Substudy. JACC 2013;61:2909-1.

1011. Sergie Z, Mehran R, Brener S, Maehara A, Fahy M, Zeymer U, Zaman A, Woehrle J, Gibson M, **Stone G.** Gender Differences in Cardiac Symptoms 30 Days After Primary PCI for Anterior Myocardial Infarction: Insights from Infuse-AMI. JACC 2013;61:2101-234.

1012. **Stone G,** Teirstein P, Meredith I, Stoler R, Rabinowitz A, Pompili V, Kabour A, Stuckey T, Curzen N, Saito S, Erglis A, Allocco D, Dawkins K. Three-Year Results of the Platinum Randomized Trial Comparing Platinum Chromium Promus Element and Cobalt Chromium Promus/ Xience V Everolimus-Eluting Stents. JACC 2013;61:2903-3.

1013. Dohi T, Mintz G, McPherson J, Bruyne B, Farhat N, Lansky A, Mehran R, Weisz G, Xu K, **Stone G,** Maehara A. The Impact of Non-Fibroatheroma Lesion Phenotype on Long-Term Clinical Outcomes: A Substudy Analysis from Prospect. JACC 2013;61:2108M-234.

1014. Kobayashi N, Maehara A, Allocco D, Witzenbichler B, Ellis S, Turco M, Ormiston J, Guagliumi G, Jiang S, McAndrew T, Dawkins K, **Stone G,** Mintz G, Weissman N. Stenting During Stemi is Association with Less Neointimal Hyperplasia: A Pooled IVUS Analysis from the Horizons-AMI and Taxus IV, V, and Atlas Trials. JACC 2013;61:2908-12.

1015. Inaba S, Mintz G, Witzenbichler B, Metzger C, Rinaldi M, Mazzaferri E, Duffy P, Weisz G, Stuckey T, Brodie B, Xu K, Mehran R, **Stone G,** Maehara A. Myocardial Bridging Does Not Affect Atherosclerosis in Adjacent Coronary Artery Segments: An Adapt-Des IVUS Sub-Study. JACC 2013;61:2108-2367.

1016. Ho Yun K, Mintz G, Witzenbichler B, Metzger C, Rinaldi M, Mazzaferri E, Duffy P, Weisz G, Stuckey T. Brodie B, Mehran R, **Stone G,** Maehara A. Relationship Between Platelet Reactivity and Culprit and Non-Culprit Lesion Morphology: the Adapt–DES IVUS Substudy. JACC 2013;61:2108M-233.

1017. Farooq V, Vergouwe Y, Genereux P, Palmerini T, Bouranats C, Caixeta A, Garcia H, Kappetein A, Morel M, Valgimigli M, Winddecker S, Dawkins K, SteyerbergE, Serruys P, **Stone G.** Prediction of One –Year Mortality in Patients with Acute Coronary Syndromes Undergoing PCI from the Acuity (Acute Catheterization and Urgent Intervention Triage Strategy) Trial Validation of the Logistic Clinical Syntax Score. JACC 2013;61:1216-215.

1018. Genereux P, Maehara A, Kirtane A, Brener S, Palmerini T, Lasalle L, McAndrew T, Lansky A, Mehran R, Mintz G, **Stone G.** Impact of Coronary Calcification on One-Year Outcomes After PCI in STEMI and NSTEMI: Pooled Analysis from Horizons and Acuity Trials. JACC 2013;61:2106-217.

1019. Madhavan M, Witzenbichler B, Genereux P, Fahy M, Mehran R, **Stone G.** Risk and Benefits of Post-Procedural Anticoagulation in Patients with STEMI Undergoing Primary PCI: Analysis form the Horizons-AMI Trial. JACC 2013;61:2909-7.

1020. Popma J, Almonacid A, Kereiakes D, Meredith I, Teirstein P, Allocco D, Dawkins K, **Stone G.** Stent Design Impacts Geometric Vessel Distortion Following Coronary Artery Stenting in Severely Angulated Lesions: Angiographic Analysis of the Platinum Trial. JACC 2013;61:2101-229.

1021. Inaba S, Mintz G, Witzenbichler B, Metzger C, Rinaldi M, Mazzaferri E, Duffy P, Weisz G, Stuckey T, Brodie B, Xu K, Mehran R, **Stone G,** Maehara A. Impact of

Positive and Negative Coronary Remodeling on Culprit Lesion Morphometry: The Adapt-DES IVUS Substudy. JACC 2013;61:2108-246.

1022. Genereux P, Maehara A, Kirtane A, Brener S, Palmerini T, Lasalle L, Sanidas E, Tarigopula M, Yadav M, McAndrew T, Fahy M, Lansky A, Mehran R, Mintz G, **Stone G.** Association Between Coronary Calcification and Bleeding After PCI in ACS: Pooled Analysis from Horizons-AMI and Acuity Trials. JACC 2013;61:1215M-201.

1023. Weisz G, Kirtane A, Xu K, Stuckey T, Witzenbichler B, Rinaldi M, Neumann F, Metzger C, Henry T, Cox D, Duffy P, Brodie B, Mazzaferri E, Parise H, Mehran R, **Stone GW.** Do Proton Pump Inhibitors Interact With Clopidogrel Insights from ADAPT-DES? JACC 62:18 SUPPL1(2013).

1024. Wang TY, Zettler M, Effron MB, McCoy L, Anstrom K, Fonarow GC, Messenger JC, **Stone GW,** Cohen D, Henry TD, Peterson E. Comparative Effectiveness of Prasugrel vs. Clopidogrel Among Acute Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: 30-Day Outcomes from the TRANSLATE-ACS Observational Study. JACC 62:18 SUPPL1(2013).

1025. Oldroyd KG, Brener S, Maehara A, El-Omar M, Witzenbichler B, Xu K, Mehran R, Gibson CM, **Stone GW.** Outcomes in STEMI Patients Treated with Clopidogrel or Prasugrel: A Propensity Adjusted Analysis from the INFUSE-AMI Trial. JACC 62:18 SUPPL1(2013).

1026. Stuckey T, Kirtane AJ, Brodie BR, Witzenbichler B, Weisz G, Rinaldi M, Neumann FJ, Chavez IJ, Metzger C, Henry TD, Cox D, Duffy PL, Mazzaferrim EL, Mehran R, Guerchicoff A, Parise H, **Stone GW.** Relationship Between High Platelet Reactivity on Clopidogrel and Outcomes After DES Implantation: Two-Year Results From the ADAPT-DES Study. JACC 62:18 SUPPL1(2013).

1027. Baber U, Mehran R, Kirtane AJ, Gurbel PA, Christodoulidis G, Witzenbichler B, Weisz G, Metzger C, Henry TD, Cox D, Duffy PL, Mazzaferri EL, Xu K, Parise H, Brodie BR, Stuckey T, **Stone GW**. Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease: Results from the ADAPT-DES Registry. JACC 62:18 SUPPL1(2013).

1028. Garg A, Brodie BR, Stuckey T, Xu K, Kirtane AJ, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger C, Henry TD, Cox D, Duffy PL, Mazzaferri EL, Mehran R, **Stone GW.** Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study. JACC 62:18 SUPPL1(2013).

1029. Kedhi E, Genereux P, Palmerini T, McAndrew T, Parise H, Dangas G, Mehran R, Ben-Yehuda O, **Stone GW.** The Impact of Coronary Lesion Severity on Drug-

eluting Stent Outcomes in Patients with and without Diabetes Mellitus. JACC 62:18 SUPPL1(2013).

1030. Dudek D, Abizaid A, Silber S, Dizon J, Costa R, Merkely B, Kornowski R, Abizaid A, Wojdyla R, Dressler O, Brener S, Yaacoby E, **Stone GW.** One-year Results From the MASTER Trial, a Prospective, Randomized, Multicenter Evaluation of an Embolic Protection Stent (MGuard) in Patients with STEMI Undergoing Primary PCI. JACC 62:18 SUPPL1(2013).

1031. Genereux P, Kirtane A, Witzenbichler B, LaSalle L, Weisz G, Xu K, Brener S, Mehran R, **Stone GW.** Angiographic Predictor of 2-Year Stent Thrombosis in Patients Receiving Drug-eluting Stents: Insights from the ADAPT-DES Study. JACC 62:18 SUPPL1(2013).

1032. Ertelt K, Genereux P, Mintz G, Reiss G, Kirtane A, Madhavan M, Fahy M, Williams M, Brener S, Mehran R, **Stone GW.** Impact Of Coronary Artery Calcification On Clinical Events In Patients Undergoing Coronary Artery Bypass Grafting: Analysis From The ACUITY (Acute Catheterization And Urgent Intervention Triage Strategy) Trial. JACC 62:18 SUPPL1(2013).

1033. Maehara A, Weisz G, Neumann F, Metzger C, Henry T, Cox D, Duffy P, Brodie B, Stuckey T, Mazzaferri E, Xu K, Mehran R, Parise H, Mintz G, **Stone GW.** Does IVUS Reduce Stent Thrombosis with DES? Two-year results from the prospective, multicenter ADAPT-DES study. JACC 62:18 SUPPL1(2013).

1034. Souza C, Mintz G, Witzenbichler B, Metzger C, Rinaldi M, Mazzaferri E, Duffy P, Weisz G, Stuckey T, Brodie B, Xu K, **Stone GW,** Maehara A. PCI Lesion Morphology According to Chronic Statin Use: An ADAPT-DES IVUS Substudy. JACC 62:18 SUPPL1(2013).

1035. Johnson N, Xu K, Maehara A, Genereux P, Kirkeeide R, Gould K, **Stone GW,** Jeremias A. Applicability of hybrid strategy (resting index plus selective FFR) to assess hemodynamic significance of coronary stenosis depends on FFR distribution. JACC 62:18 SUPPL1(2013).

1036. Bagai A, Peterson E, Honeycutt E, Effron M, **Stone GW,** Henry T, Cohen D, Anstrom K, Wang T. High On-Treatment Platelet Reactivity among Contemporary Acute Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Insights from the TRANSLATE-ACS Study. JACC 62:18 SUPPL1(2013).

1037. Kirtane A, Stuckey T, Xu K, Witzenbichler B, Weisz G, Rinaldi M, Neumann F, Metzger C, Henry T, Cox D, Duffy P, Brodie B, Mazzaferri E, Cristea E, Parise H, Mehran R, **Stone GW.** Is There a Therapeutic Window For Platelet Responsiveness Among PCI Patients? Analysis from the ADAPT-DES Study. JACC 62:18 SUPPL1(2013).

1038. Weisz G, Kirtane A, Xu K, Stuckey T, Witzenbichler B, Rinaldi M, Neumann F, Metzger C, Henry T, Cox D, Duffy P, Brodie B, Mazzaferri E, Parise H, Mehran R, **Stone GW.** The Interaction Between Clopidogrel and Calcium Channel Blockers on Platelet Reactivity and Long-Term Events after PCI. JACC 62:18 SUPPL1(2013).

1039. Trenk D, Brodie B, Büttner H, Cox D, Duffy P, Henry T, Kirtane A, Mazzaferri E, Mehran R, Metzger C, **Stone GW,** Stuckey T, Weisz G, Witzenbichler B, Xu K, Neumann F. Impact of Clopidogrel Hyporesponsiveness on Clinical Outcomes in Patients Receiving Drug-eluting Stents for Stable Coronary Disease in the ADAPT-DES Study. JACC 62:18 SUPPL1(2013).

1040. Weisz G, Kirtane A, Xu K, Stuckey T, Witzenbichler B, Rinaldi M, Neumann F, Metzger C, Henry T, Cox D, Duffy P, Brodie B, Mazzaferri E, Parise H, Mehran R, **Stone GW.** The Effect of Smoking Status on Platelet Reactivity and Long-Term Events after PCI. Does a Clopidogrel-related "Smoker's paradox" Exist? JACC 62:18 SUPPL1(2013).

1041. Vaccaro B, Kirtane A, Xu K, Witzenbichler B, Weisz G, Neumann F, Rinaldi M, Metzger C, Henry T, Cox D, Duffy P, Brodie B, Stuckey T, Mazzaferri E, Parise H, Mehran R, **Stone GW.** Correlates of High Platelet Reactivity on Clopidogrel in 8,533 Patients: An ADAPT-DES Substudy. JACC 62:18 SUPPL1(2013).

1042. Teirstein P, **Stone GW,** Meredith I, Feldman R, Rabinowitz A, Lee T, Kereiakes D, Carrié D, Allocco D, Dawkins K. Three-Year Results of the PLATINUM Small Vessel and Long Lesion Trials Evaluating the Platinum Chromium Everolimus-Eluting Stent in De Novo Coronary Artery Lesions. JACC 62:18 SUPPL1(2013).

1043. Sanidas E, Brener S, Maehara A, Genereux P, Witzenbichler B, El-Omar M, Xu K, Fahy M, Mehran R,l Gibson M, **Stone GW.** Reperfusion Success, Infarct Size and Clinical Outcomes in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Anterior Myocardial Infarction. JACC 62:18 SUPPL1(2013).

1044. Madhavan M, Genereux P, Palmerini T, Caixeta A, Yadav M, Xu K, Kirtane A, Mehran R, **Stone GW.** Relationship Between the SYNTAX Score and Major Bleeding after PCI: Analysis from the ACUITY Trial. JACC 62:18 SUPPL1(2013).

1045. Dudek D, Abizaid A, Silber S, Yaacoby E, Dizon J, Costa R, Maehara A, Dressler O, Brener S, **Stone GW.** Efficacy of an Embolic Protection Stent as a Function of Symptom Onset to Balloon Time in STEMI: The MASTER Trial. JACC 62:18 SUPPL1(2013).

1046. Guerchicoff A, Brener S, Fahy M, Gibson M, Maehara A, Mehran R, **Stone GW,** Witzenbichler B. Impact of Delay to reperfusion on Infarct Size and Clinical

Outcomes in Patients with STEMI: The INFUSE-AMI Trial. JACC 62:18 SUPPL1(2013).

1047. Madhavan M, Weisz G, Xu K, Mehran R, **Stone GW.** Comparison of Revascularization Strategies in Patients with Prior CABG Presenting with Acute Coronary Syndromes. JACC 62:18 SUPPL1(2013).

1048. Ertelt K, Genereux P, Mintz G, Kirtane A, McAndrew T, Brener S, Mehran R, **Stone GW.** Clinical Profile And Impact Of A Family History Of Premature Coronary Artery Disease On Long-term Clinical Ischemic Events In Patients Undergoing PCI For STEMI: Analysis From The HORIZONS-AMI Trial.Revascularization And Stents In Acute Myocardial Infarction) Trial. JACC 62:18 SUPPL1(2013).

1049. Dohi T, Maehara A, Mintz G, Genereux P, Brener S, Gershlick A, Mehran R, Gibson M, **Stone GW.** Clinical Utility of Peak Creatine Kinase-MB Measurements in Predicting Left Ventricular Dysfunction and Clinical Outcomes After First Anterior Myocardial Infarction: An INFUSE-AMI Sub-study. JACC 62:18 SUPPL1(2013).

1050. Wessler J, Kirtane A, Mehran R, Xu K, Genereux P, Brener S, **Stone GW.** Which Intraprocedural Thrombotic Events Impact Clinical Outcomes Following Percutaneous Coronary Intervention in ACS? A Pooled Analysis of the HORIZONS-AMI and ACUITY Trials. JACC 62:18 SUPPL1(2013).

1051. Yadav M, Genereux P, Kirtane A, Madhavan M, Xu K, Brener S, Mehran R, Stone **GW.** Baseline Thrombocytopenia: A Strong Predictor Of One-Year Adverse Ischemic Events In Patients With ACS Undergoing PCI: A Pooled analysis From ACUITY And HORIZONS-AMI Trials. JACC 62:18 SUPPL1(2013).

1052. Deliargyris E, Bernstein D, Brener S, Genereux P, Kirtane A, Mehran R, Prats J, Skerjanec S, **Stone GW.** Characterization of the Actuarial Daily Ischemic Risk in the First Year Following ST-Segment Elevation Myocardial Infarction: Analysis from the HORIZONS-AMI Trial. JACC 62:18 SUPPL1(2013).

1053. Mennuni M, Mehran R, Dangas G, Baber U, Kirtane A, Genereux P, Brener S, Feit F, Lincoff M, Ohman M, Hamon M, **Stone GW.** Which is the Ideal Revascularization Strategy in Patients Presenting with Acute Coronary Syndrome and Proximal LAD Stenosis? Results from the ACUITY Study. JACC 62:18 SUPPL1(2013).

1054. F Souza C, Mehran R, Kirtane A, Brener S, McAndrew T, Feit F, **Stone GW.** Safety and efficacy of Bivalirudin monotherapy in patients with non-ST segment elevation myocardial infarction undergoing PCI: Results from the ACUITY Study. JACC 62:18 SUPPL1(2013).

1055. Kobayashi N, Maehara A, Mintz G, Wolff S, Genereux P, Brener S, Xu K, Mehran R, C. Gibson M, **Stone GW.** Left anterior descending artery that wraps around the apex is associated with apical remodeling and subsequent heart failure in patients with anterior ST-Elevation MI: An INFUSE-AMI sub-study. JACC 62:18 SUPPL1(2013).

1056. Sanborn T, Mehran R, Genereux P, Witzenbichler B, Brener S, Kirtane A, McAndrew T, Francese D, Kornowski R, Dudek D, Nikolsky E, **Stone GW.** Reduced Bleeding Complications and Increased Event-free Survival With Femoral Vascular Closure Device Use and Bivalirudin in STEMI Patients Undergoing Primary Angioplasty in the HORIZONS-AMI Trial. JACC 62:18 SUPPL1(2013).

1057. Sanidas E, Genereux P, Palmerini T, Caixeta A, Malhotra R, Kirtane A, Xu K, Mintz G, Brener S, Mehran R, **Stone GW.** Utility of the Residual SYNTAX Score In Patients With Diabetes Mellitus After Percutaneous Coronary Intervention. JACC 62:18 SUPPL1(2013).

1058. Madhavan M, Genereux P, Rubin J, Palmerini T, Caixeta A, Xu K, Weisz G, Mehran R, **Stone GW.** The SYNTAX Score Predicts Acute Kidney Injury After PCI for NSTEACS: Analysis from the ACUITY Trial. JACC 62:18 SUPPL1(2013).

1059. Madhavan M, Weisz G, Caton M, Genereux P, Xu K, Witzenbichler B, Mehran R, **Stone GW.** Race and Outcomes after PCI for ACS: A Pooled Analysis of the HORIZONS-AMI and ACUITY Trials. JACC 62:18 SUPPL1(2013).

1060. Witzenbichler B, Brodie B, Cox D, Duffy P, Henry T, Kirtane A, Mazzaferri E, Mehran R, Metzger C, Neumann F, Parise H, **Stone GW,** Stuckey T, Weisz G, Xu K. Impact of Bifurcation Lesion Treatment with DES on Clinical Outcomes: Results from the Prospective, Multicenter ADAPT-DES Study. JACC 62:18 SUPPL1(2013).

1061. Yadav M, Genereux P, Palmerini T, Caixeta A, Madhavan M, Xu K, Kirtane A, Brener S, Mehran R, **Stone GW.** The SYNTAX Score and Risk Of Stent Thrombosis In Patients Undergoing PCI For NSTE-ACS: An ACUITY Trial PCI Cohort Analysis. JACC 62:18 SUPPL1(2013).

1062. Dohi T, Weisz G, Powers E, Steinberg D, Goldstein J, Shah P, Muller J, Mintz G, **Stone GW,** Maehara A. The Extent of Lipid-Rich Plaque Assessed by Near-Infrared Spectroscopy May Predict DES Failure: A COLOR Registry Analysis. JACC 62:18 SUPPL1(2013).

1063. Kobayashi N, Mintz G, Witzenbichler B, Metzger C, Rinaldi M, Mazzaferri E, Duffy P, Weisz G, Stuckey T, Bruce R, Brodie B, Xu K, **Stone GW,** Maehara A. Predictors of Stent Expansion After Drug-eluting Stents: An ADAPT-DES IVUS substudy. JACC 62:18 SUPPL1(2013).

1064. Omar A, Torguson R, Legutko J, Genereux P, Blankenship J, Hernandez J, Hellig F, McAndrew T, Mintz G, Singh J, Maehara A, **Stone GW,** Waksman R. The Effect Of Acute Coronary Syndrome Compared To Stable Angina On The Relationship Between Intravascular Ultrasound Minimal Luminal Area And Fractional Flow Reserve. JACC 62:18 SUPPL1(2013).

1065. Omar A, Torguson R, Genereux P, Blankenship J, Hernandez J, Hellig F, Legutko J, Mintz G, McAndrew T, Singh J, Maehara A, **Stone GW,** Waksman R. Impact Of Gender In The Relationship Between Intravascular Ultrasound And Fractional Flow Reserve. JACC 62:18 SUPPL1(2013).

1066. Johnson NP, Oldroyd K, Xu K, Maehara A, Genereux P, Gould KL, **Stone GW,** Jeremias A. What would an outcomes trial comparing FFR for all lesions versus a hybrid approach (resting index plus selective FFR) look like? JACC 62:18 SUPPL1(2013).

1067. Goto K, Mintz G, Lansky A, Weisz G, McPherson J, Bruyne B, Serruys PW, Xu K, **Stone GW,** Maehara A. Comparison of Lumen Measurements Between Quantitative Coronary Angiography and Intravascular Ultrasound: A PROSPECT substudy. JACC 62:18 SUPPL1(2013).

1068. Shimizu T, Bruyne B, Farhat N, Inaba S, Maehara A, Marso S, Mintz G, Serruys P, **Stone GW,** Weisz G. Relationship between the severity of left main coronary artery (LMCA) disease and overall coronary atherosclerotic burden: The PROSPECT study. JACC 62:18 SUPPL1(2013).

1069. Shimizu T, Hamm C, Lansky A, Lerman A, Maehara A, Mintz G, Serruys P, Stone GW, Teles RC, Templin B, Weisz G, Xu K. Total coronary artery calcification as a predictor of advanced atherosclerotic characteristics: The PROSPECT study. JACC 62:18 SUPPL1(2013).

1070. Saito S, Mintz G, Witzenbichler B, Metzger C, Rinaldi M, Mazzaferri E, Duffy P, Weisz G, Stuckey T, Brodie BR, Xu K, **Stone GW,** Maehara A. Relationship Between Renal Function and Lesion Morphology: An ADAPT-DES VH-IVUS sub-study. JACC 62:18 SUPPL1(2013).

1071. Wang L, Brodie B, Duffy P, Maehara A, Mazzaferri E, Metzger C, Mintz G, Rinaldi M, **Stone GW,** Stuckey T, Weisz G, Witzenbichler B, Xu K. Differences in Culprit Lesion Plaque Stability between Males and Females: A VH-IVUS Analysis from the ADAPT-DES Study. JACC 62:18 SUPPL1(2013).

1072. Dong L, Mintz G, Witzenbichler B, Metzger C, Rinaldi M, Mazzaferri E, Duffy PL, Weisz G, Stuckey T, Brodie B, Xu K, **Stone GW,** Maehara A. Relationship Between Plaque Morphologies And Clinical Presentation In The ADAPT-DES IVUS Substudy. JACC 62:18 SUPPL1(2013).

1073. Chen SL, Nruyen T, **Stone GW,** Zhang FF, Zhou L. Pulmonary artery denervation to treat pulmonary arterial hypertension: a single-center, prospective, first-in-man PADN-1 study. JACC 62:18 SUPPL1(2013).

1074. Kirtane A, Gada H, Bangalore S, Kereiakes D, **Stone GW.** Percutaneous Coronary Intervention is Associated with Lower Mortality Compared with Optimal Medical Therapy in Patients with Stable Ischemic Heart Disease and Objective Evidence of Ischemia or Abnormal Fractional Flow Reserve: A Meta-Analysis of Randomized Controlled Trials. JACC 62:18 SUPPL1(2013).

1075. Challa KK, Nikolsky E, Mehran R, Lansky AJ, Dangas GD, Caiexta A, McLaurin BT, Cox DA, Moses JW, Feit F, Embacher M, **Stone GW.** Drug-eluting versus bare-metal stents in treatment of diabetic patients with acute coronary syndromes: Analysis from the randomized ACUITY Trial. J Am Coll Cardiol 2010;55:A122.

1076. Jackson LR, Zettler M, Peterson E, Ju C, Effron M, Messenger J, Cohen D, **Stone GW**, Wang T. Triple Therapy after Acute Myocardial Infarction: A Comparison of Clopidogrel versus Prasugrel from the TRANSLATE-ACS Study. JACC 2014:Vol63:12:901-7 (SuppA).

1077. Qui F, Mintz G, Witzenbichler B, Metzger D, Rinaldi M, Duffy P, Weisz G, Stuckey T, Brodie B, Xu K, Kirtane A, **Stone GW,** Maehara A. Clinical Impact of Tissue Protrusion after Stent Implantation: An ADAPT-DES IVUS Substudy. JACC 2014:Vol63:12:2902-3 (SuppA).

1078. Kobayashi N, Mintz G, Witzenbichler B, Metzger C, Rinaldi M, Duffy P, Weisz G, Stuckey T, Brodie B, Xu K, Kirtane A, **Stone GW,** Maehara A. Incidence, Features and Outcomes of Edge Dissection after Drug-Eluting Stent Implantation: An ADAPT-DES IVUS Sub-study. JACC 2014:Vol63:12:2902-8 (SuppA).

1079. Kereiakes D, **Stone GW,** Teirstein P, Meredith I, Levy G, Schiele F, Downes T, Dudek D, Foster M, Buchbinder M, Lui H, Allocco D, Dawkins K. Four-Year Results of the PLATINUM Randomized Trial: Can Stent Metal Alloy Composition and Design Affect Late Clinical Outcomes? JACC 2014:Vol63:12:2905-4 (SuppA).

1080. Qui F, Mintz G, Witzenbichler B, Metzger D, Rinaldi M, Duffy P, Weisz G, Mazzaferri E, Stuckey T, Brodie B, Xu K, Kirtane A, **Stone GW,** Maehara A. Clincial Impact of Attenuated Plaque After Stent Implantation: An ADAPT-DES IVUS Sub-Study. JACC 2014:Vol63:12:2103-279 (SuppA).

1081. Souza C, Weisz G, Dohi T, Kini A, Rizik D, Brilakis E, Dixon S, Hendricks M, Powers E, Qui F, Zheng B, **Stone GW,** Mintz G, Muller J, Maehara A. The Use of Near-Infrared Spectroscopy to Identify Patients at High-Risk for Peri-

procedural Myocardial Infarction: Results from the COLOR Registry. JACC 2014:Vol63:12:2103-286 (SuppA).

1082. Souza C, Dohi T, Maehara A, Kini A, Rizik D, Brilakis E, Shunk K, Maini B, Shah P, Goto K. Matsumura M, Xu K, **Stone GW,** Mintz G, Muller J, Weisz G. Factors Associated with a Reduction of Lipid Core Plaque in Patients Undergoing PCI: Near-Infrared Spectroscopy Results from the COLOR Trial. JACC 2014:Vol63:12:2103-285 (SuppA).

1083. Qui F, Maehara A, Kini A, Rizik D, Brilakis E, Shunk K, Tobis J, Goto K, Dohi T, Xu K, **Stone GW,** Mintz G, Muller J, Weisz G. Relationship Between the Extent of Lipid-Rich Plaque Assessed by Near-Infrared Spectroscopy and Clinical Presentation: A COLOR Registry Analysis. JACC 2014:Vol63:12:2103-304 (SuppA).

1084. Souza C, Mintz G, Witzenbichler B, Metzger C, Rinaldi M, Duffy P, Weisz G, Mazzaferri E, Stuckey T, Brodie B, Xu K, Kirtane A, **Stone GW,** Maehara A. Long-Term Clinical Impact of Acute Stent Malapposition: An ADAPT-DES IVUS Substudy. JACC 2014:Vol63:12:2114M-367B (SuppA).

1085. Genereux P, Harrington R, **Stone GW,** Gibson M, Steg P, Angiolillo D, Price M, Prats J, Brener S, LaSalle L, Liu T, Todd M, Skerjanec S, Hamm C, Mahaffey K, White H, Bhatt D, CHAMPION Phoenix Investigators. Incidence and Impact of Stent Thrombosis during Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPIOON PHOENIX Trial. JACC 2014:Vol63:12:2105-290 (SuppA).

1086. Madhavan M, Genereux P, Weisz G, Parvataneni R, Mehran R, **Stone GW.** Revascularization of Calfified Target Lesions in Patients Presenting with Acute Coronary Syndromes: Analysis from the ACUITY Trial. JACC 2014:Vol63:12:2107-312 (SuppA).

1087. Kobayashi N, Maehara A, Brener S, Genereux P, Witzenbichler B, Guagliumi G, Peruga J, Xu K, Mehran R, Mintz G, **Stone GW.** LAD Wrapping Around the LV Apex Predicts Adverse Cardiac Outcomes in Anterior STEMI-A HORIZONS – AMI Sub-Study. JACC 2014:Vol63:12:2107-315 (SuppA).

1088. Thompson K, Shen YJ, Mehran R, **Stone GW,** Mansukhani P, Aharonian V, Moore N, Khan S, Bui A, L MS, Brar S. The Effect of Statin Use Prior to Angiography on the Prevention of Contrast Induced Nephropathy: A Mera-analysis of 16 Randomized Trials. JACC 2014:Vol63:12:2108-284 (SuppA).

1089. Gupta R, Kirtane A, Xu K, Witzenbicher B, Rinaldi M, Metzger C, Weisz G, Stuckey T, Brodie B, Mehran R, **Stone GW.** Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects

with Peripheral Artery Disease: Analysis from the ADAPT-DES Study. JACC 2014:Vol63:12:2108-300(SuppA).

1090. Rubin GA, Kirtane A, Weisz G, Baber U, Xu K, Parise H, Stuckey T, Witzenbichler B, Rinaldi M, Neumann FJ, Metzger C, Henry T, Cox D, Duffy P, Brodie B, Mazzaferri E, Mehran R, **Stone GW.** Impact of Hemodialysis and High Platelet Reactivity on Outcomes Following Percutaneous Coronary Intervention with Drug-Eluting Stents: JACC 2014:Vol63:12:2108-311(SuppA).

1091. Giacoppo D, Mehran R, Bansilal S, Witzenbichler B, Dangas G, Kirtane A, Parise H, Kornowski R, Brener S, Genereux P, **Stone GW.** Impact of Contrast – Induced Acute Kidney Injury After Coronary Angiography or Percutaneous Coronary Intervention on Long-Term Outcomes: A Pooled Analysis from the HORIONS-AMI and ACUITY Trials. JACC 2014:Vol63:12:2116M-367C(SuppA).

1092. Parikh P, Kirtane A, Weisz G, Studkey T, Witzenbichler B, Rinaldi M, Neumann FJ, Metzger C, henry T, Cox D, Duffy P, Brodie B, Mazzaferri E, Cristea E, Parise H, Mehran R, **Stone GW.** Two-Year Clinical Outcomes of Second Generation Versus First Generation Coronary Drug-Eluting Stents: An Analysis from ADAPT-DES. JACC 2014:Vol63:12:2111-296(SuppA).

1093. Steg PG, Mehran R, Goldstein P, Witzenbichler B, Van Hof A, Guagliumi G, Hamm C, Genereux P, Clemmensen P, Parise H, Pocock S, Gersh BJ, Bernstein D, Delizgyris EN, **Stone GW.** Bivalirudin versus Heparin with or without Glycoprotein IIb/IIIa Inhibitors in STEMI Patients Undergoing Primary PCI: A Pooled Analysis of Patient-Level Data from the HORIZONS-AMI and EUROMAX Trials. JACC 2014:Vol63:12:920-4(SuppA).

1094. White HD, Bhatt DL, Gibson M, Hamm CW, Mahaffey KW. Price MJ, Steg PG, **Stone GW,** Cortese B, Wilensky M, Deliagyris EN, Liu T, Prats J, Harrington RA. Reduced Death, Myocardial Infarction, and Early Stent Thrombosis with Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights from CHAMPION Phoenix. JACC 2014:Vol63:12:920-6(SuppA).

1095. Cavender M, Harrington R, **Stone G,** Mahaffey K, Skerjanec S, Prats J, Liu T, Day J, Deliargyris E, Bhatt D. Early benefit of cangrelor in patients undergoing PCI in CHAMPION PHOENIX. Eur Heart J 2014;35:136.

1096. Ducrocq G, Van T Hof A, Zeymer U, Witzenbichler B, Mehran R, Hamm C, Bernstein D, Prats J, Deliargyris M, **Stone G.** Post PCI anticoagulation after primary PCI: widely used but only increases bleeding. Insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials..Eur Heart J 2014;35:546.

1097. Stefanini G, Baber U, Windecker S, Morice MC, Sartori S, Leon M, **Stone G**, Steg PG, Chieffo A, Mehran R. Impact of diabetes on clinical outcomes among

women undergoing percutaneous coronary interventions with drug-eluting stents: a patient-level pooled analysis of 26 randomized trials. Eur Heart J 2014;35:888.

1098. Cavender M, Bhatt D, **Stone G.** White H, Leonardi S, Prats J, Liu T, Day J, Mahaffey K, Harrington R. Cangrelor reduces large, prognostically important, myocardial infarctions in patients undergoing PCI: findings from CHAMPION-PHOENIX. Eur Heart J 2014;35:1031.

1099. Aradi D, Kirtane A, Bonello L, Kastrati A, **Stone G,** Sibbing D. Validation of a therapeutic window for P2Y12-inhibition: collaborative analysis of the relation between platelet reactivity, stent thrombosis and bleeding. Eur Heart J 2014;35:1165.

1100. Trenk D, Neumann FJ, Kirtane A, Witzenbichler B, Weisz G, Rinaldi MJ, Metzger C, Stuckey TD, Mehran R, **Stone GW.** Patients receiving drug-eluting stents for stable coronary disease in the ADAPT-DES study: Impact of clopidogrel platelet reactivity on clinical outcomes. Eur Heart J 2014;35:349.

1101. Warren J, Mehran R , Yu J, Cox D, White HD, **Stone GW.** Incidence and Impact of Totally Occluded Culprit Arteries in patients with non-ST segment elevation. J Am Coll Cardiol. 64:11S:2014:2.

1102. Teirstein P, **Stone GW,** Meredith IT, Whitbourn RJ, McGarry TF, El-Jack S, Buchbinder M, Moses JW, Allocco DJ, Dawkins KD. J Am Coll Cardiol. 64:11S:2014:236.

1103. Serrao G, Lansky AJ, Mehran R, **Stone GW.** Predictors of LVEF improvement after primary stenting in ST-Segment elevation myocardial infarction: THE HORIZONS AMI Trial. J Am Coll Cardiol. 64:11S:2014:18.

1104. Brener S, Mehran R, Ertelt K, Genereux P, Xu K, Witzenbichler B, **Stone GW.** Predictors of Target vessel revascularization after primary percutaneous coronary intervention for acute ST-Segment elevation myocardial infarction: Lessons from HORIZONS-AMI. J Am Coll Cardiol. 64:11S:2014:19.

1105. Vandehof TP, Nijveldt R, Vandernet M, Meuwissen M, Kharrab A, Kuijt WJ, Wykrzkowska JJ, Tijssen JG, van Rossum AC, **Stone GW,** Piek J. Pressure controlled intermittent coronary sinus occlusion (PICSO) in acute ST-Segment elevation myocardial infarction: Final results of the prepare RAMSES Study. J Am Coll Cardiol. 64:11S:2014:20.

1106. Dohi T, Maehara A, Witzenbichler B, Metzger DC, Rinaldi M, Mazzaferri EL, Neumann FJ, Henry TD, Cox D, Xu K, Kirtane AJ, Mintz GS, **Stone GW.** Etiology, Frequency, and clinical outcomes of post procedural myocardial infarction after successful drug-eluting stent implantation: Two Year follow-up from the ADAPT-DES Study. J Am Coll Cardiol. 64:11S:2014:23.

1107. Dohi T, Maehara A, Witzenbichler B, Xu Ke, Nichols M, Brener S, Mehran R, Mintz GS, **Stone GW.** Clinical Predictors and long-term impact of enzymatic infarct size after primary PCI in STEMI. The HORIZONS-AMI Trial. J Am Coll Cardiol. 64:11S:2014:30.

1108. Brener S, Guerchicoff A, Witzenbichler B, Xu K, Mehran R, **Stone GW.** Impact of Pre-procedural cardiopulmonary instability in patient with acute myocardial infarction undergoing primary PCI: Insights from the HORIZONS-AMI Trial. J Am Coll Cardiol. 64:11S:2014:47.

1109. Genereux P., Yadav M. Caixeta A, Xu K, Kirtane AJ, Dangas G, Mehran R, Leon M, Serruys PW, **Stone GW.** Quantification and Impact of the proportion of coronary disease burden treated by percutaneous coronary intervention: The SYNTAX Revascularization Index. J Am Coll Cardiol. 64:11S:2014:86.

1110. Schoos M, Mehran R, Baber U, Xu K, Feit F, Gersh BJ, Ohman EM, Witzenbichler B, **Stone GW.** Frequency and Impact of Intraprocedural thrombotic events during percutaneous coronary intervention in women compared to men: Pooled analysis from the ACUITY and HORIZONS-AMI Trials. J Am Coll Cardiol. 64:11S:2014:87.

1111. Genereux P, Kirtane AJ, Yadav M, Madhavan MV, Arsenault MP, Witzenbichler B, Weisz G, Xu K, Mintz GS, Mehran R, Maehara A, **Stone GW.** Ischemic outcomes after coronary intervention of calcified lesions with drug-eluting stent: Insight from ADAPT DES study. J Am Coll Cardiol. 64:11S:2014:109.

1112. Yadav M, Genereux P, Brener S, Madhavan MV, Caixeta A, Xu K, Mehran R, Ben-Yehuda O, Mintz GS, **Stone GW.** Smokers Paradox: A Statistical artifact patient-level pooled analysis of 18 randomized controlled patients. J Am Coll Cardiol. 64:11S:2014:110.

1113. Yadav M, Genereux P, Brener S, Madhavan MV, Ben-Yehuda O, Xu K, Mintz GS, **Stone GW.** Impact of prior myocardial infarction on outcomes after percutaneous coronary intervention: A patients level pooled analysis of 18 randomized controlled trials. J Am Coll Cardiol. 64:11S:2014:120.

1114. Warren J, Mehran R, Baber U, Xu K, Giacoppo D, Gersh BJ, Witzenbichler B, Ohman EM, **Stone GW.** Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with CABG: Insights from ACUITY/HORIZONS-AMI. J Am Coll Cardiol. 64:11S:2014:123.

1115. Yadav M, Genereux P, Kirtane AJ, Witzenbichler B, Xu K, Maehara A, Mehran R, **Stone GW.** Incidence, Predictors, and Prognostic impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 64:11S:2014:127.

1116. Iqbal J, Onuma Y, Van Geuns RJ, Chevalier B, Muramatsu T, Zhang YJ, Veldhof S, Smits PC, Whitbourn RJ, Bartorelli AL, **Stone GW,** Abizaid A, Serruys PW. Diabetic patients treated with Bioresorbable vascular scaffolds show good clinical outcomes at two-year follow-up: A polled analysis from the ABSORB and SPIRIT Trials. J Am Coll Cardiol. 64:11S:2014:245.

1117. Baber U, Stafanini GG, Windecker S, Morice MC, Sartori S, Leon M, **Stone GW,** Steg PG, Chieffo A, Mehran R. Differential impact of diabetes mellitus on safety and efficacy of new versus first generation drug-eluting stents among women: A Patient level pooled analysis of 26 randomized trials. J Am Coll Cardiol. 64:11S:2014:249.

1118. Matsamura M, Mintz GS, Kang SJ, Sum S, Madden S. **Stone GW,** Muller JE, Virmani R, Maehara A. IVUS features of coronary plaques with intraplaque hemorrhage. J Am Coll Cardiol. 64:11S:2014:344.

1119. Matsamura M, Mintz GS, Witzenbichler B, Metzger DC, Rinaldi M, Xu K, Kirtane AJ, **Stone GW,** Maehara A. Relationship between peripheral artery disease and coronary plaque morphology: An ADAPT-DES Intravascular Ultrasound substudy. J Am Coll Cardiol. 64:11S:2014:346.

1120. Madhavan M, Dangas G, Genereux P, Xu K, Mehran R, **Stone GW.** Does routine post-procedural anticoagulation reduce acute stent thrombosis after Bivalirudin anticoagulation during primary PCI? The HORIZONS-AMI Trial. J Am Coll Cardiol. 64:11S:2014:463.

1121. Dangas G, Steg PG, Mehran R, Van ‘t Hof A, Schoos M, Prats J, Bernstein D, Deliagyris E, **Stone GW.** Predictors of stent thrombosis after primary percutaneous coronary intervention and risk for 30-day mortality: Analysis from the HORIZONS-AMI and EUROMAX trials. J Am Coll Cardiol. 64:11S:2014:468.

1122. Madhavan MV, Genereux P, Xu K, Dressler O, Mehran R, **Stone GW.** Impact of excess dosing of Eptifibatide during PCI for ACS: A pooled analysis from the HORIZONS-AMI and ACUITY Trials. J Am Coll Cardiol. 64:11S:2014:472.

1123. Kirtane AJ, Rinaldi M, Witzenbichler B, Weisz G, Metzger DC, Henry TD, Cox D, Mazzaferri EL, Neumann FJ, Xu K, Maehara A, Genereux P, Mehran R, **Stone GW.** J Am Coll Cardiol. 64:11S:2014:479.

1124. Bhatt DL, **Stone GW,** Mahaffey K, Gibson CM, Steg PG, Hamm C, Price MJ, Liu T, Deliagyris E, Skerjanec S, Prats J, White HD, Harrington R. Effect of Cangrelor on ischemic endpoints: Further analyses from CHAMPION PHOENIX. J Am Coll Cardiol. 64:11S:2014:482.

1125. Schoos M, Mehran R, Kirtane AJ, Yu J, Xu K, Witzenbichler B, Rinaldi M, Neumann FJ, Metzger DC, Henry TD, Cox D, Mazzaferri EL, Maehara A, **Stone GW.** Impact of HbA1c levels on residual platelet reactivity and outcomes after coronary drug-eluting stents: the ADAPT-DES Study. J Am Coll Cardiol. 64:11S:2014:483.

1126. Baber U, Mehran R, Kirtane AJ, Christodoulidis G, Maehara A, Witzenbichler B, Weisz G, Rinaldi M, Metzger DC, Henry TD, Cox D, Mazzaferri EL, Xu K, **Stone GW.** Additive and independent impact of chronic kidney disease and diabetes mellitus on high platelet reactivity and adverse events following PCI: Results from the ADAPT-DES Registry. J Am Coll Cardiol. 64:11S:2014:486.

1127. Henry TD, Peterson E, Cohen D, Ju C, **Stone GW,** Messenger JC, Fonarow GC, Effron MB, Baker BA, Zettler M, Wang TY. Safety and Effectiveness of Prasugrel vs. Clopidogrel in the setting of Bivalirudin vs Heparin use: 30-day results from TRANSLATE-ACS. J Am Coll Cardiol. 64:11S:2014:494.

1128. Trenk D, Nuehrenberg TG, Stratz C, Hochholzer W, Kirtane AJ, **Stone GW,** Neumann FJ. Antiplatelet effects of Clopidogrel and Aspirin during 6 months of follow-up after stent implantation: An ADAPT-DES Substudy. J Am Coll Cardiol. 64:11S:2014:497.

1129. Maini B, Haley O, Mumtaz M, **Stone GW.** Symptomatic Improvement with MitraClip therapy for Prohibitively high-risk patients. J Am Coll Cardiol. 64:11S:2014:789.

1130. Maini B, Haley O, Mumtaz M, **Stone GW.** Improvement in quality in patients with degenerative mitral regurgitation at prohibitive surgical risk following Transcatheter mitral valve repair with the MitraClip System. J Am Coll Cardiol. 64:11S:2014:800.

1131. Zheng B, Mintz GS, McPherson J, De Bruyne B, Farhat N, Marso S, Xu K, Serruys P, **Stone G,** Maehara A. Predictors of Plaque Rupture within Fibroatheromas in Patients with Acute Coronary Syndromes: The PROSPECT Study. JACC 2015;65/10_S, Suppl A.

1132. Genereux P, Kirtane A, Palmerini T, Witzenbichler B, Yadav M, Weisz G, Stuckey T, Francese D, Xu K, Maehara A, Mehran R, **Stone G.** Impact on Two-Year Outcomes of Percutaneous Coronary Intervention Complexity and Platelet Reactivity among Patients with Stable Coronary Artery Disease: Insight from the ADAPT-DES Study JACC 2015;65/10_S, Suppl A.

1133. **Stone G,** Teirstein P, Meredith I, Farah B, Dubois C, Feldman R, Dens J, Hagiwara N, Allocco D, Dawkins K. Final Five-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt

Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in Workhorse Lesions JACC 2015;65/10_S, Suppl A.

1134. Yu J, Mehran R, Baber U, Ooi SY, Witzenbichler B, Weisz G, Rinaldi M, Neumann FJ, Metzger D, Henry T, Cox D, Duffy P, Mazzaferri E, Brodie B, Stuckey T, Maehara A, Xu K, Kirtane A, **Stone G.** Differential Impact of High Platelet Reactivity on Clopidogrel in Women and Men Following Percutaneous Coronary Intervention (PCI) with DES JACC 2015;65/10_S, Suppl A.

1135. Maini BS, Ohara H, Maini A, Mumtaz M, **Stone G.** Symptomatic Improvement with MitraClip Therapy for Prohibitively High-Risk DMR Patients JACC 2015;65/10_S, Suppl A.

1136. O'Donoghue M, Bhatt DL, **Stone G,** Steg P, Gibson CM, Hamm C, Price M, Prats J, Liu T, Deliagyris E, Mahaffey K, White H, Harrington R. The Efficacy, Safety, and Net Clinical Benefit of Cangrelor in Women Undergoing Elective or Urgent PCI: Insights from the CHAMPION-PHOENIX Trial JACC 2015;65/10_S, Suppl A.

1137. Vora A, Peterson E, McCoy L, Effron M, Anstrom K, Faries D, Zettler M, Foranow G, baker B, **Stone G,** Wang T. Selection of Prasugrel versus Clopidogrel Among Myocardial Infarction Patients with High versus Low Predicted Mortality and Bleeding Risks: Insights from TRANSLATE-ACS JACC 2015;65/10_S, Suppl A.

1138. **Stone G,** Kirtane A, Abizaid A, Worthley S, Tunev S, Schulz-Jander D, Melder R. Preclinical Results with a Novel Internally Loaded Drug-Filled Coronary Stent JACC 2015;65/10_S, Suppl A.

1139. Shan P, Mintz G, Witzenbichler B, Metzger C, Rinaldi M, Duffy P, Weisz G, Stuckey T, Brodie B, Xu K, Kirtane A, **Stone G,** Maehara A. Does Calcium Burden Impact on Culprit Lesion Morphology and Clinical Results: An ADAPT-DES IVUS Sub-study. JACC 2015;65/10_S, Suppl A.

1140. Cavender M, Bhatt D, Stone G, Matsamura M, Witzenbichler B, Metzger C, Duffy P, Xu K, Kirtane A, **Stone G,** Maehara A. Cangrelor in Elderly Patients Undergoing PCI: Findings from CHAMPION-PHOENIX. JACC 2015;65/10_S, Suppl A.

1141. Goto K, Mintz G, Shimizu T, Matsumura M, Witzenbichler B, Metzger B, Duffy P, Xu K, Kirtane A, **Stone G,** Maehara A. Predictors of Newly Implanted Stent Expansion in In-Stent Restenotic Lesions: An ADAPT-DES IVUS Substudy. JACC 2015;65/10_S, Suppl A.

1142. Aradi D, Bonello L, Kirtane A, Kastrati A, **Stone G**, Sibbing D. Therapeutic Window for P2Y12-Receptor Inhibition: A Collaborative Analysis of the Relation

Between Platelet Reactivity, Stent Thrombosis and Bleeding. JACC 2015;65/10_S, Suppl A.

1143. Maini BS, Haley H, Maini A, Mumatz M, **Stone G.** Improvement in Quality of Life in Patients with Degenerative Mitral Regurgitation ST Prohibitive Surgical Risk Following Transcatheter Mitral Valve Repair with the Mitraclip System. JACC 2015;65/10_S, Suppl A.

1144. Genereux P, Campos C, Farooq V, Bourantas C, Mohr F, Colombo A, Morel M, Feldman T, Holmes D, Mack, Morice, Dawkins K, Kappetein A, Palmerini R, **Stone G,** Serruys P. Reasonable Revascularization After Percutaneous Coronary Intervention: Validation of the SYNTAX Revascularization Index from the SYNTAX Trial. JACC 2015;65/10_S, Suppl A.

1145. Angiolillo DJ, Bhatt D, Steg P, **Stone G,** White H, Gibson CM, Hamm C, Price M, Prats J, Liu T, Day J, Mahaffey K, Harrington R. Impact of Cangrelor Overdosing on Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention: Insights from the CHAMPION Trials. JACC 2015;65/10_S, Suppl A.

1146. Brener S, Kirtane AJ, Mehran R, Parvataneni R, **Stone GW.** The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality after DES: The ADAPT-DES study. J Am Coll Cardiol. 2015;66(15_S).

1147. Abnousi F, Sundaram V, Prats J, Deliagyris E, **Stone GW,** Hamm C, Steg PG, Gibson CM, White HD, Price MJ, Yong C, Desai M, Harrington R, Bhatt DL, Mahaffey K. Cangrelor Improves Ischemic Outcomes In Patients With Multivessel Disease And Single Vessel Disease Undergoing PCI: Insights From The CHAMPION PHOENIX Trial. J Am Coll Cardiol. 2015;66(15_S).

1148. **Stone GW,** Genereux P, White HD, Gibson CM, Hamm C, Mahaffey K, Price MJ, Prats J, Harrington R, Bhatt DL. Efficacy of Cangrelor in Lesions with High-Risk and Low-Risk Angiographic Characteristics: The CHAMPION PHOENIX trial. J Am Coll Cardiol. 2015;66(15_S).

1149. Brener S, Mehran R, Ayele G, **Stone GW.** Baseline hemoglobin level, anemia and adverse events in patients with acute coronary syndromes; Lessons from ACUITY and HORIZONS-AMI J Am Coll Cardiol 2015;66(15_S).

1150. Sharma A, Sharma SK, Garg A, Vallakati A, Marmur JD, Mukherjee D, **Stone GW.** Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Patients with ACS vs. non-ACS: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Am Coll Cardiol. 2015;66(15_S).

1151. Baber U, Giustino G, Salianski I, Aquino M, Sartori S, Stefanini GG, Steg PG, Windecker S, Leon M, **Stone GW,** Valgimigli M, Mehta L, Ortega R, Morice MC, Mehran R. Independent and Combined Effect of Chronic Kidney Disease and

Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: Results from a Patient-Level Pooled Analysis of Randomized Controlled Trials J Am Coll Cardiol. 2015;66(15_S).

1152. Rizik D, Cannon LA, Ellis S, **Stone GW,** Kennedy M, Piard-Ruster K, Staehr P, Kereiakes DJ. ABSORB III PK: Pharmacokinetics of Everolimus Eluted from the Absorb Bioresorbable Vascular Scaffold (BVS). J Am Coll Cardiol. 2015;66(15_S).

1153. Moreno R, Kim HS, Von Birgelen C, **Stone GW,** Park SJ, De La Toree Hernandez JM, Qureshi K, Dawkins KD. Efficacy and safety of platinum-chromium everolimus-eluting stents compared with other second-generation drug-eluting stents. Meta-analysis from 5 randomized trials including 7,896 patients J Am Coll Cardiol. 2015;66(15_S):. doi:10.1016.

1154.

1155. Genereux P. Giustino G, Witzenbichler B, Weisz G, Stuckey T, Rinaldi M, Neumann FJ, Metzger DC, Henry TD, Cox D, Duffy PL, Mazzaferri EL, Yadav M, Kirtane AJ, Litherland C, Mehran R, **Stone GW.** Incidence, Predictors, and Impact of Post-discharge Bleeding Compared to Myocardial Infarction After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2015;66(15_S).

1156. Kessels R, Bouchard A, Guy LG, LeClerc G, Korkmaz HI, Niessen HW, **Stone GW.** Early PICSO preserves LVEF in porcine acute myocardial infarction. J Am Coll Cardiol. 2015;66(15_S).

1157. Giustino G, Brener S, Maehara A, Genereux P, Mehran R, Dudek D, Neunteufl T, Metzger DC, Ozan MO, Gibson CM, **Stone GW.** Impact of Smoking on Infarct Size and Adverse Events in Patients With Anterior ST-Elevation Myocardial Infarction: Results From the INFUSE-AMI Trial. J Am Coll Cardiol. 2015;66(15_S).

1158. Giustino G, Dizon J, Genereux P, Mehran R, Gossl M, Gersh BJ, Ayele GM, **Stone GW.** Impact of ECG-Defined Infarct Location on Mortality in Patients with STEMI Undergoing Primary PCI: Insights from the HORIZONS-AMI Trial. J Am Coll Cardiol. 2015;66(15_S).

1159.

1160. Udelson J, Selker H, Ruthazer R, Thiele H, Patel M, Ohman EM, Maehara A, Jenkins P, Nichols M, Ben-Yehuda O, **Stone GW.** Relationship Between Therapeutic Effects on Infarct Size in Acute Myocardial Infarction and One-year Outcomes: Patient-Level Analysis of Randomized Clinical Trials. J Am Coll Cardiol. 2015;66(15_S).

1161. Giustino G, Brener S, Maehara A, Mehran R, Genereux P, Dudek D, Neunteufl T, Metzger DC, Ozan MD, Gibson CM, Stone GW. Impact of Platelet Count on Myocardial Infarct Size and Adverse Events in Anterior ST-Elevation Myocardial Infarction: Results from the INFUSE-AMI Trial. J Am Coll Cardiol. 2015;66(15_S).

1162. Giustino G, Dizon J, Genereux P, Mehran R, Gossl M, Gersh BJ, Ayele GM, **Stone GW.** Predictors of Mortality in Non-Anterior ST-segment Elevation Myocardial Infarction: Insights from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. J Am Coll Cardiol. 2015;66(15_S).

1163. Yin D, Matsumura M, Rundback JH, Yoho J, Witzenbichler B, **Stone GW,** Mintz G, Maehara A. Comparison of Plaque Morphology Between Peripheral and Coronary Artery Disease: Analysis from the CLARITY and ADAPT-DES IVUS Substudies J Am Coll Cardiol. 2015;66(15_S).

1164. Koyama K, Mintz GS, McPherson J, Farhat N, Wennerblom B, De Bruyne B, Serruys PW, **Stone GW,** Maehara A. Evolution of Plaque Volume and Lesion Morphology in Patients with Non-culprit Lesion-related Events: A serial VH-IVUS analysis from the PROSPECT study. J Am Coll Cardiol. 2015;66(15_S).

1165. Tzafriri AR, Markham P, Goshgarian J, Schulz-Jander D, Tunev S, Melder RJ, **Stone GW,** Edelman ER. Titratable drug delivery from drug filled stents. J Am Coll Cardiol. 2015;66(15_S).

1166. Teirstein P, **Stone GW,** Meredith IT, Rabinowitz AC, Pompolo VJ, Lee TC, Cannon LA, Kereiakes DJ, Mooney M, Carrie D, Saito S, Allocco DJ, Dawkins KD. Final Five-Year Outcomes Following Implantation of the Promus Element® Platinum Chromium Everolimus-Eluting Stent in De Novo Coronary Artery Lesions in Small Vessels (SV) and Long Lesions (LL): Results of the PLATINUM Small Vessel and Long Lesion Trials. J Am Coll Cardiol. 2015;66(15_S).

1167. Giustino G, Salianski O, Baber U, Sartori S, Aquino Stefanini GG, Leon M, **Stone GW,** Morice MC, Smits PC, Von Birgelen C, Mikhail G, Kastrati A, Chieffo A, Mehran R. Early- Versus New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: Results froma Patient-Level Pooled Analysis of Randomized Controlled Trials. J Am Coll Cardiol. 2015;66(15_S).

1168. Giustino F, Salianski O, Aquino M, Sartori S, Stefanini GG, Leon M, **Stone GW,** Chieffo A, Dangas G, Kandzari D, Qeisz G, Wijns WC, Serruys PW, Itchhaporia D, Mehran R. Predictive Factors of Early, Late and Very Late Atherothrombotic Events in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: Results from a Patient-Level Pooled Analysis of Randomized Controlled Trials. J Am Coll Cardiol. 2015;66(15_S).

1169. Worthley SG, Abizaid A, Kirtane AJ Simon D, Windecker S, **Stone GW.** Stent Strut Coverage and Stent Apposition After Implantation of a Novel Drug-Filled Coronary Stent: Optical Coherence Tomography Results from RevElution Trial. J Am Coll Cardiol. 2015;66(15_S).

1170. Foin N, Goshgarian J, Abizaid A, Kirtane AJ, Simon D, Windecker S, Worthley SG, **Stone GW.** Novel Drug-Filled Coronary Stent and its Impact on Mechanical Attributes J Am Coll Cardiol. 2015;66(15_S).

1171. Genereux P, Gravel GM, Witzenbichler B, Weisz G, Stuckey T, Rinaldi M, Neumann FJ, Metzger DC, Henry TD, Cox D, Duffy PL, Mazzaferri EL, Ranteke GB, Litherland C, Kirtane AJ, Mehran R, **Stone GW.** Two-Year Ischemic and Bleeding Outcomes After Coronary Intervention of Calcified vs. Non-Calcified Lesions Treated With Drug-eluting Stents: The ADAPT-DES Study. J Am Coll Cardiol. 2015;66(15_S).

1172. Genereux P, Giustino G, Witzenbichler B, Weisz G, Stuckey G, Rinaldi M, Neumann FJ, Metzger DC, Henry TF, Cox DA, Duffy PL, Mazzaferri E, Yadav M, Francese DP, Palmerini T, Kirtane AJ, Litherland C, Mehran R, **Stone GW.** Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2015;66 (15_S).

1173. Afshar AE, Giustino G, Dianai-Maleki N, Baber U, Sartori S, Aquino M, Saporito R, Steg PG, Windecker S, Leon MB, **Stone GW,** Dangas GD, Jeger RJ, Morice MC, Kimura T, Kim HS, Mehran R. Obesity Paradox in Women Undergoing Percutaneous Coronary Intervention With Drug-eluting Stents: Results From a Patient-level Pooled Analysis of Randomized Controlled Trials. Circulation. 2015;132:A18702.

1174. Vaduganathan M, Harrington RA, **Stone GW,** Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. Chronic and Acute Ischemic Heart Disease - Session Title: eAbstract Session: Chronic and Acute Ischemic Heart Disease IAbstract 18632: Variation in Patient Profiles and Outcomes in US and non-US Subgroups of the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circulation. 2015;132:A18632.

1175. Pineda AM, Chandra R, Gowani SA, Mihos CG, Santana O, Kirtane AJ, **Stone GW,** Kurlansky P, Smith CR, Beohar N. Signaling Mechanisms and Drug Discovery - Session Title: eAbstract Session: Valve SurgeryAbstract 10460: Completeness of Revascularization and its Impact on the Outcomes of a Staged Approach of Percutaneous Coronary Intervention Followed by Minimally Invasive Valve Surgery for Patients With Concomitant Coronary Artery and Valvular Heart Disease. Circulation. 2015;132:A10460.

1176. Gutierrez A, Harrington RA, **Stone GW,** Steg PG, Gibson CM,Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey K,White HD, Bhatt DL. The Effect of Cangrelor on Cardiovascular and Bleeding Events in Patients With Peripheral Artery Disease - Insights From CHAMPION PHOENIX. Circulation. 2015;132:A16894**.**

1177. Stone PH, Maehara A, Coskun AU, Maynard CC, Andreou I, Siasos G, Zaromitidou M, Fotiadis D, Stefanou K, Papafaklis M, Michalis L, Lansky AJ, Mintz GS, Serruys PW, Feldman CL, **Stone GW.** Local Low Endothelial Shear Stress (ESS) Provides Incremental Prediction of Non-culprit MACE in Addition to Plaque Burden, Minimal Lumen Area, and Plaque Morphology: The PROSPECT Study. Circulation. 2015;132:A16948.

1178. Cheolmin Lee; Akiko Maehara; Mitsuaki Matsumura; Yamamoto Myong Hwa; Annapoorna Kini; David Rizik; Eric Powers; Priti Shah; James Muller; Jordan Andrews; **Gregg W. Stone;** Gary Mintz; Stephen Nicholls; Giora Weisz. Increased Lipid-Rich Plaque But Not Greater Plaque Burden In Myocardial Infarction Lesions: The Color Registry. J Am Coll Cardiol. 2016;67(13_S):271-271.

1179. Bjorn Redfors; Rushad K. Dordi; Tullio Palmerini; Gennaro Giustino; Girma Ayele; Adriano Caixeta; Ajay Kirtane; Roxana Mehran; **Gregg W. Stone;** Philippe Genereux. Relationship Between Vessel Size, Platelet Reactivity, And Stent Thrombosis After Drug-Eluting Stent Percutaneous Coronary Artery Intervention. J Am Coll Cardiol. 2016;67(13_S):324-324.

1180. Stephen J. Nicholls; Jordan Andrews; Nisha Schwarz; Akiko Maehara; Mitsuaki Matsumura; Myong Hwa Yamamoto; Annapoorna Kini; Brijeshwar Maini; Nabil Dib; Priti Shah; James Muller; Gary Mintz; **Gregg W. Stone;** Giora Weisz. Lack Of Association Between Ldl-Cholesterol, Plaque Burden And Lipid-Rich Plaque In Coronary Lesions Requiring PCI: The Color Registry. J Am Coll Cardiol. 2016;67(13_S):367-367.

1181. Wenbin Zhang; Giora Weisz; Mitsuaki Matsumura; Myong Hwa Yamamoto; Annapoorna Kini; Emmanouil Brilakis; Kendrick Shunk; James Goldstein; Priti Shah; James Muller; Jordan Andrews; Ovidiu Dressler; Gary Mintz; Stephen Nicholls; **Gregg W. Stone;** Akiko Maehara. Plaque Characterization Informs The Risk Of Periprocedural Myocardial Infarction During PCI: The Color Registry. J Am Coll Cardiol. 2016;67(13_S):378-378.

1182. Stephen J. Nicholls; Jordan Andrews; Alex Janssan; Akiko Maehara; Mitsuaki Matsumura; Myong Hwa Yamamoto; Annapoorna Kini; Jonathan Tobis; Simon Dixon; Priti Shah; Gregg W. Stone; James Muller; Gary Mintz; Giora Weisz. Lower Plaque Lipid Content On Near-Infrared Spectroscopy In Statin-Treated Patients: Insights From The Color Registry. J Am Coll Cardiol. 2016;67(13_S):1964-1964.

1183. Stephen G. Worthley; Alexandre Abizaid; Ajay Kirtane; Daniel Simon; Stephan Windecker; **Gregg W. Stone.** Stent Strut Coverage And Apposition At 1 And 3 Months After Implantation Of A Novel Drug-Filled Coronary Stent: First Report From The Revelution Study. J Am Coll Cardiol. 2016;67(13_S):422-422.

1184. Daniel Musikantow; Ajay Kirtane; Claire Litherland; Bernhard Witzenbichler; Giora Weisz; Michael Rinaldi; David Metzger; Timothy Henry; David Cox; Thomas Stuckey; Akiko Maehara; Philippe Genereux; Roxana Mehran; **Gregg W. Stone.** Etiology, Timing And Impact Of Dual Antiplatelet Therapy Discontinuation After Drug-Eluting Stent Implantation: Insights From The Adapt-DES Study. J Am Coll Cardiol. 2016;67(13_S):186-186.

1185. Philippe Genereux; **Gregg W. Stone;** Patrick O'Gara; Guillaume M. Gravel; Bjorn Redfors; Gennaro Giustino; Philippe Pibarot; Jeroen Bax; Robert Bonow; Martin Leon. Early Aortic Valve Replacement Versus A Conservative Strategy For Asymptomatic Severe Aortic Stenosis: Meta-Analysis Of Observational Studies. J Am Coll Cardiol. 2016;67(13_S):2210-2210.

1186. Suzanne Baron; Yang Lei; Katherine Vilain; Elizabeth Magnuson; Dean Kereiakes; Stephen Ellis; **Gregg W. Stone;** David Cohen. Economic Outcomes Of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents In Patients Undergoing Percutaneous Coronary Revascularization: One Year Results From The Absorb III Trial. J Am Coll Cardiol. 2016;67(13_S):19-19.

1187. Serge Korjian; Yazan Daaboul; Deepak Bhatt; Robert Harrington; **Gregg W. Stone;** Philippe Steg; Christian Hamm; Matthew Price; Kenneth Mahaffey; Harvey White; Jayne Prats; Efthymios Deliargyris; C. Michael Gibson. Efficacy Of Cangrelor In Congestive Heart Failure Patients Undergoing PCI: A Subgroup Analysis From The Champion Pooled Database. J Am Coll Cardiol. 2016;67(13_S):536-536.

1188. Neal Narain Sawlani; Robert Harrington; **Gregg W. Stone;** Philippe Steg; C. Michael Gibson; Christian Hamm; Matthew Price; Jayne Prats; Efthymios Deliargyris; Kenneth Mahaffey; Harvey White; Deepak L. Bhatt. Impact Of Prior Cerebrovascular Events On Ischemic And Bleeding Outcomes With Cangrelor In Percutaneous Coronary Intervention. J Am Coll Cardiol. 2016;67(13_S):198-198.

1189. Hector Tamez; Philippe Genereux; Weihong Fan; Ajay Kirtane; Stephanie Plent; Efthymios Deliargyris; Jayne Prats; **Gregg W. Stone;** C. Michael Gibson; Robert Harrington; Deepak Bhatt; Duane Pinto. Cost Implications Of Procedural Thrombotic Complications In Patients Undergoing Percutaneous Coronary Intervention: Results From The Champion Phoenix Economics Study. J Am Coll Cardiol. 2016;67(13_S):209-209.

1190. Muthiah Vaduganathan; Robert Harrington; **Gregg W. Stone;** Philippe Steg; C. Michael Gibson; Christian Hamm; Matthew Price; Alberto Menozzi; Jayne Prats; Efthymios Deliargyris; Kenneth Mahaffey; Harvey White; Deepak Bhatt. The Efficacy And Safety Of Cangrelor With And Without Glycoprotein IIb/IIIa Inhibitors In Patients Undergoing Percutaneous Coronary Intervention: A Pooled Analysis Of The Champion Trials. J Am Coll Cardiol. 2016;67(13_S):452-452.

1191. Konstanze Ertelt; Sorin Brener; Roxana Mehran; Girma Minalu Ayele; **Gregg W. Stone.** Outcomes And Prognosis Of Patients With Known, Newly Diagnosed And Without Diabetes Mellitus Presenting With Acute St-Segment Elevation Myocardial Infarction: From The Horizons-AMI Study. J Am Coll Cardiol. 2016;67(13_S):577-577.

1192. **Gregg W. Stone;** Stephen Ellis; Charles Simonton; David Metzger; Ronald Caputo; David Rizik; Paul S. Teirstein; Jeffrey Popma; Jennifer Jones-McMeans; Zhen Zhang; Dean Kereiakes. Outcomes of The Absorb Bioresorbable Vascular Scaffold in Very Small and Not Very Small Coronary Arteries: The Absorb III Randomized Trial. *J Am Coll Cardiol.* 2016;67(13_S):35-35.

1193. Marina Zaromytidou; **Gregg W. Stone;** Akiko Maehara; Ahmet U. Coskun; Charles C. Maynard; Gerasimos Siasos; Ioannis Andreou; Dimitris Fotiadis; Kostas Stefanou; Michail Papafaklis; Lampros Michalis; Alexandra J. Lansky; Gary S. Mintz; Patrick W. Serruys; Charles L. Feldman; Peter H. Stone. Localization Of Culprit Endothelial Shear Stress Patterns Along The Course Of Untreated Coronary Lesions Responsible For Future MACE: The Prospect Study. *J Am Coll Cardiol.* 2016; 67(13_S):358-358.

1194. Microvascular Obstruction Is Independently Associated with Adverse Events Following Primary PCI for STEMI: A Patient-Level Pooled Analysis from 7 Randomized Trials. DeWaha S, Patel M, Granger C, Ohman EM, Maehara A, Eitel I, Ben-Yehuda O, Jenkins P, Thiele H, **Stone G,** JACC Vol. 68, No. 18_S;1.

1195. Worse Outcomes in Women Compared to Men After Primary PCI in STEMI Are Not Explained by Infarct Size: A Collaborative Patient-Level Pooled Analysis of 10 Randomized Trials. Kosmidou I, Redfors B, Dordi R, Schaefer U, Thiele H, Patel M, Udelson J, Ohman EM, Granger C, Maehara A, Kirtane A, Genereux P, Jenkins P, Ben-Yehuda O, **Stone G**. JACC Vol. 68, No. 18_S, 2.

1196. Risks and Benefits of Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery: Insights from the ACUITY trial. Ebrahimi R, Mehran R, Ben-Yehuda O, Parvataneni R, **Stone G**. JACC Vol. 68, No. 18_S, 5.

1197. Redfors B, ben-Yehuda O, Lin SH, Furer A, Kirtane A, Witzenbichler B, Weisz G, Stuckey T, Maehara A, Genereux P, Giustino G, Rinaldi M, Neumann FJ, Metzger DC, Henry T, Cox D, Duffy PL, Mazzaferri E, Ayele G, Mehran R, Mintz G. **Stone G**. Relationship Between Traditional Risk Factors, Platelet Reactivity, and Thrombotic Events: A Mediation Analysis From ADAPT-DES. JACC Vol. 68, No. 18_S, 7.

1198. Chung C, Kirtane A, Litherland C, Witzenbichler B, Weisz G, Stuckey T, Brodie B, Rinaldi M, Neumann FJ, Metzger DC, Henry T, Cox D, Duffy PL, Mazzaferri E, Mehran R, **Stone G**. Impact of Aspirin Resistance on Outcomesafter Coronary Events. JACC Vol. 68, No. 18_S, 8.

1199. Redfors B, Genereux P, Kirtane A, Pocock S, Ayele G, Deliagyris M, Mehran R, **Stone G**. Risk–Benefit Analysis of Upstream Antithrombotic Therapy in Patients with Non–ST-Segment Elevation Acute Coronary Syndromes Prior to Coronary Angiography. JACC Vol. 68, No. 18_S, 55.

1200. Furer A, Ben-Yehuda O, Redfors B, Serruys P, Gao R, Kimura T, Kereiakes D, Ellis S, Zhao W, Vu MT, Onuma Y, **Stone G**. 1-year Clinical Outcomes of Absorb Bioresorbable Vascular Scaffold (BVS) in Diabetic and Non-Diabetic Patients: Patient-Level Pooled Analysis from the ABSORB Randomized Trials. JACC Vol. 68, No. 18_S, 60.

1201. Redfors B, Palmerini T, Caixeta A, Ayele G, Francese D, Mehran R, Brilakis E, Kirtane A, Karmpaliotis D, **Stone G**, Genereux P. Impact of Chronic Total Occlusions on Revascularization Scores and Outcome Prediction. JACC Vol. 68, No. 18_S, 63.

1202. Chandrasekhar J, Redfors B, Genereux P, Kirtane A, Parvateneni R,Mehran R, **Stone G**. Comparative Efficacy and Safety of Coronary Stents in Diabetic Patients With and Without Insulin Treatment: A pooled patient level analysis from 17 randomized trials. JACC Vol. 68, No. 18_S, 65.

1203. Smits P, Ben-Yehuda O, Kosmidou I, Ozan MO, Dressler O, Jonas M, Banai S, Pruski M, Richter Y, **Stone G**. The NIREUS Randomized Trial: 1-Year Results of the BioNIR Ridaforolimus-Eluting Coronary Stent System (BioNIR) EUropean Angiography Study. JACC Vol. 68, No. 18_S, 71.

1204. Galougahi KK, Bhatti N, Shlofmitz R, Genereux P, Moses J, Kirtane A, **Stone G**, Mintz G, Karmpaliotis D, Maehara A, Leon M, Ali Z. Effects of Orbital Versus Rotational Atherectomy Facilitated PCI on the Coronary Microcirculation. JACC Vol. 68, No. 18_S, 236.

1205. Redfors B, Genereux P, Maehara A, Kirtane A, Dordi R, Witzenbichler B, Weisz G, Stuckey T, Rinaldi M, Neumann FJ, Metzger DC, Henry T, Cox D, Duffy PL, Mazzaferri E, Litherland C, Mehran R, Mintz G, **Stone G**. Outcomes After Successful PCI of Severely Calcified Lesions Using Rotational Atherectomy, Cutting Balloon, or Balloon Angioplasty only Before Second-Generation Drug-Eluting Stent Implantation. JACC Vol. 68, No. 18_S, 237.

1206. Giustino F, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A, Costa R, Hong MK, Kim BK, Jang Y, Kim HS, Park, KW, Gilard M, Morice MC, Sawaya F, Sardella G, Dangas G, Genereux P, Redfors B, Leon M, Bhatt D, **Stone G**, Colombo A. Efficacy and Safety of Long- Versus Short-Term Dual Antiplatelet Therapy Following Complex Percutaneous Coronary Intervention with Drug-Eluting Stents: A Collaborative Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Vol. 68, No. 18_S, 213.

1207. Hwang D, Lee JM, Rhee TM, Park J, Park KW, Hong MK, Jang Y, Valgimigli M, Colombo A, Gilard M, Palmerini T, **Stone G**. Kim HS. Clinical Outcomes of Dual Antiplatelet Therapy after Coronary Stenting in Patients with Chronic Kidney Disease: Patient-level Meta-analysis of 4 Randomized Clinical Trials. JACC Vol. 68, No. 18_S, 222.

1208. Giustino G, Redfors B, Schafer U, Thiele H, Patel M, Udelson J, Ohman EM, Eitel I, Granger C, Maehara A, Kirtane A, Genereux P, Jenkins P, Ben-Yehuda O, **Stone G**. Time to Reperfusion and Infarct Size in Patients With STEMI Undergoing Primary PCI: A Collaborative Patient-Level Pooled Analysis of 10 Randomized Trials. JACC Vol. 68, No. 18_S, 163.

1209. Egred M, Bagnall A, Spyridopoulos I, Purcell I, Das R, Palmer N, Grech E, Jain A, **Stone G**, Nijveldt R, Kessels R,Zaman A. Pressure-Controlled Intermittent Coronary Sinus Occlusion Reduces Infarct Size and Results in Functional Recovery After STEMI; Interim analysis of an ongoing trial. JACC Vol. 68, No. 18_S, 164.

1210. Giustino G, Redfors B, Brener S, Kirtane A, Genereux P, Maehara A, Neunteufl T, Metzger DC, Mehran R, Gibson CM, **Stone G**. Correlates and Prognostic Impact of New-Onset Heart Failure after ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Insights from the INFUSE-AMI Trial. JACC Vol. 68, No. 18_S, 166.

1211. Redfors B, Kosmidou I, Dordi R, Schafer U, Thiele H, Patel M, Udelson J, Ohman EM, Eitel I, Granger C, Maehara A, Kirtane A, Genereux P, Jenkins P, Ben-Yehuda O, **Stone G**. Worse Outcomes in Women Compared to Men After Primary PCI in STEMI Are Not Explained by Left Ventricular Morphology and Cardiac Function: A Collaborative Patient-Level Pooled Analysis from 9 Randomized Trials. JACC Vol. 68, No. 18_S, 168.

1212. Giustino G, Mehran R, Kirtane A, Redfors B, Genereux P, Dangas G, Brener S, Prats J, Deliagyris M, **Stone G**. Temporal Differences in Ischemic and Bleeding Risks after Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. JACC Vol. 68, No. 18_S, 181.

1213. Kosmidou I, Dordi R, Embacher M, Dizon J, Mehran R, Ben-Yehuda O, **Stone G**. Worsening Atrioventricular Conduction After Hospital Discharge in Patients With STEMI Undergoing Primary PCI: The HORIZONS-AMI Trial. JACC Vol. 68, No. 18_S, 198.

1214. Dordi R, Kosmidou I, Redfors B, Dizon J, Mehran R, Ben-Yehuda O, **Stone G**. Incidence, Predictors, and Outcomes of High-Grade Atrioventricular Block in Patients With STEMI Undergoing Primary PCI: The HORIZONS-AMI Trial. JACC Vol. 68, No. 18_S, 199.

1215. Embacher M, Kosmidou I, Dordi R, Redfors B, Dizon J, Mehran R, Ben-Yehuda O, **Stone G**. Correlation of Admission Heart Rate With Angiographic and Clinical Outcomes by Culprit Coronary Artery in Patients With STEMI Undergoing Primary PCI: The HORIZONS-AMI Trial. JACC Vol. 68, No. 18_S, 200.

1216. Embacher M, Kosmidou I, Dizon J, Redfors B, Dordi R, Mehran R, Ben-Yehuda O, **Stone G**. Incidence and Implications of Presentation With Ventricular Tachycardia or Fibrillation in Patients With STEMI Undergoing Primary PCI: The HORIZONS-AMI Trial. JACC Vol. 68, No. 18_S, 201.

1217. Kedhi E, Kennedy M, Maehara A, Lansky A, McANdrew T, Marso S, DeBruyne B, Serruys P, **Stone G**. Impact of Thin-Cap Fibroatheromas on Unanticipated Ischemic Events in Medically Treated Patients With Diabetes Mellitus: Insights From the PROSPECT Study. JACC Vol. 68, No. 18_S, 94.

1218. Giustino G, Baber U, Genereux P, **Stone G**, Leon M, Dangas G, Sartori S, Aquino M, Windecker S, Serruys P, Kastrati A, Wijins W, Steg PG, Stefanini G, Valgimigli M, Kimura T, Von Birgelen C, Camenzind E, Galatius S, Mehran R. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Intervention: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaborative Patient-Level Pooled Analysis. JACC Vol. 68, No. 18_S, 288.

1219. Madhavan M, Kirtane A, Redfors B, Genereux P, Smits P, Mehran R, Parvataneni R. **Stone, G**. Incidence and Predictors of Very Late Major Adverse Cardiac Events After Metallic Stents: A Patient-Level Pooled Analysis from Seventeen Randomized Trials. JACC Vol. 68, No. 18_S, 313.

1220. Yadav M, Genereux P, Redfors B, Madhavan M, Kirtane A, Parvataneni R, **Stone G**. The Smoker's Paradox Revisited: A 5-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials. JACC Vol. 68, No. 18_S, 322.

1221. Redfors B, Ben-Yehuda O, Lin SH, Furer A, Kirtane A, Witzenbichler B, Weisz G, Stuckey T, Maehara A, Genereux P, Giustino G, Rinaldi M, Neumann FJ, Metzger DC, Henry T, Cox D, Duffy PL, Mazzaferri E, Ayele G, Mehran R, Mintz G, **Stone G**. Proportion of Ischemic Risk After PCI Mediated by High Platelet Reactivity on Clopidogrel: Analysis From the ADAPT-DES Study. JACC Vol. 68, No. 18_S, 352.

1222. Parikh P, Kirtane A, Weisz G, Stuckey T, Ozan MI, Witenbichler B, Rinaldi M, Neumann FJ, Metzger DC, Henry T, Cox D, Duffy PL Brodie B, Mazzaferri E, Mehran R, **Stone G**. Underweight Status, Platelet Reactivity, and 2-Year Clinical Outcomes in Patients Undergoing PCI With DES: An ADAPT-DES Study Analysis. JACC Vol. 68, No. 18_S, 353.

1223. Kereiakes D, Ellis S, Gao R, Kimura T, Onuma Y, Piard-Ruster K, Zhang Ym Koo K, Serruys P, **Stone G**. Absorb Bioresorbable Vascular Scaffolds vs. XIENCE Everolimus-Eluting Stents: Are Clinical Outcomes Different for Men and Women? JACC Vol. 68, No. 18_S, 415.

1224. Ellis S, Lahoud R, Su X, Mc Greevy R, Serruys P, **Stone G**, Kereiakes D, Gao RL, Kimura T, Onuma Y, Cheong WF, Jones J. Outcomes After Bailout Stenting with Absorb BVS or XIENCE: Meta-analysis of Randomized Trials. JACC Vol. 68, No. 18_S, 438.

1225. Worthley S, Brilakis N, Abizaid A, Kirtane A, Simon D, Windecker S, Brar S, Meredith I, Shetty SV, Sinhal A, Popma-Almoncid A, Chamie D, Maehara A, **Stone G**. First-in-Human Clinical Study with a Novel Drug-Filled Stent: 9-Month Clinical, Angiographic, IVUS, and OCT Outcomes from the RevElution Study. JACC Vol. 68, No. 18_S, 443.

1226. Guan C, Xu B, Gao R, **Stone G**. One-Year Prognostic Utility of the SYNTAX Score II in Complex PCI with Biodegradable Polymer Drug-Eluting Stents: A PANDA III Analysis. JACC Vol. 68, No. 18_S, 44.

1227. Giustino G, Baber U, Sartori S, **Stone G**, Leon M, Windecker S, Serruys P, Kastrati A, Wijns W, Steg PG, Aquino M, Dangas G, Valgimigli M, Morice MB, Camenzind E, Weisz G, Smits P, Kandzari P, Von Birgelen C, Galatius S, Jeger R, Kimura T, Kim HS, Chieffo A, Mehran R. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Vol. 68, No. 18_S, 453.

1228. Vogel B, Baber U, Giustino G, Sartori S, **Stone G**, Windecker S, Serruys P, Camenzind E, Smits P, Kandzari D, Dangas G, Chandrasekhar J, Faggioni M, Farhan S, Jeger R, Kimura T, Mikhail G, Ortega R, Malgimigli M, Kastratic A, Mehran R. Impact of New- versus Early-Generation Drug Eluting Stents in Women according to Age: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Vol. 68, No. 18_S, 471.

1229. Giustino G, Melegari C, Baber U, Sartori S, **Stone G**, Leon, Kimura T, Aquino M, Farhan S, Dangas G, Stefanini G, Windecker S, Steg PG, Jeger R, Valgimigli M, Kastrati A, Chieffo A, Mehran R. Effect of Stent Diameter in Women Undergoing Percutaneous Coronary Intervention with Early- and New-Generation Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Vol. 68, No. 18_S, 475.

1230. Cook C, Jeremias A, Ahmad Y, Shun-Shin M, Nijer S, De Ward G, van de Hoef T, Pinto ME, Van Lavieren M, Petraco R, Al-Lamee R, Meuwissen M, Danad I, Knaapen P, Maehara A, Koo BK, Mintz G, Escaned J, **Stone G**. Piek J, Van Royen M, Davies J. Discordance In Stenosis Classification by pressure-Only

indices of stenosis severity is Related to Differences in coronary flow reserve: The RESOLVING DISCORD study. JACC Vol. 68, No. 18_S, 513.

1231. Matsumura M, Maehara A, Johnson N, Fearon W, DeBruyne B, Oldroyd K, Pijls N, Jenkins P, Mintz G, **Stone G**, Jeremias A. Qualitative Resting Wave Form Analysis to Predict an Abnormal Fractional Flow Reserve (FFR): A CONTRAST FFR Sub-Study. JACC Vol. 68, No. 18_S, 520.

1232. Ali Z, Galougahi KK, Nazif T, Maehara A, Cohen D, Hardy M, Ratner L, Collins M, Moses J, Kirtane A, Mintz G, **Stone G**, Karmpaliotis D, Leon M. Imaging and physiology-guided zero contrast percutaneous coronary intervention in advanced chronic kidney disease. JACC Vol. 68, No. 18_S, 546.

1233. Kadohira T, Redfors B, Maehara A, DeBruyne B, Serruys P, Mintz G, **Stone G**, Genereux P. Relationship Between Residual SYNTAX Score, Grayscale and Virtual Histology-IVUS Findings, and Non-Culprit Lesion-Related Major Adverse Cardiac Events: The PROSPECT Study. JACC Vol. 68, No. 18_S, 548.

1234. Koyama K, Mintz G, Redfors B, Serruys P, DeBruyne B, **Stone G**, Maehara A. Impact of the Extent of Circumferential Plaque on Non-Culprit Lesion-Related Events: A PROSPECT Substudy. JACC Vol. 68, No. 18_S, 557.

1235. **Stone G**, Abraham W, Lindenfeld J, Weissman N, Marx S, Ellis J, Crosson L, Mack M. Cardiovascular Outcomes Assessment of MitraClip Therapy in Heart Failure Patients with Functional Mitral Regurgitation (The COAPT Trial): Baseline Characteristics and Preliminary 30-Day and 1-Year Outcomes of the Roll-In Cohort. JACC Vol. 68, No. 18_S, 627.

1236. Finn M, Cloney M, Karmpaliotis D, Kirtane A, Green P, McAndrew T, Litherland C, Redfors B, Witzenbichler B, Weisz G, Stuckey TD, Brodie B, Rinaldi M, Neumann FJ, Metzger D, Henry T, Cox D, Duffy PL, Mazzaferri E, Mehran R, **Stone G.** Is Platelet reactivity associated with ischemic events following successful chronic total occlusion percutaneous coronary intervention. JACC Vol 69:11;21;1314.

1237. Genereux P, Serruys PW, Kappetein AP, Van Boven A, Hickey M, Kandzari D, Schampert E, Horkay F, Ungi I, Mansour S, Pocock S, Banning A, Taggart D, Sabate M, Gershlick A, Boonstra P, Lembo N, Puskas J, Kosmidou I, Brown WM, Mehran R, Ben-Yehuda A, Simonton C, Sabik J, **Stone G**. Outcomes of PCI versus CABG in left main disease according to syntax score by site versus angiographic core laboratory assessment: Insights from the EXCEL trial. JACC Vol 69:11;21;972.

1238. Genereux P, Serruys PW, Kappetein AP, Van Boven A, Hickey M, Kandzari D, Schampert E, Horkay F, Ungi I, Mansour S, Pocock S, Banning A, Taggart D, Sabate M, Gershlick A, Boonstra P, Lembo N, Puskas J, Kosmidou I, Brown WM, Mehran R, Ben-Yehuda A, Simonton C, Sabik J, **Stone G**. Differences and level

of agreement in syntax score assessment between site operators and angiographic core laboratory readers: Insights from the EXCEL Trial. JACC Vol 69:11;21;1147.

1239. Chandrasekhar J, Mehran R, Dangas G, McAndrew T, Zhang Y, Genereux P, Kirtane A, **Stone G**. Effect of thrombotic and bleeding risk according to platelet reactivity on 2-year mortality: The ADAPT-DES Study. JACC Vol 69:11;21;1012.

1240. Ellis SG, Gori T, Steffenino G, Kereiakes D, **Stone G**, Nef H, Brugaletta S, Testa L, Abizaid A, Kimura T, Tamburino C, Jon Van Guens R, Serruys P, Menichelli M, Cortese B, Gao RL. Clinical, angiographic and procedural correlates of ABSORB scaffold thrombosis: A matched multicenter registry analysis. JACC Vol 69:11;21;964.

1241. Maehara A, Mintz G, Serruys P, Kappetein A, Schampert E, Van Boven A, Horkay F, Ungi I, Mansour S, Banning A, Taggart D, Sabate M, Gershlick A, Bochenek A, Pomar J, Lembo N, Noiseux N, Puskas J, Brown WM, Mehran R, Ben-Yehuda O, Simonton C, Sabik J, **Stone G**. Impact of final minimal stent area by IVUS on 3-year outcome after PCI of left main coronary artery disease: the EXCEL Trial. JACC Vol 69:11;21;963.

1242. William B, **Stone G**. Introduction of the CALM II Study: A multi-center, clinded, sham-controlled pivotal trial of an endovascular carotid varostimulation implant for the treatment of resistant hypertension. JACC Vol 69:11;21;1726.

1243. Ibrahim H, McCoy L, Hess C, Akhter M, Effron M, **Stone G**, Wang T. Contemporary patterns of GP IIB/IIIA inhibitor use in patients with acute myocardial infarction undergoing PCI: Insights from the TRANSLATE ACS study. JACC Vol 69:11;21;1348.

1244. Vaduganathan M, Harrington R, **Stone G**, Steg P, Gibson CM, Hamm C, Price M, Deliagyris E, Prats J, Mahaffey K, White H, Bhatt D. Impact of periprocedural myocardial infarction in contemporary PCI: Pooled patient-level data from the CHAMPION trials. JACC Vol 69:11;21;112.

1245. Vaduganathan M, Harrington R, **Stone G**, Steg P, Gibson CM, Hamm C, Price M, Deliagyris E, Prats J, Mahaffey K, White H, Bhatt D. Cangrelor versus clopidogrel on a background of unfractionated heparin- insights from CHAMPION PHOENIX. JACC Vol 69:11;21;1345.

1246. **Stone GW**, Cavalcante R, Kappetein AP, Sabik J, Banning A, Taggart D, Sabate M, Polmar J, Boonstra P, Lembo N, Simonton C, Onuma Y, Serruys PW. Sex differences in outcomes after stenting or bypass surgery for unprotected left main disease. JACC Vol 69:11;21;980.

1247. Lee Sl, Honh MK, Im E, Shin DH, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Kim YS, Valgimigli M, Colombo A, Gilard M, Palmerini T, **Stone G**. Association between duration of dual antiplatelet therapy and angiographic multi-

vessel disease on outcomes in patients treated with newer generation drug-eluting stents. JACC Vol 69:11;21;1013.

1248. Diamond JE, Redfors B, Genereux P, Madhavan M, Kirtane A, Smits P, Mehran R, Caprihan R, Ben-Yehuda O, **Stone G**. Long-term adverse ischemic outcomes after percutaneous coronary intervention among patients with versus without prior coronary artery bypass grafting: Analysis from 17 randomized trials. JACC Vol 69:11;21;1235.

1249. Redfors B, Genereux P, Kirtane A, Witzenbichler B, Rinaldi M, Neumann FJ, Metzger D, Henry T, Cox D, Duffy PL, Mazzaferri E, Gurbel P, Brodie B, Stuckey T, McAndrew T, Diamond JE, Huang X, Mehran R, **Stone G**. Platelet reactivity and outcomes after PCI of saphenous vein grafts versus native coronary arteries: the ADAPT-DES Study. JACC Vol 69:11;21;1090.

1250. Oliver C, Sundaram V, Ding V, Yang L, Leonardi S, Lopes R, Bhatt D, **Stone G**, Steg P, Gibson CM, Hamm C, Price M, White H, Desai M, Harrington R, Lynch DR, Mahaffey K. One-Year mortality increased in patients with peri-procedural myocardial infarction: Insights from the CHAMPION Trials. JACC Vol 69:11;21;7.

1251. Bavishi C, Samady H, Moreno P, **Stone G**. Efficacy and safety of Everolimus-eluting stents versus slow-release Zotarolimus-eluting stents: A direct comparison meta-analysis of 29,286 patients – years follow-up from randomized controlled trials. JACC Vol 69:11;21;1251.

1252. Redfors B, Genereux P, Kirtane A, Witzenbichler B, Maehara A, Weisz G, McAndrew T, Mehran R, **Stone G**. Platelet reactivity and ourcomes after PCI of lesions with and without in-stent restenosis: The ADAPT-DES Study. JACC Vol 69:11;21;1023.

1253. Cavender M, Harrington R, **Stone G**, Deliagyris E, Steg P, Gibson CM, Hamm C, Price M, Prats J, Mahaffey K, White H, Bhatt D. Ischemic events occur early in patients undergoing PCI and are reduced with Cangrelor: Findings from CHAMPION PHOENIX. JACC Vol 69:11;21;25.

Invited Lectures, Seminars and Courses

1. Systolic and diastolic dysfunction in acute pulmonary edema: A prospective consecutive series. Presented at the Society of Nuclear Medicine Western Regional Meeting in San Diego, California, October 12th, 1987.

2. Is diastolic dysfunction the cause of acute pulmonary edema with normal global systolic dysfunction? Presented at the 60th Annual Scientific Sessions of the American Heart Association Meeting in Anaheim, California, November, 1987.

3. Acute outcome and long term follow-up of patients with acute myocardial infarction and single vessel disease treated with angioplasty without thrombolytic therapy. Presented at the 38th Annual Scientific Sessions of the American College of Cardiology in Anaheim, California, March 1989.

4. Factors relating to improvement in regional wall motion and ejection fraction in patients with acute myocardial infarction and single vessel disease treated with coronary angioplasty without prior thrombolytic therapy. Presented at the 62nd Annual Scientific Sessions of the American Heart Association Meeting in New Orleans, Louisiana, November, 1989.

5. Percutaneous transluminal coronary angioplasty vs. coronary artery bypass grafting for coronary artery disease. El Camino Hospital, Mountain View, CA, November 28, 1989.

6. Research aspects of guide catheter development, Advanced Cardiovascular Systems, Sunnyvale, CA, January 20, 1990.

7. Advances in coronary angioplasty, 1990. Medical Grand Rounds, El Camino Hospital, Mountain View, CA, February 23, 1990.

8. Coronary angioplasty of chronic total occlusions, at the course “Percutaneous Transluminal Coronary Angioplasty for the Advanced Dilator”, The Big Island, Hawaii, February 8, 1990.

9. Outcome following multilesion angioplasty targeted to the "culprit coronary artery" in pts with unstable angina. Presented at the 39th Annual Scientific Sessions of the American College of Cardiology in Atlanta, Georgia, March 1990.

10. Factors relating to improvement in regional wall motion and ejection fraction in patients with acute myocardial infarction and single vessel disease treated with coronary angioplasty without prior thrombolytic therapy. Presented at the 10th annual national meeting of the Society for Cardiac Angiography and Interventions in Williamsburg, Virginia, May 1990.

11. Non-ionic and low osmolar contrast agents, Presented at the Annual Scientific Conference of the National Society for Cardiovascular and Pulmonary Technology, Reno, Nevada, June 16-19, 1990.

12. Simple and complex coronary angioplasty, El Camino Hospital, Mountain View, CA, July 9, 1990.

13. Principles of Complex Coronary Angioplasty. Cardiac Catheterization Conference, Stanford University Hospital, July 16, 1990.

14. Direct angioplasty in acute myocardial infarction. El Camino Hospital, Mountain View, CA, July 23, 1990.

15. The role of coronary angioplasty in acute myocardial infarction. Presented at the course Advanced Angioplasty, San Francisco, CA, August 29, 1990.

16. New directions in coronary angioplasty. Presented at the Western Region Advisory Board Meeting, Advanced Cardiovascular Systems, Santa Clara, October 1, 1990.

17. The biological and mechanical aspects of intravascular thrombus formation. Carlsbad, CA, October 25-26, 1990.

18. Percutaneous transluminal coronary angioplasty: future research and engineering aspects. Santa Barbara, CA, October 29, 1990.

19. Principles of cardiac catheterization: the choice of radio-contrast agents. Dallas, TX, November 10, 1990.

20. Reperfusion therapy of acute myocardial infarction 1991. Grand Rounds, El Camino Hospital, Mountain View, CA, January 14, 1991.

21. New interventional approaches in the cardiac catheterization lab. Napa Valley, CA, February, 22, 1991.

22. Restenosis Update. Presented at the course Advances in Interventional Cardiology, St. Louis, MO, April 12, 1991.

23. Alternatives to open heart surgery. The Center on Aging, Mountain View, CA, July 10, 1991.

24. Complex angioplasty cases. The 1991 Cardiology Fellows Conference, ACS, Carlsbad, CA, October 12-15, 1991.

25. Direct infarct angioplasty: the optimal treatment of acute myocardial infarction? The Invasive Cardiology Group, Portland, OR, October 28, 1991.

26. Developmental aspects of ultrasonic angioplasty. ACS, Santa Clara, CA December 4, 1991.

27. Recognition and management of heart disease. The El Camino Hospital, Mountain View, CA, December 18, 1991.

28. Directional coronary atherectomy. El Camino Hospital, Cardiology Grand Rounds, Mountain View, CA, January 14, 1992.

29. Women and Heart Disease. KRFC, San Francisco, CA, February 23rd, 1992.

30. Advances in Interventional Cardiology. Palo Alto, CA, March 24th, 1992.

31. Directional Coronary Atherectomy. Department of Radiology Grand Rounds, El Camino Hospital, Mountain View, CA, April 4th, 1992.

32. Diagnosis and Treatment of Heart Disease. Los Altos, CA, April 21st, 1992.

33. Complex Coronary Angioplasty: 1992. Presented at the Course Coronary Intervention and its Aftermath. Greeley, CO. May 15, 1992.

34. Direct Infarct Angioplasty; the Optimal Treatment of Acute Myocardial Infarction. Presented at the course Coronary Intervention and its Aftermath. Greeley, CO. May 15, 1992.

35. The Management of Complications and Restenosis following Balloon Angioplasty. Presented at the 6th Annual ACS Clinical Advisory Board Meeting, Colorado Springs, CO, June 6-11, 1992.

36. Clinical Applications of Intracoronary Ultrasound Imaging. Endosonics Corp., Pleasanton, CA July 8, 1992.

37. Interventional Cardiology Product Development – Trends and Predictions. Advanced Cardiovascular Systems, Inc., Santa Clara, CA July 9, 1992.

38. New Devices in Interventional Cardiology. Medical Grand Rounds. El Camino Hospital, Mountain View, CA, July 15, 1992.

39. Direct Infarct Angioplasty: Results of the Primary Angioplasty In Myocardial Infarction Trial. Cardiology Grand Rounds. Santa Rosa Memorial Hospital, Santa Rosa, CA, July 31, 1992.

40. Results of the Primary Angioplasty In Myocardial Infarction Trial. Grand Rounds, El Camino Hospital, Mountain View, CA, September 29, 1992.

41. Future directions for directional coronary atherectomy. Devices for Vascular Intervention, Inc. Redwood City, CA, October 5th, 1992.

42. Equipment selection and medication in directional coronary atherectomy. DVI Physician Training Course. San Diego, CA October 7th, 1992.

43. Technique of Directional Coronary Atherectomy. DVI Physician Training Course. San Diego, CA October 7th, 1992.

44. Treatment of Myocardial Infarction, 1992. Internal medicine meeting, Palo Alto, CA, October 12th, 1992.

45. Direct Infarct Angioplasty: Results of the Primary Angioplasty In Myocardial Infarction Trial. Cardiology Grand Rounds. Stanford University Medical Center, October 21, 1992.

46. The Changing Face of Interventional Cardiology. at the course "High Impact Interventions", Los Altos, CA, November 12th, 1992.

47. Primary Angioplasty Reduces In-Hospital Mortality and Morbidity in Acute Anterior Myocardial Infarction - Results of the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. Presented at the 42nd Annual Scientific Sessions of the American College of Cardiology in Anaheim, CA, March 1993.

48. Initial Clinical Experience with a Novel Low-Profile Integrated Coronary Ultrasound-Angioplasty Catheter: Implications for Routine Use. Presented at the 42nd Annual Scientific Sessions of the American College of Cardiology in Anaheim, CA, March 1993.

49. Primary Angioplasty is the Preferred Therapy for Women and the Elderly with Acute Myocardial Infarction - Results of the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. Presented at the 42nd Annual Scientific Sessions of the American College of Cardiology in Anaheim, CA, March 1993.

50. Acute Outcome After Primary Angioplasty in Myocardial Infarction - The Primary Angioplasty In Myocardial Infarction (PAMI) Trial. Presented at the 42nd Annual Scientific Sessions of the American College of Cardiology in Anaheim, CA, March 1993.

51. Clinical Utility of Intracoronary Ultrasound Imaging During Angioplasty. Presented at the 1993 Scientific Sessions for the Utah Affiliate of the American Heart Association, during the course "Interventional Cardiology Symposium at Snowbird", Snowbird, Utah, April 9th, 1993.

52. New Devices for Percutaneous Coronary Intervention: 1993 Update. The California Chapter of the American Heart Association, El Camino Hospital, Mountain View, CA, April 14th, 1993.

53. Direct Infarct Angioplasty - The Preferred Alternative to Thrombolytic Therapy. Presented during the annual meeting of the American College of Cardiovascular Invasive Specialists. Las Vegas, NV, May 1st, 1993.

54. Coronary Angioplasty-Ultrasound Case Demonstrations. Centre Cardiologie du Nord, Paris, France, May 18, 1993.

55. Applications of Intracoronary Ultrasound During Angioplasty. Centre Cardiologie du Nord, Paris, France, May 19, 1993.

56. Use of Intracoronary Ultrasound During Coronary Stenting - Case Demonstrations. University Hospital, Milan, Italy, May 20, 1993.

57. New Devices for Percutaneous Coronary Intervention. Cupertino Medical Center, Cupertino, CA, May 28, 1993.

58. Intracoronary Ultrasound Imaging. Cardiac catheterization conference, St. Agnes Hospital, Fresno, CA, June 17, 1993.

59. New Applications for Intracoronary Ultrasound Imaging. Cardiology Grand Rounds, Bakersfield, CA, July 13, 1993.

60. The Role of Primary Angioplasty in Acute Myocardial Infarction. Interventional Cardiology Conference, Boise, Idaho, August 17, 1993.

61. Primary Angioplasty is the Optimal Therapy for Acute Myocardial Infarction. Annual Meeting of the National Society For Cardiovascular Technology, Los Angeles, CA, August 28, 1993.

62. Primary PTCA as the Treatment Strategy of Choice in Acute Myocardial Infarction. Kaiser San Francisco General Hospital Grand Rounds, September 8th, 1993.

63. Holmium Laser Angioplasty Demonstrations and Research Council Meeting, El Camino Hospital and Palo Alto, CA, September 10th, 1993.

64. Is the Wind Gone from GUSTO? - Results of the Primary Angioplasty in Myocardial Infarction Trial. Scripps Memorial Hospital, San Diego, CA, September 14th, 1993.

65. Treatment of Acute Myocardial Infarction with Primary PTCA. Annual Cardiology Conference, Cardiology Care Specialists, Lawton, Oklahoma, September 17th, 1993.

66. Holmium Laser Angioplasty Demonstrations and Research Council Meeting, El Camino Hospital and Sunnyvale, CA, September 20th, 1993.

67. Intracoronary Ultrasound-Angioplasty Demonstrations, Dallas, Texas, September 21st, 1993.

68. Management of the Patient with Acute Myocardial Infarction in 1993. Borgess Medical Center Annual Cardiology Symposium, Kalamazoo, Michigan, October 6th, 1993.

69. Is Prolonged Angina Free Survival Possible in Pts with Multivessel Disease Treated by PTCA?- Effect of Multiple, Repeated Procedures. Presented at the 66th Annual Scientific Sessions of the American Heart Association, Atlanta, Georgia, November 9th, 1993.

70. Primary Angioplasty Reduces Recurrent Ischemic Events Compared to tPA in Myocardial Infarction: Implications for Early Discharge. Presented at the 66th Annual Scientific Sessions of the American Heart Association, Atlanta, Georgia, November 10th, 1993.

71. Aggressive Balloon Sizing using Intracoronary Ultrasound Imaging During Percutaneous Intervention. at the course *Beyond Angiography,* Atlanta, Georgia, November 6th, 1993.

72. Rationale for Laser Angioplasty. at the Eclipse Laser Investigator's Meeting. Atlanta, Georgia, November 9th, 1993.

73. Ultrasound-Guided Coronary Intervention. Interventional Cardiology Symposium, Keynote address, Tokyo, Japan, December 18th, 1993.

74. Ultrasound Angioplasty Case Demonstrations, Mitsui Memorial Hospital, Tokyo, Japan, December 17th, 1993.

75. Lasers, Rotor-Rooters and Chicken Wire Baskets: Advances in Interventional Cardiology. Good Samaritan Hospital, San Jose, CA. January 11th, 1994.

76. FDA presentation: The role of primary angioplasty in acute myocardial infarction. Washington D.C., February 2nd, 1994.

77. Primary Angioplasty in Acute Myocardial Infarction. Medicine Grand Rounds, Peninsula Hospital, Burlingame, CA, February 22nd, 1994.

78. Controversial DCA case presentations. The 3rd annual Devices for Vascular Intervention Physician Advisory Board Meeting, Monterey, CA, March 2nd-6th, 1994.

79. The Laser Angioplasty Vs. Angioplasty (LAVA) Trial - Update. Atlanta, GA, March 13th, 1994.

80. Adverse Catheterization Laboratory Events after Primary PTCA vs. PTCA Following Thrombolytic Therapy - A Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. Presented at the 43rd Annual Scientific Sessions of the American College of Cardiology, Atlanta, Georgia, March 15, 1994.

81. Predictors of In-Hospital and 6-Month Outcome after Myocardial Infarction in the Reperfusion Era - A Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. Presented at the 43rd Annual Scientific Sessions of the American College of Cardiology, Atlanta, Georgia, March 15, 1994.

82. Primary Angioplasty in Myocardial Infarction. Fireside panel presentation, the 43rd Annual Scientific Sessions of the American College of Cardiology, Atlanta, Georgia, March 15, 1994.

83. Directional Coronary Atherectomy Physician Training Course, Devices for Vascular Intervention, Menlo Park, CA, March 25th, 1994.

84. Advances in Directional Coronary Atherectomy - a Physician's Perspective. Devices for Vascular Intervention, Redwood City, CA, March 28th, 1994.

85. Intracoronary ultrasound demonstrations. Vancouver General Hospital, Vancouver, Canada, April 5th, 1994.

86. Update on Primary Infarct Angioplasty. Presented at the American Heart Association course Update on Therapy for Cardiovascular Disease and Stroke, Portland Convention Center, Portland, OR, May 13th, 1994.

87. Laser Angioplasty Training. Latter Day Saints Hospital, Salt Lake City, Utah, July 12th, 1994.

88. PTCA in AMI: PAMI Trials. Presented at the course "Cardiovascular Interventions: Technology at the Summit, IV." Aspen, CO, August 1st, 1994.

89. Holmium Laser Facilitated Coronary Angioplasty. Presented at the course "Cardiovascular Interventions: Technology at the Summit, IV." Aspen, CO, August 2nd, 1994.

90. Directional Coronary Atherectomy Training Course. Sponsored by Devices for Vascular Intervention, Inc. Redwood City, CA, August 24th, 1994.

91. Advances in Intracoronary Ultrasound Imaging. Berlin, Germany, September 9th, 1994.

92. Clinical Utility of Intracoronary Ultrasound Imaging Using the Endosonics Cathscanner. Berlin, Germany, September 10th, 1994.

93. Potential Applications for Biologic Coatings, Berlin Germany, September 11th, 1994.

94. Lessons from the PAMI-1 Trial. Presented at the 7th Annual Interventional Cardiology Course, sponsored by William Beaumont Hospital, Detroit, Michigan, October 3rd, 1994.

95. Is Directional Coronary Atherectomy Obsolete in the Era of Stenting? Presented at the 8th Annual Advanced Cardiovascular Systems Advisory Board Meeting, Denver Colorado, October 6th, 1994.

96. Principles and Practice of Intracoronary Stenting. El Camino Hospital, Mountain View, CA, October 12th, 1994.

97. Results of Holmium Photoacoustic Laser Atherectomy - Multicenter Results. Scottsdale Memorial Hospital, Scottsdale, Arizona, October 25th, 1994.

98. Reperfusion therapy in acute myocardial infarction - primary angioplasty or thrombolysis? Mercy General Hospital, Sacramento, CA, November 1st, 1994.

99. Directional Coronary Atherectomy vs. Intracoronary Stenting. Presented to the Devices for Vascular Intervention national sales force and research division. San Francisco, CA, November 2nd, 1994.

100. Improving Results of Holmium Photoacoustic Laser Atherectomy. Presented at the Eclipse Laser Investigator's meeting at the 67th Annual Scientific Sessions of the American Heart Association, Dallas, Texas, November 13th, 1994.

101. Clinical Application of Intracoronary Ultrasound Imaging. Presented at the Course "Beyond Angiography II" at the 67th Annual Scientific Sessions of the American Heart Association, Dallas, Texas, November 12th, 1994.

102. Aggressive Angioplasty using Intracoronary Ultrasound Imaging: The CLOUT Hypothesis. Presented at the Course "Beyond Angiography II" at the 67th Annual Scientific Sessions of the American Heart Association, Dallas, Texas, November 12th, 1994.

103. What is the Optimal Means to Achieve and Sustain Perfusion in Acute Myocardial Infarction? Presented at the 67th Annual Scientific Sessions of the American Heart Association, Clinical Council of Cardiology, Dallas Texas, November 16th, 1994.

104. Who is Eligible for Early Discharge After Acute Myocardial Infarction? Presented at the 67th Annual Scientific Sessions of the American Heart Association, Clinical Council of Cardiology, Dallas Texas, November 13th, 1994.

105. What is the role of newer interventional devices in 1995? Thought Leaders in Interventional Cardiology. Stanford University Medical Center, January 20th, 1995.

106. Advances in the non-operative management of coronary artery disease. The Older Adults Resource Center. Mountain View, CA, February 8th, 1995.

107. Abstract Panel Chairman, Alternative Imaging Modalities, Transcatheter Cardiovascular Therapeutics-VII Meeting, Washington D.C., February 22nd, 1995.

108. Abstract Panel Chairman, Mechanisms of Restenosis, Transcatheter Cardiovascular Therapeutics-VII Meeting, Washington D.C., February 22nd, 1995.

109. Can the Results of Standard Balloon Angioplasty be Improved with Intracoronary Ultrasound Guidance? - The CLOUT Pilot Study. Presented at the 7th Annual Transcatheter Cardiovascular Therapeutics Meeting, Washington DC, February 23-25, 1995.

110. Holmium Laser Multicenter Registry Results: Effect of lesion morphology on procedural success and complications. - The CLOUT Pilot Study. Presented at the 7th Annual Transcatheter Cardiovascular Therapeutics Meeting, Washington DC, February 23-25, 1995.

111. PTCA vs. Thrombolysis in High Risk Patients. Presented during the course Direct PTCA in the 90's during the 44th Annual Scientific Sessions of the American College of Cardiology, New Orleans, CA, March 20th, 1995.

112. Outcome of Different Reperfusion Strategies in Thrombolytic "Eligible" Versus "Ineligible" Patients with Acute Myocardial Infarction. Presented during the 44th Annual Scientific Sessions of the American College of Cardiology, New Orleans, CA, March 22nd, 1995.

113. Is Primary Angioplasty Less Effective in Patients Presenting in the Early Morning Hours? - A Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. Presented during the 44th Annual Scientific Sessions of the American College of Cardiology, New Orleans, CA, March 22nd, 1995.

114. Does Primary Angioplasty Improve the Prognosis of Patients with Diabetes and Acute Myocardial Infarction? Presented during the 44th Annual Scientific Sessions of the American College of Cardiology, New Orleans, CA, March 22nd, 1995.

115. Course Director, The First National Interventional Fellow's Course, Stanford University Medical Center, April 8th-10th, 1995.

116. Primary infarct angioplasty. Presented at the National Interventional Fellow's Course at Stanford University Medical Center, April 8th, 1995.

117. Holmium laser angioplasty. Presented at the National Interventional Fellow's Course at Stanford University Medical Center, April 8th, 1995.

118. The CLOUT Trial. Presented at the National Interventional Fellow's Course at Stanford University Medical Center, April 8th, 1995.

119. Primary PTCA for Acute Myocardial Infarction - What Challenges Remain? Eli Lilly Research Laboratories. Indianapolis, IN, April 18th, 1995.

120. Advances in the Recognition and Treatment of Heart Disease. El Camino Hospital, Mountain View, CA, April 26th, 1995.

121. Advanced Innovations in Ultrasound Guidance of Percutaneous Cardiology Procedures. Presented at Cardiology Grand Rounds, St. John's Hospital, Detroit, MI, May 9th, 1995.

122. Advances in the Percutaneous Management of Coronary Artery Disease. Medical Grand Rounds. El Camino Hospital, Mountain View, CA, June 27th, 1995.

123. Interpretation and Application of Intracoronary Ultrasound Imaging. St. Bernadine Hospital Division of Cardiology, San Bernadino, CA, July 18th, 1995.

124. Proctoring of Intracoronary Ultrasound Imaging cases. St. Bernadine Hospital, San Bernadino, CA, July 18th, 1995.

125. Treatment of Heart Disease: Beyond the Balloon. Cupertino Medical Center, Cupertino, CA, July 24th, 1995.

126. Rotational Atherectomy: Technique, Results and Future Expectations. Presented at the 1st meeting of the Congress of the Latin American Society of Interventional Cardiology, Maksoud Plaza, Sao Paulo, Brazil, July 28th, 1995.

127. Acute Myocardial Infarction: Angioplasty vs. Thrombolysis. Presented at the 1st meeting of the Congress of the Latin American Society of Interventional Cardiology, Maksoud Plaza, Sao Paulo, Brazil, July 29th, 1995.

128. High Speed Rotational Atherectomy: Present Results and Future Applications. Presented at the course Cardiovascular Interventions: Technology at the Summit V. Aspen, Colorado, August 4th, 1995.

129. PTCA in Acute Myocardial Infarction: PAMI I, II and III - Update 1995. Presented at the course Cardiovascular Interventions: Technology at the Summit V. Aspen, Colorado, August 6th, 1995.

130. Advanced Rotational Atherectomy Concepts and Techniques. University of California at San Diego, August 16th, 1995.

131. Is it Ethical not to Perform Primary PTCA in Acute Myocardial Infarction? Presented at the Annual Meeting of the Advanced Cardiovascular Systems Physician Advisory Board Meeting. Tucson, AZ, August 28th, 1995.

132. Is Intracoronary Ultrasound Imaging Required for Stent Implantation? Presented at the Annual Meeting of the Advanced Cardiovascular Systems Physician Advisory Board Meeting. Tucson, AZ, August 28th, 1995.

133. The Second Primary Angioplasty in Myocardial Infarction Trial. Presented at the Annual Complex Coronary Interventions Conference, Biwako Lakeside, Shiga Prefecture, Japan, September 8th, 1995.

134. Advanced Concepts in Intracoronary Ultrasound Guided Percutaneous Intervention. Presented at the Annual Complex Coronary Interventions Conference, Biwako Lakeside, Shiga Prefecture, Japan, September 9th, 1995.

135. The Optimal Stent Implantation Studies - the Role of Intravascular Ultrasound Guidance. Presented at the Annual Meeting of the Endosonics Physician Advisory Board, Sacramento, CA, September 11th, 1995.

136. Primary PTCA Vs. Thrombolysis for Acute Myocardial Infarction. Presented at the American Heart Association's 63rd Annual Fall Symposium, Los Angeles, CA, September 13th, 1995.

137. Coronary Stenting in 1995. Presented at the course Strategies for Intervention in Complex Coronary Artery Disease: A Real World Approach. Kansas City, MO, September 14th, 1995.

138. Direct PTCA in the Setting of Acute Myocardial Infarction - PAMI Results and Beyond. Presented at the course Strategies for Intervention in Complex Coronary Artery Disease: A Real World Approach. Kansas City, MO, September 15th, 1995.

139. Heparin Coated Stenting in Acute Myocardial Infarction. Johnson & Johnson Interventional Systems, Warren, NJ, Sept. 19th, 1995.

140. Primary Angioplasty in Acute Myocardial Infarction - 1995. The John L. Locke Symposium, Swedish Medical Center, Seattle, Wash., October 6th, 1995.

141. Cost effective approach to the patient with coronary artery disease. Case presentations. The John L. Locke Symposium, Swedish Medical Center, Seattle, Wash., October 6th, 1995.

142. Procedural guidance of complex coronary angioplasty procedures with intravascular ultrasound. Presented during the course “Beyond Angiography III” at the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 11th, 1995.

143. The Optimal Stent Implantation Trial. Presented during the course “Beyond Angiography III” at the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 11th, 1995.

144. Aggressive stent implantation with intravascular ultrasound guidance. Presented during the course “Beyond Angiography III” at the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 11th, 1995.

145. Primary stenting in acute myocardial infarction. Presented during the course “Thrombolysis and Interventional Therapy in Acute Myocardial Infarction”, at the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 12th, 1995.

146. The PAMI Stent Trial - Interim Results. Presented during the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 12th, 1995.

147. Primary Stenting in AMI. Presented at the International Heparin Coated Stent Investigator's meeting in Anaheim, CA, November 12th, 1995.

148. The Routine Use of Intra-Aortic Balloon Pumping After Primary PTCA Improves Clinical Outcomes in Very High Risk Patients with Acute Myocardial Infarction - Results of the PAMI-2 Trial. Presented during the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 13th, 1995.

149. Is Prophylactic IABP Use Beneficial or Harmful in a High Risk Elderly Population with Acute Myocardial Infarction? - PAMI-2. Presented during the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 13th, 1995.

150. Primary PTCA in Acute Myocardial Infarction: Where We've Been and Where We're Going. Presented at the course "management of Cardiovascular Problems in 1995: Greater Simplicity and Efficacy from Technological Progress. Laguna Niguel, CA, December 9th, 1995.

151. Advanced Techniques in Coronary Stenting - Live Case Demonstrations. Rigshospitalet, National University, Copenhagen, Denmark, December 18th, 1995.

152. Reperfusion Therapies for Acute Myocardial Infarction. Rigshospitalet, National University, Copenhagen, Denmark, December 18th, 1995.

153. Primary PTCA Workshop for the Interventionalists of Denmark. Rigshospitalet, National University, Copenhagen, Denmark, December 18th, 1995.

154. Advantages of Coronary Stenting Using Intracoronary Ultrasound Imaging.

Presented at the JJIS Congress on Coronary and Peripheral Disease Management, Tucson, Arizona, January 16, 1996.

155. Advanced Intracoronary Ultrasound Case Demonstrations - Session Chairman and Moderator. At the Interactive Course on Intravascular Ultrasound, Montreal Heart Institute, Montreal, Canada, January 19th, 1996.

156. Update on Ultrasound-Stent Trials. At the course Intravascular Ultrasound for the Interventionalist, Stanford University, Stanford, CA, January 26th, 1996.

157. Workshops on Ultrasound Guided Stent Implantation. At the course Intravascular Ultrasound for the Interventionalist, Stanford University, Stanford, CA, January 26th- 27th, 1996.

158. Interventional Treatment of Acute Myocardial Infarction - What's New in 1996? Cardiology Grand Rounds, University of California at San Diego Medical Center, January 31, 1996.

159. Optimal Techniques for Stent Implantation. Presented at the 11th Annual Demonstrations Course on Interventional Cardiology and Advanced Coronary Stenting, Snowmass, CO, February 19th, 1996.

160. Direct PTCA for Acute Myocardial Infarction: The PAMI I and II Trials. Presented at the 11th Annual Demonstrations Course on Interventional cardiology and Advanced Coronary Stenting, Snowmass, CO, February 21st, 1996.

161. Stenting in Acute Myocardial Infarction. Presented at the 11th Annual Demonstrations Course on Interventional Cardiology and Advanced Coronary Stenting, Snowmass, CO, February 21st, 1996.

162. Vascular Remodeling in Coronary Artery Disease and Restenosis. Presented at the course Intracoronary Ultrasound Imaging: An Introduction for Interventional Cardiology. San Antonio, TX, February 23rd, 1996.

163. Intravascular Ultrasound Applications During PTCA. Presented at the course Intracoronary Ultrasound Imaging: An Introduction for Interventional Cardiology. San Antonio, TX, February 23rd, 1996.

164. Stents in Acute Myocardial Infarction. Presented at the symposium Direct PTCA in Acute Myocardial Infarction, Washington, D.C., February 29th, 1996.

165. Algorithms for Multi-Device, Lesion-Specific Angioplasty. Presented at the Transcatheter Cardiovascular Therapeutics-VIII Meeting, Washington, D.C., March 1st, 1996.

166. Stents for Acute Myocardial Infarction: Early results from the PAMI Stent Pilot

Study. Presented at the Transcatheter Cardiovascular Therapeutics-VIII Meeting, Washington, D.C., March 1st, 1996.

167. The PAMI-2 Trial: Perspectives on Prophylactic IABP Use and Early Discharge after Direct PTCA in Acute Myocardial Infarction. Presented at the Transcatheter Cardiovascular Therapeutics-VIII Meeting, Washington, D.C., March 2nd, 1996.

168. Insights from the Optimal Stent Implantation Trials. Presented at the Transcatheter Cardiovascular Therapeutics-VIII Meeting, Washington, D.C., March 2nd, 1996.

169. Ultrasound Guided Stent Implantation. Stanford, CA, March 5th, 1996.

170 Primary PTCA for Acute Myocardial Infarction - The PAMI Trials. Presented at the 14th Annual Cardiovascular Nursing Scientific Sessions of the American Heart Association, Millbrae, CA, March 22nd, 1996.

171. Advanced Cardiovascular Systems MultiLink Stent Research and Development Board Meeting, Orlando, Florida, March 24th, 1996.

172. Treatment of Acute Myocardial Infarction with Stents and Other New Technologies. Presented at the 45th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 24th, 1996.

173. Primary Stenting for Acute Myocardial Infarction. Presented at the PAMI Investigator's Meeting, Orlando, Florida, March 24th, 1996.

174. Improved Outcomes of Balloon Angioplasty with Intracoronary Ultrasound Guidance - Core Lab Angiographic and Ultrasound Results from the CLOUT Study. Presented at the 45th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 26th, 1996.

175. What is the Optimal Pressure for Stent Implantation (How High is High)? Presented at the 45th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 26th, 1996.

176. Variability in Balloon Sizing During Routine PTCA - Quantitative Coronary and Ultrasound Analysis. Presented at the 45th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 27th, 1996.

177. Choice of Interventional Device Based on Lesion Morphology and Clinical Presentation. Luncheon panel session chairman. Presented at the 45th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 27th, 1996.

178. High Speed Rotational Atherectomy - What's New in 1996?. Presented at the

XVIII Meeting of the Brazilian Society of Cardiology, Natal, Brazil, April 11th, 1996.

179. Ultrasound Insights into Coronary Angioplasty and Stenting. Presented at the XVIII Meeting of the Brazilian Society of Cardiology, Natal, Brazil, April 12th, 1996.

180. New Horizons for Treatment of Acute Myocardial Infarction - Primary Stenting. Presented at the XVIII Meeting of the Brazilian Society of Cardiology, Natal, Brazil, April 13th, 1996.

181. Course Director, The 2nd Annual National Interventional Fellows' Course, Durham, North Carolina, April 18th-20, 1996.

182. Beyond Primary PTCA. Presented at the 2nd Annual Duke-Stanford National Interventional Fellows' Course, Durham, North Carolina, April 19th, 1996.

183. Ultrasound Guided Coronary Intervention. Presented at the 2nd Annual Duke-Stanford National Interventional Fellows' Course, Durham, North Carolina, April 21st, 1996.

184. Update on primary PTCA - The PAMI II and III Trials. Presented at the course Cardiology Fiesta in San Antonio: Update on Cardiac Diagnostic and Therapeutic Techniques, San Antonio, Texas, April 25th, 1996.

185. Primary Stenting in Acute Myocardial Infarction. Presented at the course "State of the Art Update on Interventional Cardiology - Where Are We Going?", Chicago, IL, June 2nd, 1996.

186. Better balloon angioplasty with ICUS imaging. Presented at the course "Intracoronary Ultrasound Imaging: An Introduction for Interventional Cardiology". Winston-Salem, NC, June 7th, 1996.

187. The Role of Intracoronary Ultrasound Imaging during Stent Implantation. Presented at the course "Intracoronary Ultrasound Imaging: An Introduction for Interventional Cardiology". Winston-Salem, NC, June 7th, 1996.

188. PTCA and Stenting in Acute Myocardial Infarction - The PAMI Trials: Update 1996. Presented at the course "Cardiovascular Interventions - Technologies at the Summit VI", Aspen, CO, August 1st, 1996.

189. Intravascular Ultrasound Imaging during Elective Coronary Stent Implantation. Presented at the course "Cardiovascular Interventions - Technologies at the Summit VI", Aspen, CO, August 2nd, 1996.

190. New Concepts in Intravascular Ultrasound Guided Stent Implantation. Presented at the XVIIIth Congress of the European Society of Cardiology Annual Scientific

Sessions, August 27th, 1996, Birmingham, U.K.

191. Primary Stenting in Acute Myocardial Infarction: Interim Report from the PAMI Stent Pilot Trial. Presented at the XVIIIth Congress of the European Society of Cardiology Annual Scientific Sessions, August 27th, 1996, Birmingham, U.K.

192. Defining the Relationship Between Implantation Pressure and Stent Expansion: Core Lab Results from the Optimal Stent Implantation (OSTI) Trial. Presented at the XVIIIth Congress of the European Society of Cardiology Annual Scientific Sessions, August 29th, 1996, Birmingham, U.K.

193. Angioplasty and Stenting in Acute Myocardial Infarction. Thought Leaders in Interventional Cardiology: Round Table Sessions. Detroit, MI, September 5th-6th, 1996.

194. Utility of ReoPro in Interventional Cardiology - A Real World Analysis. Presented at the course New Directions in Interventional Cardiology, September 8th, 1996, San Francisco, CA.

195. Stenting in Acute Myocardial Infarction - The PAMI Stent Pilot Trial Results. Presented at the course New Directions in Interventional Cardiology, September 8th, 1996, San Francisco, CA.

196. Direct PTCA in the Treatment of Myocardial Infarction. Lessons from the PAMI Trials, and Beyond. Presented at the course Strategies for Intervention in Complex Coronary Artery Disease: A "Real" World Approach. September 11th, 1996, Kansas City, MO.

197. Primary Stenting in Acute Myocardial Infarction. Presented at the PAMI Investigators' Meeting, September 17th, Dallas, TX.

198. Stents for Acute Myocardial Infarction. Presented at the course Coronary Interventions: 1996. The Scripps Clinic and Research Foundation, October 4th, 1996, San Diego, CA.

199. Treatment of Acute Myocardial Infarction: Is Thrombolytic Therapy Passé? Presented at the course Coronary Interventions: 1996. The Scripps Clinic and Research Foundation, October 4th, 1996, San Diego, CA.

200. Basic Principles of Intravascular Ultrasound and IVUS Guided Stenting. The Cordis/JJIS Palmaz-Schatz Stent Certification Course. San Diego, CA, October 6th, 1996.

201. Advanced Concepts in Intravascular Ultrasound Guided Stent Implantation. Presented at the course Coronary Interventions: 1996. The Scripps Clinic and

Research Foundation, October 6th, 1996, San Diego, CA.

202. Complex Coronary Stenting: Advanced Case Review. Presented at the course Coronary Interventions: 1996. The Scripps Clinic and Research Foundation, October 6th, 1996, San Diego, CA.

203. The Use of Glycoprotein IIb-IIIa Receptor Antagonists During Complex Coronary Intervention. Cardiology Grand Rounds. Queen of the Valley Hospital, Napa, CA, October 8th, 1996.

204. Primary Stenting in Acute Myocardial Infarction - the Next Breakthrough. Presented at the course "Advanced Cardiovascular Guidance" in Atlanta, Georgia, October 18th, 1996.

205. Primary PTCA in Acute Myocardial Infarction - Technique, Results of Studies, and How to Establish a Primary PTCA Program. Torrance Memorial Hospital, Torrance, CA, October 28th, 1996.

206. Improved Results of Balloon Angioplasty with Intravascular Ultrasound Guidance. Presented at the course Beyond Angiography IV. New Orleans, LA, October 9th, 1996.

207. Should the Risk of Delaying Reperfusion Prohibit Inter-Hospital Transfer to Perform Primary PTCA in Acute Myocardial Infarction? Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 12th, 1996.

208. A Prospective, Multicenter Trial of Primary Stenting in Acute Myocardial Infarction - The PAMI Stent Pilot Study. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 13th, 1996.

209. Primary Angioplasty Reduces Hospital Costs While Improving Outcomes in AMI - Comprehensive Cost Efficacy Analysis from the PAMI Study. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 12th, 1996.

210. A Prospective, Randomized, Multicenter Comparison of Laser Angioplasty Versus Balloon Angioplasty - The LAVA Trial. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 12th, 1996.

211. Correlation of Angiographic and Ultrasound Measures in Patients Undergoing Coronary Stenting Vs. Balloon Angioplasty. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 11th, 1996.

212. Incidence and Implications of Coronary Dissection after PTCA Using Oversized Balloons with Intravascular Ultrasound Guidance -The CLOUT Trial. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 11th, 1996.

213. Primary Angioplasty in Patients with Prior Bypass Surgery. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 11th, 1996.

214. The Central Unifying Concept of TIMI-3 Flow after Primary PTCA and Thrombolytic Therapy in Acute Myocardial Infarction. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 12th, 1996.

215. Defining the Relationship Between Stent Implantation Pressure and Optimal Expansion - Core Lab Analysis from the OSTI Trial. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 11th, 1996.

216. Clinical Trials with Intravascular Ultrasound Imaging. Presented at the course "Intravascular Ultrasound Applications - An Interactive Telemedicine Training Program " in Cincinnati, OH, November 18th, 1996.

217. Primary Stenting in Acute Myocardial Infarction. Presented at the course "Emerging Applications for Stents: A Thought Leader's Forum. New York City, NY, December 4th, 1996.

218. Subacute Thrombosis is No Longer a Problem (Debate). Presented at the Third Thoraxcenter Course on Coronary Stenting, Congress Center Erasmus University, Rotterdam, The Netherlands, December 12th, 1996.

219. The OSTI I and II Trials. Presented at the Third Thoraxcenter Course on Coronary Stenting, Congress Center Erasmus University, Rotterdam, The Netherlands, December 13th, 1996.

220. The PAMI Stent Pilot Trial. Presented at the Third Thoraxcenter Course on Coronary Stenting, Congress Center Erasmus University, Rotterdam, The Netherlands, December 13th, 1996.

221. Role of Glycoprotein IIb/IIIa Receptor Antagonists during PTCA. Presented at Medical Grand Rounds, Washington Hospital, Fremont, CA, January 17th, 1997.

222. Intravascular Ultrasound Guidance of Coronary Stenting: Case Demonstrations. Presented at the course Applied Intravascular Ultrasound for the Interventionalist, San Francisco, CA, January 23rd, 1997.

223. Treatment of Acute Myocardial Infarction: GUSTO vs. PAMI. Presented at the course Advanced Coronary Stenting: Fourteenth Annual International Symposium, in Miami Beach, FL, January 24th, 1997.

224. Primary Stenting in Acute Myocardial Infarction. Presented at the course Advanced Coronary Stenting: Fourteenth Annual International Symposium, in Miami Beach, FL, January 25th, 1997.

225. IVUS Study of Balloon Pressure and Stent Deployment: The OSTI Study. Presented at the course Advanced Coronary Stenting: Fourteenth Annual International Symposium, in Miami Beach, FL, January 25th, 1997.

226. The PAMI Trials. Presented at the Xth International Congress of Endovascular Interventions, Phoenix, AZ, February 10th, 1997.

227. Clinical Utility of IVUS and Review of Clinical IVUS Trials. Presented at the course "Intravascular Ultrasound Applications - An Interactive Telemedicine Training Program " in Cincinnati, OH, February 13th, 1997.

228. Stents as Primary Treatment for Acute Myocardial Infarction. Presented at the course "Seventh Annual Symposium on Coronary Stenting", San Diego, CA, March 12th, 1997.

229. Optimal intracoronary stent placement guided by intravascular ultrasound. Presented at the course "IVUS 1997", San Diego, CA, March 15th, 1997.

230. Stenting in Acute Myocardial Infarction. Presented at the course "Myocardial reperfusion X: Concepts and Controversies. Anaheim, CA, March 15th, 1997.

231. TIMI-3 flow or time to reperfusion - what's really important in reperfusion therapy of AMI? Presented at the course "Primary PTCA in the 90's - State of the Art and Future Breakthroughs". Anaheim, CA, March 17th, 1997.

232. Stenting in Acute Myocardial Infarction. Presented at the course "Primary PTCA in the 90's - State of the Art and Future Breakthroughs". Anaheim, CA, March 17th, 1997.

233. Clinical, Angiographic and Ultrasound Predictors of Stent Expansion After High Pressure Implantation. Presented at the 46th Annual Scientific Sessions off the American College of Cardiology, Anaheim, CA, March 18th, 1997.

234. The Optimal Stent Implantation Trial - Final Core Lab Angiographic and Ultrasound Analysis. Presented at the 46th Annual Scientific Sessions off the American College of Cardiology, Anaheim, CA, March 19th, 1997.

235. Safety and Feasibility of Primary Stenting in Acute Myocardial Infarction - In-hospital and 30 Day Results of the PAMI Stent Pilot Trial. Presented at the 46th Annual Scientific Sessions off the American College of Cardiology, Anaheim, CA, March 19th, 1997.

236. Use and usefulness of ReoPro in acute ischemic syndromes. Presented to the Department of Cardiology, Alta Bates Medical Center, Berkeley, CA, March 26th, 1997.

237. Course Director, The Third National Interventional Cardiology Fellow's Course, San Jose, CA, April 10th-12th, 1997.

238. Subacute Stent Thrombosis - Prediction and Prevention. Presented at the Third National Interventional Cardiology Fellow's Course, San Jose, CA, April 11th, 1997.

239. Advances in Primary PTCA - Cost-effectiveness, Early Discharge, and Primary Stenting. Presented at the Third National Interventional Cardiology Fellow's Course, San Jose, CA, April 12th, 1997.

240. Reperfusion Therapy in Acute Myocardial Infarction. Presented at the course "Madrid Interventional Cardiology (MIC) '97", Madrid, Spain, April 16th, 1997.

241. Results of the PAMI-III Stent Pilot Trial. Presented at the course "Madrid Interventional Cardiology (MIC) '97", Madrid, Spain, April 17th, 1997.

242. Treatment of the Thrombus Containing Lesion. Presented at the course "Madrid Interventional Cardiology (MIC) '97", Madrid, Spain, April 18th, 1997.

243. Primary Coronary Intervention in Acute Myocardial Infarction - The Preferred Approach. Presented at the course "Cardiology Fiesta in San Antonio", San Antonio, TX, April 24th, 1997.

244. Coronary Stents 1997. Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, April 30th, 1997.

245. Heparin Coated Stents - Promise or Reality. Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, April 30th, 1997.

246. Impact of IVUS in Coronary Artery Stenting. Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, April 30th, 1997.

247. Primary Angioplasty in Acute Myocardial Infarction - Optimal Reperfusion in 1997? Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, April 30th, 1997.

248. Primary Stenting in Acute Myocardial Infarction. Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, April 30th, 1997.

249. IVUS Contribution in Coronary Artery Disease and in Stent Implantation. Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, May 1st, 1997.

250. Direct PTCA, Stenting and IVUS in AMI. Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, May 1st, 1997.

251. Primary Angioplasty and Stenting in Acute Myocardial Infarction. Orange County Medical Association, Santa Ana, CA, May 13th, 1997.

252. Advances in Mechanical Reperfusion of Acute Myocardial Infarction - Primary Angioplasty and Primary Stenting. Keynote address at the 20th Annual Scientific Meeting for Coronary Thrombolysis, Tokyo, Japan, May 31st, 1997.

253. Clinical Utility of Intracoronary Ultrasound Imaging; Present Status and Future Forecast. Volpe, Welty and Brown. San Francisco, June 9th, 1997.

254. Angioplasty and New Devices in Acute Myocardial Infarction. Presented at the 4th Annual Mayo Clinic Interventional Cardiology Symposium. Rochester, Minnesota, June 12th, 1997.

255. Optimizing Coronary Intervention with Intracoronary Ultrasound. Presented at the 4th Annual Mayo Clinic Interventional Cardiology Symposium. Rochester, Minnesota, June 12th, 1997.

256. Current Status of the PAMI Trials. Presented at the Fifth Annual Inter-American Symposium on Contemporary Approaches to the Treatment of Cardiovascular Disease. Key Biscayne, FL, June 13th, 1997.

257. Stenting in Acute Myocardial Infarction. Presented at the Fifth Annual Inter-American Symposium on Contemporary Approaches to the Treatment of Cardiovascular Disease. Key Biscayne, FL, June 13th, 1997.

258. Use of IIb/IIIa Inhibitors in Acute Coronary Syndromes. Presented at the Fifth Annual Inter-American Symposium on Contemporary Approaches to the Treatment of Cardiovascular Disease. Key Biscayne, FL, June 13th, 1997.

259. U.S. Interventional Cardiology Opinion Leader's Meeting, Cordis/JJIS Corporations, West Palm Beach, FL, June 19th-20th, 1997.

260. Intracoronary Stenting in Acute Myocardial Infarction. Presented at the course "Intervention in Acute Coronary Syndromes", Allegheny General Hospital, Pittsburgh, PA, June 21st, 1997.

261. Guidant/ACS MultiLink Stent Training Course. Dallas, TX, June 30th, 1997.

262. Stenting and New Devices in Acute Myocardial Infarction. Americus Research Foundation keynote speaker, Charlotte, NC, July 1st, 1997.

263. Primary Angioplasty vs. Thrombolytic Therapy in Acute Myocardial Infarction. Cardiovascular Conference, Presbyterian Hospital, Charlotte, NC, July 2nd, 1997.

264. Stenting in Acute Myocardial Infarction - Update of the PAMI Stent Pilot Trial. Presented at the course "Cardiovascular Interventions: Technology at the Summit VII", Aspen, CO, July 24th, 1997.

265. Ultrasound Imaging in Coronary Stenting. Presented at the course "Cardiovascular Interventions: Technology at the Summit VII", Aspen, CO, July 24th, 1997.

266. The CADILLAC Trial - Update. U.S. Investigator's Meeting. San Francisco, CA, July 28th, 1997.

267. The CADILLAC Trial - Update. European Investigator's Meeting. Stockholm, Sweden, August 23rd, 1997.

268. The CADILLAC Trial - Update. U.S. Investigator's Meeting. Washington D.C., September 24th, 1997.

269. Stenting in Acute Myocardial Infarction. Presented at the course "Mechanical Reperfusion in Acute MI: New Approaches and Future Breakthroughs" at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 24th, 1997.

270. Acute MI Stenting: An Introduction to CADILLAC. Presented at the course "The Advanced MultiLink Intracoronary Stent: Harmonizing Design and Function" at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 25th, 1997.

271. Elective or Provisional Stenting for Acute Myocardial Infarction. Presented at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 28th, 1997.

272. Glycoprotein IIb/IIIa Receptors Antagonists. Presented at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 26th, 1997.

273. Acute Myocardial Infarction in Women - Balancing the Risks and Benefits of Treatment Alternatives. Presented at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 26th, 1997.

274. The CADILLAC Trial - Examining the Role of Glycoprotein IIb/IIIa Receptors Antagonists and New Devices in Acute Myocardial Infarction. Presented at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 26th, 1997.

275. IVUS Guidance of Coronary Stenting is a Must! (Debate). Presented at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 28th, 1997.

276. Optimizing the Results of Coronary Stenting. Presented at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 28th, 1997.

New concepts in in-stent restenosis. Guidant Radiation Therapy Advisory Board Meeting. Washington D.C., September 28th, 1997.

277. Clinical Utility of Intravascular Ultrasound - Review of Clinical Trials. Presented at the course "Intravascular Ultrasound Applications - An Interactive Telemedicine Training Program " in Cincinnati, OH, October 9th, 1997.

278. The Guidant/ACS Multi-Link Stent Training Course, Santa Clara, CA, October 10th, 1997.

279. Primary Stenting in Acute Myocardial Infarction. Presented at the symposium "Interventional Cardiology: Toward the 3rd Millennium", San Francisco, CA. October 15th, 1997.

280. Stents as Primary Therapy for Acute Myocardial Infarction: what's the data? Presented at the course "Coronary Interventions: 1997", San Diego, CA, October 16th, 1997.

281. New Concepts in Stent Delivery: Maximizing the MLD - Is it Balloon Pressure or Size? Presented at the course "Coronary Interventions: 1997", San Diego, CA, October 16th, 1997.

282. Practical Aspects of Direct Intervention in Acute Myocardial Infarction: Pharmaceutical Adjuncts, Tips, Tricks and Technical Pearls. Presented at the

course "Coronary Interventions: 1997", San Diego, CA, October 16th, 1997.

283. Revascularization Time in Unstable Angina. Presented at the XXIV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 19th, 1997.

284. Controversy: Acute Myocardial Infarction - Angioplasty or Thrombolytics? Presented at the XXIV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 19th, 1997.

285. Angioplasty in Unstable Angina. Presented at the XXIV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 19th, 1997.

286. Angioplasty in Acute Myocardial Infarction. Presented at the XXIV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 20th, 1997.

287. Post Infarction Strategies: The PAMI Trials. Presented at the XXIV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 20th, 1997.

288. Stents in Acute Myocardial Infarction. Presented at the XXIV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 20th, 1997.

289. Primary PTCA or Primary Stenting in AMI? Presented at the course "Acute Coronary Syndromes: New Drugs and Devices", Pasadena, CA, November 1, 1997.

290. Cardiogenic Shock: Can it be Treated? Presented at the course "Acute Coronary Syndromes: New Drugs and Devices", Pasadena, CA, November 1, 1997.

291. Beyond Primary PTCA: Stenting and Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction. Chicago, IL, November 6th, 1997.

292. Primary Mechanical Reperfusion in Acute Myocardial Infarction. Grand Rounds, Northwestern University Medical Center, Chicago, IL, November 7th, 1997.

293. Revascularization Strategies in Acute Myocardial Infarction. Presented at the course “Acute Management Strategies in Unstable Ischemic Syndromes”, November 8th, 1997.

294. Course Coordinator, “Establishing a High Quality Primary PTCA Program”. Presented at the 70th Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 10th, 1997.

295. Comparative Analysis of Primary PTCA vs. Thrombolytic Therapy. Presented as part of the course “Establishing a High Quality Primary PTCA Program” at the 70th Annual Scientific Sessions of the American Heart Association, Orlando, FL,

November 10th, 1997.

296. Glycoprotein IIb/III Blockade in Acute Myocardial Infarction: Urgent Reflow and its Preservation. Presented at the course “Advancing Treatment and Prevention of Acute Coronary Syndromes: From Parenteral to Oral Glycoprotein Blockade”, Orlando, FL, November 10th, 1997.

297. Maximizing outcomes of coronary stenting with focal balloon stent expansion: The OSTI Trials. Evening Seminar, Orlando, FL, November 11th, 1997.

298. Improved Procedural Results of Coronary Stenting with Focal Balloon “Overexpansion” - The OSTI-2A Trial. Presented at the 70th Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 11th, 1997.

299. Is Stenting the Treatment of Choice for Thrombus Containing Lesions? Core Lab Analysis from the PAMI Stent Pilot Trial. Presented at the 70th Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 11th, 1997.

300. Improved Short-term Outcomes of Primary Stenting Compared to Primary Angioplasty in Acute Myocardial Infarction - The PAMI Stent Pilot Trial. Presented at the 70th Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 12th, 1997.

301. The Role of Stenting and Adjunctive Pharmacotherapy in Acute Myocardial Infarction. DANAMI-2 meeting, Aarhus, Denmark, November 21st, 1997.

302. Primary Angioplasty is Superior to Thrombolytic Therapy in Acute Myocardial Infarction (debate - protagonist). Presented at the course "4th Annual Point/Counterpoint in Interventional Cardiology", December 5th, 1997, NYC, NY.

303. Stenting in AMI: The PAMI, GRAMI, PASTA. PRISM, FRESCO and CADILLAC trials. Presented at the Cardiovascular Summit and 4th Thoraxcenter Course on Cardiovascular Stenting, December 12th, 1997, Erasmus University, Rotterdam, The Netherlands.

304. Intravascular ultrasound applications during complex coronary stenting. The New Jersey Society of Interventional Cardiology, Newark, New Jersey, January 6th, 1998.

305. Beyond Primary PTCA: Stenting and Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction. Cardiology Grand Rounds, The New Jersey University Hospital/School of Medicine and Dentistry, Newark, New Jersey, January 7th, 1998.

306. Visiting Professor's Rounds. Case Presentations. The New Jersey University Hospital/School of Medicine and Dentistry, Newark, New Jersey, January 7th,

1998.

307. Primary Angioplasty vs. Thrombolytic Therapy for Acute Coronary Ischemia. Presented at the Tenth Anniversary International Symposium on Vascular Diagnosis and Intervention, Miami, FL, January 13th, 1998.

308. Reperfusion therapy in women. Presented at the course "Women's Health Issues after Coronary Interventions", Washington, DC, January 23rd, 1998.

309. Stenting in Acute Coronary Syndromes. Cordis/Johnson and Johnson U.S. Key Opinion Leader Board Meeting, Miami, FL, January 26th-28th, 1998.

310. Advances in the treatment of myocardial infarction. St. Bernadine's Medical Center, San Bernardino, CA, February 4th, 1998.

311. Beyond Primary PTCA: Stenting and Abciximab in Acute Myocardial Infarction. Presented at the 11th Annual International Congress of Endovascular Interventions, Phoenix, CA, February 11th, 1998.

312. IVUS guided complex coronary stenting: New concepts and advanced techniques. Presented at the First Annual International Tropical Retreat, Hawaii, February 24th, 1998.

313. Stenting in acute myocardial infarction. Presented at the First Annual International Tropical Retreat, Hawaii, February 27th, 1998.

314. Present status of coronary stenting and IIb/IIIa receptor blockade in acute myocardial infarction. Lilly Research Labs, Indianapolis, IN, March 3rd, 1998.

315. Clinical challenges in interventional cardiology. ACS Radiation Therapy Advisory Board Meeting, Washington D.C., March 8th, 1998.

316. Stenting in AMI - PAMI Stent and CADILLAC. Presented at the course "Myocardial Reperfusion XI: Concepts and Controversies". Atlanta, GA, March 28th, 1998.

317. Reperfusion Strategies in Acute Myocardial Infarction: Focus on Stenting. Presented at the course "A New Generation of Coronary Stenting: Technique, Pharmacology and Design". Atlanta, GA, March 29th, 1998.

318. Stenting in Acute Myocardial Infarction - Non-Heparin Coated. Presented at the course Primary PTCA the Next Generation: Stenting and IIb/IIIa Receptor Blockade in AMI. Atlanta, GA, March 31st, 1998.

319. In-hospital and late outcomes following primary stenting in acute myocardial infarction - comparison with primary PTCA. Presented at the 47th Annual

Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 31, 1998.

320. Primary stenting in acute myocardial infarction is associated with a low rate of late adverse events - The PAMI Stent Pilot. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 31, 1998.

321. Adverse outcomes prior to hospital discharge after primary stenting for acute myocardial infarction are often predictable, and related to correctable technical factors. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 31, 1998.

322. Incidence and predictors of 6 month angiographic restenosis and reocclusion after primary infarct stenting - core lab analysis from the PAMI Stent Pilot Study. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 31, 1998.

323. Incremental value of IVUS after coronary stenting when a "perfect" angiographic result is obtained. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 30, 1998.

324. Improved procedural results of coronary stenting with focal balloon “overexpansion” - final core lab analysis from the prospective, multicenter OSTI-2A trial. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 29, 1998.

325. Lack of relationship between the time to reperfusion and short-term mortality after primary infarct angioplasty. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 31, 1998.

326. Primary Angioplasty: Where, When and How. Fireside Panel Presentation at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 29, 1998.

327. U.S. Eclipse Percutaneous Transluminal Myocardial Revascularization Meeting. Atlanta, GA, April 1st, 1998.

328. Tips and Tricks in Ultrasound Guided Stenting. Presented at the course "IVUS, Flow and Pressure Applications in Interventional Cardiology: Case Review with the Experts". San Jose, CA, April 23rd, 1998.

329. Primary PTCA is Superior to Thrombolytic Therapy in Acute Myocardial Infarction - Case Closed. Presented at the Fourth National Interventional Cardiology Fellows Course, San Jose, CA, April 26th, 1998.

330. IIb/IIIa Receptor Blockade and Primary Stenting in Acute Myocardial Infarction . Presented at the Fourth National Interventional Cardiology Fellows Course, San Jose, CA, April 26th, 1998.

331. The PAMI Stent Randomized Trial - In-Hospital and 30 Day Results. Presented at the Eighth Annual Symposium on Coronary Stenting, San Diego, CA, May 7th, 1998.

332. Percutaneous Transluminal Myocardial Revascularization (PTMR): The Eclipse System and Studies. Presented at the Eighth Annual Symposium on Coronary Stenting, San Diego, CA, May 7th, 1998.

333. Real World Stenting - Comparative Studies and Complex Case Review. Presented at the course Complex Coronary and Vascular Interventions, San Francisco, CA, May 9th, 1998.

334. New approaches to heart disease. Guidant multi-disciplinary advisory board meeting. Indianapolis, IN, May 20th, 1998.

335. Interpreting the stent vs. stent randomized comparative trials. University of Texas Medical Center, Houston, TX, May 28th, 1998.

336. Percutaneous transluminal myocardial revascularization – The Eclipse system and studies. Presented at the course “Angiogenesis and Direct Myocardial Revascularization”, Chantilly, Virginia, June 3rd, 1998.

337. Mechanical Approach to the AMI Patient. Presented at the Seventh Annual Symposium on Advanced Cardiovascular Interventions. Hilton Head, SC, June 12th, 1998.

338. Advances in Intravascular Ultrasound Guidance of Coronary Intervention. Walnut Creek, CA, June 23rd, 1998.

339. The EPISTENT Study – Application to the treatment of acute ischemic syndromes. Presented at the course "Madrid Interventional Cardiology (MIC) '98", Madrid, Spain, July 8th, 1998.

340. The evolution of interventional treatment of the patient with acute myocardial infarction. Presented at the course "Madrid Interventional Cardiology (MIC) '98", Madrid, Spain, July 9th, 1998.

341. Percutaneous transluminal myocardial revascularization by laser – evidence and technique. Presented at the course "Madrid Interventional Cardiology (MIC) '98", Madrid, Spain, July 9th, 1998.

342. Stenting in Acute Myocardial Infarction – Is it Justified?. Presented at the course “Cardiovascular Interventions: Technology at the Summit, VIII”, Aspen, CO, July 24th, 1998.

343. Advanced Concepts and Techniques in Intravascular Ultrasound Guided Stenting. Presented at the course “Cardiovascular Interventions: Technology at the Summit, VIII”, Aspen, CO, July 24th, 1998.

344. Advanced Stent Workshop. Presented at the course “Cardiovascular Interventions: Technology at the Summit, VIII”, Aspen, CO, July 25th, 1998.

345. Primary PTCA vs. Thrombolytic Therapy in AMI: An Evidence Based Summary. National Acute Myocardial Infarction Advisory Board Meeting. Aspen, CO, July 25th, 1998.

346. Trials in intravascular ultrasound imaging. Endosonics Clinical Advisory Board Meeting, Chicago, IL, August 22nd, 1998.

347. Optimizing Outcomes after Coronary Stenting: Physics or Meta-Physics? Presented at the course "Coronary Interventions: 1998", San Diego, CA, September 5th, 1997.

348. PAMI, FRESCO, Zwolle, Stentim, GRAMI, PASTA, PRISAM and CADILLAC – Stenting in Acute Myocardial Infarction. Presented at the course "Coronary Interventions: 1998", San Diego, CA, September 6th, 1997.

349. TMR and PTMR – Clinical Update. Presented at the course "Coronary Interventions: 1998", San Diego, CA, September 7th, 1997.

350. Course Director, “Vascular Visions”, Cardiovascular Training and Education Center, Washington Hospital Center, September 15th-16th, 1998.

351. Interventional Trials in Acute Myocardial Infarction. Presented at the course “International Summit on Acute Coronary Care”, Portobuffole, Italy, September 18th, 1998.

352. Course Co-Director, Transcatheter Cardiovascular Therapeutics X, Washington DC, October 6th-11th, 1998.

353. PTCA in Acute Ischemic Syndromes. Presented during the Interventional Cardiology Self-Assessment and Review Course at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 6th, 1998.

354. Case Demonstrations – Unstable Ischemic Syndromes and Acute Myocardial Infarction. Presented during the “Interventional Cardiology Self-Assessment and Review Course” at Transcatheter Cardiovascular Therapeutics X, Washington

DC, October 6th, 1998.

355. Case Demonstrations – Pharmacologic Adjuncts During PTCA, Featuring the IIb/IIIa Inhibitors. Presented during the "Interventional Cardiology Self-Assessment Course" at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 7th, 1998.

356. Abstract Session Moderator, Transcatheter Cardiovascular Therapeutics X, Washington DC, October 7th, 1998.

357. Surgical and Catheter-based Laser Myocardial Revascularization – A Valuable Therapeutic Intervention. Point-Counterpoint Discussion. Presented during Transcatheter Cardiovascular Therapeutics X, Washington DC, October 7th, 1998.

358. Course Director, Comprehensive Management of the AMI Patient: From Reperfusion Therapy to Rhythm Stabilization. Washington DC, October 7th, 1998.

359. Integrating Pharmacotherapy with Mechanical Reperfusion in AMI. Presented during the course "Comprehensive Management of the AMI Patient: From Reperfusion Therapy to Rhythm Stabilization" at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 7th, 1998.

360. Impact of New Pharmacologic Agents in the Treatment of Acute Thrombotic Syndromes. Presented during the course "The Role of the Platelet in Acute Coronary Syndromes: A new Perspective for the 21st Century" at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 7th, 1998.

361. Clinical Trials for the Next Generation of Devices. FDA Town Hall Meeting, Event Moderator. Transcatheter Cardiovascular Therapeutics X, Washington DC, October 8th, 1998.

362. The Cardiovascular Dynamics Self Expanding Arterial Liner (SEAL) Stent. Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 8th, 1998.

363. Current standards and future trends in the management of acute myocardial infarction: Harmonizing interventional and pharmacological approaches. Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 8th, 1998.

364. Perspectives on Stents in Acute Myocardial Infarction: U.S. Trials (PAMI-Stent and CADILLAC). Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 9th, 1998.

365. Can the case be made for routine IVUS guidance? – Maximizing stent lumen dimensions with pressure and volume (OSTI-1 and OSTI-2 results). Presented at

Transcatheter Cardiovascular Therapeutics X, Washington DC, October 10th, 1998.

366. The Choice for women with acute myocardial infarction: Primary angioplasty is the way to go! (debate). Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 10th, 1998.

367. Summarizing the preliminary Clinical Trial data with the Eclipse Percutaneous Transmural Revascularization (PTMR) System. Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 10th, 1998.

368. Does the heparin-coated stent provide enhanced clinical utility? Insights from Benestent II, TOSCA and PAMI-Stent. Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 10th, 1998.

369. Choosing the right stent: Stents are more different than alike – design definitely counts! (Debate). Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 11th, 1998.

370. Lesion specific stenting: Acute myocardial infarction lesions. Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 11th, 1998.

371. Is IVUS guided stenting necessary, helpful or worthless? Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 11th, 1998.

372. The realities of provisional stenting: A strategy whose time has come and gone! (Debate). Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 11th, 1998.

373. IVUS guidance during stenting: optimizing acute and late results. Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 11th, 1998.

374. Stenting in Acute Myocardial Infarction. Presented at the 4th Complex Coronary Intervention Conference, Himeji City, Japan, October 22nd, 1998.

375. Live case demonstrations. Presented at the 4th Complex Coronary Intervention Conference, Himeji City, Japan, October 23rd, 1998.

376. Stent vs. stent comparisons – making sense of the randomized trials. Presented at the 4th Complex Coronary Intervention Conference, Himeji City, Japan, October 23rd, 1998.

377. The Next Frontier in Treating the Patient with Acute Myocardial Infarction: Stents and IIb/IIIa inhibitors. “Cardiology Grand Rounds – Fall 1998”, Allegheny General Hospital, October 29th, 1998.

378. Long-term results following “maximal stenting” using ultrasound guided balloon overexpansion - the Second Optimal Stent Implantation Study. Presented at the 71st Scientific Sessions of the American Heart Association, Dallas, TX, November 9th, 1998.

379. Angiographic luminal “gain” occurs within the first 6 months after stenting thrombotic lesions in patients with acute myocardial infarction - a unique phenomenon. Presented at the 71st Scientific Sessions of the American Heart Association, Dallas, TX, November 10th, 1998.

380. Percutaneous myocardial laser revascularization in patients with class III-IV angina and lesions at high risk for restenosis - results of a phase I study as a preamble to a large, randomized trial. Presented at the 71st Scientific Sessions of the American Heart Association, Dallas, TX, November 10th, 1998.

381. Does stent implantation in acute myocardial infarction degrade TIMI flow and result in higher early mortality than PTCA? - The PAMI Stent Randomized Trial. Presented at the 71st Scientific Sessions of the American Heart Association, Dallas, TX, November 9th, 1998.

382. Stenting of thrombotic lesions in acute myocardial infarction results in less late loss and greater freedom from restenosis than non-thrombotic lesions - core lab analysis from the PAMI Stent Pilot Trial. Presented at the 71st Scientific Sessions of the American Heart Association, Dallas, TX, November 9th, 1998.

383. The powerful interaction between age and gender in determining short-term mortality after mechanical reperfusion therapy in acute myocardial infarction. Insights from the PAMI Stent Randomized Trial. Presented at the 71st Scientific Sessions of the American Heart Association, Dallas, TX, November 9th, 1998.

384. By sealing dissection planes, primary stenting reduces ischemia driven target vessel revascularization at 30 days compared to primary PTCA - Analysis from the PAMI Stent Randomized Trial. Presented at the 71st Scientific Sessions of the American Heart Association, Dallas, TX, November 10th, 1998.

385. Novel IVUS Insights into Optimal Stenting techniques. Presented at the course Beyond Angiography V. Dallas, TX, November 7th, 1998.

386. Are IIB/IIIA Antagonists Required During Infarction Interventions? Not Yet Proven! Presented during the 14th International Workshop on Thrombolysis and Interventional Therapy. Dallas, TX, November 7th, 1998.

387. The role of IABP in AMI. Datascope Benchmark Registry Advisory Board Meeting. Dallas, TX, November 8th, 1998.

388. How To select the right devices for primary PTCA in acute myocardial infarction. Session Moderator. The 71st Scientific Sessions of the American Heart Association, Dallas, TX, November 9th, 1998.

389. Perspectives on IIB/IIIA Use in Acute Myocardial Infarction. Presented at the 71st Scientific Sessions of the American Heart Association, Dallas, TX, November 9th, 1998.

390. Primary angioplasty in acute myocardial infarction. Presented at the Cordis Interventional Course for Cardiology Fellows, Washington DC, December 3rd, 1998.

391. Adjunct therapy use in acute myocardial infarction. Presented at the Cordis Interventional Course for Cardiology Fellows, Washington DC, December 3rd, 1998.

392. Integrating Pharmacotherapy with Mechanical Reperfusion in Acute Myocardial Infarction. Presented at the annual meeting of the Washington State chapter of the ACC, Bellevue, WA, December 5th, 1998.

393. Subacute thrombosis – scope of the problem. Biocompatibles Ltd. Clinical Advisory Board meeting. Washington DC, December 6th, 1998.

394. New Vistas in Acute-Care Cardiovascular Therapeutics. Research Seminar. San Francisco, December 18th, 1998.

395. Expanded use of GP IIB/IIIA inhibitors during percutaneous interventions. Presented at the International Symposium on Endovascular Therapy (ISET), Miami Beach, January 22nd, 1999.

396. Value of intravascular ultrasound imaging during coronary stenting. Presented at the International Symposium on Endovascular Therapy (ISET), Miami Beach, January 22nd, 1999.

397. Understanding the U.S. multicenter stent trials. Are all stents equal? Presented at the International Symposium on Endovascular Therapy (ISET), Miami Beach, January 22nd, 1999.

398. Laser based myocardial revascularization and angiogenesis. Presented at the 22nd Annual Cardiovascular Symposium: New Horizons and Therapies. Fort Lauderdale, FL, February 4th, 1999.

399. Stenting in AMI – Review of Randomized Trials. Presented at the 22nd Annual Cardiovascular Symposium: New Horizons and Therapies. Fort Lauderdale, FL, February 4th, 1999.

400. Integrating Pharmacotherapy with Angioplasty in Acute Ischemic Syndromes. Presented at the 22nd Annual Cardiovascular Symposium: New Horizons and Therapies. Fort Lauderdale, FL, February 4th, 1999.

401. Stent design, form and function. Fort Lauderdale, FL, February 5th, 1999.

402. Advances in the Treatment of Acute Myocardial Infarction. Presented at "Case Reviews in Interventional Cardiology", Washington DC, February 10th, 1999.

403. Live case moderator at the course Cardiovascular Radiation Therapy III. Washington DC, February 18th and 19th, 1999.

404. Review of Available Investigational Radiation Systems at the course Cardiovascular Radiation Therapy III. Washington DC, February 19th 1999.

405. Treatment of Acute Myocardial Infarction. Presented at the Board Review Course Cardiovascular Interventions '99, Tampa Bay, FL, Feb. 27th, 1999.

406. The Role of Stents in Acute Myocardial Infarction. Presented at the 48th Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7th-10th, 1999.

407. Routine stent implantation reduces restenosis after primary angioplasty in acute myocardial infarction – results from the PAMI Stent Randomized Trial. Presented at the 48th Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7th-10th, 1999.

408. Predictors of six month event-free survival after mechanical reperfusion in acute myocardial infarction - the PAMI Stent Randomized Trial. Presented at the 48th Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7th-10th, 1999.

409. Differential effects of stenting and angioplasty in women versus men undergoing a primary mechanical reperfusion strategy in acute myocardial infarction - the PAMI Stent Randomized Trial. Presented at the 48th Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7th-10th, 1999.

410. Long-term influence of CPK-MB elevation on mortality after percutaneous intervention – analysis of 7359 patients. Presented at the 48th Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7th-10th, 1999.

411. What is the clinical significance of an elevated CPK-MB band fraction after percutaneous intervention if the total CPK is normal? Presented at the 48th Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7th-10th, 1999.

412. Outcomes of bail-out stenting after failed primary angioplasty in acute myocardial infarction – analysis from the PAMI Stent Randomized Trial. Presented at the 48th Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7th-10th, 1999.

413. 2.5 year follow-up of the CLOUT study – long-term implications for an aggressive IVUS guided balloon angioplasty strategy Presented at the 48th Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7th-10th, 1999.

414. Primary Stenting and Acute MI: PAMI Stent and CADILLAC. Presented at the symposium "Mission Possible: GP IIb/IIIa Inhibition for Acute Myocardial Infarction", New Orleans, March 6th, 1998.

415. Chronic total occlusions – the final frontier. The Intraluminal Therapeutics Advisory Board meeting. New Orleans, March 7th, 1999.

416. Is thrombectomy necessary in AMI intervention? The annual Endicor Advisory Board meeting. New Orleans, March 6th, 1999.

417. Selection of Stents for Complex Lesions – Case Examples. Presented at the 5th Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 7th, 1999.

418. Conservative and Invasive Strategies in Acute Coronary Syndromes – Integrating IIb/IIIa Receptor Blockade. Presented at the 5th Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 8th, 1999.

419. Stenting and IIb/IIIa Inhibitors in Acute Myocardial Infarction – randomized Trials and Personal Perspectives. Presented at the 5th Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 9th, 1999.

420. Percutaneous Transmyocardial Revascularization by Laser. Presented at the 5th Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 10th, 1999.

421. The Interventional Approach to MI – New Therapeutic Strategies. Presented at the course "Cardiology Fiesta in San Antonio: Update on Cardiac Diagnostic and Therapeutic Techniques", San Antonio, TX, April 15th, 1999.

422. Gamma Radiation: Review of Systems and Studies. Presented at the course "The Third Annual Frontiers in Interventional Cardiology: Device and

Pharmacology Synergy for the New Millennium", Houston, TX, April 15th, 1999.

423. Transmyocardial Laser Recanalization for Disabling Angina: Hope or Hype? Presented at the course "The Third Annual Frontiers in Interventional Cardiology: Device and Pharmacology Synergy for the New Millennium", Houston, TX, April 16th, 1999.

424. Direct PTCA – Not Lytics of IIb/IIIa antagonists is the simplest and best way to treat acute MI. Presented at the course "The Third Annual Frontiers in Interventional Cardiology: Device and Pharmacology Synergy for the new Millennium", Houston, TX, April 17th, 1999.

425. Debate: Primary PTCA in Acute MI is the Optimal reperfusion Strategy in Acute MI. Presented at the Inland Empire Heart Institute First Annual Cardiac Symposium, San Bernardino, CA, April 17th, 1999.

426. Understanding stent design: Analysis of the U.S. stent vs. stent comparative trials. Presented at the course "Advanced Coronary Stenting", Washington DC, April 26th, 1999.

427. Complex Coronary Stenting using Intravascular Ultrasound Guidance I. Presented at the course "Advanced Coronary Stenting", Washington DC, April 26th, 1999.

428. Complex Coronary Stenting with Intravascular Ultrasound Guidance II: Advanced case demonstrations. Presented at the course "Advanced Coronary Stenting", Washington DC, April 27th, 1999.

429. Approach to the thrombotic lesion and acute myocardial infarction. Presented at the course "Advanced Coronary Stenting", Washington DC, April 27th, 1999.

430. Antiplatelet and Antithrombotic Therapy: New Treatment Paradigms. Presented at the course "Interventional Cardiology for the Next Millennium", Washington DC, April 28th, 1999.

431. Pharmacologic and mechanical reperfusion in acute myocardial infarction. Presented at the course "Interventional Cardiology for the Next Millennium", Washington DC, April 28th, 1999.

432. Percutaneous laser myocardial revascularization – the non-guided approach. Presented at the course "Interventional Cardiology for the Next Millennium", Washington DC, April 29th, 1999.

433. Primary PTCA vs. Thrombolytic Therapy: Detailed Review of the Clinical Trials. Presented at the course "Primary PTCA: The Expert Approach", Washington DC,

May 5th, 1999.

434. Primary Stenting in AMI: Observations, Insights, and Randomized Trials. Presented at the course “Primary PTCA: The Expert Approach”, Washington DC, May 5th, 1999.

435. Use of IIb/IIIa Inhibitors During AMI Intervention. Presented at the course “Primary PTCA: The Expert Approach”, Washington DC, May 5th, 1999.

436. The Importance of Patency and Time to Patency in Reperfusion Therapy in AMI. Presented at the course “Primary PTCA: The Expert Approach”, Washington DC, May 6th, 1999.

437. Understanding the critical differences between contrast agents. Presented at the course “Primary PTCA: The Expert Approach”, Washington DC, May 6th, 1999.

438. A balanced view of IIb/IIIa inhibitor use. Centocor/Lilly Advisory Board Meeting. Atlanta, GA, May 10th, 1999.

439. Prevention of restenosis with intravascular ultrasound imaging. Presented at the course “Treatment of In-Stent Restenosis”, Washington DC, May 13th, 1999.

440. Management of diffuse disease with non-guided percutaneous transmyocardial laser revascularization. Presented at the course “Treatment of In-Stent Restenosis”, Washington DC, May 14th, 1999.

441. Mechanical reperfusion therapy and the role of adjunctive pharmacologic agents in acute myocardial infarction. Presented at the Endovascular Therapy Course (ETC) 1999, Paris, France, May 20th, 1999.

442. Controversy: Will the new drugs equalize outcomes between pharmacologic and mechanical reperfusion therapy in AMI? – *No!* Presented at the Endovascular Therapy Course (ETC) 1999, Paris, France, May 21st, 1999.

443. Review of Intravascular Ultrasound Trials. Presented at the course “Intravascular Ultrasound Imaging and Physiology Applications”, Washington DC, May 24th, 1999.

444. Application of Intravascular Ultrasound in Complex Stenting – Advanced Case Review. Presented at the course “Intravascular Ultrasound Imaging and Physiology Applications”, Washington DC, May 24th, 1999.

445. Small vessel stents for acute and threatened closure – insights from the U.S. Trial registry data. Presented at the course “The Small Vessel Summit”, Washington DC, May 26th, 1999.

446. Design and *In-Vitro* advantages of the heparin-coated stent. Presented at the course "The Small Vessel Summit", Washington DC, May 26th, 1999.

447. Heparin-coated stenting in AMI – the PAMI Trials. Presented at the course "The Small Vessel Summit", Washington DC, May 26th, 1999.

448. Controversies in the management of acute ischemic syndromes. Presented at Cardiology Grand Rounds, Monroe Medical Center, Delaware, June 1st, 1999.

449. Live case demonstration – Eclipse PTMR. Presented at the course "2nd Annual Angiogenesis and DMR Symposium", Washington DC, June 9th, 1999.

450. Can recently formed PTMR channels protect from acute or subacute ischemia? Results of a human pilot phase study. Presented at the course "2nd Annual Angiogenesis and DMR Symposium", Washington DC, June 10th, 1999.

451. CPK Elevations after Percutaneous Intervention – Innocent Bystander or Harbinger of Death? Presented at the course "Controversies in Interventional Cardiology" Washington DC, June 14th, 1999.

452. IIb/IIIa Antagonists should be used Routinely in all Percutaneous Interventions – Pro and Con. Presented at the course "Controversies in Interventional Cardiology" Washington DC, June 14th, 1999.

453. Laser Myocardial Revascularization for Refractory Ischemia – A Clinically Useful Tool, or all Hype and no Substance? Presented at the course "Controversies in Interventional Cardiology" Washington DC, June 15th, 1999.

454. Stenting in AMI: Final Results of Stent-PAMI and Update on CADILLAC. Presented at the course "Eighth Annual Advanced Cardiovascular Interventions Symposium", Hilton Head, South Carolina, June 17th, 1999.

455. Practical Procedural Approaches to PTMR. Presented at the course "Eighth Annual Advanced Cardiovascular Interventions Symposium", Hilton Head, South Carolina, June 18th, 1999.

456. Small vessel stents for acute and threatened closure – insights from the U.S. Trial registry data. Presented at the course "The Small Vessel Summit", Washington DC, June 16th, 1999.

457. Design and *In-Vitro* advantages of the heparin-coated stent. Presented at the course "The Small Vessel Summit", Washington DC, June 16th, 1999.

458. Clinical studies with the heparin-coated stent. Presented at the course "The Small Vessel Summit", Washington DC, June 16th, 1999.

459. Lessons from the PAMI Stent Trial. Presented at the 3rd Annual International Conference on Interventional Cardiology, Jerusalem, Israel, June 29th, 1999.

460. Interventional Cardiology Board Review Workshop. Presented at the course "Seventh Annual New Devices Seminar for the Cardiac and Peripheral Vascular Laboratories", Orlando, FL, July 3rd, 1999.

461. Radiation Vascular Therapy. Presented at the course "Seventh Annual New Devices Seminar for the Cardiac and Peripheral Vascular Laboratories", Orlando, FL, July 5th, 1999.

462. Anti-Platelet Therapy in Interventional Cardiology. Presented at the course "Seventh Annual New Devices Seminar for the Cardiac and Peripheral Vascular Laboratories", Orlando, FL, July 5th, 1999.

463. Anti-Platelet Therapy Workshop. Presented at the course "Seventh Annual New Devices Seminar for the Cardiac and Peripheral Vascular Laboratories", Orlando, FL, July 5th, 1999.

464. IIb/IIIa blockade in acute ischemic syndromes prior to (and during) cardiac catheterization – Evidence for routine use from PRISM, PRISM PLUS, PURSUIT, PARAGON and CAPTURE. Presented at the course "Acute Ischemic Syndromes: Pharmacologic and Mechanical Approaches", Washington DC, July 7th, 1999.

465. Invasive vs. Conservative Management of Acute Ischemic Syndromes – TIMI-3B, VANQUISH, FRISC-II. Presented at the course "Acute Ischemic Syndromes: Pharmacologic and Mechanical Approaches", Washington DC, July 8th, 1999.

466. PTCA and stenting in AMI: Harmonizing Pharmacologic and Mechanical Approaches. Presented at the course "Acute Ischemic Syndromes: Pharmacologic and Mechanical Approaches", Washington DC, July 8th, 1999.

467. CPK elevations after percutaneous intervention: Harmless bystander or harbinger of death? Presented at the course "Acute Ischemic Syndromes: Pharmacologic and Mechanical Approaches", Washington DC, July 8th, 1999.

468. New surgical and percutaneous strategies in patients with unapproachable refractory ischemic syndromes. Presented at Cardiology Grand Rounds, University of Colorado, July 12th, 1999.

469. Insights into stenting and pharmacotherapy in acute myocardial infarction. Presented at the Interventional Cardiology Research Conference, University of Colorado, July 12th, 1999.

470. Visiting Professorship, The University of Colorado, July 12th, 1999.

471. Direct Myocardial Revascularization for Patients with Non-Revascularizable Coronary Artery Disease. Presented at Cardiology Grand Rounds, The University of Colorado, July 12th, 1999.

472. New Insights into Stenting and IIb/IIIa Inhibitor Use in Acute Myocardial Infarction. Presented at the city-wide Denver Cardiovascular Research Conference, Denver, CO, July 12th, 1999.

473. Approach to the Patient with Acute Myocardial Infarction. Presented at the course "Interventional Cardiology for the Next Millennium", Washington DC, July 22nd, 1999.

474. IIb/IIIa Inhibitors Before, During and After Percutaneous Intervention. Presented at the course "Cardiovascular Interventions: Technology at the Summit, IX", Aspen, CO, July 29th, 1999.

475. Stenting in AMI – Insights from the PAMI Stent Trial. Presented at the course "Cardiovascular Interventions: Technology at the Summit, IX", Aspen, CO, July 29th, 1999.

476. Clinical significance of peri-procedural myocardial infarction. Presented at the course "Cardiovascular Interventions: Technology at the Summit, IX", Aspen, CO, July 29th, 1999.

477. IVUS Guided Maximal Stenting - The OSTI-2 Trial. Presented at the course "Cardiovascular Interventions: Technology at the Summit, IX", Aspen, CO, July 29th, 1999.

478. Stent Design Considerations II: Does Stent Design Matter? Results of the U.S. Stent vs. Stent Comparative Trials. Presented at the course "Advanced Coronary Stenting", Washington DC, August 2nd, 1999.

479. Complex Coronary Stenting with Intravascular Ultrasound Guidance II: Complex Case Review. Presented at the course "Advanced Coronary Stenting", Washington DC, August 2nd, 1999.

480. Approach to the thrombotic lesion and acute myocardial infarction. Presented at the course "Advanced Coronary Stenting", Washington DC, August 3rd, 1999.

481. Why thrombolytic therapy will never equal primary PTCA: The pathology and pathophysiology of acute myocardial infarction. Presented at the course "Primary PTCA – The Expert Approach", Washington DC, August 16th, 1999.

482. Primary PTCA vs. Thrombolytic Therapy: Detailed Review of the Clinical trials. Presented at the course "Primary PTCA – The Expert Approach", Washington

DC, August 16th, 1999.

483. Primary Stenting in AMI: Observations, Insights, and Randomized Trials. Presented at the course “Primary PTCA – The Expert Approach”, Washington DC, August 16th, 1999.

484. Use of IIb/IIIa inhibitors during AMI intervention. Presented at the course “Primary PTCA – The Expert Approach”, Washington DC, August 16th, 1999.

485. The importance of patency and time to patency. Presented at the course “Primary PTCA – The Expert Approach”, Washington DC, August 17th, 1999.

486. Challenges to the acceptance of IVUS guided imaging and physiologic lesion assessment. Endosonics Scientific Advisory Board Meeting, September 22nd 1999, Washington DC.

487. Routine vs. Provisional Stenting in Small Vessels: Pro and Con. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 26th, 1999, Washington DC.

488. Non-heparin-coated stenting and PTCA in AMI with and without IIb/IIIa inhibition. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 24th, 1999, Washington DC.

489. TCT Evolutionary Changes – Roadmap for the Future. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 23rd, 1999, Washington DC.

490. IVUS Guided maximal “overstenting” – Clinical and angiographic results of the OSTI-II trial. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 24th, 1999, Washington DC.

491. Tirofiban Use in Percutaneous Coronary Interventions: U.S. Pharmacodynamic Data. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 23rd, 1999, Washington DC.

492. The CADILLAC Trial. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 23rd, 1999, Washington DC.

493. Harmonizing Pharmacologic and Mechanical Reperfusion Strategies in AMI: CADILLAC I, CADILLAC II and PercuSurge AMI. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 22nd, 1999, Washington DC.

494. OSTI-1 and OSTI-2: “Stentus Maximus”. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999,

Washington DC.

495. Distal Protection During Angioplasty and Stenting in AMI. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.

496. New Therapeutic Approaches in Acute Myocardial Infarction: The Integration of Pharmacologic and Interventional Strategies. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 23rd, 1999, Washington DC.

497. Design and Rationale of the TARGET Trial. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.

498. The EndiCOR X-Sizer Thrombectomy/Atherectomy Device. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.

499. Interpreting CPK-MB and Troponin Elevations after Percutaneous Interventions – Can the Different Viewpoints be Reconciled? Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 23rd, 1999, Washington DC.

500. The Guidant FlexiCut – The Next Generation Directional Atherocath. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.

501. The X-Site Suture Based Vascular Closure Device. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.

502. Consequences of CPK-MB Elevations after Percutaneous Intervention: Important or Overblown? Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 22nd, 1999, Washington DC.

503. Hybrid Approaches: Laser Myocardial Revascularization as an Adjunct to Percutaneous Intervention. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.

504. The Embolic Protections (EPI) Distal Filter. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.

505. The Endosonics Integrated IVUS Brachytherapy System. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 26th,

1999, Washington DC.

506. Intraluminal Therapeutics – Spectroscopic Guidance for Chronic Total Occlusions. Presented at the 11th Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.

507. Improved outcomes of stenting and angioplasty with intravascular ultrasound. Presented at the 5th Complex Coronary Intervention Course (CCIC), October 8th, 1999, Shiga, Japan.

508. New approaches to acute myocardial infarction and cardiogenic shock. Presented at the 5th Complex Coronary Intervention Course (CCIC), October 8th, 1999, Shiga, Japan.

509. Intravascular ultrasound insights into vascular brachytherapy mechanisms and complications. Presented at the 5th Complex Coronary Intervention Course (CCIC), October 9th, 1999, Shiga, Japan.

510. Advances in stent design improve clinical results. Presented at the 5th Complex Coronary Intervention Course (CCIC), October 9th, 1999, Shiga, Japan.

511. Treatment of acute coronary syndromes, including AMI. Presenting at the 11th annual Cardiovascular Consultant's Course for the Practicing Physician, Boston University, Boston, MA, October 14th, 1999.

512. Update on Percutaneous Transluminal Myocardial Revascularization. Presented at the course Coronary Interventions: 1999. The Scripps Clinic and Research Foundation, October 15th, 1999, San Diego, CA.

513. Advances in the interventional treatment of acute myocardial infarction – harmonizing mechanical and pharmacological approaches. Presented at the course Coronary Interventions: 1999. The Scripps Clinic and Research Foundation, October 16th, 1999, San Diego, CA.

514. New drugs and devices for acute coronary syndromes. Presented at the course Coronary Interventions: 1999. The Scripps Clinic and Research Foundation, October 16th, 1999, San Diego, CA.

515. Stenting in Acute Myocardial Infarction. Presented at the course "Advanced Coronary Stenting", Washington DC, October 19th, 1999.

516. Adjunct pharmacologic interventions during coronary stenting. Presented at the course "Advanced Coronary Stenting", Washington DC, October 19th, 1999.

517. Primary PTCA vs. Thrombolytic Therapy – Is the debate over? Presented at the course “Controversies in Interventional Cardiology”, Washington DC, October 25th, 1999.

518. Laser myocardial revascularization is a clinically useful tool: Pro and Con. Presented at the course “Controversies in Interventional Cardiology”, Washington DC, October 25th, 1999.

519. Primary PTCA: The Expert Approach. Presented at the course “Harmonizing Pharmacologic and Mechanical Approaches in Acute Ischemic Syndromes”, Washington DC, December 8th, 1999.

520. A balanced view of the appropriate use (and abuse) of glycoprotein IIb/IIIa inhibitor therapy in the cath lab. Presented at the course “Harmonizing Pharmacologic and Mechanical Approaches in Acute Ischemic Syndromes”, Washington DC, December 8th, 1999.

521. Acute Infarct Angioplasty. The Cordis Opinion Leader’s Advisory Board Meeting. January 13th – 14th, 2000, Coral Gables, FL.

522. Reviewing the stent vs. stent U.S. clinical trials: Are there any real differences? Presented at ISET 2000, the 12th Annual International Symposium on Endovascular Therapy, January 23th, 2000, Miami Beach, Fl.

523. Debate: Provisional stenting – stent selectively or stent them all? Pro! Presented at ISET 2000, the 12th Annual International Symposium on Endovascular Therapy, January 23th, 2000, Miami Beach, Fl.

524. Controversy: Should IIb/IIIa antagonists be used in every coronary intervention? Presented at ISET 2000, the 12th Annual International Symposium on Endovascular Therapy, January 23th, 2000, Miami Beach, Fl.

525. Stent design and performance – from bench to bedside. University of Washington, St. Louis presentation, February 4th, 2000, St. Louis, MO.

526. Stent therapy for acute myocardial infarction. Presented at the 9th Annual Cardiovascular Conference at Beaver Creek, CO, February 9th, 2000.

527. Patient selection for multivessel stenting vs. coronary bypass. Presented at the 9th Annual Cardiovascular Conference at Beaver Creek, CO, February 9th, 2000.

528. Update: Principles and practice of coronary brachytherapy. Presented at the 9th Annual Cardiovascular Conference at Beaver Creek, CO, February 9th, 2000.

529. Controversial case presentations. Presented at the 9th Annual Cardiovascular Conference at Beaver Creek, CO, February 9th, 2000.

530. Radiocontrast nephropathy – scope of the problem. Neurox Pharmaceuticals/Abbott Advisory Board on contrast nephropathy. Palm Springs, CA, February 12th, 2000.

531. Datascope Benchmark Steering Committee meeting. Philadelphia, PA, March 4th, 2000.

532. Treatment of the lesions complicated by thrombus. Presented at the VIII Curso de Cardiologia Intervencionista, March 9th, 2000, Mexico City, Mexico.

533. Complex case demonstrations/moderation. Presented at the VIII Curso de Cardiologia Intervencionista, March 9th, 2000, Mexico City, Mexico.

534. Differences in Stent Design: Theoretical Considerations and Clinical Implications. March 11th, 2000, San Diego, CA.

535. Will the addition of GP IIb/IIIa inhibitors and thrombolytic therapy to primary PCI improve outcomes? Presented at the Acute Coronary Syndromes Town Hall Meeting: Applying Clinical Trials to Practice. March 11th, 2000, Anaheim, CA.

536. Are stents + GP IIb/IIIa inhibitors the new standard of care in patients with acute coronary syndromes? Presented at the Acute Coronary Syndromes Town Hall Meeting: Applying Clinical Trials to Practice. March 11th, 2000, Anaheim, CA.

537. Applications for distal protection. EPI Advisory Board Meeting. March 12th, 2000, Anaheim, CA.

538. Distal protection in AMI. PercuSurge Medical Advisory Board meeting. March 12th, 2000, Anaheim, CA.

539. Primary PTCA for acute myocardial infarction. Symposium presentation at the 49th Annual Scientific Sessions of the American College of Cardiology, March 13th, 2000, Anaheim, CA.

540. First United States experience with a novel atherectomy and thrombectomy device in thrombotic lesions in native coronary arteries and saphenous vein grafts. Presented at the 49th Annual Scientific Sessions of the American College of Cardiology, March 13th, 2000, Anaheim, CA.

541. A Prospective, Multicenter Trial of the Safety, Feasibility, and Efficacy of Ultrasound Guided “Maximal” Stenting to the Media-Adventitial Border - Final Late Clinical and Angiographic Results from the OSTI-2 Study. Presented at the 49th Annual Scientific Sessions of the American College of Cardiology, March 13th, 2000, Anaheim, CA.

542. Relative prognostic importance of preserved antegrade coronary blood flow before compared to after angioplasty in patients undergoing primary PTCA. Presented at the 49th Annual Scientific Sessions of the American College of Cardiology, March 15th, 2000, Anaheim, CA.

543. Restenosis after saphenous vein graft intervention. Radiance Medical Systems Scientific Advisory Board meeting. March 13th, 2000, Anaheim, CA.

544. Beyond TIMI-3 flow: The importance of restored myocardial perfusion for survival in high risk patients undergoing primary or rescue PTCA. Presented at the 49th Annual Scientific Sessions of the American College of Cardiology, March 15th, 2000, Anaheim, CA.

545. X-TRACT Update. EndiCOR Medical Scientific Advisory Board meeting. March 14th, 2000, Anaheim, CA.

546. Acute Myocardial Infarction Angioplasty: When, Where, Whom? Presented at the 49th Annual Scientific Sessions of the American College of Cardiology, March 15th, 2000, Anaheim, CA.

547. Recent and future advances in the treatment of ischemic heart disease. Presented at the Bracco Diagnostics Advisory Board Meeting, March 17th, 2000, New York City, NY.

548. Does stent design matter? Comparative analysis of the U.S. stent vs. stent trials. Presented at the 6th Annual North American Interventional Cardiology Fellows Course, San Jose, CA, March 29th, 2000.

549. Old and new paradigms in the treatment of acute myocardial infarction. Presented at the 6th Annual North American Interventional cardiology Fellows Course, San Jose, CA, March 30th, 2000.

550. Rational application of glycoprotein IIb/IIIa inhibitors – an evidence based approach. Presented at the 6th Annual North American Interventional cardiology Fellows Course, San Jose, CA, March 30th, 2000.

551. Intra-aortic balloon counterpulsation in acute myocardial infarction and cardiogenic shock. Presented at the 6th Annual North American Interventional cardiology Fellows Course, San Jose, CA, March 30th, 2000.

552. Harmonizing pharmacologic and mechanical reperfusion strategies in acute myocardial infarction. Presented at the 12th International Congress of Interventional Cardiology, Campos de Jordao, Brazil, April 7th, 2000.

553. Brachytherapy: Ready for routine use? Presented at the 12th International Congress of Interventional Cardiology, Campos de Jordao, Brazil, April 8th, 2000.

554. Intracoronary ultrasound use for borderline lesion assessment and stent guidance. Presented at the 12th International Congress of Interventional Cardiology, Campos de Jordao, Brazil, April 8th, 2000.

555. Recent advances in the diagnosis and treatment of acute myocardial infarction. Presented at the 10th Annual Andreas Gruentzig Emory Practical Interventional Cardiology Course, Atlanta, GA, April 15th, 2000.

556. Direct Intervention for AMI – What's new? Presented at the course "Preceptorship in Coronary Artery Disease Management", New York City, NY, April 17th, 2000.

557. History of mechanical reperfusion therapy in acute myocardial infarction. Presented at the 20th Anniversary of the Mid America Heart Institute, Cardiovascular Care for a New Age, April 19th, 2000.

558. Debate: PTCA vs. CABG in Diabetics with Multivessel Coronary Artery Disease – Angioplasty is the way to go! Presented at the 4th Annual Frontiers in Interventional cardiology Course, Houston, TX, April 29th, 2000.

559. Clinical Implications of the ESPRIT Trial. Presented at the Merck Interventional Cardiology Consultants Meeting, Los Angeles, CA, April 30th, 2000.

560. Stent Deployment Strategies. Presented at the 23rd Annual Scientific Sessions of the Society for Cardiac Angiography and Interventions, Charleston, SC, May 5th, 2000.

561. Pitfalls of Radiation Therapy I: late Stent Thrombosis. Presented at the Radiation Readiness Seminar, New York City, NY, May 12th, 2000.

562. Percutaneous Interventions in Thrombus Rich lesions. Presented at the Paris Course on Revascularization, Paris, France, May 25th, 2000.

563. Primary PTCA in AMI – The real World. Presented at the Paris Course on Revascularization, Paris, France, May 26th, 2000.

564. Debate: Aggressive vs. Conservative management of Acute ischemic Syndromes: The Aggressive Approach. Presented at the course "Athens 2000", Athens, Greece, May 27th, 2000.

565. Adjunctive Pharmacologic Therapy during Stent Implantation. Presented at the course "Athens 2000", Athens, Greece, May 27th, 2000.

566. Pharmacologic and Interventional Reperfusion Strategies in Acute myocardial Infarction. Presented at the course “Athens 2000”, Athens, Greece, May 27th, 2000.

567. Primary Mechanical reperfusion Therapy in AMI. Presented at the course “Athens 2000”, Athens, Greece, May 28th, 2000.

568. Distal protection and stent grafts to reduce distal embolization and restenosis in saphenous vein grafts. Presented at the 6th Biennial Meeting of the International Andreas Gruentzig Society, Crete, Greece, May 30th, 2000.

569. New Directions for AMI therapy. Presented at St. Mary’s Hospital, Novi, MI, June 3rd, 2000.

570. Current Concepts and Future Directions in AMI therapy. Cardiology Grand Rounds, St. Joseph’s Hospital, Syracuse, NY, June 7th, 2000.

571. The Case for Tirofiban: Update on the Target Trial. Presented at the 9th Annual Advanced cardiovascular Interventions Symposium, Hilton Head, SC, June 14th, 2000.

572. PTMR techniques: Equipment, Guidance and Mapping. Presented at the 9th Annual Advanced cardiovascular Interventions Symposium, Hilton Head, SC, June 14th, 2000.

573. Microvascular preservation and distal protection. Presented at the 3rd Live Symposium of Complex Coronary Cases. Mt. Sinai Hospital, New York City, NY, June 16th, 2000.

574. IVUS in PTCA and Stenting. Presented at the 3rd Live Symposium of Complex Coronary Cases. Mt. Sinai Hospital, New York City, NY, June 17th, 2000.

575. The Role of GP IIb/IIIa Inhibitors in Acute Coronary Syndromes: Trial Update, and combination with LMWH. Puerto Rico, June 18th, 2000.

576. Vascular Brachytherapy: Restenosis Cured? Presented at the 13th Asian Congress of Cardiology Meeting, Singapore, June 23rd, 2000.

577. Debate: Primary Angioplasty or Thrombolytic Therapy for AMI? Presented at the 13th Asian Congress of Cardiology Meeting, Singapore, June 23rd, 2000.

578. Current Status and Future Directions in Stent Design. Presented at the 13th Asian Congress of Cardiology Meeting, Singapore, June 23rd, 2000.

579. Current and Future Strategies for Treatment of Acute Myocardial Infarction. Presented at the 13th Asian Congress of Cardiology Meeting, Singapore, June 24th, 2000.

580. An overview of the thrombotic syndromes: variations in management. Presented at 8th Annual New Devices Seminar for the Cardiac and Peripheral Laboratories, Orlando, FL, June 30th, 2000.

581. Strategies for medical or mechanical management of AMI. Presented at 8th Annual New Devices Seminar for the Cardiac and Peripheral Laboratories, Orlando, FL, June 30th, 2000.

582. Aggressive Treatment of Acute Coronary Syndromes. Denver CO, July 25th, 2000.

583. Stenting, IIb/IIIa Inhibitors and Distal protection in AMI. Presented at Cardiology Grand Rounds, The University of Colorado Health Sciences Center, Denver CO, July 26th, 2000.

584. Radiation Pitfalls: Late Stent Thrombosis. Presented at the Radiation Readiness Seminar, Lenox Hill Hospital, New York City, NY, July 27th, 2000.

585. Transport for Primary PTCA in AMI: The American Experience. Presented at the XXIIth Congress of the European Society of Cardiology, Amsterdam, the Netherlands, August 28th, 2000.

586. Revascularization options in patients with multivessel coronary artery disease. Presented at the course “New Frontiers in Treatment of Coronary heart Disease”, Atlanta, GA. September 6th, 2000.

587. Cutting through the hype: How to choose and selectively apply glycoprotein IIb/IIIa inhibitors. Presented at the course “Advanced Coronary Stenting”, New York, City, NY, September 7th, 2000.

588. Approach to the thrombotic lesion and acute myocardial infarction. Presented at the course “Advanced Coronary Stenting”, New York, City, NY, September 7th, 2000.

589. Improving outcomes through IVUS and Physiologic lesion Assessment. Presented at the course “Advanced Coronary Stenting”, New York, City, NY, September 8th, 2000.

590. Keynote address: The application of brachytherapy to ischemic coronary artery disease. Presented at the 5th Annual Vanderbilt University course “Interventional Approaches for a New Age”, Nashville, TN, September 15th, 2000.

591. Evolving Concepts in the Understanding of Glycoprotein IIb/IIIa Inhibitors. Presented at Cardiology Grand Rounds, St. Francis Hospital, Roslyn, NY, September 19th, 2000.

592. The CADILAC Trial – First Presentation of 6 Month Results. Closed Research Update. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 17th, 2000.

593. Overview of Acute Coronary Syndromes: Therapeutic Strategies. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 17th, 2000.

594. Primary PTCA in AMI: Current Concepts and Standards. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 17th, 2000.

595. Benefits of IIb/IIIa Inhibitors in AMI: Insights from CADILAC. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 18th, 2000.

596. The CADILLAC Trial – 30 Day Results. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 18th, 2000.

597. Proving Facilitated Primary PTCA – Introduction to the CADILLAC-II Trial. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 18th, 2000.

598. TCT 2001 Opening Address – Interventional Therapy Beyond the Millennium. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 19th, 2000.

599. Late Breaking Trial: CADILLAC 6 Month Results – Controlled Abciximab and Device Evaluation to Lower Late Angioplasty Complications. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 19th, 2000.

600. A Prospective, Randomized Placebo-Controlled Trial of Fenoldopam to Prevent Contrast Nephropathy in Patients Undergoing Percutaneous Intervention – The CONTRAST Trial. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 19th, 2000.

601. Beyond TIMI-3 Flow: Protected Stent Intervention in AMI. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 19th, 2000.

603. Harmonizing Pharmacologic and Mechanical Treatment Strategies in Acute Myocardial Infarction. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 20th, 2000.

604. Saphenous Vein Graft Intervention: The Need for Distal Protection. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 20th, 2000.

606. Chronic Total Occlusions: The Last Refuge of the Cardiac Surgeon. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 20th, 2000.

607. Debate: High vs. Low Pressure Stenting - Higher Means Bigger, and Bigger is Better. Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 21st, 2000.

610. Debate: PTCA vs. Stenting for Small Vessels - Stent Routinely! Presented at the 12th Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 21st, 2000.

612. Primary Angioplasty vs. Stenting for Treatment of AMI. Cardiology Grand Rounds. Montefiore Medical Center and the Albert Einstein College of Medicine. Bronx, New York, October 31, 2000.

613. Stenting and Platelet Glycoprotein IIb/IIIA Receptor Blockade in AMI: The CADILLAC Trial. Presented at the 16th International Symposium on Thrombolysis and Interventional Therapy in AMI. New Orleans, LA, November 11, 2000.

614. Stents and GP IIb/IIIa Inhibitors in AMI: From CADILLAC I to CADILLAC II. Presented at the symposium Defining New Guidelines and Studies in ACS. November 11, 2000.

615. Interventional Cardiology “From Bench to Bedside and Beyond” Case Demonstrations. Presented at the 73rd Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 12, 2000.

616. Optimizing Primary PTCA in AMI. Presented at the 73rd Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 13, 2000.

617. Impact of Race on Clinical Outcome after Percutaneous Coronary Interventions: Results in 6945 patients. Presented at the 73rd Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 13, 2000.

618. A Prospective, Randomized, Multicenter Trial of Percutaneous Transmyocardial Laser Revascularization in Patients with Non-recanalizable Chronic Total

Occlusions. Presented at the 73rd Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 14, 2000.

619. A Prospective Randomized Trial Comparing Primary Balloon Angioplasty With or Without Abciximab To Primary Stenting With or Without Abciximab In Acute Myocardial Infarction – Primary Endpoint Analysis from the CADILLAC Trial. Presented at the 73rd Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 14, 2000.

620. Stenting in Acute Coronary Syndromes. Session Moderator. The 73rd Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 15, 2000.

621. The TARGET Trial – Late Breaking Results. Interventional Research Update – Glycoprotein IIb/IIIa Inhibitors in PCI and ACS. New Orleans LA, November 15th, 2000.

622. GP IIb/IIIa appropriate use from the ED to the CCL. Grand Rounds, Beth Israel Medical Center, New York, New York. November 20th, 2000.

623. The TARGET Trial – Implications for Patient Care. Sentara Hospital Cardiology Grand Rounds. Norfolk, Virginia, November 29, 2000.

624. Management of In-stent Restenosis. Cardiology Grand Rounds. Norfolk, Virginia, November 29, 2000.

625. TARGET Design and Rationale. Presented at the Merck TARGET and TACTICS Consultants Meeting, Orlando Florida, December 2, 2000.

626. Debate: Management of Multivessel CAD in Diabetics - An Aggressive Interventional Approach. Presented during the course Point-Counterpoint, New York, New York, December 10, 2000.

627. Radiation Pitfalls: Late Stent Thrombosis. Presented during the Radiation Readiness Seminar, New York, NY, December 12, 2000.

628. Primary PTCA in AMI: New Concepts and Future Directions. Grand Rounds, Vassar Hospital, Poughkeepsie, NY, December 18, 2000.

629. Incorporating IIb/IIIa Inhibitors and Revascularization Strategies in an Integrated Patient Care Program. Merck Consultants Meeting, New York, NY, December 20, 2000.

630. Complex Case Presentations. North General Hospital Cardiac Cath Conference, NYC, NY, January 4, 2001.

631. Live case demonstrations. The 10th Singapore Live Interventions in Vascular Endotherapy Course, Singapore, January 16, 2001.

632. State of the Art in Coronary Interventions in Acute Coronary Syndromes. Presented at The 10th Singapore Live Interventions in Vascular Endotherapy Course, Singapore, January 16, 2001.

633. New Milestones with GP IIb/IIIa Inhibition in Acute Coronary Syndromes. Presented at The 10th Singapore Live Interventions in Vascular Endotherapy Course, Singapore, January 17, 2001.

634. Integrating Pharmacologic and Mechanical Approaches into a Rational Strategy for Patients with Acute Coronary Syndromes. Cardiology Grand Rounds, Deborah Heart and Lung Center, Browns Mills, NJ, January 25th, 2001.

635. Transport Strategies for Patients with Acute Myocardial Infarction. Warren, New Jersey, January 26th, 2001.

636. Special Lecture: Overview of the PAMI and CADILLAC Trials. Presented at The Tenth Annual Cardiovascular Conference at Beaver Creek, Colorado, February 14, 2001.

637. Distal Protection Devices for Coronary Intervention. Presented at The Tenth Annual Cardiovascular Conference at Beaver Creek, Colorado, February 15, 2001.

638. Acute Coronary Syndromes: GP IIb/IIIa Inhibitors and Low Molecular Weight Heparins. Presented at Cardiology Grand Rounds, Morristown Memorial Hospital, Morristown NJ, March 9, 2001.

639. A Unifying Approach to IIb/IIIa Inhibitor Use in ACS and PCI. Presented at the symposium “ACS and AMI – Pharmacologic and Interventional Synergies”, Orlando, Florida, March 16, 2001.

640. IIb/IIIa Inhibitors in Primary PTCA and stenting – RAPPORT and CADILLAC. Presented at the symposium “ACS and AMI – Pharmacologic and Interventional Synergies”, Orlando, Florida, March 16, 2001.

641. Primary Angioplasty in AMI: Stent vs. No Stent. Presented in the symposium “Decision Making During Percutaneous Coronary Interventions” at the 50th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 18th, 2001.

642. New Coronary Devices: Thrombus Removal. Presented at the 50th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 18th, 2001.

643. A Prospective, Multicenter, International Randomized Trial Comparing Four Reperfusion Strategies in Acute Myocardial Infarction: Principal Report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC). Presented at the 50th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 19th, 2001.

644. Rationale Application of IIb/IIIa Inhibitors: When to Use and When Not to Use. Presented at the 50th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 20th, 2001.

645. Harmonizing Pharmacologic and Mechanical Reperfusion Strategies in Acute Myocardial Infarction. Cardiology Grand Rounds, Lankenau Hospital, Wynnewood, PA, March 28, 2001.

646. Harmonizing Pharmacologic and Mechanical Reperfusion Strategies in Acute Myocardial Infarction. Cardiology Grand Rounds, Bryn Mawr Hospital, PA, March 28, 2001.

647. New Strategies in Acute Coronary Syndromes – TARGET and TACTICS. Dayton, Ohio, March 29th, 2001.

648. A Unifying Approach to IIb/IIIa Inhibitor Use in ACS and PCI. Cardiology Grand Rounds. University of Cincinnati Hospital, Cincinnati Ohio, March 30th, 2001.

649. Rational Application of IIb/IIIa Agents: An Evidence Based Approach. Presented at the 7th North American Interventional Cardiology Fellow's Course, San Jose, CA, April 6th, 2001.

650. New Strategies in AMI: Thrombectomy, Distal Protection, Facilitated Angioplasty and More. Presented at the 7th North American Interventional Cardiology Fellow's Course, San Jose, CA, April 7th, 2001.

651. Contemporary Management of Acute Myocardial Infarction. Presented at Cardiology Grand Rounds, Case Western Reserve University Hospital, Cleveland, Ohio, April 24, 2001.

652. Controversies in the Treatment of Patients with Acute Coronary Syndromes. Presented at the Cardiac Catheterization Conference, Case Western Reserve University Hospital, Cleveland, Ohio, April 24, 2001.

653. Acute Coronary Syndromes – Update. Trenton , New Jersey, May 3, 2001.

654. The NICE Trials – Enoxaparin with and without GP IIb/IIIa inhibitors. Pharmacia Advisory Board Meeting. Chicago, IL, May 8, 2001

655. The role of GP IIb/IIIa Inhibitors in Acute Coronary Syndromes. Westport, CT, May 10, 2001

656. Opening Plenary Keynote Address: Interventional Cardiology 2000 – The Year in Review. Presented at the 24th Annual Scientific Sessions of the Society of Cardiac Angiography and Interventions, Houston, Texas, May 17th, 2001.

657. Controversies in Direct Myocardial Revascularization and Angiogenesis: Implications of the DIRECT Trial. Presented at the 24th Annual Scientific Sessions of the Society of Cardiac Angiography and Interventions, Houston, Texas, May 17th, 2001.

658. Opening Plenary Address: Acute MI - From Clinical Trials to Clinical Practice. Presented at the Euro-PCR 2001 Course, Paris, France, May 22nd, 2001.

659. Evidence Based Medicine – Approach to the Patient with Unstable Angina. Presented at the Euro-PCR 2001 Course, Paris, France, May 23rd, 2001.

660. Thrombus Removal Devices: Past, Present and Future. Presented at the Euro-PCR 2001 Course, Paris, France, May 23rd, 2001.

661. Applying Evidence Based Medicine to the Management of Acute Coronary Syndromes – What we have learned from clinical studies with GP IIb/IIIa antagonists? Presented at the course "New Paradigms in the treatment of ACS". Held during the Euro-PCR 2001 Course, Paris, France, May 23rd, 2001.

662. A Taste of TCT at Euro-PCR: Pharmacologic and Interventional Strategies in AMI. Presented at the Euro-PCR 2001 Course, Paris, France, May 24th, 2001.

664. Assessment of Reperfusion: Salvaging the Myocardium. Presented at the Euro-PCR 2001 Course, Paris, France, May 25th, 2001.

665. Management of Clot Burden - Adjunctive use of IIb/IIIa agents. Presented at the course AET/All That Jazz, New York, NY, June 6, 2001.

666. GP IIb/IIIa therapy in Acute Coronary Syndromes – when is it appropriate? New York City, NY, June 7, 2001

667. TARGET Trial 6 month data – What It Means. Presented at the Merck Regional Consultants Meeting. Chicago, IL, June 9, 2001.

668. Acute Coronary Syndromes. St. Luke's Hospital, Grand Rounds, St. Louis, Missouri, June 13, 2001.

669. Optimal management of acute coronary syndromes - integrating GP IIb/IIIa trials. Cardiology grand rounds. Barnes Jewish Hospital/Washington University. St. Louis, Missouri, June 13, 2001.

670. Acute Coronary Syndromes – The Aggressive Approach (Debate). Presented at the course "A Live Symposium of Complex Cases", Mt. Sinai Medical Center, New York, NY, June 15, 2001.

671. TARGET & TACTICS – What they mean for the practicing interventional cardiologist. Ft. Lauderdale , FL, June 26, 2001

672. Cardiology cath lab conference - Interactive case review session. Memorial Regional Hospital, Hollywood, FL, June 26, 2001

673. TARGET & TACTIS. Implications for Safe and Effective Drug Use. Cardiology Grand Rounds, Sarasota Memorial Hospital, Sarasota, FL, June 26, 2001

674. Acute MI: Stenting with Thrombolysis: GP IIb/IIIa's or distal protection. Presented at the New Devices Seminar – UPMC, Orlando, FL, June 30, 2001.

675. The new antithrombotics and GP IIb/IIIa's – what the interventionalist needs to know. Presented at the New Devices Seminar – UPMC, Orlando, FL, July 3, 2001.

676. The TAXUS Trials: Rationale, Experimental Design and Enrollment Status. Presented at TCT 2001, the 13th Annual Scientific Sessions, Washington DC, September 11th, 2001.

677. Primary Angioplasty in AMI – State-of-the-Art Comparison with Thrombolytic Therapy. Presented at TCT 2001, the 13th Annual Scientific Sessions, Washington DC, September 11th, 2001.

678. Algorithms for Management of Patients with Acute Coronary Syndromes, and in those Undergoing PCI: Implications of the TARGET Trial. Presented at TCT 2001, the 13th Annual Scientific Sessions, Washington DC, September 11th, 2001.

679. The TARGET Trial – 6 Month Results. Presented at TCT 2001, the 13th Annual Scientific Sessions, Washington DC, September 12th, 2001.

680. TAXUS I-IV: Local drug delivery with a taxol coated stent. Presented at TCT 2001, the 13th Annual Scientific Sessions, Washington DC, September 12th, 2001.

681. The TAXUS Trials: Methodology, Stent and Polymer Design, and Trial Overview. Webcast on TCTMD.com, September 24th, 2001.

682. Use of Low Molecular Weight Heparins in patients with acute coronary syndromes – transitioning to the cath lab. Aventis Regional Consultant's Meeting. Las Vegas, NV, October 21st, 2001.

683. Pharmacologic and interventional strategies for acute coronary syndromes. Presented at Coronary Interventions: 2001. The Scripps Clinic and Research Foundation, October 17th, 2001, San Diego, CA.

684. Intervention in acute myocardial infarction – what every interventionalist needs to know. Presented at Coronary Interventions: 2001. The Scripps Clinic and Research Foundation, October 17th, 2001, San Diego, CA.

685. Johnson and Johnson – Role in Interventional Cardiology. Panel presenter at the Phoenix Medical Devices CEO Conference, Phoenix, AZ, October 26th, 2001.

686. Current treatment strategies in AMI. Keynote speaker. Presented at the 3rd Annual Update in Cardiovascular Diseases course, St. Joseph's Hospital, Phoenix, AZ, October 27th, 2001.

687. Distal Protection Strategies in AMI – Beyond Stents and Drugs. Presented at the 17th Annual Symposium on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction, Anaheim, CA, Nov. 10th, 2001.

688. What constitutes optimal mechanical reperfusion therapy in AMI? Presented at the course "Interventional Cardiology – Bench to Bedside and Beyond" at the 74th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 11th, 2001.

689. How To Manage Acute ST-Elevation MI. Presented at the course "Interventional Cardiology – Bench to Bedside and Beyond" at the 74th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 11th, 2001.

690. What is Vulnerable Plaque, and What Determines Treatment Success? Presented at the Vulnerable Plaque Symposium at the 74th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 12th, 2001.

691. Safety and Efficacy of Distal Protection During Saphenous Vein Graft Intervention with the EPI FilterWire EX™ - First Report from the U.S. Phase I Feasibility Study. Presented at the 74th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 13th, 2001.

692. How To Reconcile Exercise Test Results with IVUS and Doppler. Presented at the 74th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 14th, 2001.

693. Abciximab vs. Tirofiban in Patients Undergoing PCI – Interpreting TARGET. Presented at the Merck Regional Consultants Meeting. New York City, NY, November 17th, 2001.

694. Current concepts and future approaches in AMI intervention. Presented at the XIth Annual Meeting of the Interventional Cardiology Society of Mexico, Cozumel, Mexico, November 23rd, 2001.

695. An overview of drug eluting stents. Presented at the XIth Annual Meeting of the Interventional Cardiology Society of Mexico, Cozumel, Mexico, November 24th, 2001.

696. Harmonizing Pharmacological and Mechanical Strategies in AMI. Cardiology Grand Rounds, University of Virginia, Charlottesville, VA, January 15, 2002.

697. The Guidant Galileo Vascular Brachytherapy system. Regional training. New York, NY, January 30, 2002.

698. Interventional Problems: A lesion specific approach. Presented at the 2nd Joint Interventional Meeting (JIM), Rome, Italy, February 6th, 2002.

699. Combination pharmacologic reperfusion regimens, alone and prior to PTCA. Presented at the 2nd Joint Interventional Meeting (JIM), Rome, Italy, February 6th, 2002.

700. The TAXUS I-VII trials. Presented at the 2nd Joint Interventional Meeting (JIM), Rome, Italy, February 6th, 2002.

701. Protection from distal embolization during AMI intervention: the Emerald Trial. Presented at the 2nd Joint Interventional Meeting (JIM), Rome, Italy, February 7th, 2002.

702. Overview of TAXUS Trials and Results. Presented at the 2nd Joint Interventional Meeting (JIM), Rome, Italy, February 7th, 2002.

703. Overview of AMI Intervention and the CADILLAC Trial. Presented at the 2nd Joint Interventional Meeting (JIM), Rome, Italy, February 7th, 2002.

704. Update: Interventional Therapy for AMI. Eleventh Annual Cardiovascular Conference at Beaver Creek, Beaver Creek, CO, February 13, 2002.

705. Taxol Drug-eluting stents. Eleventh Annual Cardiovascular Conference at Beaver Creek, Beaver Creek, CO, February 13, 2002.

706. The Great cases at TCT. Eleventh Annual Cardiovascular Conference at Beaver Creek, Beaver Creek, CO, February 14th, 2002

707. Drug Eluting Stents in Perspective. Who needs bypass surgery today? In 2 years? Presented at the symposium “Enter the Drug-Eluting Stent Revolution – A Critical Appraisal”, Atlanta, GA, March 16th, 2002.

708. Results and Trials with a Polymer-based Paclitaxel Delivery System – TAXUS I-VII. Presented at the symposium “Enter the Drug-Eluting Stent Revolution – A Critical Appraisal”, Atlanta, GA, March 16th, 2002.

709. Adverse Outcomes from a Taxane-loaded Polymeric Sleeved Stent: Final Results from the SCORE Trial. Presented at the symposium “Enter the Drug-Eluting Stent Revolution – A Critical Appraisal”, Atlanta, GA, March 16th, 2002.

710. In vitro Studies and Clinical Trials with the JoMed Tacrolimus Eluting Ceramic and PTFE Stents. Presented at the symposium “Enter the Drug-Eluting Stent Revolution – A Critical Appraisal”, Atlanta, GA, March 16th, 2002.

711. Filer Devices; Taped Interventional Case Presentations. Presented at the 51st Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 17th, 2002.

712. Impact of Clinical Syndrome Acuity on the Differential Response to Two Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial. Presented at the 51st Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 17th, 2002.

713. Primary PCI for AMI: State of the Art. Plenary Session. Presented at the 51st Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 18th, 2002.

714. Primary Stenting Optimizes the Outcome of Women With Acute Myocardial Infarction: Results From the CADILLAC Trial. Presented at the 51st Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 18th, 2002.

715. Embolic Filter Devices. Plenary Session. Presented at the 51st Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 20th, 2002.

716. Drug-eluting Stents: A breakthrough Technology. Presented at the Prudential Securities 3rd Annual “Ask the Doctors” conference. New York City, NY, March 26th, 2002.

717. Distal Vascular Protection Devices: Concept, Technology Overview and Clinical Trials. Presented at Medical Grand Rounds, Henry Ford Hospital, Detroit, MI, April 4th, 2002.

718. Development and results of a polymer based taxol eluting stent. Presented at the 8th Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 17th, 2002.

719. Perspectives of long-term anti-platelet therapy after PCI. Presented at the 8th Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 17th, 2002.

720. PCI applications of GP IIb/IIIa inhibitors and thienopyridines. Presented at the 8th Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 18th, 2002.

721. Thrombectomy, distal protection and pharmacologic facilitation of primary angioplasty. Presented at the 8th Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 18th, 2002.

722. The evolution of restenosis solutions. Presented at the 8th Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 19th, 2002.

723. Direct PCI for AMI: Adjunctive strategies and pharmacologic facilitation. Presented at the course "Hot Topics in Coronary Artery Disease Treatment", April 26th, 2002, New York City, NY.

724. Distal protection update: Tips and tricks. Presented at the course "Hot Topics in Coronary Artery Disease Treatment", April 26th, 2002, New York City, NY.

725. Vascular Brachytherapy Training Program, Moderator New York City, NY, May 13th, 2002.

726. SVG BRITE. Late Breaking Trial. Presented at EuroPCR 2002, Paris, France, May 22nd, 2002.

727. The FIRE Trial – Phase II Registry Results. Late Breaking Trial. Presented at EuroPCR 2002, Paris, France, May 22nd, 2002.

728. AMISTAD-II. Late Breaking Trial. Presented at EuroPCR 2002, Paris, France, May 22nd, 2002.

729. Should we facilitate primary PCI in AMI – NO! Presented at EuroPCR 2002, Paris, France, May 22nd, 2002.

730. ACS and Non ST Segment Elevation MI – Frequently asked questions. Presented at EuroPCR 2002, Paris, France, May 23rd, 2002.

731. SVG Treatment Options – distal protection, thrombectomy and covered stents. Presented at EuroPCR 2002, Paris, France, May 23rd, 2002.

732. Beyond the open artery – patient management in AMI. Presented at EuroPCR 2002, Paris, France, May 24th, 2002.

733. Reperfusion Therapy in AMI – The First Blush. Presented at the course "Frontiers in Cardiac Care", Northwestern University, Evanston, IL, June 1st, 2002.

734. Medical and interventional considerations in the diabetic patient. Presented at the Academic Scientific Conference, Lenox Hill Hospital, New York City, NY, June 5th, 2002.

735. Impact of New Devices in AMI; Thrombectomy and Distal Protection. Cath Lab Digest Symposium, Las Vegas, NV, June 7, 2002.

736. The TAXUS Trials. Videoconference to Annual Interventional Cardiology Trial, Turkey, June 7

737. Drug Coated Stents and Taxol

738. Presented at the Academic Scientific Conference, Lenox Hill Hospital, New York City, NY, June 12th, 2002.

739. Case presentations: NY Metropolitan cath lab conference, New York City, NY.

740. Drug Eluting Stents in Clinical Practice. Presented at the TAXUS Key Opinion Leader Presentation Review Session. Chicago, IL, July 16, 2002

741. Direct PCI for AMI in 2002: Adjunctive therapies? Stents? Thrombectomy? Pharmacologic facilitation? Presented at the Center of Excellence Meeting, New York City, NY, July 19th, 2002.

742. Distal protection update: tips and tricks. Presented at the Center of Excellence Meeting, New York City, NY, July 19th, 2002.

743. Direct PCI for AMI in 2002: Adjunctive therapies? Stents? Thrombectomy? Pharmacologic facilitation? Presented at the Center of Excellence Meeting, New York City, NY, August 23rd, 2002.

744. Distal protection update: tips and tricks. Presented at the Center of Excellence Meeting, New York City, NY, August 23rd, 2002.

745. Guidant Vulnerable Plaque Working Group Meeting, Moderator, Chicago, IL. August 26th, 2002.

746. The need for distal protection during vascular intervention. Presented at the Medtronic Distal Protection Symposium, Newport, Rhode Island, August 29, 2002.

747. Distal protection in acute myocardial infarction. Presented at the Medtronic Distal Protection Symposium, Newport, Rhode Island, August 29, 2002.

748. The future is now. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 24th, 2002.

749. Clinical Outcomes with Polymer and Non Polymer Based Taxol Drug Eluting Stents. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 24th, 2002.

750. The X-TRACT Trial. Late Breaking Trial Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 24th, 2002.

751. FDA Town hall Meeting – Introduction and Goals. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 24th, 2002.

752. Chronic Total Occlusions – evolutionary therapeutic perspectives. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 25th, 2002.

753. The CONTRAST Trial – interim report. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 25th, 2002.

754. Lecturer: TAXUS 2002: State of the Stent. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 25th, 2002.

755. Distal Protection During Acute Myocardial Infarction Angioplasty. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 25th, 2002.

756. An overview of the Bivalirudin Clinical Development Program. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 25th, 2002.

757. Chronic Total Occlusions – A Comprehensive Overview of Current and Future Treatment Strategies. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 25th, 2002.

758. VasoScience program for phototherapy of vulnerable plaque and restenosis. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27th, 2002.

759. Implications of pre-procedural Clopidogrel to GP IIb/IIIa use and outcomes in patients with ACS and non-ACS undergoing PCI – TARGET insights. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27th, 2002.

760. Session: Harmonizing Pharmacologic and Mechanical Approaches in ACS and AMI – PART 1: Upstream use of bivalirudin in patients undergoing an early invasive strategy – rationale and design of the ACUITY trial. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27th, 2002.

761. Med Systems – trans-aortic valve forward flow support. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27th, 2002.

762. X-SIZER I – insights from X-TRACT in patients with acute coronary syndromes. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27th, 2002.

763. Validation of a vulnerable plaque detection modality – what would a clinical trial look like? Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27th, 2002.

764. Primary Mechanical Reperfusion in AMI. 5th Annual Interventional Cardiology Self-Assessment & Review Course. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27th, 2002.

765. Featured Lecture: The US Pivotal trials of polymer based Taxol slow-rate release delivery – 30 day results of TAXUS IV and TAXUS V update. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 28th, 2002.

766. The CADILLAC Trial: 2002 Update. Presented at the 14th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 28th, 2002.

767. The TAXUS Trials. Videoconference to South Africa Interventional Cardiology Society. October 8, 2002

768. Moderator, New York Metropolitan Cath Lab Conference, New York City, New York, October 10th, 2002.

769. Other Drugs and Clinical Trials with Drug-Eluting Stents (Taxol and Beyond). The Drug Eluting Stent Symposium, Short Hills, NJ, October 16, 2002.

770. Vascular brachytherapy training program, Moderator. New York City, NY, October 17th, 2002.

771. Distal protection devices and results. Academic Scientific Conference. Lenox Hill Hospital, October 30th, 2002.

772. Aggrastat vs. ReoPro, matching the adjunctive therapy to the patient. Scripps Clinic Coronary Interventions 2002, November 1st, 2002

773. Lecture: Technique Boutique: Evolving therapies for AMI. Scripps Clinic Coronary Interventions 2002, November 1st, 2002

774. Myocardial Salvage: New strategies in AMI and ACS drugs, thrombectomy, distal protection, facilitated PTCA and beyond. New Cardiovascular Horizons. New Orleans, LA, November 2nd, 2002.

775. IIb/IIIa Inhibitors, Thienopyridines and New Anti-Thrombotic Agents in Acute Coronary Syndromes. Presented to Cardiology Grand Rounds, University of Texas Health Science Center, San Antonio, TX, November 7th, 2002.

776. Current Management of ST Segment Elevation MI. The San Antonio Cardiology Society, San Antonio, TX, November 7th, 2002.

777. PCI in AMI: CADILLAC Trial Update. The 7th International Symposium on Interventional Cardiology and Live Demonstration Course, Beijing, China, November 10th, 2002.

778. Drug-Eluting Stents – The Real World. The 7th International Symposium on Interventional Cardiology and Live Demonstration Course, Beijing, China, November 10th, 2002.

779. Management of Complications of PCI. The 7th International Symposium on Interventional Cardiology and Live Demonstration Course, Beijing, China, November 10th, 2002.

780. Vulnerable Plaque Detection: Thermographic Systems. Session moderator. The 4th Vulnerable Plaque Symposium. Chicago, IL, November 16th, 2002.

781. Update on the CADILLAC Trial. The 18th Annual George Washington Symposium on Thrombolysis and Interventional Therapy in AMI. Chicago, IL, November 16th, 2002.

782. New Advances in the Prevention of Radiocontrast Nephropathy. Presented at the course " Controversies in Endovascular Treatment of Peripheral Vascular Disease. Chicago, IL, November 16th, 2002.

783. Prospective, Randomized Evaluation of Thrombectomy Prior to Intervention in Diseased Saphenous Vein Grafts and Thrombus Containing Native Coronary Arteries. The X-TRACT Trial. Late Breaking Clinical Trial. Presented at the 75th Annual Scientific Sessions of the American Heart Association, Chicago, IL, November 17th, 2002.

784. Beta Radiation for De Novo and In-stent Restenotic Lesions in Saphenous Vein Grafts: The SVG BRITE Trial. Presented at the 75th Annual Scientific Sessions of the American Heart Association, Chicago, IL, November 17th, 2002.

785. Renal Insufficiency and Coronary Artery Disease. Session Moderator. The 75th Annual Scientific Sessions of the American Heart Association, Chicago, IL, November 18th, 2002.

786. Prospective, Randomized Comparison of Distal Protection During Coronary Intervention with a Filter-based Device and Balloon Occlusion and Aspiration System. The FIRE Trial. Presented at a symposium during the 75th Annual Scientific Sessions of the American Heart Association, Chicago, IL, November 18th, 2002.

787. The TAXUS Trials – Clinical Update. Presented at a symposium during the 75th Annual Scientific Sessions of the American Heart Association, Chicago, IL, November 18th, 2002.

788. Clinical and experimental outcomes with paclitaxel-eluting stents. The Drug Eluting Stent Symposium, New York City, December 2nd, 2002.

789. Further Improving Outcomes of Primary PTCA. Presented at the 2nd annual International Interventional Cardiology Symposium and Live Demonstration Course, Cardiologica Clinica C. Costantini, Curitiba, Brazil, December 5th, 2002.

790. RAVEL vs. SIRIUS vs. TAXUS-II: Explaining the Differences. Presented at the 2nd annual International Interventional Cardiology Symposium and Live Demonstration Course, Cardiologica Clinica C. Costantini, Curitiba, Brazil, December 6th, 2002.

790. Catheter Based Management of ACS: Vision for the future. Presented at the course “Hot Topics in Coronary Artery Disease Treatment”, New York City, NY, January 17th, 2003.

791. Drug-Eluting Stent Update: “These things really work”. Presented at the course “Hot Topics in Coronary Artery Disease Treatment”, New York City, NY, January 17th, 2003.

792. New interventional approaches in acute myocardial infarction. Presented at the 15th International Symposium on Endovascular Therapy, Miami, FL, January 19th, 2003.

793. Paclitaxel-eluting stents – an update. Presented at the 15th International Symposium on Endovascular Therapy, Miami, FL, January 19th, 2003.

794. Drug-Eluting Stents: A Breakthrough Technology. Presented at Grand Rounds, St. Luke’s Roosevelt Hospital, New York City, NY, January 22nd, 2003.

795. TAXUS III, IV and V. Presented at the annual Cardiovascular Revascularization Therapies Course, Washington DC, January 27th, 2003.

796. Acute Coronary Syndromes: Should Everyone go to the Cath Lab? Presented at the annual Cardiovascular Revascularization Therapies Course, Washington DC, January 27th, 2003.

797. Keynote address: State-of-the-Art Management of Acute Myocardial Infarction. Presented at the annual Cardiovascular Revascularization Therapies Course, Washington DC, January 28th, 2003.

798. Chronic Total Occlusions: Evolutionary Therapeutic Perspectives. Presented at the annual Cardiovascular Revascularization Therapies Course, Washington DC, January 28th, 2003.

799. Vulnerable plaque detection and treatment: the next holy grail. Keynote address at the AG Edwards annual scientific symposium on Emerging Medical Technologies, New York City, NY, February 11th, 2003.

800. The TAXUS Trials. Presented at the Joint Interventional Meeting (JIM) 2003, Rome, Italy, February 13th, 2003.

801. Distal protection: Occlusion balloons vs. filters. Presented at the Joint Interventional Meeting (JIM) 2003, Rome, Italy, February 13th, 2003.

802. Hot Topics: REPLACE-2. TCTMD.com Webcast, February 19th, 2003.

803. Drug-Eluting Stents and Anti-Proliferative Therapies. Medical Grand Rounds. Scottsdale Shea Hospital, Scottsdale, AZ, February 20th, 2003.

804. Radiocontrast nephropathy update. Presented at the 6th Thought Leader's Summit, Puerto Rico, March 14th, 2003.

805. Distal protection update. Presented at the 6th Thought Leader's Summit, Puerto Rico, March 14th, 2003.

806. Drug-eluting Stent Overview: Comparison of Sirolimus and Paclitaxel. Abbott Laboratories, Abbott Park, IL, March 28, 2003.

807. Great Cypher cases. Presenting at the symposium "Enter the Drug-eluting Stent Revolution: A critical appraisal II", Chicago, IL, March 28th, 2003.

808. Status Update: TAXUS IV, V and VI. Presenting at the symposium "Enter the Drug-eluting Stent Revolution: A critical appraisal II", Chicago, IL, March 28th, 2003.

809. Problem Solving for Myocardial Infarction Intervention: Management of Intraluminal Thrombus. Presented at the 52nd Annual Scientific Sessions of the American College of Cardiology, Chicago, IL, March 29th, 2003.

810. The Drug Eluting Stent Revolution: Status of Paclitaxel. Presented at the 52nd Annual Scientific Sessions of the American College of Cardiology, Chicago, IL, March 29th, 2003.

811. The Management of Acute Myocardial Infarction 2003 and Beyond. Presented at the 52nd Annual Scientific Sessions of the American College of Cardiology, Chicago, IL, March 29th, 2003.

812. A Prospective, Randomized Trial of Thromboatherectomy During Intervention of Thrombotic Native Coronary Arteries and Saphenous Vein Grafts. The X-TRACT Trial. Presented at the 52nd Annual Scientific Sessions of the American College of Cardiology, Chicago, IL, March 30th, 2003.

813. A Prospective Randomized Multicenter Trial Comparing Distal Protection During Saphenous Vein Graft Intervention With a Filter Based Device Compared to Balloon Occlusion and Aspiration: The FIRE Trial. Presented at the 52nd Annual Scientific Sessions of the American College of Cardiology, Chicago, IL, March 30th, 2003.

814. A Prospective, Randomized Placebo-Controlled Multicenter Trial Evaluating Fenoldopam Mesylate for the Prevention of Contrast Induced Nephropathy: The CONTRAST Trial. Presented at the 52nd Annual Scientific Sessions of the American College of Cardiology, Chicago, IL, April 1st, 2003.

815. Drug-eluting Stents III: Paclitaxel. Presented at the 9th Annual National Interventional Cardiology Fellow's Course, San Jose, CA, April 9th, 2003.

816. Presented at the 9th Annual National Interventional Cardiology Fellow's Course, San Jose, CA, April 9th, 2003.

817. The Impact of Drug-eluting Stents. Presented at the 9th Annual National Interventional Cardiology Fellow's Course, San Jose, CA, April 9th, 2003.

818. Chronic total occlusions: The last frontier. Presented at the 9th Annual National Interventional Cardiology Fellow's Course, San Jose, CA, April 9th, 2003.

819. Distal protection devices in vein grafts and native coronary arteries. Presented at the 9th Annual National Interventional Cardiology Fellow's Course, San Jose, CA, April 10th, 2003.

820. AMI Intervention II: Beyond primary PTCA. Presented at the 9th Annual National Interventional Cardiology Fellow's Course, San Jose, CA, April 11th, 2003.

821. Distal Protection Devices in Vascular Intervention. Presented at the course "Hot Topics in Coronary Intervention", April 24th, 2003.

822. Primary angioplasty in AMI: State of the Art and Future Approaches. Presented at the course "Hot Topics in Coronary Intervention", April 24th, 2003.

823. The ACUITY Trial: background and rationale. Presented at the EuroPCR course, Paris, France, May 20th, 2003.

824. Thrombolysis vs. Primary PTCA: The debate is over! Presented at the EuroPCR course, Paris, France, May 22nd, 2003.

825. Saphenous vein graft intervention – overview of the problem. Presented at the EuroPCR course, Paris, France, May 22nd, 2003.

826. Distal protection devices, thrombectomy and PTFE stent grafts: Use during SVG intervention. Presented at the EuroPCR course, Paris, France, May 22nd, 2003.

827. Applying the CREDO and CURE results to thienopyridine use strategies in ACS and PCI. Presented at the EuroPCR course, Paris, France, May 22nd, 2003.

828. Acute MI without critical lesions. Presented at the EuroPCR course, Paris, France, May 22nd, 2003.

829. Back to Andreas: PCI of diseased SVGs. Presented at the EuroPCR course, Paris, France, May 23rd, 2003.

830. Highlights in Interventional Cardiology from EuroPCR. Presented at the course Coronary Intervention 2003, Atlanta, GA, May 28th, 2003.

831. Drug-Eluting Stents: overview and strategies for case selection and technique. Presented at the 12th annual Advanced Cardiovascular Interventions Symposium, Hilton Head, SC, June 16th, 2003.

832. New directions for distal protection during saphenous vein graft intervention. Presented at the 12th annual Advanced Cardiovascular Interventions Symposium, Hilton Head, SC, June 16th, 2003.

833. The rising tide of drug-eluting stent therapy: Fully justified and here's why. Presented at the 12th annual Advanced Cardiovascular Interventions Symposium, Hilton Head, SC, June 17th, 2003.

834. Complex drug-eluting stent cases. Presented at the 12th annual Advanced Cardiovascular Interventions Symposium, Hilton Head, SC, June 17th, 2003.

835. TAXUS: The Race for Leadership. Keynote address at the annual Boston Scientific Technology Awards Dinner, Cambridge, MA, June 17th, 2003.

836. Complex Drug-eluting Stent Cases. Presented at the Advanced Endovascular Therapies course, New York City, NY, June 19th, 2003.

837. The Case for Aggressive Drug-eluting Stent Use. Presented at the Advanced Endovascular Therapies course, New York City, NY, June 19th, 2003.

838. TAXUS Update. Presented at the Advanced Endovascular Therapies course, New York City, NY, June 19th, 2003.

839. The Enigma of Chronic Total Occlusions: Are we making progress? Presented at the 11th Annual New Devices Seminar, Orlando, FL, July 4th, 2003.

840. AMI Intervention: Are New Technologies Better than Primary PTCA? Presented at the 11th Annual New Devices Seminar, Orlando, FL, July 5th, 2003.

841. Primary Angioplasty in AMI: Advancing the State-of-the-Art. Presented at the 3rd annual "Summer in Seattle: Interventional Cardiac and Vascular Therapies Conference", in Seattle, WA, July 17th, 2003.

842. Primary PCI for ST Segment Elevation Acute Myocardial Infarction. Presented at the IX Congress of SOLACI and XXV Congress of the SBHCI, Sao Paulo, Brazil, July 23rd, 2003.

843. Treatment of patients with Acute MI and large thrombus burden. Presented at the IX Congress of SOLACI and XXV Congress of the SBHCI, Sao Paulo, Brazil, July 23rd, 2003.

844. What is the role of the mechanical approach in the management of intraluminal thrombus? Presented at the IX Congress of SOLACI and XXV Congress of the SBHCI, Sao Paulo, Brazil, July 23rd, 2003.

845. Paclitaxel: State-of-the-Art. Presented at the IX Congress of SOLACI and XXV Congress of the SBHCI, Sao Paulo, Brazil, July 24th, 2003.

846. TAXUS Program Update: Looking Beneath the Surface. Presented at the IX Congress of SOLACI and XXV Congress of the SBHCI, Sao Paulo, Brazil, July 24th, 2003.

847. Distal Protection in Acute Myocardial Infarction: Preliminary EMERALD findings. Presented at the IX Congress of SOLACI and XXV Congress of the SBHCI, Sao Paulo, Brazil, July 24th, 2003.

848. In the era of drug-eluting stents, bypass surgery will be of historical interest only (debate). Presented at the IX Congress of SOLACI and XXV Congress of the SBHCI, Sao Paulo, Brazil, July 24th, 2003.

849. Treatment of vascular disease with distal protection devices. Presented at the IX Congress of SOLACI and XXV Congress of the SBHCI, Sao Paulo, Brazil, July 25th, 2003.

850. New strategies for acute myocardial infarction and acute coronary syndromes. Center of Excellence meeting, Lenox Hill Hospital, New York City, NY, August 1st, 2003.

851. Moderator and chair, The Nephrotoxicity Roundtable, Trenton, NJ, August 16th, 2003.

852. The Problem of Contrast-Induced Nephrotoxicity. The Nephrotoxicity Roundtable, Trenton, NJ, August 16th, 2003.

853. Future Therapies for Acute Myocardial Infarction: Thrombectomy and Distal Protection Devices. Presented at the Annual Scientific Sessions of the European Society of Cardiology, Vienna, Austria, September 1st, 2003.

854. Prevention of Restenosis with Paclitaxel-eluting Stents. Presented at the Annual Scientific Sessions of the European Society of Cardiology, Vienna, Austria, September 2nd, 2003.

855. TCT 2003: A new venue, a new format, and the new Academy of Transcatheter Cardiovascular Therapeutics. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 15th, 2003.

856. TAXUS IV – The Pivotal, Prospective, Randomized Trial of the Polymer-based, Slow-rate Release Paclitaxel Eluting Stent. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 15th, 2003.

857. TAXUS IV - Clinical overview and subset analysis. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 15th, 2003.

858. Clinical Imperatives of drug-eluting stents. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 15th, 2003.

859. The Impact of Embolic Protection Devices on Myocardial Preservation. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 16th, 2003.

860. Is heparin obsolete? The emergence and appropriate use of low molecular weight heparins and direct thrombin inhibitors. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 16th, 2003.

861. TAXUS IV: The pivotal trial in perspective. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 16th, 2003.

862. Presentation of the 1st Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 17th, 2003.

863. TCT Synthesis: Late Breaking Clinical Trials. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 17th, 2003.

864. Vulnerable Plaque Tomorrow: The Maturation of a New Subspecialty—Development Requirements and Insightful Speculation. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 17th, 2003.

865. Thermocore Experiences, and PARACHUTE/TEMPO Directions. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18th, 2003.

866. The Mode of Action of Paclitaxel as an Anti-restenosis Therapy: New Mechanistic Insights. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18th, 2003.

867. The TAXUS IV "Mega-Trial". Study design, clinical outcomes and angiographic results. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18th, 2003.

868. The TAXUS-V Studies: Emphasizing Diffuse Disease and In-Stent Restenosis. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18th, 2003.

869. The TAXUS programs: New trials and directions. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18th, 2003.

870. The "hot topic". Is bivalirudin poised to "replace" heparin and IIb/IIIa inhibitors in ACS? Design, rationale and status of ACUITY. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18th, 2003.

871. Primary mechanical reperfusion in AMI. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18th, 2003.

872. Balloon occlusion and aspiration in AMI: First report from the EMERALD Trial. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18th, 2003.

873. Case presentations: Embolic protection in acute myocardial infarction. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18th, 2003.

874. Clinical debates 1. Are bare stents an acceptable alternative in certain lesion subsets? Global use of DES should be the standard .....rationing is unconscionable! Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 19th, 2003.

875. GuardWire in AMI—EMERALD Roll-in Results and Randomized Trial Status. Presented at the 15th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18th, 2003.

876. The TAXUS-IV Trial. Presented at the TEAM course; Endovascular and Myocardial Therapy, Madrid, Spain, October 1st, 2003.

877. The TAXUS Trials: How do they affect stent choice? Presented at the TEAM course; Endovascular and Myocardial Therapy, Madrid, Spain, October 1st, 2003.

878. Pharmacologic Facilitation in Acute Myocardial Infarction is Not Necessary. Presented at the TEAM course; Endovascular and Myocardial Therapy, Madrid, Spain, October 2nd, 2003.

879. Evolving Therapies for Acute Myocardial Infarction: Combining Drugs with Devices. Presented at the course Coronary Interventions 2003, La Jolla, CA, October 8th, 2003.

880. Drug-Eluting Stents: Late Breaking Paclitaxel Results. Presented at the course Coronary Interventions 2003, La Jolla, CA, October 8th, 2003.

881. Drug-Eluting Stents: A Real World Perspective. Presented at the course Coronary Interventions 2003, La Jolla, CA, October 8th, 2003.

882. Late Breaking Drug-eluting Stent Trials: TAXUS-IV, FUTURE-II and ENDEAVOR. Presented at the Guidant Interventional Fellows Program, Napa Valley, CA, October 11th, 2003.

883. Acute Myocardial Infarction Therapy 2003. Presented at the Guidant Interventional Fellows Program, Napa Valley, CA, October 11th, 2003.

884. TAXUS-IV – What can be learned from the pivotal trial? Presented at the Boston Scientific National sales meeting, Chicago, IL, November 3rd, 2003.

885. Downstream Protection During STEMI PCI: The Latest EMERALD Results and Other Experiences. Presented at the 19th International Symposium on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction. Orlando, FL, November 8th, 2003.

886. Distal Protection Devices and Adjunctive Pharmacologic Therapy for SVG and Thrombus Containing Lesions. Presented at the course Standards in ACS for 2004 from Diagnosis to Discharge, Orlando, FL, November 8th, 2003.

887. Ongoing Trials in ACS: ACUITY Presented at the course Standards in ACS for 2004 from Diagnosis to Discharge, Orlando, FL, November 8th, 2003.

888. Adjunctive Antiplatelet/Thrombolytic therapy for facilitated PCI. Presented at the Cardiovascular Seminar Immediate PCI for STEMI during the 76th Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 9th, 2003

889. Primary Angioplasty in Acute Myocardial Infarction with Distal Protection of the Microcirculation: Results from the Roll-in Phase of the EMERALD Trial. Presented during the 76th Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 10th, 2003.

890. TAXUS IV: The Pivotal Trial in Perspective. Orlando, FL, November 10th, 2003.

891. The Pivotal US Study of the Slow-Rate Polymer-Based Paclitaxel-Eluting TAXUS Stent in Patients with De Novo Coronary Lesions: 1-Year Clinical Results of the TAXUS –IV Trial. Presented during the 76th Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 11th, 2003.

892. Perspectives from the TAXUS Trials on drug-eluting stents. Presented at the course Current Concepts in Cardiovascular Management, Buffalo, NY, November 21st, 2003.

893. Saphenous vein graft attrition and intervention. Presented at the course Current Concepts in Cardiovascular Management, Buffalo, NY, November 21st, 2003.

894. Rationale for embolic protection in acute myocardial infarction angioplasty. Presented at the course "Advanced Interventional Approaches", December 1st, 2003, New York, NY.

895. Paclitaxel-eluting stents – the new gold standard? Presented at the course "Advanced Interventional Approaches", December 2nd, 2003, New York, NY.

896. Drug-eluting stents, 2004 and beyond. Cardiology Grand Rounds. Beth Israel Hospital, New York City, NY, January 12th, 2003.

897. Paclitaxel and sirolimus eluting stents: Are there any differences? Presented at the symposium "Drug-eluting Stents Today and Tomorrow. New York City, NY, January 21st, 2004.

898. What it means to be a cardiologist. Parkway Elementary School, Greenwich, CT, January 22nd, 2004.

899. The Interventional Landscape of Drug-Eluting Stents. Presented at the Guidant National Sales Meeting, Dallas, TX, January 25th, 2004.

900. The Present and Future of Drug-eluting Stent Technology. Presented at Guidant Corporation, Santa Clara, CA, January 26th, 2004.

901. TAXUS Technology and Promise. Presented at the National Boston Scientific Sales Meeting, New York City, February 1st, 2004.

902. Top clinical trials at TCT2003. Presented at the Joint Interventional Meeting (JIM) 2004. Rome, Italy, February 12th, 2003.

903. Proper management of diseased saphenous vein grafts. Presented at the Joint Interventional Meeting (JIM) 2004. Rome, Italy, February 12th, 2003.

904. TAXUS trials update and subgroup analysis. Presented at the Joint Interventional Meeting (JIM) 2004. Rome, Italy, February 1st, 2003.

905. Troubling Issues: In stent Thrombosis and Off-Label Use in the Drug-Eluting Stent Era: Insights and Recommendations. Presented at the Symposium "ENTER THE DRUG-ELUTING STENT REVOLUTION III: CLINICAL IMPACT AND EVOLVING PERSPECTIVES", New Orleans, March 6th, 2004.

906. Vignettes from Important New (Ongoing or Completed) TAXUS Clinical Trials. Presented at the Symposium "ENTER THE DRUG-ELUTING STENT REVOLUTION III: CLINICAL IMPACT AND EVOLVING PERSPECTIVES", New Orleans, LA, March 6th, 2004.

907. Taped Interventional Case Highlights Session. Presented at the 53rd Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 7th, 2004.

908. Distal Protection of the Microcirculation in Acute Myocardial Infarction. Presented at the 53rd Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 7th, 2004.

909. Primary Angioplasty in Acute Myocardial Infarction with Distal Protection of the Microcirculation: Principal Results from the Prospective, Randomized EMERALD Trial. Presented at the 53rd Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 7th, 2004.

910. The TAXUS Program: A Comprehensive Analysis. presented at the symposium "Clinical Insights from the TAXUS Experience", , New Orleans, LA, March 7th, 2004.

911. Preventing Contrast Nephropathy. Presented at the 53rd Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 9th, 2004.

912. Reduction in Late Loss and Restenosis in Patients With Small Vessels Treated With the Slow Rate-Release, Polymer-Based Paclitaxel-Eluting Stent: Results from TAXUS-IV. Presented at the 53rd Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 9th, 2004.

913. Direct PCI for AMI in 2004: Adjunctive therapies? Stents? Thrombectomy? Pharmacologic Facilitation? Presented at the course "Hot Topics in Coronary Artery Disease Treatment", New York City, NY, March 19th, 2004.

914. Drug Coated Stent Overview: Latest Data, Latest Controversies. Presented at the course "Hot Topics in Coronary Artery Disease Treatment", New York City, NY, March 19th, 2004.

915. The integrated use of adjunctive pharmacology and device-based therapy to manage thromboembolic coronary artery disease. Presented at the 19th Annual Interventional Cardiology Symposium, Snowmass, CO, March 24th, 2004.

916. Direct thrombin inhibition in the cath lab. Presented at the 19th Annual Interventional Cardiology Symposium, Snowmass, CO, March 24th, 2004.

917. Paclitaxel: Clinical trials update. Presented at the 19th Annual Interventional Cardiology Symposium, Snowmass, CO, March 25th, 2004.

918. The three most important clinical trials in interventional cardiology within the last year. Presented at the 19th Annual Interventional Cardiology Symposium, Snowmass, CO, March 26th, 2004.

919. The TAXUS Program: The drug, the polymer, the stent, the trials. Presented at the 10th Annual North American Interventional Cardiology Fellow's Course, San Jose, March 31st, 2004.

920. Drug-eluting stent terminology: What you need to know. Presented at the 10th Annual North American Interventional Cardiology Fellow's Course, San Jose, April 1st, 2004.

921. Proven drug-eluting Stent Systems I: Polymer –based paclitaxel release. Presented at the 10th Annual North American Interventional Cardiology Fellow's Course, San Jose, April 1st, 2004.

922. AMI Intervention II: Beyond Primary PTCA. Presented at the 10th Annual North American Interventional Cardiology Fellow's Course, San Jose, April 2nd 2004.

923. Interventional Pharmacology IV: Bivalirudin in ACS and PCI. Presented at the 10th Annual North American Interventional Cardiology Fellow's Course, San Jose, April 2nd 2004.

924. The TAXUS Program: Technology and Trial Update. Minneapolis, Minn., April 16th, 2004.

925. Drug-eluting Stent Technology: Current Landscape and Future Directions. Grand Rounds and visiting professorship, Mayo Clinic, Rochester, Minn., April 17th, 2004.

926. The Drug-eluting Stent Revolution: Implications for patient care. Garfield, NJ, April 22nd, 2004.

927. The TAXUS Stent: Technology and Trials. Webcast, May 12th, 2004.

928. Direct PCI for acute myocardial infarction. Adjunctive therapies? Stents? Thrombectomy? Distal Protection? Presented at the course “Hot Topics in Coronary Artery Disease Treatment”, New York City, NY, May 21st, 2004.

929. The EMERALD Trial. Presented at the EuroPCR symposium, Paris, France, May 25th, 2004.

930. Distal Protection in AMI-Lessons from EMERALD. Presented at the EuroPCR symposium, Paris, France, May 25th, 2004.

931. Optimizing the Care of High-Risk Patients. Presented at the EuroPCR symposium, Paris, France, May 26th, 2004.

932. IIb/IIIa inhibitors during acute MI: in which patients, when, abciximab or small molecules. Presented at EuroPCR 2004, Paris, France, May 26th, 2004.

933. Chronic total occlusions – the need to revascularize. Presented at EuroPCR 2004, Paris, France, May 26th, 2004.

934. Complex vulnerable plaque presentations. Presented at EuroPCR 2004, Paris, France, May 26th, 2004.

935. The Great “non-debate”: Why TAXUS is better. Presented at EuroPCR 2004, Paris, France, May 27th, 2004.

936. Selected role of distal protection in acute myocardial infarction – case presentations. Presented at EuroPCR 2004, Paris, France, May 27th, 2004.

937. Keynote closing symposium. Profiling tomorrow's patient. Presented at EuroPCR 2004, Paris, France, May 28th, 2004.

938. Selected cases from EuroPCR 2004 – Did we adhere to, ignore or anticipate guidelines? The verdict and economic implications. Presented at EuroPCR 2004, Paris, France, May 28th, 2004.

939. TAXUS Technologies and Trials. Evening symposium, Philadelphia, PA, June 2nd, 2004.

940. Innovative approaches to reperfusion therapy in acute myocardial infarction. Cardiology Grand Rounds, Hospital of the University of Pennsylvania, Philadelphia, PA, June 3rd, 2004.

941. Distal protection in acute myocardial infarction. Presented at the course “Intervention 2004”, Boston, MA, June 3rd, 2004.

942. Design and Rationale of the Prospect Trial. Presented at the 2nd Vulnerable Plaque Symposium, Taormina, Sicily, June 8th, 2004.

943. Keynote lecture: The Impact of Drug-Eluting Stents Now and in the Future. Presented at the 13th annual Advanced Cardiovascular Interventions Symposium, Hilton Head, SC, June 15th, 2004.

944. Complex drug-eluting stent cases. Presented at the 13th annual Advanced Cardiovascular Interventions Symposium, Hilton Head, SC, June 15th, 2004.

945. Complications of Coronary Angioplasty – My Worst Case in the Last 12 Months. Presented at the 18th Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July 19th, 2004.

946. Distal Protection in Acute Myocardial Infarction – Is it Necessary? Presented at the 18th Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July 19th, 2004.

947. Highlights from the TAXUS Trials. Presented at the 18th Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July2 0th, 2004.

948. Controversial Case of the Day. Presented at the 18th Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July 20th, 2004.

949. Success and Outstanding Results: The Best Case I did in the last 12 months. Presented at the 18th Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July 21st, 2004.

950. Invasive detection of the vulnerable plaque. Presented at the 18th Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July 21st, 2004.

951. First implantation of a new percutaneous aortic valve. Presented at the 18th Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July 21st, 2004.

952. TCT at SOLACI 2004 – A Glimpse At A Future Soon To Be. Presented at the 10th Annual SOLACI Conference, Buenos Aires, Argentina, August 4th, 2004.

953. Percutaneous Approaches to Diseased Heart Valves. Presented at the 10th Annual SOLACI Conference, Buenos Aires, Argentina, August 4th, 2004.

954. Current Standards and Future Directions For: Drug-Eluting Stents. Presented at the 10th Annual SOLACI Conference, Buenos Aires, Argentina, August 4th, 2004.

955. Training and Accreditation in Interventional Cardiology: The Academy of TCT Vision. Presented at the 10th Annual SOLACI Conference, Buenos Aires, Argentina, August 4th, 2004.

956. Transferring Acute MI Patients: Is it always the best option.? Presented at the 10th Annual SOLACI Conference, Buenos Aires, Argentina, August 4th, 2004.

957. Is Unfractionated Heparin Obsolete? The Role of Low Molecular Weight Heparin and Direct Thrombin Inhibitors in PCI and ACS. Presented at the 10th Annual SOLACI Conference, Buenos Aires, Argentina, August 5th, 2004.

958. My Best Dream, My Worst Nightmare. Presented at the 10th Annual SOLACI Conference, Buenos Aires, Argentina, August 5th, 2004.

959. Drug-eluting stents and stent thrombosis. Presented at the Materials Science in Drug-eluting Stent Summit. Santa Clara, CA, August 9th, 2004.

960. Direct thrombin inhibitors in ACS, AMI and PCI. Cardiology Grand Rounds, Beth Israel Newark Hospital, August 13th, 2004.

961. Management of ST-segment elevation acute myocardial infarction. Presented at the ACCF/SCAI Interventional cardiology Board Review Course, Atlanta, GA, August 21st, 2004.

962. Direct thrombin inhibition in acute coronary syndromes and acute myocardial infarction. Presented at the Annual Scientific Sessions of the European Society of Cardiology, Munich, German, August 28th, 2004.

963. Perspectives on the seminal events of the last year that have shaped up a subspecialty. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 27th, 2004, Washington, DC.

964. Drug-eluting stent “euphoria” in the U.S.: An evidence-based medicine analysis and future clinical initiatives. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 27th, 2004, Washington, DC.

965. Translation of Evidence-Based Medicine Into Clinical Practice Recommendations: An In-Depth Analysis of the “New” ACC/AHA Guidelines for Management of ST-Segment Elevation MI. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 27th, 2004, Washington, DC.

966. Advantages of direct Thrombin Inhibition in High and Low Risk Patients. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 27th, 2004, Washington, DC.

967. Paclitaxel-eluting Stents. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 28th, 2004, Washington, DC.

968. EMERALD (distal protection - GuardWire based): Overview and subgroup analysis. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 28th, 2004, Washington, DC.

969. Have Drug Eluting Stents Tipped the Scales Toward Percutaneous Intervention In Patients with Diabetes Mellitus? Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 28th, 2004, Washington, DC.

970. Multimodality Imaging of Vulnerable Plaque. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 28th, 2004, Washington, DC.

971. The EMERALD Trial – Lessons Learned. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29th, 2004, Washington, DC.

972. Introduction - The TCT Health and Human Services Town Hall Meeting: Scientific, Regulatory and Reimbursement Outlook from the FDA, NIH and CMS. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29th, 2004, Washington, DC.

973. Current standards and proposed directions in pharmacologic and device-based approaches for primary angioplasty. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29th, 2004, Washington, DC.

974. TCT Late Breaking Clinical Trials – TCT 2004 Synthesis. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29th, 2004, Washington, DC.

975. TAXUS IV – Two year results from the pivotal prospective, randomized trial of the slow-release polymer-based paclitaxel-eluting TAXUS stent. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29th, 2004, Washington, DC.

976. Presentation of the 2nd Thomas J. Linnemeier Award – Spirit of Interventional Cardiology Young Investigator Award. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29th, 2004, Washington, DC.

977. The EMERALD Trial of Distal Protection in AMI: First report of the 6-month Results. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29th, 2004, Washington, DC.

978. What Future Clinical Challenges Should Be Addressed with the TAXUS Stent Program? Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29th, 2004, Washington, DC.

979. Sirolimus and Paclitaxel Drug Eluting Stents I: Descriptions, Indication and Clinical Outcomes. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 30th, 2004, Washington, DC.

980. Evidence-based medicine analysis of current DES clinical use guidelines: A roadmap for clinicians. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 30th, 2004, Washington, DC.

981. Primary Mechanical Reperfusion in Acute MI. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 30th, 2004, Washington, DC.

982. The Guidant BVS Bioabsorbable Stent Program. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 30th, 2004, Washington, DC.

983. Bivalirudin in ACS: Insights from REPLACE-2, and ACUITY Update. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 30th, 2004, Washington, DC.

984. The impact of elution rates and release kinetics on DES results. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 30th, 2004, Washington, DC.

985. Zen Philosophy: The Key to CTO Success. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1st, 2004, Washington, DC.

986. A synthesis and status update of the TAXUS clinical trial program. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1st, 2004, Washington, DC.

987. Optimizing Outcomes of primary PCI: From CADILLAC to HORIZONS. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1st, 2004, Washington, DC.

988. A brief status update on HORIZONS (TAXUS vs. bare metal stents and bivalirudin vs. UFH). Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1st, 2004, Washington, DC.

989. The PROSPECT Trial: Design and Rational for a Vulnerable Plaque Natural History Study. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1st, 2004, Washington, DC.

990. Distal Protection in AMI I: The EMERALD trial-First presentation and analysis of the 6 month results. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1st, 2004, Washington, DC.

991. TAXUS V: 30 day Clinical Outcomes (1st presentation). Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1st, 2004, Washington, DC.

992. From Syntax to Horizons: Brief Overview and Update of Ongoing and "Next Generation" TAXUS Clinical Trials. Presented at the 16th Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1st, 2004, Washington, DC.

993. Long-term durability of paclitaxel-eluting stents. Webcast on TCTMD.com, October 13th, 2004.

994. Highlights from TCT 2004. Webcast to the Charles Rivers Laboratories Cardiovascular Interventional Symposium, October 13th, 2004.

995. Post market surveillance for a new drug-eluting stent. Presented at the 2nd Dartmouth Device Development Symposium, Woodstock, Vermont, October 14th, 2004.

996. Drug-eluting stents: A transforming technology. Presented at the annual meeting of the New York State chapter of the American College of Cardiology, NY, NY, October 16th, 2004.

997. Drug-eluting Stent Indications: Are there any differences between Japan and the rest of the world? Presented at the CCT2004 Course, Kobe, Japan, October 20th, 2004

998. Directions in Pharmacologic and device-based approaches for primary angioplasty. Presented at the CCT2004 Course, Kobe, Japan, October 21st, 2004

999. Final EMERALD Results and future primary angioplasty directions. Presented at the CCT2004 Course, Kobe, Japan, October 21st, 2004

1000. New Insights of Polymeric Paclitaxel Eluting Stent- from the latest clinical trials and real world registries. Presented at the CCT2004 Course, Kobe, Japan, October 21st, 2004

1001. Advantage of CTO crossing with new generation guidewires. Presented at the CCT2004 Course, Kobe, Japan, October 22nd, 2004.

1002. The Future of Interventional Cardiology. Presented t Cardiology Grand Rounds. St. Francis Hospital, Long Island, NY, October 27th, 2004.

1003. Protective Devices with STEMI PCI: The prognosis for Success after EMERALD. Presented at the 20th International Symposium on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction, New Orleans, LA, November 6th, 2004.

1004. Discussant – A Randomized, Double-Blind, placebo-Controlled Trial of Glycoprotein IIb/IIIa Inhibition with Abciximab in Patients with Diabetes Undergoing Percutaneous Coronary Intervention (ISAR-SWEET Trial). Presented at the 77th Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 7th, 2004.

1005. New Applications for Drug Eluting Coronary Artery Stents. Presented at the 77th Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 8th, 2004.

1006. Durability of the Polymer-Based Paclitaxel-eluting TAXUS stent: Two year Results from the TAXUS-IV Trial. Presented at the 77th Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 8th, 2004.

1007. Outcomes of the Polymer-Based Paclitaxel-eluting TAXUS Stent in Complex Lesions: First Report from the TAXUS-V Pivotal Randomized Trial. Presented at the 77th Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 8th, 2004.

1008. Are we preventing or just delaying Restenosis with drug-eluting stents? A data overview of the TAXUS II and TAXUS IV 2-year results and the TAXUS I 3-year results Presented at the 77th Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 8th, 2004.

1009. How to Use PCI to Treat Difficult Subsets of Patients: Saphenous Vein Grafts. Presented at the 77th Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 9th, 2004.

1010. Guidewires and the Zen Master Approach to CTO Recanalization. Presented at the Workshop on Highly Stenoses Lesions course, New York City, NY, November13th, 2004.

1011. Drug: Eluting Stents: The Science and Technology Behind the Revolution. Houston, Texas, November 18th, 2004.

1012. Drug-eluting Stents: A transforming, revolutionary technology. Cardiology Grand Rounds, Methodist Hospital, Houston, Texas, November 19th, 2004.

1013. Clinical Experiences and Insights into Treatment Strategies with Drug-Eluting Stents. Cardiology Grand Rounds, St. Luke's Hospital, Texas Heart Institute, Houston, Texas, November 19th, 2004.

1014. Optimal reperfusion in AMI (what have we learned from mechanical reperfusion trials)? Presented at the TEAM course, Madrid, Spain, November 22nd, 2004.

1015. Drug Eluting Stents and New Materials – TAXUS program and beyond. Presented at the TEAM course, Madrid, Spain, November 22nd, 2004.

1016. Controversy–Thrombectomy and / or distal protection in AMI. Presented at the TEAM course, Madrid, Spain, November 23rd 2004.

1017. Drug Eluting Stents - What is beyond the TAXUS program. Presented at the TEAM course, Madrid, Spain, November 23rd 2004.

1018. Vulnerable Plaque – New Diagnostic and Treatment Vistas. Presented at the TEAM course, Madrid, Spain, November 23rd 2004.

1019. Drug-eluting stents – Data, Devices, Differences. Massachusetts General Hospital Department of Cardiology, Boston, MA, December 7th, 2004.

1020. Impact of Drug-eluting Stents on Patients, Physicians and Society. Cardiology Grand Rounds, Massachusetts General Hospital, Boston, MA, December 8th, 2004.

1021. Acute Myocardial Infarction: Evidence Based Medicine Update. Center of Excellence Meeting, New York City, NY, December 10th, 2004.

1022. The Present and Future Role of Direct Thrombin Inhibitors in PCI, ACS and AMI. Presented at the 15th Annual ISET Course, Miami, FL, January 16th, 2005.

1023. Current Standards and Future Directions in Pharmacologic and Mechanical Approaches for Primary PCI. Presented at the 15th Annual ISET Course, Miami, FL, January 16th, 2005.

1024. The present and future of direct thrombin inhibitors. Presented at Advanced Angioplasty 2005, British Interventional Cardiology Society, London, UK, January 26th, 2005.

1025. Drug-eluting Stents: The Journey Continues. Keynote lecture. Presented at Advanced Angioplasty 2005, British Interventional Cardiology Society, London, UK, January 26th, 2005.

1026. TAXUS consistency over time & Future TAXUS Directions. Broadcast to Malaysia, January 29th, 2005.

1027. Chronic total occlusions – what have we learned in the last year? Presented at the 2nd International CTO Summit, New York City, NY, February 4th, 2004.

1028. Chronic Total Occlusions. The Last Frontier. Milford Hospital, Connecticut, February 10th, 2004.

1029. TAXUS V: Complex stenting with the paclitaxel-eluting stent. Presented at the JIM2005 meeting, Rome, Italy, February 17th, 2005.

1030. Percutaneous aortic valve replacement: CoreValve. Presented at the JIM2005 meeting, Rome, Italy, February 17th, 2005.

1031. An Overview perspectives from the late-breaking clinical trials at TCT 2004. Presented at the JIM2005 meeting, Rome, Italy, February 17th, 2005.

1032. Contrasts and comparisons of the PCI guidelines from Europe and US. Presented at the JIM2005 meeting, Rome, Italy, February 17th, 2005.

1033. Current Status of protection devices. Presented at the JIM2005 meeting, Rome, Italy, February 18th, 2005.

1034. TAXUS update. Presented at the course “Enter the Drug-Eluting Stent Revolution IV: Clinical Impact and Evolving Perspectives”, Orlando, FL, March 5th, 2005.

1035. Clinical Outcomes of PCI in High Risk Patients. Presented at the course “Pharmacologic Efficacy in Interventions: Contributions of Ischemia and Bleeding”, Orlando, FL, March 5th, 2005.

1036. Outcomes of the Polymer-Based, Paclitaxel-Eluting TAXUS Stent In Complex Lesions: Principal Clinical and Angiographic Results From the TAXUS-V Pivotal Randomized Trial. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 6th, 2005.

1037. Perspectives on the ENDEAVOR-II trial. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 6th, 2005.

1038. A Prospective, Randomized U.S. Trial of the PTFE Covered JOSTENT for the Treatment of Diseased Saphenous vein Grafts: The BARRICADE Trial. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 6th, 2005.

1039. Effectiveness of Distal Embolic Protection During Primary Angioplasty: Final 6-month Results from the Prospective, Randomized, EMERALD Trial.. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 6th, 2005.

1040. Predictors and Clinical Impact of the Procedural ACT level in Patient Receiving Bivalirudin during PCI: A REPLACE II Sub Study. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 6th, 2005.

1041. TAXUS Trials Meta Analysis: A critical analysis. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 6th, 2005.

1042. Predictors of Infarct Size by Technetium-99m Sestamibi Imaging After Angioplasty in Acute Myocardial Infarction: Meta-analysis from Four Contemporary Randomized Trials. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 7th, 2005.

1043. Primary Percutaneous Coronary Intervention for Myocardial Infarction in Women. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 7th, 2005.

1044. Thirty Day and Six Month Outcomes after Saphenous Vein Graft Stenting with Distal Protection in patients Excluded from Randomized Trials: The FilterWire EX High Risk Registry. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 8th, 2005.

1045. A Prospective, Multicenter Randomized Trial of the Paclitaxel-Eluting Stent vs. Vascular Brachytherapy in Patients with Coronary In-Stent Restenosis: The TAXUS-V ISR Trial. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 8th, 2005.

1046. Paclitaxel-eluting stents: From Technology to Trials to Widespread Application. Boston, MA, March 16th, 2005.

1047. Drug-eluting stents: Evidence-based Medicine and New Directions. Cardiology Grand Rounds, Tufts-New England Medical Center, Boston, MA, March 17th, 2005.

1048. Vulnerable Plaque Natural History Clinical Trials: From PROSPECT to PREVAIL. Presented at the 20th Annual Interventional Cardiology 2005: The International Symposium, March 22nd, 2005, Snowmass, CO.

1049. New Data from the TAXUS Stent Clinical Trials. Presented at the 20th Annual Interventional Cardiology 2005: The International Symposium, March 22nd, 2005, Snowmass, CO.

1050. An Evidence-Based Medicine Analysis of DES Clinical Trial Results: Defining Practice Standards. Presented at the 20th Annual Interventional Cardiology 2005: The International Symposium, March 23rd, 2005, Snowmass, CO.

1051. A comprehensive Assessment of Acute MI Therapies: Primary PCI: Adjunctive Pharmacology, DES, and Infarct Size Reduction. Presented at the 20th Annual Interventional Cardiology 2005: The International Symposium, March 23rd, 2005, Snowmass, CO.

1052. An Evidence Based Medicine Examination of the DES Clinical Trial Results. Presented at China Interventional Therapeutics 2005, April 1st, 2005, Beijing, China.

1053. The Diagnosis and Treatment of Vulnerable Plaque. Presented at China Interventional Therapeutics 2005, April 1st, 2005, Beijing, China.

1054. Case Reviews from the U.S. CTO Symposium. Presented at China Interventional Therapeutics 2005, April 1st, 2005, Beijing, China.

1055. The Future of Interventional Cardiology. Presented at China Interventional Therapeutics 2005, April 2nd, 2005, Beijing, China.

1056. Reperfusion therapy in acute myocardial infarction; update 2005. Cardiology Fellow's Rounds, Columbia University Medical Center, NY, NY, April 8th, 2005.

1057. Current and evolving status of bivalirudin as the foundation anticoagulant in ACS and PCI. Angiomax consultant's meeting. NY, NY, April 9th, 2005.

1058. Drug-eluting stents: Current concepts, future directions. Presented at the 2nd annual Cardiac and Vascular Symposium: Innovations 2005, University of Maryland, April 13th, 2005.

1059. Putting DES to the Test: Treatment of High Risk Lesions. Presented at the 11th annual Interventional Cardiology Fellow's Course, Boston, MA, April 13th, 2005.

1060. Drug-eluting stents: Components, Trials and Terminology. Presented at the 11th annual Interventional Cardiology Fellow's Course, Boston, MA, April 14th, 2005.

1061. Drug-eluting stent systems I: Polymer-based paclitaxel release. Presented at the 11th annual Interventional Cardiology Fellow's Course, Boston, MA, April 14th, 2005.

1062. Evidence-based medicine guidelines to drug-eluting stent use. Presented at the 11th annual Interventional Cardiology Fellow's Course, Boston, MA, April 14th, 2005.

1063. The Future of PCI in ACS: Adjunctive devices and pharmacologic strategies. Presented at the 11th annual Interventional Cardiology Fellow's Course, Boston, MA, April 14th, 2005.

1064. Angioplasty in AMI I: primary PCI state of the art. Presented at the 11th annual Interventional Cardiology Fellow's Course, Boston, MA, April 15th, 2005.

1065. Chronic total occlusions: lessons from the summit. Presented at the 11th annual Interventional Cardiology Fellow's Course, Boston, MA, April 15th, 2005.

1066. Strengths and Weaknesses of the TAXUS stent. Presented at the 10th Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 28th, 2005.

1067. Recent updates from the TAXUS Trials. Presented at the 10th Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 28, 2005.

1068. Results of the Pivotal TAXUS-V Trial in Complex Patients. Presented at the 10th Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 28, 2005.

1069. The Emerald Trial - Lessons learned. Presented at the 10th Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 29, 2005.

1070. Optimizing outcomes of Primary PCI: From CADILLAC to HORIZONS. Presented at the 10th Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 29, 2005.

1071. Zen Philosophy – the key to CTO successes. Presented at the 10th Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 30, 2005.

1072. Evidence-Based Medicine analysis of Current DES clinical Use Guidelines: A roadmap for Clinicians. Presented at the 10th Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 30, 2005.

1073. The Future of Interventional Cardiology in Acute Coronary Syndromes. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Ponte Verde beach, FL, May 4th, 2005.

1074. Perspectives on the Clinical Outcomes with the TAXUS stent. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Ponte Verde Beach, FL, May 5th, 2005.

1075. The invasive approach to non ST-segment elevation myocardial infarction. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Ponte Verde Beach, FL, May 5th, 2005.

1076. An evidence-based medicine approach to drug-eluting stent usage. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Ponte Verde Beach, FL, May 6th, 2005.

1077. Paclitaxel-eluting Stents. Presented at Medical Grand Rounds, Columbia Presbyterian Medical Center, New York City, May 18th, 2005.

1078. The Pivotal TAXUS-V trial: Insights to drug-eluting stents in complex lesions. Presented at the TAXUS Speaker's Bureau, Minneapolis, MN, May 19th, 2005.

1079. Perspectives on Paclitaxel-eluting Stent Safety and Efficacy from the TAXUS Trials Meta-Analysis. Presented at the TAXUS Speaker's Bureau, Minneapolis, MN, May 19th, 2005

1080. Interpreting the "Head to Head" Cypher vs. TAXUS Trials. Presented at the TAXUS Speaker's Bureau, Minneapolis, MN, May 19th, 2005.

1081. Novel insight from the TAXUS-V trial. Presented at the EuroPCR meeting, May 25th, 2005, Paris, France.

1082. New evidence based medicine findings on drug eluting stents: Insights from ACC 2005 randomized clinical trials. Presented at the EuroPCR meeting, May 25th, 2005, Paris, France.

1083. The impact of elution rates on DES results. Presented at the EuroPCR meeting, May 25th, 2005, Paris, France.

1084. The future of anticoagulation therapy in patients undergoing percutaneous coronary intervention. Presented at the EuroPCR meeting, May 25th, 2005, Paris, France.

1085. Chronic Total Occlusions: Latest Guidewire Techniques. Presented at the EuroPCR meeting, May 26th, 2005, Paris, France.

1086. DES in complex lesion. A technical case review. Presented at the EuroPCR meeting, May 26th, 2005, Paris, France.

1087. Pharmacologic prevention of contrast-induced nephropathy. Presented at the EuroPCR meeting, May 26th, 2005, Paris, France.

1088. Contrast optimization techniques-managing risk patients. Presented at the EuroPCR meeting, May 27th, 2005, Paris, France.

1089. Intervention of the future and future intervention. Presented at the EuroPCR meeting, May 27th, 2005, Paris, France.

1090. Chronic total occlusions: lessons from the summit. Webcast June 1st, 2005.

1091. Update on distal protection and thrombectomy devices. Presented at the course Intervention 2005, New York City, NY, June 2nd, 2005.

1092. Reperfusion therapy in acute myocardial infarction. Presented at the course Advances in the Treatment of Coronary Artery Disease, June 3rd, 2005, New York City, NY.

1093. Drug-eluting stent update: current results and future directions. Presented at the 6th Moscow International Course on Endovascular Surgery of Congenital and Acquired Heart Diseases, Coronary and Vascular Pathology, Moscow, Russia, June 9th, 2005.

1094. Optimal treatment of degenerated saphenous vein grafts. Presented at the 6th Moscow International Course on Endovascular Surgery of Congenital and Acquired Heart Diseases, Coronary and Vascular Pathology, Moscow, Russia, June 9th, 2005.

1095. The Future of Transcatheter Valvular Therapies. Presented at the 6th Moscow International Course on Endovascular Surgery of Congenital and Acquired Heart Diseases, Coronary and Vascular Pathology, Moscow, Russia, June 10th, 2005.

1096. A Natural History Study: The PROSPECT Trial. Presented at the 3rd International Vulnerable Plaque meeting – VPM2005, Capri, Italy, June 13th, 2005.

1097. Drug-eluting stents for intermediate lesions: Rationale and results. Presented at the annual SOLACI meeting, Mexico City, Mexico, July 20th, 2005

1098. TAXUS vs. Cypher – are there any meaningful differences? Presented at the annual SOLACI meeting, Mexico City, Mexico, July 20th, 2005.

1099. Drug-eluting stents for specific angiographic subsets. Presented at the annual SOLACI meeting, Mexico City, Mexico, July 20th, 2005.

1100. A day in the life of TCT. Presented at the annual SOLACI meeting, Mexico City, Mexico, July 21st, 2005.

1101. The TAXUS program – current status and future directions. Presented at the annual SOLACI meeting, Mexico City, Mexico, July 21st, 2005.

1102. Drug-eluting stent update: The evidence is mounting. Presented at the 1st Midwest Regional Heart and Vascular Meeting, Boyne Falls, Michigan, July 30th, 2005.

1103. TAXUS Current Status and Future Directions. BSC National Sales Meeting, Cleveland, Ohio, August 17th, 2005.

1104. Sinoplasty treatment of mitral regurgitation. Presented at Multidisciplinary Rounds, Columbia University Medical Center, New York City, NY, August 25th, 2005.

1105. Acute myocardial infarction therapies. Columbia University Medical Center, New York City, NY, August 25th, 2005.

1106. New directions in primary angioplasty. Cardiology Grand Rounds, Columbia University Medical Center, New York City, NY, September 8th, 2005.

1107. Moderator and edited live case presentations. Mitral valve technologies. At the AATS Postgraduate course "Valvular Heart disorders", Chicago, IL, September 9th and 10th, 2005.

1108. Role and Perspectives of Bivalirudin in PCI. Presented at the Annual TEAM Course, Madrid, Spain, September 21st, 2005.

1109. Lessons learned from TAXUS V. Presented at the Annual TEAM Course, Madrid, Spain, September 21st, 2005.

1110. Thrombus containing lesions and stent thrombosis in DES. Presented at the Annual TEAM Course, Madrid, Spain, September 22nd, 2005.

1111. The ZoMaxx DES Program. Presented at the Annual TEAM Course, Madrid, Spain, September 22nd, 2005.

1112. Anticoagulation in PCI Debate: Pro Bivalirudin. Presented at the Annual TEAM Course, Madrid, Spain, September 22nd, 2005.

1113. TAXUS V – Complex Intervention. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27th, 2005.

1114. Primary Angioplasty – New Approaches. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27th, 2005.

1115. A Critical Appraisal of the “Head-to-Head” Cypher vs. TAXUS Trials. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27th, 2005.

1116. New Strategies to diagnose and treat vulnerable plaque. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27th, 2005.

1117. Drug-eluting stent update: TAXUS and Everolimus stents. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27th, 2005.

1118. The MPS integrated next-generation cath-lab system. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27th, 2005.

1119. TAXUS DES Safety and Efficacy. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27th, 2005.

1120. When to use DES: Evidence-based Medicine Guidance. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27th, 2005.

1121. The SPIRIT Trials: Design and Rationale. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 28th, 2005.

1122. Forthcoming TCT Highlights 2005. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 28th, 2005.

1123. Lessons from the first two CTO Summits. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 16th, 2005.

1124. TCT 2005 Crossfire: Trials, Tribulations, Current Trends and Future Projections. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 17th, 2005.

1125. Paclitaxel-eluting stents: Update 2005. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 17th, 2005.

1126. PROSPECTS for the invasive and non-invasive diagnosis of vulnerable plaque: Surveying the landscape and narrowing the field. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 17th, 2005.

1127. Bivalirudin in PCI: A Risk-Benefit Analysis (and ACUITY Preamble). Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 17th, 2005.

1128. First presentation of the 3-year TAXUS-IV results. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 18th, 2005.

1129. Thrombectomy in STEMI - Late breaking trial dynamic commentary. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 19th, 2005.

1130. The Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 19th, 2005.

1131. A Future Vision for Interventional Cardiovascular Medicine: Clinical, Regulatory, Scientific and Socioeconomic Perspectives. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 19th, 2005.

1132. Overall State of Embolic Protection. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 19th, 2005.

1133. Vulnerable Plaque: The PROSPECT for Vulnerable Plaque Detection and Treatment. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 19th, 2005.

1134. BVS – 3rd Generation Stents: Here today, gone tomorrow . Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 19th, 2005.

1135. A Radical New Approach to Angiography and Angioplasty Guidance: The MPS-Ready Cath Lab and PCI Applications. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20th, 2005.

1136. Evidence-based medicine analysis of current DES clinical use guidelines: A roadmap for practicing interventionalists. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20th, 2005.

1137. Do you want the truth? A CYPHER vs. TAXUS mega-trial is required to resolve comparative safety and efficacy issues! Presented at the 17th annual scientific

sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20th, 2005.

1138. Bivalirudin in ACS and high risk patients: ACUITY trial update. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20th, 2005.

1139. Primary Mechanical Reperfusion in Acute ST-segment MI. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20th, 2005.

1140. Updated meta-analysis of TAXUS clinical trials: safety and efficacy demonstrated in 3,445 randomized patients. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20th, 2005.

1141. TAXUS - First presentation of the 3 year TAXUS data. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20th, 2005.

1142. Drug-eluting stents and bivalirudin in AMI: HORIZONS rationale, design and status. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20th, 2005.

1143. Everolimus drug-eluting stents: Technical aspects and a comprehensive review of the EU and US Guidant SPIRIT program. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20th, 2005.

1144. The Corazon aortic valve remodeling concept and procedure. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20th, 2005.

1145. Do Drug Release Kinetics and Dose kinetics Impact DES outcomes II? Final PISCES and COSTAR I Results. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20th, 2005.

1146. Synergistic efficacy from combined zotarolimus and dexamethasone elution: Platform for a next generation DES stent. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 21st, 2005.

1147. Multimodality imaging of the coronary tree in patients with acute coronary syndromes: The PROSPECT natural history study. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 21st, 2005.

1148. Supersaturated Aqueous Oxygen: AMIHOT I analysis and AMIHOT II status. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 21st, 2005.

1149. Induced hypothermia to prevent contrast nephropathy. Presented at the 17th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 21st, 2005.

1150. Conflict of Interest: Device Development Clinical Phase. Understanding the role of the Clinician Investigator. Presented at the 3rd Dartmouth Device Development Symposium, October 27th, 2005, Woodstock, VT.

1151. Optimizing the results of primary angioplasty in acute myocardial infarction. Medical Grand Rounds, Stamford Hospital, Stamford, CT, November 9th, 2005.

1152. Percutaneous coronary intervention in patients with diabetes mellitus. Presented during the webcast “Complex lesion and patient intervention”, November 9th, 2005.

1153. Should the use of Bivalirudin Extent to the Emergency Room? Presented at the course CRT at AHA, November 12th, 2005.

1154. Emerging Developments and Future Directions in the Detection of Vulnerable Patients and Vulnerable Plaques. Presented at the SHAPE Meeting at the 78th annual scientific sessions of the American Heart Association, Dallas, TX, November 14th, 2005.

1155. Topic: DES: Current Data, Unapproved Indications, Oral antiplatelet Rx and Late Stent Thrombosis. Presented at the 78th annual scientific sessions of the American Heart Association, Dallas, TX, November 12th, 2005.

1156. How to detect Vulnerable plaque with new imaging methods: CTA, MRI, and IVUS. Presented at the 78th annual scientific sessions of the American Heart Association, Dallas, TX, November 14th, 2005.

1157. Latest Clinical Trial Results with Drug-eluting stents. Presented at the 78th annual scientific sessions of the American Heart Association, Dallas, TX, November 14th, 2005.

1158. The ACUITY Trial. Presented at the 78th annual scientific sessions of the American Heart Association, Dallas, TX, November 14th, 2005.

1159. Beneficial effect of the 2.25mm Paclitaxel-Eluting TAXUS Stent in Patients with Small coronary arteries: Results from the TAXUS V Trial. Presented at the 78th

annual scientific sessions of the American Heart Association, Dallas, TX, November 15th, 2005

1160. Three-Year Safety and Efficacy of the Polymer-Based Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial. Presented at the 78th annual scientific sessions of the American Heart Association, Dallas, TX, November 15th, 2005.

1161. The approach to complex chronic total coronary occlusions. Columbia University Medical Center, November 30th, 2005.

1162. Clinical trial update in acute myocardial infarction – post TCT/AHA synthesis. Presented at the course "Advanced Interventional Therapies", New York City, NY, December 2nd, 2005.

1163. Clinical trial update with drug-eluting stents – post TCT/AHA synthesis. Presented at the course "Advanced Interventional Therapies", New York City, NY, December 3rd, 2005.

1164. Imaging the Vulnerable Patient – the Interventional Approach. Presented at the 38th Annual New York Cardiovascular Symposium Major Topics in Cardiology Today, New York, NY, December 9th, 2005.

1165. Drug-eluting Stent Update 2006. Cardiology Grand Rounds, St. Vincent's Hospital, New York City, NY, January 12th, 2006.

1166. Current standards and future directions in primary angioplasty for acute myocardial infarction. Cardiology Grand Rounds, Montefiore Medical Center, Bronx, NY, January 17th, 2006.

1167. Pre-emptive stenting of vulnerable plaque and moderate lesions. Boston Scientific Corp. Scientific Advisory Board Meeting, Boston, MA, January 18th, 2006.

1168. Drug-eluting stents: Where are we, what challenges remain? Boston Scientific Corp. Scientific Advisory Board Meeting, Boston, MA, January 18th, 2006.

1169. Current and future therapies to enhance myocardial salvage after acute myocardial infarction. The 2nd International Conference on Cell Therapy in Cardiovascular Diseases. New York City, NY, January 20th, 2006.

1170. Drug- Eluting Stents: Current Status of Adjunctive Pharmacologic Therapy. Presented at the 16th Annual ISET Course, Miami, FL, January 22nd, 2006.

1171. Drug- Eluting Stent Randomized Trials: Are There Meaningful Differences Between the Devices? Presented at the 16th Annual ISET Course, Miami, FL, January 22nd, 2006.

1172. Chronic Total Occlusions: Current Perspectives. Presented at the 16th Annual ISET Course, Miami, FL, January 22nd, 2006.

1173. ACUITY Trial: A landmark investigation in patients with acute coronary syndromes. Medicine's Advisory Board Meeting, New York City, NY, February 4th, 2006.

1174. Chronic Total Occlusions: Penetrating Insights. Keynote address. Abbott Vascular Devices National Sales Meeting, Austin TX, February 7th, 2006.

1175. Drug-eluting Stents: Current Insights and a Vision for the Future. Presented at the 28th annual Cardiovascular Symposium, Holy Cross Hospital, Ft. Lauderdale, FL, February 10th, 2006.

1176. Use of Bivalirudin in Acute Coronary Syndromes: From the emergency room to the cath lab. Presented at the Joint Interventional Meeting (JIM) 2006, Rome, Italy, February 15th, 2006.

1177. Perspectives on saphenous vein graft intervention. Presented at the Joint Interventional Meeting (JIM) 2006, Rome, Italy, February 16th, 2006.

1178. The Xience Drug-eluting Stent: pre0clinical and clinical update. Presented at the Joint Interventional Meeting (JIM) 2006, Rome, Italy, February 17th, 2006.

1179. Outcomes with the TAXUS stent in complex lesions and patients. Presented at the Joint Interventional Meeting (JIM) 2006, Rome, Italy, February 17th, 2006.

1180. Lessons in Recanalizing Chronic Total occlusions from the First Two CTO Summits. Presented at the 3rd International CTO Summit, February 23rd, 2006.

1181. Contemporary strategies in the Management of Non ST-segment Elevation MI. Presented at medical Grand Rounds, University of San Diego California, March 1st, 2006, San Diego, California.

1182. TAXUS RCT meta-analysis and registries: Insights and unsettled issues. Presented at the 5th Annual Course "Enter the DES Revolution: A Critical Appraisal", Atlanta, GA, March 11th, 2006.

1183. Everolimus Elution from a Durable Polymer: Xience. Presented at the 5th Annual Course "Enter the DES Revolution: A Critical Appraisal", Atlanta, GA, March 11th, 2006.

1184. Prospective, Randomized Comparison of Heparin Plus IIb/IIIa Inhibition Vs. Bivalirudin With or Without IIb/IIIa Inhibition in Patients With Acute Coronary

Syndromes: The ACUITY Trial. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 12th, 2006.

1185. Vulnerable Plaque the Future: Devices or Drugs? Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 12th, 2006.

1186. A Prospective, Multicenter, Randomized Trial Evaluating the TAXUS Paclitaxel-Eluting Coronary Stent Versus Vascular Brachytherapy for the Treatment of Bare Metal Stent In-Stent Restenosis: The TAXUS-V ISR Trial. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 12th, 2006.

1187. Drug eluting Stents in Complex Lesions: An Evidence-Based Medicine Approach. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 12th, 2006.

1188. Prospective, Randomized Comparison of Routine Upfront Initiation Versus Selective Use of Glycoprotein IIb/IIIa Inhibitors in Patients with Acute Coronary Syndromes: The ACUITY Timing Trial. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 13th, 2006.

1189. Do the Traditional Risk Factors of Vessel Size, Lesion Length and Diabetes Mellitus Predict Restenosis with TAXUS Stents? Insights from a TAXUS Meta-Analysis. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 13th, 2006.

1190. Acute Myocardial Infarction and Cardiogenic Shock: Future Directions. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 13th, 2006.

1191. Role of Direct Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS. Presented during the course “Optimizing Outcomes in ACS and PCI: Evaluating the Findings from Late-Breaking Clinical Trials in Antithrombin Therapy”, Atlanta, GA, March 14th, 2006.

1192. Update on TAXUS V ISR. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 14th, 2006.

1193. Putting DES to the Test: The TAXUS Clinical Program. Atlanta, GA, March 15th, 2006.

1194. New insights into the treatment of patients with acute coronary syndromes. Medical Grand Rounds, Beth Israel Medical Center, New York City, NY, March 27th, 2006.

1195. Advances in primary angioplasty for acute myocardial infarction. Presented at the course “Update in Cardiovascular Medicine”, Southbury, CT, March 28th, 2006.

1196. CTO Angioplasty II: Basic and advanced techniques. Presented at the 12th Annual North American Interventional Cardiology Fellow’s Course, San Jose, CA, March 29th, 2006.

1197. Drug Eluting Stents – Current Landscape. Presented at the 12th Annual North American Interventional Cardiology Fellow’s Course, San Jose, CA, March 29th, 2006.

1198. Proven Drug-Eluting Stent Systems II: Polymer-based paclitaxel release. Presented at the 12th Annual North American Interventional Cardiology Fellow’s Course, San Jose, CA, March 30th, 2006.

1199. Emerging Drug-Eluting Stent Systems II: Xience V and ZoMaxx. Presented at the 12th Annual North American Interventional Cardiology Fellow’s Course, San Jose, CA, March 30th, 2006.

1200. Evidence-based medicine guidelines to drug-eluting stent use. Presented at the 12th Annual North American Interventional Cardiology Fellow’s Course, San Jose, CA, March 31st, 2006.

1201. Cypher vs. Taxus – A critical review of the evidence. Presented at the 12th Annual North American Interventional Cardiology Fellow’s Course, San Jose, CA, March 31st, 2006.

1202. Angioplasty in AMI: Primary PCI state of the art. Presented at the 12th Annual North American Interventional Cardiology Fellow’s Course, San Jose, CA, April 1st, 2006.

1203. Interventional Pharmacology IV: Bivalirudin in ACS and PCI. Presented at the 12th Annual North American Interventional Cardiology Fellow’s Course, San Jose, CA, April 1st, 2006.

1204. Expanding Use of Bivalirudin Beyond PCI: Lessons from ACUITY to EVLOUTION. Presented at the annual Cardiovascular Revascularization Therapy course, Washington DC, April 3rd, 2006.

1205. Superior Strategies for AMI Management – No need for facilitated pharmacology. Presented at the annual Cardiovascular Revascularization Therapy course, Washington DC, April 3rd, 2006.

1206. The PROSPECT Trial: Design and Rationale for a Vulnerable Plaque Natural History Study. Presented at the annual Cardiovascular Revascularization Therapy course, Washington DC, April 3rd, 2006.

1207. Should Non-obstructive Lesions be Treated with DES? Presented at the annual Cardiovascular Revascularization Therapy course, Washington DC, April 3rd, 2006.

1208. The ACUITY Trial. Presented at the annual Cardiovascular Revascularization Therapy course, Washington DC, April 4th, 2006.

1209. CIT Crossfire – Current status and future direction in interventional vascular therapies. Satellite transmission to the annual China Interventional Therapies course, April 6th, 2006.

1210. Invasive and non-invasive vulnerable plaque detection. Presented at the 11th Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 25, 2006.

1211. The TAXUS Clinical Trial Program. Presented at the 11th Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 26, 2006.

1212. The XIENCE Clinical Trial Program. Presented at the 11th Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 26, 2006.

1213. Defending percutaneous aortic valve replacement. Presented at the 3rd Transcatheter Valve Symposium, San Francisco, CA, April 28th, 2006.

1214. Detection of Vulnerable Plaque: Invasive and Non-invasive Imaging Approaches. Bristol-Myers Squibb, Boston, Mass, May 3rd, 2006.

1215. Basic CTO techniques: Wires, Guides, Patient Issues. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Chicago, IL, May 12th, 2006.

1216. Prospects for the Invasive and Non-Invasive Identification of Vulnerable Plaque. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Chicago, IL, May 12th, 2006.

1217. Mechanical Thrombectomy for AMI: Its Day is Done. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Chicago, IL, May 12th, 2006.

1218. Dedicated devices for CTO treatment. Presented at EuroPCR, Paris, France, May 16th, 2006.

1219. Perspective: an evidence-based medicine review of new DES clinical trials. Presented at EuroPCR, Paris, France, May 17th, 2006.

1220. Xience V - A Next Generation DES. Presented at EuroPCR, Paris, France, May 17th, 2006.

1221. Upstream Treatment of ACS Patients- Insights from ACUITY. Presented at EuroPCR, Paris, France, May 18th, 2006.

1222. Drug-Eluting stents of the future: combining and antiproliferative and an anti-inflammatory agent for enhanced efficacy. Presented at EuroPCR, Paris, France, May 19th, 2006.

1223. Replacement of Unfractionated Heparin. Presented at the course Advances in Interventional Cardiology, Munich, Germany, May 20th, 2006.

1224. The PROSPECT Trial. Presented at the 4th Vulnerable Plaque Meeting (VPM), Capri, Italy, May 21st, 2006.

1225. The VIP Program. Presented at the 4th Vulnerable Plaque Meeting (VPM), Capri, Italy, May 21st, 2006.

1226. Late Breaking Trials from EuroPCR. Webcast. Clinicaltrials.duke.org, May 5th, 2006.

1227. Vulnerable Plaque – The Next Five Years. Presented at the course VIP 2006: A Vulnerable Plaque Summit. Houston, Texas, June 10th, 2006.

1228. Keynote address: Optimizing the Results of Upstream Pharmacologic Therapy in Acute Coronary Syndromes: Insights from ACUITY. Presented at the 15th Advanced Cardiovascular Interventions Symposium, June 15th, 2006.

1229. Drug-eluting stents and direct thrombin inhibitors in STEMI: Update of HORIZONS. Presented at the 15th Advanced Cardiovascular Interventions Symposium, June 16th, 2006.

1230. Basic and advanced techniques in CTO recanalization. CTO preceptorship course, Columbia University Medical Center, June 19th, 2006.

1231. Optimizing upstream treatment of patients with acute coronary syndromes – the ACUITY Trial. Presented at Cardiac Catheterization Conference, Columbia University Medical Center, June 20th, 2006.

1232. Update in Acute Myocardial Infarction Therapies. Presented at the course “Clinical Advances in Cardiology”, Naples Florida, June 24th, 2006.

1233. Coronary Artery Disease and Atherosclerosis NHLBI Level 1 Working Group. June 27th and 28th, Bethesda, Md.

1234. DES Guideline Update. Presented at the course TOPIC 2006, Tokyo, Japan, July 21st, 2006.

1235. Current Consensus and future direction of PCI for chronic total occlusions. Presented at the course TOPIC 2006, Tokyo, Japan, July 21st, 2006.

1236. Detection and treatment of vulnerable plaque. Presented at the course TOPIC 2006, Tokyo, Japan, July 21st, 2006.

1237. Primary Angioplasty in Acute Myocardial Infarction: A Primer for Interventional Cardiology Fellows. Fellows Conference. New York Presbyterian Hospital, Columbia University Medical Center, July 31st, 2006.

1238. Bivalirudin – a new player in primary percutaneous coronary intervention. Presented at the annual Scientific Sessions of the European Society of Cardiology, Barcelona, Spain, September 4th, 2006.

1239. Role of new devices in CTO angioplasty. Presented at the annual Scientific Sessions of the European Society of Cardiology, Barcelona, Spain, September 4th, 2006.

1240. Upstream treatment of ACS patients – Insights and Conclusions from ACUITY. Presented at the annual Scientific Sessions of the European Society of Cardiology, Barcelona, Spain, September 4th, 2006.

1241. XIENCE V: Components review of a drug-eluting stent. Presented at the annual Scientific Sessions of the European Society of Cardiology, Barcelona, Spain, September 5th, 2006.

1242. CoreValve Revalving Percutaneous Aortic Valve Replacement: Update 2006. Presented at the PICS annual meeting, Las Vegas, NV, September 12th, 2006.

1243. Debate: All patients with stroke and PFO should be entered in randomized trials: Pro. Presented at the PICS annual meeting, Las Vegas, NV, September 12th, 2006.

1244. Challenges and Pitfalls in Designing Meaningful Clinical Trials Using New Percutaneous Therapies in patients with Mitral Regurgitation. Presented at the PICS annual meeting, Las Vegas, NV, September 13th, 2006.

1245. Anticoagulation in the ACS Patient from Presentation to PCI. Beth Israel Deaconess Cardiology Grand Rounds, Boston, Mass, September 15th, 2006.

1246. Basic and advanced techniques in CTO recanalization. CTO preceptorship course, Columbia University Medical Center, September 25th, 2006.

1247. The ACUITY Trial: Insights beneath the surface. Boston, MA, September 30, 2006.

1248. Are drug-eluting stents over-used? Are they safe and effective? Presented at the 6th Controversies and Advances in the Treatment of Cardiovascular Diseases course, Los Angeles, CA, October 6th, 2006.

1249. Are heparin and glycoprotein IIb/IIIa inhibitors on their way out? New antithrombotic and antiplatelet agents. Presented at the 6th Controversies and Advances in the Treatment of Cardiovascular Diseases course, Los Angeles, CA, Washington DC, October 6th, 2006.

1250. PCI Pharmacology – What's Really Important. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 22nd, 2006.

1251. Lessons from the CTO Summit: Highlights from Three Years of Unadulterated Live Cases. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 22nd, 2006.

1252. CTO Recanalization: Core Concepts. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 22nd, 2006.

1253. TCT Crossfire: Recasting the Landscape of Interventional Cardiovascular Medicine. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 23rd, 2006.

1254. DES Evidenced-Based Medicine: Perspectives on Emerging Safety Concerns, Real World Outcomes and Use Recommendations. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 23rd, 2006.

1255. PROSPECTS for the Prevention of Death and Myocardial Infarction: From Natural History Studies to Novel Therapeutic approaches. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 23rd, 2006.

1256. Drug-eluting Stents: What we've learned so far. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 23rd, 2006.

1257. ACUITY PCI: A prospective trial of patients with acute coronary syndromes undergoing PCI after randomization to heparin plus glycoprotein IIb/IIIa inhibitors vs. bivalirudin with or without glycoprotein IIb/IIIa inhibitors: Thirty day clinical and angiographic core laboratory results. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 24th, 2006.

1258. Independent patient level Independent Physician-Assessed Patient Level Meta-Analyses: Randomized Trials. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 24th, 2006.

1259. Shifting Paradigms in Pharmacologic and Interventional Therapies for Acute Coronary Syndromes and Acute Myocardial Infarction. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 24th, 2006.

1260. Primary Angioplasty in AMI: Current Standards and Future Directions. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 24th, 2006.

1261. CTO angioplasty is difficult: Why bother? Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 24th, 2006.

1262. The TCT 2006 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 24th, 2006.

1263. Taking the Evidence-Based Approach to ACS: Examination of New Trial Data. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 25th, 2006.

1264. Xience and ZoMaxx in Perspective. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 25th, 2006.

1265. Evidence-Based Medicine Update on DES Use Guidelines: Highlighting the Meaningful Changes in 2006. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26th, 2006.

1266. Antithrombotic alternatives for patients with ACS managed invasively: Making the case for: Bivalirudin for the best overall outcomes (and most cath lab compatible). Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26th, 2006.

1267. Virtual histology II: First presentation of the baseline clinical features and plaque characteristics from the PROSPECT Trial. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26th, 2006.

1268. An Updated Meta-Analysis of the TAXUS Randomized Controlled Trials. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26th, 2006.

1269. Primary Mechanical Reperfusion in Acute MI. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26th, 2006.

1270. Systemic Hypothermia to Prevent Contrast Nephropathy: The COOL-RCN Pilot and Randomized Trials. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26th, 2006.

1271. The Abbott ZODIAC and Clever Combination Drug-Eluting Stent Program: Device, Description, Experimental Results and Future Directions. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, October 26th, 2006.

1272. DES and Bivalirudin in AMI: Clinical trial perspectives and HORIZONS update. Presented at the 18th annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26th, 2006.

1273. Acute Antithrombotic therapy post ACUITY and ISAR-REACT 2 Debate: GP IIb/IIIa inhibitors: Do they Remain a Critical Component of Care in High-Risk ACS Patients? Presented at the Global Cardiovascular Summit, Chicago, IL, November 10th, 2006.

1274. Comparison of Heparin Plus IIb/IIIa Inhibition Versus Bivalirudin With or Without IIb/IIIa Inhibition in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The ACUITY Trial. Presented at the 79th annual scientific sessions of the American Heart Association, Chicago, IL, November 14th, 2006.

1275. Long-Term Outcomes Following Treatment of In-Stent Restenosis with Drug-Eluting Stents: Insights from the TAXUS Meta-Analysis. Presented at the 79th annual scientific sessions of the American Heart Association, Chicago, IL, November 14th, 2006.

1276. Systemic Hypothermia to Prevent Contrast Nephropathy: The COOL RCN Pilot Trial. Presented at the 79th annual scientific sessions of the American Heart Association, Chicago, IL, November 15th, 2006.

1277. Reperfusion in acute myocardial infarction – Evidence-based medicine. Presented at the 7th New Frontiers in Interventional Cardiology Course, Krakow, Poland, December 1st, 2006.

1278. Drug-eluting stent controversies and future directions. Presented at the 7th New Frontiers in Interventional Cardiology Course, Krakow, Poland, December 1st, 2006.

1279. Pharmacologic therapies in the high risk patient with acute coronary syndromes. Presented at the 7th New Frontiers in Interventional Cardiology Course, Krakow, Poland, December 1st, 2006.

1280. Perspectives on the safety and efficacy of drug-eluting stents, and regulatory recommendations. FDA advisory panel presentation. Gaithersburg, MD, December 7th, 2006.

1281. Perspectives on the safety and efficacy of drug-eluting stents, and evidence-based medicine recommendations. Presented at the course "Advanced Interventional Strategies", New York City, NY, December 15th, 2006.

1282. Basic and advanced techniques for CTO recanalization. CTO preceptorship course, Columbia University Medical Center, New York City, NY, December 18th, 2006.

1283. Safety and efficacy of drug-eluting stents – the whole story. Foundation for Cardiovascular Medicine, San Diego, CA, December 20th, 2006.

1284. Basic and advanced techniques for CTO recanalization. CTO preceptorship course, Columbia University Medical Center, New York City, NY, January 8th, 2006.

1285. Reperfusion strategies to improve ventricular function in acute myocardial infarction. Presented at the Third International Conference on Cell Therapy for Cardiovascular Disease. New York City, NY, January 18th, 2007.

1286. Drug-eluting Stents: Current Status, Evidence Based and New Developments. Presented at the International Symposium on Endovascular Therapy 2007 course, Hollywood, FL, January 28th, 2007.

1287. Drug-eluting Stents and Late or Very Late Stent Thrombosis - What are the Facts? Presented at the International Symposium on Endovascular Therapy 2007 course, Hollywood, FL, January 28th, 2007.

1288. The Current Status of Adjunctive Pharmacological Therapy: Antiplatelet Therapy. Presented at the International Symposium on Endovascular Therapy 2007 course, Hollywood, FL, January 28th, 2007.

1289. Technical Lessons from the CTO Summit: Highlights from 3 Years of Unadulterated Live Cases. Presented at the 4th International Chronic Total Occlusion Summit, New York City, NY, February 22nd, 2007.

1290. The Drug-eluting Stent Controversy: Risks and Benefits of Widespread use. Cardiology Grand Rounds. Columbia University Medical Center, NY, NY, March 6th, 2007.

1291. Insights into Drug-eluting Stent Usage. Presented at the Thought Leaders Summit, Miami, FL, March 9th, 2007.

1292. Diagnosing vulnerable plaques and vulnerable patients. Presented at the Thought Leaders Summit, Miami, FL, March 9th, 2007.

1293. Future Technologic Developments to Reduce Stent Thrombosis: Bioabsorbable Stent; Non-Polymer Stents; Stents which promote Rapid Re-endothelialization. Presented at the CVI SES Symposium, Philadelphia, PA, March 13th, 2007.

1294. Evidence Based Medicine Indications for DES Usage: US Recommendations. Presented at the 6th annual "Enter the Drug-eluting Stent Revolution: A Critical Appraisal" course, New Orleans, LA, March 23rd, 2007.

1295. The Next Wave of DES in the US: The Abbott Xience V DES Program. Presented at the 6th annual "Enter the Drug-eluting Stent Revolution: A Critical Appraisal" course, New Orleans, LA, March 23rd, 2007.

1296. Clinical, Angiographic and IVUS Results from the Pivotal United States Randomized SPIRIT -III Trial of the Xience V Everolimus Eluting Coronary Stent System in Patients with Coronary Artery Disease. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 24th, 2007.

1297. Are Paclitaxel-eluting stents safe and effective compared to Bare Metal Stents? Long-term Results from the TAXUS Meta-analysis. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 25th, 2007.

1298. Update on Evolving Drug-Eluting Stent Programs: The XIENCE V Stent and the SPIRIT Trials. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 25th, 2007.

1299. What will 2007 unveil for DES – understanding the clinical data landscape. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 25th, 2007.

1300. Stent Selection for the Management of ST Segment Elevation Myocardial Infarction. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 26th, 2007.

1301. A Prospective, Natural History Study of Multimodality Invasive Imaging to Characterize Vulnerable Plaque: First Report of the Baseline Findings from the PROSPECT Trial. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 26th, 2007.

1302. A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes: Final One-Year Results From the ACUITY Trial. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 26th, 2007.

1303. Pharmacologic therapies in acute coronary syndromes. Cardiology grand rounds, Yale New Haven Medical Center, New Haven, CT, March 28th, 2007.

1304. Lessons Learned from the US 2007 CTO Summit. Presented at the course China Interventional Therapies, Beijing, China, March 30th, 2007.

1305. Drug-eluting stents: Delivering What We have Learned So Far. Presented at the course China Interventional Therapies, Beijing, China, March 30th, 2007.

1306. Drug-Eluting Stent Thrombosis: Facts and Perspectives – U.S. Insights. Presented at the course China Interventional Therapies, Beijing, China, March 31st, 2007.

1307. SPIRIT III: 9-Month Results of the US Pivotal Trial. Presented at the course China Interventional Therapies, Beijing, China, March 31st, 2007.

1308. Proven Drug-Eluting Stent Systems II: TAXUS. Presented at the 13th annual Interventional Cardiology Fellow's Course, Boston, MA, April 12th, 2007.

1309. Emerging Drug-Eluting Stent Systems II: Xience and Costar. Presented at the 13th annual Interventional Cardiology Fellow's Course, Boston, MA, April 12th, 2007.

1310. Evidence-Based Medicine Guidelines to Drug-Eluting Stent Use. Presented at the 13th annual Interventional Cardiology Fellow's Course, Boston, MA, April 13th, 2007.

1311. Interventional Pharmacology IV: Bivalirudin in ACS and PCI. Presented at the 13th annual Interventional Cardiology Fellow's Course, Boston, MA, April 14th, 2007.

1312. Drug-eluting stents: Controversies and Unsettled Issues. Great Neck, NY, April 19th, 2007.

1313. Landmark Trials in Acute Coronary Syndromes. Presented at the course "EDICT for ACS", New York City, NY, April 21st, 2007.

1314. 2007 Guidelines Update for DES: An Evidence Based Medicine Critical Analysis. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 25th, 2007.

1315. Should DES use be reduced due to safety concerns? Important Messages from the Randomized DES Trials. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 25th, 2007.

1316. Debate: Adjunct Pharmacology in ACS and PCI: Bivalirudin for the Best Overall Outcomes and Most Cath Lab Compatible. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 25th, 2007.

1317. Clinical Features and Plaque Characteristics from the PROSPECT Trial. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 25th, 2007.

1318. SPIRIT III (US Pivotal Study Results for Xience V Everolimus Eluting Coronary Stent). Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 25th, 2007.

1319. Taking the Evidence Based approach to ACS: Examination of New Antithrombin Trial Data. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 25th, 2007.

1320. ACUITY PCI: A prospective trial of patients with Acute Coronary Syndromes Undergoing PCI After Randomization to Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibitors: 30- Day clinical and Angiographic Core lab Results. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 26th, 2007.

1321. SPIRIT-III: Clinical Angiographic & IVUS Results from the Pivotal US Randomized SPIRIT-III Trial of the Xience V Everolimus Eluting Coronary Stent System in Patients with Coronary Artery Disease. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 26th, 2007.

1322. Current Status of Percutaneous Mitral Valve Annuloplasty Performed Through the Coronary Sinus. Presented at the 6th ACTS course, New York City, NY, May 2nd, 2007.

1323. The Drug-eluting Stent Controversy: Laying out the facts. Presented at the Big Ten Cardiovascular Summit, Columbus, Ohio, May 5th, 2007.

1324. Primary angioplasty in acute myocardial infarction; Update 2007. Presented at the new Milford Cardiovascular Summit, New Milford, CT, May 8th, 2007.

1325. Late stent thrombosis. Presented at the annual scientific sessions of the Society of Cardiac Angiography and Interventions, Orlando, FL, May 10th, 2007.

1326. The Xience V stent and the SPIRIT III trial. Presented at the annual scientific sessions of the Society of Cardiac Angiography and Interventions, Orlando, FL, May 11th, 2007.

1327. Stents vs. Statins: An Academic Debate. Presented at the Midwest Fellows Forum, Chicago, IL, May 17th, 2007.

1328. Spirit First 3-Year Update, and SPIRIT II+III Meta-analysis. Presented at EuroPCR, Barcelona, Spain, May 22nd, 2007.

1329. Drug-eluting stent safety and efficacy: On-label and off-label perspectives. Presented at EuroPCR, Barcelona, Spain, May 24th, 2007.

1330. The Prospect Trial Presented at the 4th Symposium on the Burden of Atherothrombotic Disease: Diagnosis and Therapy. New York City, NY, July 10th, 2007.

1331. Drug-eluting stent late thrombosis: What are the data and how should we respond? Presented at the 16th annual Advanced Cardiovascular Interventions course, Hilton Head, SC, July 12th, 2007.

1332. Vulnerable Plaque – Should we stent it? Presented at the 5th Vulnerable Plaque meeting, Santorini Greece, June 18th, 2007.

1333. The PROSPECT Trial – Baseline findings. Presented at the 5th Vulnerable Plaque meeting, Santorini Greece, June 18th, 2007.

1334. The long and winding road of interventional cardiology: A personal perspective. Presented at the 7th International Congress on Complications During Coronary interventions: Management and Prevention. Lausanne, Switzerland, June 20th, 2007.

1335. The technique of PCI. CTO: Too much hype? Presented at the 7th International Congress on Complications During Coronary interventions: Management and Prevention. Lausanne, Switzerland, June 20th, 2007.

1336. Bivalirudin in low and high risk patients undergoing PCI. Presented at the 7th International Congress on Complications During Coronary interventions: Management and Prevention. Lausanne, Switzerland, June 20th, 2007.

1337. Basic and advanced angioplasty techniques for CTO intervention. CTO preceptorship, New York City, NY, June 25th, 2007.

1338. Update on everolimus-eluting stents. Clinical cardiology research conference. Columbia University Medical Center, NYC, NY, June 28th, 2007.

1339. CYPHER: Safety and Efficacy. Presented at the SOLACI ’07 meeting, Buenos Aires, Argentina, July 4th.

1340. The paclitaxel family of stents. Presented at the SOLACI ’07 meeting, Buenos Aires, Argentina, July 4th.

1341. Antithrombin update – Role in PCI, ACS and AMI. Presented at the SOLACI ’07 meeting, Buenos Aires, Argentina, July 6th.

1342. Late DES Events: Do They Modify the Indications? Presented at the SOLACI ’07 meeting, Buenos Aires, Argentina, July 6th.

1343. DES in the Daily Practice: The importance of the Technique. Presented at the SOLACI ’07 meeting, Buenos Aires, Argentina, July 6th.

1344. The COURAGE trial in perspective. . Presented at the SOLACI ’07 meeting, Buenos Aires, Argentina, July 6th.

1345. Valvular Heart Disease: The year in Review: Progress Made – We still have a long way to go. Presented at the SOLACI ’07 meeting, Buenos Aires, Argentina, July 6th.

1346. Keynote address: TAXUS Stent Experiences. Presented at the annual TOPIC course, Tokyo, Japan, July 19th, 2007.

1347. DES thrombosis: Is it real or over-exaggerated? Presented at the annual TOPIC course, Tokyo, Japan, July 19th, 2007.

1348. CTO: Where are we now? Where are we going? Insights from the cases done in the past NY CTO summits. Presented at the annual TOPIC course, Tokyo, Japan, July 20th, 2007.

1349. Angioplasty strategies in acute myocardial infarction: Update 2007. Cardiology fellows conference, Columbia University Medical Center, New York City, NY, July 23rd, 2007.

1350. Challenges in Clinical Trial Design for Transcatheter Mitral Valve Therapies. Presented at the PICS 2007 course, Las Vegas, NV, July 24th, 2007.

1351. Angioplasty under Fire: An Interventionalist’s Perspective. Presented at the Summer in Seattle meeting, Seattle, WA August 1st, 2007.

1352. DES: Real World Outcomes. Presented at the Summer in Seattle meeting, Seattle, WA August 2nd, 2007.

1353. Safety and efficacy of everolimus-eluting stents. Presented at ANZET Interventional Cardiology, August 9th, 2007, Christchurch, New Zealand.

1354. My Worst Nightmare and Greatest Triumphs. Presented at ANZET Interventional Cardiology, August 9th, 2007, Christchurch, New Zealand

1355. Just how important is time to reperfusion in primary angioplasty for AMI? Presented at ANZET Interventional Cardiology, August 9th, 2007, Christchurch, New Zealand.

1356. Chronic total occlusion angioplasty: Update 2007. Columbia University Medical Center, New York, NY, August 27th, 2007.

1357. Myocardial and Microcirculatory Protection in Acute Coronary Syndromes. Presented at the course "Coronary Artery Disease: Prevention, Detection, and Treatment. Las Vegas, NV, September 10th, 2007.

1358. COURAGE: Interventional Perspectives. Presented at the course "Coronary Artery Disease: Prevention, Detection, and Treatment. Las Vegas, NV, September 11th, 2007.

1359. Future Directions: Can we Build Better Drug Eluting Stents? Presented at the course "Coronary Artery Disease: Prevention, Detection, and Treatment. Las Vegas, NV, September 11th, 2007.

1360. Chronic Total Occlusions: Rationale and Technique. Transmitted to the 1st Indian Cardiology Fellow's Course, New Delhi, India, October 1st, 2009.

1361. Management of Stable CAD: Should the Courage Trial Change Our Practice? Presented at the course Controversies and Advances in the Treatment of Cardiovascular Disease, Los Angeles, CA, October 5th, 2007.

1362. Drug-Eluting Stents: Do the Risks Outweigh the Benefits? Presented at the course Controversies and Advances in the Treatment of Cardiovascular Disease, Los Angeles, CA, October 5th, 2007.

1363. The Future of Interventional Cardiology: State of the Art lecture. Presented at the course Controversies and Advances in the Treatment of Cardiovascular Disease, Los Angeles, CA, October 5th, 2007.

1364. Diagnostic technique to identify and characterize vulnerable plaques. Transmitted to Padua, Italy, October 9th, 2007.

1365. The Drug-eluting Stent Controversy: Implications for Widespread Use. Presented at the annual meeting of the New York Cardiologic Society, New York City, NY, October 13th, 2007.

1366. PCI Pharmacology – Everything you need to know. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 19th, 2007.

1367. The Updated CRF Evidence-Based Medicine Guidelines for DES use. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 20th, 2007.

1368. Optimizing the Management of UA/NSTEMI: What the New Guidelines Tell Us". Spotlight for thehheart.org. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21st, 2007.

1369. The Drug Eluting Stent Controversy: Evidence Bases Medicine or Medicine by Media? Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21st, 2007.

1370. Virtual Histology II: Multimodality Imaging of the Coronary Tree in patients with Acute Coronary Syndromes: Final baseline PROSPECT Results. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21st, 2007.

1371. The “Live Case” approach to CTO Angioplasty: Lessons from 4 years of the CTO Summit. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21st, 2007.

1372. Safety and Efficacy of DES in AMI: perspectives from the randomized trials and registries and HORIZONS update. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21st, 2007.

1373. The Xience V DES System: Technical Review and Clinical Trial Updates (SPIRIT 1-4 and Registries). Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21st, 2007.

1374. Drug-Eluting Stents in Acute Myocardial Infarction. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21st, 2007.

1375. The Journey of Percutaneous Cardiovascular Intervention: From Empiricism to Evidence-based Medicine; From Balloons to Innovative Biotech Devices; the Next Challenges? Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 22nd, 2007.

1376. A Celebration of 30 years of PCI; Featuring Dolph Bachmann, who underwent the World's First Coronary Angioplasty by Andreas Gruentzig on September 16, 1977. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 22nd, 2007.

1377. An Evidence-Based Medicine Assessment of Drug-Eluting Stents: Safety and Efficacy for "On-Label" and "Off-Label" Clinical Indications. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 22nd, 2007.

1378. SPIRIT III: A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in patients with Coronary artery disease: 1-Year Follow-Up and Subgroup Analysis. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 22nd, 2007.

1379. The Evolving Antithrombotic landscape for patients with ST-Elevation myocardial infarction – what's on the HORIZON? Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 22nd, 2007.

1380. AMIHOT II: A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Primary Angioplasty in Anterior Myocardial Infarction. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 23rd, 2007.

1381. TAXUS Landmark analysis: Impact of Long-Term Clopidogrel Usage of Death, Myocardial Infarction and Stent Thrombosis. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 23rd, 2007.

1382. Characterization of non-flowing limiting coronary lesions: PROSPECT and Beyond. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 24th, 2007.

1383. HORIZONS AMI: A Prospective, randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction: 30 Day Results. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 25th, 2007.

1384. TCT 2007 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 24th, 2007.

1385. Embolic protection in SVGs and AMI: From theory to evidence. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 25th, 2007.

1386. The Best TCT 2007 Late Breaking Trials Revisited: A Critical Reappraisal of their Likely Impact. Presented at the 19th annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 25th, 2007.

1387. Bivalirudin in the STEMI PCI Patient: New Findings from Horizons. Presented at the 23rd Annual International Symposium on Interventional and Pharmacologic Reperfusion for ST-Elevation MI. Orlando, FL, November 3rd, 2007.

1388. Drug-Eluting Stents: Do the Outcomes Justify Their Use? Presented at the 80th annual scientific sessions of the American Heart Association, Orlando, FL, November 4th, 2007.

1389. Effect of Prolonged Thienopyridine Use on Long-term Clinical Outcomes After Drug-eluting Stents: Landmark Analysis from the TAXUS Trials. Presented at the 80th annual scientific sessions of the American Heart Association, Orlando, FL, November 5th, 2007.

1390. Best of Sessions: Clinical and Research Highlights from Recent Cardiology Programs – Transcatheter Cardiovascular Therapeutics 2007. Presented at the 80th annual scientific sessions of the American Heart Association, Orlando, FL, November 5th, 2007.

1391. HORIZONS AMI. Presented at the 80th annual scientific sessions of the American Heart Association, Orlando, FL, November 6th, 2007.

1392. Use of virtual histology to detect vulnerable plaque: The PROSPECT Trial. Presented at the VH Summit, Miami, FL, November 10th, 2007.

1393. Potential directions for treatment of vulnerable plaque. Presented at the VH Summit, Miami, FL, November 11th, 2007.

1394. The Truth About The Thrombosis Problem With Drug Eluting Stents In The Coronary Circulation: It's Not As Bad As We Have Been Led To Believe. Presented at the 34th annual Veith symposium, New York, NY, November 15, 2007.

1395. Mitral Valve Technologies for Percutaneous Repair of Mitral Regurgitation (Overview of Edwards MONARC). Presented at the Innovations in Cardiovascular Innovations (ICI 2007) Meeting, Tel Aviv Israel, December 1st, 2007.

1396. Direct Thrombin Inhibitors. Presented at the Innovations in Cardiovascular Innovations (ICI 2007) Meeting, Tel Aviv Israel, December 1st, 2007.

1397. Invasive Imaging Modalities for Vulnerable Plaque – The PROSPECT STUDY. Presented at the Innovations in Cardiovascular Innovations (ICI 2007) Meeting, Tel Aviv Israel, December 2nd, 2007.

1398. Overview of the Edwards MONARC mitral valve annuloplasty device. Presented at the Innovations in Cardiovascular Innovations (ICI 2007) Meeting, Tel Aviv Israel, December 2nd, 2007.

1399. Chronic total occlusions: basic and advanced techniques. Columbia University Medical Center, New York City, NY, December 17th, 2007.

1400. Bivalirudin in ACS, PCI and STEMI. Critical Care Grand Rounds, Columbia University Medical Center, December 20th, 2007, New York City, NY.

1401. Clinical trial design: The bivalirudin example. Columbia University Medical Center Cardiology journal club, January 4th, 2008, New York City, NY.,

1402. New insights into the safety and efficacy of current generation DES. Broadcast to India for the ICER course. January 12th, 2008.

1403. Update on PCI Pharmacology: Antithrombins. Presented at the 20th annual ISET course, Hollywood, FL, January 18th, 2008.

1404. Drug-eluting stents: Controversies and unsettled issues. Presented at the 20th annual ISET course, Hollywood, FL, January 18th, 2008.

1405. PCI should be the choice for most patients with stable coronary artery disease. Presented at the 20th annual ISET course, Hollywood, FL, January 18th, 2008.

1406. Primary angioplasty in AMI: New Horizons. Presented to the 3rd AMI symposium via video link, New Delhi, India, January 25th, 2008.

1407. New Insights into the future of PCI. Presented at the CCT2008 Course, Kobe, Japan, January 31st, 2008.

1408. The SPIRIT Trial Updates. Presented at the CCT2008 Course, Kobe, Japan, January 31st, 2008.

1409. The PROSPECT for Vulnerable Plaque Detection. Presented at the CCT2008 Course, Kobe, Japan, January 31st, 2008.

1410. Safety and Efficacy of DES: Present and Future. Presented at the CCT2008 Course, Kobe, Japan, February 2nd, 2008.

1411. What Should the Impact of the COURAGE Trial Be on Interventional Cardiology? - Intervention for Everyone. Presented at the CRT 2008 course, Washington DC, February 11th, 2008.

1412. The PROSPECT Trial: First Glimpse into the Study. Presented at the CRT 2008 course, Washington DC, February 11th, 2008.

1413. How long should we prescribe Clopidogrel? Presented at the CRT 2008 course, Washington DC, February 11th, 2008.

1414. How to Anticoagulate Your Patient in 2008: Insights for ACUITY and HORIZONS Trials. Presented at the CRT 2008 course, Washington DC, February 12th, 2008.

1415. Is Viability Assessment Necessary Prior to CTO Angioplasty? Should the COURAGE Nuclear Substudy Impact our Thinking? Presented at the 5th INTERNATIONAL CHRONIC TOTAL OCCLUSION SUMMIT, New York, NY, February 21st, 2008.

1416. Angioplasty or Medications for Coronary Artery Disease. Medical Grand Rounds, UMDNJ, Newark, NJ, February 26th, 2008.

1417. The role of Bivalirudin in patients with acute coronary syndromes and myocardial infarction: New Horizons. Cardiology Grand Rounds, St. Francis Hospital, Long Island, NY, March 5th, 2008.

1418. PCI in the Modern Era: Indications and accomplishments – a COURAGE Rebuttal. Presented at the 2008 China Interventional Therapeutics Course, Beijing, China, March 20th, 2008.

1419. Xience V: Update on the SPIRIT Trials. Presented at the 2008 China Interventional Therapeutics Course, Beijing, China, March 20th, 2008.

1420. Vulnerable Plaque Identification is Problematic but Transcatheter treatment is realistic. Presented at the 2008 China Interventional Therapeutics Course, Beijing, China, March 21st, 2008.

1421. DES Safety: What have we learned in 2007? Presented at the 2008 China Interventional Therapeutics Course, Beijing, China, March 21st, 2008.

1422. What's Next: XIENCE/PROMUS. Presented at the 5th annual "The Drug-Eluting Stent Revolution" meeting, Chicago, IL, March 28th, 2008.

1423. Safety and effectiveness of Bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: The HORIZONS AMI Trial. Presented at the

57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 29th, 2008.

1424. Shifting the paradigm: The concept of net adverse clinical events. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 29th, 2008.

1425. Reducing Infarct Size in Acute Myocardial Infarction with Supersaturated Oxygen Therapy: From Theory to Practice Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 29th, 2008.

1426. New Treatment Options for STEMI: Role of Direct Thrombin Inhibitors and Drug-eluting Stents: A view to the HORIZON. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 30th, 2008.

1427. Critical Commentary: Pretreatment With a High Loading Dose of Clopidogrel and Value of Abciximab During Primary Coronary Intervention in Patients With Acute Myocardial Infarction. Results of the Randomized BRAVE-3 Trial. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 30th, 2008.

1428. Comprehensive Analysis of Drug-eluting Stent Safety and Efficacy. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 30th, 2008.

1429. COURAGE: Has the Dust Settled? Protagonist View. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 31st, 2008.

1430. A New Era in STEMI Care- Everything is Illuminated: NACE and MACE shed light on the CASE. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 31st, 2008.

1431. Is Diabetes a Risk Factor for Restenosis and Adverse Clinical Outcomes After Paclitaxel-Eluting Stent Implantation? Pooled Analysis of the TAXUS IV and TAXUS V Trials. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, April 1st, 2008.

1432. Registry Data on Stent Thrombosis, MI and Death. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, April 1st, 2008.

1433. Drug-Eluting Stent Systems II: TAXUS. Presented at the 14th annual National Interventional Fellow's Course, San Jose, CA, April 3rd, 2008.

1434. Drug-Eluting Stent Systems IV: Xience/Promus. Presented at the 14th annual National Interventional Fellow's Course, San Jose, CA, April 3rd, 2008.

1435. Evidence Based Medicine Guidelines to Drug-Eluting Stent Use (On label and Off Label). Infarct size reduction with supersaturated oxygen: AMIHOT I and II results. Presented at the 14th annual National Interventional Fellow's Course, San Jose, CA, April 4th, 2008.

1436. Angioplasty in AMI I: Primary PCI State of the Art. Presented at the 14th annual National Interventional Fellow's Course, San Jose, CA, April 4th, 2008.

1437. Interventional Pharmacology IV: Bivalirudin in ACS and PCI. Presented at the 14th annual National Interventional Fellow's Course, San Jose, CA, April 4th, 2008.

1438. Clinical strategies in acute myocardial infarction. Presented at the course "State of the Heart", Los Angeles, CA, April 25th, 2008.

1439. Outcomes with bivalirudin in patients with NSTEMI and STEMI. Jersey Shore Medical Center, April 30th, 2008.

1440. Replacing heparin in patients with coronary artery disease: It's about time! Cardiology grand rounds, UMDNJ, Newark, NY, May 7, 2008.

1441. Acute MI Management 2008. Presented at the Brooklyn Cardiovascular Symposium, SUNY Downstate, Brooklyn, NY, May 10th, 2008.

1442. SPIRIT III - 2 Year Clinical Results. Presented at the EuroPCR meeting, Barcelona, Spain, May 13th, 2008.

1443. DES should be used in most patients undergoing PCI. SPIRIT III - 2 Year Clinical Results. Presented at the EuroPCR meeting, Barcelona, Spain, May 14th, 2008.

1444. Stenting of vulnerable plaque: will we do it? – Yes!. SPIRIT III - 2 Year Clinical Results. Presented at the EuroPCR meeting, Barcelona, Spain, May 14th, 2008.

1445. Optimizing upstream management of STEMI and NSTEMI - the case for a consistent strategy for patients undergoing PCI. SPIRIT III - 2 Year Clinical Results. Presented at the EuroPCR meeting, Barcelona, Spain, May 15th, 2008.

1446. Infarct size reduction with SSO_2: AMIHOT I and AMIHOT II. SPIRIT III - 2 Year Clinical Results. Presented at the EuroPCR meeting, Barcelona, Spain, May 15th, 2008.

1447. Comprehensive analysis of drug-eluting stent safety and efficacy. Dartmouth Hitchcock Medical Center Cardiology Grand Rounds, Lebanon, NH May 22, 2008.

1448. Vulnerable Plaque: Pathophysiology, Diagnosis and therapy. Columbia University Medical Center, New York, NY, June 5th, 2008.

1449. CoreValve Technique and Complications. Presented at the course Transcatheter Valve Therapies, June 6th, 2008, Seattle, WA.

1450. Emerging Device-based Therapies for Mitral Regurgitation. Presented at the course Transcatheter Valve Therapies, June 7th, 2008, Seattle, WA.

1451. Clinical Trial Basics: Study Design Methodology, Endpoints, Bio-Statistics, and Assessment of Outcomes. Presented at the course Transcatheter Valve Therapies, June 8th, 2008, Seattle, WA.

1452. Invasive Detection of Vulnerable Plaque: Preliminary Results from Prospect and Beyond. Presented at the annual C3 course, Baltimore, MD, June 10th, 2008.

1453. Should PCI Be the Treatment of Choice for Chronic Stable Angina? Presented at the annual C3 course, Baltimore, MD, June 10th, 2008.

1454. Optimal antithrombotic and antiplatelet strategies in patients undergoing PCI. Cardiology conference, Cornell - New York Hospital, June 12th, 2008.

1455. The SPIRIT Family of Trials. Video presentation to the New Delhi Interventional Cardiology course, India, June 12th, 2008.

1456. The Impact of Interventional Cardiology on Acute MI Outcomes: Do Catheters Save Lives? Presented at the Columbia University Cardiovascular Research Initiative Symposium, Columbia University Medical Center, New York, NY, June 17th, 2008.

1457. The HORIZONS-AMI Trial. Brigham and Women's Hospital eJournal club, July 1st, 2008.

1458. Safety and Efficacy of DES in the real world. Presented at the annual TOPIC course, Tokyo, Japan, July 18th, 2008.

1459. DES Long-term Safety and Efficacy" Focus on AMI and new stent technology. Presented at the annual TOPIC course, Tokyo, Japan, July 18th, 2008.

1460. SPIRIT III 2-year results. Presented at the annual TOPIC course, Tokyo, Japan, July 18th, 2008.

1461. Current status and future perspective of CTO PCI: Insights from the cases done in the past NY CTO Summits. Presented at the annual TOPIC course, Tokyo, Japan, July 19th, 2008.

1462. Reperfusion options in acute myocardial infarction: 2008 update. Cardiology Fellow rounds, Columbia University Medical Center, NY, NY, July 22, 2008.

1463. Vulnerable Plaque/PROSPECT Study. Presented at SOLACI '08. August 6th, 2008, Cancun, Mexico.

1464. Controversy: DES should be used more widely (PRO). Presented at SOLACI '08. August 6th, 2008, Cancun, Mexico.

1465. Update on Xience-V/Promus Program . Presented at SOLACI '08. August 6th, 2008, Cancun, Mexico.

1466. Evolving Strategies for Acute Myocardial Infarction. Presented at SOLACI '08. August 7th, 2008, Cancun, Mexico.

1467. SPIRIT III Update – Drug-Eluting and Bare metal Stents: An Evolving Standard of Care. Presented at SOLACI '08. August 7th, 2008, Cancun, Mexico.

1468. New Approaches to Myocardial Salvage. Presented at SOLACI '08. August 8th, 2008, Cancun, Mexico.

1469. Safety, efficacy and cost-effectiveness of drug-eluting stents: Focus on off-label use. Center for Medicare and Medicaid Services, Washington DC, August 12th, 2008.

1470. Drug-eluting stents: Efficacy Clearly Outweighs Safety Concerns. Presented at the course Controversies and Advances in the Treatment of Cardiovascular Disease, Los Angeles, CA, September 5th, 2008.

1471. Beginning and advanced strategies for chronic total occlusions. Columbia University Medical Center, NY, NY, September 8th, 2008.

1472. Drug-eluting stent update. Delivered at the course "Update in Cardiovascular Care Symposium", Syracuse, NY, September 12th, 2008.

1473. Drug-eluting stents in 2008: Safety and Efficacy Re-examined. Presented at the 19th Annual Coronary Interventions Course, San Diego, CA, September 18th, 2008.

1474. Primary PCI in 2008: Which Drugs, Which Stents: Presented at the 19th Annual Coronary Interventions Course, San Diego, CA, September 19th, 2008.

1475. Drug-eluting Stent Evidence-Based medicine: The New Trials: Presented at the 19th Annual Coronary Interventions Course, San Diego, CA, September 19th, 2008.

1476. PCI Pharmacology: Everything you wanted to know. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 11th, 2008.

1477. STEMI and NSTEMI pharmacology confusion: How to choose and use antithrombins (unfractionated and low molecular weight heparins, Bivalirudin, Fondaparinux) and antiplatelet agents (aspirin, Clopidogrel and Prasugrel). Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 12th, 2008.

1478. DES may Reduce Mortality: Columbia-CRF Mega Meta-Analysis. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 12th, 2008.

1479. Has Prevention of Hemorrhagic Complications Emerged as the #1 Goal in NSTE-ACS? Lessons from the ACUITY Trial. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 12th, 2008.

1480. Introducing Important New Studies to Watch… ADAPT DES. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 12th, 2008.

1481. The Search for Vulnerable Plaque: PROSPECT and Beyond. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 13th, 2008.

1482. Mechanisms Underlying the Reduction in Mortality With Bivalirudin in Primary PCI: New Insights From HORIZONS-AMI. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 13th, 2008.

1483. Does Late Catch-Up Mean Late “Clinical” Restenosis? Reconciling the SPIRIT II and III Trial Results. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 13th, 2008.

1484. Reduction of Infarct Size With Supersaturated Oxygen Therapy: Insights from AMIHOT II. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 13th, 2008.

1485. The Xience V/Promus Everolimus-Eluting Stent: Device Description and Comprehensive Update of the Clinical Trial Program Results. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 13th, 2008.

1486. Why are New Device Randomized Trials for Mitral Regurgitation a Clinical Trialist's Nightmare? Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 13th, 2008.

1487. Linking Plaque Composition to Events: Insights from PROSPECT. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 13th, 2008.

1488. New Paradigms of Care for ST-Elevation Myocardial Infarction (STEMI): Focusing on Mortality and Attributable Death Analysis in Cath-Based Care: What Do Device and Drug Trials Teach Us? Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 13th, 2008.

1489. Reducing Infarct Size in Acute Myocardial Infarction: From Theory to Practice. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 13th, 2008.

1490. Resetting the Goals? Weighing the Relative Risks of Ischemic and Hemorrhagic Complications. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 14th, 2008.

1491. COOL RCN: A Prospective, Randomized Trial Examining the Safety and Efficacy of Systemic Hypothermia for the Prevention of Radiocontrast Nephropathy. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 14th, 2008.

1492. Future Interventional Approaches to Improve AMI Outcomes. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 14th, 2008.

1493. XIENCE V – New Clinical Data. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 14th, 2008.

1494. Limitations of primary PCI in AMI and the promise of intracoronary local drug delivery. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 15th, 2008.

1495. HORIZONS-AMI: A Prospective, Randomized Trial of Paclitaxel-eluting Stents versus Bare Metal Stents in Patients with Acute ST-segment Elevation

Myocardial Infarction. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 15th, 2008.

1496. HORIZONS at 1 Year: Safety and efficacy of drug-eluting stents in AMI. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 15th, 2008.

1497. The Top Late Breaking Trials from TCT 2008: Synthesis, Accolades and Healthy Critique. Presented at the 20th annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 17th, 2008.

1498. Complex Lesion Subsets: Left Main Lesions. Presented at the annual scientific sessions of the American Heart Association, New Orleans, LA, November 8th, 2008.

1499. Drug-Eluting Stents vs. Bare-Metal Stents for Primary PCI. Presented at the 24th annual International Symposium on Interventional and Pharmacological Reperfusion for ST-Elevation MI, New Orleans, LA, November 8th, 2008.

1500. Clinical Controversies: ACS Anticoagulants: Anything but LMWH. Presented at the annual scientific sessions of the American Heart Association, New Orleans, LA, November 9th, 2008.

1501. Limiting Myocardial Infarct Size: Thrombectomy and Filter Devices. Presented at the annual scientific sessions of the American Heart Association, New Orleans, LA, November 9th, 2008.

1502. Optimizing Outcomes in AMI. Presented at the course Clinical Controversies in Managing Coronary Artery Disease – Integrating the Most Recent Clinical Trial Results, New Orleans, LA, November 9th, 2008.

1503. Like most American Hospitals, my hospital does not have an on-site cath lab. My AMI patient should receive: Primary PCI by being transferred ASAP. Presented at the course Great Cardiology Debates, New Orleans, LA, November 9th, 2008.

1504. Drug-Eluting Stent versus Bare Metal Stent Use: Meta-Analysis of Randomized Trials and Observational Studies. Presented at the annual scientific sessions of the American Heart Association, New Orleans, LA, November 12th, 2008.

1505. Vulnerable Plaque Etiology, Diagnosis and Natural History. Cardiology Fellow's Conference, Columbia University Medical Center, New York, NY, November 19th, 2008.

1506. Medical therapy or stenting for stable coronary artery disease: Was the COURAGE trial misleading? Presented at the 35th annual Veith symposium, New York, NY, November 21, 2008.

1507. New Paradigms in the Treatment of Patients with STEMI. Presented at the course EDICT for ACS. Cleveland Ohio, November 22nd, 2008.

1508. TCT meets PCI: Valve highlights from TCT2008. Presented at the course “PCI”, Munich, Germany, December 5th, 2008.

1509. Meta-Analysis of SPIRIT II & III: Two Year Results. Presented at the ICI2008 Course, Tel Aviv, Israel, December 8th, 2008.

1510. A Clinical View on the Role of Developments in Medicine: New Imaging Frontiers to Improve Clinical Outcomes. Presented at the ICI2008 Course, Tel Aviv, Israel, December 8th, 2008.

1511. Invasive Imaging for Vulnerable Plaque – PROSPECT Trial Results. Presented at the ICI2008 Course, Tel Aviv, Israel, December 9th, 2008.

1512. Vulnerable Plaque: Major Advances of Interest to All Vascular Practitioners. Presented at the annual ISET Symposium, Hollywood, FL, January 19th, 2009.

1513. Advances and Challenges in Intravascular Imaging. Presented at the annual ISET Symposium, Hollywood, FL, January 19th, 2009.

1514. The death of CME: A course director’s perspective. Presented at the annual ISET Symposium, Hollywood, FL, January 19th, 2009.

1515. Top Trials from TCT 2008. Presented at the annual ISET Symposium, Hollywood, FL, January 20th, 2009.

1516. Balancing the Risk of Ischemia vs. Hemorrhagic Complications. Presented at the annual ISET Symposium, Hollywood, FL, January 20th, 2009.

1517. Xience V: New Insights from the SPIRIT Trials. Presented at the CCT 2009 course, Kobe, Japan, January 30th, 2009.

1518. New Insights into DES safety and efficacy. Presented at the CCT 2009 course, Kobe, Japan, January 30th, 2009.

1519. Breakthrough strategies for primary PCI in STEMI. Presented at the CCT 2009 course, Kobe, Japan, January 31st, 2009.

1520. Primary PCI Breakthroughs. Presented at the 9th annual Joint Interventional Meeting, Rome, Italy, February 12th, 2009.

1521. New Paradigms of Care for STEMI: Superior Pharmacological Strategies for Reducing Complications and Death Associated with Invasive Management. Presented at the 9th annual Joint Interventional Meeting, Rome, Italy, February 13th, 2009.

1522. New Insights to Antithrombotic Drug Selection and Pivotal Trial Design. Merck Research Laboratories, Rahway, NJ, February 19th, 2009.

1523. Novel Imaging Modalities and Vulnerable Plaque. Merck Research Laboratories, Rahway, NJ, February 19th, 2009.

1524. Perspectives on DES Use in Acute Myocardial Infarction. Presented at the course The Drug-Eluting Stent Revolution VIII, Orlando, FL, March 27th, 2009.

1525. Everolimus-eluting Stent Update. Presented at the course The Drug-Eluting Stent Revolution VIII, Orlando, FL, March 27th, 2009.

1526. Comparing First and Second Generation DES: Safety & Efficacy in Elective PCI. Presented at the Annual Scientific Sessions of the American College of Cardiology, Orlando, FL, March 28th, 2009.

1527. ST-Elevation Myocardial Infarction (STEMI): Focusing on Mortality and Attributable Death Analysis in the Primary PCI Setting – What Do Landmark Drug and Device Trials Teach Us? Presented at the course Critical Advances in the Evolving Science and Medicine of STEMI Management and High Risk ACS, Orlando, FL, March 28th, 2009.

1528. Resolving Pharmacologic and Invasive Controversies for Primary PCI in Acute MI. Presented at the Annual Scientific Sessions of the American College of Cardiology, Orlando, FL, March 29th, 2009.

1529. How to Choose the Best Stent During Primary PCI: Lessons from Randomized Trials and Registries. Presented at the Annual Scientific Sessions of the American College of Cardiology, Orlando, FL, March 29th, 2009.

1530. Reperfusion Strategies in AMI: 2009 State of the Art. Grand Rounds, Winthrop Hospital, Mineola, NY, April 7th, 2009.

1531. HORIZONS AMI: Implications for Pharmaco-Adjunctive Therapy and DES Use. Presented at the TCT Asia-Pacific Summit, Seoul Korea, April 22nd, 2009.

1532. Revived indications for thrombus aspiration during primary PCI: Unanswered questions after TAPAS. Presented at the TCT Asia-Pacific Summit, Seoul Korea, April 22nd, 2009.

1533. STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and low Molecular heparins, Bivalirudin, Fondaparinux) and antiplatelet agents (Aspirin, Clopidogrel and Prasugrel). Presented at the TCT Asia-Pacific Summit, Seoul Korea, April 22nd, 2009.

1534. Comparison of DES versus BMS in Real World Registries. Presented at the TCT Asia-Pacific Summit, Seoul Korea, April 22nd, 2009.

1535. New Paradigms of Care for ST-Elevation Myocardial Infarction (STEMI)L Focusing on Mortality and Attributable Death Analysis in Cath Based Care: What Do device and Drug Trials Teach Us? Presented at the TCT Asia-Pacific Summit, Seoul Korea, April 22nd, 2009.

1536. The Latest Updates in DES clinical data. Presented at the TCT Asia-Pacific Summit, Seoul Korea, April 22nd, 2009.

1537. HORIZONS AMI: A Large Prospective Randomized Trial of DES vs. BMS in Patients with STEMI. Presented at the TCT Asia-Pacific Summit, Seoul Korea, April 23rd 2009.

1538. Linkage of Current Plaque Vulnerability to Future Events: Evidence from the PROSPECT Study. Presented at the TCT Asia-Pacific Summit, Seoul Korea, April 23rd 2009.

1539. The PROMUS stent and future device iterations. Presented at the TCT Asia-Pacific Summit, Seoul Korea, April 23rd 2009.

1540. Scientific Breakthrough: The Revolution of Bioabsorbable Technology. Presented at the SCAI annual scientific sessions, Las Vegas, NV, May 7th, 2009.

1541. Optimum Pharmacologic Management with Primary PCI for STEMI: How Does HORIZONS Change the Paradigm? Presented at the SCAI annual scientific sessions, Las Vegas, NV, May 7th, 2009.

1542. Ischemic and Hemorrhagic Complications of PCI. Presented at the 15th annual National Interventional Cardiology Felloe's Course, Miami, FL, May 11th, 2009.

1543. Reperfusion Therapy in STEMI II: Selecting then Optimal Pharmacology and Stent. Presented at the 15th annual National Interventional Cardiology Felloe's Course, Miami, FL, May 12th, 2009.

1544. TAXUS Preclinical Foundation and Clinical Results. Presented at the 15th annual National Interventional Cardiology Felloe's Course, Miami, FL, May 12th, 2009.

1545. XIENCE V / PROMUS Preclinical Foundation and Clinical Results. Presented at the 15th annual National Interventional Cardiology Felloe's Course, Miami, FL, May 12th, 2009.

1546. Direct thrombin inhibition with bivalirudin in ACS and PCI. Presented at the 15th annual National Interventional Cardiology Felloe's Course, Miami, FL, May 13th, 2009.

1547. Medical Device Development: Dream or Nightmare? Presented at the Medtech 2009 Conference, Duke University Fuqua School of Business, Durham, NC, May 14th, 2009.

1548. Position Statement III: all patients with acute myocardial infarction should undergo primary PCI, all with Bivalirudin, most with drug eluting stents. Presented at the EuroPCR 2009 conference, Barcelona, Spain, May 21, 2009.

1549. The Everolimus-Eluting Stent: Update 2009. New York City, NY, May 26th, 2009.

1550. Acute MI Management 2009: State-of-the-Art. Cardiology Grand Rounds, St. Luke's Hospital, New York City, NY, May 27th, 2009.

1551. How Good is the Evidence? Data Gaps and Future Clinical Trial Proposals to Clarify Current Controversies in Left Main and Bifurcation Treatment. Presented at the 3rd Left Main and Bifurcation Summit, New York City, NY, June 6th, 2009.

1552. Keynote address: natural history of vulnerable plaque. Presented to the NIH Vulnerable Plaque Working Group Meeting, Bethesda, MD, June 8, 2009.

1553. Update on Reperfusion Therapy in AMI. Presented at the course How to Cope with Global Pandemic of Cardiovascular Disease, Hallym University, Seoul, Korea, June 9th, 2009.

1554. Vulnerable plaque detection: PROSPECT. Presented at the VPM course, Athens, Greece, June 23rd, 2009.

1555. Transcatheter Devices for Mitral Valve Repair: Surveying the Landscape. Presented at the Transcatheter Valve Therapies 2009 course, Seattle, WA, June 25th, 2009.

1556. The MONARC coronary sinus annuloplasty system. Presented at the Transcatheter Valve Therapies 2009 course, Seattle, WA, June 26th, 2009.

1557. Summary thoughts: Mitral valve technologies. Presented at the Transcatheter Valve Therapies 2009 course, Seattle, WA, June 26th, 2009.

1558. Reperfusion therapies in acute myocardial infarction. Cardiology Fellows Rounds, New York Presbyterian Hospital, New York City, NY, July 13th, 2009.

1559. The importance of ischemic and bleeding complications during PCI. Presented at the TOPIC 2009 course, Tokyo, Japan, July 15th, 2009.

1560. Perspectives in future drug-eluting stents. Presented at the TOPIC 2009 course, Tokyo, Japan, July 15th, 2009.

1561. Appropriate use of drug-eluting stents in unprotected left main disease and acute myocardial infarction. Presented at the TOPIC 2009 course, Tokyo, Japan, July 15th, 2009.

1562. Transcatheter mitral valve therapy. Presented at the TOPIC 2009 course, Tokyo, Japan, July 15th, 2009.

1563. Emerging everolimus-eluting stents. Presented at the TOPIC 2009 course, Tokyo, Japan, July 15th, 2009.

1564. Presented at the TOPIC 2009 course, Tokyo, Japan, July 15th, 2009.

1565. PCI Pharmacology: Most important advances from the last year. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 20th, 2009.

1566. Updates from Ongoing DAPT Studies: US – ADAPT-DES Registry. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 21st, 2009.

1567. Prospect I: Prelude to the Clinical Trial Results. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 21st, 2009.

1568. The XIENCE V/PROMUS Everolimus-Eluting Stent: Comprehensive Update of the Clinical Trial Program (Featuring the First Presentation of the SPIRIT III 3-Year Results). Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 21st, 2009.

1569. Long-Term Safety and Clinical Efficacy Outcomes of the Paclitaxel-Eluting Stent from a Patient-Level Pooled Analysis of the TAXUS Clinical Trials. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 22nd, 2009.

1570. Pharmacology II - Fear Bleeding More Than Clot? Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 22nd, 2009.

1571. An Overview of New Interventional Therapies under Investigation for Treatment of Mitral Regurgitation. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 22nd, 2009.

1572. TCT in San Francisco: Focus on Education, Innovation, Evidence, and Patients - The Next 20 Years! Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 23rd, 2009.

1573. SPIRIT IV. A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 23rd, 2009.

1574. Framing the Clinical Evidence-Based Medicine Issues (Lessons from ACUITY, HORIZONS, OASIS, and TRITON). Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 23rd, 2009.

1575. Framing the Issues How Often Should DES be Used in STEMI? And Which DES? Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 23rd, 2009.

1576. XIENCE SPIRIT IV One Year Results. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 23rd, 2009.

1577. PROSPECT: A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 24th, 2009.

1578. The 1st Geoffrey O. Hartzler Master Clinical Operator Award. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 24th, 2009.

1579. The 2009 TCT Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 24th, 2009.

1580. Transradial Intervention 2009: the changing landscape. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 24th, 2009.

1581. PROSPECT II: Plaque Characterization Predicts Future Events. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 24th, 2009.

1582. The Central Role of Ischemia in Predicting Prognosis After PCI. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 24th, 2009.

1583. Results of PROSPECT and future prospects for intracoronary imaging. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 25th, 2009.

1584. HORIZONS-AMI. 2-Year Follow-up From a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare Metal Stents in STEMI. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 25th, 2009.

1585. The Top Late Breaking Trials from TCT 2009: Synthesis and Healthy Critique. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, September 25th, 2009.

1586. Drug-eluting stent update. Velocity Studios, Pittsburgh, PA, October 26th, 2009.

1587. Improving Outcomes in Acute Myocardial Infarction. Presented at the Ninth Annual Cardiovascular Symposium @ UT Southwestern, Dallas, TX, October 27th, 2009.

1588. Relative Importance of Ischemic and Hemorrhagic Complications after PCI. University of Minnesota, Cardiac Catheterization Lab Conference, Minneapolis, MN, October 28th, 2009.

1589. Detection of vulnerable plaque: Dream or reality?. University of Minnesota, Fellow's Conference, Minneapolis, MN, October 28th, 2009.

1590. New approaches to optimize primary angioplasty in acute myocardial infarction. University of Minnesota Grand Rounds, Minneapolis, MN, October 28th, 2009.

1591. Latest advances in the treatment of acute myocardial infarction. Scripps Clinic Coronary Interventions 2009, La Jolla, CA, October 29th, 2009.

1592. Prospects for the detection of vulnerable plaque. Presented at the 3rd Indo-European Course on Revascularization, George Pompidou Hospital, Paris, France, November 3rd, 2009.

1593. Optimal stent and pharmacology selection in acute myocardial infarction. Presented at the 3rd Indo-European Course on Revascularization, George Pompidou Hospital, Paris, France, November 4th, 2009.

1594. Best of Cardiovascular Meetings: Clinical and Research Highlights from TCT 2009. Presented at the annual scientific sessions of the American Heart Association, Orlando, FL, November 16th, 2009.

1595. New Drug-eluting Stent Clinical Development: What can we expect? Presented at the annual scientific sessions of the American Heart Association, Orlando, FL, November 16th, 2009.

1596. IVUS and Virtual Histology: Routine or Selective? Presented at the annual scientific sessions of the American Heart Association, Orlando, FL, November 16th, 2009.

1597. Vulnerable Plaques: Implications For Vascular Surgeons And Interventionalists And What Can Be Done About Them? Presented at the Veith Vascular Symposium, New York City, NY, November 19th, 2009.

1598. Everolimus-eluting stent update: The SPIRIT III and IV trials. Presented at the Interventional Cardiovascular Innovations course, Tel Aviv, Israel, December 7th, 2009.

1599. Frequency of Vulnerable Plaque: Is there an opportunity for invasive detection? Presented at the Interventional Cardiovascular Innovations course, Tel Aviv, Israel, December 7th, 2009.

1600. Overview of Percutaneous Mitral Valve Therapies. Presented at the Interventional Cardiovascular Innovations course, Tel Aviv, Israel, December 8th, 2009.

1601. Primary PCI for AMI: Progress and unmet needs. Presented at the Interventional Cardiovascular Innovations course, Tel Aviv, Israel, December 8th, 2009.

1602. Invasive Imaging to Detect Vulnerable Plaque. Presented at the Clinical Biomarkers in ACS meeting. Princeton, NJ, December 10th, 2009.

1603. ACS: New Aspects in Interventional Management. Presented at the annual ACC New York Cardiovascular Symposium, New York, NY, December 11th, 2009.

1604. Established antiplatelet agents in cardiovascular disease. Presented at the ISET annual conference, Hollywood, FL, January 18th, 2010.

1605. New antiplatelet agents in cardiovascular disease. Presented at the ISET annual conference, Hollywood, FL, January 18th, 2010.

1606. Direct thrombin inhibition in ACS and PCI. Presented at the ISET annual conference, Hollywood, FL, January 18th, 2010.

1607. Why is prolonged antiplatelet therapy required with drug–eluting stents? Presented at the ISET annual conference, Hollywood, FL, January 18th, 2010.

1608. Special Lecture 1 – PROSPECT Trial. Presented at the annual CCT course, Kobe, Japan, January 29th, 2010.

1609. Xience V Overview and SPIRIT Family of Data. Presented at the annual CCT course, Kobe, Japan, January 29th, 2010.

1610. PROSPECT and Beyond. Presented at the annual CCT course, Kobe, Japan, January 29th, 2010.

1611. Future PCI direction: Lesson from PROSPECT. Presented at the annual CCT course, Kobe, Japan, January 29th, 2010.

1612. CTO Milieu and Technique Issues: Guiding Catheters, Vascular Access (transradial options), Contralateral Injections, Contrast Management, and Advice for the "Non-Expert". Presented at the 7th annual International CTO Summit, New York City, NY, February 4th, 2010.

1613. Perspective on left main coronary intervention: Introduction to the EXCEL trial. Presented at the annual Joint Interventional Meeting (JIM), Rome, Italy, February 11th, 2010.

1614. Should the Guidelines for Unprotected LM Change? Presented at the 2010 Cardiovascular Revascularization Therapies course, Washington DC, February 22nd, 2010.

1615. Debate: DES Should Be Used for Over 75% of the PCIs. Presented at the 2010 Cardiovascular Revascularization Therapies course, Washington DC, February 22nd, 2010.

1616. Take Home Message from PROSPECT. Presented at the 2010 Cardiovascular Revascularization Therapies course, Washington DC, February 22nd, 2010.

1617. Novel Trial Design Focus - Left Main and "All Comers" DES Studies: Left Main Interventional View. Presented at the 2010 Cardiovascular Revascularization Therapies course, Washington DC, February 23rd, 2010.

1618. Drug-eluting stents: Current status and future developments. Broadcast to the Crossroads in Interventional Cardiology Course, Venice, Italy, March 2nd, 2010.

1619. Invasive Detection of Vulnerable Plaque: Clinical and Mechanistic Insights from PROSPECT. Presented at the Interventional Cardiology 2010 25th Annual International Symposium, March 10th, 2010.

1620. The Next US/EA/Asia/South America Randomized Left All-Comers Trial Design. Presented at the Interventional Cardiology 2010 25th Annual International Symposium, March 10th, 2010.

1621. Left Main PCI: Selection and Strategies. Presented at the annual scientific sessions of the American College of Cardiology, Atlanta, GA, March 13th, 2010.

1622. Landscape of Percutaneous Approaches to Mitral Regurgitation. Presented at the annual scientific sessions of the American College of Cardiology, Atlanta, GA, March 14th, 2010.

1623. Dual Antiplatelet Therapy in PCI: Strategies for Risk Reduction in Drug-Eluting Stent Patients. Presented at the annual scientific sessions of the American College of Cardiology, Atlanta, GA, March 15th, 2010.

1624. Future directions: Transcatheter mitral valve repair. Presented at the Global Heart Valve Summit 2010, New York City, NY, March 20th, 2010.

1625. CTO angioplasty: Basic and advanced techniques. New York-Presbyterian Hospital, New York City, NY, March 22, 2010.

1626. Superior Outcomes of XIENCE V: A Look inside Clinical Evidence of XIENCE V in the Largest RCT. Presented at the China Interventional therapies Course, Beijing, China, April 1st, 2010.

1627. Expert Commentary. PROBE: A Prospective Multicenter Randomized Trial of PROSTENT Bioabsorbable Polymer vs. FIREBIRD Durable Polymer Sirolimus-Eluting Stent. Presented at the China Interventional therapies Course, Beijing, China, April 1st, 2010.

1628. Expert Commentary. DK-CRUSH II: A Prospective Randomized Trial of Double-Kissing Crush Technique vs. Provisional Stenting Technique for Coronary Bifurcation Lesions. Presented at the China Interventional therapies Course, Beijing, China, April 1st, 2010.

1629. Vulnerable Plaque: Lessons from PROSPECT and Future Clinical Research Directions. Presented at the China Interventional therapies Course, Beijing, China, April 2nd, 2010.

1630. A Milestone Study for Left Main Treatment: EXCEL. Presented at the China Interventional therapies Course, Beijing, China, April 2nd, 2010.

1631. Timing of angiography and revascularization in UA/NSTEMI. Cardiac Catheterization Conference, Washington Hospital Center, Washington DC, April 7th, 2010.

1632. Current DES, Future DES with Biodegradable Coatings/No Coatings and Bioabsorbable stents. Transmitted to the BASICS+ course in Belgrade, Serbia, April 12th, 2010.

1633. Drug-eluting stents: an evidence based medicine approach. Cardiology Grand Rounds, Mount Sinai Medical Center, Miami, FL, April 22nd, 2010.

1634. Introducing EXCEL: The Definitive Unprotected Left Main Randomized Trial. Presented at the annual TCT-Asia Pacific Summit, Seoul, South Korea, April 28th, 2010.

1635. Bioabsorbable and Polymer-Free DES: Current and New Technologies. Presented at the annual TCT-Asia Pacific Summit, Seoul, South Korea, April 28th, 2010.

1636. Does PROSPECT Support the use of invasive imaging to diagnose and treat vulnerable plaque with DES? Presented at the annual TCT-Asia Pacific Summit, Seoul, South Korea, April 28th, 2010.

1637. Milestone for left main PCI: Upcoming EXCEL LM Trial. Presented at the annual TCT-Asia Pacific Summit, Seoul, South Korea, April 29th, 2010.

1638. Presented at the annual TCT-Asia Pacific Summit, Seoul, South Korea, April 29th, 2010. Motivation, Objective and Implication of EXCEL Study.

1639. DES Trial Overview and Stent Update. Presented at the annual Jeresaty Cardiovascular Symposium, St. Francis Hospital, Hartford, CT, May 6th, 2010.

1640. Reperfusion Therapy in STEMI II: Pharmacology and stent selection. Presented at the annual North American Interventional Cardiology Fellow's Course, Miami, FL, May 11th, 2010.

1641. XIENCE V/PROMUS preclinical foundation and clinical results. Presented at the annual North American Interventional Cardiology Fellow's Course, Miami, FL, May 11th, 2010.

1642. Bivalirudin in ACS and PCI. Presented at the annual North American Interventional Cardiology Fellow's Course, Miami, FL, May 11th, 2010.

1643. Current Controversies in Interventional Management for Acute Coronary Syndromes. Presented at the course "Translating Science into Practice: Recent Advances Across the Spectrum of Cardiology Care". The Johns Hopkins University School of Medicine. May 13th, 2010.

1644. New Diagnostic Approaches for Vulnerable Plaque. Cardiology Grand Rounds. University Hospitals, Case Western Reserve, Cleveland, Ohio, May 20th, 2010.

1645. Understanding the Safety Advantages of the Everolimus-Eluting Stent. Presented at the annual EuroPCR conference, Paris, France, May 25th, 2010.

1646. GuideLiner introduction and illustrative case, Presented at the annual EuroPCR conference, Paris, France, May 26th, 2010.

1647. Drug-eluting Stents: What's coming over the safety horizon? Presented at the annual EuroPCR conference, Paris, France, May 27th, 2010.

1648. Everolimus-Eluting Stent updates and BSC Future DES Program. Presented at the annual EuroPCR conference, Paris, France, May 27th, 2010.

1649. Patient Selection and technique considerations for left main intervention. Presented at the annual EuroPCR conference, Paris, France, May 28th, 2010.

1650. Controversies in Acute Myocardial Infarction Reperfusion Therapy. Presented at the annual EuroPCR conference, Paris, France, May 28th, 2010.

1651. Drug Elution in Preventing Restenosis. Presented at the New Cardiovascular Horizons Course, New Orleans, LA, June 4th, 2010.

1652. The EVEREST II Trial: Critique from a Clinical Trialist. Presented at the Transcatheter Valve Therapies course, Seattle, WA, June 7th, 2010.

1653. The Future of Coronary Revascularization. Cardiology Grand Rounds, Duke University Medical Center, Durham, NC, June 14th, 2010,

1654. Is the pre-emptive diagnosis and treatment of vulnerable plaque possible? Clinical Research Conference, Duke University Medical Center, Durham, NC, June 15th, 2010,

1655. Clinical Update on Vulnerable Plaque and Patients. Presented at the course Interventional Cardiology Montreal, Montreal, Canada, June 17th, 2010.

1656. Next generation drug-eluting stents. Presented at the course Interventional Cardiology Montreal, Montreal, Canada, June 18th, 2010.

1657. Can we identify vulnerable plaque? PROSPECT Update. Presented at the Vulnerable Plaque Meeting (VPM), Cascais, Portugal, June 22nd, 2010.

1658. Role of bare and drug eluting stents in the management of the CAD spectrum. Visiting professor "Meet the Expert" lectureship. Gregorio Maranon Hospital, Madrid, Spain, June 25th, 2010.

1659. Strategies for Risk reduction in Drug-Eluting Stent Patient. Presented at the annual TOPIC course, Tokyo, Japan, July 15th, 2010.

1660. Understanding the Safety Advantage of Everolimus-eluting Stents. Presented at the annual TOPIC course, Tokyo, Japan, July 15th, 2010.

1661. Efficacy and safety of DES for off-label indications. Presented at the annual TOPIC course, Tokyo, Japan, July 15th, 2010.

1662. Detection of Vulnerable Plaque: Is it Possible? Presented at the annual TOPIC course, Tokyo, Japan, July 16th, 2010.

1663. The Breakthrough Everolimus-eluting Stent: Device Design and Clinical Trials. Presented at the annual TOPIC course, Tokyo, Japan, July 16th, 2010.

1664. Clinical decision making III: Current and Future DES. Presented at the annual TOPIC course, Tokyo, Japan, July 16th, 2010

1665. Current generation DES. Presented at the annual TOPIC course, Tokyo, Japan, July 16th, 2010.

1666. Identification of vulnerable plaque. Skirball Center for Cardiovascular Research, Orangeburg, NY, July 23rd, 2010.

1667. Emerging Direction in Dual Antiplatelet Therapies for High-Risk Patients with ACS. Webcast, July 23rd, 2010.

1668. 2nd & 3rd Generation DES: Putting the Data in Perspective. Presented at the 58th annual scientific sessions of the Cardiac Society of Australia and New Zealand. Adelaide, Australia, August 4th, 2010.

1669. Predicting Future Coronary Events: Lessons from the PROSPECT Trial. Presented at the 58th annual scientific sessions of the Cardiac Society of Australia and New Zealand. Adelaide, Australia, August 4th, 2010.

1670. Future Directions in PCI: PROSPECT and beyond. Presented at the 58th annual scientific sessions of the Cardiac Society of Australia and New Zealand. Adelaide, Australia, August 5th, 2010.

1671. Current status of Percutaneous Mitral Valve Repair & Techniques. Presented at the 58th annual scientific sessions of the Cardiac Society of Australia and New Zealand. Adelaide, Australia, August 5th, 2010.

1672. Intravascular Ultrasound: Does it still have a role in this era of new imaging technologies? Presented at the 58th annual scientific sessions of the Cardiac Society of Australia and New Zealand. Adelaide, Australia, August 5th, 2010.

1673. Role of integrated images in the treatment of vulnerable plaque. Presented at the annual SOLACI scientific congress, Buenos Aires, Argentina, August 11th, 2010.

1674. A personalized approach to the treatment of acute coronary syndromes: Balancing ischemia vs. bleeding. Presented at the annual SOLACI scientific congress, Buenos Aires, Argentina, August 11th, 2010.

1675. Clinical Pathophysiology: Lessons from PROSPECT- New Insights on diagnosis and treatment of vulnerable plaque. Presented at the annual SOLACI scientific congress, Buenos Aires, Argentina, August 12th, 2010.

1676. Transcatheter Valve Therapy: Countdown to PARTNER and EVEREST - Latest Perspectives on Percutaneous Aortic and Mitral Valve Implantation. Presented at the annual SOLACI scientific congress, Buenos Aires, Argentina, August 12th, 2010.

1677. SPIRIT family of Data: A Growing Body of Evidence. Presented at the annual SOLACI scientific congress, Buenos Aires, Argentina, August 12th, 2010.

1678. Coronary perforation. Presented at the Global Endovascular Complications Course, Jackson Hole, Wyoming, August 23rd, 2010.

1679. Laser salvage of an undilatable lesion. Presented at the Global Endovascular Complications Course, Jackson Hole, Wyoming, August 25th, 2010.

1680. PCI Pharmacology: Antiplatelet and antithrombin agents. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 20th, 2010, Washington, DC.

1681. The Oculostenotic Reflex Revisited: Implications for Choosing between DES and BMS. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 21st, 2010, Washington, DC.

1682. XIENCE V / PROMUS Everolimus-Eluting Stents: New Insights from the SPIRIT/COMPARE Meta-analysis and Other Randomized Trials. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 21st, 2010, Washington, DC.

1683. Implications from PROSPECT and Future Directions. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 21st, 2010, Washington, DC.

1684. Responding To Clinical Equipoise: The EXCEL Trial. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 21st, 2010, Washington, DC.

1685. Rationale and Design of the VERDICT and CANARY Studies. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 21st, 2010, Washington, DC.

1686. Aspiration Thrombectomy in AMI: Opinionated Position Statement. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 21st, 2010, Washington, DC.

1687. Thienopyridine Considerations in ACS and PCI: Making Difficult Decisions Today. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 22nd, 2010, Washington, DC.

1688. Transcatheter Mitral Valve Therapies: A Series of Unanswered Questions. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 22nd, 2010, Washington, DC.

1689. Selection Criteria for Drug-Eluting Versus Bare Metal Stents: The HORIZONS-AMI Trial. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 22nd, 2010, Washington, DC.

1690. Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Four-Year Clinical Outcomes from the SPIRIT III Trial. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 22nd, 2010, Washington, DC.

1691. CABG vs. PCI for the Majority of Patients with Left Main Disease? Today and Tomorrow. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 22nd, 2010, Washington, DC.

1692. ADP antagonist Trials in PCI: Knowns and Unknowns. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 22nd, 2010, Washington, DC.

1693. Detection of Vulnerable Plaques: Are We Close to Clinical Applicability? Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 23rd, 2010, Washington, DC.

1694. TCT Responds to "Medicine in Evolution": The Next Five Years Will Transform Interventional Cardiovascular Medicine! Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 23rd, 2010, Washington, DC.

1695. SPIRIT IV: Two-Year Results from a Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 23rd, 2010, Washington, DC.

1696. Overview of guide catheter extension and clinical uses. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 24th, 2010, Washington, DC.

1697. The TCT2010 Geoffrey O. Hartzler Master Clinical Operator Award. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 24th, 2010, Washington, DC.

1698. Left Atrial Appendage Occlusion Trials: What went right? What went wrong? Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 25th, 2010, Washington, DC.

1699. The TCT 2010 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 25th, 2010, Washington, DC.

1700. HORIZONS-AMI: Three-Year Follow-up from a Prospective Randomized Trial of Antithrombin Strategies and Drug-Eluting Stents in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 25th, 2010, Washington, DC.

1701. The Top Late Breaking Trials from TCT 2010: Synthesis and Healthy Critique. Presented at the 22nd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, September 25th, 2010, Washington, DC.

1702. Stents or Surgery for Left Main Disease: Today's Evidence and the Upcoming EXCEL Trial. HeartSource Meeting. Columbia University Medical Center, NY, NY, October 5th, 2010.

1703. Surgery for Left Main Disease: The Days are Numbered. Presented at the 10th annual Controversies and Advancement in the Treatment of Cardiovascular Disease course. Los Angeles, CA. October 7th, 2010.

1704. A Prospective, Multicenter Randomized Trial of Heparin Plus GPIIb/IIIa Inhibitors vs. Bivalirudin, and DES vs. BMS in STEMI: Final 3-Year Report from the HORIZONS-AMI Trial. Transmitted to the Scripps annual intervention course, La Jolla, CA, October 14th, 2010.

1705. Diagnosis of Vulnerable Plaque and Patients. Cardiology Grand Rounds, University of Miami Hospital, Miami, Fla, October 19th, 2010.

1706. Pharmacology and stent selection in acute myocardial infarction. Cardiology Grand Rounds, NYU Hospital, New York, NY, October 22nd, 2010.

1707. Predictors and implications of bleeding in ACS and PCI. Acute Coronary Syndromes Expert Forum. New York, NY, October 25th, 2010.

1708. Prevention of Acute MI: The Culprit Is Shifting to the Severe, Bulky Plaque. Presented at the annual scientific sessions of the American Heart Association, Chicago, IL, November 14th, 2010.

1709. Are the Clinical Outcomes with Everolimus-eluting versus Paclitaxel-eluting Coronary Stents Different in Patients With and Without Diabetes? Insights from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE Randomized Trials. Presented at the annual scientific sessions of the American Heart Association, Chicago, IL, November 14th, 2010.

1710. Is Premature Thienopyridine Discontinuation Safe with Everolimus-Eluting Stents? Analysis from the SPIRIT IV Trial. Presented at the annual scientific sessions of the American Heart Association, Chicago, IL, November 15th, 2010.

1711. Best of Cardiovascular Meetings: Clinical and Research Highlights from Recent Programs - Transcatheter Cardiovascular Therapeutics. Presented at the annual scientific sessions of the American Heart Association, Chicago, IL, November 16th, 2010.

1712. Established and New Antiplatelet agents. Presented at the annual Veith course, New York City, NY, November 18th, 2010.

1713. Evolution of DES Safety. Presented at the Polymer Science Summit, New York City, NY, November 18th, 2010.

1714. Future DES Platforms. Presented at the Polymer Science Summit, New York City, NY, November 18th, 2010.

1715. Selection of DES vs. BMS in STEMI. Web presentation to Washington Hospital Center Cath Conference, Washington DC, November 24th, 2010.

1716. The Top Late-Breaking Trials from TCT 2010 Synthesis and Healthy Critique. Presented at the PCI Live Course, Munich, Germany, December 2nd, 2010.

1717. Overview of Antiplatelet Therapy. Presented at the PCI Live Course, Munich, Germany, December 2nd, 2010.

1718. Transcatheter approaches to aortic stenosis and left main disease. Presented at the PCI Live Course, Munich, Germany, December 3rd, 2010.

1719. Challenges in the treatment of acute myocardial infarction. A glimpse into the future. Manchester UK Cardiology Conference, December 7th, 2010.

1720. Controversies in the interventional treatment of patients with acute coronary syndromes. CardioCare Live, New York City, December 9th, 2010.

1721. Drug Choices for Drug-eluting Stents: Lessons from Coronary Applications. Presented at the annual ISET Symposium, Miami, FL, January 17th, 2011.

1722. The FAME Trial: How Should it Change Clinical Practice? Presented at the annual ISET Symposium, Miami, FL, January 17th, 2011.

1723. Thrombus Aspiration and/or IC Pharmacotherapy: Which Therapy and for Whom? Presented at the 10th Joint Interventional Meeting (JIM), Rome Italy, February 10th, 2011.

1724. The EXCEL Trial: Rationale, Final Study Design and Status. Presented at the 8th annual Chronic Total Occlusion Summit and Left Main Coronary Occlusions Course. New York City, NY, February 14th, 2011.

1725. Debate: DES Should Be Used as the Default Stent for ACS. Presented at the annual CRT meeting, Washington DC, February 28th, 2011.

1726. New Analysis from the PROSPECT Trial. Presented at the annual CRT meeting, Washington DC, February 28th, 2011.

1727. Debate: Unprotected Left Main: How Should We Treat Them? Most Patients with Left Main Disease Should Be Treated with PCI….TODAY. Presented at the annual CRT meeting, Washington DC, February 28th, 2011.

1728. Keynote Lecture: The Five Best Trials from 2010 that May Impact My Practice. Presented at the annual CRT meeting, Washington DC, February 28th, 2011.

1729. Clinical Trial Update and Novel Clinical Trial Designs – EXCEL. Presented at the annual CRT meeting, Washington DC, March 1st, 2011.

1730. The challenges of designing clinical trials for functional mitral regurgitation. Presented at the Mitral Valve Disease Advisory Summit. Los Angeles, CA, March 4th, 2011.

1731. Patient-and Lesion-Specific Factors Affecting Safety and Efficacy of DES Versus BMS. Presented at the course Discussing Real World Considerations for DES: Applying Clinical Evidence to Predict Clinical Outcomes, NY, NY, March 5th, 2011.

1732. Dual Antiplatelet Therapy and Thrombotic Complications: Drug Selection and Resistance. Presented at the course Discussing Real World Considerations for DES: Applying Clinical Evidence to Predict Clinical Outcomes, NY, NY, March 5th, 2011.

1733. Duration and Discontinuation of Antiplatelet Therapy. Presented at the course Discussing Real World Considerations for DES: Applying Clinical Evidence to Predict Clinical Outcomes, NY, NY, March 5th, 2011.

1734. Pharmacology and Stent Decisions in STEMI. Cardiology Fellows Rounds, Columbia University Medical Center, NY, NY, March 18th, 2011.

1735. Impact of Major Bleeding after cardiac surgery on subsequent mortality: The ACUITY Trial. Presented at the annual scientific sessions of the American College of Cardiology, New Orleans, LA, April 3rd, 2011.

1736. A Prospective, Randomized, Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial. Presented at the annual scientific sessions of the American College of Cardiology, New Orleans, LA, April 4th, 2011.

1737. PCI vs. CABG for left main intervention: Resolving equipoise. Cardiology grand rounds, Methodist University Hospital, Memphis, TN, April 13th, 2011.

1738. Anti-Platelet Agents in ACS and PCI: Making Difficult Decisions Today. Cardiology grand rounds, Methodist Hospital, Krannert Institute of Cardiology, Indianapolis, IN, April 19th, 2011.

1739. Implications from the PROSPECT trial for drug discovery. Merck Research Laboratories, Rahway, NJ, April 22nd, 2011.

1740. DES in left main disease: New Guidelines and Updates from EXCEL. Presented at the TCT Aaia-Pacific Summit, Seoul, South Korea, April 27th, 2011.

1741. Xience Platform Safety Update. Presented at the TCT Aaia-Pacific Summit, Seoul, South Korea, April 27th, 2011.

1742. New Insights About XIENCE V Safety. Presented at the TCT Aaia-Pacific Summit, Seoul, South Korea, April 27th, 2011.

1743. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease (SPIRIT IV). Presented at the TCT Aaia-Pacific Summit, Seoul, South Korea, April 28th, 2011.

1744. PCI in Left Main Disease: The EXCEL Trial. Presented at the TCT Aaia-Pacific Summit, Seoul, South Korea, April 28th, 2011.

1745. Results from the PLATINUM trial. Presented at the TCT Aaia-Pacific Summit, Seoul, South Korea, April 28th, 2011.

1746. New Drug-eluting Stent Safety Insights. Webcast to the Belgium Interventional Cardiology Group, May 2nd, 2011.

1747. Multilmodality coronary imaging. Aleglitizard development group, Boston, MA, April 4th, 2011.

1748. Drug-eluting stents for STEMI: Is the benefit worth the risk? Presented at the annual scientific sessions of the Socity for Cardiac Angiography and Interventions, May 5th, 2011.

1749. Multivessel CAD: Risk Stratification. Presented at the annual scientific sessions of the Socity for Cardiac Angiography and Interventions, May 6th, 2011.

1750. Bivalirudin in ACS and PCI. Presented at the 17th annual Interventional cardiology Fellow's Course, Miami, FL, May 9th, 2011.

1751. Reperfusion Therapy in STEMI Part 2: Pharmacology and Stent Selection. Presented at the 17th annual Interventional cardiology Fellow's Course, Miami, FL, May 10th, 2011.

1752. Everolimus-Eluting Stents: Preclinical Foundation and Clinical Results. Presented at the 17th annual Interventional cardiology Fellow's Course, Miami, FL, May 10th, 2011.

1753. Patient-oriented drug-eluting stent had to head comparisons: Everolimus-eluting stents. Presented at the annual EuroPCR course, May 18th, 2011.

1754. Drug-eluting stents and transcatheter valve therapies: Today's technologies and tomorrow's developments. Presented at the New York Cardio-renal conference, New York, NY, May 20th, 2011.

1755. 2011 Year in Review: Mitral Valve Therapies. Presented at the annual Transcatheter Valve Therapeutics course, Vancouver, Canada, June 5th, 2011.

1756. Everest II 2-year follow-up results. Presented at the annual Transcatheter Valve Therapeutics course, Vancouver, Canada, June 5th, 2011.

1757. Final Scorecard on the Protect AF Study: Misguided or Bullseye? Presented at the annual Transcatheter Valve Therapeutics course, Vancouver, Canada, June 7th, 2011.

1758. The CANARY Trial. Presented at the 9th annual VPM course, Cascais, Portugal, June 20th, 2011.

1759. Hematology practice by cardiologists: From heparin, through enoxaparin to bivaluridin. Presented at the 9th annual VPM course, Cascais, Portugal, June 21st, 2011.

1760. The intermediate lesion: Whether and When to Intervene: I will use PROSPECT criteria to decide. Presented at the 9th annual VPM course, Cascais, Portugal, June 21st, 2011.

1761. Xience V vs. the others – meta-analysis of the long-term results. Presented at the 9th annual VPM course, Cascais, Portugal, June 21st, 2011.

1762. The REVA Stent. Presented at the 9th annual VPM course, Cascais, Portugal, June 21st, 2011.

1763. MitraClip for Functional vs. Degernative Mitral Regurgitation. Presented at the Multidisciplinary Advisory Board, Chicago, IL, June 27, 2011.

1764. The future of clinical research in the US. Presented at the annual Institute of Medicine Forum for Drug Discovery, Nerw York, NY, June 28th, 2011.

1765. A Stent is a Stent is a Stent - Are all stents the same? Presented at the Great Minds symposium, Hong Kong, July 30th, 2011.

1766. Use of VH-IVUS in Clinical Practice. Presented at the Great Minds symposium, Hong Kong, July 31st, 2011.

1767. Natural History of Coronary Atherosclerosis. Presented at Grand Rounds, Morristown Memorial Hospital, Morristown, NJ, August 5th, 2011.

1768. Use of Virtual Histology in the Cath Lab: Perspectives after PROSPECT. Transmitted to the Scripps annual intervention course, La Jolla, CA, September 22nd, 2011.

1769. New therapies to salvage myocardium in STEMI – What does the future hold? Presented to the Skirball Center for Cardiovascular Research, Orangeburg, NY, September 30th, 2011.

1770. PCI vs CABG for left main disease: Evidence review and ongoing trials. Presented at the CACI meeting, Buenos Aires, Argentina, October 2nd, 2011.

1771. Mortality from bleeding in patients with PCI for ACS. Presented at the CACI meeting, Buenos Aires, Argentina, October 2nd, 2011.

1772. Cath lab special strategies for STEMI: Stent selection and aspiration. Presented at the CACI meeting, Buenos Aires, Argentina, October 2nd, 2011.

1773. Update on percutaneous treatment of mitral insufficiency. Presented at the Argentine Society of Cardiology annual scientific sessions. Buenos Aires, Argentina, October 3rd, 2011.

1774. Mitral regurgitation: Percutaneous therapies for heart failure patients. Presented at the Argentine Society of Cardiology annual scientific sessions. Buenos Aires, Argentina, October 3rd, 2011.

1775. Device Regulation in the US: Too strict and impeding innovation and pushing research offshore, or too lax and exposing patients to unproven devices? Presented at the meeting “Rescuing Clinical Trials in the US: A call for action”. Mclean, VA, October 6th, 2011.

1776. The EXCEL Trial: Design, Status, and Timelines. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 7th, 2011.

1777. Interventional Pharmacology in STEMI: Guidelines and Practice Outcomes. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 7th, 2011.

1778. Everolimus-Eluting Stents 2011/2012: Stent Design Evolution, Clinical Trial Update. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 7th, 2011.

1779. PCI Today: Best Practices, Optimal Outcomes, and Limitations: When Do I Prefer CABG for MVD? Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 8th, 2011.

1780. Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from the SPIRIT III Trial. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 8th, 2011.

1781. A Large-Scale Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Three-Year Clinical Outcomes from the SPIRIT IV Trial. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 8th, 2011.

1782. Stent Thrombosis and Dual Antiplatelet Interruption: Insights from the XIENCE V Everolimus-Eluting Coronary Stent System Trials. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 8th, 2011.

1783. How Can the Current DES Results Get Any Better? And What Kinds of Trials Will This Take? Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 8th, 2011.

1784. Conceptual Redesign: Today's Culprit vs. Future Culprits: Ischemia Today vs. Tomorrow. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 8th, 2011.

1785. The Potential for Coronary Drug Coated Balloons: Indications, Opportunities and Challenges. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 8th, 2011.

1786. TCT Director Keynote Address: Contemporary and Evolving Approaches to Optimizing Outcomes in High-Risk ACS: A Near Future Vision Statement Focused on Advances in Anticoagulation. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 8th, 2011.

1787. Unmet Needs, MGuard and the Master Trial. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 9th, 2011.

1788. ADAPT-DES: A Large-Scale, Prospective, Multicenter Registry Examining the Relationship of Platelet Responsiveness and Stent Thrombosis After DES Implantation. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 9th, 2011.

1789. Patient Selection for Bivalirudin: In Whom Should it be Required vs. Preferred vs. May Not be Necessary? Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 9th, 2011.

1790. Detection of Vulnerable Plaque: Are We Close to Clinical Applicability? Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 10th, 2011.

1791. Spotlight Lecture: Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI: The Forest and the Trees. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 10th, 2011.

1792. Randomized Trials Remain the Gold Standard. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 10th, 2011.

1793. Next Generation DES (Including Bioabsorbable Scaffolds): Proving Safety and Efficacy: Physician-scientist Perspectives. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 10th, 2011.

1794. Vulnerable Plaque: The Wild Card Factor. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 10th, 2011.

1795. Clopidogrel, Prasugrel and Ticagrelor During Primary PCI: Clinical Outcomes. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 10th, 2011.

1796. TCT 2011 Late Breaking Trials Critique and Interpretation. Presented at the 23rd annual scientific sessions of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, November 11th, 2011.

1797. Best of Cardiovascular Meetings: Clinical and Research Highlights from Recent Programs: TCT2011. Presented at the annual scientific sessions of the American Heart Association, Orlando, FL, November 14th, 2011.

1798. Detection of vulnerable plaque – and what to do about them! Presented at the annual Veith Symposium, November 17th, 2011, New York City, NY.

1799. Modern antithrombotic treatment of patients with ACS – an overview. Presented at the PCI Live course in Munich, Germany, December 1, 2011.

1800. Evidence-based Hihglights of TCT2011. Presented at the PCI Live course in Munich, Germany, December 2, 2011.

1801. Importance of Complete Revascularization after PCI. Presented at the Innovations in Cardiovascular Interventions meeting (ICI2011), Tel Aviv, Israel, December 4th, 2011.

1802. New Imaging Insights to Plaque Vulnerability – Implications for local therapy. Presented at the Innovations in Cardiovascular Interventions meeting (ICI2011), Tel Aviv, Israel, December 5th, 2011.

1803. Complex Coronary Lesions and the Role of Guide Extension. Presented at the Innovations in Cardiovascular Interventions meeting (ICI2011), Tel Aviv, Israel, December 5th, 2011.

1804. AMI Unmet Needs: MGuard and the MASTER Trial. Presented at the Innovations in Cardiovascular Interventions meeting (ICI2011), Tel Aviv, Israel, December 5th, 2011.

1805. DAPT Interruption after DES – Is it Safe? Presented at the Innovations in Cardiovascular Interventions meeting (ICI2011), Tel Aviv, Israel, December 5th, 2011.

1806. MitraClip Treatment for Functional Mitral regurgitation and Heart Failure Presented at the Innovations in Cardiovascular Interventions meeting (ICI2011), Tel Aviv, Israel, December 5th, 2011.

1807. Personalized Intervention: Insights from ADAPT-DES. Presented at the Innovations in Cardiovascular Interventions meeting (ICI2011), Tel Aviv, Israel, December 5th, 2011.

1808. How to do it Right from COURAGE to FAME to ISCHEMIA. Presented at the Innovations in Cardiovascular Interventions meeting (ICI2011), Tel Aviv, Israel, December 6th, 2011.

1809. The WaveCrest LAA Closure System. Presented at the Innovations in Cardiovascular Interventions meeting (ICI2011), Tel Aviv, Israel, December 6th, 2011.

1810. Keynote address: Game changers in percutaneous intervention - A nostalgic past and exciting future. Presented at the Cardiology Society of India annual scientific sessions, Mumbai, India, December 8th, 2011.

1811. Optimizing outcomes in primary angioplasty for acute myocardial infarction. Presented at the Cardiology Society of India annual scientific sessions, Mumbai, India, December 8th, 2011.

1812. Vulnerable plaque: From bedside to bench. Prestented at Cardiology Grand Rounds, Columbia University Medical Center, New York, NY, December 20th, 2011.

1813. The Future of Plaque Differentiation: Stable versus Unstable. Presented at the annual ISET meeting, Miami, Fl, January 16th, 2012.

1814. The Use of Alternative Anticoagulants for Cardiac and Vascular Procedures. Presented at the annual ISET meeting, Miami, Fl, January 16th, 2012.

1815. Left Main Interventions: Patient Selection, Techniques and Outcomes. Presented at the annual ISET meeting, Miami, Fl, January 16th, 2012.

1816. Stent and Pharmacology Selection in STEMI for Primary PCI. Presented at the annual ISET meeting, Miami, Fl, January 16th, 2012.

1817. The Changing Landscape of Interventional Cardiology. Gilead National Meeting, Orlando, FL, January 26th, 2012.

1818. Lessons from the ADAPT-DES Registry on the Relationship of Platelet Responsiveness and Stent Thrombosis after DES Implantation. Presented at the annual CRT course, Washington DC, February 7th, 2012.

1819. My Projection: DES will be the default therapy for STEMI. Presented at the annual CRT course, Washington DC, February 7th, 2012.

1820. What does the future hold for the treatment of unprotected left main disease? Presented at the annual CRT course, Washington DC, February 7th, 2012.

1821. Are the guidelines lagging in regards to left main stenting? Presented at the annual CRT course, Washington DC, February 7th, 2012.

1822. Left Main Stenting Guidelines. Presented at the annual Joint Interventional Meeting, Rome, Italy, February 9th, 2012.

1823. Marquis keynote lecture: Treatment of acute myocardial infarction: Yesterday, today and tomorrow. Presented at the Scottsdale Interventional Forum 2012 course, Phoenix, AZ, February 16th, 2012.

1824. Left Main PCI: Where do we go from here? Presented at the Scottsdale Interventional Forum 2012 course, Phoenix, AZ, February 16th, 2012.

1825. Two-stent techniques for left main distal bifurcation disease: How to choose? Presented at the course Complex PCI: left main and CTO intervention, Feb 23rd, 2012, New York City, NY.

1826. Primary PCI 2012: State-of-the-Art. Cardiology rounds, Coulumbai Unvierstiy Medical Center, February 29th, 2012.

1827. Five Essential Therapies to Improve Outcomes in Primary PCI. Presented at the China Interventional Therapies Meeting, Beijing, China, March 16th, 2012.

1828. Future Directions for the Treatment of Multivessel Disease: Do Second Generation DES Improve Outcomes? Presented at the China Interventional Therapies Meeting, Beijing, China, March 17th, 2012.

1829. EXCEL Trial: 2012 Update. Presented at the China Interventional Therapies Meeting, Beijing, China, March 17th, 2012.

1830. Optimal duration of dual anti-platelet therapy after DES: What is known and what is not. Presented at the China Interventional Therapies Meeting, Beijing, China, March 17th, 2012.

1831. Controversy I: Current drug-eluting stents are not only more effective, but are safer than bare metal stents and should be used in >90% of (stented) patients. Presented at the annual scientific sessions of the American College of Cardiology, Chicago, IL, March 23rd, 2012.

1832. Invasive Imaging of Subclinical Disease. Presented at the annual scientific sessions of the American College of Cardiology, Chicago, IL, March 24th, 2012.

1833. Optimal Anticoagulation: Overview of Bivalirudin. Presented at the annual scientific sessions of the American College of Cardiology, Chicago, IL, March 24th, 2012.

1834. INFUSE AMI: a 2x2 Factorial, Multicenter, Prospective, Randomized Evaluation of Intracoronary Abciximab and Aspiration Thrombectomy in Patients Undergoing Primary PCI for Anterior STEMI. Presented at the annual scientific sessions of the American College of Cardiology, Chicago, IL, March 25th, 2012.

1835. Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions. Presented at the annual scientific sessions of the American College of Cardiology, Chicago, IL, March 25th, 2012.

1836. Use of Intravascular Ultrasound to Identify Calcified Coronary Lesions for Treatment Using Orbital Atherectomy before Stenting. Presented at the annual scientific sessions of the American College of Cardiology, Chicago, IL, March 25th, 2012.

1837. Pitfalls in Current Studies of Percutaneous Therapy for MR. Presented at the annual scientific sessions of the American College of Cardiology, Chicago, IL, March 26th, 2012.

1838. Does Evolving Stent Technology Alter Use of Antiplatelet Agents in ACS? Discovery Channel course Variability of Response to Oral Antiplatelet Therapy: Managing the ACS Patient in Light of Current Evidence, New York City, NY, March 31st, 2012.

1839. In search of vulnerable plaque. Cardiology Grand Rounds, William Beaumont Hospital, Detroit, MI, April 2nd, 2012.

1840. A Brief History of Primary PCI in STEMI: Looking backwards and looking ahead. Cardiology Fellow's Rounds, William Beaumont Hospital, Detroit, MI, April 2nd, 2012.

1841. Current and Future Directions in Stenting: Promises and Pitfalls. Presnted at the Mayo Clinic Cardiology in the Capital course, Washington DC, April 12th, 2012.

1842. The COAPT trial. Presented at the New York Heart Society Valves annual meeting, New York City, NY, April 13th, 2012.

1843. What are the unanswered questions and unmet clinical needs for antithrombotic therapy? A North American perspective. Presented at the Thrombosis Global Therapeutic Expert Forum, April 17th, 2012, New York City, NY.

1844. Clinical Applications of Multimodality Imaging: Vulnerable Plaque. Presented at the 18th annual Interventional Cardiology Fellows Course, Miami, FL, April 20th, 2012.

1845. Reperfusion Therapy in STEMI: Guidelines, Strategies, Pharmacology, and Stent Selection. Presented at the 18th annual Interventional Cardiology Fellows Course, Miami, FL, April 21st, 2012.

1846. Everolimus-Eluting Stents: Preclinical Foundation and Clinical Results. Presented at the 18th annual Interventional Cardiology Fellows Course, Miami, FL, April 21st, 2012.

1847. Bivalirudin in ACS and PCI. Presented at the 18th annual Interventional Cardiology Fellows Course, Miami, FL, April 22nd, 2012.

1848. What's Known and Unknown about LM PCI: Transitioning from SYNTAX to EXCEL. Presented at the TCTAP Summit, Seoul, S. Korea, April 25th, 2012.

1849. New Insights Regarding the safety and efficacy of DAPT after Stenting. Presented at the TCTAP Summit, Seoul, S. Korea, April 25th, 2012.

1850. PCI Today – Best Practices, Optimal Outcomes and Limitations: When Do I Prefer CABG for MVD? Presented at the TCTAP Summit, Seoul, S. Korea, April 25th, 2012.

1851. Current Status of the EXCEL Trial. Presented at the TCTAP Summit, Seoul, S. Korea, April 26th, 2012.

1852. Clinical Outcome of the PLATINUM Trial. Presented at the TCTAP Summit, Seoul, S. Korea, April 26th, 2012.

1853. Reduction of Thrombus: Routine vs Selective Aspiration. Presented at the TCTAP Summit, Seoul, S. Korea, April 26th, 2012.

1854. Evidence-Based Pharmacotherapy for ACS Patients: The Forest and the Trees. Presented at the TCTAP Summit, Seoul, S. Korea, April 26th, 2012.

1855. Lessons from the Pooled data using Xience Everolimus-eluting stent. Presented at the TCTAP Summit, Seoul, S. Korea, April 26th, 2012.

1856. New Insights Regarding the safety and efficacy of DAPT after Stenting. Presented at the TCTAP Summit, Seoul, S. Korea, April 26th, 2012.

1857. Role of IVUS and FFR in 2012: How to Improve Outcomes. Presented at TCT Mediterrnaean 2012, Limassol, Cyprus, May 4th, 2012.

1858. High Risk and STEMI PCI: Role of Bivalirudin**.** Presented at TCT Mediterrnaean 2012, Limassol, Cyprus, May 4th, 2012.

1859. Evolving stent design and acute coronary syndromes. The Discovery Channel, Silver Springs, Md., May 19th, 2012.

1860. Mitral Valve Trial Endpoints. Presented at the Mital VARC meeting, Washington, DC, May 23rd, 2012.

1861. DES in 2012: Lessons learned about safety and efficacy. Presented at TCT Russia, Moscow, Russia, May 28th, 2012.

1862. DES in complex multi-vessel disease. Presented at TCT Russia, Moscow, Russia, May 28th, 2012.

1863. Current challenges and unmet needs in STEMI and the Master Trial. Design Presented at TCT Russia, Moscow, Russia, May 28th, 2012.

1864. Near Infrared Spectroscopy: Interventional Role and Emerging Data. Presented at TCT Russia, Moscow, Russia, May 28th, 2012.

1865. Featured Lecture: The challenges of catheter based therapies for MR. Presented at TCT Russia, Moscow, Russia, May 29th, 2012.

1866. Direct annuloplasty devices and emerging therapeutic approaches. Presented at TCT Russia, Moscow, Russia, May 29th, 2012.

1867. Primary PCI in the USA: the ongoing progress and the remaining challenges. Presented at TCT Russia, Moscow, Russia, May 30th, 2012.

1868. Mitral Valve Therapies: The Year in Review. Presented at the annual Transcatheter Valve Therapies (with LAA Occlusion) Course, Seattle, WA, June 3rd, 2012.

1869. The COAPT Trial: an Introduction and Overview. Presented at the annual Transcatheter Valve Therapies (with LAA Occlusion) Course, Seattle, WA, June 4th, 2012.

1870. Mitral Valve Therapies in 2020: A Personal Prediction of "What Will Be" (and What Won't!). Presented at the annual Transcatheter Valve Therapies (with LAA Occlusion) Course, Seattle, WA, June 4th, 2012.

1871. The Evolving Standard of Care: Oral Antithrombotic Agents for Stroke Prevention in Atrial Fibrillation. Presented at the annual Transcatheter Valve Therapies (with LAA Occlusion) Course, Seattle, WA, June 5th, 2012.

1872. In search of vulnerable plaque. Cardiology Grand Rounds, Montefiore Hospital, Bronx, NY, June 12, 2012.

1873. Treatment of acute myocardial infarction. Cardiology Fellow's Rounds, Montefiore Hospital, Bronx, NY, June 12, 2012.

1874. New antithrombotic and antiplatelet agents in acute coronary syndromes. Critical Care Grand Rounds, New York Presybeterian Hospital, New York City, NY, June 14th, 2012.

1875. New concepts in vulnerable plaque. Presented at the 2012 live symposium of complex coronary and vascular cases. Mt Sinai Hospital, New York City, NY, June 15th, 2012.

1876. Insights from INFUSE AMI Randomized Trial: IC Abciximab and Aspiration Thrombectomy in Patients with Large Anterior Wall MI. Presented at the 8th annual Complex Cardiovascular Catheter Therapeutics (C3): Advanced Endovascular and Coronary Intervention Global Summit, Orlando, FL, June 20th, 2012.

1877. Novel insights from the VERDICT study. Presented at the 10th Vulnerable Plaque Meeting, Athens, Greece, June 26th, 2012.

1878. Novel insights from the Canary trial. Presented at the 10th Vulnerable Plaque Meeting, Athens, Greece, June 26th, 2012.

1879. Bivalirudin is the anticoagulant choice for all cardiac interventional procedures. Presented at the 10th Vulnerable Plaque Meeting, Athens, Greece, June 26th, 2012.

1880. The ABSORB Global Clinical Program. Presented at the 10th Vulnerable Plaque Meeting, Athens, Greece, June 26th, 2012.

1881. Detection and treatment of vulnerable plaque; The next frontier. Cardiology grand rounds, Christiana Healthcare System, Newark, Delaware, July 11, 2012,

1882. Coronary Calcification: Implications and Future Directions. Presented at the ACC/ISCTR Translational Cardiovascular Conference. Washington DC, July 20th, 2012.

1883. Stent Thrombosis and DAPT Interruption: Insight from the XIENCE Trials. Presented at the annual TOPIC course, Tokyo, Japan, July 26th, 2012.

1884. Longitudinal Stent Deformation Frequency, Implications, Prevention and Treatment. Presented at the annual TOPIC course, Tokyo, Japan, July 26th, 2012.

1885. Diagnosis of vulnerable plaque: The next frontier for intravascular imaging. Presented at the annual TOPIC course, Tokyo, Japan, July 26th, 2012.

1886. Two year results from PLATINUM Trial. Presented at the annual TOPIC course, Tokyo, Japan, July 26th, 2012.

1887. Clinical Decision-Making: How to choose between antithrombin and antiplatelet agents. Presented at the annual TOPIC course, Tokyo, Japan, July 26th, 2012.

1888. Presented at the annual TOPIC course, Tokyo, Japan, July 26th, 2012.

1889. Antiplatelet agent update. Nursing cath lab rounds, Columbia University Medical Center, New York City, NY, July 31st, 2012.

1890. Pharmacology in and beyond the cath lab. CIVT Education Series. Columbia University Medical Center, New York City, NY, July 31st, 2012.

1891. Current and future DES technology: Results today and tomorrow. Presented by webcast to the Advanced Cardiovascular Solutions course, Hyderabad, India, August 3rd, 2012.

1892. Left Main PCI: From SYNTAX to EXCEL. Presented by webcast to the Annual SOLACI Scientific Sessions, Mexico City, Mexico, August 9th, 2012.

1893. Overview of Pharmacology for PCI. Presented at the CUMC Fellows Course, September 7th, 2012, New York City, NY.

1894. Advances in Anti-platelet therapy for ACS. Presented at the course “Update in Cardiology 2012.” Chicago, IL, September 12th, 2012.

1895. Anti-platelet therapy choices in NSTEMI and STEMI: The Columbia Pathway. Cardiology grand rounds. Montreal Jewish Hospital, Montreal, Canada, September 13th, 2012,

1896. Progress in Treating and Preventing Acute Myocardial Infarction. Presented at the course “Courdiosource 2012.” New York City, NY, September 13th, 2012.

1897. Functional Mitral Regurgitation is a ventricular disease and should be treated with minimally invasive techniques. Presented at the courseContraoversies and Advances in the Treatment of Cardiovascular Disease. Los Angeles, CA, September 22th, 2012.

1898. Evolution in Reperfusion Therapy. Simon Dack Lectureship (Visiting Professor), Mt Sinai Hospital, New York City, NY, September 24th, 2012.

1899. Pathophysiology and Detection of Vulnerable Plaque. Cardiology Grand Rounds, Beth Israel Hospital, New York City, NY, September 24th, 2012.

1900. Unprotected left main disease: PCI or CABG? Presented at the course “Dilemmas in Cardiovascular Disease”, Washington DC, October 5th, 2012.

1901. Role of Platelet Function Testing in Anti-Platelet Agent Decision-Making. Presented at the Cardiometabolic Health Congress, Boston, MA, October 12th, 2012.

1902. Everolimus-Eluting Stents: SPIRIT and PLATINUM Update. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 22nd, 2012.

1903. The EXCEL Trial: Novel Aspects and Status Update. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 22nd, 2012.

1904. Pharmacotherapy for PCI in STEMI. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 22nd, 2012.

1905. What Definition Should Be Used to Define Periprocedural MI in Clinical Trials and Practice? Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 22nd, 2012.

1906. Longitudinal Stent Deformation One Year Later: How Important an Issue Is This? Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 22nd, 2012.

1907. VERDICT/FIRST: Prospective, Multicenter Study Examining the Correlation between IVUS and FFR Parameters in Intermediate Lesions. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 22nd, 2012.

1908. Implication of peri-procedural biomarker elevation after stent implication: Analysis from the pooled XIENCE V trials. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 23rd, 2012.

1909. What Will We Learn from the EXCEL Trial that We Do Not Already Know? Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 23rd, 2012.

1910. Bivalirudin Reduces Cardiac Mortality in Patients with and Without Major Bleeding: The HORIZONS-AMI Trial. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 23rd, 2012.

1911. A New Paradigm Revisited: From Ischemia to Vulnerable Plaque. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 23rd, 2012.

1912. The Mitral VARC Initiative. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 23rd, 2012.

1913. The New Anticoagulants: A Meaningful Step Forward? Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 23rd, 2012.

1914. The COAPT Trial. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 23rd, 2012.

1915. ABSORB III and IV Pivotal Clinical Trial Program. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 23rd, 2012.

1916. A Memorial to Geoffrey O. Hartzler, MD: Introduction to an Extraordinary Life. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 24th, 2012.

1917. MASTER: A Prospective, Randomized Trial of a PET Micronet Mesh-Covered Stent vs. Standard Stents in Patients with ST-Segment Elevation Myocardial Infarction. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 24th, 2012.

1918. Bivalirudin: New Analyses, New Studies. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 24th, 2012.

1919. Evolutionary Revascularization Strategies for Coronary Artery Disease: From Anatomy to Ischemia to Vulnerable Plaque. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 24th, 2012.

1920. MitraClip for Functional MR: COAPT: Update and Expectations. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 24th, 2012.

1921. The Positive and Negative Impact of Incomplete Revascularization after PCI. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 24th, 2012.

1922. MASTER Trial design and results. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 24th, 2012.

1923. ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel Hyporesponsiveness on Patient Outcomes. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 25th, 2012.

1924. COAPT Trial Design: Is This a Viable Alternative Model? Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 25th, 2012.

1925. How Beneficial are best in class DES and potent ADP antagonists – Anticipating HORIZONS AMI II. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 25th, 2012.

1926. The Interventional Pharmacotherapy Legacy: Facilitating and Transforming Clinical Outcomes. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 26th, 2012.

1927. Late Breaking Trial Critique and Interpretation. Presented at Transcatheter Cardiovascular Therapeutics, Miami, FL, October 26th, 2012.

1928. Catheter-based Treatment of Mitral Regurgitation. Presented at NewYork-Presbyterian Hospital Heart Center Symposium, November 12th, 2012.

1929. New Concepts Regarding the Importance of Plaque Instability in Coronary and Vascular Disease. Presented at the annual Veith Vascular Symposium, New York City, NY, November 16th, 2012.

1930. Deferral: How to Make the Right Decision. Presented at the Innovtions in Cardiovascualr Interventions Meeting 2012, Tel Aviv, Israel, December 3rd, 2012.

1931. Left Main Stenting: Design and Status of the EXCEL Trial. Presented at the Innovtions in Cardiovascualr Interventions Meeting 2012, Tel Aviv, Israel, December 3rd, 2012.

1932. MitraClip for Functional Mitral Regurgitation: The COAPT Trial. Presented at the Innovtions in Cardiovascualr Interventions Meeting 2012, Tel Aviv, Israel, December 3rd, 2012.

1933. Management of thrombus – from aspiration to embolic protection stents. Presented at the Innovtions in Cardiovascualr Interventions Meeting 2012, Tel Aviv, Israel, December 3rd, 2012.

1934. The MASTER Trial: Superior Results with the MGuard Embolic Protection Stent Compared to Standard Stents in Acute Myocardial Infarction. Presented at the Innovtions in Cardiovascualr Interventions Meeting 2012, Tel Aviv, Israel, December 4th, 2012.

1935. Anticoagulation For Stroke Prevention in Patients With Atrial Fribrillation. Presented at the Dallas-Leipzig Valve 2012 course, Dallas, TX, December 5th, 2012

1936. Valve Disease: The Best of TCT 2012. Presented at the Dallas-Leipzig Valve 2012 course, Dallas, TX, December 6th, 2012.

1937. The PROSPECT Study as a model- Three invasive imaging modes for understanding native atherosclerosis and stenting deployment. Presented at the annula ACC NY Cardiovascular Symposium, New York, NY, December 7th, 2012.

1938. The elusive search for vulnerable plaque. Presented at cardiology grand rounds, Cedars-Sinai Medical Center, Los Angeles, CA, December 13th, 2012.

1939. Revascularization options in multivessel disease – evidence-based medicine decision-making. Cardiology core curriculm, Columbia University Medical Center, New York City, NY, December 20, 2012.

1940. Progress in Coronary Stenting. CardioCare Live webcast. New York City, NY, January 16th, 2013.

1941. Are bioabsorbable stents the future? Presented at the annual ISET Endovascular Therapy course, Miami, FL, January 21st, 2013.

1942. Update on Mitral Valve Therapies. Presented at the annual ISET Endovascular Therapy course, Miami, FL, January 21st, 2013.

1943. Approaches to thrombus in STEMI. Presented at the course Integrated Management of Acute and Chronic Coronary Artery Disease, Innsbruck, Austria, January 27th, 2013.

1944. Coronary stenting: Past, present and future. Presented at the course Integrated Management of Acute and Chronic Coronary Artery Disease, Innsbruck, Austria, January 28th, 2013.

1945. The evolution of stent technology. Presented at the 16th Tremblant Interventional Cardiology Course, Tremblant, Canada, January 31st, 2013.

1946. Evolution of Coronary Revascularisation: From anatomy to ischemia to vulnerable plaque. Presented at the 16th Tremblant Interventional Cardiology Course, Tremblant, Canada, February 1st, 2013.

1947. Coronary Revascularization Dilemmas: Medical Therapy, PCI or CABG? Cardiology grand rounds, Coulumbia University Medical Center, New York, NY, February 5th, 2012.

1948. The Importance of River-PCI. Presented at the annual Joint Interventional Meeting (JIM), Rome, Italy, February 15th, 2013.

1949. Clinical evidence of a novel Embolic Protection Stent in STEMI. Presented at the annual Joint Interventional Meeting (JIM), Rome, Italy, February 15th, 2013.

1950. How to Improve Left Main PCI Outcomes Today: What Every Operator Must Know. Presented at the 10th CTO and Left Main Summit, New York City, NY, February 23rd, 2013.

1951. New Insights into the Mortality Benefit of Bivalirudin. Presented at the CRT 2013 course, Washington, DC, February 24th, 2013.

1952. INFUSE AMI: Lessons from a Mid-Sized Randomized Study. Presented at the CRT 2013 course, Washington, DC, February 24th, 2013.

1953. Can Imaging Modalities Detect Vulnerable Plaque? Presented at the CRT 2013 course, Washington, DC, February 25th, 2013.

1954. The BVS ABSORB Clinical Trial Program. Presented at the CRT 2013 course, Washington, DC, February 25th, 2013.

1955. Keynote Lecture: The Five Best Trials from 2012 that May Impact My Practice. Presented at the CRT 2013 course, Washington, DC, February 25th, 2013.

1956. Perspectives on PCI vs. Medical Therapy in Stable Coronary Artery Disease.Presented ag the course: OPTIMIZING PCI OUTCOMES: A VISION FOR 2013, in conjunction with the annual American College of Cardiology Scientific Sessions, San Francisco, CA, March 8th, 2013.

1957. Bivalirudin with Provisional GPIIb/IIIa Inhibition – the Data are Clear! Presented at the annual American College of Cardiology Scientific Sessions, San Francisco, CA, March 9th, 2013.

1958. Management Dilemmas in Chronic Coronary Artery Disease. Guideline Based Therapy versus Intervention: Well, The patient needs some metal. Presented at the annual American College of Cardiology Scientific Sessions, San Francisco, CA, March 10th, 2013.

1959. Intracoronary Abciximab and Aspiration Thrombectomy During Primary PCI for Anterior STEMI: One-Year Results from the Randomized INFUSE-AMI Trial. Presented at the annual American College of Cardiology Scientific Sessions, San Francisco, CA, March 11th, 2013.

1960. Perspectives on Left Main Revascularization: Existing Guidelines do not address current clinical practice. Presented at the annual American College of Cardiology Scientific Sessions, San Francisco, CA, March 11th, 2013.

1961. Update on the MitraClip and the COAPT Trial. Presented at the annual American College of Cardiology Scientific Sessions, San Francisco, CA, March 11th, 2013.

1962. The EXCEL Trial: A randomized trial of PCI vs CABG in patients with unprotected left main disease. Cardiothoracic surgery conference, Columbia University Medical Center, New York City, NY, March 14th, 2013.

1963. The Expanding landscape of adjunctive pharmacology before, during and after PCI. Presented at the annual China Interventional Therapeutics course, Beijing, China, March 21st, 2013.

1964. Intracoronary Abciximab in Acute Myocardial Infarction. Presented at the annual China Interventional Therapeutics course, Beijing, China, March 21st, 2013.

1965. Left Main Intervention – From Pre-Intervention Assessment to Stent Optimization. Presented at the annual China Interventional Therapeutics course, Beijing, China, March 21st, 2013.

1966. Transcatheter Mitral valve repair alternatives for functional MR: Devices and Studies (including COAPT). Presented at the annual China Interventional Therapeutics course, Beijing, China, March 22nd, 2013.

1967. Can we Optimize DAPT protocol after DES? Early DAPT discontinuation after XIENCE stents. Presented at the annual China Interventional Therapeutics course, Beijing, China, March 22nd, 2013.

1968. Adjunctive Pharmacotherapy in Primary PCI: From HORIZONS-AMI I to II. Presented at the annual China Interventional Therapeutics course, Beijing, China, March 22nd, 2013.

1969. Coronary DCB Applications: Future Role of DCB in a Mature DES Market. Presented at the annual China Interventional Therapeutics course, Beijing, China, March 22nd, 2013.

1970. Acute coronary syndromes: State-of-the Art. Presened at the Centre De Recherche, Laval Hospital, March 28th, 2013, Quebec City, Canada.

1971. Anti-platelet agent decisions in ACS. Presented at the Centre Hospitalier de L'Universite de Montreal, March 28th, 2013, Montreal, Canada.

1972. STEMI Intervention: Current and future drugs, devices and tehccniques. Presented at the Montreal Heart Institute, March 28th, 2013, Montreal, Canada.

1973. Coronary Revascularization Dilemmas: Medical therapy, PCI or CABG? Cardiology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA, April 3rd, 2013.

1974. The History and Future of STEMI Interventions. Cardiology Fellow's Conference, Cedars-Sinai Medical Center, Los Angeles, CA, April 3rd, 2013.

1975. Coronary Revascularization Decisions: Medical Therapy vs. PCI vs. Bypass Surgery. Cardiology Grand Rounds, Northwestern Medical Center, Chicago, IL, April 8th, 2013.

1976. Vulnerable Plaque: The secret to preventing death and myocardial infarction. Cardiology Grand Rounds, Hartford Hospital, Hartford, CT, April 9th, 2013.

1977. How and When to Use IVUS to Improve Procedural Outcomes. Presented at the National Interventional Cardiology Fellow's Course, San Jose, CA, April 15th, 2013.

1978. Drug-Eluting Stents: Past, Present, and Future. Presented at the National Interventional Cardiology Fellow's Course, San Jose, CA, April 15th, 2013.

1979. Left Main Disease: PCI vs CABG. Presented at the National Interventional Cardiology Fellow's Course, San Jose, CA, April 15th, 2013.

1980. Antithrombin Pharmacology for the Interventionalist. Presented at the National Interventional Cardiology Fellow's Course, San Jose, CA, April 16th, 2013.

1981. Percutaneous Mitral Valve Interventions - Where Are We and Where Are We Going? Presented at the Cardiology Napa Valley Course, Napa Valley, CA, April 18th, 2013.

1982. State of the Art Management of Acute Myocardial Infarction – the Latest Drugs, Devices, Techniques. Presented at the Cardiology Napa Valley Course, Napa Valley, CA, April 18th, 2013.

1983. Left Main Intervention in 2013: The EXCEL Trial at NYP. Cardiology Catheterization Conference, New York Presbyterian Hospital, NY, April 23rd, 2013.

1984. Current and future DES. Transmitted to the annual TCTAP course, Seoul, South Korea, April 23rd, 2013.

1985. Did the EVEREST II Trial Matter? Presented at the annual AATS Mitral Conclave, New York City, NY, May 2nd, 2013.

1986. The place of unprotected left main intervention in 2013. Presented at the Emory Practical Intervention Course (EPIC 2013), Atlanta Georgia, May 3rd, 2013.

1987. The Essentials of PCI Pharmaoclogy. Cardiology Fellow's Course, Columbia University Medical Center, New York City, NY, May 20th, 2013.

1988. Revascularization alternatives for left main coronary artery disease. Presented at the Montreal Live Course, Montreal, Canada, June 10th, 2013.

1989. Medical Therapy, PCI or CABG for Patients with Diabetes and Coronary Artery Disease. Presented at the Montreal Live Course, Montreal, Canada, June 11th, 2013.

1990. Mitral Valve Therapies: The Year in Review. Presented at the course Transcatheter Cardiovascular Therapeutics, Vancouver, Canada, June 13th, 2013.

1991. Randomized Trials of the MitraClip in FMR: From COAPT to RESHAPE. Presented at the course Transcatheter Cardiovascular Therapeutics, Vancouver, Canada, June 14th, 2013.

1992. Rationale and Design of the PROSPECT II Study and PROSPECT ABSORB Trial. Presented at the annual Vulnerable Plaque Meeting (VPM2013), Paris, France, June 24th, 2013.

1993. Can QCA and/or IVUS substitute for FFR? VERDICT FIRST results. Presented at the Geoffrey O. Hartzler Interventional Cardiology Symposium, Maui, Hawaii, June 15th, 2013.

1994. STEMI Intervention for Thrombus, aspiration, Abciximab, Mesh-covered stents. Presented at the Geoffrey O. Hartzler Interventional Cardiology Symposium, Maui, Hawaii, June 16th, 2013.

1995. Current status of left main stenting – Anticipating EXCEL. Presented at the Geoffrey O. Hartzler Interventional Cardiology Symposium, Maui, Hawaii, June 17th, 2013.

1996. The First Inaugural Geoffrey O. Hartzler Memorial lecture. Presented at the Geoffrey O. Hartzler Interventional Cardiology Symposium, Maui, Hawaii, June 17th, 2013.

1997. The Promise of Bioabsorable Stents: The ABSORB III and IV Trials. Presented at the Geoffrey O. Hartzler Interventional Cardiology Symposium, Maui, Hawaii, June 19th, 2013.

1998. Why do we need bioabsorbable coronary scaffolds in the 21st century? Presented at the annual SOLACI scientific sessions, Sao Paulo, Brazil, July 23rd, 2013.

1999. ABSORB III and IV Pivotal Clinical Trial Program. Presented at the annual SOLACI scientific sessions, Sao Paulo, Brazil, July 23rd, 2013.

2000. Bioabsorbable scaffolds for vulnerable plaque. Presented at the annual SOLACI scientific sessions, Sao Paulo, Brazil, July 23rd, 2013.

2001. Left main PCI Vs. CABG: Predicting the EXCEL trial results. Presented at the annual SOLACI scientific sessions, Sao Paulo, Brazil, July 24th, 2013.

2002. Bioabsorbable Scaffolds: The fourth revolution in Interventional Cardiology. Presented at the annual SOLACI scientific sessions, Sao Paulo, Brazil, July 24th, 2013.

2003. Efficacy of the Mguard EPS in STEMI insights from the MASTER Trial. Presented at the annual SOLACI scientific sessions, Sao Paulo, Brazil, July 24th, 2013.

2004. The Evolution of Primary PCI: Innovations in devices and anti-coagulation over the last thirty years - Have they improved outcomes? Transmitted to the annual ACVS course in Hyderabad, India, August 9th, 2013.

2005. ABSORB III and IV Pivotal Clinical Trial Program. New York Presybterian Hospital, Cardiac catheterization conference, August 20th, 2013, New York City, NY.

2006. Novel Adjunctive therapies in primary percutaneous coronary intervention: Intracoronary pharmacotherapy. Presented at the annual European Society of Cardiology scientific sessions, Amsterday, The Netherlands, September 2nd, 2013.

2007. Phamracology in patients undergoing percutaneous coronary intervention: State of the art review. Columbia University Medical Center, NY, NY, September 6th, 2013.

2008. The Changing Landscape of Interventional Pharmacotherapy. Presented at PriMed 2013, Boston, MA, September 19th, 2013.

2009. Use of the MitraClip for Patients with Degenerative and Functional Mitral Regurgitation. Presened at the course “Cardiology Update: A Patient Management Approach. Atlantic City, NJ, September 28th, 2013.

2010. The Importance of Ischemia in Coronary Revascularization Decisions. Presened at the course “Cardiology Update: A Patient Management Approach. Atlantic City, NJ, September 28th, 2013.

2011. Acute Coronary Syndromes: Risk stratification and antiplatelet agent decisions. New York Cardiology Fellows, NY, NY, October 1st, 2013.

2012. Preventing Recurrent Acute Coronary Syndromes: Improving Clinical Outcomes through Evidence-based Antiplatelet Therapy and Continuing Comprehensive

Care, Cardiology Grand Rounds, Brookdale University Hospital and Medical Center, Brooklyn, NY, October 2nd, 2013.

2013. The Changing Landscape of Oral Antiplatelet Therapy in ACS Management. Presented at the course “Reducing Risk in the Acute Coronary Syndrome Patient: Insights for Primary Care Clinicians”. Cleveland, Ohio, October 4th, 2013.

2014. Secondary Prevention in Acute Coronary Syndromes: Antiplatelet agents and beyond. Presented at the Primed Internal Medicine Update meeting, Tampa, FL, October 8th, 2013.

2015. Preventing Recurrent Acute Coronary Syndromes: Improving Clinical Outcomes through Evidence-based Antiplatelet Therapy and Continuing Comprehensive Care. Cardiology Grand Rounds. East Orange General Hospital, East Orange, NJ, October 15th, 2013.

2016. A Critical Appraisal of PCI in Patients with Left Main and Three Vessel Disease. Transmitted to the annual scientific sessions of the Internvetgional Cardiology Society of Argentina (CACI), Buenos Aires, Argentina, October 18th, 2013.

2017. Demonstration of Clinical Superiority with a Bioresorbable vascular Scaffold: The ABSORB IV Clinical Trial. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 27th, 2013.

2018. Importance of Angina after PCI. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 27th, 2013.

2019. ABSORB IV Trial Design. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 27th, 2013.

2020. ABSORB III Summary and the ABSORB IV Trial. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 28th, 2013.

2021. Seminal Events in STEMI Reperfusion Therapy. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 28th, 2013.

2022. Current Status of COAPT and ReSHAPE. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 28th, 2013.

2023. Stents and Pharmacotherapy in STEMI: Anticipating HORIZONS-AMI II. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 28th, 2013.

2024. You Want to Improve Outcomes in DES Patients? The Right Pharmacotherapy Is More Important than the Right Stent! Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 28th, 2013.

2025. The Final Word in Left Main Stenting? Novel Aspects and Status Update of the EXCEL Trial. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 28th, 2013.

2026. Do We Really Need Bioresorbable Scaffolds in the USA? Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 28th, 2013.

2027. Overview of Prospect II and PROSPECTABSORB. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 28th, 2013.

2028. Should Diabetes Modulate the PCI vs CABG Equation? Life Is Not So Simple – It's the Anatomy, Not the Diabetes Per Se! Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 29th, 2013.

2029. EuroMax: Critical Appraisal and Clinical Implications. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 30th, 2013.

2030. Medical, Transcatheter and Surgical Therapies for Ischemic MR. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 30th, 2013.

2031. Primary PCI for STEMI: A Resounding Victory and Future Challenges. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 30th, 2013.

2032. Rationale for Bioresorbable Vascular Scaffolds as a VP Shield: The PROSPECT ABSORB Trial. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 30th, 2013.

2033. Therapeutic Alternatives for Intracoronary Thrombus: The MASTER Results in Perspective. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 30th, 2013.

2034. Stent Selection and Antiplatelet Agent Decisions in STEMI: A Preview to HORIZONS-AMI II. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 30th, 2013.

2035. TCT 2013 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 31st, 2013.

2036. Acute vs. Chronic Antithrombotic Management in ACS: Need for a Paradigm Shift? Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 31st, 2013.

2037. Is Cangrelor Necessary to Improve Outcomes After Primary PCI? I'm Sure: Cangrelor Is Required! Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 31st, 2013.

2038. Long-Term Safety and DAPT Interruption: Insights from XIENCE Clinical Trials. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 31st, 2013.

2039. Cangrelor Will Be the New Standard of Care for STEMI Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, TCT 2013, San Francisco, CA, October 31st, 2013.

2040. Oral antiplatelet agents in Non-ST-segment Elevation ACS: Gocus on unstable angina and NSTEMI. Dallas, TX, November 17th, 2013.

2041. Clinical Performance of DES: Is there Room for Improvement? Presented at the IX Columbian Congress of Inerventional Cardiology and Peripheral Vascular Disease. Medellin, Columbia, November 22nd, 2013.

2042. DES Evolution (Metallic DES with Bioresorbable Polymers and BRS): Do They Offer a Clinical Advantage? Presented at the IX Columbian Congress of Inerventional Cardiology and Peripheral Vascular Disease. Medellin, Columbia, November 22nd, 2013.

2043. Clinical Update: PCI in STEMI. Presented at the IX Columbian Congress of Inerventional Cardiology and Peripheral Vascular Disease. Medellin, Columbia, November 22nd, 2013.

2044. Preventing Recurrent Acute Coronary Syndromes: Improving Clinical Outcomes through Evidence-based Antiplatelet Therapy and Continuing Comprehensive Care, Cardiology Grand Rounds, Lutheran Medical Center, Brooklyn, NY, November 27th, 2013.

2045. Overview of Current DES: Are there still unmet needs? Presented at the Innovations in Cardiovascular Interventions meeting (ICI), Tel Aviv, Israel, December 2nd, 2013.

2046. MASTER Trial Results in Perspective. Presented at the Innovations in Cardiovascular Interventions meeting (ICI), Tel Aviv, Israel, December 2nd, 2013.

2047. MGUARD Stent in STEMI: The MASTER I and MASTER II Trials. Presented at the Innovations in Cardiovascular Interventions meeting (ICI), Tel Aviv, Israel, December 2nd, 2013.

2048. Detection and Treatment of Vulnerable Plaque: The PROSPECT II And PROSPECT ABSORB Studies. Presented at the Innovations in Cardiovascular Interventions meeting (ICI), Tel Aviv, Israel, December 3rd, 2013.

2049. Mitral Clip in Functional MR: The COAPT Trial. Presented at the Innovations in Cardiovascular Interventions meeting (ICI), Tel Aviv, Israel, December 3rd, 2013.

2050. The 10-year evolution of metallic DES: what we have learned. Presented at the BVS Forum, Catania, Italy, December 4th, 2013.

2051. Overview of Bioresorbable devices: what is the pipeline? Presented at the BVS Forum, Catania, Italy, December 4th, 2013.

2052. The ABSORB Clinical Trial Program. Presented at the BVS Forum, Catania, Italy, December 5th, 2013.

2053. Bioresorbable scaffolds for vulnerable plaque. Presented at the BVS Forum, Catania, Italy, December 5th, 2013.

2054. Current Long-term DAPT Studies: Does it really matter? Presented at the Cardiovascular Clinical Trialists Forum, Paris, France, December 7th, 2013.

2055. Coronary Revascularization Dilemmas: Medical Therapy, PCI or CABG? Cardiology Grand Rounds, Mt. Sinai Hospital, Miami, FL, December 19th, 2013.

2056. ABSORB: Novel Applications of Bioresorbable Vascular Scaffold/ABSORB: landscape and Latest Clinical Update. Presented at the TCT at TTT 2014 course, Taipei, Tawan, January 10th, 2014.

2057. Exploring Best Practices with New Antiplatelet Agents. Presented at the TCT at TTT 2014 course, Taipei, Tawan, January 11th, 2014.

2058. The OPTIMIZE and ARCTIC-INTERRUPTION Trials. Presented at the TCT at TTT 2014 course, Taipei, Tawan, January 11th, 2014.

2059. The EUROMAX and SAFE-PCI trials. Presented at the TCT at TTT 2014 course, Taipei, Tawan, January 11th, 2014.

2060. Keynote address: The next DES revolution. Presented at the TCT at TTT 2014 course, Taipei, Tawan, January 12th, 2014.

2061. Keynote address: Atherosclerotic Plaque: How Will We Treat It in the Future? Presented at the annual ISET course, Miami, FL, January 20th, 2014.

2062. Transcatheter Mitral Valve Repair with MitraClip. Presented at the annual ISET course, Miami, FL, January 20th, 2014.

2063. Novel P2Y12 inhibitors in adult and pediatric patients: Stepping up to the plate(let). Cardiology Grand Rounds, Columbia University Medical Center, NY, NY, January 21st, 2014.

2064. Diagnosis and Treatment of Vulnerable Plaque: The Solution to the Cardiovascular Epidemic? Cardiovascular Grand Rounds, Ohio State Medical Center, Columbus, Ohio, January 31st, 2014.

2065. Treatment and prevention of acute coronary syndromes. Cardiology Grand Rounds, East Orange Hospital, East Orange, NJ, February 4th, 2014.

2066. The landscape of antiplatelet agents in patients with cardiovascular disease. Cardiology and Family Practice Rounds. Mississauga Hospital, Mississauga, Ontario, February 6th, 2014.

2067. Novel approaches to partients with acute coronary syndromes: Today and tomorrow. Cardiology Grand Rounds, Hamilton Health Sciences, Hamilton, Canada. February 6th, 2014.

2068. Revascularization Decisions in Simple and Complex Coronary Artery Disease. Toronto, Canada, February 6th, 2014.

2069. The unmet clinilca need for a rapid acting raoiud offset IV P2Y12 platelet inhibitor. Presented to the CDER advisory committee, White Oak, Maryland, February 12th, 2014.

2070. What are the remaining controversies in STEMI management? JIM annual meeting, Rome, Italy, February 13th, 2014.

2071. Update on the Latest Mitral Clip Studies. Presented at the annual CRT course, Washington DC, February 23rd, 2013.

2072. HORIZONS AMI II Trial Design and Rationale. Presented at the annual CRT course, Washington DC, February 23rd, 2013.

2073. PROSPECT II Rationale Design and Expectations. Presented at the annual CRT course, Washington DC, February 23rd, 2013.

2074. The BVS ABSORB III and IV Clinical Trial Update. Presented at the annual CRT course, Washington DC, February 24th, 2013.

2075. Future Indication for BRS Technology the Golden Tube. Presented at the annual CRT course, Washington DC, February 24th, 2013.

2076. The Five Best Trials from 2013 that may IMPACT my Practice. Presented at the annual CRT course, Washington DC, February 24th, 2013.

2077. COAPT: Progress Report. Presented at the annual CRT course, Washington DC, February 24th, 2013.

2078. EXCEL and NOBLE: Where do Left Main Trials Stand in the Shadows of SYNTAX and FREEDOM? Presented at the annual Chronic Total Occlusion and Left Mian Summit. New York City, NY, March 1st, 2014.

2079. Treatment of STEMI: Yesterday, Today and Tomorrow. Presented at the 10th annual Scottsdale Interventional Forum, Phoenix, AZ, March 6th, 2014.

2080. Persistent Dilemmas Amidst Advances in Unprotected Left Main Percutaneous Revascularization. Presented at the 10th annual Scottsdale Interventional Forum, Phoenix, AZ, March 7th, 2014.

2081. Bioresorbable Scaffolds: Where We Came from and Where We Are Going. Presented at China Interventional Therapeutics, Shanghai, China, March 19th, 2014.

2082. From Coronary Revascularization to Vascular Restoration: Why Do We Need BRS. Presented at China Interventional Therapeutics, Shanghai, China, March 19th, 2014.

2083. What Did We Learn from PROSPECT I and an Introduction to PROSPECT II. Presented at China Interventional Therapeutics, Shanghai, China, March 19th, 2014.

2084. New Studies and Rationale for MitraClip in Functional MR Patients (COAPT and RESHAPE). Presented at China Interventional Therapeutics, Shanghai, China, March 19th, 2014.

2085. STEMI Approaches: Current State and Future Developments. Presented at China Interventional Therapeutics, Shanghai, China, March 20th, 2014.

2086. Left Main Disease Is Not Surgical Disease Any More - EXCEL Study. Presented at China Interventional Therapeutics, Shanghai, China, March 21st, 2014.

2087. Adjunctive Pharmacotherapy in Primary PCI: From HORIZONS-AMI to EUROMAX. Presented at China Interventional Therapeutics, Shanghai, China, March 21st, 2014.

2088. Can IVUS (or OCT) be Used to Determine Lesion Significance? Updates from VERDICT/FIRST. Presented at the American College of Cardiology Annual Scientific Sessions, Washington, DC, March 28th, 2014

2089. Perspectives on PCI vs CABG in the Diabetic Patient: The FREEDOM to Disagree with FREEDOM. Presented at the course Optimizing PCI Outcomes: A Vision for 2014. Washington, DC, March 28th, 2014

2090. Left Main or Multivessel Disease: More Options for the Heart Team! Presented at the American College of Cardiology Annual Scientific Sessions, Washington, DC, March 30th, 2014

2091. Novel Stents for STEMI. Presented at the American College of Cardiology Annual Scientific Sessions, Washington, DC, March 31st, 2014

2092. PCI or CABG for Left Main Disease? PCI is preferred! Presented at the American College of Cardiology Annual Scientific Sessions, Washington, DC, March 31st, 2014.

2093. Revascualrization Clincial Decision-making in Coronary Artery Disease: A rational algorithm. Cardiology Grand Rounds, University of California at San Francisco, April 2nd, 2014, San Francisco, CA.

2094. From coronary revascularization to vascular restoration: Why do we need BRS? Presented at GI2 (Global Sumit Innovations in Intervention), Sao Paulo, Brazil, April 7th, 2014.

2095. Clinical Results with the SYNERGY Stent. Presented at GI2 (Global Sumit Innovations in Intervention), Sao Paulo, Brazil, April 7th, 2014.

2096. Left Main Stenting: The dissociation between clinical practice and evidence based medicine. Presented at GI2 (Global Sumit Innovations in Intervention), Sao Paulo, Brazil, April 8th, 2014.

2097. A close look at new therapies: prasugrel and ticagrelor. Presented during the course “The Acute Coronary Syndrome Patient, Orlando, FL, April 12th, 2014.

2098. State-of-the-Art in ACS and STEMI: Risk Stratification, Reperfusion Strategies, and Guidelines. Presented at the National Interventional Cardiology Fellows Course, Las Vegas, NV, April 12th, 2014.

2099. Drug-Eluting Stents: Past, Present, and Future. Presented at the National Interventional Cardiology Fellows Course, Las Vegas, NV, April 12th, 2014.

2100. Antiplatelet Therapy for the Interventionalist. Presented at the National Interventional Cardiology Fellows Course, Las Vegas, NV, April 12th, 2014.

2101. Imaging Prior and During Implantation: Is eyeballing sufficient? Presented at the BRS-ARC meeting, Rotterdam, The Netherlands, April 14th, 2014.

2102. Periprocedural MI (always within 48 hs): The SCAI consensus. Presented at the BRS-ARC meeting, Rotterdam, The Netherlands, April 14th, 2014.

2103. Patient Reported Outcomes (PRO)… and health economics: ABSORB IV example. Presented at the BRS-ARC meeting, Rotterdam, The Netherlands, April 15th, 2014.

2104. Transcatheter mitral valve intervention: My personal predictions for 2020. Presented at the 2014 annual SOLACI meeting, Buenos Aires, Argentina, April 23rd, 2014.

2105. EXCEL and NOBLE: Where do left main trials stand in the shadows of SYNTAX and FREEDOM. Presented at the 2014 annual SOLACI meeting, Buenos Aires, Argentina, April 23rd, 2014.

2106. Bioresorbable Vascular Scaffolds: From Imaging to Evidence. Presented at the 2014 annual SOLACI meeting, Buenos Aires, Argentina, April 23rd, 2014.

2107. From HORIZONS to EUROMAX: Bivalirudin or UFH plus GPIIb/IIIa inhibitors? Presented at the 2014 annual SOLACI meeting, Buenos Aires, Argentina, April 23rd, 2014.

2108. Approaches to stable coronary disease treatment - In favor of revascularization: Ischemia makes the difference. Presented at the 2014 annual SOLACI meeting, Buenos Aires, Argentina, April 23rd, 2014.

2109. State of the Art Management of Acute Myocardial Infarction – the Latest Drugs, Devices, and Techniques. Presented at the course Cardiology Napa Valley 2014, Piedmont Heart Institute & Minneapolis Heart Institute, Napa, California, May 8th, 2014.

2110. Percutaneous Mitral Valve Interventions - Where Are We and Where Are We Going? Presented at the course Cardiology Napa Valley 2014, Piedmont Heart Institute & Minneapolis Heart Institute, Napa, California, May 8th, 2014.

2111. The MVARC Initiative - Summary of Findings. Presented at the course Valves in the Heart of the Big Apple VIII: Evaluation and Management of Valvular Heart Disease 2014, New York, NY, May 9th, 2014.

2112. Detection and treatment of vulnerable plaque: From PROSPECT I to PROSPECT II. Skane University Hospital, Lund, Sweden, Masy 19th, 2014.

2113. ABSORB IV: A clinical evaluation of Absorb bioresorbable vascular scaffolds compared to e verolimus-eluting stents in patients with de novo native coronary artery lesions. EuroPCR annual conference, Paris, France, May 20th, 2014.

2114. HORIZONS-AMI II: Harmonizing Outcomes with Revascularisation and Stents in Acute Myocardial Infarction II trial. EuroPCR annual conference, Paris, France, May 20th, 2014.

2115. MASTER II: MGuard Prime stent system clinical trial in patients with acute STEMI. EuroPCR annual conference, Paris, France, May 20th, 2014.

2116. COAPT: Cardiovascular Outcomes Assessment of the MitraClip Therapy. EuroPCR annual conference, Paris, France, May 20th, 2014.

2117. The Bioresorbable vascular scaffold: acute performance and safety: Summary results. EuroPCR annual conference, Paris, France, May 20th, 2014.

2118. Clinical perspectives on the evolution of DES: Past, present and future. EuroPCR annual conference, Paris, France, May 21st, 2014.

2119. Therapeutic Options for Intracoronary Thrombus. Presented at the SCAI annual scientific sessions, Las Vegas, NV, May 30th, 2014.

2120. Management of acute coronary syndromes: From unstable angina to NSTEMI to STEMI. Presented at the course Internal Medicine Update, Columbia University Medical Center, New York, NY, June 4th, 2014.

2121. Mitral Valve Therapies: The Year in Review. Presented at the annual Transcatheter Valve Therapies course, Vancouver, Canada, June 5th, 2014.

2122. MitraClip Randomized Trials and Registries. Presented at the annual Transcatheter Valve Therapies course, Vancouver, Canada, June 5th, 2014.

2123. The Future is Now for Transcatheter Mitral Interventions: New Technical Approaches, Trial Design and What the FDA Wants to See. Presented at the PICS/AICS 2014 course, Chicago, IL, June 9th, 2014.

2124. Thromboaspiration in STEMI: Con! Presented at the course Montreal Live 2014. Montreal, Canada, June 12th, 2014.

2125. Novel stents in STEMI: A view to the future. Presented at the course Montreal Live 2014. Montreal, Canada, June 12th, 2014.

2126. Bioresorbable Vascular Scaffolds: Challenges and Opportunities in Today's Clinical Practice. Presented at TCT Russia 2014, Moscow, Russia, June 17th, 2014.

2127. Stent Selection for Primary PCI. Presented at TCT Russia 2014, Moscow, Russia, June 17th, 2014.

2128. State of the Art Lecture: Detection and Treatment of Vulnerable Plaque. Presented at the Newcastle Complex Coronary Interventions Course, Freeman Hospital, Newcastle Upon Tyne, UK, June 19th, 2014.

2129. The Bioresorbable Vascular Scaffold Revolution. Presented at the Newcastle Complex Coronary Interventions Course, Freeman Hospital, Newcastle Upon Tyne, UK, June 19th, 2014.

2130. Pharmacotherapy and Primary PCI. Presented at the Newcastle Complex Coronary Interventions Course, Freeman Hospital, Newcastle Upon Tyne, UK, June 20th, 2014.

2131. The CANARY Trial. Presented at the annual Vulnerable Plaque Meeting, Windsor, UK, June 24th, 2014.

2132. PROSPECT II: Imaging and Intervention. Presented at the annual Vulnerable Plaque Meeting, Windsor, UK, June 24th, 2014.

2133. Bivalirudin in ACS and PCI. Presented by webcast to the course "Update on Anticoagulant Therapy in ACS. Mumbai, India, July 5th, 2014.

2134. Stents and Pharmacotherapy in STEMI: The Evolution to HORIZONS II. Presented at the Geoffrey O. Hartzler Interventional Cardiology Symposium, Maui, Hawaii, July 14th, 2014.

2135. Bioabsorbable Vascular Scaffolds from Concept to Proof (ABSORB III and IV). Presented at the Geoffrey O. Hartzler Interventional Cardiology Symposium, Maui, Hawaii, July 14th, 2014.

2136. Detection and Treatment of Vulnerable Plaque from PROSPECT to PROSPECT II to PROSPECT ABSORB. Presented at the Geoffrey O. Hartzler Interventional Cardiology Symposium, Maui, Hawaii, July 16th, 2014.

2137. The Wavecrest Device: Attributes and Basic Technique. Presented at the Left Atrial Appendage Occlusion: A Technique Oriented Course, Chicago, IL, July 17th, 2014.

2138. Safety and Efficacy of the Wavecrest: First-in-Human Experiences and Future Trials. Presented at the Left Atrial Appendage Occlusion: A Technique Oriented Course, Chicago, IL, July 19th, 2014.

2139. A Preview to ABSORB III/IV. Presented at the course BioResorbable Vascular Scaffolds: Transformational Technology for PCI, Boston, MA, July 24th, 2014.

2140. BRS Capping of Vulnerable Plaque and PROSPECT ABSORB. Presented at the course BioResorbable Vascular Scaffolds: Transformational Technology for PCI, Boston, MA, July 25th, 2014.

2141. What I Have Learned That is Most Important: Clinical Outcomes. Presented at the course BioResorbable Vascular Scaffolds: Transformational Technology for PCI, Boston, MA, July 25th, 2014.

2142. Is Thrombus Aspiration needed in Primary PCI? Presented at the Annual Scientific Sessions of the European Society of Cardiology, Barcelona, Spain, August 31st, 2014.

2143. Implications of Invasive Detection of Plaque Vulnerability. Presented at the Annual Scientific Sessions of the European Society of Cardiology, Barcelona, Spain, September 1st, 2014.

2144. Strategy Trials – Important or Impossible? SYNTAX/EXCEL. Presented at the Annual Scientific Sessions of the European Society of Cardiology, Barcelona, Spain, September 2nd, 2014.

2145. CANARY: Evaluation of the Relationship Between Intravascular Ultrasound and Near Infrared Spectroscopy Lipid Parameters with Periprocedural Myonecrosis, with an Integrated Randomized Trial of Distal Protection to Prevent PCI-Related Myocardial Infarction. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 13th, 2014.

2146. Setting the Stage: Most Important Mitral Regurgitation Studies and Events of the Last 12 Months. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 13th, 2014.

2147. PCI vs CABG: PCI for Most! Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 13th, 2014.

2148. The Great Debate: What to do with Functionally Insignificant Vulnerable Plaque? I Want to Treat Them! Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 13th, 2014.

2149. Relationship Between Infarct Size and Subsequent Mortality Following Primary PCI for STEMI: A Pooled Patient Level Analysis From 10 Trials. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 14th, 2014.

2150. Focal Treatment of Vulnerable Plaque: Stents, Scaffolds, and Prospect II. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 14th, 2014.

2151. Bivalirudin vs Heparin Monotherapy in STEMI: Debating the Merits: The Data Strongly Supports Bivalirudin! Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 14th, 2014.

2152. Novel Stent Designs in STEMI. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 14th, 2014.

2153. Evolution of PCI Therapy Towards Bioresorbable Scaffolds. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 14th, 2014.

2154. VELOCITY: A Prospective, Randomized Trial of Peritoneal Hypothermia in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 15th, 2014.

2155. Should Cangrelor Pretreatment Be Used in Nearly All Patients with STEMI and NSTEMI and Many with Stable CAD? Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 15th, 2014.

2156. Levels of Technical Efficacy and Clinical Evidence Required to Increase Physician Adoption for Coronary Indication. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 15th, 2014.

2157. The ABSORB III-IV trial(s): What will we learn? Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 15th, 2014.

2158. Debate. Heparin with Bailout GP IIb/IIIa Inhibitor Use Should Be Standard Pharmacotherapy for All Patients Undergoing Primary PCI. Con: Follow the Data - and Save the Patient! Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 16th, 2014.

2159. Absorb III/IV: Angina and Ischemia Hypothesis. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 16th, 2014.

2160. Are the Current Clinical Trial Pathways for New Mitral Valve Therapies Practical? A Future Roadmap to Consider! Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 16th, 2014.

2161. Cangrelor Will Be the New Standard of Care for STEMI. Outcomes with an Embolic Protection Stent in STEMI. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 16th, 2014.

2162. Implications and Critical Appraisal of the Late-Breaking Clinical Trials and First Reports at TCT 2014. Presented at the annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 17th, 2014.

2163. The Modern Treatment of Acute Myocardial Infarction. Presented at the course Progress in Cardiovascular Therapeutics, Geneva, Switzerland, October 2nd, 2014.

2164. Oral Antiplatelet Therapies for Acute Coronary Syndromes: Exploring Pharmacologic Profiles, Efficacy, and Safety. Cardiometabolic Conference, Las Vegas, NV, October 11th, 2011.

2165. Improving Quality of Life: Absorb II Angina Data. Presented at the 35th annual GISE conference, Genoa, Italy, October 15th, 2014.

2166. PMVR Today and a glimpse into the future. Presented at the 35th annual GISE conference, Genoa, Italy, October 16th, 2014.

2167. State of the Art and Future Perspectives on: Percutaneous approach to mitral valve repair status. Presented at the 35th annual GISE conference, Genoa, Italy, October 16th, 2014.

2168. State of the Art and Future Perspectives on: New pharmacological options in PCI treated patients. Presented at the 35th annual GISE conference, Genoa, Italy, October 16th, 2014.

2169. Bioresorbable Vascular Scaffolds: A True Breakthrough Technology. Presented at the 35th annual GISE conference, Genoa, Italy, October 16th, 2014.

2170. Vulnerable Plaque: PROSPECT 2 Study. Presented at the annual CCT meeting, Kobe, Japan, October 31st, 2014.

2171. Medical, surgical and transcatheter therapies for mitral regurgitation. Medical Grand Rounds. Beth Israel Medical Centre, New York, NY, November 11th, 2014.

2172. Ilumien II: A comparison of OCT-guided and IVUS-guided stent implantation. OCT Roundtable Advisory Board, Chicago, IL, November 14th, 2014.

2173. Supersaturated Oxygen in STEMI to Reduce Infarct Size. Presented during the annual Scientific Sessions of the American Heart Association, Chicago, IL, November 16th, 2014.

2174. State of the Art Thrombus Management in STEMI. Presented during the annual Scientific Sessions of the American Heart Association, Chicago, IL, November 17th, 2014.

2175. Diagnosis And Prophylactic Treatment Of Vulnerable Plaques: Can Their Vulnerability Be Decreased By Stenting. Presented at the annual VEITH course, New York City, NY, November 18th, 2014.

2176. Will Drug-Eluting Fully Bioresorbable Scaffolds Prove Advantageous In the Coronary Arteries? Presented at the annual VEITH course, New York City, NY, November 19th, 2014.

2177. A historical look at AMI therapies: From yesterday to today to tomorrow. Cardiology Grand Rounds, Baptist Medical Center, Miami, FL, November 20th, 2014.

2178. Prevention and treatment of interventional complications. American College of Cardiology Extended Learning Program. Singapore, Singapore, November 22nd, 2014.

2179. Identifying and Assessing Potential Candidates for MitraClip. American College of Cardiology Extended Learning Program. Singapore, Singapore, November 23rd, 2014.

2180. The MitraClip: Reimbursement not Regulation Limits Adoption. Presented at the Dallas Leipzig Valves course, Dallas, TX, December 11th, 2014.

2181. The MASTER II Trial: Comparison of the MGuard Embolic Protection Stent with Standard Stents in Acute Myocardial Infarction. Presened at the annual Innovations in Crdiovascular Interventions meeting, Tel Aviv, Israel, December 15th, 2014.

2182. Proof of the Safety and Efficacy of Left Main Stenting: The EXCEL Trial. Presened at the annual Innovations in Crdiovascular Interventions meeting, Tel Aviv, Israel, December 15th, 2014.

2183. MASTER I and MASTER II Trials: Meta-Analysis and 30 Day Update. Presened at the annual Innovations in Crdiovascular Interventions meeting, Tel Aviv, Israel, December 15th, 2014.

2184. Proof of the Promise of Bioresorbable Scaffolds: The ABSORB III and IV Randomized Trials. Presened at the annual Innovations in Crdiovascular Interventions meeting, Tel Aviv, Israel, December 15th, 2014.

2185. The Next Generation Stents and antiplatelet regimens in STEMI. Presened at the annual Innovations in Crdiovascular Interventions meeting, Tel Aviv, Israel, December 16th, 2014.

2186. Bioresorbable Scaffolds to Prevent Late Stent-Related Events in Coronary Applications. Presented at the annual ISET symposium, Miami, FL, February 2nd, 2015.

2187. Mitral Valve Therapies: Present Successes and Future Developments. Presented at the annual ISET symposium, Miami, FL, February 2nd, 2015.

2188. Limitations of Metallic DES, & Proving Superiority of BRS. Presented at the course Bioresorbable Vascular Scaffolds: A One-Day Case-Based Technique-Oriented Course, Rome, Italy, February 11th, 2015.

2189. Thoughtful commentary: The DAPT Controversy after the DAPT Trial. Presented at the annual Joint Interventional Meeting (JIM), Rome, Italy, February 12th, 2015.

2190. To Treat or not to treat functionally insignificant vulnerable plaque. Presented at the annual Joint Interventional Meeting (JIM), Rome, Italy, February 13th, 2015.

2191. Antithrombin alternatives during primary PCI in STEMI. Presented at the annual Joint Interventional Meeting (JIM), Rome, Italy, February 14th, 2015.

2192. Bivalirudin is Superior to Heparin for ACS Patients. Presented at the annual CRT meeting, Washington DC, February 22nd, 2015.

2193. Novel Therapeutic Pathways in the Secondary Prevention of Atherothrombotic Events in AMI Presented at the annual CRT meeting, Washington DC, February 22nd, 2015.

2194. Diagnosis (NIRS) and Treatment (BVS) of Vulnerable Plaque: PROSPECT II. Presented at the annual CRT meeting, Washington DC, February 22nd, 2015.

2195. Optimization of Anticoagulation for STEMI Therapy. Presented at the annual CRT meeting, Washington DC, February 22nd, 2015.

2196. Antiplatelet Therapy for STEMI: The Case for Cangrelor. Presented at the annual CRT meeting, Washington DC, February 22nd, 2015.

2197. Role of Bivalirudin post HEAT PPCI. Presented at the annual CRT meeting, Washington DC, February 23rd, 2015.

2198. Optimizing Clinical Trial Designs for Mitral Therapy. Presented at the annual CRT meeting, Washington DC, February 23rd, 2015.

2199. Does BRS technology reduce angina?. Presented at the annual CRT meeting, Washington DC, February 23rd, 2015.

2200. The BVS ABSORB III and IV Clinical Trial Update. Presented at the annual CRT meeting, Washington DC, February 23rd, 2015.

2201. 2201. The journey to eradicate vulnerable plaque. Upsalla Cardiovascular Reseach Center, Upsalla, Sweden, March 4th, 2015.

2202. Non-obstructive ACS is a real Phenomenon. Presented during the annual scientific sessions of the American College of Cardiology, San Diego, CA, March 14th, 2015.

2203. Final Five-Year Results of the Platinum Chromium Promus Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in Workhorse Lesions. Presented during the annual scientific sessions of the American College of Cardiology, San Diego, CA, March 14th, 2015.

2204. Treatment of Choice in the Acute Phase: Bivalirudin Has the Best Benefit-Risk Profile. Presented during the annual scientific sessions of the American College of Cardiology, San Diego, CA, March 14th, 2015.

2205. Preclinical Results with a Novel Internally Loaded Drug-Filled Coronary Stent. Presented during the annual scientific sessions of the American College of Cardiology, San Diego, CA, March 14th, 2015.

2206. Update on ABSORB III and IV. Presented during the annual scientific sessions of the American College of Cardiology, San Diego, CA, March 15th, 2015.

2207. For AMI, Purpose Built Stents are Best. Presented during the annual scientific sessions of the American College of Cardiology, San Diego, CA, March 15th, 2015.

2208. Presented during the annual scientific sessions of the American College of Cardiology, San Diego, CA, March 14th, 2015.

2209. Critical appraisal of the TOTAL trial. Presented during the annual scientific sessions of the American College of Cardiology, San Diego, CA, March 16th, 2015.

2210. Bioresorbable Scaffolds: the 4th Revolution? Presented at the annual China Interventional Therapeutics course, Beijing, China, March 20th, 2015.

2211. The Ultimate EXCEL Study. Presented at the annual China Interventional Therapeutics course, Beijing, China, March 21st, 2015.

2212. Functionally insignificant vulnerable plaque: Do you want to treat? Yes, we have data, PROSPECT, We need more data, PROSPECT 2 study. Presented at the annual China Interventional Therapeutics course, Beijing, China, March 21st, 2015.

2213. Update on the ABSORB Clinical Program: Long-Term Data and Long-Term Benefits. Presented at the annual China Interventional Therapeutics course, Beijing, China, March 21st, 2015.

2214. How to Design and Perform BRS Clinical Trials in China. Presented at the annual China Interventional Therapeutics course, Beijing, China, March 22nd, 2015.

2215. Indications for MitrClip Treatment in 2015. Presented at the 4th Annual Innovations in Valve and Structural Heart Disease, Nassau, Bahamas, April 3rd, 2015.

2216. Novel Transcatheter Approaches to Mitral Valve Replacement. Presented at the 4th Annual Innovations in Valve and Structural Heart Disease, Nassau, Bahamas, April 3rd, 2015.

2217. Primary and Secondary Prevention Strategies in ACS. Presented at the Primary Care Women's Health Forum 2015, Charleston, West Virgina, April 16, 2015.

2218. Bivalirudin in PCI and ACS: A systematic review. Webcast to Cipla Univeristy, India. April 18th, 2015.

2219. Mitral Valve Academic Research Consortium Report: An Update. Presented at the AATS 2015 Mitral Valve Conclave, New York, NY, April 24th, 2015.

2220. Bioresorbable Scaffolds in a "Nutshell": Updates and Expectations. Presented at the annual TCTAP Angioplasty Summit, Seoul, S. Korea, April 29th, 2015.

2221. Evolution of BVS, Unique Benefits, and Clinical Perspectives of Angina. Presented at the annual TCTAP Angioplasty Summit, Seoul, S. Korea, April 29th, 2015.

2222. Focal Treatment of Vulnerable Plaque: Stents, Scaffolds and PROSPECT II. Presented at the annual TCTAP Angioplasty Summit, Seoul, S. Korea, April 29th, 2015.

2223. The Unmet Needs in PCI. Presented at the annual TCTAP Angioplasty Summit, Seoul, S. Korea, April 29th, 2015.

2224. UFH Versus Bivalirudin in ACS: Which One Should I Use? Presented at the annual TCTAP Angioplasty Summit, Seoul, S. Korea, April 30th, 2015.

2225. PLATO: Impact on the management of ACS and personalizing treatment with Ticagrelor. Presented at the annual TCTAP Angioplasty Summit, Seoul, S. Korea, April 30th, 2015.

2226. Vulnerable Plaque Detection and Treatment: PROSPECT II and PROSPECT ABSORB. Presented at the annual TCTAP Angioplasty Summit, Seoul, S. Korea, April 30th, 2015.

2227. Future Roadmap for Mitral Valve Therapies. Presented at the annual TCTAP Angioplasty Summit, Seoul, S. Korea, April 30th, 2015.

2228. Dual Antiplatelet Therapy for Coronary Artery Disease. Presented at the annual TCTAP Angioplasty Summit, Seoul, S. Korea, April 30th, 2015.

2229. Cangrelor Will be the New Standard of Care for STEMI. Presented at the annual scientific sessions of the Society of Cardiovascular Angiography and Interventions, San Diego, CA, May 7th, 2015.

2230. Antiplatelet Therapy for ACS – Secondary Management. Presented at the annual scientific sessions of the Society of Cardiovascular Angiography and Interventions, San Diego, CA, May 7th, 2015.

2231. State-of-the-Art in ACS and STEMI: Risk Stratification and Reperfusion Strategies. Presented at the annual National Interventional Cardiology Fellow's Course, Miami, Fl, May 15th, 2015.

2232. Drug-Eluting Stents: Past, Present, and Future. Presented at the annual National Interventional Cardiology Fellow's Course, Miami, Fl, May 15th, 2015.

2233. Antiplatelet Therapy for the Interventionalist. Presented at the annual National Interventional Cardiology Fellow's Course, Miami, Fl, May 15th, 2015.

2234. ILUMIEN II: Comparison of stent expansion guided by OCT and IVUS. Presented at the annual EuroPCR symposium, Paris, France, May 20th, 2015.

2235. The unmet clinical need in PCI. Presented at the annual EuroPCR symposium, Paris, France, May 20th, 2015.

2236. Controversies with DES: What makes sense and what 's the data? Presented at the annual EuroPCR symposium, Paris, France, May 20th, 2015.

2237. ILUMEN III – Optimize PCI: Rationale and design. Presented at the annual EuroPCR symposium, Paris, France, May 21st, 2015.

2238. Cangrelor in Patients Undergoing PPCI. Cardiac Catheterizationlaboratory Conference, Columbia University Medical Center, New York Presbyterian Hospital, NY, NY, May 26th, 2015.

2239. A Template for Transcatheter Mitral Randomized Trials: Essentials From the Mitral VARC Initiative. Presented at the Transcatheter Valve Therapy Chicago meeting, Chicago, IL, June 5th, 2015.

2240. Closing the Gap I: COAPT, MitraFR, and RESHAPE 1 and 2. Presented at the Transcatheter Valve Therapy Chicago meeting, Chicago, IL, June 5th, 2015.

2241. OCT-Guided Stenting: The ILUMIEN Trials: CRF Webcast. NY, NY, June 8th, 2015.

2242. How could fully bioresorbable vascular scaffolds improve PCI outcomes? Presented at the annual TCT Russia course, Moscow, Russia, June 18th, 2015.

2243. Risk stratification and patient selection and interventional pharmacology for acute coronary syndromes. Applying the guidelines into real world situations. Presented at the annual TCT Russia course, Moscow, Russia, June 18th, 2015.

2244. Bioresorbable Vascular Scaffolds: Will they live up to the hype? Presented at the annual TCT Russia course, Moscow, Russia, June 18th, 2015.

2245. What is more predictive of clinical events: Angina symptoms, ischemia or anatomic burden? Presented at the Vulnerable Patient Meeting, Madrid, Spain, June 21, 2015.

2246. Interventional Approach: From CVLPRIT/PRAMI (treatment of non-culprit obstructive lesions) to PROSPECT ABSORB studies (treatment of non-culprit obstructive lesions). Presented at the Vulnerable Patient Meeting, Madrid, Spain, June 21, 2015.

2247. Balancing ischemia and bleeding risk: The bivalirudin story. Presented at the Vulnerable Patient Meeting, Madrid, Spain, June 23, 2015.

2248. What would it take to prove the promise of local treatment of VP? Presented at the Vulnerable Patient Meeting, Madrid, Spain, June 23, 2015.

2249. Proving superiority of bioresorbable scaffolds. Presented at the annual TOPIC meeting, Tokyo, Japan, July 10th, 2015.

2250. Dual antiplatelet agent controversies: Drug choice, loading and duration. Presented at the annual TOPIC meeting, Tokyo, Japan, July 10th, 2015.

2251. Vulnerable Plaque Detection and Treatment: Is it a reality? Presented at the annual TOPIC meeting, Tokyo, Japan, July 10th, 2015.

2252. Antiplatelet Therapy for the Interventionalist. Presented at the course Controversies in ACS Management, Beiijing, China, July 11th, 2015.

2253. How to Optimize complex PCI outcomes. Presented at the course Optimizing ACS management: Lessons from Recent Antithrombin and Antiplatelet Studies, Beiijing, China, July 11th, 2015.

2254. How to organize and lead large scale clinical trials, and other life lessons. Presented at the course Optimizing ACS management: Lessons from Recent Antithrombin and Antiplatelet Studies, Beiijing, China, July 11th, 2015.

2255. Overview of interventional antiplatelet therapy. Presented at the course Controversies in ACS Management, Tianjian, China, July 12th, 2015.

2256. Hot topics in ACS management. Presented at the course Controversies in ACS Management, Tianjian, China, July 12th, 2015.

2257. Keynote lecture: Update on Stent Technology- Better than Ever or Do We Need To Do More? Presented at TCT India Next, Bangalore, India, August 14th, 2015.

2258. The Role of Adjunctive Pharmacology in STEMI PCI. Presented at TCT India Next, Bangalore, India, August 14th, 2015.

2259. Peri-infarct zone pacing to prevent adverse left ventricular remodeling in patients with very large myocardial infarction: The PromPT trial. Presented at the European Society of Cardiology Annual Scientific Sessions, London, UK, August 30th, 2015.

2260. The ABSORB STEMI - TROFI II trial: Critical appraisal. Presented at the European Society of Cardiology Annual Scientific Sessions, London, UK, September 1st, 2015.

2261. MitraClip for Functional Mitral Regurgitation in Heart Failure. Heart Failure Society of America annual scientific session, National Harbor, Maryland, September 29th, 2015.

2262. Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 11th, 2015.

2263. The New MVARC Consensus Documents: Take-home Messages. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 11th, 2015.

2264. Specialized Stents in STEMI: MGuard – From MASTER I to MASTER II. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 11th, 2015.

2265. Rationale for and Design of HORIZONS-ABSORB. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 11th, 2015.

2266. Update on Ongoing MitraClip Randomized Trials. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 11th, 2015.

2267. Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? Yes, an Evidence-Based Position. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 11th, 2015.

2268. Can Peri-infarct Pacing Prevent Adverse Left Ventricular Remodeling After Large MI? From MENDMI to PromPT. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 11th, 2015.

2269. Balancing Safety and Efficacy Endpoints – How Do “Net Clinical Benefit” and “Quality of Life” Fit Into the Equation? FOCUS on DAPT, PEGASUS, and MATRIX: Clinical/Trialist Perspective. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 12th, 2015.

2270. ABSORB Meta-analysis: Outcomes in from a patient level meta-analysis of the 4 randomized ABSORB Trials. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 12th, 2015.

2271. Bivalirudin, Cangrelor and Ticagrelor in STEMI: The Perfect Marriage? Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 12th, 2015.

2272. Myocardial Perfusion, Salvage, and Infarct Size After STEMI: What Are the Remaining Challenges? Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 13th, 2015.

2273. ABSORB Clinical Trial Data. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 13th, 2015.

2274. TCT 2015 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 13th, 2015.

2275. Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics – The CHAMPION PHOENIX Trial. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 13th, 2015.

2276. Cangrelor: Novel Uses of a Rapidly Acting IV P2Y12 Inhibitor in PCI. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 13th, 2015.

2277. The Drug-Filled Stent: Start the ReVolution. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 14th, 2015.

2278. Role of Cangrelor in NSTEACS: Should All Patients Receive It? Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 14th, 2015.

2279. Identifying and Studying Data Gaps: Cangrelor Use – What's Settled, and What's Not? Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 14th, 2015.

2280. Featured Lecture: One-Year Patient-Level Pooled Meta-analysis From 4 ABSORB Trials in 3389 Randomized Patients. Presented at the 27th annual

Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 14th, 2015.

2281. Assessing Whether Superiority Exists: Design, Rationale, and Status of ABSORB IV. Presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, October 14th, 2015.

2282. Mitral Valve Repair Versus Replacement. Presented at the 36th annual GISE Congress, Genoa, Italy, October 28th, 2015.

2283. TCT 2015 - What are the key LBCT messages for the clinical practitioner? Presented at the 36th annual GISE Congress, Genoa, Italy, October 29th, 2015.

2284. State of the art and future perspectives on: Transcatheter Mitral Valve Repair: When and How? Presented at the 36th annual GISE Congress, Genoa, Italy, October 29th, 2015.

2285. Bioresorbable vascular scaffolds: From theory to Absorb III. Presented at the annual Veith course. New York City, NY, November 20th, 2015.

2286. Recent Practice Changing Trials: TOTAL. Presented at the annual Controversies and Advances in the Treatment of Cardiovascular Disease course, Los Angeles, CA, November 21st, 2015.

2287. Keynote Lecture State of the Art: Interventional Treatment of Acute Myocardial Infarction. Presented at the annual Controversies and Advances in the Treatment of Cardiovascular Disease course, Los Angeles, CA, November 21st, 2015.

2288. Bioabsorbable Stents will be the Standard of Care. Presented at the annual Controversies and Advances in the Treatment of Cardiovascular Disease course, Los Angeles, CA, November 21st, 2015.

2289. Detection and treatment of vulnerable plaque: The holy grail. Cardiovascular medicine grand rounds, Yale University Medical Center, New Haven, CT, December 1st, 2015.

2290. Cangrelor: When and How Should We Use it? Presented at the annual Innovations in Cardiovascular Interventions meeting, Tel Aviv, Israel, December 14th, 2015.

2291. Can Peri-infarct Pacing Prevent Adverse Left Ventricular Remodeling After Large MI? Presented at the annual Innovations in Cardiovascular Interventions meeting, Tel Aviv, Israel, December 14th, 2015.

2292. Why Use BVS Rather than Metallic DES? Presented at the annual Innovations in Cardiovascular Interventions meeting, Tel Aviv, Israel, December 14th, 2015.

2293. Bioresorable Scaffolds: ABSORB III and ABSORB Meta-Analysis. Presented at the annual Innovations in Cardiovascular Interventions meeting, Tel Aviv, Israel, December 14th, 2015.

2294. Treatment of Functional MR: Anticipating COAPT. Presented at the annual Innovations in Cardiovascular Interventions meeting, Tel Aviv, Israel, December 15th, 2015.

2295. The Pharmacology of Interventional Cardiology. Presented at Physician's rounds, Columbia University Medical Center, New York Presbyterian Hospital, January 6th, 2016.

2296. Revascularization Controversies in Managing Patients with Coronary Artery Disease. Presented at Medical Grand Rounds, Columbia University Medical Center, New York Presbyterian Hospital, January 6th, 2016.

2297. Bioresorbable Vascular Scaffolds in PCI. Cardiology Grand Rounds, Montefiore Medical Center, Bronx, NY, January 26th, 2016.

2298. ABSORB update: what have we learned?" Presented at the annual Joint International Meeting (JIM), Milan, Italy, February 10th, 2016.

2299. The Drug-filled Polymer-free Stent. Presented at the annual Joint International Meeting (JIM), Milan, Italy, February 11th, 2016.

2300. Is Bivalirudin Superior to Heparin for ACS Patients? Presented at the annual CRT meeting, Washington DC, February 21st, 2016.

2301. ABSORB III: Pivotal Trial Main Results. Presented at the annual CRT meeting, Washington DC, February 21st, 2016.

2302. Diagnosis NIRS and Treatment BVS of Vulnerable Plaque: PROSPECT II. Presented at the annual CRT meeting, Washington DC, February 21st, 2016.

2303. Antiplatelet Therapy for STEMI: The Case for Cangrelor. Presented at the annual CRT meeting, Washington DC, February 21st, 2016.

2304. Detection and Treatment of Vulnerable Plaque: a Paradigm shift. Cardiology grand rounds, St. Lukes, Mt Sinai Hospital, New York, NY, February 24th, 2016.

2305. Interventional Cardiology Beyond 2016: What Does the Future of Stent Design Look Like? Presented at the EPIC meeting, Emory Convention Center, Atlanta, GA, March 3rd, 2016.

2306. Why Does PCI Remain the Centerpiece for Revascularization in Multivessel CAD? Presented at the EPIC meeting, Emory Convention Center, Atlanta, GA, March 3rd, 2016.

2307. Advancing TMVR Therapies: Why COAPT is an Essential Trial. Presented at the Scottsdale Interventional Forum, Phoenix, AZ, March 10th, 2016.

2308. Interventional Management of Unprotected Left Main Coronary Artery Disease: Patient Selection and Technique Optimization. Presented at the Scottsdale Interventional Forum, Phoenix, AZ, March 11th, 2016.

2309. Identification of the embolic-prone lesion. Presented at the course Intravascualr Imaging and Coronary Physiology 2016, New York City, NY, March 12th, 2016.

2310. ABSORB Meta-Analysis. Presented at the annual CIT symposium, Beijing, China, March 18th, 2016.

2311. Antiplatelet therapy for interventionalist. Presented at the annual CIT symposium, Beijing, China, March 18th, 2016.

2312. Predicting and Preventing Distal Embolization. Presented at the annual CIT symposium, Beijing, China, March 18th, 2016.

2313. Bioresorbable Vascular Scaffolds: From ABSORB III to the Future. Presented at the annual CIT symposium, Beijing, China, March 18th, 2016.

2314. New Studies and Rationale for MitraClip in Functional MR Patients (anticipating COAPT). Presented at the annual CIT symposium, Beijing, China, March 19th, 2016.

2315. The risk of scaffold thrombosis of BRS is comparable to metallic DES. Presented at the annual CIT symposium, Beijing, China, March 19th, 2016.

2316. Left Main PCI: Anticipating EXCEL. Presented at the annual CIT symposium, Beijing, China, March 19th, 2016.

2317. Antiplatelet therapy for interventionalists – beyond the basics. Presented at the annual CIT symposium, Beijing, China, March 19th, 2016.

2318. Evolving Perspectives on heparin and bivalirudin use in STEMI. Shenyang Military Hospital, Shenyang, China, March 20th, 2016.

2319. Detection & Treatment of Vulnerable Plaque: Science Fiction or Reality? Cardiology Grand Rounds, presented at the University of Illinois, Chicago, IL, March 31st, 2016.

2320. The Importance of Coronary Calcification in Complex PCI: Data and Devices. Presented at the course “The Interventional Toolbox for Complex Higher-Risk (and Indicated) Patients (CHIP)”, Chicago, IL, April 1st, 2016.

2321. Debate: Duration of Antiplatelet Therapy Post Stenting: Case Settled. Presented at the American College of Cardiology Annual Scientific Session, Chicago, IL, April 2nd, 2016.

2322. Debate: Bivalirudin 2015- When, Where and With What? Bivalirudin is 1st Choice for ACS. Presented at the American College of Cardiology Annual Scientific Session, Chicago, IL, April 3rd, 2016.

2323. Outcomes of the ABSORB Bioresorbable Vascular Scaffold in very small and not very small coronary arteries: The ABSORB III Randomized Trial. Presented at the American College of Cardiology Annual Scientific Session, Chicago, IL, April 3rd, 2016.

2324. State-of-the-Art Lecture: Advances in Drug Eluting Stent Technology and Outcomes. Presented at the course: Mayo Clinic State-of-the-Art Cardiovascular Update: A Case-Based Approach from the Heart of Manhattan. New York City, NY, April 7th, 2016.

2325. Drug-Eluting Stents: Past, Present, and Future. Presented at the annual North American Interventional Cardiology Fellow's course, Orlando, FL, April 15th, 2016.

2326. State-of-the-Art in ACS and STEMI: Risk Stratification and Reperfusion Strategies. Presented at the annual North American Interventional Cardiology Fellow's course, Orlando, FL, April 15th, 2016.

2327. Lessons from the ABSORB Trials. Transmitted to the National Interventional Cardiology India course, Hydrabad, India, April 15th, 2016.

2328. ABSORB III: Current and Future Use of Bioresorbable. Presented at the annual TCTAP scientific sessions, Seoul, S. Korea, April 27th, 2016.

2329. Why do we Need a Fully Bioresorbable Vascular Scaffold? From Absorb III and ABSORB Meta-Analysis to the Future. Presented at the annual TCTAP scientific sessions, Seoul, S. Korea, April 27th, 2016

2330. Management of Stable Coronary Heart Disease with Objective Ischemia: COURAGE, FAME and Recent Meta-analysis. Presented at the annual TCTAP scientific sessions, Seoul, S. Korea, April 27th, 2016.

2331. Drug-eluting stents vs Bioresorbable Vascular Scaffolds: Is Newer better? Presented at the annual TCTAP scientific sessions, Seoul, S. Korea, April 27th, 2016.

2332. The future PROSPECT for the role of antiplatelet therapy. Presented at the annual TCTAP scientific sessions, Seoul, S. Korea, April 27th, 2016.

2333. BRS: From ABSORB III to the Future. Presented at the annual TCTAP scientific sessions, Seoul, S. Korea, April 28th, 2016.

2334. Left Main PCI: Anticipating EXCEL. Presented at the annual TCTAP scientific sessions, Seoul, S. Korea, April 28th, 2016.

2335. Cardiology Grand Rounds. Coronary Revascularization Dilemmas: Medical Therapy, PCI or CABG? Cedars-Sinai Medical Center, Los Angeles, CA, May 3rd, 2016.

2336. What will be the Role of Polymer Free Stents and Biodegradeable Scaffolds in Contemporary PCI? Presented at the annual scientific sessions of the Society of Cardiovascular Angiography and Interventions, Orlando, FL, May 4th, 2016.

2337. Bioresorbable Scaffolds in STEMI: from TROFI II to HORIZONS-ABSORB. Presented at the annual scientific sessions of the Society of Cardiovascular Angiography and Interventions, Orlando, FL, May 4th, 2016.

2338. Intravenous P2Y12 Inhibition for STEMI: The New Standard? Presented at the annual scientific sessions of the Society of Cardiovascular Angiography and Interventions, Orlando, FL, May 6th, 2016.

2339. Clinical Data to Support BVS Safety and Efficacy: The ABSORB Studies. Presented at the annual scientific sessions of the Society of Cardiovascular Angiography and Interventions, Orlando, FL, May 6th, 2016.

2340. Acute Pharmacology Heparin versus Bivalirudin: will there ever be consensus? Presented at the annual scientific sessions of the Society of Cardiovascular Angiography and Interventions, Orlando, FL, May 6th, 2016.

2341. Clinical Outcomes following Coronary Revascularization with the Everolimus-eluting BRS in Patients with Diabetes: The ABSORB trial diabetic study. Presented at the annual EuroPCR conference, Paris, France, May 18th, 2016.

2342. HORIZONS-ABSORB – Harmonizing outcomes with revascularization, stents and ABSORB in acute myocardial infarction. Presented at the annual EuroPCR conference, Paris, France, May 17th, 2016.

2343. Reducer: Coronary artery sinus reducer for refractory angina. Presented at the annual EuroPCR conference, Paris, France, May 18th, 2016.

2344. Advantages of desaminotyrosine polycarbonate polymers. Presented at the annual EuroPCR conference, Paris, France, May 18th, 2016.

2345. PROSPECT II: Providing regional observations to study predictors of events in the coronary tree – II. Presented at the annual EuroPCR conference, Paris, France, May 18th, 2016.

2346. 13th Annual Peter F. Cohn Lecture. Revascularization Controversies in Simple vs. Complex Coronary Artery Disease: How to choose between Medical Therapy, PCI and CABG. Stoney Brook Medical Center, May 25th, 2016, Stony Brook, NY.

2347. Keynote address. Trancatheter Repair and Replacement: State-of-the-art 2016. Presented at the Trancatheter Valve Therapies course 2016, Chicago, IL, June 16th, 2016.

2348. Bivalirudin and Cangrelor: From one Horizon to the Next. Presented at the Vulnerable Patient and Plaque Meeting (VPM), Reykjavik, Iceland, 2016, June 27th, 2016.

2349. Why do we need the ISCHEMIA trial? Presented at the Vulnerable Patient and Plaque Meeting (VPM), Reykjavik, Iceland, 2016, June 28th, 2016.

2350. Treatment of Vulnerable Plaque: From PROSPECT - ABSORB to PREVENT. Presented at the Vulnerable Patient and Plaque Meeting (VPM), Reykjavik, Iceland, 2016, June 28th, 2016.

2351. Polymer free stent technology – pros and cons. Presented at the annual Geoffrey O. Hartzler Interventional Cardiology Symposium, Maui, Hawaii, July 11th, 2016.

2352. Ticagrelor, Cangrelor and Bivalirudin is the perfect combination for STEMI Patients. Presented at the annual Geoffrey O. Hartzler Interventional Cardiology Symposium, Maui, Hawaii, July 12th, 2016.

2353. Keynote Lecture – Bioresorbable Scaffolds: From Today to Tomorrow. Presented at the annual TOPIC 2016 meeting, Tokyo, Japan, July 22, 2016.

2354. Left Main Intervention Today and Tomorrow: How Will EXCEL change practice? Presented at the annual TOPIC 2016 meeting, Tokyo, Japan, July 22, 2016.

2355. BRS Clinical Update. Presented at the annual TOPIC 2016 meeting, Tokyo, Japan, July 22, 2016.

2356. The Future of Interventional Cardiology - 10 New Innovations. Presented at TCT India 2016, New Delhi, India, August 5th, 2016.

2357. Update on percutaneous mitral valve repair and replacement. Presented at TCT India 2016, New Delhi, India, August 5th, 2016.

2358. Essentials of ABSORB III. Presented at TCT India 2016, New Delhi, India, August 5th, 2016.

2359. The primary endpoint is positive, is that enough? A clinical perspective. Presented at the annual scientific sessions of the European Society of Cardiology, Rome, Italy, August 29th, 2016.

2360. Update on clinical data after bioresorbable vascular device implantation. Presented at the annual scientific sessions of the European Society of Cardiology, Rome, Italy, August 30th, 2016.

2361. Controlled and sustained drug elution without a polymer. Presented at the annual scientific sessions of the European Society of Cardiology, Rome, Italy, August 30th, 2016.

2362. PCI, CABG or Medical therapy: Revascularization Decisions in Coronary Artery Disease. Presented at Grand Rounds, Lincolm Medical Center, Bronx, NY, September 2nd, 2016.

2363. The Latest Clinical Update: What to expect from bioresorbable scaffolds. Presented at the 64th Annual Scientific Sessions of the Japanese College of Cardiology, September 24th, 2016, Tokyo, Japan.

2364. Keynote address: Bioresorbable scaffolds for stble coronary artery disease, STEMI and vulnerable plaque. Presented at the 64th Annual Scientific Sessions of the Japanese College of Cardiology, September 24th, 2016, Tokyo, Japan.

2365. Duration of DAPT: DAPT Duration Should be as Short as PossiblePresented at the Cardiometabolic Health Congress 2016, October 6th, 2016, Boston, MA.

2366. Pretreat or not to pretreat? No one should be pretreated – Use cangrelor! Presented at the Cardiometabolic Health Congress 2016, October 6th, 2016, Boston, MA.

2367. NOACs vs Warfarin: Warfarin remains the safe and effective gold standard. Presented at the Cardiometabolic Health Congress 2016, October 6th, 2016, Boston, MA.

2368. How Should Coronary Revascularization Decisions be Made: Anatomy, Angina or Ischemia? Cardiology Grand Rounds, Massachusettes General Hospital, October 6th, 2016, Boston, MA.

2369. The Clinical Need for Innovative Coronary Stents. Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 29th, 2016.

2370. Bioresorbable Scaffolds: Arguing for Expanded Us. Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 29th, 2016.

2371. Cardiovascular Outcomes Assessment of MitraClip Therapy in Heart Failure Patients with Functional Mitral Regurgitation (The COAPT Trial): Baseline Characteristics and Preliminary 30-Day and 1-Year Outcomes of the Roll-In Cohort. Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 29th, 2016.

2372. An Overview of Endovascular Carotid Barostimulation: A Novel Interventional Approach to Hypertension Treatment. Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 30st, 2016.

2373. Should Bivalirudin Only Be Used with a Prolonged Post-PCI Infusion? Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 30st, 2016.

2374. Should Clinical Trial Interpretation Be Dominated by a P-Value of 0.05 for the Primary Endpoint? Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 30st, 2016.

2375. Early and Late Results With the Wavecrest LAA Occluder (and Future Studies). Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 30st, 2016.

2376. Update on RCTs in FMR, and First Report of the COAPT Roll-in Patients. Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 30st, 2016.

2377. EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery Diseas. Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 31st, 2016.

2378. The FDA Town Hall Meeting: Evolution of a Decades Long Collaboration Between Physician-Scientists, Industry, Regulators, and Payors. Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 31st, 2016.

2379. EXCEL Top Line Results Revisited. Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 31st, 2016.

2380. Benefit of Supersaturated Oxygen for Large Anterior STEMI: From ICI-HOT to Approval? Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 31st, 2016.

2381. When There Are No Revascularization Options: Indications and Evidence for the Coronary Sinus Reducer in the CHIP Patient. Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 31st, 2016.

2382. What Have We Learned From Randomized Trials and Registries About the Safety and Efficacy of Bioresorbable Vascular Scaffolds? Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, October 31st, 2016.

2383. The NIH-sponsored HYBRID Revascularization Trial. Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, November 1st, 2016.

2384. Learnings From A Pivotal Transcatheter Mitral Device Trial: Can The MVARC/COAPT Paradigm Be Shortened? Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, November 1st, 2016.

2385. The Importance of Coronary Calcification in Complex PCI: Data and Devices. Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2016, Washington DC, November 1st, 2016.

2386. Left main revascularization: The EXCEL trial. Presented at the annual Veith Symposium, New York City, NY, Nov. 19th, 2016.

2387. How to perform great clinical trials. Keynote address at the 9th CBS course on Left Main and Bifurcation Treatment, Nanjing, China, December 2nd, 2016.

2388. The EXCEL trial: new insights into Left Main stenting. Presented at the 9th CBS course on Left Main and Bifurcation Treatment, Nanjing, China, December 2nd, 2016.

2389. Near Infrared Spectroscopy to detect vulnerable plaque: The PROSPECT II Study. Presented at the annual ICI course, Tel Aviv Israel. December 5th, 2016.

2390. Bioresorbable Scaffold Treatment of Vulnerable Plaques: The PROSPECT-ABSORB Trial. Presented at the annual ICI course, Tel Aviv Israel. December 5th, 2016.

2391. Polymer Free Stents: The Medtronic Drug-Filled Stent and Results of the REVOLUTION Study. Presented at the annual ICI course, Tel Aviv Israel. December 5th, 2016.

2392. MitraClip for Secondary MR in Heart Failure: COAPT Design and Results from the Run-in Phase. Presented at the annual ICI course, Tel Aviv Israel. December 5th, 2016.

2393. Revascularization Controversies in Managing Patients with Coronary Artery Disease: Medical Therapy, PCI or CABG? Cardiology Grand Rounds, Washington University - St. Louis, St. Lous, MO, February 1st, 2017.

2394. Detection and Treatment of Vulnerable Plaque: Science fiction or reality? Cardiology Grand Rounds, New York University, New York, NY, February 3rd, 2017.

2395. From Idea to Change-in-Practice: Which data you need to change guidelines? Presented at the Mitral Valve Meeting, Zurich Switzerland, February 5th, 2017.

2396. Dreams and Realities: The dawn of mitral and tricuspid interventions. The evidence. Presented at the Mitral Valve Meeting, Zurich Switzerland, February 5th, 2017.

2397. Perspectives on the ABSORB randomized trials: Take home messages for the clinical practitioner. Presented at the annual Joint Intervention Meeting (JIM), Milan, Italy, February 8th, 2017.

2398. FANTOM: A radio-opaque desaminotyrosine polycarbonate-based scaffold. Presented at the annual Joint Intervention Meeting (JIM), Milan, Italy, February 8th, 2017.

2399. The Great Debate. BRS – an important need. Presented at the annual Joint Intervention Meeting (JIM), Milan, Italy, February 8th, 2017.

2400. Clinical Crossroads on optimal acute and long term antithrombotic therapy in patients treated with PCI. Presented at the annual Joint Intervention Meeting (JIM), Milan, Italy, February 8th, 2017.

2401. Case Presentations from the Literature: Were they interpreted properly? Presented at the meeting "Mechanisms of BRS Failure: Imaging Findings and Classification Scheme", Ckirball Center for Innovation, Orangeburg, NY, February 17th, 2017.

2402. ABSORB III: Pivotal Trial Main Results. Presented at the annual CRT meeting, February 19th, Washington DC, 2017.

2403. Should Cangrelor Be Used in Most STEMI Patients? Presented at the annual CRT meeting, February 19th, Washington DC, 2017.

2404. OCT vs. IVUS vs. Angio Guidance of Stent Implantation: The Randomized ILUMIEN III Trial. Presented at the annual CRT meeting, February 19th, Washington DC, 2017.

2405. BRS Next Large Trials, what in the Horizon. The REDUCER for Refractory Angina: COSIRA II. Presented at the annual CRT meeting, February 19th, Washington DC, 2017.

2406. Diagnosis NIRS and Treatment BVS of Vulnerable Plaque: PROSPECT II. Presented at the annual CRT meeting, February 19th, Washington DC, 2017.

2407. BRS Next Large Trials, what in the Horizon. Presented at the annual CRT meeting, February 19th, Washington DC, 2017.

2408. Impact of Technique and DAPT Duration on Early, Late and Very Late Outcomes after Absorb BVS Implantation: Analysis from ABSORB II, ABSORB Japan, ABSORB China, ABSORB II and ABSORB Extend. Presented at the annual CRT meeting, February 20th, Washington DC, 2017.

2409. What Is New With Metallic Stents? Presented at the annual CRT meeting, February 20th, Washington DC, 2017.

2410. Non-Polymeric DES Development: Update On the Drug-Filled Stent. Presented at the annual CRT meeting, February 20th, Washington DC, 2017.

2411. A Brief Update on PCI for LMCA Disease. Presented at the course “The Interventional Toolbox for Complex Higher-Risk (and Indicated) Patients (CHIP)” at the 2017 Scientific Sessions of the American College of Cardiology, Washington DC, March 16th, 2017.

2412. STEMI vs NSTEMI vs Stable CAD – Post PCI DAPT Duration Accoring to the Complexity of Disease. Presented at the 2017 Scientific Sessions of the American College of Cardiology, Washington DC, March 18th, 2017.

2413. Insights from EXCEL and NOBLE. Presented at the 2017 Scientific Sessions of the American College of Cardiology, Washington DC, March 18th, 2017.

2414. MitraClip: Current Data Overview. Presented at the 2017 Scientific Sessions of the American College of Cardiology, Washington DC, March 18th, 2017.

2415. The Evolution of PCI – A 40-Year History. Presented at the 2017 Scientific Sessions of the American College of Cardiology, Washington DC, March 19th, 2017.

2416. Featured Lecture: Leaving Nothing Behind - Devices, Clinical Applications and Emerging Data. Presented at the annual China Interventional Therapeutics meeting, Beijing, China, March 30th, 2017.

2417. Plenary session presentation: EXCEL and NOBLE. Presented at the annual China Interventional Therapeutics meeting, Beijing, China, March 31st, 2017.

2418. Update on Primary PCI 2017: Pharmacology. Presented at the annual China Interventional Therapeutics meeting, Beijing, China, March 31st, 2017.

2419. New Insights from the ABSORB Clinical Trial Program. Presented at the annual China Interventional Therapeutics meeting, Beijing, China, March 31st, 2017.

2420. Bioresorbable Scaffolds in Patients with Stable CAD and ACS. Presented at the annual China Interventional Therapeutics meeting, Beijing, China, April 1st, 2017.

2421. Insights from EXCEL and NOBLE and Future Guidelines. Presented at the annual China Interventional Therapeutics meeting, Beijing, China, April 1st, 2017.

2422. The dilemma of managing functional MR: Perspectives from COAPT and other Clinical Trials. Presented at the annual China Interventional Therapeutics meeting, Beijing, China, April 1st, 2017.